REPORT

FINAL REPORT - CHRONIC TOXICITY

AND ONCOGENICITY

VOLUME I

AN ASSESSMENT OF THE

CHRONIC TOXICITY AND

ONCOGENICITY OF

AROCLOR-1016, AROCLOR-1242,

AROCLOR-1254, AND

AROCLOR-1260 ADMINISTERED

IN DIET TO RATS

To

Environmental Research Center

General Electric Company

Battelle
. . . Putting Technology To Work

February, 1997

801960

FINAL REPORT - CHRONIC TOXICITY AND ONCOGENICITY

on

AN ASSESSMENT OF THE CHRONIC TOXICITY AND ONCOGENICITY OF AROCLOR-1016, AROCLOR-1242, AROCLOR-1254, AND AROCLOR-1260 ADMINISTERED IN DIET TO RATS

to

Environmental Research Center
General Electric Company

Study Initiation Date: December 18, 1992
Study Completion Date: February 25, 1997

February, 1997

by

Michael J. Brunner, Timothy M. Sullivan, Allen W. Singer, Michael J. Ryan, John D. Toft, II, Ronald S. Menton, Steven W. Graves, and Arthur C. Peters

BATTELLE
505 King Avenue
Columbus, Ohio 43201-2693

801961

GOOD LABORATORY PRACTICES COMPLIANCE STATEMENT

Study Title: An Assessment of the Chronic Toxicity and Oncogenicity of Aroclor-1016, Aroclor-1242, Aroclor-1254, and Aroclor-1260 Administered in Diet to Rats

Final Chronic Toxicity and Oncogenicity Report

Battelle Study Number: SC920192

The in-life and postmortem portions of this study performed by Battelle were conducted in compliance with the Environmental Protection Agency's Good Laboratory Practice Standards (40 CFR Part 792). Tissue and sample analyses performed by Northeast Analytical, Inc., vaginal cytology evaluations performed by Novel Pharmaceutical, and Appendix F, *Characterization of PCB Composition, Tissue Acculation, and Correlations with Tumorigenicity in Chronically Dosed Male and Female Sprague-Dawley Rats* are excepted from the Good Laboratory Practices Compliance Statement. This study was conducted according to the study protocol and Battelle's Standard Operating Procedures. Any deviations are listed in Appendix A. The data presented accurately reflect the results of this study.

Arthur C. Peters Feb. 25, 1997

Arthur C. Peters, D.V.M. Date
Study Director

801962

QUALITY ASSURANCE STATEMENT

This study was inspected by the Quality Assurance Unit and reports were submitted to the Study Director and management as follows:

Phase Inspected	Date Inspected	Date Reported to Study Director	Date of Report to Management
Dose Preparation	1/25/93	2/2/93	2/2/93
Dose Analysis	1/27/93	2/2/93	2/2/93
Quarantine Room Inspection	1/29/93	2/2/93	2/2/93
Body weights/tattooing	2/3/93	3/1/93	3/1/93
Ophthalmic exams	2/3/93	3/1/93	3/1/93
Body weights/clinical observations	2/8/93	3/1/93	3/1/93
Body weights/euthanasia	2/17/93	3/1/93	3/1/93
Tissue collection/organ weights	2/17/93	3/1/93	3/1/93
Dose preparation	4/26/93	5/3/93	5/3/93
Body weights/clinical observations/feed consumption	4/26/93	5/3/93	5/3/93
Lipid analysis: carcass weights/ homogenization/extraction/concentration	5/11/93	6/1/93	6/1/93
Ophthalmic exams	5/12/93	6/1/93	6/1/93
Liquid chromatography of lipid extract	5/17/93	6/1/93	6/1/93
Blood collection/euthanasia	5/18/93	6/1/93	6/1/93
Necropsy/tissue collection/organ weights	5/18/93	6/1/93	6/1/93
Dosed feed sample collection	6/21/93	6/30/93	6/30/93
Dose analysis	6/30/93	6/30/93	6/30/93
Body weights/clinical observations/feed consumption	7/7/93	11/1/93	11/1/93
Blood collection	8/9/93	8/31/93	8/31/93
Necropsy/tissue collection/organ weights/ blood collection	8/9/93	8/31/93	8/31/93
Urinalysis/hematologies/clinical chemistries	8/11/93	8/31/93	8/31/93
Animal room analysis	8/11/93	8/31/93	8/31/93
Ophthalmic exams	8/16/93	8/31/93	8/31/93
Dose preparation	9/13/93	10/1/93	10/1/93
Dosed feed sample collection	11/1/93	12/1/93	12/1/93
Lipid analysis: extraction/filtration/ concentration	11/10/93	12/1/93	12/1/93

801963

QUALITY ASSURANCE STATEMENT (Continued)

Phase Inspected	Date Inspected	Date Reported to Study Director	Date of Report to Management
Lipid analysis: column preparation/liquid chromatography elution	11/11/93	12/1/93	12/1/93
Ophthalmic exams	11/12/93	12/1/93	12/1/93
Blood collection/euthanasia/necropsy/tissue collection/organ weights	11/16/93	12/1/93	12/1/93
Dose analysis	12/30/93	1/4/94	1/4/94
Body weights/clinical observations/feed consumption	1/10/94	1/31/94	1/31/94
Dose preparation	1/10/94	1/31/94	1/31/94
Ophthalmic exams	2/2/94	3/1/94	3/1/94
Blood collection	2/10/94	3/1/94	3/1/94
Necropsy/organ weights/body burden tissue collections/weights	2/14/94	3/1/94	3/1/94
Blood collection	2/14/94	3/1/94	3/1/94
Urine collection	2/15/94	3/1/94	3/1/94
Gross necropsy/tissue collection	2/16/94	3/1/94	3/1/94
Blood collection	2/16/94	3/1/94	3/1/94
Urinalysis/clinical laboratory blood processing/analysis	2/18/94	3/1/94	3/1/94
Dose preparation	4/18/94	5/9/94	5/9/94
Body weights/clinical observations/feed consumption	5/9/94	6/1/94	6/1/94
Dosed feed sample collection	5/13/94	6/1/94	6/1/94
Ophthalmic exams	8/11/94	9/1/94	9/1/94
Urine collection/vaginal cytologies	8/12/94	9/1/94	9/1/94
Blood collection/necropsy/tissue collection/ organ weights	8/15/94	9/1/94	9/1/94
Blood collection/euthanasia	2/9/95	3/1/95	3/1/95
Necropsy/tissue collection/organ weights	2/9/95	3/1/95	3/1/95
Fecal collection	2/13/95	3/1/95	3/1/95
Dosed feed sample collection	2/14/95	3/1/95	3/1/95
Histology tissue processing	5/15/95	6/1/95	6/1/95

801964

QUALITY ASSURANCE STATEMENT (Continued)

	Phase Inspected	Date Inspected	Date Reported to Study Director	Date of Report to Management
Data audits:		3/8/93	3/8/93	6/3/93
"		3/15/93	3/15/93	4/15/93
"		4/6/93	4/6/93	5/5/93
"		4/15/93	4/15/93	9/8/93
"		5/27/93	5/27/93	9/19/94
"		8/18/93	8/18/93	2/2/94
"		1/7/94	1/7/94	8/19/94
"		2/4/94	2/4/94	3/15/94
"		2/23/94	2/23/94	5/2/94
"		2/28/94	2/28/94	3/10/94
"		4/11/94	4/11/94	5/20/94
"		4/15/94	4/15/94	8/1/94
"		4/26/94	4/26/94	8/11/94
"		8/12/94	8/12/94	3/8/95
"		8/12/94	8/12/94	3/14/95
"		9/14/94	9/14/94	3/15/95
"		9/16/94	9/16/94	3/15/95
"		9/16/94	9/16/94	3/15/95
"		9/16/94	9/16/94	3/15/95
"		11/22/94	11/22/94	12/15/94
"		12/15/94	12/15/94	3/30/95
"		2/9/95	2/9/95	6/2/95
"		2/21/95	2/21/95	5/9/95
"		3/6/95	3/6/95	6/2/95
"		4/24/95	4/24/95	5/3/95
"		4/28/95	4/28/95	9/22/95
"		5/2/95	5/2/95	5/4/95
"		5/24/95	5/24/95	5/30/95
"		6/6/95	6/6/95	8/29/95
"		6/8/95	6/8/95	12/7/95
"		10/30/95	10/30/95	11/29/95
"		11/2/95	11/2/95	6/1/96
"		11/3/95	11/3/95	1/22/96
Data audits:		11/13/95	11/13/95	1/19/96

801965

QUALITY ASSURANCE STATEMENT (Continued)

Phase Inspected	Date Inspected	Date Reported to Study Director	Date of Report to Management
Report audits:	7/26/95	7/26/95	9/22/95
"	8/1/95	8/1/95	9/25/95
"	8/8/95	8/8/95	9/22/95
"	8/22/95	8/22/95	9/22/95
"	9/22/95	9/22/95	10/2/95
"	10/2/95	10/2/95	1/19/96
"	10/2/95	10/2/95	10/10/95
"	10/6/95	10/6/95	11/21/95
"	10/6/95	10/6/95	10/31/95
"	10/20/95	10/20/95	12/7/95
"	10/31/95	10/31/95	11/8/95
"	10/31/95	10/31/95	11/20/95
"	11/16/95	11/16/95	11/20/95
"	11/21/95	11/21/95	12/5/95
"	11/21/95	11/21/95	1/29/96
"	2/23/96	2/23/96	2/3/97
"	2/26/96	2/26/96	3/8/96
"	2/29/96	2/29/96	4/4/96
"	3/5/96	3/5/96	5/17/96
"	3/8/96	3/8/96	5/15/96
"	3/14/96	3/14/96	5/17/96
"	3/15/96	3/15/96	5/16/96
"	3/18/96	3/18/96	5/16/96
"	3/21/96	3/21/96	12/4/96
"	3/22/96	3/22/96	5/16/96
"	5/28/96	5/28/96	5/31/96
"	6/1/96	6/1/96	6/1/96
"	6/25/96	6/25/96	2/21/97
"	12/5/96	12/5/96	12/6/96
Report audits	1/15/97	1/15/97	2/21/97

Melissa Miller 2/20/97
Quality Assurance Unit Date
Health Division

801966

FINAL REPORT - CHRONIC TOXICITY AND ONCOGENICITY

on

AN ASSESSMENT OF THE CHRONIC TOXICITY AND ONCOGENICITY OF AROCLOR-1016, AROCLOR-1242, AROCLOR-1254 AND AROCLOR-1260 ADMINISTERED IN DIET TO RATS

February, 1997

Michael J. Brunner, B.S.
Study Coordinator — Feb 25, 1997 Date

Timothy M. Sullivan, Ph.D., D.A.B.T.
Senior Program Manager — Feb. 25, 1997 Date

Michael J. Ryan, D.V.M., Ph.D., D.A.C.V.P.
Study Pathologist (~~Female~~ Rats) — Feb 25, 1997 Date

John D. Toft, II, D.V.M., M.S., D.A.C.V.P.
Study Pathologist (Male Rats) — Feb. 25, 1997 Date

Allen W. Singer, D.V.M., D.A.C.V.P., D.A.B.T.
Manager Pathology — Feb 25, 1997 Date

Ronald S. Menton, Ph.D.
Statistician — Feb 25, 1997 Date

Steven W. Graves, B.S.
Study Chemist — 2/25/97 Date

Arthur C. Peters, D.V.M.
Study Director — February 25, 1997 Date

801967

VOLUME I
CONTENTS

		Page
COMPLIANCE STATEMENT		ii
QUALITY ASSURANCE STATEMENT		iii
SIGNATURE PAGE		vii
1.0	EXECUTIVE SUMMARY	1
2.0	INTRODUCTION	11
3.0	EXPERIMENTAL DESIGN	13
4.0	MATERIALS AND METHODS	15
4.1	Test and Control Substances	15
4.2	Dose Preparation	16
4.3	Dose Analyses and Homogeneity, and Stability	17
4.4	Experimental Animals	18
4.4.1	Animal Receipt, Quarantine, and Animal Group Assignment	19
4.4.2	Animal Identification	20
4.4.3	Animal Housing and Environmental Conditions	21
4.5	Clinical Observations	21
4.6	Body Weight	22
4.7	Feed/Test Substance Consumption	22
4.8	Ophthalmic Examination	22
4.9	Clinical Pathology	23
4.9.1	Hematology	23
4.9.2	Serum Chemistry	24
4.9.3	Urinalyses	24
4.10	Organ Weights	24
4.11	Necropsy	25
4.12	Histopathology	26
4.13	Assessment of Female Reproductive Tract	27
4.14	Additional Sample Collections	28
4.15	Lipid Analysis	29
4.16	Fecal Collection	29
4.17	Data Management	30
4.18	Statistical Analysis	30
4.19	Health and Safety	32
4.20	Specimen Storage and Record Archives	33

801968

VOLUME I
CONTENTS (Continued)

		Page
5.0	RESULTS	34
5.1	Dose Analysis	34
5.1.1	Reference Dose Analysis	36
5.1.2	Analysis for Cross-Contamination	36
5.2	Animal Survival	37
5.3	Clinical Observations	40
5.4	Body Weights	41
5.5	Feed Consumption	45
5.6	Test Substance Consumption	45
5.7	Ophthalmic Evaluations	46
5.8	Clinical Pathology	47
5.8.1	Hematology	47
5.8.2	Serum Chemistry	50
5.8.3	Urinalysis	54
5.9	Organ Weights	54
5.10	Necropsy	63
5.11	Histopathology	76
5.12	Assessment of Female Reproductive Tracts	110
6.0	DISCUSSION/CONCLUSION	112
7.0	REFERENCES	116
8.0	ACKNOWLEDGMENTS	117

801969

VOLUME I
CONTENTS (Continued)

Page

9.0 FIGURES

Figure 1. Survival Curve for Aroclor-1016 Core/Interim Subgroup Male Rats 118

Figure 2. Survival Curve for Aroclor-1242 Core/Interim Subgroup Male Rats 119

Figure 3. Survival Curve for Aroclor-1254 Core/Interim Subgroup Male Rats 120

Figure 4. Survival Curve for Aroclor-1260 Core/Interim Subgroup Male Rats 121

Figure 5. Survival Curve for Aroclor-1016 Core/Interim Subgroup Female Rats . . 122

Figure 6. Survival Curve for Aroclor-1242 Core/Interim Subgroup Female Rats . . 123

Figure 7. Survival Curve for Aroclor-1254 Core/Interim Subgroup Female Rats . . 124

Figure 8. Survival Curve for Aroclor-1260 Core/Interim Subgroup Female Rats . . 125

Figure 9. Survival Curve for Aroclor-1016 Stop Study Subgroup Female Rats 126

Figure 10. Survival Curve for Aroclor-1242 Stop Study Subgroup Female Rats 127

Figure 11. Survival Curve for Aroclor-1254 Stop Study Subgroup Female Rats 128

Figure 12. Survival Curve for Aroclor-1260 Stop Study Subgroup Female Rats 129

Figure 13. Group Mean Weekly Body Weights for Aroclor-1016 Core/Interim Subgroup Male Rats 130

Figure 14. Group Mean Weekly Body Weights for Aroclor-1242 Core/Interim Subgroup Male Rats 131

801970

VOLUME I
CONTENTS (Continued)

Page

Figure 15. Group Mean Weekly Body Weights for Aroclor-1254 Core/Interim Subgroup Male Rats 132

Figure 16. Group Mean Weekly Body Weights for Aroclor-1260 Core/Interim Subgroup Male Rats 133

Figure 17. Group Mean Weekly Body Weights for Aroclor-1016 Core/Interim Subgroup Female Rats 134

Figure 18. Group Mean Weekly Body Weights for Aroclor-1242 Core/Interim Subgroup Female Rats 135

Figure 19. Group Mean Weekly Body Weights for Aroclor-1254 Core/Interim Subgroup Female Rats 136

Figure 20. Group Mean Weekly Body Weights for Aroclor-1260 Core/Interim Subgroup Female Rats 137

Figure 21. Group Mean Weekly Body Weights for Aroclor-1016 Stop Study Subgroup Female Rats 138

Figure 22. Group Mean Weekly Body Weights for Aroclor-1242 Stop Study Subgroup Female Rats 139

Figure 23. Group Mean Weekly Body Weights for Aroclor-1254 Stop Study Subgroup Female Rats 140

Figure 24. Group Mean Weekly Body Weights for Aroclor-1260 Stop Study Subgroup Female Rats 141

Figure 25. Group Mean Feed Consumption for Aroclor-1016 Core/Interim Subgroup Male Rats 142

Figure 26. Group Mean Feed Consumption for Aroclor-1242 Core/Interim Subgroup Male Rats 143

Figure 27. Group Mean Feed Consumption for Aroclor-1254 Core/Interim Subgroup Male Rats 144

801971

VOLUME I
CONTENTS (Continued)

Page

Figure 28. Group Mean Feed Consumption for Aroclor-1260 Core/Interim Subgroup Male Rats 145

Figure 29. Group Mean Feed Consumption for Aroclor-1016 Core/Interim Subgroup Female Rats 146

Figure 30. Group Mean Feed Consumption for Aroclor-1242 Core/Interim Subgroup Female Rats 147

Figure 31. Group Mean Feed Consumption for Aroclor-1254 Core/Interim Subgroup Female Rats 148

Figure 32. Group Mean Feed Consumption for Aroclor-1260 Core/Interim Subgroup Female Rats 149

Figure 33. Group Mean Feed Consumption for Aroclor-1016 Stop Study Subgroup Female Rats 150

Figure 34. Group Mean Feed Consumption for Aroclor-1242 Stop Study Subgroup Female Rats 151

Figure 35. Group Mean Feed Consumption for Aroclor-1254 Stop Study Subgroup Female Rats 152

Figure 36. Group Mean Feed Consumption for Aroclor-1260 Stop Study Subgroup Female Rats 153

10.0 TABLES

Table 1. Dose Formulation Schedule 154

Table 2. Dose Analysis Results for Aroclor-1016 162

Table 3. Homogeneity Results for Aroclor-1016 164

Table 4. Dose Analysis Results for Aroclor-1242 165

Table 5. Homogeneity Results for Aroclor-1242 166

801972

VOLUME I
CONTENTS (Continued)

		Page
Table 6.	Dose Analysis Results for Aroclor-1254	167
Table 7.	Homogeneity Results for Aroclor-1254	169
Table 8.	Dose Analysis Results for Aroclor-1260	170
Table 9.	Homogeneity Results for Aroclor-1260	172
Table 10.	Referee Dose Analysis Results	173
Table 11.	Animal Survival Probability Comparisons for Core and Interim Subgroup Male Rats	174
Table 12.	Animal Survival Probability Comparisons for Core and Interim Subgroup Female Rats	176
Table 13.	Animal Survival Probability Comparisons for Stop Study Subgroup Female Rats	178
Table 14.	Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats	180
Table 15.	Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats	198
Table 16.	Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats	216
Table 17.	Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats	232
Table 18.	Group Mean Body Weights (g) for Core, Interim, and Stop Study Subgroup Female Rats	250
Table 19.	Group Mean Body Weights (g) for Stop Study Subgroup Female Rats Following Treatment Cessation	268
Table 20.	Significant Body Weight Differences Between Aroclor Test Substances for Core/Interim and Stop Study Subgroup Male and Female Rats	277

801973

VOLUME I
CONTENTS (Continued)

		Page
Table 21.	Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats	279
Table 22.	Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study Subgroup Female Rats	296
Table 23.	Group Mean Body Weight Gains (g/day) by Week for Stop Study Subgroup Female Rats Following Treatment Cessation	313
Table 24.	Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats	322
Table 25.	Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study Subgroup Female Rats	339
Table 26.	Group Mean Feed Consumption (g/day) for Stop Study Subgroup Female Rats Following Treatment Cessation	357
Table 27.	Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats	366
Table 27A.	Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats	383
Table 28.	Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study Subgroup Female Rats	400
Table 28A.	Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup Female Rats	418
Table 29.	Group Mean Feed Consumption Per Body Weight (g/kg/day) for Stop Study Subgroup Female Rats Following Treatment Cessation	435
Table 30.	Group Mean Total Feed and Test Substance Consumption for Core and Interim Subgroup Male Rats	444
Table 31.	Group Mean Total Feed and Test Substance Consumption for Core, Interim, and Stop Study Subgroup Female Rats	445

801974

VOLUME I
CONTENTS (Continued)

		Page
Table 32.	Summary of Ophthalmic Examinations for Core and Interim Subgroup Male Rats	446
Table 33.	Summary of Ophthalmic Examinations for Core and Interim Subgroup Female Rats	447
Table 34.	Group Mean Hematology Values for Core Subgroup Male Rats	448
Table 35.	Group Mean Hematology Values for Core Subgroup Female Rats	451
Table 36.	Group Mean Cell Differential Counts for Core Subgroup Male Rats	454
Table 37.	Group Mean Cell Differential Counts for Core Subgroup Female Rats	457
Table 38.	Group Mean Serum Chemistry Values for Core Subgroup Male Rats	460
Table 39.	Group Mean Serum Chemistry Values for Core Subgroup Female Rats	463
Table 40.	Group Mean Serum Enzyme Values for Core Subgroup Male Rats	466
Table 41.	Group Mean Serum Enzyme Values for Core Subgroup Female Rats	468
Table 42.	Group Mean Serum Electrolyte Values for Core Subgroup Male Rats	470
Table 43.	Group Mean Serum Electrolyte Values for Core Subgroup Female Rats	471
Table 44.	Group Mean Urinalysis Values for Core Subgroup Male Rats	474

801975

VOLUME I
CONTENTS (Continued)

		Page
Table 45.	Group Mean Urinalysis Values for Core Subgroup Female Rats	475
Table 46.	Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, Serum Electrolyte Values for Core Subgroup Male and Female Rats	476
Table 47.	Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Male Rats	490
Table 48.	Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Male Rats	496
Table 49.	Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios and Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Male Rats	502
Table 50.	Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios and Organ-to-Brain Weight Ratios for the 105-Week Termination Male Rats	508
Table 51.	Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios and Organ-to-Brain Weight Ratios for the 13-Week Interim Termination Female Rats	514
Table 52.	Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratio and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Female Rats	520
Table 53.	Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratio and Organ-to-Brain Weight Ratios for the 39-Week Interim Termination Female Rats	526
Table 54.	Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Female Rats	532

801976

VOLUME I
CONTENTS (Continued)

Page

VOLUME I
CONTENTS (Continued)

Page

Table 55. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios and Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Female Rats 538

Table 56. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios and Organ-to-Brain Weight Ratios for the 105-Week Termination Female Rats 544

Table 57. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios and Organ-to-Brain Weight Ratios for the 78-Week Stop Study B Termination Female Rats 550

Table 58. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios and Organ-to-Brain Weight Ratios for the 105-Week Stop Study A Termination Female Rats 551

Table 59. Significant Mean Organ-to-Brain Weight Ratio Differences Between Aroclor Test Substances for Male and Female Rats 552

VOLUME II

Table 60. Incidence Summary of Gross Necropsy Observations at the 26-Week Interim Termination for Male Rats 553

Table 61. Incidence Summary of Gross Necropsy Observations at the 52-Week Interim Termination for Male Rats 554

Table 62. Incidence Summary of Gross Necropsy Observations at the 78-Week Interim Termination for Male Rats 556

Table 63. Incidence Summary of Gross Necropsy Observations at the 105-Week Termination for Male Rats 559

801977

Table 64. Incidence Summary of Gross Necropsy Observations at Unscheduled Termination (0-12 Months) for Core and Interim Subgroup Male Rats 564

Table 65. Incidence Summary of Gross Necropsy Observations at Unscheduled Termination (12-18 Months) for Core and Interim Subgroup Male Rats 567

Table 66. Incidence Summary of Gross Necropsy Observations at Unscheduled Termination (18-24 Months) for Core Subgroup Male Rats 571

Table 67. Incidence Summary of Gross Necropsy Observations at the 26-Week Interim Termination for Female Rats 577

Table 68. Incidence Summary of Gross Necropsy Observations at the 39-Week Interim Termination for Female Rats 578

Table 69. Incidence Summary of Gross Necropsy Observations at the 52-Week Interim Termination for Female Rats 579

Table 70. Incidence Summary of Gross Necropsy Observations at the 78-Week Interim Termination for Female Rats 580

Table 71. Incidence Summary of Gross Necropsy Observations at the 105-Week Termination for Female Rats 582

Table 72. Incidence Summary of Gross Necropsy Observations at the 78-Week Termination for Stop Study B Female Rats 587

Table 73. Incidence Summary of Gross Necropsy Observations at the 105-Week Termination for Stop Study A Female Rats 589

Table 74. Incidence Summary of Gross Necropsy Observations at Unscheduled Termination (0-12 Months) for Core, Interim and Stop Study Subgroup Female Rats 592

Table 75. Incidence Summary of Gross Necropsy Observations at Unscheduled Termination (12-18 Months) for Core and Interim Subgroup Female Rats 595

Table 76. Incidence Summary of Gross Necropsy Observations at Unscheduled Termination (18-24 Months) for Core Subgroup Female Rats 599

801978

VOLUME II
CONTENTS (Continued)

		Page
Table 77.	Incidence Summary of Gross Necropsy Observations at Unscheduled Termination (12-18 Months) for Stop Study Subgroup Female Rats	606
Table 78.	Incidence Summary of Gross Necropsy Observations at Unscheduled Termination (18-24 Months) for Stop Study A Subgroup Female Rats	609
Table 79.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 26-Week Interim Termination for Male Rats	613
Table 80.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 52-Week Interim Termination for Male Rats	617
Table 81.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 78-Week Interim Termination for Male Rats	623
Table 82.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 105-Week Termination for Male Rats	630
Table 83.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at Unscheduled Termination (0-12 Months) for Core and Interim Subgroup Male Rats	641
Table 84.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at Unscheduled Termination (12-18 Months) for Core and Interim Subgroup Male Rats	648
Table 85.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at Unscheduled Termination (18-24 Months) for Core and Interim Subgroup Male Rats	660
Table 86.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 13-Week Interim Termination for Female Rats	676
Table 87.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 26-Week Interim Termination for Female Rats	680
Table 88.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 39-Week Interim Termination for Female Rats	684

801979

VOLUME II
CONTENTS (Continued)

		Page
Table 89.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 52-Week Interim Termination for Female Rats	688
Table 90.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 78-Week Interim Termination for Female Rats	693
Table 91.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 105-Week Termination for Female Rats	699
Table 92.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 78-Week Termination for Stop Study B Female Rats	709
Table 93.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at the 105-Week Termination for Stop Study A Female Rats	714
Table 94.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at Unscheduled Termination (0-12 Months) for Core, Interim, and Stop Study Subgroup Female Rats	721
Table 95.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at Unscheduled Termination (12-18 Months) for Core and Interim Subgroup Female Rats	727
Table 96.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at Unscheduled Termination (18-24 Months) for Core Subgroup Female Rats	736
Table 97.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at Unscheduled Termination (12-18 Months) for Stop Study Subgroup Female Rats	748
Table 98.	Incidence Summary of Microscopic Observations (Non-Neoplastic) at Unscheduled Termination (18-24 Months) for Stop Study A Subgroup Female Rats	755
Table 99.	Incidence Summary of Microscopic Observations (Neoplastic) at the 26-Week Interim Termination for Male Rats	764
Table 100.	Incidence Summary of Microscopic Observations (Neoplastic) at the 52-Week Interim Termination for Male Rats	768

801980

VOLUME II
CONTENTS (Continued)

		Page
Table 101.	Incidence Summary of Microscopic Observations (Neoplastic) at the 78-Week Interim Termination for Male Rats	772
Table 102.	Incidence Summary of Microscopic Observations (Neoplastic) at the 105-Week Termination for Male Rats	776
Table 103.	Incidence Summary of Microscopic Observations (Neoplastic) at Unscheduled Termination (0-12 Months) for Core and Interim Subgroup Male Rats	782
Table 104.	Incidence Summary of Microscopic Observations (Neoplastic) at Unscheduled Termination (12-18 Months) for Core and Interim Subgroup Male Rats	787
Table 105.	Incidence Summary of Microscopic Observations (Neoplastic) at Unscheduled Termination (18-24 Months) for Core Subgroup Male Rats	794
Table 106.	Incidence Summary of Microscopic Observations (Neoplastic) at the 13-Week Interim Termination for Female Rats	802
Table 107.	Incidence Summary of Microscopic Observations (Neoplastic) at the 26-Week Interim Termination for Female Rats	805
Table 108.	Incidence Summary of Microscopic Observations (Neoplastic) at the 39-Week Interim Termination for Female Rats	808
Table 109.	Incidence Summary of Microscopic Observations (Neoplastic) at the 52-Week Interim Termination for Female Rats	812
Table 110.	Incidence Summary of Microscopic Observations (Neoplastic) at the 78-Week Interim Termination for Female Rats	816
Table 111.	Incidence Summary of Microscopic Observations (Neoplastic) at the 105-Week Termination for Female Rats	820
Table 112.	Incidence Summary of Microscopic Observations (Neoplastic) at the 78-Week Stop Study B Termination for Female Rats	826

801981

VOLUME II
CONTENTS (Continued)

		Page
Table 113.	Incidence Summary of Microscopic Observations (Neoplastic) at the 105-Week Stop Study A Termination for Female Rats	830
Table 114.	Incidence Summary of Microscopic Observations (Neoplastic) at Unscheduled Termination (0-12 Months) for Core, Interim, and Stop Study Subgroup Female Rats	835
Table 115.	Incidence Summary of Microscopic Observations (Neoplastic) at Unscheduled Termination (12-18 Months) for Core and Interim Subgroup Female Rats	839
Table 116.	Incidence Summary of Microscopic Observations (Neoplastic) at Unscheduled Termination (18-24 Months) for Core Subgroup Female Rats	844
Table 117.	Incidence Summary of Microscopic Observations (Neoplastic) at Unscheduled Termination (12-18 Months) for Stop Study Subgroup Female Rats	852
Table 118.	Incidence Summary of Microscopic Observations (Neoplastic) at Unscheduled Termination (18-24 Months) for Stop Study A Subgroup Female Rats	857
Table 119.	Dose-Response Tumor Analysis for Core Subgroup Male Rats	863
Table 120.	Dose-Response Tumor Analysis for Core Subgroup Female Rats	872
Table 121.	Dose-Response Tumor Analysis for Stop Study A Subgroup Female Rats	883
Table 122.	Statistical Comparison (p-values) of Tumor Occurrence Among Aroclor Test Substances for Core Subgroup Male Rats	894
Table 123.	Statistical Comparison (p-values) of Tumor Occurrence Among Aroclor Test Substances for Core Subgroup Female Rats	895
Table 124.	Statistical Comparison (p-values) of Tumor Occurrence Between Core Subgroup Male and Female Rats	896

801982

VOLUME II
CONTENTS (Continued)

Page

Table 125. Statistical Comparison (p-values) of Tumor Occurrence Among Aroclor Test Substances for Stop Study A Subgroup Female Rats 897

Table 126. Statistical Comparison (p-values) of Tumor Occurrence Between Core and Stop Study A Subgroup Female Rats 898

APPENDIX A

Protocol A-1
Amendments A-35
Deviations A-40
Summary of Statistical Methods A-46

APPENDIX B

Dose Analysis of Aroclor 1016 in Rodent Feed B-1
Dose Analysis of Aroclor 1242 in Rodent Feed B-21
Dose Analysis of Aroclor 1254 in Rodent Feed B-41
Dose Analysis of Aroclor 1260 in Rodent Feed B-61
Results of Analyses for Cross-Contamination B-81

801983

VOLUME III

APPENDIX C

		Page
Table C-1.	Individual Clinical Observations for Core and Interim Subgroup Male Rats	C-1
Table C-2.	Individual Clinical Observations for Core, Interim, and Stop Study Subgroup Female Rats	C-96
Table C-3.	Individual Body Weights (g) for Core and Interim Subgroup Male Rats	C-277
Table C-4.	Individual Body Weights (g) for Core, Interim, and Stop Study Subgroup Female Rats	C-434

VOLUME IV

APPENDIX C (Continued)

Table C-5.	Individual Body Weight Gains (g) for Core and Interim Subgroup Male Rats	C-662
Table C-6.	Individual Body Weight Gains (g) for Core, Interim, and Stop Study Subgroup Female Rats	C-810
Table C-7.	Individual Feed Consumption (g/day) for Core and Interim Subgroup Male Rats	C-1033
Table C-8.	Individual Feed Consumption (g/day) for Core, Interim, and Stop Study Subgroup Female Rats	C-1184

801984

VOLUME V

Page

Table C-9. Individual Total Feed and Test Substance Consumption for Core and Interim Subgroup Male Rats C-1410

Table C-10. Individual Total Feed and Test Substance Consumption for Core, Interim, and Stop Study Subgroup Female Rats C-1452

Table C-11. Individual Abnormal Ophthalmology Examinations for Core and Interim Subgroup Male Rats C-1529

Table C-12. Individual Abnormal Ophthalmology Examinations for Core and Interim Subgroup Female Rats C-1534

APPENDIX D

Key to Abbreviations for Clinical Pathology Parameters D-1

Table D-1. Individual Hematology Values for Core Subgroup Male Rats D-2

Table D-2. Individual Hematology Values for Core Subgroup Female Rats D-24

Table D-3. Individual White Cell Differential Counts for Core Subgroup Male Rats D-46

801985

VOLUME V (Continued)

APPENDIX D

		Page
Table D-4.	Individual White Cell Differential Counts for Core Subgroup Female Rats	D-68
Table D-5.	Individual Serum Chemistry Values for Core Subgroup Male Rats	D-90
Table D-6.	Individual Serum Chemistry Values for Core Subgroup Female Rats	D-112
Table D-7.	Individual Serum Enzyme Values for Core Subgroup Male Rats	D-134
Table D-8.	Individual Serum Enzyme Values for Core Subgroup Female Rats	D-156
Table D-9.	Individual Serum Electrolyte Values for Core Subgroup Male Rats	D-178
Table D-10.	Individual Serum Electrolyte Values for Core Subgroup Female Rats	D-201
Table D-11.	Individual Urine Chemistry Values for Core Subgroup Male Rats	D-224
Table D-12.	Individual Urine Chemistry Values for Core Subgroup Female Rats	D-246
Table D-13.	Individual Urine Microscopic Examination Values for Core Subgroup Male Rats	D-267
Table D-14.	Individual Urine Microscopic Examination Values for Core Subgroup Female Rats	D-289

APPENDIX E

Table E-1.	Individual Animal Disposition of Scheduled Termination Male Rats	E-1
Table E-2.	Individual Animal Disposition of Unscheduled Termination Male Rats	E-21
Table E-3.	Individual Animal Disposition of Scheduled Termination Female Rats	E-42

801986

VOLUME VI

APPENDIX E (Continued)

		Page
Table E-4.	Individual Animal Disposition of Unscheduled Termination Female Rats	E-78
Table E-5.	Individual Absolute Organ Weights, Organ-to-Body Weights, and Organ-to-Brain Weights for Male Rats	E-104
Table E-6.	Individual Absolute Organ Weights, Organ-to-Body Weights, and Organ-to-Brain Weights for Female Rats	E-334

VOLUME VII

Table E-7.	Individual Correlated Gross Necropsy Observations Versus Microscopic Diagnosis for Male Rats	E-661
Table E-8.	Individual Correlated Gross Necropsy Observations Versus Microscopic Diagnosis for Female Rats	E-971

VOLUME VIII

Table E-9.	Individual Microscopic Observations for Male Rats	E-1416

VOLUME IX

Table E-9.	Individual Microscopic Observations for Male Rats	E-1944

VOLUME X

Table E-10.	Individual Microscopic Observations for Female Rats	E-2425

801987

VOLUME XI

APPENDIX E (Continued)

Page

Table E-10. Individual Microscopic Observations for Female Rats E-3110

VOLUME XII

Table E-11. Individual Special Histological Comments on Tissues for Male Rats E-3783

Table E-12. Individual Special Histological Comments on Tissues for Female Rats E-3814

Table E-13. Symbols, Abbreviations, and Codes Used in the Microscopic Evaluation of Tissues for Male Rats E-3818

Table E-14. Symbols, Abbreviations, and Codes Used in the Microscopic Evaluation of Tissues for Female Rats E-3819

APPENDIX F

Characterization of PCB Composition, Tissue Accumulation, and Correlations with Tumorigenicity in Chronically Dosed Male and Female Sprague-Dawley Rats F-1

801988

1.0 EXECUTIVE SUMMARY

Study Design and Methods

The potential chronic toxicity and oncogenicity of four commercial polychlorinated biphenyl (PCB) test substances were evaluated in Sprague-Dawley rats that received test substance daily in the diet for up to two years. The intent of the study was to compare the dose response and sex differences within each test substance, to rank the response between the four test substances, and to determine if there was any reversibility of observed effects. A one year neurotoxicity evaluation was also conducted.

Male and female Sprague-Dawley rats 6 to 8 weeks of age were assigned to one of three treatment subgroups; Core, Interim, or Stop Study (females only). Each subgroup included each of the four test substances (Aroclor-1016, Aroclor-1242, Aroclor-1254, and Aroclor-1260) administered at two or three dietary concentrations to separate dose groups. Additional groups of male and female rats received control diet. Animal assignment was done within each subgroup and sex to provide homogeneous group mean body weights at the start of the study. Core subgroup animals were scheduled to receive control diet or diet containing one of the four test substances for at least 104 weeks. Interim subgroup rats were scheduled to receive a control diet or diet containing one of the four test substances until termination at one of a series of interim necropsies. Stop Study subgroup rats were scheduled to receive one of the four test substances for 52 weeks, and subsequently to receive control feed until termination after either 78 or 104 weeks. The following table summarizes the study design.

Test Substance	Dose Group (ppm)	Core Subgroup[a]		Interim Subgroup		Stop Study Subgroup Females	
		Male	Female	Male[b]	Female[c]	Subgroup A[d]	Subgroup B[e]
Control	0	100	100	18	30	--	--
Aroclor-1016	50	50	50	18	30	24	6
	100	50	50	18	30	24	6
	200	50	50	18	30	24	6
Aroclor-1242	50	50	50	18	30	24	6
	100	50	50	18	30	24	6
Aroclor-1254	25	50	50	18	30	24	6
	50	50	50	18	30	24	6
	100	50	50	18	30	24	6
Aroclor-1260	25	50	50	18	30	24	6
	50	50	50	18	30	24	6
	100	50	50	18	30	24	6

a. Scheduled termination after 104 weeks of treatment.
b. Scheduled termination after 26, 52, and 78 weeks of treatment (6/group/interval).
c. Scheduled termination after 13, 26, 39, 52, and 78 weeks of treatment (6/group/interval).
d. Scheduled termination after 104 weeks of treatment.
e. Scheduled termination after 78 weeks of treatment.

Stability and homogeneity of each of the Aroclor test substances in diet were confirmed. Dose concentration analyses were also done to confirm the nominal concentrations of test material in diet, with additional referee analyses conducted by an independent laboratory.

Animals were observed at least twice daily for morbidity and mortality. Clinical observations for evidence of toxicity were recorded at least weekly. Body weights were determined prior to study initiation, weekly thereafter, and at termination. Feed consumptions were determined weekly. Ophthalmology examinations were performed on all Core and Interim subgroup animals prior to treatment, on all high dose and control animals from the Core subgroup at 104 weeks, and prior to necropsy for all high dose and control animals from the Interim subgroup scheduled for necropsy at 13 (females only), 26, 39 (females only), 52 or 78 weeks. Hematology, serum chemistry, and urinalysis parameters were evaluated in 10 Core subgroup animals/sex/dose group at 26, 52, 78, and 104 weeks of treatment.

Scheduled termination was conducted after 104 weeks of treatment for Core subgroup animals; after 13 (females only), 26, 39 (females only), 52, or 78 weeks of treatment for

Interim subgroup animals; and after 78 or 104 weeks of treatment for Stop Study subgroup animals. Gross necropsies were conducted on all animals at scheduled terminations. Specified organ weights were collected and gross lesions found at necropsy recorded. Complete histopathological evaluations were performed on all control and high-dose animals from the Core and Stop Study A subgroups at scheduled termination, and from the 52- and 78-week Interim subgroup animals. Histopathological evaluations of the liver, brain, mammary gland, and all gross lesions were performed on all animals from the Stop Study B subgroup, on mid- and low-dose group animals from the Core and Stop Study A subgroups at scheduled termination, from the 26-, 52- and 78-week Interim subgroup animals, and on the 13- and 39-week Interim subgroup animals (females only). Thyroids were evaluated microscopically for the mid- and low-dose Core subgroup males, in addition to the evaluation of thyroids from the controls and high-dose Core subgroup males done as part of the complete histopathological evaluation described above. Necropsies and complete histopathological evaluations were also conducted for all animals found dead or euthanized in a moribund condition.

In addition to the routine histopathological evaluations of the ovaries and vagina, the stage of the estrous cycle at the time of termination was estimated for all control and high-dose Interim subgroup females at the 26-week, 52-week and 78-week necropsies. Vaginal cytologies were also performed on 15 rats/group from the Core subgroup just prior to 78 weeks for evaluation of the estrous cycle.

Summary Results

Results of dose concentration analyses were within (or very close to) acceptable limits and confirmed that diet preparation was acceptable. Referee analyses were consistent with these results.

Results of the one year neurotoxicity evaluation study component which have been reported separately (Final Neurotoxicity and Neuropathology Report on "An Assessment of the Chronic Toxicity and Oncogenicity of Aroclor-1016, Aroclor-1242, Aroclor-1254, and Aroclor-1260 Administered in Diet to Rats", March 15, 1995, Battelle Study No. SC920192) showed no Aroclor test substance-related effects on Functional Observational Battery, Motor Activity, or neuropathologic evaluations.

Interpretation of survival data was based on survival probability at final termination estimated by the Kaplan-Meier method. Survival for Aroclor-dosed Core/Interim subgroup males was generally comparable to that of the male controls. Although sporadic statistically significant decreased survival compared to control was observed in several dosed male groups, these decreases were not dose-related and were not considered treatment-related. Survival was greater for female than for male animals for most of the Aroclor test substance-treated groups. Survival was increased in a dose-related and generally statistically significant manner compared to control in the Core/Interim female subgroups for Aroclor-1016, Aroclor-1242, and Aroclor-1260. Survival for the Aroclor-1254 Core/Interim female subgroup was statistically significantly increased at 25 ppm only, but was comparable to controls in the other two dose groups. Significant differences were detected in comparisons of survival of Aroclor-1254 dosed females with each of the other Aroclor test substances, which had generally higher survival. The survival advantage over control was generally maintained after dosing was discontinued among the Stop Study subgroup females, which showed dose-related or significantly increased survival compared to the Core/Interim control females for Aroclor-1242, Aroclor-1254, and Aroclor-1260.

No treatment-related clinical signs were observed during the study in either male or female animals. Incidental findings were consistent with those observed in the control groups and did not suggest any Aroclor test substance-induced toxicity.

No treatment-related effects on group mean body weights were seen in Core/Interim subgroup males dosed with Aroclor-1016, Aroclor-1242, or Aroclor-1260. Dose-related and statistically significant decreases in body weight occurred for Aroclor-1254 males in the 50 and 100 ppm dose group. There was no treatment-related effect on body weight for Core/Interim subgroup females dosed with Aroclor-1016. In general, however, females showed more marked body weight effects than did males. Statistically significant decreases in group mean body weights occurred in Core/Interim subgroup females at the 100 ppm dose level of Aroclor-1242, all dose levels of Aroclor-1254, and at the 100 ppm dose level of Aroclor-1260. The most marked effects on body weight occurred for the Aroclor-1254 100-ppm dose group females, with mean body weight in that group 21 percent lower than control at one year, and 28 percent lower than control at two years. For both sexes, animals dosed with Aroclor-1254 consistently had lower body weights than animals dosed with any of the other Aroclor test substances. Aroclor-1242, Aroclor-1254 and Aroclor-1260 Stop Study

female group mean body weights showed a gradual return to values comparable to the Core female control group mean body weights after treatment cessation.

There was no apparent diminished palatability with any of the Aroclor-dosed diets when compared to the control. Sporadic differences from controls in feed consumption were noted for both males and females, particularly in the Aroclor-1254 dose groups; however, feed consumption was generally similar to control in all treated groups. The total Aroclor exposure (mg/kg) increased in proportion to ppm in the diet. Exposure to test substance on a mg/kg/day basis was slightly greater for females than for males.

No treatment-related findings were noted during ophthalmic evaluations. Abnormal findings noted appeared to be congenital, or typical manifestations of age, and lacked relationship to treatment.

Evaluation of group mean hematology data from a subset of Core animals showed no treatment-related effects in males receiving Aroclor-1016, Aroclor-1242, or Aroclor-1260. Red blood cell parameters including hemoglobin (HGB), hematocrit (HCT) and mean corpuscular hemoglobin (MCH) were decreased for Aroclor-1254 males in the 50 and 100 ppm dose groups, with the decreases most evident at 105 weeks. In females, animals receiving Aroclor-1016 showed generally statistically significant decreases in red blood cell parameters including erythrocytes (RBC), HGB, HCT, mean corpuscular volume (MCV), and MCH at all doses tested by the 105-week interval. Similar findings were noted at 105 weeks for Aroclor-1242 dosed females in the 100 ppm dose group, and for females receiving Aroclor-1260 in the 25, 50 and 100 ppm dose groups. Females receiving Aroclor-1254 showed an earlier onset of this effect, with generally statistically significant differences from controls present in two or more red blood cell parameters by 26 weeks in the 50 and 100 ppm dose groups, with the findings extending to the 25 ppm dose group by week 105. At 105 weeks, mean RBC, HGB, and HCT in Aroclor-1254 at the 25, 50 and 100 ppm dose groups were decreased in females compared to control, with the decreases ranging from 8-19 percent (RBC), 18-29 percent (HGB) and 19-29 percent (HCT), respectively. The decreases in red blood cell parameters in females were most marked for Aroclor-1254, followed by Aroclor-1260 $\approx$ Aroclor-1242 $>$ Aroclor-1016. Effects on red blood cell parameters were more severe in females than in males for all of the Aroclor-dosed groups. Although other hematologic parameters showed sporadic statistically significant differences from control, no dose- or treatment-relationships were evident.

Evaluation of group mean serum chemistry data from a subset of Core animals showed changes in parameters generally associated with altered liver function. Increased cholesterol relative to controls was seen in most Aroclor test substance-dosed male groups, but appeared treatment-related only for Aroclor-1254 males). Increases in mean cholesterol concentrations relative to controls were also seen in males dosed with Aroclor-1016 and Aroclor-1260, however, these increases were not consistently dose- or time-related and were considered of equivocal relationship to treatment. A slight and sporadic increase in aspartate aminotransferase (AST) was noted for males receiving Aroclor-1254, but this change was not dose- or time-related and is considered of equivocal relationship to treatment. Effects on serum chemistry parameters were more marked in females than in males for most Aroclor test substance-dosed groups. Increased cholesterol was present in females exposed to Aroclor-1242, Aroclor-1254, and Aroclor-1260, which was both more marked than seen in the males and more consistent in dose and/or time relationship. Mean cholesterol in Aroclor-1254 dosed females at study termination was increased two- to three-fold over control. Females receiving Aroclor-1254, and to a lesser extent Aroclor-1242 or Aroclor-1260, showed time- and dose-related increases in serum gamma-glutamyltransferase (GGT). Females receiving Aroclor-1242 or Aroclor-1254, and to a lesser extent Aroclor-1260, showed dose- and time-related increases in AST. Females dosed with Aroclor-1254 also showed dose-related increases in alanine aminotransferase (ALT) and equivocal increases in total bilirubin. The effects on hepatic-related serum chemistry parameters in females were most marked for Aroclor-1254, followed by Aroclor-1260 $\approx$ Aroclor-1242 $>$ Aroclor-1016. Although other serum chemistry parameters showed statistically significant differences from controls, these findings were not dose-related and were not considered treatment-related. There were also no treatment-related effects on urinalysis parameters.

Evaluation of group mean organ weight data (normalized as organ-to-brain weight ratios) in Core/Interim subgroup males showed increased organ-to-brain weight ratios primarily for liver and thyroid for all Aroclor test substances; these findings were generally minimal and not clearly dose- or time-related. The magnitude of the effect on organ-to-brain weight ratios in males for both liver and thyroid was: Aroclor-1254 $>$ Aroclor-1260 $>$ Aroclor-1242 $\approx$ Aroclor-1016. The effects in Core/Interim subgroup females on the liver-to-brain weight ratios were marginally greater than those seen in the males, and in contrast to the males, the liver-to-brain weight ratios for the females were generally increased in a dose-

and time-related manner relative to control. The mean liver-to-brain weight ratio in the Aroclor-1254 100-ppm dose group females was increased more than two-fold over control. The magnitude of the effect on liver-to-brain weight ratios in females was: Aroclor-1254 > Aroclor-1260 > Aroclor-1242 > Aroclor-1016. Stop Study subgroup females also showed increased mean liver-to-brain weight ratios compared to the respective Core control females; the pattern was generally similar to that seen in the treated Core females. No effects were noted on female thyroid-to-brain weight ratios.

At necropsy, the livers from both male and female Core/Interim subgroup Aroclor test substance-dosed animals showed the preponderance of treatment-related gross lesions; characterized as enlargement, discoloration, foci, and nodules and masses. These gross lesions generally correlated histomorphologically with hepatocellular hypertrophy, accumulation of pigment, areas of altered tinctorial properties, and neoplasms, respectively. The incidence of grossly observed liver nodules and/or masses was increased in females, and was most increased in females dosed with Aroclor-1254, followed by Aroclor-1260 > Aroclor-1242 ≈ Aroclor-1016. Stop Study subgroup females generally showed an increased incidence of liver masses compared to the respective Core Controls, but showed a decreased incidence compared to the respective treated Core groups. Males dosed with Aroclor-1242, Aroclor-1254 and Aroclor-1260 showed a non-dose-related increased incidence of enlarged thyroids. For Core subgroup females, the incidence of grossly observed mammary masses was decreased compared to control for Aroclor-1242, Aroclor-1254 (high-dose) and, to a lesser extent, Aroclor-1260.

Consistent with the indications of target organ toxicity noted above, the liver was the primary target tissue identified at histopathological evaluation of Core/Interim subgroup and Stop Study animals. The major treatment-related histomorphologic findings in male rats for the liver were hepatocellular hypertrophy and hepatic foci. The incidence of hepatocellular hypertrophy approached near maximal response by 52 weeks, while the severity generally continued to progress in a dose- and time-related manner. The incidences of hepatic foci increased slightly with time after 52 weeks for all Aroclor test substances and control, and with the exception of Aroclor-1016, were slightly increased compared to the control incidence at 105 weeks. The incidences of hepatocyte vacuolization and bile duct hyperplasia were also increased in male groups dosed with Aroclor-1254 and Aroclor-1260. The incidences of hepatic neoplasms in male groups receiving any of the four Aroclor test substances were not

statistically significantly different from the control incidence, with the exception of a slight but statistically significant increase in incidence for the Aroclor-1260 100-ppm dose group.

Other potentially treatment-related microscopic findings in males included non-dose-related increased incidences of thyroid follicular cell hyperplasia for male groups dosed with Aroclor-1254 and Aroclor-1260 and non-dose-related increased incidences of thyroid follicular cell adenomas for male groups receiving Aroclor-1242, Aroclor-1254 and Aroclor-1260, but not for males exposed to Aroclor-1016.

The liver was also the primary target tissue for Aroclor test substance-dosed females, which showed relatively more severe effects than did the males. The major treatment-related histomorphologic findings in female rats for the liver were hepatocellular hypertrophy, hepatic foci and neoplasms (primarily benign hepatocellular adenomas). Hepatocellular hypertrophy generally progressed in females in a dose- and time-related manner for each Aroclor test substance. The incidence of hepatocellular hypertrophy approached maximal response by 26 weeks, while the severity generally continued to increase thereafter, generally reaching maximal response by 78 weeks. Hepatic foci increased in incidence, for all Aroclor test substances, with time, but lacked a clear dose response, and no differences between Aroclor test substances were evident. The incidences of hepatocyte vacuolization and bile duct hyperplasia were increased for all Aroclor test substance-dosed female groups. Females receiving Aroclor-1242 and Aroclor-1254 also showed an increased incidence of liver pigment. Hepatic neoplastic responses (primarily hepatocellular adenomas) occurred for females for all Aroclor test substances at each exposure concentration, except for Aroclor-1016 in the 50 ppm dose group. The neoplastic response differences between Aroclor test substances followed the progression: Aroclor-1254 >> Aroclor-1260 > Aroclor-1242 >> Aroclor-1016.

There was no indication of increased non-neoplastic or neoplastic findings for the thyroid for females in any Aroclor test substance-dosed group. The incidence of spontaneous mammary neoplasms was statistically significantly decreased for several Aroclor test substance-dosed Core groups when compared to control, and this decrease was evident to a greater or lesser extent for each Aroclor test substance. Evaluation of the female reproductive tract (including staging of the estrous cycle as previously described) showed no treatment-related findings for any of the Aroclor test substances.

Discontinuing exposure to the Aroclor test substances (as assessed in the Stop Study subgroup) resulted in a decrease (or lack of progression) in hepatotoxicity compared to that seen with continued exposure. A decrease (or lack of progression) in the severity and/or incidence of hepatocellular hypertrophy, vacuolization and bile duct hyperplasia was evident, particularly for Aroclor-1016 and Aroclor-1242. A statistically significant decrease in the incidence of hepatic neoplasms compared to the respective continued exposure Core/Interim subgroup was seen for Aroclor-1016 and Aroclor-1254, and the incidence of hepatic neoplasms in the Stop Study A Aroclor-1016 dosed females was lower than that of the Core control group females. The Stop Study A females did not show a decreased incidence of mammary gland neoplasms, as was previously described for the continuous exposure (Core) groups.

In conclusion, survival was not adversely affected by exposure to the Aroclor test substances; rather, survival in males was generally comparable to that of the controls, and in females, a survival advantage was evident for females exposed to Aroclor-1016, Aroclor-1242, and Aroclor-1260. This survival advantage generally persisted following cessation of exposure in Stop Study females. Treatment-related toxicity was identified for all of the Aroclor test substances evaluated, although no clinical signs of toxicity were evident. Treatment-related toxicity was generally more severe for females exposed to the Aroclor test substances. Decreased body weights were seen only in males receiving Aroclor-1254, and in females receiving all Aroclor test substances, except Aroclor-1016. Decreases in red blood cell parameters were noted for males receiving Aroclor-1254 and for all Aroclor test substance-exposed female groups. The liver was the primary target organ. Chronic exposure to each Aroclor test substance caused hepatotoxicity evidenced by changes in serum chemistry parameters, increases in liver-to-brain weight ratios and an increased incidence and severity of hepatic non-neoplastic lesions for both males and females. The hepatotoxicity predominantly followed the pattern: Aroclor-1254 > Aroclor-1260 > Aroclor-1242 > Aroclor-1016.

Treatment-related hepatic neoplasms were primarily benign and were not associated with increased mortality. In males, the only statistically significant increases in hepatic neoplasms were found for Aroclor-1260 in the 100-ppm dose group males. In females, statistically significant increases in hepatic neoplasms were seen for all Aroclor test substance-dosed groups except for Aroclor-1016 in the 50-ppm dose group. The incidence of these findings in females paralleled the pattern of hepatotoxicity described above.

Discontinuing exposure to the Aroclor test substances (as assessed in the female Stop Study subgroup) resulted in a decrease (or lack of progression) in toxic responses when compared with continued exposure groups. This is evidenced by the recovery of group mean body weights to values comparable to control, a decrease (or lack of progression) in the severity of some non-neoplastic liver lesions, and for Aroclor-1016 and Aroclor-1254, a statistically significant decrease in the incidence of hepatic neoplasms compared to groups with continuing exposure to these Aroclor test substances. Although the survival advantage in treated Core group females, was generally still apparent for the Stop Study subgroup animals, no protective inhibition of spontaneous mammary gland neoplasms (as had been seen in some Core subgroup Aroclor test substance-exposed females) was evident.

2.0 INTRODUCTION

U.S. production of polychlorinated biphenyls (PCBs) peaked in 1970 when 85 million pounds were produced (as reviewed in ATSDR, 1993). Production of PCBs in the United States was halted in October, 1977, due to the potential for bioaccumulation and persistence of PCBs in the environment. Although PCBs are no longer produced in the United States, many of the transformers and capacitors which were produced containing PCBs are still operational. This equipment is of concern since it represents a potential source for continued exposure to PCBs in the environment and humans (ATSDR, 1993).

Evaluation of the toxicity of PCBs is complicated by the fact that PCBs were produced and sold as mixtures of different congeners (209 possible) (Erickson, 1985). The primary concern for effects from PCBs in humans is intermediate/chronic oral exposure (i.e., through food). Once ingested, PCBs distribute initially to the liver and muscle followed by redistribution to fat, skin, and fat-containing organs (ATSDR, 1993). The several test substances used in the current study differed in the average chlorination present in the mixture, with approximately 42 percent chlorine by weight in Aroclor-1016 and Aroclor-1242, 54 percent in Aroclor-1254 and 60 percent in Aroclor-1260 (SANSS, 1990 and Hutzinger *et al.*, 1974).

The major target organ for PCBs is the liver. Hepatic effects which may include enzyme induction, liver enlargement, fat deposition, and necrosis, appear to be reversible at low doses. In addition, PCBs can produce stomach and thyroid alterations, immuno-suppressive effects, and porphyria in animals (ATSDR, 1993).

The objective of this study was to assess and compare in rats the potential chronic toxicity and oncogenicity of four commercial polychlorinated biphenyl (PCB) test substances administered daily in the diet for up to two years. General Electric Company was the Sponsor of the study. Dr. Brian A. Mayes was designated as the Sponsor's Project Monitor and approved the study protocol. Barbara H. Neal of Jellinek, Schwartz and Connolly, Inc. assisted Dr. Mayes in monitoring the study. The study was conducted at Battelle in compliance with the Environmental Protection Agency's Good Laboratory Practice Standards (40 CFR Part 792) and the study was listed on Battelle's Master Study Schedule. The study protocol, amendments to the protocol, and protocol deviations are contained in Appendix A. An associated neurotoxicity study was reported separately (Battelle Report Number

SC920192, issued March, 1995). Some references to the neurotoxicity study are made in Appendix A.

The study was conducted at Battelle under the direction of Dr. Arthur C. Peters, Study Director. The in-life portion of the chronic toxicity and oncogenicity study began on February 8, 1993 (Day 1) for the males and on February 16, 1993 (Day 1) for the females, and ended on February 10, 1995 for the males and on February 22, 1995 for the females.

3.0 EXPERIMENTAL DESIGN

There were 866 male and 1340 female Sprague-Dawley rats (Charles River Laboratories, Portage, Michigan) used for this two-year chronic toxicity and oncogenicity study. The three treatment subgroups defined for the four test substances were designated as Core, Interim, and Stop Study. The Stop Study subgroup was further subdivided into Stop Study A and Stop Study B subgroups. Each test substance was administered in the diet at two or three dietary concentrations to separate dose groups. An additional group of rats received control feed.

The Core subgroup for each test substance was composed of 50 rats/sex/dose group and the Interim subgroup was composed of 18 male and 30 female rats/group. The control dose group was composed of 100 Core and 18 Interim subgroup males and 100 Core and 30 Interim subgroup females. The Stop Study subgroups (A and B) were composed entirely of female rats which represented the 11 Aroclor-treated dose groups. Twenty-four rats/group and 6 rats/group made up the Stop Study A and Stop Study B subgroups, respectively. There were no control dose group animals designated to the Stop Study subgroup. Comparisons for the Stop Study subgroup were made relative to the Core and Interim subgroup control females.

The initiation of treatment was staggered by sex, with female animals starting dose exposure 8 days after the male animals. Core and Interim subgroup rats were scheduled to receive test substance or control feed, as appropriate, for at least 104 weeks. Stop Study subgroup animals were scheduled to receive test substance for 52 weeks after which time they were to receive control feed until Week 78 (Stop Study B termination), or at least Week 104 (Stop Study A termination).

Core subgroup rats were scheduled for termination after completion of 104 weeks of dose administration. Six Interim subgroup rats/sex/group were scheduled for termination after 13 (female only), 26, 39 (female only), 52, and 78 weeks of dose administration. The following table summarizes the study design.

Test Substance	Dose Group (ppm)	Core[a] Subgroup		Interim Subgroup		Stop Study Subgroup Females	
		Male	Female	Male[b]	Female[c]	Subgroup A[d]	Subgroup B[e]
Control	0	100	100	18	30	--	--
Aroclor-1016	50	50	50	18	30	24	6
	100	50	50	18	30	24	6
	200	50	50	18	30	24	6
Aroclor-1242	50	50	50	18	30	24	6
	100	50	50	18	30	24	6
Aroclor-1254	25	50	50	18	30	24	6
	50	50	50	18	30	24	6
	100	50	50	18	30	24	6
Aroclor-1260	25	50	50	18	30	24	6
	50	50	50	18	30	24	6
	100	50	50	18	30	24	6

a. Scheduled necropsy after 104 weeks of treatment.
b. Scheduled necropsy after 26, 52, and 78 weeks of treatment (6/group/interval).
c. Scheduled necropsy after 13, 26, 39, 52, and 78 weeks of treatment (6/group/interval).
d. Scheduled necropsy after 104 weeks of treatment.
e. Scheduled necropsy after 78 weeks of treatment.

Measures of toxicity recorded included animal survival, clinical observations (weekly), body weights (weekly and at termination), feed consumption (weekly), ophthalmic examinations (prestudy, and at interim and final necropsies), and hematology, serum chemistry and urinalysis (every 26 weeks). Postmortem studies included gross necropsy, selected organ weights and histopathologic evaluation of selected tissues.

4.0 MATERIALS AND METHODS

4.1 Test and Control Substances

The test substances used in this study were supplied by AccuStandard, Inc. (New Haven, Connecticut).

Test Substances Lot Numbers

Test Substance	Lot Number
Aroclor-1016	129
Aroclor-1242	01141
Aroclor-1254	122-078
Aroclor-1260	021-020

Aroclor is a registered trademark of Monsanto Company. The test substances were received at Battelle on December 14, 1992 and were given the following Battelle-Assigned Substance Numbers (ASNs):

Assigned Substance Numbers

Test Substance	Substance Number
Aroclor-1016	1340
Aroclor-1242	1341
Aroclor-1254	1343
Aroclor-1260	1342

An additional shipment (from the same lots) of Aroclor-1016, Aroclor-1254, and Aroclor-1260 was received at Battelle on March 30, 1994. The bulk test substances were stored at room temperature in sealed containers as required by the Sponsor. Archival samples were taken from each test substance and were stored at $\leq$ -20°C and will be maintained at a storage facility designated by the Sponsor.

4.2 Dose Preparation

Dose Formulation. All doses were formulated for oral administration in Purina Certified Rodent Diet® No. 5002 according to the schedule in Table 1. Dosed feed blends were prepared in the following manner. To facilitate mixing, the required amount of test substance was weighed into a glass container and dissolved in hexane. The solution was then transferred to a volumetric flask, diluted to volume with hexane, and mixed. Blank feed was weighed into a stainless steel mixing bowl with four hundred mL of the test substance/hexane solution to prepare a premix. The mixture was stirred with a mechanical mixer to evenly coat the feed with the chemical and the hexane was allowed to evaporate. Nitrogen was used periodically to aid in the evaporation of the hexane. The initial 400 g of feed coated with the test substance were transferred into a stainless steel bucket to make a premix. Approximately 3600 g of blank feed were then weighed and approximately 400 g added to the coated mixture in the bucket and the contents stirred thoroughly with a spatula. The stainless steel bowl that contained the initial coated feed was rinsed with blank feed and poured into the bucket. The remainder of the blank feed was added incrementally with stirring after each addition until all the blank feed was used.

An additional amount of blank feed was weighed and about half of it was added to a Patterson-Kelley 10 ft.^{3} Cross Flow Blender. The premix was added with nearly equal amounts spread across both loading ports of the blender. The premix container was rinsed with additional blank feed that was added to the blender. The remaining additional feed was added to the blender with distribution nearly equal between the two shells. The dosed feed was then blended for about fifteen minutes before dispensing.

Control feed was prepared in a similar procedure without adding test substance. Hexane was mixed with blank feed premix which was blended with additional blank feed, as described above, to make the control feed.

As animal attrition occurred, batch volumes were decreased to minimize waste. The formulation procedure stated above remained constant throughout the study. Formulated volumes were decreased by changing the amount of additional feed added to each 4-kg premix.

Blender Decontamination. After each set of Aroclor batches was prepared, the Patterson-Kelley blender was cleaned. The interior and exterior of the blender were vacuumed with a HEPA vacuum cleaner and then rinsed with water. The interior of the blender was then sprayed with 1,1,1-trichloroethane and swabbed with a mop dampened with the solvent. The interior of the blender was sprayed again with solvent and allowed to air dry. The exterior of the blender was wiped with a paper tower or sponge dampened with the solvent and allowed to air dry.

Sampling. Analysis and archival samples were taken from every batch prepared. Homogeneity samples were taken on a quarterly basis by removing samples from the top left, top right, and bottom of the blender. Animal room samples and cross-contamination samples were taken every six months. The cross-contamination samples were taken from a feed mixture prepared by filling the blender with 110 kg of blank feed after the blender had been cleaned and mixing the blank feed for about fifteen minutes. Samples were taken from the blender and the remaining feed was discarded.

4.3 Dose Analyses, Homogeneity, and Stability

Dose analysis method performance evaluations (MPEs) and dose stability studies were conducted for each Aroclor. Results of these tests along with the dose analysis methods are provided for each Aroclor in Appendix B.

For the MPEs, vehicle, matrix, and solvent standard curves of the specific Aroclors were evaluated by Gas Chromatography (GC) with Electron Capture Detection (ECD) to determine precision, accuracy, sensitivity, and recovery of the analytical method. Two separate stock standards were prepared by dissolving the appropriate amount of the specific Aroclor in hexane:acetone (1:1). The final concentrations of all solvent, vehicle, and matrix standards were identical. Working solvent standards were prepared at four different concentrations by diluting the stocks to the desired concentration. Matrix standard curves were prepared by diluting the stock solutions with blank feed extract to a concentration equal to the solvent standards. Vehicle standard curves were generated by spiking feed with the appropriate amount of the stock standard, drying the sample, and extracting with the hexane:acetone solvent. The low and high standards were prepared in triplicate for the

vehicle standard curve. A four-point standard curve was prepared for each sample type using the chromatographic response ratios of single injections of each standard.

For homogeneity analysis, although samples were taken (as described above) from every concentration on the quarterly schedule, one randomly selected dose concentration for each Aroclor test substance was analyzed each quarter.

For the dose stability studies, a 5-kg batch of a 25 ppm formulation was prepared and analyzed. Samples of approximately 20 g were removed and sealed in amber glass bottles for use in the stability study (see Appendix B for specific days that samples were removed for analysis). Three samples were removed from each storage temperature on the designated study days. The stability study was conducted for a 42-day period at three temperatures, -20°C, 5°C and ambient (approximately 25°C). A 5-g portion was removed from each sample, extracted and analyzed using the methods described in Appendix B. A four-point standard curve, which ranged in final concentration from approximately 2.0 to 3.7 μg/mL (depending upon the specific Aroclor), was prepared on each analysis day. The concentrations of the samples were calculated using the standard curve, the chromatographic response ratio of the samples, and their dilutions and weights.

Selected samples of prepared diet from each of the four Aroclor test substances were collected at approximately 5 week intervals and submitted to Northeast Analytical Laboratories for referee analyses.

4.4 Experimental Animals

A total of 2206 Sprague-Dawley rats (866 male and 1340 female) were required for this study. Animals were obtained from Charles River Laboratories (Portage, Michigan). Animals were 6 to 7 weeks (males) and 7 to 8 weeks (females) of age at the initiation of treatment. The Sprague-Dawley rat was chosen as the test system because this strain has been used in previous PCB safety evaluation studies and rats are a species of choice for chronic toxicity and carcinogenicity studies. A large data base is available for this strain. Housing and care conformed to the *Guide for the Care and Use of Laboratory Animals*, NIH Publication No. 86-23. The study was approved by the Battelle Institutional Animal Care and Use Committee before implementation.

4.4.1 Animal Receipt, Quarantine, and Group Assignment

Male and female rats were received at Battelle on January 26, 1993, 13 days (males) and 21 days (females) prior to the initiation of dosing. During the quarantine period, all males were individually housed in Rooms 7C-068, -070, -074, -076 and -081. Females were housed in pairs in Rooms 7C-014, -043, -044, -045, -046 and -301 and moved to individual cages at randomization five days before initiation of dose exposure. The animals were acclimated to the environmental conditions that were used for the study and were observed twice daily for signs of disease or abnormality that would make any animal unfit for study. Animals were released for the study by written authorization of the staff veterinarian.

Prior to group assignment, the male and female rats were designated into separate pools for assignment to one of the three subgroups (Core, Interim, or Stop Study [females only]). Each pool was created proportionally to the subgroups it represented.

Animals within each subgroup were assigned to study groups on Day -5 (five days prior to initiation of dosing) by sex and body weight using a computer software program (Xybion Medical Systems, Version 4.1.7) that employed an algorithm for assignment of animals to treatment groups based on body weight. This program provided for homogenous group mean body weights (i.e., no statistically significant differences among groups by ANOVA, $p > 0.05$). A cross-reference file of pre-study and study identification animal numbers was maintained in the computer database and study files. On Day -5, male group body weight means ranged from 212 to 213 grams and female group body weight means ranged from 194 to 196 grams.

After group assignment, the males were reassigned to their respective test substance rooms of 7C-068 (Aroclor-1016), 7C-070 (Aroclor-1242), 7C-074 (Aroclor-1254), 7C-076 (Aroclor-1260) and 7C-081 (Control). Females were introduced into the appropriate test substance rooms the morning of first dose administration and designation to their respective dose groups. Animals not assigned to specific dose groups were removed from study.

After 52 weeks of dose administration, Stop Study subgroup animals were given control feed instead of test article for a recovery period which extended until termination. These Stop Study animals were removed from their respective rooms and reassigned to Room 7C-080 at the time of change to control feed.

Serum was collected during quarantine from 5 excess rats/sex for evaluation of selected antibody titers during quarantine. Samples of serum were analyzed by Microbiological Associates, Inc. (Rockville, Maryland) for determination of Sendai (Send), Pneumonia Virus of Mice (PVM), Rat Coronavirus/Sialodacryoadentis (RCV/SDA), Kilham Rat Virus (KRV), Toolan's H-1 Virus (H-1), and *Mycoplasma pulmonis* (MPUL). There were no significant titers to the infectious agents evaluated.

4.4.2 Animal Identification

Animals were identified by a temporary number on each cage card during quarantine. After group assignment, animals were assigned a unique study identification number and permanently identified by tail tattoo. A color-coded card displaying the study, animal, and group number was affixed to each cage. Animal identification numbers are shown in the following table:

Study Identification Numbers

Test Substance	Conc. (ppm)	Core Subgroup		Interim Subgroup		Stop Study Subgroup Females	
		Male	Female	Male	Female	Subgroup A	Subgroup B
Control	0	1-100	3001-3100	101-118	3101-3130	--	--
Aroclor-1016	50	201-250	3201-3250	251-268	3251-3280	3281-3304	3305-3310
	100	401-450	3401-3450	451-468	3451-3480	3481-3504	3505-3510
	200	601-650	3601-3650	651-668	3651-3680	3681-3704	3705-3710
Aroclor-1242	50	801-850	3801-3850	851-868	3851-3880	3881-3904	3905-3910
	100	1001-1050	4001-4050	1051-1068	4051-4080	4081-4104	4105-4110
Aroclor-1254	25	1201-1250	4201-4250	1251-1268	4251-4280	4281-4304	4305-4310
	50	1401-1450	4401-4450	1451-1468	4451-4480	4481-4504	4505-4510
	100	1601-1650	4601-4650	1651-1668	4651-4680	4681-4704	4705-4710
Aroclor-1260	25	1801-1850	4801-4850	1851-1868	4851-4880	4881-4904	4905-4910
	50	2001-2050	5001-5050	2051-2068	5051-5080	5081-5104	5105-5110
	100	2201-2250	5201-5250	2251-2268	5251-5280	5281-5304	5305-5310

4.4.3 Animal Housing and Environmental Conditions

Animals were individually housed during treatment in suspended stainless steel wire-mesh cages on multi-tiered racks. Animals were assigned to separate rooms for each test substance or control, and all animals were allowed *ad libitum* access to Purina Certified Rodent Diet® No. 5002 (Purina Mills, Inc., Richmond, Indiana) in meal form. Contaminant analysis of each feed lot was supplied by the vendor and contained no more than 0.15 ppm polychlorinated biphenyls. The manufacturer's certificates of analysis were placed in the study file. Water from the Columbus municipal system was used without further treatment and supplied *ad libitum* via an automatic watering system. The water source, which conforms with EPA water standards, was sampled from a central or sipper tube location, analyzed prior to treatment initiation and then on a semiannual basis for microbes and other contaminants, including polychlorinated biphenyls. There were no reported or known feed or water contaminants that would have interfered with the purpose or conduct of the study.

The environmental conditions of the animal study room conformed to the following: (1) the light/dark cycle was held at 12 hours of light and dark each day during the study using fluorescent lighting, starting at 6:00 a.m. each day; (2) the room temperature and relative humidity controls were set to 66 to 78°F and 40 to 70 percent, respectively; and (3) fresh air was supplied to the rooms at a rate providing a minimum of ten changes of room air per hour.

4.5 Clinical Observations

Animals were observed twice daily during the quarantine and treatment periods for mortality/moribundity (once in the morning and once in the afternoon, at least 6 hours apart 7 days/week). Animals whose condition made it unlikely that they would survive until the next observation period (as determined by the study director, toxicologist, coordinator, and/or clinical veterinarian) were killed, necropsied, and protocol-specified tissues were collected. Additionally, all animals except those in Stop Study B subgroup were closely examined on a weekly basis for clinical signs of abnormality. Stop Study B subgroup females were examined weekly for the first 13 weeks, and then every fourth week until termination.

Palpation for tissue masses was performed as a part of each scheduled weekly clinical observation. The general location and approximate size of tissue masses were recorded.

4.6 Body Weight

Individual body weights were recorded on Day -5, Day 1, and at weekly intervals thereafter until termination.

4.7 Feed/Test Substance Consumption

Feed consumption (g/day) was estimated weekly throughout the treatment period for each animal until termination. Feed consumption was measured quantitatively by offering a weighed filled feed cup at the beginning of each measurement interval which was reweighed after 7 days. The difference in weight divided by the interval (days) was taken as a measurement of feed consumed per day. In rare instances, the interval for feed consumption was less or greater than 7 days due to a change in schedule. Spilled feeders were noted in the Xybion database and the data excluded from calculated means and statistical comparisons. Spilled feeders occurred for less than 1 percent of the samples during the length of the study and had no impact on feed consumption results.

Feed consumption normalized to body weight (g/kg/day) was calculated as a group mean value weekly by dividing the group mean feed consumption by the group mean body weight. A summation of the normalized values was performed to determine the total feed consumption (g/kg). Test substance consumption (mg/animal) was calculated by summing the total feed consumed for each animal and multiplying by the target concentration of the test substance in the feed. Test substance consumption (mg/kg) was calculated on a weekly basis by dividing the test substance consumption by the group mean body weight. A summation of the weeks was performed to calculate the total test substance consumption (mg/kg).

4.8 Ophthalmic Examinations

Ophthalmic examinations were performed on all Core and Interim subgroup animals during the quarantine period. Core subgroup animals from the high dose groups (Aroclor-

1016, 200 ppm; Aroclor-1242, 100 ppm; Aroclor-1254, 100 ppm; and Aroclor-1260, 100 ppm) and control group were examined after 104 weeks of treatment. Interim subgroup animals from the high dose groups and control group were examined during the week prior to scheduled necropsy after 13 (female), 26, 39 (female), 52 and 78 weeks. Tropicamide hydrochloride (Mydriacyl® 1%) was used as a mydriatic.

4.9 Clinical Pathology

The first 10 animals/sex/group from the Core subgroup were designated at the start of study for clinical pathology evaluations. In the event of an unscheduled death, the next available animal numerically was substituted. Blood samples for clinical pathology evaluations were obtained from the retro-orbital sinus of fasted animals. Prior to blood collection, animals were anesthetized by utilizing a mixture of carbon dioxide/oxygen. Hematology, serum chemistry, and urinalysis evaluations were performed after 26, 52, 78, and 104 weeks of treatment.

Blood was collected into collection tubes containing EDTA as an anticoagulant for hematology samples. The collection tubes for serum chemistry did not contain an anticoagulant, and serum was separated by centrifugation after clotting.

4.9.1 Hematology

Hematology parameters measured or calculated were as follows:

Hematocrit (HCT), %	Mean Corpuscular Hemoglobin (MCH), pg
Erythrocyte Count (RBC), $10^6/\mu L$	Mean Corpuscular Volume (MCV), fL
Total White Cell Count (WBC), $10^3/\mu L$	Mean Corpuscular Hemoglobin Concentration (MCHC), g/dL
Differential White Cell Count, %	Hemoglobin (HGB), g/dL
Platelet Count (PLAT), $10^3/\mu L$	Reticulocyte Count (RET), %

4.9.2 Serum Chemistry

Serum chemistry parameters measured or calculated were as follows:

Lactate Dehydrogenase (LDH), IU/L	Calcium (Ca), mg/dL
Creatine Kinase (CK), IU/L	Phosphorus (PHOS), mg/dL
Total Protein (TP), g/dL	Total Bilirubin (TBIL), mg/dL
Albumin (ALB), g/dL	Alkaline Phosphatase (ALP), IU/L
Blood Urea Nitrogen (BUN), mg/dL	Alanine Aminotransferase (ALT), IU/L
Creatinine (CREA), mg/dL	Aspartate Aminotransferase (AST), IU/L
Sodium (Na), mEq/L	Gamma-Glutamyltransferase (GGT), IU/L
Potassium (K), mEq/L	Total Cholesterol (CHOL), mg/dL
Chloride (Cl), mEq/L	Glucose (GLU), mg/dL

4.9.3 Urinalyses

Urine was collected overnight prior to clinical pathology blood collection after 26, 52, 78, and 104 weeks of treatment. The urine was collected in a chilled vessel using metabolism cages, which facilitated separation of urine from fecal contaminants. Animals had *ad libitum* access to water, but not to feed, during urine collection. Samples were analyzed for the following:

Volume (VOL), mL	Urine Protein* (PROT)
Specific Gravity (SPG), g/mL	Occult Blood* (O. BLD)
Urine pH* (pH)	Color (COL)
Bilirubin* (BIL)	Appearance (APPR)
Ketones* (KET)	Microscopic Examination of Sediment
Urobilinogen* (UBLG)	
Urine Glucose* (GLU)	*Qualitative Determination (urine chemistry dip sticks)

4.10 Organ Weights

Selected organs were removed for organ weight determinations at scheduled necropsies. The liver and brain from all Core, Interim, Stop Study A, and Stop Study B subgroup animals were weighed prior to fixation and prior to any sampling for body burden analyses (as described in Section 4.14).

In addition, the following tissues were weighed prior to fixation from all Interim subgroup and from 10/sex/group Core subgroup animals: adrenal glands, epididymides, heart, kidneys, lungs, ovaries, prostate, seminal vesicles (including coagulating glands), submaxillary (submandibular) salivary glands, spleen (52, 78, and 104 weeks only), testes, thymus, and uterus.

The following tissues were weighed after fixation from all Interim subgroup and from 10/sex/group Core subgroup animals: pituitary and thyroid gland (including parathyroids).

Tissues were not weighed from animals found dead or terminated in a moribund condition.

4.11 Necropsy

A gross necropsy was performed in the presence of a veterinary pathologist on all study animals killed at a scheduled necropsy. Animals were weighed on the day of necropsy, killed by CO_2 overdose and exsanguinated. Interim necropsies were performed on up to 6 surviving males/Interim subgroup after 26, 52, and 78 weeks and on up to 6 surviving females/Interim subgroup after 13, 26, 39, 52, and 78 weeks. Up to six females/Stop Study B subgroup also were killed after 78 weeks. A final necropsy was performed on all surviving Core and Stop Study A subgroup animals after 104 weeks. A gross necropsy was performed on all animals that were found dead or killed in a moribund condition.

Samples of tissues and organs listed in the following table were obtained from each animal, examined for any gross lesions and then placed in containers of 10 percent neutral buffered formalin, except the eyes and testes, which were fixed in Bouin's solution. All wet tissues were retained at Battelle until authorization by the Sponsor for transfer to an approved archive facility.

Tissue and Organs

Adrenals	Pancreas
Aorta	Parathyroids
Brain (3 levels)	Pituitary gland
Cecum	Prostate
Colon	Rectum
Duodenum	Salivary glands (sublingual and submaxillary)
Epididymides	Sciatic nerve
Esophagus	Seminal vesicles
Exorbital lacrimal glands	Skin
Eyes	Spinal cord (cervical, mid-thoracic, and lumbar)
Femoris muscle	Spleen
Harderian glands	Sternum and marrow
Heart	Stomach
Ileum	Testes
Jejunum	Thymus
Kidneys	Thyroid
Liver (left and median lobes)	Tongue
Lungs (with main stem bronchi)	Trachea
Mammary gland[1]	Urinary bladder
Mesenteric lymph node(s)	Uterus (corpus, cervix)
Optic nerve(s)	Vagina[2]
Ovaries and Oviducts	All gross lesions and tumors

[1] Number and multiplicity of mammary tumors recorded.
[2] See Section 4.13 Assessment of Female Reproductive Tract for discussion.

The scapulo-humoral and coxo-femoral joints were examined grossly but not preserved.

4.12 Histopathology

A complete histopathological evaluation was performed on the control and the high dose groups from all four Aroclor test substances from the Core, Stop Study A, and the Interim subgroup animals terminated at 52-week and 78-weeks. Complete histopathologic evaluations also were done on all animals that died or were necropsied prior to scheduled termination. Tissues from animals processed for histopathology evaluations were embedded in paraffin, sectioned at 4 to 6 μm, stained with hematoxylin and eosin and the slides were evaluated by the Study Pathologist(s) (board certified).

Histopathologic evaluations of the liver, brain, mammary gland, and all gross lesions were performed on all Stop Study B subgroup animals, all mid- (where applicable) and low-dose animals from the Core and Stop Study A subgroup at scheduled termination, and from

the Interim subgroup animals at 26-, 52-, and 78-weeks and on the Interim subgroup animals (females only) terminated at 13- and 39-weeks. Thyroid glands were evaluated from all Core subgroup males at the low- and mid-dose groups in addition to the evaluation of thyroids from the control and high-dose Core subgroup males performed as part of the complete histopathic evaluation described above.

A group of independent pathologists (Pathology Working Group) conducted a peer review as part of the study and the results of this review were shared with the Study Pathologist(s) for consideration in the final report.

4.13 Assessment of Female Reproductive Tract

Vaginal Cytology

Vaginal cytologies were performed on females from each of the 12 groups in the Core subgroup prior to 78 weeks for evaluation of the estrous cycle. The 15 surviving females with the highest identification number per treatment group were sampled by vaginal lavage between 8 a.m. and noon for 12 consecutive days. No substitutions were made once sampling had initiated. Cells of vaginal washings were fixed to slides, stained, and coverslipped. Slides from each high dose group and the controls were examined microscopically for the stage of estrus by Novel Pharmaceuticals, Inc., Lexington, KY. Findings were reported as stage of estrus (proestrus, estrus, metestrus, diestrus) for each female sampled.

Histopathology

Histologic sections of both the ovary and the vagina from all control females and from the high-dose group of each Aroclor test substance terminated after 26, 52, or 78 weeks. The ovaries and vaginas were subjected to routine examination for lesions and abnormalities.

In addition, the stage of the estrous cycle at the time of termination was estimated in each animal, based on the histologic appearance of the vagina. The criteria used to stage the cycle are those reported by Yuan and Carlson (1987).

4.14 Additional Sample Collections

Tissue samples, approximately 1 gram, of the right lobe of liver, perirenal adipose, mammary adipose, and right brain (cerebrum, cerebellum, and brain stem) were collected, weighed, prepared, and frozen for possible body burden analyses. Samples were placed into glass containers closed with Teflon®-lined screw caps and kept at approximately -70°C. Collection of designated tissues from 6 male and 6 female cull animals were harvested after group assignments to provide samples for potential baseline information. Tissues were also retained from up to 6 males in each treatment group designated for termination at 26, 52, and 78 weeks and from up to 6 females in each treatment group designated for termination at 13, 26, 39, 52, and 78 weeks. Samples from up to 6 females in each treatment group were collected in the Stop Study B subgroups at 78 weeks. Also collected were samples from 6 males and females in each treatment group in the Core subgroup and 6 females in the Stop Study A subgroup. The last 6 surviving animals numerically per group from the Core and Stop Study A subgroups were designated for tissue harvest.

A sample of blood serum was retained at the 78- and 105-week necropsies. Samples of up to 10 mL of blood were collected and the serum separated. Animals were anesthetized using an injectable barbiturate prior to blood collection. The separated serum was held frozen at approximately -20°C. The animals subsequently were necropsied as described in Section 4.11.

Two additional liver samples also were retained at each collection period for possible additional analysis and were labeled as liver iron and liver porphyrin analysis samples. Approximately 1 gram of tissue from the right lobe of the liver was retained, frozen and labeled for porphyrin analyses, and the caudate lobe of the liver was retained, frozen and labeled for iron analyses. In instances where substantially less than 1 gram of tissue was available from the caudate lobe, a portion of the left lateral lobe also was retained. Samples were stored frozen at approximately -70°C.

Additional 1-gram samples of liver tissue were collected at the 78- and 105-week necropsies. Four samples of liver of normal appearance were collected from up to six animals in each treatment group. These four samples were collected as additions to the liver samples described above. From livers with tumorous-appearing tissue, samples were excised from up to 3 tumorous lesions per animal. Scheduled histopathology always took precedence,

so tumorous tissue was collected only when sufficient tissue remained after normal histopathologic sampling. Similarly, at these time points, a 1-gram sample of mammary tissue also was collected. These additional samples were frozen in liquid nitrogen and held at approximately -70°C.

Selected analysis of the tissue samples described in this section were conducted for the Sponsor at an independent laboratory. Summary results provided by General Electric Company are attached in Appendix F for reference purposes.

Carcasses were saved in a frozen state at approximately -20°C for possible future analyses. They will be discarded without examination, upon Sponsor approval, after acceptance of the final report.

4.15 Lipid Analyses

Carcasses from 4 cull animals of each sex from prestudy rats were analyzed at Battelle for lipid determinations based on AOAC methods 985.15 and 982.27 to establish baseline total body fat values. Subsequently, 3 male control group carcasses were analyzed after 26, 52, or 78 weeks on study, and 3 female control group carcasses were analyzed after 13, 26, 39, 52, or 78 weeks on study. Six additional animals/sex were analyzed for whole body fat analysis at 52 weeks. Battelle-generated data were placed in the study file. Three male and female control group carcasses were collected at 105 weeks (stored at approximately -20°C) and were subsequently analyzed by Northeast Analytical Laboratories, Schenectady, NY.

4.16 Fecal Collection

Fecal samples were collected from 4 to 6 Stop Study A subgroup females from the Aroclor-1016, 50 ppm; Aroclor-1242, 100 ppm; Aroclor-1254, 100 ppm; and Aroclor-1260, 100 ppm dose groups after one year of treatment. Individual animals were allowed to roam freely on clean cage paper and their droppings were collected, combined per dose group, and placed into 20-mL plastic containers. Samples were held frozen at approximately -70°C until shipment to Northeast Analytical Laboratories, Schenectady, NY.

Fecal samples were collected from male and female Core and Stop Study (females) subgroup animals designated for body burden analysis after 104 weeks of treatment. The six

surviving animals with the highest identification number per group were sampled for up to five consecutive days within a period of 2 weeks prior to termination. In the case of an unscheduled death during the collection period, substitutions were made at the discretion of the Study Director or Study Coordinator. Animals were housed in metabolism cages and had *ad libitum* access to both food and water during the sampling period. A final empty feeder weight was taken prior to placement of animals in metabolism cages to conclude feed consumption measurements on these animals. Clinical observations and body weights occurred as scheduled. Samples were held frozen at approximately -70°C until shipment to Northeast Analytical Laboratories, Schenectady, NY.

Battelle-generated data were placed in the study file. Independent analyses by Northeast Analytical Laboratories are on file with General Electric Company.

4.17 Data Management

In-life and postmortem animal data were collected using the Xybion Path/Tox® data system Version 4.1.7 (in-life) and 4.1.8 (postmortem) (Xybion Medical Systems Corporation, Cedar Knolls, NJ). Body weights, feed consumption, clinical observations and organ weights were recorded on-line with the Battelle VAX computer system. Data collected off-line (e.g. gross necropsy observations) were key-entered into the Xybion Path/Tox system and reviewed for accuracy of transcription before statistical analyses were performed. Xybion data were transferred electronically to the statistical database for analysis.

4.18 Statistical Analysis

The primary objective of the statistical analysis was to determine whether the administration of Aroclor test substances in diet resulted in increased tumor occurrence. Additional analyses were conducted to determine the effects of each Aroclor test substance on mortality, body weight, body weight gain, clinical pathology, and organ weights. Details of the statistical methods used are provided in Appendix A.

Four types of hypotheses were tested to assess and compare the effects of the four test substances:

- Dose effect assessments within each Aroclor test substance were made by comparing responses for each dose group and sex to the control animals of the respective sex for the parameters specified in the first paragraph of this section;
- Pairwise comparisons between Aroclor test substances were made at the 50- and 100-ppm dose levels (chosen because these concentrations were used for all four test substances) for all specified parameters;
- Comparisons between sexes were made for tumor incidence and survival at the 50- and 100-ppm dose levels of each Aroclor test substance;
- Comparisons between the Core and Stop Study female subgroups were made for tumor incidence at all dose levels, and for body weight and organ weight at the 50- and 100-ppm dose levels for each Aroclor test substance.

Separate dose effect assessments of survival were made for each Aroclor test substance and Core/Interim males, Core/Interim females, and Stop Study females. These assessments utilized Tarone's test for linear trend, and Cox's log rank test for pairwise comparisons. Kaplan-Meier survival probabilities were calculated for the control and each dose group. Comparisons between Aroclor test substances and between sexes were made using proportional hazards regression.

In-life statistical analyses were performed on body weights, feed consumption, compound consumption, organ weights, and quantitative clinical pathology parameters. Dose group versus control comparisons were made using either Dunnett's test or t-tests with adjustment for multiple comparisons, following a preliminary analysis to select the appropriate test procedure. Comparisons between Aroclor test substances were made using analysis of variance (ANOVA) procedures appropriate for each type of data. Comparisons between Core and Stop Study females were made using ANOVA procedures for body weights and for liver and thyroid organ weights where data were collected for the Stop Study subgroups.

Because copious in-life data were generated for some parameters, summary tables were devised with coding of statistical differences for various groups and subpopulations. These tables were prepared for body weights (Table 20), and for clinical pathology (Table 43) and organ weight (Table 56) parameters selected by the Study Director as relevant to interpretation of the results. The tables were constructed so that test substances at a given timepoint and common dose concentration of either 50 or 100 ppm that were statistically equivalent have at least one letter in common (A, B and/or C). Test substances that were statistically

different do not have any letters in common. [For example, if the "body weight letters" for the four test substances were A, A, B, and A (Aroclor-1016, -1242, -1254, and -1260, respectively), the average body weight for Aroclor-1254 was statistically different from those of the other three test substances, and the mean body weights for the other three substances were equivalent.]

Three approaches were employed for dose effect assessment of the tumor data. (1) Fatal tumor analysis methods utilized the age at death to compare tumor onset rates over time. (2) Incidental methods were used to compare probabilities of tumor observation among study groups, after controlling for age at death. (3) Unadjusted methods were used to compare the total number of tumors observed among study groups without adjusting for the varying times at which tumors were observed. Fatal statistical methods employed Cox's (1972) log rank test used for pairwise comparisons of each dose group with the control group and Tarone's (1975) test for linear trend with increasing dose. Incidental statistical methods employed logistic regression for pairwise comparisons of each dosed group with the control group and to test for a linear trend with increasing dose. Unadjusted statistical methods employed Fisher's exact test for pairwise comparisons of each dosed group with the control group and Cochran-Armitage test for linear trend with increasing dose (Armitage, 1971; Gart *et al.*, 1979). All reported p-values were two-sided with no corrections for continuity. Comparisons between Aroclor test substances, between sexes, and between Core and Stop Study subgroup females were conducted using logistic regression.

4.19 Health and Safety

Several engineering controls and written procedures were instituted to minimize exposure of the study staff, minimize cross-contamination between the different Aroclor test substances, and to protect facilities and the environment. Personal protective equipment also ensured that exposure of study staff to the Aroclor test substances did not exceed the 8-hour exposure limits detailed by OSHA (i.e., 1 mg/m^3 for Aroclor-1242 and 0.5 mg/m^3 for Aroclor-1254).

The study containment area was made up of 6 animal treatment rooms, a dose preparation suite, and a cage wash room. These rooms were operated on a one-way traffic flow concept. With the exception of the control room, the air flow pattern produced study

rooms that were negative with respect to both the clean and soiled corridors. The dose preparation area (especially the feed mix room) was under negative pressure relative to the study rooms. All rooms were HEPA-filtered and the prefilters were changed on a regular basis.

All staff working on the study received training on the MSDS for PCBs as well as existing regulations and written procedures established for the conduct of the studies. These procedures included employee protection, waste collection and disposal, and necropsy/ pathology procedures. With the exception of the control room, staff and study monitors wore a full complement of personal protective clothing and equipment in conformance with containment area egress procedures.

Air samples were collected periodically to evaluate both personal exposure and room contamination. Results throughout the study did not show levels above the OSHA 8-hour limits. Initially, sanitization of animal caging equipment was performed by dedicated mechanical washers located within the containment area. The water generated in the washing process, and aqueous waste from the dose preparation area, were collected and sampled for contamination. Analysis of the aqueous waste samples revealed PCB concentrations close to background (i.e., 20 ppb average for dose preparation area, 3 ppb average for cage wash area). The wash function was subsequently transferred to the Laboratory Animal Resources general cage-washing facility in Building 7C. Water samples continued to be collected on a monthly basis to assure that contamination was below action levels.

4.20 Specimen Storage and Record Archives

Records of animal receipt, quarantine, animal dosing, body weights, and other information pertinent to the conduct of the study (Battelle Study Number SC920192) are contained in binders labelled, "An Assessment of the Chronic Toxicity and Oncogenicity of Aroclor-1016, Aroclor-1242, Aroclor-1254, and Aroclor-1260 Administered in Diet to Rats." These and all other raw data collected will be maintained in Battelle's archives or a Sponsor designated archival facility, along with a copy of the protocol and final report. Pathology specimens (i.e., wet tissues, blocks and slides) will be retained at Battelle until disposition by direction of the Project Monitor.

5.0 RESULTS

5.1 Dose Analysis

Samples were removed for analysis as described in Section 4.3. Dose concentration, homogeneity, and cross-contamination samples were analyzed according to the methods described in Appendix B. The results for all control feed preparations were 0 and were not tabulated. Results represent duplicate analyses except where indicated.

Stability studies conducted at three temperatures (-20°C, 5°C, and 25°C) for up to 42 days indicated adequate stability for Aroclor-1242, -1254, and -1260. For Aroclor-1016, an approximate 10 percent loss from feed at all temperatures was measured. Although samples were taken out as long as 42 days, the loss appeared to have occurred early and did not continue with time. The losses of Aroclor-1016 observed in the stability study were attributed to volatility and not degradation since Aroclor-1016 contains a larger volatile component than the other test substances and similar losses were not seen with the other test substances. Results of these stability studies are included in Appendix B. Each batch of diet was used and discarded within 35 days of preparation as specified in the protocol and was acceptable by the stability studies.

Aroclor-1016

The results of the concentration and homogeneity analyses for Aroclor-1016 are given in Tables 2 and 3 respectively.

Analysis results indicated that the batches were homogenous and the preadministration values were within the concentration range specified by protocol with the exception of 1016-029. Due to a calculation error, the concentrations for batches 1016-029 and 1016-030 were incorrect. For a more complete description, see the deviation report in Appendix A. A remix was performed, batch 1016-029A, and analyzed along with the original preparation. The results of this analysis confirmed that the initial batch was improperly prepared and that the remix batch was acceptable.

The postadministration analyses values generally agreed with the preadministration values. The postadministration results were also within the acceptance limits specified for the

preadministration concentration in all but three samples, batches 1016-003, 1016-101 and 1016-102, with the worst case being a difference of 13 percent.

Aroclor-1242

The results of the concentration and homogeneity analyses for Aroclor-1242 are given in Tables 4 and 5 respectively.

Analysis results indicated that the batches were homogenous and the preadministration values were within the concentration range specified by protocol. The postadministration analyses values generally agreed with the preadministration values. The postadministration results were also within the acceptance limits specified for the preadministration concentration in all cases.

Aroclor-1254

The results of the concentration and homogeneity analyses for Aroclor-1254 are given in Tables 6 and 7 respectively.

Analysis results indicated that the batches were homogenous and the preadministration values were within the concentration range specified by protocol. The postadministration analyses values generally agreed with the preadministration values. The postadministration results were also within the acceptance limits specified for the preadministration concentration in all but batch 1254-099, where the difference was 14 percent higher than the target concentration.

Aroclor-1260

The results of the concentration and homogeneity analyses for Aroclor-1260 are given in Tables 8 and 9 respectively.

Analysis results indicated that the batches were homogenous and the preadministration values were within the concentration range specified by protocol. The postadministration analyses values generally agreed with the preadministration values except batch 1260-006, for which the increase was 14 percent. The postadministration results were also within the

acceptance limits specified for the preadministration concentration in all but two samples. In batches 1260-097 and 1260-099, an apparent problem with the internal standard resulted in reported values that are believed to be 5 to 10 percent higher than the actual concentration.

5.1.1 Referee Dose Analysis

Randomly selected samples of prepared Aroclor test diets were submitted to Northeast Analytical Laboratories, Schenectady, NY for corroborative analysis. Results of these independent analyses as provided by the Sponsor are compiled in Table 10 for reference purposes. There was good agreement with the Battelle data.

5.1.2 Analysis for Cross-Contamination

A single blender was used for dose preparation of all test substances. At 6-month intervals, after preparation of a test substance diet, the blender was cleaned and blank feed was placed into the blender and mixed. Samples were analyzed to determine if any residual test substance from the previous batch of dosed feed was present. Cross-contamination samples were collected according to the following schedule:

Cross-Contamination Sample Collection Schedule

Determination of Residual Aroclor			
Aroclor-1016	**Aroclor-1242**	**Aroclor-1254**	**Aroclor-1260**
1/19/93	1/26/93	1/29/93	2/2/93
6/29/93	7/6/93	7/12/93	7/19/93
12/13/93	12/20/93	12/28/93	1/3/94
5/31/94	6/6/94	6/13/94	6/20/94
10/17/94	10/24/94	10/31/94	11/7/94

Analysis of cross-contamination samples indicated that levels of residual Aroclor were below the level of the lowest diluted standard, which confirmed that there was no contamination. This was the case for all the Aroclor test substances. Cross-contamination evaluation results are reported in Appendix B.

5.2 Animal Survival

Animal survival is summarized in Tables 11, 12, and 13 for Core/Interim subgroup males, Core/Interim subgroup females, and Stop Study subgroup females, respectively. Survival probability is shown in Figures 1 through 12. Individual animal dispositions are summarized in Table E-1, Volume V (scheduled male terminations); Table E-2, Volume V (unscheduled male terminations); Table E-3, Volume V (scheduled female terminations); and Table E-4, Volume V (unscheduled female terminations).

Interpretation of survival data was based on survival probability at the final termination estimated by the method of Kaplan-Meier. The Kaplan-Meier analysis was selected because it utilizes the data from scheduled interim terminations in estimation of final termination survival probabilities.

Survival differences between the sexes were present in the Core subgroup animals. Survival was higher for females than males for most of the Aroclor test substance-treated groups.

Aroclor-1016

In males, survival probability was significantly less for the Core/Interim 100 ppm dose group when compared to the controls, but no dose-related trend was evident. Survival in the 200 ppm Core/Interim group was comparable to the controls, and no relation of survival to Aroclor-1016 treatment was indicated.

In females, survival probability was significantly greater for the Core/Interim 50, 100, and 200 ppm dose groups when compared to the controls with a significant trend of increased survival with increased concentration.

In the Stop Study females, survival probabilities were generally comparable to the Core/Interim subgroup control females.

Aroclor-1016 - Kaplan-Meier Survival Probabilities

Test Substance	Conc. (ppm)	Core/Interim Male	Core/Interim Female	Stop Study Female
Control	0	42	31	31[1]
Aroclor-1016	50	29	**40[a]**	**42[a]**
	100	**27[a]**	**43[a]**	43
	200	49	**49[b]**	24

1. Core/Interim female control group data.
a. Statistically significant from control by $p \leq 0.05$.
b. Statistically significant from control by $p \leq 0.01$.

Aroclor-1242

In males, survival probability for Core/Interim subgroup animals was comparable to the controls.

In females, survival probability was significantly greater for the Core/Interim 50 and 100 ppm dose groups compared to the controls, with a significant trend of increased survival with increased concentration.

In the Stop Study females, survival probability was significantly greater for the 100 ppm dose group compared to the Core/Interim female controls, with a significant trend of increased survival with increased concentration.

Aroclor-1242 - Kaplan-Meier Survival Probabilities

Test Substance	Conc. (ppm)	Core/Interim Male	Core/Interim Female	Stop Study Female
Control	0	42	31	31[1]
Aroclor-1242	50	48	**46[a]**	40
	100	33	**51[b]**	**45[b]**

1. Core/Interim female control group data.
a. Statistically significant from control by $p \leq 0.05$.
b. Statistically significant from control by $p \leq 0.01$.

Aroclor-1254

In males, survival probability was significantly less for the Core/Interim 50 ppm dose group compared to the controls, but no dose-related trend was evident, with survival in the 25 and 100 ppm dose groups comparable to the controls, demonstrating a lack of treatment effect.

In females, survival probability was greater for the Core/Interim 25 ppm dose group compared to the controls. Survival probability for the other groups was comparable to controls, and no treatment effect was indicated.

In the Stop Study females, survival probabilities were higher for the 50 and 100 ppm dose groups compared to the Core/Interim female controls, with a significant dose-related trend of increased survival with increased concentration.

Aroclor-1254 - Kaplan-Meier Survival Probabilities

Test Substance	Conc. (ppm)	Core/Interim Male	Core/Interim Female	Stop Study Female
Control	0	42	31	31[1]
Aroclor-1254	25	42	**65**[b]	46
	50	**21**[b]	34	**59**[b]
	100	40	39	**59**[a]

1. Core/Interim female control group data.
a. Statistically significant from control by $p \leq 0.05$.
b. Statistically significant from control by $p \leq 0.01$.

Aroclor-1260

In males, survival probability for the Core/Interim treated animals was statistically comparable to the controls.

In females, survival probability was significantly greater for the Core/Interim 100 ppm dose group compared to the controls, with a statistically significant trend of increased survival with increased concentration.

In the Stop Study females, survival probabilities were significantly greater for the 25 ppm and 100 ppm dose groups compared to the Core/Interim female controls.

Aroclor-1260 - Kaplan-Meier Survival Probabilities

Test Substance	Conc. (ppm)	Core/Interim Male	Core/Interim Female	Stop Study Female
Control	0	42	31	31[1]
Aroclor-1260	25	47	38	**61**[b]
	50	33	43	24
	100	30	**45**[a]	**53**[a]

1. Core/Interim female control group data.
a. Statistically significant from control by $p \leq 0.05$.
b. Statistically significant from control by $p \leq 0.01$.

5.3 Clinical Observations

The incidence of abnormal clinical observations is summarized in Table 14 for males, Table 15 for Core and Interim females and Table 16 for Stop Study females. Individual animal data are summarized in Table C-1, Volume III (males) and Table C-2, Volume III (females).

Animals receiving test substance exhibited signs similar to the controls. There were no clinical signs related to treatment and no overt toxicological findings were observed.

Incidental findings of localized lesions, digestive disorder, abnormal appearance, locomotor/behavior changes, oral cavity disorders, respiratory problems, swellings and tissue masses appeared sporadically among the various dose groups for both males and females.

No treatment-related clinical changes occurred in the males during the study. Some of the more prevalent findings observed included ocular discharge, nasal discharge, and long/ crooked teeth.

Similarly, females exhibited incidental clinical findings, including ocular discharge, ventral abdominal swellings, ventral thorax swellings, ventral abdominal tissue masses, and ventral thorax tissue masses.

5.4 Body Weights

The group mean body weights are presented in Table 17 (Core/Interim males), Table 18 (Core/Interim/Stop Study females), and Table 19 (Stop Study females following treatment cessation) and in Figures 13-24. Significant body weight differences between test substances are provided in Table 20. The group mean weight gain data are presented in Tables 21, 22, and 23. Individual body weight data are provided in Table C-3, Volume III (males) and Table C-4, Volume III (females). Individual body weight gain data are provided in Table C-5, Volume III (males) and Table C-6, Volume III (females).

Stop Study A and B female body weights are included with Core/Interim mean body weights through Week 52 and for subsequent weeks are presented separately from the Core/Interim body weights. The Stop Study A and B body weights are grouped together from Week 53 through Week 78, at which point the Stop Study B subgroup animals were terminated.

Male controls had a net average body weight gain of 503 grams from Day 1 to Day 722. Female controls had a net average gain of 270 grams from Day 1 to Day 722. Both sexes exhibited the typical pattern of early growth and age decline (Figure 13 through Figure 24).

No effects on body weight were observed in Aroclor-1016. Effects on body weights for each of the remaining Aroclor test substances are described below. A greater effect on body weight was observed in the females than in the males. The greatest effect on body weight was associated with Aroclor-1254. In both sexes, body weights at 50 and 100 ppm of Aroclor-1254 consistently were significantly less than animals that received 50 or 100 ppm of any of the other three Aroclor test substances (Table 20).

For Stop Study females, all dose groups which had treatment-related body weight effects showed recovery of the body weight deficit 7 to 8 months after treatment cessation to levels comparable to the Core subgroup female controls.

Aroclor-1016

There were no meaningful effects on body weight. The group mean body weights at selected time points expressed as a percentage of control (abstracted from Tables 17, 18, and 19) are presented below.

Aroclor-1016 Group Mean Body Weight (Percentage of Control Weight) for Core/Interim Subgroup Males and Females and Stop Study Females

Week of Study	Males			Females[1]			Stop Study Females[2]		
	50 ppm	100 ppm	200 ppm	50 ppm	100 ppm	200 ppm	50 ppm	100 ppm	200 ppm
13	104	101	103	101	101	98	--	--	--
26	106[b]	103	104	101	102	99	--	--	--
52	104	101	104	99	102	97	102	102	99
78	103	101	103	101	105	98	98	108	98
104	103	97	100	109	105	103	97	110	105

1. Includes data from Stop Study females until cessation of treatment after Week 52.
2. Data from Core/Interim female controls used for comparison.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Aroclor-1242

There were no meaningful effects on group mean body weight for males in the 50 ppm or 100 ppm dose groups.

Females in the 100 ppm dose group showed consistently statistically significant lower group mean body weights relative to controls from Week 19 through Week 71, with the exception of Week 26. Body weights in the 100 ppm dose group remained depressed through study termination. There were no effects on body weight of females in the 50 ppm dose group.

For Stop Study females, group mean body weights were depressed following treatment cessation, but rebounded to levels comparable to the control females prior to study termination. Stop Study female group mean body weights in the 100 ppm dose group remained depressed following treatment cessation and were statistically significantly low from Week 53 through Week 73.

The group mean body weights at selected time points, expressed as a percentage of control (abstracted from Tables 17, 18, and 19) are presented below.

Aroclor-1242 Group Mean Body Weight (Percentage of Control Weight) for Core/Interim Subgroup Males and Females and Stop Study Females

Week of Study	Males		Females[1]		Stop Study Females[2]	
	50 ppm	100 ppm	50 ppm	100 ppm	50 ppm	100 ppm
13	103	102	100	98	--	--
26	**105[a]**	103	102	**96[a]**	--	--
52	103	101	100	**90[b]**	100	**89[b]**
78	101	95	99	**90[a]**	97	92
104	103	95	99	90	101	101

1. Includes data from Stop Study females until cessation of treatment after Week 52.
2. Data from Core/Interim female controls used for comparison.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Aroclor-1254

Male group mean body weights were depressed in the 100 ppm dose group and the decreases were statistically significant from Week 6 through termination when compared to the controls. In the 50 ppm dose group, decreased body weights were apparent by Week 40 and were periodically statistically significantly decreased after Week 54. There was no meaningful effect on body weights in the 25 ppm dose group in males.

Female group mean body weights were depressed in the 100 ppm dose group and were statistically significantly low when compared to the controls from Week 5 through termination. Body weights in the 50 ppm dose group were periodically statistically significantly decreased by Week 11 through termination. In the 25 ppm dose group, body weights for females were periodically statistically significantly less than control from Week 39 through Week 68.

For Stop Study females, group mean body weights were depressed following treatment cessation but rebounded to levels comparable to the control females prior to study termination. Stop Study female body weights were depressed following treatment cessation in all dose groups and were statistically significantly decreased compared to the controls in the

100 ppm dose group from Week 53 though Week 72. The body weight depression in the 50 ppm dose group was statistically significant from Week 53 though Week 75. In the 25 ppm dose group, body weight depressions were statistically significant from Week 53 through Week 64.

The group mean body weights at selected time points, expressed as a percentage of control (abstracted from Tables 17, 18, and 19) are presented below.

Aroclor-1254 Group Mean Body Weight (Percentage of Control Weight) for Core/Interim Subgroup Males and Females and Stop Study Females

Week of Study	Males			Females[1]			Stop Study Females[2]		
	25 ppm	50 ppm	100 ppm	25 ppm	50 ppm	100 ppm	25 ppm	50 ppm	100 ppm
13	102	101	93[b]	98	96[a]	91[b]	--	--	--
26	104	100	91[b]	96[a]	92[a]	86[b]	--	--	--
52	101	97	87[b]	92[b]	87[b]	79[b]	91[a]	86[b]	82[b]
78	98	92[a]	84[b]	93	88[b]	78[b]	99	91	93
104	94	88	82[b]	85[a]	85	72[b]	98	98	99

1. Includes data from Stop Study females until cessation of treatment after Week 52.
2. Data from Core/Interim female controls used for comparison.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Aroclor-1260

Males exhibited no apparent effect on group mean body weight at any dose level.

Female group mean body weights in the 100 ppm dose group were periodically significantly decreased compared to the controls from Week 43 through Week 53. There were no effects on body weight in the 50 or 25 ppm dose groups for female animals.

For Stop Study females, group mean body weights were depressed following treatment cessation but rebounded to levels comparable to the control females prior to study termination. Stop Study female body weights were depressed compared to control females following treatment cessation in the 100 ppm dose group and the differences were statistically significant from Week 53 through Week 82.

The group mean body weights at selected time points, expressed as a percentage of control (abstracted from Tables 17, 18, and 19) are presented below.

Aroclor-1260 Group Mean Body Weight (Percentage of Control Weight) for Core/Interim Subgroup Males and Females and Stop Study Females

Week of Study	Males			Females[1]			Stop Study Females[2]		
	25 ppm	50 ppm	100 ppm	25 ppm	50 ppm	100 ppm	25 ppm	50 ppm	100 ppm
13	102	103	103	100	99	98	--	--	--
26	**105[a]**	**106[b]**	**105[a]**	101	101	98	--	--	--
52	102	103	100	100	97	**93[a]**	97	98	**89[b]**
78	99	98	98	103	101	96	103	98	91
104	95	99	91	106	104	93	110	107	99

1. Includes data from Stop Study females until cessation of treatment after Week 52.
2. Data from Core/Interim female controls used for comparison.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

5.5 Feed Consumption

The group mean feed consumption (g) is summarized in Tables 24, 25, and 26 and group mean feed consumption per body weight (g/kg) is summarized in Tables 27, 28, and 29 for Core/Interim males, Core/Interim/Stop Study females, and Stop Study females following treatment cessation, respectively. Individual animal data are summarized in Table C-7, Volume IV, for males and Table C-8, Volume IV, for females. Figures 25 through 36 show graphs of feed consumption as g/kg/day.

The consumption per kg of body weight differed between sexes and was consistent with the normal sex-dependent pattern of feed consumption. There appeared to be no diminished palatability with any of the Aroclor test substances when compared with the control, although sporadic statistically significant decreases ($p \leq 0.05$) in feed consumption were observed in both the males and females treated with Aroclor-1254.

5.6 Test Substance Consumption

Group mean test article consumption for the Core/Interim subgroup males are presented in Table 27A and for Core/Interim and Stop Study females are shown in Table 28A. Summary calculations of ingested test substance are presented in Table 30 and

Table 31 for males and females, respectively. Individual animal Aroclor test substance consumption data are provided in Table C-9, Volume V and Table C-10, Volume V.

The total Aroclor test substance exposure (in mg per kg body weight) increased in proportion to ppm administered in the diet. The daily exposure index (mg/kg/day) differed between the sexes with the exposure level being generally slightly higher for females than for males.

Test Substance Consumption

Test Substance	Conc. (ppm)	Test Substance Consumption (mg/kg)[a]		Test Substance Consumption (mg/kg/day) (lowest-highest weekly value)	
		Males	Females	Males	Females
Control	0	0	0	0	0
Aroclor-1016	50	1435	1962	1.5-4.4	1.9-4.3
	100	2865	3898	3.0-8.8	4.2-8.8
	200	5744	8119	6.4-17.4	9.0-19.0
Aroclor-1242	50	1423	2020	1.6-4.3	2.1-4.7
	100	2917	4155	3.2-8.7	4.4-9.0
Aroclor-1254	25	725	1011	0.8-2.2	1.1-2.2
	50	1467	2091	1.6-4.3	2.3-4.5
	100	3127	4383	3.5-8.3	5.1-9.0
Aroclor-1260	25	747	978	0.9-2.2	1.0-2.3
	50	1458	2002	1.6-4.3	2.2-4.8
	100	2987	4158	3.3-8.5	4.5-9.3

a. Summation over 104 weeks of weekly test substance ingestion averaged over all animals (Core, Interim, Stop Study) exposed to test substance each week. (Stop Study data after cessation of exposure after Week 52 are not included).

5.7 Ophthalmic Evaluations

The incidence of abnormal ophthalmic findings are summarized in Table 32 and Table 33 for control and high-dose males and females, respectively. Individual animal data are provided in Tables C-11, Volume V, and C-12, Volume V, for males and females, respectively.

Corneal lesions, lens lesions, periocular discharge, persistent vascularization, persistent pupillary membranes, hemorrhages, and the inability for the iris to dilate properly

were noted during the ophthalmic examinations. Corneal lesions were observed during every examination period. Corneal lesions are not uncommon in rodents and are often attributed to irritation or injury to the eye. Vasculature associated with a corneal lesion is attributed to the healing process. Periocular discharge (chromodacryorrhea) was observed in rats at the 26-, 52-, 78-, and 104-week examinations. Secretion of pigmented tears is a normal physiological process in the rat. Persistent pupillary membranes and persistent primary vitreous (persistent hyaloid vessels) were occasionally seen, and were considered to be congenital. The inability to completely dilate the iris was observed during the quarantine, 78-, and 104-week examinations. This may have been caused by anterior or posterior synechiae.

The abnormal findings recorded at ophthalmic examination appeared to be incidental lesions related to age, or developmental in nature. No compound-related findings were observed.

5.8 Clinical Pathology

The results of the clinical pathology tests conducted on Core subgroup males and females (up to 10/sex/dose group) are summarized by group with means and results of statistical comparisons in Tables 34 through 45. Significant differences in response between the Aroclor test substances are summarized in Table 46 for parameters considered by the Study Director to be potentially relevant to data interpretation. The individual animal data are contained in Tables D-1 through D-14, Volume V.

5.8.1 Hematology

Hematologic effects from administration of Aroclor test substances to animals were limited to decreases in mean erythrocytes, generally with concomitant decreases in mean hemoglobin and hematocrit, and associated depressions in mean corpuscular volume, mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration. With the exception of equivocal effects in males at the 50 and 100 ppm dose of Aroclor-1254, these effects were limited to females. The severity of the effects was greatest in the 100 ppm dose Aroclor-1254 females.

Although other hematologic parameters showed statistically significant differences from controls, these changes were sporadic, lacked a dose-response relationship and were not considered effects related to Aroclor test substance administration.

Aroclor-1016

Aroclor-1016 produced no treatment-related effects on hematologic parameters in males.

In females, a treatment-related decrease in mean erythrocytes with concomitant decreases in hemoglobin and hematocrit was evident in the 100 and 200 ppm dose group females at 78 weeks, and in all dose groups at 105 weeks. The decreases in means of all three parameters: erythrocytes, hemoglobin, and hematocrit were statistically significant ($p \leq 0.05$ or $p \leq 0.01$) in the 100 ppm dose group only at 78 weeks, and in all dose groups at 105 weeks (with the exception of the decrease in mean hematocrit in the 50 ppm dose group). At 105 weeks, mean erythrocytes, hemoglobin and hematocrit in treated groups were decreased compared to controls from 11-19%, 13-18% and 11-19%, respectively.

Aroclor-1242

Aroclor-1242 produced no treatment-related effects on hematologic parameters in males.

In females, a treatment-related decrease in mean erythrocytes with concomitant decreases in hemoglobin and hematocrit was evident in the 100 ppm dose group animals at 105 weeks. The decrease in erythrocytes was not statistically significant, probably due to a relatively large standard deviation, but the decreases in hemoglobin and hematocrit were statistically significant ($p \leq 0.05$ or $p \leq 0.01$) in the 100 ppm dose group at week 105. Although statistically significant decreases ($p \leq 0.05$ or $p \leq 0.01$) in hemoglobin and hematocrit were also present at earlier intervals in the 100 ppm dose group, the erythrocyte counts at the earlier intervals were comparable to controls and the changes in hemoglobin and hematocrit at these earlier intervals were not considered biologically meaningful. At 105 weeks, erythrocytes, hemoglobin and hematocrit in the 100 ppm female dose group were decreased compared to controls by 14%, 21% and 21%, respectively.

Aroclor-1254

Aroclor-1254 produced equivocal treatment-related effects on hematologic parameters in the 50 and 100 ppm dose group males at 105 weeks. Depressed mean erythrocytes, hemoglobin and hematocrit were present. Although the decreases were not statistically significantly different from controls (probably, for hemoglobin and hematocrit, due to the magnitude of the standard deviations), the decreases are considered equivocally related to treatment. At 105 weeks, mean erythrocytes in the 50 and 100 ppm dose group males were decreased only 1-4% compared to controls, however, mean hemoglobin was decreased 11% and hematocrit was decreased 7%, compared to controls.

In females, a treatment- and dose-related decrease in mean erythrocytes with concomitant decreases in hemoglobin and hematocrit was evident in the 50 and 100 ppm dose group females at all intervals from week 52 to week 105, and in the 25 ppm dose group females at 105 weeks only. For the 50 and 100 ppm dose group animals, the decreases in mean hemoglobin and hematocrit were statistically significant ($p \leq 0.05$ or $p \leq 0.01$) at all intervals tested (except for mean hematocrit at week 26 for the 50 ppm dose group females). The decrease in mean erythrocytes in the 50 and 100 ppm dose group females was statistically significant ($p \leq 0.01$) at week 105 only, however, the decreases in mean erythrocytes at weeks 52 and 78 were also considered treatment related because of the correlating decreases in hemoglobin and hematocrit. In the 25 ppm dose group females, statistically significant decreases ($p \leq 0.05$ or $p \leq 0.01$) in mean hemoglobin and hematocrit were present at 105 weeks only; mean erythrocytes in the 25 ppm dose group females were not statistically significantly decreased compared to controls, but the observed depression at 105 weeks was considered part of the dose response. At 105 weeks, mean erythrocytes, hemoglobin and hematocrit in treated groups were decreased compared to controls from 8-19%, 18-29% and 19-29%, respectively.

Aroclor-1260

Aroclor-1260 produced no treatment-related effects on hematologic parameters in males.

In females, a treatment- and dose-related decrease compared to controls in mean erythrocytes with concomitant decreases in hemoglobin and hematocrit was evident in the 25, 50 and 100 ppm dose group females at 105 weeks. The decreases in mean erythrocytes, hemoglobin, and hematocrit were statistically significant ($p \leq 0.05$ or $p \leq 0.01$) at 105 weeks in all dose groups compared to controls. At 105 weeks, mean erythrocytes, hemoglobin and hematocrit in treated groups were decreased compared to controls from 14-22%, 16-25% and 16-26%, respectively.

5.8.2 Serum Chemistry

Treatment-related effects on serum chemistry in males included increases in cholesterol concentration and aspartate aminotransferase (AST) activity in Aroclor-1254 treated rats. At selected intervals, females receiving Aroclor-1242, Aroclor-1254 and Aroclor-1260 showed increases in cholesterol concentrations and increases in AST and gamma-glutamyltransferase (GGT) activities. Increased alanine aminotransferase (ALT) activity and total bilirubin concentration were also seen in females receiving Aroclor-1254.

Although other serum chemistry parameters showed statistically significant differences from controls, these changes were sporadic, lacked a dose-response relationship and were not considered to be related to Aroclor test substance administration.

Aroclor-1016

Aroclor-1016 produced no treatment-related effects on serum chemistry parameters in males. The statistically significant differences compared to controls in mean cholesterol concentrations measured for the 50, 100 and 200 ppm male dose groups at 52 weeks are interpreted to be spurious because of the absence of a dose relationship and a lack of consistent findings at other time points.

Aroclor-1016 produced no treatment-related effects on serum chemistry parameters in females.

Aroclor-1016 - Mean Cholesterol Concentration (mg/dL) in Core Subgroup Males and Females

Conc. (ppm)	Males				Females			
	Week of Study				Week of Study			
	26	52	78	105	26	52	78	105
Control	96	110	173	157	118	180	146	136
50	123	**168[a]**	167	176	106	136	197	162
100	117	**153[a]**	209	217	123	153	168	167
200	114	**136[a]**	184	210	127	167	214	180

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Aroclor-1242

Aroclor-1242 produced no treatment-related effects on serum chemistry parameters in males.

In females, a dose-related increase in mean cholesterol concentration compared to controls was observed. The elevations in cholesterol concentration increased as the study progressed. Mean cholesterol concentrations were statistically significantly increased compared to controls in the 100 ppm dose group at 78 and 105 weeks.

Mean AST activity was increased compared to controls in females in the 100 ppm dose group; the increase was statistically significant ($p \leq 0.05$) at the 52-week interval. Increased mean GGT activity compared to controls was seen in the 100 ppm dose group at 78 and 105 weeks. The increase in activity at 78 weeks was statistically significant ($p \leq 0.05$). The relationship between the increase in GGT activity and exposure to Aroclor-1242 was considered equivocal.

Aroclor-1242 - Mean Cholesterol Concentration (mg/dL) in Core Subgroup Males and Females

Conc. (ppm)	Males				Females			
	Week of Study				Week of Study			
	26	52	78	105	26	52	78	105
Control	96	110	173	157	118	180	146	136
50	108	125	181	208	110	146	184	225
100	127	142	209	166	128	211	240[b]	277[b]

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Aroclor-1254

In males, a treatment-related increase compared to controls in mean cholesterol concentration was observed. Cholesterol was consistently elevated compared to controls, and concentrations increased as the study progressed, however, a dose-related trend was not seen. Mean cholesterol concentrations were statistically significantly increased compared to controls in the 25 ppm dose group at 52 and 105 weeks, in the 50 ppm dose group at 52 weeks, and in the 100 ppm dose group at 26, 52 and 105 weeks.

Mean AST activity was increased compared to controls in males in the 50 and 100 ppm dose groups; the differences were statistically significant ($p \leq 0.05$ or $p \leq 0.01$) at 52 weeks. This finding was considered equivocally related to treatment because of the absence of a dose response at most intervals and the lack of increasing severity over time.

In females, a treatment-related increase in mean cholesterol concentration was observed. Cholesterol was generally elevated compared to controls, concentrations increased as the study progressed, and a dose-related pattern was evident. Mean cholesterol concentrations were statistically significantly increased compared to controls at 78 and 105 weeks in the 25 ppm dose group, and at 26, 78 and 105 weeks in the 50 and 100 ppm dose groups. Treatment-related increases in mean ALT and AST activities was observed. Mean ALT activities were statistically significantly increased compared to control ($p \leq 0.05$) in the 50 and 100 ppm dose groups at 105 weeks, and mean AST activity was statistically significantly increased compared to controls ($p \leq 0.05$ or $p \leq 0.01$) in the 50 and 100 ppm dose groups at 26, 52, and 105 weeks.

Increased mean GGT activity was seen at weeks 78 and 105 in the 25, 50 and 100 ppm dose groups. Mean GGT activities obtained for the 50 ppm dose group at 105 weeks, and for the 100 ppm dose group at 78 and 105 weeks were statistically significantly increased compared to controls ($p \leq 0.05$ or $p \leq 0.01$).

A statistically significantly increase compared to controls ($p \leq 0.05$ or $p \leq 0.01$) in mean total bilirubin concentration was present at all 3 dose levels at 78 weeks and in the 50 and 100 ppm dose group females at 105 weeks. This finding is considered equivocally related to treatment.

Aroclor-1254 - Mean Cholesterol Concentration (mg/dL) in Core Subgroup Males and Females

Conc. (ppm)	Males				Females			
	Week of Study				Week of Study			
	26	52	78	105	26	52	78	105
Control	96	110	173	157	118	180	146	136
25	123	**160[a]**	203	**262[a]**	145	176	**225[a]**	**254[b]**
50	128	**151[b]**	193	222	**191[b]**	223	**265[b]**	**360[b]**
100	**164[b]**	**194[b]**	241	**259[a]**	**193[b]**	226	**255[a]**	**287[b]**

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Aroclor-1260

Aroclor-1260 produced no treatment-related effects on serum chemistry parameters in males.

In females, a treatment related increase compared to controls in mean cholesterol concentrations was observed. Cholesterol was consistently elevated compared to controls, concentrations increased as the study progressed, and a dose-related pattern was evident. Mean cholesterol concentrations were statistically significantly increased compared to controls at 78 and 105 weeks in the 50 ppm dose group and at 26, 78 and 105 weeks in the 100 ppm dose group.

Increased mean GGT activities compared to controls were seen at week 105 in the 25, 50 and 100 ppm dose group females. The increase in GGT activity at 50 ppm was

statistically significantly increased compared to controls ($p \leq 0.01$). The relationship between this finding and Aroclor-1260 exposure was considered equivocal.

Aroclor-1260 - Mean Cholesterol Concentration (mg/dL) in Core Subgroup Males and Females

Conc. (ppm)	Males				Females			
	Week of Study				Week of Study			
	26	52	78	105	26	52	78	105
Control	96	110	173	157	118	180	146	136
25	98	119	169	226	127	157	162	147
50	111	160	189	207	151	200	**233[b]**	**237[a]**
100	120	**143[a]**	197	207	**161[a]**	244	**260[b]**	**273[b]**

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

5.8.3 Urinalyses

There were no treatment-related effects on urinalysis parameters seen in any treatment group throughout the study. Group mean urinalysis values for Core subgroup males and females are found in Tables 41 and 42, respectively.

5.9 Organ Weights

Various organs, specified by protocol and amendment, were weighed during the scheduled Core, Interim, and Stop Study necropsies. Group mean absolute organ weight ratios, organ-to-body weight, and organ-to-brain weight ratio data are summarized separately by sex and for each necropsy interval, as applicable, in Table 47 through Table 58. Table 59 presents a summary of the statistical analysis comparing mean organ-to-brain weight ratios for liver and thyroid of the various test substances to each other at common feed concentrations of 50 and 100 ppm. Individual organ weight data are presented in Table E-5 (males) and Table E-6 (females), Volume VI.

The following discussion focuses on organ-to-brain weight ratio differences to normalize for spurious changes due to decreased body weight. Treatment-related organ weight effects were identified for the liver and thyroid for males and the liver for females. The findings in males were not clearly dose- or time-related; the liver-to-brain weight ratio

increases in females were marginally greater than those seen in males and were more consistently dose- and time-related. Other organ-to-brain weight ratios showed sporadic differences in treated groups compared to controls; these findings were not considered related to Aroclor test substance administration.

Aroclor-1016

Treated males exhibited increases of 2 to 17 percent in mean liver-to-brain weight ratios when compared to the controls at 26 weeks. By 52 weeks, the mean liver-to-brain weight ratios were increased 18 to 36 percent over the mean control weights, reaching statistical significance in the 200 ppm dose group. Mean liver-to-brain weight ratios for the 50, 100, and 200 ppm dose groups remained elevated when compared to the controls at 78 weeks, however the liver-to-brain weight ratios of males were only elevated 3 to 5 percent at 105 weeks, for the 100 and 200 ppm dose groups, respectively, compared to the controls.

Treated females exhibited no meaningful increases in mean liver-to-brain weight ratios at 13 weeks compared to controls. Treated females exhibited increases of 18 to 24 percent in mean liver-to-brain weight ratios when compared to the controls at 26 weeks. This trend of increased liver-to-brain weight ratios was still evident but diminished at 39 weeks. By 52 weeks, the increased mean liver-to-brain weight ratios were not evident for the 50 and 100 ppm dose group but persisted for the 200 ppm dose group, which showed a 13-percent increase compared to the controls. The mean liver-to-brain weight ratios for the 100 and 200 ppm dose group females were increased (7-11%) when compared to the controls at 78 weeks. The Stop Study B females, terminated at 78 weeks, showed no differences in liver-to-brain weight ratios compared to the control Interim termination females (in contrast to the increases in liver-to-brain weight ratios noted at 100 and 200 ppm in the corresponding treated Interim termination females). In the treated Core females, the mean liver-to-brain weight ratios for the 50, 100, and 200 ppm dose groups were increased (9-25%) when compared to the Core controls at 105 weeks, and the differences reached statistical significance for the 100 and 200 ppm dose groups. The treated Stop Study A females showed a non-dose-related increase in mean liver-to-brain weight ratios compared to the Core controls, which was statistically significant for the 50 ppm dose group only.

Aroclor-1016 - Mean Liver-to-Brain Weight Ratios (%) for Core/Interim Subgroup Males

Concentration (ppm)	Core/Interim Subgroup Males			
	Week of Study			
	26	52	78	105
Control	1182	1112	1059	1177
50 ppm	1387	1401	1201	1070
100 ppm	1201	1317	1583	1237
200 ppm	1244	**1516[a]**	1422	1216

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Aroclor-1016 - Mean Liver-to-Brain Weight Ratios (%) for Core/Interim Subgroup Females and Stop Study Subgroup Females

Concentration (ppm)	Core/Interim Subgroup Females						Stop Study Subgroup Females	
	Week of Study							
	13	26	39	52	78	105	B	A
Control	624	598	690	789	885	784	885*	784**
50 ppm	628	726	738	737	765	853	833	**1015[a]**
100 ppm	657	744	711	734	984	**970[b]**	881	909
200 ppm	653	706	789	890	947	**980[a]**	809	886

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.
* Weights from Control Female 78 - Week Interim Termination.
** Weights from Control Female 105 - Week Termination.

The mean thyroid-to-brain weight ratios were slightly increased in males for the 50, 100, and 200 ppm dose groups at 26 weeks compared to controls. This trend of increased thyroid-to-brain weight ratios generally continued at the 52-, 78-, and 105-week necropsies. Although the mean thyroid-to-brain weight ratios of treated males were greater when compared to the controls, none of these differences reached statistical significance.

No treatment-related effects were seen for thyroid-to-brain weight ratios for females.

Aroclor-1016 - Mean Thyroid-to-Brain Weight Ratios (%) for Core/Interim Subgroup Males

Concentration (ppm)	Core/Interim Subgroup Males			
	Week of Study			
	26	52	78	105
Control	1.21	1.99	2.30	2.10
50 ppm	1.41	2.14	2.45	2.07
100 ppm	1.73	2.38	2.96	2.75
200 ppm	1.56	2.56	3.46	2.35

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Aroclor-1242

Treated males exhibited increases of 2 to 16 percent in mean liver-to-brain weight ratios when compared to the controls at 26 weeks. By 52 weeks, the mean liver-to-brain weight ratios were 37 to 47 percent increased over the mean control weights, reaching statistical significance for the 50 ppm dose group, but not for the 100 ppm dose group. Mean liver-to-brain weight ratios for the 50 and 100 ppm dose groups remained elevated when compared to the controls at 78 weeks. The 100 ppm dose group mean liver-to-brain weight ratio was elevated compared to control by 9 percent at 105 weeks.

Treated females exhibited no meaningful effects on mean liver-to-brain weight ratios at 13 weeks. Treated females exhibited slight increases (6 to 23 percent) in mean liver-to-brain weight ratios when compared to the controls at 26 weeks. This trend of increased mean liver-to-brain weight ratios in the dosed animals was also noted at 39 weeks, but the differences from control were not remarkable at 52 and 78 weeks. The Stop Study B females, terminated at 78 weeks, showed no remarkable dose-related difference in mean liver-to-brain weight ratios compared to control, although a marginal increase compared to control was present for the 50 ppm dose group. In Core treated females, mean liver-to-brain weight ratios were 16 to 39 percent increased at 105 weeks with the increase for the 100 ppm dose group reaching statistical significance. Stop Study A females showed increased mean liver-to brain weight ratios compared to controls, with the magnitude of the increase generally similar to that seen in the corresponding Core dosed groups.

Aroclor-1242 - Mean Liver-to-Brain Weight Ratios (%) for Core/Interim Subgroup Males and Females and Stop Study Subgroup Females

Concentration (ppm)	Core/Interim Subgroup Males				Core/Interim Subgroup Females						Stop Study Subgroup Females	
	Week of Study				Week of Study							
	26	52	78	105	13	26	39	52	78	105	B	A
Control	1182	1112	1059	1177	624	598	690	789	855	784	885*	784**
50 ppm	1377	**1636**[a]	1297	1175	565	737	815	800	814	909	931	959
100 ppm	1202	1518	1200	1279	673	635	810	755	925	**1086**[b]	811	1035

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.
* Weights from Control Female 78 - Week Interim Termination.
** Weights from Control Female 105 - Week Termination.

The mean thyroid-to-brain weight ratios were 32 to 65 percent increased in males for the 50 and 100 ppm dose groups at 26 weeks and reached statistical significance for the 100 ppm dose group. This trend of increased thyroid-to-brain weight ratios continued at the 52-, 78-, and 105-week necropsies. Although the mean thyroid-to-brain weight ratios for treated males at the latter intervals were increased compared to the controls, none of these differences reached statistical significance.

No treatment-related effects were seen for thyroid-to-brain weight ratios in females.

Aroclor-1242 - Mean Thyroid-to-Brain Weight Ratios (%) for Core/Interim Subgroup Males

Concentration (ppm)	Core/Interim Subgroup Males			
	Week of Study			
	26	52	78	105
Control	1.21	1.99	2.30	2.10
50 ppm	1.60	2.24	2.48	4.93
100 ppm	**2.00**[a]	2.41	2.75	2.62

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Aroclor-1254

Treated males exhibited increases of 13 to 31 percent in mean liver-to-brain weight ratios when compared to the controls at 26 weeks. By 52 weeks, the mean liver-to-brain weight ratios were 30 to 45 percent increased over the mean control weights, reaching statistical significance for the 50 and 100 ppm dose groups. Mean liver-to-brain weight ratios for the 25, 50, and 100 ppm dose groups remained elevated when compared to the controls at 78 weeks and 105 weeks. Although these were probably treatment-related effects, none of the differences from control were statistically significant.

Treated females showed increases of 13 to 33 percent in mean liver-to-brain weight ratios when compared to the controls at 13 weeks for the 50 and 100 ppm dose groups. The increase for the 100-ppm dose group was statistically significant. The liver-to-brain weight ratios remained elevated compared to controls with statistically significant differences from control at 100 ppm at 26 weeks. The trend of increased liver weight continued through 78 weeks. The Stop Study B females, terminated at 78 weeks, also showed a dose-related increase in mean liver-to-brain weight ratios compared to controls; the magnitude of the increase was slightly less than that seen in the corresponding Interim termination dosed females. In Core treated females, liver-to-brain weight ratios were 54 to 120 percent elevated compared to controls at 105 weeks, with statistically significant differences from control for the 25, 50, and 100 ppm dose groups. Stop Study A females also showed a dose-related increase in mean liver-to-brain weight ratios compared to Core controls (statistically significant at 100 ppm only); the magnitude of the increase was less than that seen in the corresponding treated Core females.

Aroclor-1254 - Mean Liver-to-Brain Weight Ratios (%) for Core/Interim Subgroup Males and Females and Stop Study Subgroup Females

Concentration (ppm)	Core/Interim Subgroup Males				Core/Interim Subgroup Females						Stop Study Subgroup Females	
	Week of Study				Week of Study							
	26	52	78	105	13	26	39	52	78	105	B	A
Control	1182	1112	1059	1177	624	598	690	789	885	784	885*	784**
25 ppm	1341	1443	1508	1346	577	637	730	862	964	**1206[b]**	931	1096
50 ppm	1332	**1550[a]**	1286	1304	702	743	861	910	1113	**1584[b]**	937	1260
100 ppm	1552	**1615[a]**	1604	1411	**831[a]**	**868[a]**	874	937	1502	**1722[b]**	1049	**1256[b]**

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.
* Weights from Control Female 78 - Week Interim Termination.
** Weights from Control Female 105 - Week Termination.

The mean thyroid-to-brain weight ratios were increased 20 to 67 percent compared to controls in males for the 25, 50, and 100 ppm dose groups at 26 weeks, with the increase being statistically significant at 100 ppm. The trend of increased thyroid-to-brain weight ratios continued at 52 weeks, with the 50 ppm dose group being statistically significantly increased compared to control. At 78 weeks, thyroid-to-brain weight ratios for the 25 and 100 ppm dose groups were elevated but none of the increases were significant statistically. All three dose groups showed elevated thyroid-to-brain weight ratios compared to control at 105 weeks, and the increase for the 25 ppm dose group was statistically significant. Although the mean thyroid-to-brain weight ratios for the 50 and 100 ppm dose groups were increased compared to control, and the increases were considered biologically meaningful, the differences from control were not statistically significant due to the high standard deviations.

No treatment related effects were seen for thyroid-to-brain weight ratios in females.

Aroclor-1254 - Mean Thyroid-to-Brain Weight Ratios (%) for Core/Interim Subgroup Males

Concentration (ppm)	Core/Interim Subgroup Males			
	Week of Study			
	26	52	78	105
Control	1.29	1.99	2.30	2.10
25 ppm	1.92	2.22	3.30	**2.87[a]**
50 ppm	1.55	**3.07[a]**	2.11	8.39
100 ppm	**2.16[a]**	2.43	2.80	6.40

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Aroclor-1260

Treated males exhibited increases of 5 to 23 percent in mean liver-to-brain weight ratios when compared to the controls at 26 weeks. By 52 weeks, the mean liver-to-brain weight ratios for treated males were 24 to 66 percent increased over the mean control weights, reaching statistical significance for the 100 ppm dose group. Mean liver-to-brain weight ratios for the 25, 50, and 100 ppm dose groups remained elevated when compared to the controls at 78 and 105 weeks.

Treated females exhibited no meaningful increases in mean liver-to-brain weight ratios at 13 weeks compared to controls. Treated females exhibited increases of 30 to 34 percent in mean liver-to-brain weight ratios when compared to the controls at 26 weeks, the differences being statistically significant at 50 and 100 ppm. This trend of increased liver-to-brain weight ratios continued through 78 weeks. Stop Study B females, terminated at 78 weeks, showed non-dose-related increases in mean liver-to-brain weight ratios compared to control; the magnitude of the increases was slightly greater than that seen in the corresponding treated Interim termination females. In Core females, mean liver-to-brain weight ratios for the 25, 50, and 100 ppm dose groups showed statistically significant increases compared to control at 105 weeks. The mean liver-to-brain weight ratios at 100 ppm was almost two-fold greater than control at 105 weeks. Stop Study A females also showed dose-related increases in liver-to brain weight ratios compared to control (statistically significant at 50 and 100 ppm); the increases at 25 and 50 ppm were similar in magnitude to the increases seen for the

corresponding treated Core females, but the increase at 100 ppm was less compared to the increase for the corresponding treated Core 100 ppm dose group.

Aroclor-1260- Mean Liver-to-Brain Weight Ratios (%) for Core/Interim Subgroup Males and Females and Stop Study Subgroup Females

Concentration (ppm)	Core/Interim Subgroup Males				Core/Interim Subgroup Females						Stop Study Subgroup Females	
	Week of Study				Week of Study							
	26	52	78	105	13	26	39	52	78	105	B	A
Control	1182	1112	1059	1177	624	598	690	789	885	784	885*	784**
25 ppm	1242	1380	13[illegible]	1316	702	777	780	862	890	**984[a]**	986	1105
50 ppm	1373	147[illegible]	1462	1336	645	**801[a]**	851	728	908	**1086[b]**	1024	**1097[b]**
100 ppm	1448	**1850[a]**	147[illegible]	1315	627	**796[a]**	818	978	912	**1510[b]**	946	**1144[b]**

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.
* Weights from Control Female 78 - Week Interim Termination.
** Weights from Control Female 105 - Week Termination.

The mean thyroid-to-brain weight ratios were 17 to 32 percent increased in males for the 25, 50, and 100 ppm dose groups at 26 weeks. This trend of increased thyroid-to-brain weight ratios continued at 52 weeks, with the increase at 100 ppm reaching statistical significance. Thyroid-to-brain weight ratios for treated male groups remained increased compared to controls at 78 and 105 weeks. The mean thyroid-to-brain weight ratios for the 25 ppm dose group was statistically significantly increased compared to control at 105 weeks.

No treatment-related effects were seen for thyroid-to-brain weight ratios in females.

Aroclor-1260 - Mean Thyroid-to-Brain Weight Ratios (%) for Core/Interim Subgroup Males

Concentration (ppm)	Core/Interim Subgroup Males			
	Week of Study			
	26	52	78	105
Control	1.29	1.99	2.30	2.10
25 ppm	1.61	2.26	2.68	**3.00[a]**
50 ppm	1.51	2.80	2.85	2.61
100 ppm	1.70	**3.05[a]**	3.28	2.67

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

5.10 Necropsy

Tables summarizing the incidences of gross lesions for each sex and for all test substances were prepared for each scheduled termination with the exception of the 13-week interim females, for which no gross lesions were noted at necropsy. The table numbers that are appropriate to each termination are as follows: Tables 60, 61, 62, and 63 correspond to the 26-week, 52-week, 78-week, and 105-week termination males, respectively. Incidence summaries for the unscheduled-death males are presented in Tables 64 (0-12 months on test), 65 (12-18 months on test), and 66 (18-24 months on test). Tables summarizing the gross observations in females are Tables 67, 68, 69, 70, and 71 for the 26-week, 39-week, 52-week, 78-week, and 105-week terminations, respectively. Stop Study B females terminated at 78 weeks have necropsy data summarized in Table 72, and Stop Study A females terminated at 105 weeks have gross data summarized in Table 73. Incidence summaries for the unscheduled-death females are presented in Tables 74 (Core/Interim and Stop Study A and B females, 0-12 months); 75 (Core/Interim, 12-18 months); 76 (Core, 18-24 months); 77 (Stop Study A and B females, 12-18 months); and 78 (Stop Study A females, 18-24 months). Individual animal gross pathology results with correlating microscopic lesions are listed in Appendix Table E-7 for males and Appendix Table E-8 for females.

Treatment-related changes were confined to the liver (both sexes), thyroid gland (males only), and mammary gland (females only).

In the liver, one such change was generalized hepatic discoloration, which may have been the result of accumulations of porphyrins or stored iron [Smith, A. G., *et al.*, 1990]. Affected livers were a dark mahogany rather than the typical medium brown coloration. A second liver finding attributed to Aroclor exposure was increased numbers of liver foci (pinpoint or larger discrete areas of discoloration), which usually corresponded to foci of cellular alteration upon microscopic examination. Some rats had livers which appeared enlarged at necropsy. This is a subjective observation, dependent upon the overall size, age, and condition of any affected animal, but generally was supported by increased liver weight, compared to concurrent controls. Microscopically, the enlarged/heavier liver correlated with treatment-related hepatocyte hypertrophy. In addition, an apparent increase in space-occupying nodules and masses that protruded upward from the liver surface was catalogued for some of the treatment groups. Such nodules and masses generally were discolored, either

tan or mottled light and dark, when compared to the surrounding liver parenchyma. By convention, nodules were 5 mm or less in all dimensions, while masses were greater than 5 mm in at least one dimension, but otherwise there was no great difference in appearance between these lesions. In some cases, the nodules or even the masses corresponded microscopically to foci of cellular alteration, but most often they were determined to be hepatocellular adenomas or carcinomas by microscopic examination.

Smooth nodular hepatic deformities, without discoloration, which protruded into the hiatal areas of the diaphragm occasionally were found at necropsy. Microscopic examination revealed these lesions to be irregularities of hepatic shape due to an incidental developmental anomaly [Boorman, G. A., *et al.*, 1990)].

The incidence of enlarged thyroid glands was slightly increased in males in several of the treatment-groups when compared to controls. This is also a subjective observation, but it generally correlated with the mean thyroid-to-brain weight ratio increases in some groups of dosed males compared to controls. Microscopic examination showed increased incidences of follicular cell hyperplasia and/or follicular cell adenomas in some groups.

The incidence of mammary gland masses was decreased in some treated female groups. Masses of varying sizes, shapes and anatomic locations were the most frequently observed gross change involving the mammary gland of females. Other gross mammary gland changes observed in females included, in order of decreasing incidence: cysts, enlargement and nodules.

Aroclor-1016

Gross Findings - Liver. Aroclor-1016 produced no remarkable increases in gross liver changes in males. The incidence of relevant macroscopic liver lesions in Core males receiving Aroclor-1016 is depicted in the following table.

In females, no significant gross lesions were noted at the 13- or 26-week interim necropsy time points. A single liver focus was observed in one 50 ppm dose group female at 39 weeks, and a single liver mass in a 50 ppm dose group female was the only hepatic finding at 52 weeks. One control female had a liver focus documented at 39 weeks. At 78 weeks, liver foci were observed in two 50 ppm and one 200 ppm dose group females, and one 100 ppm dose group female had a liver mass. In Stop Study B females at 78 weeks, the only

relevant liver lesion was a mass observed in a 100 ppm dose group female. No liver lesions were present in controls at 78 weeks. No remarkable increases in gross liver changes were observed in treated Core or Stop Study A females compared to Core controls. The incidence of relevant macroscopic liver lesions in Core group females and Stop Study A females is depicted in the following table.

Aroclor-1016 - Incidence of Relevant Macroscopic Liver Lesions in Core Subgroup Males and Females and Stop Study A Subgroup Females

	Core Subgroup Animals								Stop Study A Subgroup		
Sex	**Male**				**Female**				**Female**		
Dose (ppm)	0	50	100	200	0	50	100	200	50	100	200
Liver # Necropsied	100	50	50	50	100	50	50	50	24	24	24
Enlarged	5 (5)	0 (0)	1 (2)	3 (6)	0 (0)	0 (0)	1 (2)	0 (0)	1 (4)	0 (0)	0 (0)
Discoloration	5 (5)	1 (2)	3 (6)	3 (6)	5 (5)	7 (14)	2 (4)	3 (6)	1 (4)	2 (8)	1 (4)
Focus	15 (15)	3 (6)	7 (14)	9 (18)	8 (8)	13 (26)	8 (16)	10 (20)	3 (13)	0 (0)	2 (8)
Mass	9 (9)	1 (2)	3 (6)	3 (6)	2 (2)	1 (2)	4 (8)	1 (2)	0 (0)	0 (0)	0 (0)
Nodule	1 (1)	1 (2)	1 (2)	1 (2)	0 (0)	1 (2)	1 (2)	4 (8)	0 (0)	0 (0)	1 (4)

( ) = Percentage

Gross Findings - Thyroid Gland. In males, Aroclor-1016 produced no remarkable increases in gross thyroid gland changes through 78 weeks. The incidence of enlarged thyroids seen in the Core group animals receiving 100 ppm and 200 ppm was also not remarkable when compared to the incidence in Core controls, and this finding is not considered treatment-related. The incidence of relevant macroscopic thyroid gland lesions in Core group males receiving Aroclor-1016 is depicted in the following table.

Aroclor-1016 produced no treatment-related increases in thyroid gland enlargement in females.

Aroclor-1016 - Incidence of Relevant Macroscopic Thyroid Gland Lesions in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	50	100	200
Thyroid Gland # Necropsied	100	50	50	50
Enlarged	4 (4)	0 (0)	2 (4)	1 (2)

( ) = Percentage

Gross Findings - Mammary Gland. Aroclor-1016 produced no treatment-related changes in incidence in mammary gland lesions in males.

In females, administration of Aroclor-1016 had no apparent effect on the incidence of macroscopic mammary gland masses. In females, a mammary gland mass was first observed at 39 weeks in one 100 ppm dose group female. Mammary gland masses were present in one 50 ppm and one 100 ppm dose group female at 52 weeks. No gross mammary gland masses were observed in control females through 52 weeks. At 78 weeks, mammary gland masses were seen in two 50 ppm, one 100 ppm and two 200 ppm dose group females. A mammary gland nodule was also noted at 78 weeks in one 200 ppm dose group female. In Stop Study B females, mammary gland masses were present in two, one and two females in the 50, 100 and 200 ppm dose groups, respectively. Two mammary gland masses and one nodule were recorded for female controls at 78 weeks. In Core group females, a slight decrease in the incidence of mammary gland masses was noted in the 50 ppm dose group compared to Core controls. The incidence of mammary gland masses in Stop Study A females was comparable to that in the Core controls. The incidence of relevant macroscopic mammary gland lesions in Core and Stop Study A females receiving Aroclor-1016 is depicted in the following table.

Aroclor-1016 - Incidence of Relevant Macroscopic Mammary Gland Lesions in Core and Stop Study A Subgroup Females

	Core Subgroup Females				Stop Study A Subgroup Females		
Dose (ppm)	0	50	100	200	50	100	200
Mammary Gland # Necropsied	100	50	50	50	24	24	24
Enlarged	6 (6)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (4)
Mass	51 (51)	18 (36)	26 (52)	30 (60)	11 (46)	13 (54)	10 (42)
Nodule	1 (1)	0 (0)	0 (0)	0 (0)	1 (4)	0 (0)	0 (0)
Cyst	5 (5)	1 (2)	4 (8)	1 (1)	1 (4)	0 (0)	1 (4)

( ) = Percentage

Aroclor-1242

Gross Findings - Liver. In males, an enlarged liver was observed in one animal in the 50 ppm dose group at 26 weeks, and liver foci were present for one 50 ppm animal at 78 weeks. No remarkable liver lesions were present in control males through 78 weeks. No remarkable increases in gross liver changes were observed in treated Core group males compared to Core controls. The incidence of relevant macroscopic liver lesions in Core group males receiving Aroclor-1242 is depicted in the following table.

In females, gross lesions for the liver were first noted at 26 weeks, and consisted of discoloration for one animal in the 100 ppm dose group. At 39 weeks, three females each in the 50 and 100 ppm dose groups had liver discoloration. Gross liver pathology at 52 weeks was limited to one 100 ppm female with liver discoloration. At 78 weeks, observed liver lesions for females included: an enlarged liver for one 100 ppm, foci for one 50 ppm and four 100 ppm, masses for two 100 ppm, and a liver nodule for one 100 ppm dose group animals. Stop Study B animals had liver foci in one 50 ppm female and in three 100 ppm females at 78 weeks. No remarkable liver lesions were present in comparable female controls at 78 weeks. A dose-related increase in macroscopic liver foci and masses was observed in Core group females as depicted below. Stop Study A females had a decreased incidence of liver foci, when compared to treated Core group females, but the incidence of macroscopic masses in Stop Study A females was not decreased compared to the incidence in the

corresponding treated Core group females, and the incidence of foci and masses was increased compared to Core controls. The incidence of relevant macroscopic liver lesions in Core and Stop Study A females is depicted in the following table.

Aroclor-1242 - Incidence of Relevant Macroscopic Liver Lesions in Core Subgroup Males and Females and Stop Study A Subgroup Females

	Core Subgroup Animals						Stop Study A Subgroup	
Sex	**Male**			**Female**			**Female**	
Dose (ppm)	0	50	100	0	50	100	50	100
Liver # Necropsied	100	50	50	100	50	50	24	24
Enlarged	5 (5)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (4)	1 (4)
Discoloration	5 (5)	2 (4)	7 (14)	5 (5)	4 (8)	3 (6)	2 (8)	0 (0)
Focus	15 (15)	12 (24)	12 (24)	8 (8)	16 (32)	29 (58)	3 (13)	5 (21)
Mass	9 (9)	2 (4)	4 (8)	2 (2)	7 (14)	12 (24)	3 (13)	6 (25)
Nodule	1 (1)	0 (0)	2 (4)	0 (0)	0 (0)	2 (4)	1 (4)	3 (13)

( ) = Percentage

Gross Findings - Thyroid Gland. In males, Aroclor-1242 produced no remarkable increases in gross thyroid gland changes through 78 weeks. Slight increases in the incidence of enlarged thyroid glands were observed in treated Core group males compared to Core controls. The incidence of relevant macroscopic thyroid gland lesions in Core males receiving Aroclor-1242 is depicted in the following table.

Aroclor-1242 produced no treatment-related increases in the incidence of thyroid gland enlargement in females.

Aroclor-1242 - Incidence of Relevant Macroscopic Thyroid Gland Lesions in Core Subgroup Males

	Core Subgroup Males		
Dose (ppm)	0	50	100
Thyroid Gland # Necropsied	100	50	50
Enlarged	4 (4)	6 (12)	5 (10)

( ) = Percentage

Gross Findings - Mammary Gland. Aroclor-1242 produced no treatment-related changes in incidence for mammary gland masses in males.

In females, a mammary gland mass was first noted in one 50 ppm dose group female at 39 weeks. No mammary gland changes were observed in females at 52 weeks. No mammary gland masses were recorded for control females through 52 weeks. At 78 weeks, a mammary gland mass was observed in one 50 ppm dose group female. In Stop Study B animals, a mammary gland mass was found in one 50 ppm and one 100 ppm dose group females. Two mammary gland masses and one nodule were recorded for control females at 78 weeks. In Core group females, treatment with Aroclor-1242 caused an apparent decrease in the incidence of macroscopic mammary masses compared to the incidence in Core group controls. In Stop Study A females, however, the incidence of mammary masses was comparable to that in Core group controls. The incidence of relevant macroscopic mammary gland lesions in Core and Stop Study A subgroup females is depicted in the following table.

Aroclor-1242 - Incidence of Relevant Macroscopic Mammary Gland Lesions in Core and Stop Study A Subgroup Females

	Core Subgroup Females			Stop Study A Subgroup Females	
Dose (ppm)	0	50	100	50	100
Mammary Gland # Necropsied	100	50	50	24	24
Enlarged	6 (6)	0 (0)	0 (0)	0 (0)	0 (0)
Mass	51 (51)	18 (36)	18 (36)	13 (54)	14 (58)
Nodule	1 (1)	0 (0)	1 (2)	0 (0)	0 (0)
Cyst	5 (5)	6 (12)	5 (10)	0 (0)	0 (0)

( ) = Percentage

Aroclor-1254

Gross Findings - Liver. In males at 26 weeks, a generalized mottled yellow/red or pale discoloration of the liver was observed in two 100 ppm males and one 50 ppm male. Also, one 50 ppm and one 100 ppm male had enlarged livers. At 52 weeks, the only gross liver abnormality in males was hepatic discoloration in one 100 ppm rat. At 78 weeks, hepatic lesions including discoloration in one 25 ppm male and foci in one 50 ppm and three 100 ppm males were observed. No liver lesions were present in controls terminated at 78 weeks. Core group males exposed to Aroclor-1254 showed a dose-related increased incidence of macroscopic liver foci compared to Core group controls. The incidence of relevant macroscopic liver lesions in Core males receiving Aroclor-1254 is depicted in the table below.

In females, no gross lesions were noted in any of the 13-week interim females. All females in the 25-, and 50-, and 100 ppm groups had liver discoloration at 26 weeks. At 39 weeks, dark discoloration of the livers was apparent in three, five and six animals in the 25, 50 and 100 ppm dose groups, respectively. At 52 weeks, liver discoloration was present in three 50 ppm and three 100 ppm dose group females; and two 100 ppm females also had liver foci. At 78 weeks, liver lesions in females included: foci in three 25 ppm, six 50 ppm and four 100 ppm dose group animals; masses in two 100 ppm dose group animals; and a nodule in one 50 ppm and one 100 ppm dose group animals. In addition, one Stop Study B 100 ppm female had a liver mass and another 100 ppm female had a liver nodule; liver foci were observed in one 25 ppm, three 50 ppm and five 100 ppm females. No liver lesions were present in controls at 78 weeks. Treated Core group females exhibited dose-related increases in both foci and masses compared to Core group controls. Foci and masses also were increased in Stop Study A females (compared to Core controls), although less so than in Core females in the corresponding treated groups. The incidence of relevant macroscopic liver lesions in Core and Stop Study A females receiving Aroclor-1254 is depicted in the following table.

Aroclor-1254 - Incidence of Relevant Macroscopic Liver Lesions in Core Subgroup Males and Females and Stop Study A Females

	Core Subgroup Animals								Stop Study A Subgroup		
Sex	**Male**				**Female**				**Female**		
Dose (ppm)	0	25	50	100	0	25	50	100	25	50	100
Liver # Necropsied	100	50	50	50	100	50	50	50	24	24	24
Enlarged	5 (5)	5 (10)	4 (8)	4 (8)	0 (0)	2 (4)	3 (6)	6 (12)	2 (8)	1 (4)	0 (0)
Discoloration	5 (5)	6 (12)	7 (14)	12 (24)	5 (5)	3 (6)	11 (22)	4 (8)	3 (13)	3 (13)	0 (0)
Focus	15 (15)	16 (32)	15 (30)	23 (46)	8 (8)	32 (64)	31 (62)	41 (82)	9 (38)	8 (33)	11 (46)
Mass	9 (9)	3 (6)	3 (6)	5 (10)	2 (2)	17 (34)	21 (42)	27 (54)	5 (21)	6 (25)	5 (21)
Nodule	1 (1)	0 (0)	0 (0)	1 (2)	0 (0)	4 (8)	2 (4)	5 (10)	0 (0)	1 (4)	0 (0)

( ) = Percentage

Gross Findings - Thyroid Gland. In males, Aroclor-1254 produced no remarkable increases in gross thyroid gland changes through 78 weeks. In Core group males, slight, non dose-related, increases in the incidence of enlarged thyroid glands were observed in all treated groups of males compared to the incidence of this finding in Core group controls. The incidence of relevant macroscopic thyroid gland lesions in Core group males receiving Aroclor-1254 is depicted in the following table.

No treatment-related enlarged thyroid glands were observed in females.

Aroclor-1254 - Incidence of Relevant Macroscopic Thyroid Gland Lesions in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	25	50	100
Thyroid Gland # Necropsied	100	50	50	50
Enlarged	4 (4)	5 (10)	11 (22)	5 (10)

( ) = Percentage

Gross Findings - Mammary Gland. Aroclor-1254 produced no treatment-related changes in incidence in mammary gland masses in males.

In females, gross changes involving the mammary gland were first seen at 39 weeks, for the 50 and 100 ppm dose group animals, although no mammary gland masses were observed at this time point. At 52 weeks, a mammary gland mass was seen in one 50 ppm female. No gross mammary gland masses were recorded for control females through 52 weeks. At 78 weeks, mammary gland masses were observed in one 25 ppm and two 50 ppm dose group females. In addition, mammary gland nodules were seen in two 50 ppm dose group animals at 78 weeks. Mammary gland masses in Stop Study B animals were found in two 25 ppm, one 50 ppm, and one 100 ppm dose group females. In addition, a mammary gland nodule was seen in one 25 ppm female. Two mammary gland masses and one nodule were recorded for female controls at 78 weeks. In treated Core group females, a decrease in the incidence of mammary masses was noted in the 100 ppm animals, while other dose groups and all Stop Study A females had incidences of mammary masses which were comparable to or slightly greater than Core controls. The incidence of relevant macroscopic mammary gland lesions in Core and Stop Study A females is depicted in the following table.

Aroclor-1254 - Incidence of Relevant Macroscopic Mammary Gland Lesions in Core Subgroup and Stop Study A Subgroup Females

	Core Subgroup Females				Stop Study A Subgroup Females		
Dose (ppm)	0	25	50	100	25	50	100
Mammary Gland # Necropsied	100	50	50	50	24	24	24
Enlarged	6 (6)	0 (0)	2 (4)	1 (2)	0 (0)	1 (4)	1 (4)
Mass	51 (51)	26 (52)	32 (64)	12 (24)	16 (67)	18 (75)	15 (63)
Nodule	1 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Cyst	5 (5)	1 (2)	0 (0)	2 (4)	4 (17)	2 (8)	1 (4)

( ) = Percentage

Aroclor-1260

Gross Findings - Liver. In males, hepatic findings were first noted at 52 weeks, with liver discoloration identified for one 100 ppm dose group animal. At 78 weeks, liver lesions were limited to foci in two 50 ppm and one 100 ppm males, and a nodule in a 25 ppm male. Treated Core group males showed a dose-related increase in macroscopic liver foci and an increase in liver masses at the highest dose. The incidence of relevant macroscopic liver lesions in Core group males receiving Aroclor-1260 is depicted in the table below.

In females, hepatic lesions were first seen at 26 weeks, consisting of liver discoloration and a hepatic nodule in one animal each at 100 ppm. At 39 weeks, two 25 ppm, three 50 ppm, and three 100 ppm dose group females had liver discoloration. Additional liver lesions observed at 39 weeks included foci in one 100 ppm female, and a nodule in another 100 ppm dose group female. At 52 weeks, liver discoloration was seen in one 50 ppm and three 100 ppm dose group animals, and a liver focus was noted in one 100 ppm dose group animal. At 78 weeks, liver foci were observed in one 25 ppm, two 50 ppm and three 100 ppm dose group females; liver masses were seen in one 50 ppm and one 100 ppm dose group female; and liver nodules were noted in two 50 ppm dose group females. Stop Study B females had gross liver lesions consisting of foci in two 100 ppm and a mass in one 100 ppm dose group animals. In contrast, no liver lesions were present in comparable female controls at 78 weeks. Treated Core group females showed a dose-related increase in both liver foci and masses compared to Core group controls. The incidences of liver foci and masses (including nodules) were comparable between the Stop Study A females and the treated Core group females. The incidence of relevant macroscopic liver lesions in Core and Stop Study A females is depicted in the following table.

Aroclor-1260 - Incidence of Relevant Macroscopic Liver Lesions in Core Subgroup Males and Females in Stop Study A

	Core Subgroup Animals								Stop Study A Subgroup		
Sex	Male				Female				Female		
Dose (ppm)	0	25	50	100	0	25	50	100	25	50	100
Liver # Necropsied	100	50	50	50	100	50	50	50	24	24	24
Enlarged	5 (5)	2 (4)	4 (8)	4 (8)	0 (0)	1 (2)	3 (6)	6 (12)	1 (4)	0 (0)	1 (4)
Discoloration	5 (5)	7 (14)	10 (20)	4 (8)	5 (5)	5 (10)	3 (6)	7 (14)	1 (4)	4 (17)	2 (8)
Focus	15 (15)	11 (22)	16 (32)	18 (36)	8 (8)	12 (24)	14 (28)	17 (34)	3 (13)	6 (25)	8 (33)
Mass	9 (9)	2 (4)	4 (8)	9 (18)	2 (2)	5 (10)	8 (16)	22 (44)	3 (13)	3 (13)	13 (54)
Nodule	1 (1)	3 (6)	2 (4)	1 (2)	0 (0)	3 (6)	2 (4)	2 (4)	0 (0)	1 (4)	4 (17)

( ) = Percentage

Gross Findings - Thyroid Gland. In males, Aroclor-1260 produced no remarkable increases in gross thyroid gland changes through 78 weeks. In treated Core group males, enlarged thyroid glands were observed in five 25 ppm, five 50 ppm and four 100 ppm dose group males. Enlarged thyroid glands also were seen in four Core group controls. Thus, in Core group males, slight increases in the incidence of enlarged thyroid glands were observed for the 25, 50 and 100 ppm dose groups, compared to Core group controls. The incidence of relevant macroscopic thyroid gland lesions in Core group males is depicted in the following table.

There was no treatment-related increased incidence of enlarged thyroids for females.

Aroclor-1260 - Incidence of Relevant Macroscopic Thyroid Gland Lesions in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	25	50	100
Thyroid Gland # Necropsied	100	50	50	50
Enlarged	4 (4)	5 (10)	5 (10)	4 (8)

( ) = Percentage

Gross Findings - Mammary Gland. Aroclor-1260 produced no treatment-related changes in incidence in mammary gland masses in males.

In females, mammary gland masses were first seen in two 25 ppm dose group animals at 52 weeks. No gross mammary gland masses were recorded for control females through 52 weeks. At 78 weeks, mammary gland masses were observed in three 25 and two 50 ppm dose group animals, and one 100 ppm female. Mammary gland masses in Stop Study B animals were found in two 25 ppm, one 50 ppm and one 100 ppm dose group females. In addition, a mammary gland nodule was seen in one 50 ppm dose group female. Two mammary gland masses and one nodule also were recorded for female controls at 78 weeks. Treated Core group animals had a slightly decreased incidence of gross mammary masses compared to Core group controls. Stop Study A females, however, showed a higher incidence of mammary gland masses than that found in the corresponding treated Core females, but the incidence was similar to the Core group controls. The incidence of relevant macroscopic mammary gland lesions in Core and Stop Study A subgroup females is depicted in the following table.

Aroclor-1260 - Incidence of Relevant Macroscopic Mammary Gland Lesions in Core and Stop Study A Subgroup Females

	Core Subgroup Females				Stop Study A Subgroup Females		
Dose (ppm)	0	25	50	100	25	50	100
Mammary Gland # Necropsied	100	50	50	50	24	24	24
Enlarged	6 (6)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Mass	51 (51)	18 (36)	18 (36)	22 (44)	16 (67)	10 (42)	12 (50)
Nodule	1 (1)	0 (0)	1 (2)	1 (2)	1 (4)	0 (0)	0 (0)
Cyst	5 (5)	6 (12)	2 (4)	1 (2)	1 (4)	0 (0)	1 (4)

( ) = Percentage

5.11 Histopathology

Pathology data were summarized by lesion type, sex, and scheduled termination, as follows:

Summary Tables of Male Rat Histopathology Data

Termination	Lesion Type	Table	Lesion Type	Table
26-Week	Non-Neoplastic	79	Neoplastic	99
52-Week	Non-Neoplastic	80	Neoplastic	100
78-Week	Non-Neoplastic	81	Neoplastic	101
105-Week	Non-Neoplastic	82	Neoplastic	102
Unscheduled, 0-12 Months	Non-Neoplastic	83	Neoplastic	103
Unscheduled, 12-18 Months	Non-Neoplastic	84	Neoplastic	104
Unscheduled, 18-24 Months	Non-Neoplastic	85	Neoplastic	105

Summary Tables of Female Rat Histopathology Data

Termination	Lesion Type	Table	Lesion Type	Table
13-Week	Non-Neoplastic	86	Neoplastic	106
26-Week	Non-Neoplastic	87	Neoplastic	107
39-Week	Non-Neoplastic	88	Neoplastic	108
52-Week	Non-Neoplastic	89	Neoplastic	109
78-Week	Non-Neoplastic	90	Neoplastic	110
105-Week	Non-Neoplastic	91	Neoplastic	111
78-Week Stop Study B	Non-Neoplastic	92	Neoplastic	112
105-Week Stop Study A	Non-Neoplastic	93	Neoplastic	113
Unscheduled, 0-12 Months	Non-Neoplastic	94	Neoplastic	114
Unscheduled, 12-18 Months	Non-Neoplastic	95	Neoplastic	115
Unscheduled, 18-24 Months	Non-Neoplastic	96	Neoplastic	116
Unscheduled, 12-18 Months, Stop Study	Non-Neoplastic	97	Neoplastic	117
Unscheduled, 18-24 Months, Stop Study	Non-Neoplastic	98	Neoplastic	118

Individual histopathology results for all animals are listed in Appendix Table E-9 for males and Appendix Table E-10 for females. Histologically, exposure to the test substances caused a constellation of non-neoplastic liver changes in both sexes which included: centrilobular hepatocellular hypertrophy with cytoplasmic microvacuolization; hepatocellular

cytoplasmic macrovacuolization; hepatocellular foci of cellular alteration; and bile duct hyperplasia. For females, sinusoidal pigment deposition was also present. In addition, increased numbers of several types of liver tumors also were found in many groups of animals exposed to the test substances. These included hepatocellular adenomas and carcinomas, and a relatively sparse incidence of mixed hepatocellular-bile duct tumors (hepatocholangiomas, hepatocholangiocarcinomas). Other liver tumors, including pure bile duct origin tumors, were not observed at an increased incidence in the livers of treated animals, and are not further discussed in this report. Non-neoplastic changes involving the thyroid glands consisted of follicular cell hyperplasia in some groups of treated males. Increased numbers of thyroid follicular cell adenomas were also seen in some groups of treated males, but not females. In some groups of females, however, treatment-related decreases in mammary gland tumor incidence were observed. Histologic lesions were catalogued using published criteria [Standard System of Nomenclature, STP; Boorman, G. A., *et al.*, 1990].

Most other changes seen microscopically were present in approximately equal numbers across control and Aroclor test substance-treated groups, with the exception of alveolar cell hyperplasia, which was noted more frequently in males given 100 ppm of Aroclor-1254. This change, thought to be a response to chronic lung inflammation or irritation, was interpreted to be of no direct relationship to the Aroclor test substance administration. Except as discussed below, all microscopic observations were interpreted to be incidental to Aroclor test substance exposure.

Liver - Non-Neoplastic. Centrilobular hepatocellular hypertrophy was characterized by enlarged cell size, cytoplasmic microvacuolization, and narrowed sinusoids. The enlarged size was due principally to an increase in cytoplasm, although some nuclei also were enlarged. The hepatocytes at the center of the hepatic lobules were affected the most, with a gradual decrease in cell size toward normal as the portal triads were approached. Severity grades were assigned based on average cell size of the affected centrilobular hepatocytes, as well as the fraction of the lobule containing affected cells. The median liver lobe had slightly more severe involvement with this lesion than the left lateral lobe, perhaps reflecting different flow rates of portal blood to these two lobes. Centrilobular hypertrophy correlated with the gross observation of "enlarged liver" and the increased liver weights described earlier.

"Vacuolization, hepatocyte" was the term used when large, clear "macrovesicular" cytoplasmic vacuoles were seen. Almost all such vacuoles were found in the hepatocytes that were affected by centrilobular hypertrophy. Therefore, animals affected by both centrilobular hypertrophy and centrilobular vacuolization had hepatocytes containing both micro- and macrovacuoles. Hepatocellular cytoplasmic (micro) vacuoles were seen in some of the treated animals without any strong dose-response pattern but were not found at all in controls. By contrast, macrovesicular vacuoles were seen in a few controls as well as treated animals, and may represent accumulations of lipids within hepatocytes.

Foci of cellular alteration (basophilic, eosinophilic, clear cell, and mixed) also were observed in the livers of some animals, including controls. Altered foci appear to be related to Aroclor test substance administration based upon an increased incidence in some groups of treated animals, compared to applicable controls. These lesions were diagnosed when clusters of hepatocytes were observed with altered cytoplasmic staining qualities, characterized as basophilic, eosinophilic, clear (unstained), or mixed. Diagnostic criteria for foci of cellular alteration also included the presence of discontinuous patterns of vascularization in the hepatic parenchyma. Eosinophilic foci were increased the most in Aroclor test substance-exposed animals, followed by clear and mixed cell foci. The relationship of basophilic focus formation to the test substances was less clear except for Aroclor-1016 and Aroclor-1242.

Pigment was diagnosed when a gray or brown material filled the cytoplasm of cells lining the hepatic sinusoids. The nature of the pigment is unknown, and special stains to attempt identification were not performed. The identity of the cells containing the pigment was uncertain, although the cells are presumed to be Kupffer cells (fixed macrophages) or Ito cells (fat-storing cells), based on light microscopic appearance. Occasionally, a small amount of yellow-brown pigment compatible with hemosiderin was found in the portal triad region. However, the small amount of hemosiderin in the portal triad region for the females on this study was not considered to be an unusual finding in aging females, and was not tabulated as a lesion for them. Thus, all of the females with the lesion pigment entered in tables had a distinct gray/brown pigmentation in the liver.

Biliary duct hyperplasia consisted of excessive numbers of bile duct profiles in liver sections. This diagnosis also was made when small oval-shaped cells were seen in increased numbers at the periphery of lobules.

Liver - Neoplastic. The combined incidence of primary benign liver tumors (hepatocellular adenomas and/or hepatocholangiomas), and primary malignant liver tumors (hepatocellular carcinomas and/or hepatocholangiocarcinomas) was assessed to investigate the extent of treatment on total liver tumor development.

Primary hepatic neoplasms were increased in several groups of Aroclor test substance-treated animals. Hepatocellular adenomas were diagnosed when aggregations of hepatocytes were found having clear discontinuities of lobular pattern and vascularization from surrounding liver parenchyma, having compression of surrounding hepatocytes, and having a diameter roughly equal to ten hepatic lobules or more. Large foci of cellular alteration were not always easily distinguished from small hepatocellular adenomas. Hepatocellular carcinomas were diagnosed when proliferative hepatocellular lesions were found which also exhibited the added features of acinus formation within the tumors, trabecularization of thick hepatic cords, cytologic atypia, invasion and/or metastasis. Large adenomas were not always easily distinguished from carcinomas.

Mixed hepatocellular/bile duct tumors also were seen. These consisted of hepatocellular neoplasms which also contained an element of proliferating bile ductules. In all cases, the hepatocellular element of the tumor was more prominent than the bile ductular component. The criteria mentioned above for distinguishing hepatocellular adenomas and carcinomas were applied to distinguish the benign mixed tumors (hepatocholangiomas) from the malignant mixed tumors (hepatocholangiocarcinomas).

Thyroid. Follicular cell hyperplasia of the thyroid gland in males was characterized by focal (usually well demarcated), enlarged follicles, sometimes containing multiple smaller follicles, or follicles with papillary infoldings of the lining epithelium. The number of epithelial cells lining the enlarged follicle was increased, usually by papillary infolding of simple cuboidal or columnar epithelium into the lumen or by stratification of the follicular epithelial cells.

Also seen at increased incidence in rats exposed to the Aroclor test substances were thyroid follicular cell adenomas, which were increased in some groups of exposed males only. Follicular cell adenomas were well circumscribed, expansile tumors which compressed the adjacent, normal thyroid follicles. Tumor cells tended to be slightly smaller than normal, and stain more hyperchromatic. The epithelium in these tumors formed irregular follicular

structures or papilliferous structures in cystic spaces. Thyroid follicular cell carcinomas also had follicular or papillary patterns of growth, but were larger, exhibited cellular atypia, frequently had some surrounding capsule, and had evidence of capsule invasion or metastasis.

Mammary. In contrast to tumors in liver and thyroid, tumors of the mammary gland were less common in many groups of females exposed to the test substances than in control females. Mammary tumors seen in this study were of typical morphology, with the most common presentation being large fibrous masses with scattered mammary acini ("fibroadenoma").

Aroclor-1016

Liver - Non-Neoplastic. In males at 26 weeks, centrilobular hepatocellular hypertrophy was observed in the 50, 100 and 200 ppm dose groups. At each successive scheduled necropsy, the hypertrophy tended to increase in incidence and/or severity. No hepatocellular hypertrophy was observed through 78 weeks in control males. Generally, the severity of hypertrophy was greatest in the 200 ppm dose group males, and was marginally greater in males than females. In Core group males, a dose-related increase in the severity and incidence of centrilobular hepatocellular hypertrophy was identified.

In females, centrilobular hepatocellular hypertrophy was found only in the 100 and 200 ppm dose groups at 13 and 26 weeks. Hepatocellular hypertrophy was also present in the 50 ppm dose group at 39 weeks. At each successive scheduled necropsy, the hypertrophy tended to increase in incidence and severity. Generally, the severity of hypertrophy was greatest for the 200 ppm dose group. No hepatocellular hypertrophy was observed through 78 weeks in control females. In Core group females, a dose-related increase in the severity and incidence of centrilobular hepatocellular hypertrophy was identified, although the severity was less than that seen at the 78-week interim necropsy. In Stop Study B subgroup females, no hepatocellular hypertrophy was observed for any dose group. Also, no hepatocellular hypertrophy was seen for controls at the 78-week interim necropsy. In Stop Study A females, the incidence and severity of hypertrophy was less than that of the Core group females in corresponding dose groups, but was increased compared to the Core controls.

In males, hepatocyte vacuolization was first seen at 26 weeks in two 200 ppm dose group animals and was noted sporadically at successive interim terminations. No hepatocellular vacuolization was observed through 78 weeks in control males. Hepatocyte vacuolization was present in all groups of Core males, including controls.

In females, hepatocyte vacuolization was first seen at 39 weeks in two 200 ppm dose group animals, and was noted sporadically at successive interim terminations. No hepatocyte vacuolization was observed through 78 weeks in control females. Hepatocyte vacuolization was present for all Core female dose groups, and was increased in incidence and severity in these animals in a dose-related pattern. In Stop Study B females, hepatocyte vacuolization was present at a low incidence for all treated groups. In Stop Study A females, the incidence of hepatocellular vacuolization was less for all dose groups compared to corresponding treated Core group females and similar to that seen in Core controls.

In males, hepatocellular foci were first detected in treated and control animals at 52 weeks, and the incidence was sporadic and not dose-related. Foci of various types became more common in treated males after the 78-week interim necropsy. In treated Core group animals, the incidence of eosinophilic foci was increased when compared to Core controls.

In females, hepatocellular foci were first detected at 26 weeks, and the incidence was sporadic and not dose-related. Foci were noted for the first time for control animals, at a low incidence, at the 78-week interim necropsy time point. Foci of various types became more common in treated females at and after the 78-week interim termination, with the incidence of both eosinophilic and basophilic foci increasing in a dose-related pattern in Core group females. For Stop Study B females, hepatocellular foci were noted at a low incidence for all groups, including corresponding controls, at week 78. The incidence of foci for Stop Study A females was generally similar to the corresponding treated Core group females.

Aroclor-1016 produced no microscopic evidence of pigment-laden sinusoidal cells in males.

In females at 13 weeks, pigment-laden sinusoidal cells were observed in one control animal. Pigment-laden sinusoidal cells were first seen in treated females at 39 weeks for one 200 ppm dose group animal. At 52 weeks, pigment was observed in one 50 ppm, one 100 ppm, and two 200 ppm dose group females. At 78 weeks, pigment was seen in only two 200 ppm dose group females. Hepatic pigment was not seen in Stop Study B females, or in control females through 78 weeks. In Core group females, pigment was observed in seven

controls and two 50 ppm, three 100 ppm, and seven 200 ppm dose group animals. In Stop Study A females, the incidence of hepatic pigment was less for all dose groups when compared to corresponding treated Core group females.

In males at 26 weeks, minimal bile duct hyperplasia was observed in two 100 ppm dose group animals. In both control and treated rats, bile duct hyperplasia became gradually more common and slightly more severe throughout the study. In Core group males receiving 200 ppm, there was a slight increase in the average severity of bile duct hyperplasia when compared to Core controls.

In females at 26 weeks, minimal bile duct hyperplasia was observed in three 100 and two 200 ppm dose group animals. In both control and treated rats, bile duct hyperplasia became gradually more common and slightly more severe throughout the study. In Stop Study B females, there was an increase in incidence and severity of bile duct hyperplasia at 78 weeks, compared with the corresponding controls. In Core group females, there were dose-related increases in incidence and/or severity in bile duct hyperplasia compared to Core controls. In Stop Study A females, the incidence and severity of bile duct hyperplasia was less for animals receiving 100 or 200 ppm compared to corresponding treated Core group females. The incidence of relevant microscopic liver lesions in Core males and females and Stop Study A females receiving Aroclor-1016 is depicted in the following tables.

Aroclor-1016 - Incidence of Relevant Microscopic Non-neoplastic Liver Lesions in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	50	100	200
Number Examined Microscopically	100	50	50	50
Hypertrophy, Hepatocyte, Centrilobular	0 (0.0)	18 (0.6)	34 (1.3)	44 (2.3)
Hyperplasia, Bile Duct	70 (1.1)	38 (1.2)	35 (1.1)	37 (1.4)
Vacuolization, Hepatocyte	32 (0.6)	18 (0.6)	18 (0.6)	22 (0.8)
Basophilic Cell Focus	7	3	5	2
Clear Cell Focus	17	1	3	9
Eosinophilic Cell Focus	2	5	2	6
Mixed Cell Focus	5	1	4	2

( ) = Average Severity

Aroclor-1016 - Incidence of Relevant Microscopic Non-Neoplastic Liver Lesions in Core and Stop Study A Subgroup Females

	Core Subgroup Females				Stop Study A Subgroup Females		
Dose (ppm)	0	50	100	200	50	100	200
Number Examined Microscopically	100	50	50	50	24	24	24
Hypertrophy, Hepatocyte, Centrilobular	0 (0.0)	21 (0.6)	30 (1.0)	42 (1.8)	10 (0.5)	8 (0.5)	10 (0.7)
Hyperplasia, Bile Duct	40 (0.7)	28 (0.8)	31 (1.1)	43 (1.5)	20 (1.5)	8 (0.5)	12 (0.9)
Pigment	7 (0.1)	2 (0.1)	3 (0.1)	7 (0.2)	1 (0.4)	1 (0.4)	0 (0.0)
Vacuolization, Hepatocyte	13 (0.2)	15 (0.5)	17 (0.5)	17 (0.5)	3 (0.3)	2 (0.8)	2 (0.8)
Basophilic Cell Focus	5	12	11	12	6	3	4
Clear Cell Focus	2	3	1	2	1	4	0
Eosinophilic Cell Focus	4	12	13	24	8	4	4
Mixed Cell Focus	8	5	9	6	3	0	2

( ) = Average Severity

Liver - Neoplastic. Aroclor-1016 produced no treatment-related increases in hepatocellular neoplasms in male rats. The incidence of relevant liver neoplasms in Core group males receiving Aroclor-1016 is depicted in the following table.

Aroclor-1016 - Incidence of Relevant Liver Neoplasms in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	50	100	200
Number Examined Microscopically	100	50	50	50
Hepatocellular Adenoma	4 (4)	1 (2)	1 (2)	2 (4)
Hepatocellular Carcinoma	3 (3)	1 (2)	1 (2)	2 (4)
Males with Liver Neoplasms[1]	7 (7)	2 (4)	2 (4)	4 (8)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 119 for statistical analysis of individual tumor types.

In females, hepatic neoplasms were not seen in control or treated rats at the 13-, 26-, 39-, or 52-week interim necropsy time points. At 78 weeks, hepatocellular adenomas were seen in one 100 ppm dose group female, and one 100 ppm Stop Study B female. No hepatocellular neoplasms were observed in control females at 78 weeks. In Core group females, hepatocellular adenomas were seen in one control animal and one 50 ppm, five 100 ppm, and five 200 ppm dose group females. A hepatocellular carcinoma was seen in one 100 ppm dose group female. Hepatocellular carcinomas were not observed for any Core control female animals. The combined tumor incidence for the Core group females receiving 100 and 200 ppm was statistically significantly increased from Core controls. The incidence of hepatocellular neoplasms was decreased in Stop Study A females compared to treated Core group females. The incidence of relevant liver neoplasms in Core males and females and Stop Study A females receiving Aroclor-1016 is depicted in the table below.

Aroclor-1016 - Incidence of Relevant Liver Neoplasms in Core and Stop Study A Subgroup Females

	Core Subgroup Females				Stop Study A Subgroup Females		
Dose (ppm)	0	50	100	200	50	100	200
Number Examined Microscopically	100	50	50	50	24	24	24
Hepatocellular Adenoma	1 (1)	1 (2)	5 (10)	5 (10)	0 (0)	0 (0)	0 (0)
Hepatocellular Carcinoma	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
Females with Liver Neoplasms[1]	1[c] (1)	1 (2)	6[b] (12)	5[a] (10)	0 (0)	0 (0)	0 (0)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 120 (Core animals) and Table 121 (Stop Study animals) for statistical analysis of individual tumor types.

a. Statistically significant increase ($p \leq 0.05$) in incidence of primary hepatic neoplasms using unadjusted statistical tests.

b. Statistically significant increase ($p \leq 0.01$) in incidence of primary hepatic neoplasms using unadjusted statistical tests.

c. Statistically significant trend test ($p \leq 0.01$) using unadjusted statistical tests. Test significant for Core subgroup only.

Thyroid Gland - Non-Neoplastic. In males, follicular cell hyperplasia of the thyroid gland was not observed through 78 weeks. In Core group males, follicular cell hyperplasia was seen in one control animal and one 50 ppm, three 100 ppm, and one 200 ppm dose group males. The follicular cell hyperplasia in Core group males receiving Aroclor-1016 is not considered treatment-related. The incidence is depicted in the following table.

Aroclor-1016 produced no treatment-related increases in follicular cell hyperplasia of the thyroid gland in females.

Aroclor-1016 - Incidence of Thyroid Gland Follicular Cell Hyperplasia in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	50	100	200
Number Examined Microscopically	100	50	50	50
Hyperplasia, Follicular Cell	1 (0.0)	1 (0.0)	3 (0.1)	1 (0.1)

( ) = Average Severity

Thyroid Gland - Neoplastic. In males, thyroid gland follicular cell neoplasms were not detected through 78 weeks. A slight non dose-related increase in thyroid follicular cell neoplasms was seen in treated Core group animals compared with Core controls. In Core group males, follicular cell adenomas were observed in 3, 2 and 0, and follicular cell carcinomas in 1, 1, and 1 animals each for the 50, 100 and 200 ppm dose groups, respectively. In Core controls, a follicular cell adenoma was seen in one male, and a follicular cell carcinoma was seen in another. The low incidence and inverse dose-response suggests that the thyroid gland neoplasms in Core group males are not treatment-related. The incidence is depicted in the following table.

Aroclor-1016 produced no treatment-related increases in thyroid gland neoplasms in females.

Aroclor-1016 - Incidence of Relevant Thyroid Gland Neoplasms in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	50	100	200
Number Examined Microscopically	100	50	50	50
Follicular Cell Adenoma	1 (1)	3 (6)	2 (4)	0 (0)
Follicular Cell Carcinoma	1 (1)	1 (2)	1 (2)	1 (2)
Males with Thyroid Neoplasms[1]	2 (2)	4 (8)	3 (6)	1 (2)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 119 for statistical analysis of individual tumor types.

Mammary Gland - Neoplastic. Aroclor-1016 produced no treatment-related changes in mammary gland neoplasm incidence in males.

In females, mammary gland neoplasms were not observed at the 13- or 26-week interim necropsy time points. At 39 weeks, a mammary gland adenoma was observed in one 100 ppm dose group female. At 52 weeks, a mammary gland adenocarcinoma was seen in one 50 ppm dose group female, and a fibroadenoma was seen in one 100 ppm dose group female. No mammary gland neoplasms were seen in control animals at the 39- and 52-week interim necropsy time points. At 78 weeks, mammary gland adenomas were observed in two 50 ppm dose group animals and adenocarcinomas were seen in one female each in the 100 and 200 ppm dose groups. One mammary gland adenoma and two fibroadenomas were seen in control females at 78 weeks. For treated Core animals, the incidence of mammary neoplasms was comparable to that in the Core controls. For Stop Study A females, the incidence of tumors decreased for the 200 ppm dose group compared with the Core controls. The incidence of relevant mammary gland neoplasms in Core and Stop Study A females receiving Aroclor-1016 is depicted in the following table.

Aroclor-1016 - Incidence of Relevant Mammary Gland Neoplasms in Core and Stop Study A Subgroup Females

	Core Subgroup Females				Stop Study A Subgroup Females		
Dose (ppm)	0	50	100	200	50	100	200
Number Examined Microscopically	100	50	50	50	24	24	24
Fibroadenoma	34 (34)	17 (34)	15 (30)	20 (40)	10 (42)	12 (50)	7 (29)
Adenoma	14 (14)	2 (4)	9 (18)	9 (18)	0 (0)	2 (8)	0 (0)
Adenocarcinoma	15 (15)	3 (6)	8 (16)	2 (4)	2 (8)	2 (8)	2 (8)
Females with Mammary Neoplasms[1]	54 (54)	20 (40)	28 (56)	28 (56)	11 (46)	15 (63)	9 (38)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 120 (Core animals) and Table 121 (Stop Study animals) for statistical analysis of individual tumor types.

Aroclor-1242

Liver - Non-Neoplastic. In males, minimal to mild centrilobular hepatocellular hypertrophy was observed in three 50 ppm and five 100 ppm dose group animals at 26 weeks. At each successive scheduled necropsy thereafter, hepatocellular hypertrophy was present in nearly all rats examined, with severity generally increasing with time. No hepatocellular hypertrophy was observed through 78 weeks for control animals. Hepatocellular hypertrophy was present in most treated Core (but not control) males.

In females, minimal to mild hepatocellular hypertrophy was found in three 50 ppm and six 100 ppm dose group females at 13 weeks. At 26 weeks, hepatocellular hypertrophy of minimal to mild severity was observed in six females each for the 50 and 100 ppm dose groups. At each successive scheduled necropsy thereafter, hepatocellular hypertrophy was present in nearly all rats, with severity generally increasing with time. The severity was generally greater for females than for males at corresponding time points and dose groups. No hepatocyte hypertrophy was observed for controls through 78 weeks. Hepatocyte hypertrophy was present for most treated Core (but not control) animals. Hepatocellular

hypertrophy was less severe in Stop Study B and A females compared to the corresponding treated 78-week interim and Core group females, respectively.

In males, hepatocyte vacuolization was generally present in a varying number of treated animals at each scheduled necropsy time point. No marked increase in incidence or severity was observed through 78 weeks; however, treated Core animals receiving 50 and 100 ppm showed a slightly greater incidence than Core group controls.

In females, hepatocyte vacuolization was noted for only one 50 ppm dose group female at 13 weeks and six 50 ppm and five 100 ppm animals at 39 weeks. It was not seen at 26 or 52 weeks, but was present in six 50 ppm and five 100 ppm dose group females at 39 weeks and in two 50 ppm and four 100 ppm animals by 78 weeks. No hepatocyte vacuolization was observed for controls through 78 weeks. More Core group females, than males, showed hepatocellular vacuolization by the end of the study. Hepatocyte vacuolization was less severe in Stop Study B and A females compared to the corresponding treated 78-week interim and Core group females, respectively.

In males, foci of cellular alteration were not observed at 26 weeks. Foci were sporadically seen at a low incidence in treated animals at the 52- and 78-week interim necropsies. A focus of cellular alteration was noted in one control male at 52 weeks. In Core group males, the incidence of eosinophils and mixed cell foci of cellular alteration was increased sufficiently, compared to control, to suggest that this finding was treatment-related.

In females, foci of cellular alteration were not observed through 26 weeks. At 39 weeks, foci were seen in six 100 ppm dose group animals. At 52 weeks, foci were seen in five 50 ppm and two 100 ppm dose group females. At 78 weeks, foci were observed in two control, and in five 50 ppm and five 100 ppm dose group females. There was a marked increase in the numbers of foci in Core group females compared to Core controls, with eosinophilic foci being most prevalent, followed by (in order of decreasing frequency) mixed cell, basophilic, and clear cell foci. Foci were observed at a similar incidence in both the Stop Study B females and in the corresponding controls. With the exception of a slight decreased incidence of clear and mixed cell foci, foci were observed at a similar incidence in the Stop Study A females as in the corresponding treated Core group females.

Aroclor-1242 produced no microscopic evidence of pigment-laden sinusoidal cells in males.

In females, pigment-laden sinusoidal cells were not observed at 13 weeks. At 26 weeks, minimal to mild pigment accumulation was diagnosed in one 50 ppm and five 100 ppm dose group females. A generally similar (but variable) incidence was seen in these dose groups throughout the rest of the study. Pigment accumulation was observed for only one control, at 13 weeks. The incidence for Core group and Stop Study A animals is depicted in the tables below. For Stop Study B females, pigment accumulation was noted for one animal each in the 50 and 100 ppm dose groups. A lower incidence and severity of pigment accumulation was seen in Stop Study A females than in the corresponding treated Core group females.

In males, bile duct hyperplasia was first observed at 52 weeks. Initially, the severity of the hyperplasia was minimal. This lesion increased in both incidence and severity at 78 weeks. Bile duct hyperplasia was noted for three controls each at 52 and 78 weeks. Although bile duct hyperplasia was present in 70% of the Core control males, it was more prevalent and severe in the treated Core group animals.

In females, bile duct hyperplasia was first observed in one 50 ppm dose group animal at 26 weeks. Initially, the severity of the hyperplasia was minimal. This lesion generally increased in both incidence and severity at successive terminations. Bile duct hyperplasia was noted for one and two control animals each at 39 and 78 weeks, respectively. Although bile duct hyperplasia was present in 40% of the Core control females, it was more prevalent and severe in the treated Core group animals. Bile duct hyperplasia was noted in Stop Study B females at a slightly greater incidence and severity compared with the corresponding controls. The incidence and severity of bile duct hyperplasia was less for the Stop Study A females than for the corresponding treated Core group females. The incidence of microscopic non-neoplastic liver lesions in Core group males and females and Stop Study A females receiving Aroclor-1242 is depicted in the following tables.

Aroclor-1242 - Incidence of Relevant Microscopic Non-Neoplastic Liver Lesions in Core Subgroup Males

	Core Subgroup Males		
Dose (ppm)	0	50	100
Number Examined Microscopically	100	50	50
Hypertrophy, Hepatocyte, Centrilobular	0 (0.0)	41 (1.5)	45 (2.1)
Hyperplasia, Bile Duct	70 (1.1)	45 (1.5)	40 (1.5)
Vacuolization, Hepatocyte	32 (0.6)	25 (1.0)	36 (1.4)
Basophilic Cell Focus	7	2	2
Clear Cell Focus	17	7	4
Eosinophilic Cell Focus	2	9	8
Mixed Cell Focus	5	11	7

( ) = Average Severity

Aroclor-1242 - Incidence of Relevant Microscopic Non-Neoplastic Liver Lesions in Core and Stop Study A Subgroup Females

	Core Subgroup Females			Stop Study A Subgroup Females	
Dose (ppm)	0	50	100	50	100
Number Examined Microscopically	100	50	50	24	24
Hypertrophy, Hepatocyte, Centrilobular	0 (0.0)	44 (1.8)	44 (2.5)	15 (1.2)	20 (1.8)
Hyperplasia, Bile Duct	40 (0.7)	42 (1.5)	44 (2.2)	17 (1.1)	20 (1.5)
Pigment	7 (0.1)	14 (0.4)	13 (0.4)	2 (0.2)	3 (0.1)
Vacuolization, Hepatocyte	13 (0.2)	33 (0.9)	28 (0.9)	7 (0.5)	5 (0.2)
Basophilic Cell Focus	5	16	10	9	8
Clear Cell Focus	2	7	8	1	0
Eosinophilic Cell Focus	4	38	39	8	16
Mixed Cell Focus	8	21	19	3	7

( ) = Average Severity

Liver - Neoplastic. Aroclor-1242 produced no treatment-related increases in hepatocellular neoplasms in males. The incidence of relevant liver neoplasms in Core males receiving Aroclor-1242 is depicted in the following table.

Aroclor-1242 - Incidence of Relevant Liver Neoplasms in Core Subgroup Males

	Core Subgroup Males		
Dose (ppm)	0	50	100
Number Examined Microscopically	100	50	50
Hepatocellular Adenoma	4 (4)	1 (2)	3 (6)
Hepatocellular Carcinoma	3 (3)	1 (2)	1 (2)
Males with Liver Neoplasms[1]	7 (7)	1 (2)	4 (8)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 119 for statistical analysis of individual tumor types.

In females, hepatic neoplasms were not seen in control or treated rats at the 13-, 26-, 39-, or 52-week interim necropsy time points. At 78 weeks, hepatocellular adenomas were observed in two 100 ppm dose group females. No hepatocellular neoplasms were seen in control females through 78 weeks. The incidence of liver neoplasms for Core group females receiving 50 or 100 ppm was statistically increased compared to Core controls. No hepatic neoplasms were observed for Stop Study B females. The incidence of liver neoplasms in Stop Study A females was slightly decreased compared to the corresponding treated Core group females, but remained statistically increased compared to the Core controls. The incidence of relevant liver neoplasms in Core and Stop Study A females receiving Aroclor-1242 is depicted in the following table.

Aroclor-1242 - Incidence of Relevant Liver Neoplasms in Core and Stop Study A Subgroup Females

	Core Subgroup Females			Stop Study A Subgroup Females	
Dose (ppm)	0	50	100	50	100
Number Examined Microscopically	100	50	50	24	24
Hepatocellular Adenoma	1 (1)	10 (20)	12 (24)	3 (13)	6 (25)
Hepatocellular Carcinoma	0 (0)	0 (0)	2 (4)	1 (4)	0 (0)
Hepatocholangioma	0 (0)	1 (2)	2 (4)	0 (0)	1 (4)
Hepatocholangiocarcinoma	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Females with Liver Neoplasms[1]	1[c] (1)	11[b] (22)	15[b] (30)	3[a] (13)	6[b] (25)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 120 (Core animals) and Table 121 (Stop Study animals) for statistical analysis of individual tumor types.

a. Statistically significant increase ($p \leq 0.05$) in incidence of primary hepatic neoplasms using unadjusted statistical tests.

b. Statistically significant increase ($p \leq 0.01$) in incidence of primary hepatic neoplasms using unadjusted statistical tests.

c. Statistically significant trend test ($p \leq 0.01$) using unadjusted statistical tests. Test significant for both Core and Stop Study A subgroups.

Thyroid Gland - Non-Neoplastic. In males, follicular cell hyperplasia of the thyroid gland was not observed through 78 weeks. In Core group males, follicular cell hyperplasia was seen in four 50 ppm and three 100 ppm dose group animals. One Core control male exhibited follicular cell hyperplasia. The slight, treatment-related, increased incidence of follicular cell hyperplasia in Core males receiving Aroclor-1242 is depicted in the following table.

Aroclor-1242 produced no treatment-related increases in follicular cell hyperplasia of the thyroid gland in females.

Aroclor-1242 - Incidence of Thyroid Gland Follicular Cell Hyperplasia in Core Subgroup Males

	Core Subgroup Males		
Dose (ppm)	0	50	100
Number Examined Microscopically	100	50	50
Hyperplasia, Follicular Cell	1 (0.0)	4 (0.2)	3 (0.1)

( ) = Average Severity

Thyroid Gland - Neoplastic. In males, thyroid gland follicular cell neoplasms were not detected through 78 weeks. In Core group males, follicular cell adenomas were observed in five 50 ppm and five 100 ppm dose group animals. In Core control males, a follicular cell adenoma was seen in only one animal. Follicular cell carcinomas were found in similar incidence in treated Core group animals and in Core controls. The slight, treatment-related, increased incidence of thyroid gland neoplasms in Core males receiving Aroclor-1242 is depicted in the following table.

Aroclor-1242 produced no treatment-related increases in thyroid gland neoplasms in females.

Aroclor-1242 - Incidence of Relevant Thyroid Gland Neoplasms in Core Subgroup Males

	Core Subgroup Males		
Dose (ppm)	0	50	100
Number Examined Microscopically	100	50	50
Follicular Cell Adenoma	1 (1)	5 (10)	5 (10)
Follicular Cell Carcinoma	1 (1)	2 (4)	1 (2)
Males with Thyroid Neoplasms[1]	2[c] (2)	7[b] (14)	6[a] (12)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 119 for statistical analysis of individual tumor types.

a. Statistically significant increase ($p \leq 0.05$) in incidence of primary thyroid follicular cell neoplasms using unadjusted statistical tests.

b. Statistically significant increase ($p \leq 0.01$) in incidence of primary thyroid follicular cell neoplasms using unadjusted statistical tests.

c. Statistically significant trend test ($p \leq 0.05$) using unadjusted statistical tests.

Mammary Gland - Neoplastic. Aroclor-1242 produced no treatment-related changes in incidence of mammary gland neoplasms in males.

In females, mammary gland neoplasms were not observed through the 52-week interim necropsy time point. At 78 weeks, a mammary gland fibroadenoma was observed in one 50 ppm dose group female, and one adenoma and two fibroadenomas were seen in control females. The incidence of mammary gland neoplasms for the treated Core group females was statistically significantly decreased, while the incidence for Stop Study A females was unchanged, compared to Core controls. The incidence of mammary gland neoplasms in Core and Stop Study A females receiving Aroclor-1242 is depicted in the following table.

Aroclor-1242 - Incidence of Relevant Mammary Gland Neoplasms in Core and Stop Study A Subgroup Females

	Core Subgroup Females			Stop Study A Subgroup Females	
Dose (ppm)	0	50	100	50	100
Number Examined Microscopically	100	50	49	24	24
Fibroadenoma	34 (34)	17 (34)	16 (33)	10 (42)	11 (46)
Adenoma	14 (14)	3 (6)	2 (4)	2 (8)	0 (0)
Adenocarcinoma	15 (15)	2 (4)	1 (2)	2 (8)	2 (8)
Females with Mammary Neoplasms[1]	54[c] (54)	19 (38)	18 (37)	13 (54)	13 (54)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 120 (Core animals) and Table 121 (Stop Study animals) for statistical analysis of individual tumor types.

c. Statistically significant negative trend ($p \leq 0.05$) in incidence of primary mammary gland neoplasms for Core subgroup only.

Aroclor-1254

Liver - Non-Neoplastic. In males, centrilobular hepatocellular hypertrophy was observed in the majority of Aroclor-1254 treated animals at every interim necropsy time point. The severity of centrilobular hepatocellular hypertrophy increased with time. No hepatocellular hypertrophy was observed for controls through 78 weeks. Hepatocellular hypertrophy was present for almost all treated Core (but not Core control) males.

In females, centrilobular hepatocellular hypertrophy was observed in the majority of Aroclor-1254 treated animals at every interim necropsy time point. The severity of centrilobular hepatocellular hypertrophy increased with time. No hepatocellular hypertrophy was observed through 78 weeks for controls. The severity of centrilobular hepatocellular hypertrophy was decreased slightly for treated Core group animals compared to that seen at the 78-week interim necropsy, but the incidence and severity compared to Core controls was increased. The apparent decrease in severity at 105 weeks was attributed to age- and test substance-related liver pathology which altered large areas of the hepatic parenchyma, and in which hypertrophy would otherwise have been diagnosed. Centrilobular hepatocellular hypertrophy for Stop Study B and A females was less in average severity than that in the corresponding treated 78-week interim and Core group females, respectively.

In males, hepatocyte vacuolization was observed in two, two and six males at 26 weeks in the 25, 50 and 100 ppm dose groups, respectively. The majority of males showed this finding at 52 weeks, while the incidence was slightly decreased at 78 weeks. No hepatocyte vacuolization was observed through 78 weeks for controls. In Core group males, the incidence and severity for all treated groups exceeded that in the Core controls.

In females, hepatocyte vacuolization was first seen in one 100 ppm dose group animal at 13 weeks. This finding was not present at 26 weeks, but was seen in the majority of treated females at the 39-, 52- and 78-week interim necropsy time points. No hepatocyte vacuolization was observed through 78 weeks for controls. The incidence and severity of this finding was increased in treated Core group females compared to Core controls. Hepatocyte vacuolization for Stop Study B and A females was less in average severity than that in the corresponding treated 78-week interim and Core group females, respectively.

In males, foci of cellular alteration were not seen in treated groups at the 26- and 52-week interim necropsy time points. One focus was observed in a control animal at 52 weeks.

At 78 weeks, foci were seen in three, two and two males in the 25, 50 and 100 ppm dose groups, respectively. In Core group males, the incidence of foci was slightly higher than that seen in males at the 78-week interim necropsy. The incidence of all types of foci, with the exception of basophilic foci, was increased in treated Core group males compared to control.

In females, foci of cellular alteration were not seen at the 13- or 26-week interim necropsy time points. They were first observed in one, two and two animals from the 25, 50, and 100 ppm dose groups, respectively, at the 39-week interim necropsy. At the 52-week interim necropsy, foci were observed in 3, 4 and 4 animals in the 25, 50 and 100 ppm dose group, respectively. Foci of cellular alteration increased in incidence as the study progressed. Foci were first noted in two control animals at 78 weeks. The incidences of foci of all types were increased in the treated Core group females compared to Core controls, with the increases most striking for the eosinophilic and mixed cell foci. Liver foci were generally similar in incidence in the Stop Study B and A females compared to the corresponding treated 78-week interim and Core group females, respectively.

Aroclor-1254 produced no microscopic evidence of pigment-laden sinusoidal cells in males.

In females, treatment-related liver pigment was first observed at 13 weeks for one animal each in the 25 and 100 ppm dose groups. It was then seen consistently at each subsequent interim necropsy time point in the majority of treated females. Pigment accumulation was observed in a single control animal at 13 weeks. The incidence of pigment in Core group females was increased in a dose-related manner compared to Core controls. In the Stop Study B and A females, the incidence of pigment was decreased compared to the corresponding treated 78-week interim and Core group females, respectively.

In males, bile duct hyperplasia was diagnosed for one animal each in the 25 and 50 ppm dose groups at the 26 week interim necropsy. It was observed more frequently as the study progressed. Bile duct hyperplasia was observed in three control males each at the 52- and 78-week interim necropsies. Treated Core group males showed an increased incidence and severity for this finding compared to Core controls.

In females, bile duct hyperplasia was first diagnosed at the 26-week interim necropsy in three 100 ppm dose group animals. It was observed more frequently as the study progressed. Bile duct hyperplasia was observed in one and two control females at the 39- and 78-week necropsies, respectively. Treated Core group females showed an increased incidence

and severity for this finding compared to Core controls. Stop Study B females showed a similar incidence to that in the corresponding treated 78-week interim groups. Stop Study A females had both a lower incidence and group average severity of bile duct hyperplasia than did either the Stop Study B or treated Core group females. The incidences of relevant microscopic non-neoplastic liver lesions in Core males and females and Stop Study A females receiving Aroclor-1254 are depicted in the following tables.

Aroclor-1254 - Incidence of Relevant Microscopic Non-Neoplastic Liver Lesions in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	25	50	100
Number Examined Microscopically	100	50	50	50
Hypertrophy, Hepatocyte, Centrilobular	0 (0.0)	41 (2.1)	49 (2.9)	47 (3.1)
Hyperplasia, Bile Duct	70 (1.1)	43 (1.7)	46 (1.6)	46 (2.0)
Vacuolization, Hepatocyte	32 (0.6)	37 (1.8)	42 (1.9)	45 (2.3)
Basophilic Cell Focus	7	3	2	2
Clear Cell Focus	17	11	11	17
Eosinophilic Cell Focus	2	14	12	13
Mixed Cell Focus	5	18	6	5

( ) = Average Severity

Aroclor-1254 - Incidence of Relevant Microscopic Non-Neoplastic Liver Lesions in Core and Stop Study A Subgroup Females

	Core Subgroup Females				Stop Study A Subgroup Females		
Dose (ppm)	0	25	50	100	25	50	100
Number Examined Microscopically	100	49	50	50	24	24	24
Hypertrophy, Hepatocyte, Centrilobular	0 (0.0)	48 (3.1)	46 (3.3)	49 (3.8)	17 (1.5)	20 (1.8)	17 (1.9)
Hyperplasia, Bile Duct	40 (0.7)	44 (2.3)	46 (2.4)	48 (2.9)	18 (1.1)	21 (1.8)	21 (1.8)
Pigment	7 (0.1)	9 (0.2)	16 (0.4)	21 (0.5)	1 (0.0)	2 (0.1)	5 (0.2)
Vacuolization, Hepatocyte	13 (0.2)	36 (1.2)	41 (1.4)	43 (1.4)	8 (0.4)	7 (0.3)	12 (0.5)
Basophilic Cell Focus	5	9	5	5	4	10	3
Clear Cell Focus	2	3	3	4	1	3	0
Eosinophilic Cell Focus	4	43	40	46	14	17	18
Mixed Cell Focus	8	19	20	24	5	10	11

( ) = Average Severity

Liver - Neoplastic. Aroclor-1254 produced no treatment-related increases in hepatocellular neoplasms in males. The incidence of relevant liver neoplasms in Core group males receiving Aroclor-1254 is depicted in the following table.

Aroclor-1254 - Incidence of Relevant Liver Neoplasms in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	25	50	100
Number Examined Microscopically	100	50	50	50
Hepatocellular Adenoma	4 (4)	2 (4)	2 (4)	6 (12)
Hepatocellular Carcinoma	3 (3)	2 (4)	2 (4)	0 (0)
Males with Liver Neoplasms[1]	7 (7)	4 (8)	4 (8)	6 (12)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 119 for statistical analysis of individual tumor types.

In females, no liver tumors were observed through 52 weeks. At 78 weeks, hepatocellular adenomas were seen in one 50 ppm and two 100 ppm dose group females. No liver tumors were observed for controls through 78 weeks. A marked increase in benign liver tumors were seen for the treated Core group females, with a lesser increase for malignant liver tumors. The incidence of combined liver neoplasms in treated Core groups was statistically significantly increased compared to Core controls. Stop Study B females showed an increased incidence of liver neoplasms when compared to controls at 78 weeks, but a generally similar incidence when compared to treated animals at the 78-week interim necropsy. Stop Study A females had statistically significantly increased incidences of liver tumors relative to Core controls, but decreased incidences of liver tumors when compared to treated Core group females; the decreases were statistically significant for the 50 and 100 ppm dose groups. The incidence of relevant liver neoplasms in Core and Stop Study A females receiving Aroclor-1254 is depicted in the table below.

Aroclor-1254 - Incidence of Relevant Liver Neoplasms in Core and Stop Study A Subgroup Females

	Core Subgroup Females				Stop Study A Subgroup Females		
Dose (ppm)	0	25	50	100	25	50	100
Number Examined Microscopically	100	50	50	50	24	24	24
Hepatocellular Adenoma	1 (1)	18 (36)	26 (52)	27 (54)	4 (17)	7 (29)	6 (25)
Hepatocellular Carcinoma	0 (0)	0 (0)	4 (8)	6 (12)	1 (4)	2 (8)	1 (4)
Hepatocholangioma	0 (0)	2 (4)	6 (12)	1 (2)	0 (0)	0 (0)	0 (0)
Females with Liver Neoplasms[1]	1[c] (1)	19[b] (38)	28[b] (56)	28[b] (56)	5[b] (21)	7[b] (29)	6[b] (25)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 120 (Core animals) and Table 121 (Stop Study animals) for statistical analysis of individual tumor types.

b. Statistically significant increase ($p \leq 0.01$) in incidence of primary hepatic neoplasms using unadjusted statistical tests.

c. Statistically significant trend test ($p \leq 0.01$) using unadjusted statistical tests. Trend test was significant for both Core and Stop Study A subgroups.

Thyroid Gland - Non-Neoplastic. In males, follicular cell hyperplasia was not observed through 78 weeks. In Core group males, follicular hyperplasia was increased in a non dose-related manner compared to Core controls. The incidence of follicular cell hyperplasia in Core group males receiving Aroclor-1254 is depicted in the following table.

Aroclor-1254 produced no treatment-related increases in follicular cell hyperplasia of the thyroid gland in females.

Aroclor-1254 - Incidence of Thyroid Gland Follicular Cell Hyperplasia in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	25	50	100
Number Examined Microscopically	100	50	50	50
Hyperplasia, Follicular Cell	1 (0.0)	12 (0.4)	6 (0.2)	6 (0.3)

( ) = Average Severity

Thyroid Gland - Neoplastic. In males, thyroid gland follicular cell neoplasms were not detected through 78 weeks. In treated Core group males, follicular cell adenomas were statistically significantly increased compared to Core controls, in a non dose-related manner. The incidence of follicular cell carcinomas was similar between treated Core group males and Core controls. Combined incidences for follicular cell neoplasms were statistically significantly increased in all treated Core groups compared to Core controls. The majority of the thyroid neoplasms were benign tumors (adenomas). The incidence of relevant thyroid gland neoplasms in Core males receiving Aroclor-1254 is depicted in the following table.

Aroclor-1254 produced no treatment-related increases in thyroid gland tumors in females.

Aroclor-1254 - Incidence of Relevant Thyroid Gland Neoplasms in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	25	50	100
Number Examined Microscopically	100	50	50	50
Follicular Cell Adenoma	1 (1)	6 (12)	4 (8)	5 (10)
Follicular Cell Carcinoma	1 (1)	1 (2)	3 (6)	1 (2)
Males with Thyroid Neoplasms[1]	2[c] (2)	7[b] (14)	7[b] (14)	6[a] (12)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 119 for statistical analysis of individual tumor types.

a. Statistically significant increase ($p \leq 0.05$) in incidence of primary thyroid follicular cell neoplasms using unadjusted statistical tests.

b. Statistically significant increase ($p \leq 0.01$) in incidence of primary thyroid follicular cell neoplasms using unadjusted statistical tests.

c. Statistically significant trend test ($p \leq 0.05$) using unadjusted statistical tests.

Mammary Gland - Neoplastic. Aroclor-1254 produced no treatment-related changes in the mammary gland neoplasm incidence in males.

In females, mammary gland neoplasms were not observed through 39 weeks. At 52 weeks, a single fibroadenoma was observed in a 50 ppm dose group female. At 78 weeks, an adenocarcinoma was observed in one 25 ppm dose group female, adenomas were seen in two 50 ppm dose group females, and fibroadenomas were seen in three 50 ppm dose group

females. One adenoma and two fibroadenomas were observed in control animals at 78 weeks. In Core group females, the incidence of combined mammary gland neoplasms was statistically decreased in 100 ppm dose group animals when compared to Core controls. In the Stop Study A females, the incidence of mammary gland tumors in the 25, 50 and 100 ppm dose groups was slightly increased over that seen in Core controls. The incidence of mammary gland tumors in the Stop Study A females was also increased over that in the corresponding treated Core group females, with the difference being statistically significant for the 100 ppm dose group. The incidence of relevant mammary gland neoplasms in Core and Stop Study A females receiving Aroclor-1254 is depicted in the following table.

Aroclor-1254 - Incidence of Relevant Mammary Gland Neoplasms in Core and Stop Study A Subgroup Females

	Core Subgroup Females				Stop Study A Subgroup		
Dose (ppm)	0	25	50	100	25	50	100
Number Examined Microscopically	100	50	50	49	24	24	24
Fibroadenoma	34 (34)	22 (44)	29 (58)	10 (20)	12 (50)	15 (63)	11 (46)
Adenoma	14 (14)	4 (8)	3 (6)	3 (6)	4 (17)	4 (17)	2 (8)
Adenocarcinoma	15 (15)	1 (2)	3 (6)	1 (2)	2 (8)	2 (8)	2 (8)
Females with Mammary Neoplasms[1]	54[f] (54)	26 (52)	34 (68)	13[e] (27)	16 (67)	18 (75)	14 (58)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 120 (Core animals) and Table 121 (Stop Study animals) for statistical analysis of individual tumor types.
e. Statistically significant decrease ($p \leq 0.01$) in incidence of mammary neoplasms using unadjusted statistical tests.
f. Statistically significant negative trend test ($p \leq 0.05$) using unadjusted statistical tests (Table 120). Trend test statistically significant for Core subgroup only.

Aroclor-1260

Liver - Non-Neoplastic. In males, centrilobular hepatocellular hypertrophy was observed in the majority of Aroclor-1260 treated rats at every interim necropsy time point. No hepatocellular hypertrophy was observed for controls through 78 weeks. Hepatocellular hypertrophy was present for almost all treated Core (but not Core control) males. Severities generally increased with time. The incidence and severity of centrilobular hepatocellular hypertrophy was increased in treated Core group males compared to Core controls.

In females, centrilobular hepatocellular hypertrophy was observed in the majority of Aroclor-1260 treated rats at every interim necropsy time point. Severities generally increased through 78 weeks. No hepatocellular hypertrophy was observed for controls through 78 weeks. The severity of centrilobular hepatocellular hypertrophy declined somewhat for treated Core group animals at 105 weeks compared to that seen at 78 weeks. The apparent decrease in severity at 105 weeks was attributed to age- and test substance-related liver pathology which altered large areas of the hepatic parenchyma, and in which hypertrophy would otherwise have been diagnosed. Hepatocellular hypertrophy was present for almost all treated Core (but not Core control) females. There was very little difference in average severity scores for hepatocellular hypertrophy between the Stop Study B and A females and the corresponding treated 78 week Interim and Core groups, respectively.

In males, hepatocyte vacuolization was observed sporadically among animals at the 26- and 52-week interim necropsy time points. Approximately half of the males examined at 78 weeks had evidence of hepatocyte vacuolization. No hepatocyte vacuolization was observed for controls through 78 weeks. In Core group males, the incidence and severity of hepatocyte vacuolization was greater in all treated groups compared to Core controls.

In females, hepatocyte vacuolization was first observed in five 50 ppm and five 100 ppm dose group animals at the 39-week interim necropsy. Approximately half of the rats examined at each successive scheduled necropsy had evidence of hepatocyte vacuolization. No hepatocyte vacuolization was observed for controls through 78 weeks. In treated Core group animals, the incidence and severity of hepatocyte vacuolization exceeded that of the Core controls. Stop Study B females showed a generally similar severity but slightly decreased incidence compared to the corresponding treated groups at 78 weeks. Stop Study A females

exhibited slight decreases in the average severity scores for hepatocyte vacuolization compared to corresponding treated Core groups.

In males, foci of cellular alteration were not observed at the 26- or 52-week interim necropsy time points. A focus was only observed for one control male at the 52-week interim necropsy. At 78 weeks, foci were seen in three 50 ppm and one 100 ppm dose group animals. In treated Core group males, the incidence of both eosinophilic and mixed cell foci were markedly greater than that observed for Core controls.

In females, foci of cellular alteration were not observed at the 13-week interim necropsy. At 26 weeks, eosinophilic foci were seen in two 100 ppm dose group females. At 39 weeks, foci were seen in two 25 ppm, two 50 ppm and two 100 ppm dose group females. At 52 weeks, foci were seen in four 25 ppm and four 100 ppm dose group animals. Foci were seen in five, five, and four females in the 25, 50, and 100 ppm dose groups, respectively, at 78 weeks. A low incidence of foci was seen in the control animals at 78 weeks. In treated Core group females, the incidence of eosinophilic and mixed cell foci were clearly increased compared to Core controls. The incidence of foci in Stop Study B females was similar to that of the corresponding treated females at 78 weeks. Both eosinophilic and mixed cell foci were reduced in incidence in the Stop Study A females when compared to the treated Core group females, although their incidence was still increased relative to the Core controls. Basophilic foci were observed at a generally similar incidence in Stop Study A females compared to the treated Core groups.

Aroclor-1260 produced no microscopic evidence of pigment-laden sinusoidal cells in males.

In females, pigment-laden sinusoidal cells were not observed for treated animals at the 13-week interim necropsy. Liver pigment was only observed for one control female at 13 weeks. Liver pigment was observed in a sporadic, and generally non dose-related incidence through subsequent interim necropsies. Treated Core group females showed a non dose-related increased incidence of pigment compared to Core controls. The incidence and severity of pigment accumulation in Stop Study B females was similar to that of the corresponding treated females at 78 weeks. The incidence of pigment in Stop Study A females was also increased in a non dose-related pattern compared to the Core controls, and was similar to that seen in treated Core groups.

In males, bile duct hyperplasia was first diagnosed at the 52-week interim necropsy in six, two and one animals in the 25, 50 and 100 ppm dose groups, respectively. As the study progressed, bile duct hyperplasia was seen more frequently. Bile duct hyperplasia was seen in three control males each at 52- and 78-weeks. Treated Core group males showed an increased incidence and severity for this finding compared to Core controls.

In females, bile duct hyperplasia was first diagnosed at the 26-week interim necropsy in two 25 ppm dose group animals. As the study progressed, bile duct hyperplasia was seen more frequently. Bile duct hyperplasia was observed in one and two control females at the 39- and 78-week necropsies, respectively. Treated Core group females showed an increased incidence and severity for this finding compared to Core controls. Stop Study B females showed an incidence and severity for bile duct hyperplasia similar to that in treated females at 78 weeks, but Stop Study A females had both a lower incidence and average group severity for this lesion than did either the Stop Study B females or treated Core group females. The incidence of microscopic non-neoplastic liver lesions in Core males and females and Stop Study A females receiving Aroclor-1260 is depicted in the following table.

Aroclor-1260 - Incidence of Relevant Microscopic Non-Neoplastic Liver Lesions in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	25	50	100
Number Examined Microscopically	100	50	50	50
Hypertrophy, Hepatocyte, Centrilobular	0 (0.0)	44 (2.2)	45 (2.3)	42 (2.2)
Hyperplasia, Bile Duct	70 (1.1)	45 (1.7)	43 (1.7)	40 (1.4)
Vacuolization, Hepatocyte	32 (0.6)	36 (1.3)	24 (1.0)	32 (1.4)
Basophilic Cell Focus	7	3	3	1
Clear Cell Focus	17	8	4	5
Eosinophilic Cell Focus	2	11	18	12
Mixed Cell Focus	5	13	10	13

( ) = Average Severity

Aroclor-1260 - Incidence of Relevant Microscopic Non-Neoplastic Liver Lesions in Core and Stop Study A Subgroup Females

	Core Subgroup Females				Stop Study A Subgroup Females		
Dose (ppm)	0	25	50	100	25	50	100
Number Examined Microscopically	100	50	50	50	24	24	24
Hypertrophy, Hepatocyte, Centrilobular	0 (0.0)	41 (1.6)	42 (1.9)	42 (2.4)	16 (1.2)	15 (1.5)	23 (2.6)
Hyperplasia, Bile Duct	40 (0.7)	40 (1.4)	44 (1.7)	44 (2.2)	8 (0.7)	15 (1.2)	21 (1.6)
Pigment	7 (0.1)	12 (0.3)	8 (0.2)	3 (0.1)	0 (0.0)	3 (0.1)	2 (0.1)
Vacuolization, Hepatocyte	13 (0.2)	18 (0.5)	23 (0.7)	28 (0.7)	3 (0.2)	8 (0.5)	10 (0.4)
Basophilic Cell Focus	5	6	11	5	5	3	7
Clear Cell Focus	2	2	0	2	0	1	1
Eosinophilic Cell Focus	4	31	36	36	11	14	14
Mixed Cell Focus	8	9	12	18	6	9	7

( ) = Average Severity

Liver - Neoplastic. In males, no liver neoplasms were seen through the 52 week necropsy. At 78 weeks, adenomas were present for one animal each in the 50 and 100 ppm dose groups. No liver neoplasms were noted for controls through 78 weeks. In treated Core group animals, there was a statistically significant increase in the incidence of hepatic

neoplasms for the 100 ppm dose group animals compared to Core controls. The incidence of relevant liver neoplasms in Core group males receiving Aroclor-1260 is depicted in the following table.

Aroclor-1260 - Incidence of Relevant Liver Neoplasms in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	25	50	100
Number Examined Microscopically	100	50	50	50
Hepatocellular Adenoma	4 (4)	2 (4)	5 (10)	7 (14)
Hepatocellular Carcinoma	3 (3)	1 (2)	1 (2)	3 (6)
Hepatocholangioma	0 (0)	0 (0)	0 (0)	2 (4)
Males with Liver Neoplasms[1]	7[c] (7)	3 (6)	6 (12)	10[a] (20)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 119 for statistical analysis of individual tumor types.

a. Statistically significant increase ($p \leq 0.05$) in incidence of primary hepatic neoplasms using unadjusted statistical tests.

c. Statistically significant trend test ($p \leq 0.05$) using unadjusted statistical tests.

In females, hepatocellular adenomas were first detected in one animal at 50 ppm, and in two animals at 100 ppm at the 78-week interim necropsy. No liver neoplasms were noted for controls through 78 weeks. The incidence of hepatocellular adenomas in treated Core group females was statistically significantly increased for all groups compared to control. In the Stop Study B females, a hepatocellular adenoma was observed in one 100 ppm female. In Stop Study A females, the incidence of liver tumors was statistically significantly increased compared to Core controls, however, the incidence of adenomas for the 25 and 50 ppm dose group Stop Study A females was statistically significantly decreased compared to treated Core females. Stop Study A females receiving 100 ppm had a non-statistically significant increased incidence of adenomas compared to Core 100 ppm dose group females. The incidence of relevant liver neoplasms in Core and Stop Study A females receiving Aroclor-1260 is depicted in the table below.

Aroclor-1260 - Incidence of Relevant Liver Neoplasms in Core and Stop Study A Subgroup Females

	Core Subgroup Females				Stop Study A Subgroup Females		
Dose (ppm)	0	25	50	100	25	50	100
Number Examined Microscopically	100	50	50	50	24	24	24
Hepatocellular Adenoma	1 (1)	9 (18)	10 (20)	21 (42)	4 (17)	3 (13)	15 (63)
Hepatocellular Carcinoma	0 (0)	1 (2)	1 (2)	5 (10)	0 (0)	0 (0)	3 (13)
Hepatocholangioma	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
Females with Liver Neoplasms[1]	1[c] (1)	10[b] (20)	11[b] (22)	24[b] (48)	4[b] (17)	3[a] (13)	17[b] (71)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 120 (Core animals) and Table 121 (Stop Study animals) for statistical analysis of individual tumor types.

a. Statistically significant increase ($p \leq 0.05$) in incidence of primary hepatic neoplasms using unadjusted statistical tests.

b. Statistically significant increase ($p \leq 0.01$) in incidence of primary hepatic neoplasms using unadjusted statistical tests.

c. Statistically significant trend test ($p \leq 0.01$) using unadjusted statistical tests. Trend test was positive for both Core and Stop Study A subgroups.

Thyroid Gland - Non-Neoplastic. In males, follicular cell hyperplasia of the thyroid gland was first observed at the 78-week interim necropsy in one 100 ppm dose group animal. No follicular cell hyperplasia was observed for controls through 78 weeks. In treated Core group males, the incidence of follicular cell hyperplasia was increased in a non dose-related manner compared to Core controls. One Core control male exhibited follicular cell hyperplasia. The incidence of follicular cell hyperplasia in Core males receiving Aroclor-1260 is depicted in the following table.

Aroclor-1260 produced no treatment-related increases in follicular cell hyperplasia of the thyroid gland in females.

Aroclor-1260 - Incidence of Thyroid Gland Follicular Cell Hyperplasia in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	25	50	100
Number Examined Microscopically	100	50	50	50
Hyperplasia, Follicular Cell	1 (0.0)	6 (0.2)	9 (0.3)	5 (0.2)

( ) = Average Severity

Thyroid Gland - Neoplastic. In males, thyroid gland follicular cell neoplasms were not detected through 78 weeks. Follicular cell carcinomas were found at a similar incidence in Core control and treated Core group males. In Core males, the combined incidence of both benign and malignant thyroid gland follicular neoplasms in the 25 and 50 ppm dose groups were statistically increased compared to Core controls. The majority of the thyroid gland follicular cell tumors were benign (adenomas); no increased incidence in follicular cell carcinomas was observed. The incidence of relevant thyroid gland neoplasms in Core males receiving Aroclor-1260 is depicted in the following table.

Aroclor-1260 produced no treatment-related increases in thyroid gland neoplasms in females.

Aroclor-1260 - Incidence of Relevant Thyroid Gland Neoplasms in Core Subgroup Males

	Core Subgroup Males			
Dose (ppm)	0	25	50	100
Number Examined Microscopically	100	50	50	50
Follicular Cell Adenoma	1 (1)	6 (12)	4 (8)	3 (6)
Follicular Cell Carcinoma	1 (1)	1 (2)	1 (2)	1 (2)
Males with Thyroid Neoplasms[1]	2 (2)	7[b] (14)	5[a] (10)	4 (8)

( ) = Percentage

1. Animals with one or more of the listed tumors. Statistical analysis results are summarized in this table for the total combined tumor incidence only. See Table 119 for statistical analysis of individual tumor types.

a. Statistically significant increase ($p \leq 0.05$) in incidence of primary thyroid follicular cell neoplasms using unadjusted statistical tests.

b. Statistically significant increase ($p \leq 0.01$) in incidence of primary thyroid follicular cell neoplasms using unadjusted statistical tests.

Mammary Gland - Neoplastic. Aroclor-1260 produced no treatment-related changes in mammary gland neoplasm incidence in males.

In females, mammary gland neoplasms were not observed through 39 weeks. At 52 weeks, mammary gland fibroadenomas were observed in two 25 ppm dose group females; no mammary gland neoplasms were seen in control females at 52 weeks. At 78 weeks, mammary gland fibroadenomas were observed for two, two and one animals in the 25, 50 and 100 ppm dose groups, respectively. Mammary gland adenomas were seen for one animal each in the 25 and 50 ppm dose groups, and a mammary gland adenocarcinoma was seen in one female in the 50 ppm dose group. One adenoma and two fibroadenomas were seen in control females at 78 weeks. In treated Core group females, the incidence of all mammary gland neoplasms was decreased in all dose groups when compared to Core controls (statistically significantly decreased for the 25 and 50 ppm dose groups). The incidence of combined mammary neoplasms in the Stop Study A females was non-statistically significantly increased in the 25 ppm dose group from that of the Core controls. The incidence of relevant mammary gland neoplasms in Core and Stop Study females receiving Aroclor-1260 is depicted in the following table.

6.0 DISCUSSION/CONCLUSION

This study, which was designed to evaluate the chronic toxicity and oncogenicity of four PCB mixtures (Aroclor-1016, Aroclor-1242, Aroclor-1254, and Aroclor-1260), met all of the objectives set forth in the protocol. During the 2 years of dietary exposure to PCBs, daily observations for appearance and behavior did not reveal any clinical signs of toxicity attributable to treatment. Similarly, detailed evaluations during the first year of the study for neurotoxicity and neuropathology (which have been reported separately), lacked evidence of functional or morphological effects attributable to PCB exposure.

Survival for Aroclor-treated males was generally similar to control. Survival for females, on the other hand, was enhanced for all Aroclor mixtures, with the greatest increases evident for the Aroclor-1016, Aroclor-1242 and Aroclor-1260 Core treatment groups, and the Aroclor-1254 and Aroclor-1260 Stop Study groups.

Dose- and sex-dependent decreases in group mean body weight gains were measured in several (excluding Aroclor-1016) treatment groups (relative to control), with females exhibiting a greater response than males. Dose-related decreases in group mean body weights were clearly evident for both males and females for Aroclor-1254, with lesser effects also evident for females at the highest dietary concentrations of both Aroclor-1242 and Aroclor-1260. In all instances, when exposure to PCBs was discontinued (Stop Study animals), group mean body weights returned to control values, indicating reversibility in the effect. Although sporadic decreases in group mean feed consumption were measured for both males and females in the Aroclor-1254-treated groups, feed consumption was generally similar to control for all groups, with intake (mg/kg/day) of Aroclor test substances greater for females than males.

Measurements of hematologic indices in males showed group mean decreases, relative to control, in red blood cell parameters (HB, HCT and MCH) for animals receiving Aroclor-1254. The decreases were most consistently measured at 105 weeks, the conclusion of the study.

Hematologic indices for females (RBC, HB, HCT, MCV and MCH) showed both dose- and time-related group mean decreases, relative to control, for each Aroclor. The decreases were most notable for Aroclor-1254, followed by Aroclor-1260 > > Aroclor-1242 > Aroclor-1016.

Serum chemistries for males were generally unremarkable, with increased cholesterol and a suggestion for increased group mean aspartate aminotransferase (AST) in Aroclor-1254 groups (relative to control), which was not dose- or time-related.

Serum chemistries for females showed dose- and time-related group mean increases, relative to control, for gamma glutamyltransferase (GGT), AST and cholesterol for Aroclor-1242, Aroclor-1254 and Aroclor-1260, and for ALT for Aroclor-1254. No treatment-related effects on serum chemistry parameters were evident for Aroclor-1016. The increases were most notable for Aroclor-1254, followed by Aroclor-1260 > > Aroclor-1242. These increases were attributed to alterations in hepatic function, which was supported by evidence of morphologic changes, as described below.

Sporadic treatment-related organ weight increases (normalized as organ-to-brain weight ratios) were identified for males for liver and thyroid gland. The group mean increases, relative to control, were not consistently dose- or time-related for either organ for any of the Aroclor test substances evaluated.

For females, group mean liver-to-brain weight ratios (relative to control) were generally increased in a dose- and time-related manner, with the magnitude and consistency of the effect following a pattern of Aroclor-1254 > Aroclor-1260 > Aroclor-1242 > > Aroclor-1016.

At necropsy, treatment-related macroscopic findings were most evident for liver from both males and females. The liver changes which were most notable were: enlargement, discoloration, foci, and nodules and masses. These changes generally correlated histomorphologically with hepatocellular hypertrophy, accumulation of pigment, areas of altered tinctorial properties, and neoplasms, respectively. The incidence and severity of macroscopic changes followed the same general pattern identified for histomorphologic lesions, as described below.

The key treatment-related histomorphologic diagnoses for the liver were hepatocellular hypertrophy, hepatic foci and neoplasms for both males and females. For males, the incidence of hepatocellular hypertrophy approached near maximum response by week 52, while the severity generally continued progressing in a dose- and time-related manner. For Aroclor-1260, the severity appeared to reach a maximum response by 52 weeks, while continued exposure showed slight increases for the remaining Aroclors, with time. The incidence of hepatic foci increased slightly with time for all Aroclor test substances and

control, and with the exception of Aroclor-1016, were slightly greater than in control at 105 weeks. Hepatic neoplastic responses for Aroclor-treated males were not different from control, with the exception of a slight increase for Aroclor-1260 at 100 ppm. A dose-independent increased incidence for thyroid neoplasms (adenomas) was also noted in males for Aroclor-1242, Aroclor-1254 and Aroclor-1260, but not for Aroclor-1016.

For females, hepatocellular hypertrophy generally progressed in a dose- and time-related manner for each Aroclor test substance. The incidence of hepatocellular hypertrophy approached maximal response by 26 weeks, while the severity generally continued to increase thereafter, reaching maximal response by 78 weeks. Hepatic foci increased in incidence, for all Aroclors, with time, but lacked clear dose-dependence. Hepatic neoplastic responses (overwhelmingly diagnosed as adenomas) for Aroclor-treated females, showed clear dose- and Aroclor-related differences. Statistically significant increased incidences were measured in females for all Aroclors at all exposure concentrations, except for Aroclor-1016 at 50 ppm. The neoplastic response differences between Aroclor mixtures followed a progression of Aroclor-1254 > > Aroclor-1260 > Aroclor-1242 > > Aroclor-1016. The incidence of mammary neoplasms was noted to be statistically significantly decreased for several Aroclor-treated groups. The decrease was particularly striking for Aroclor-1254 at 100 ppm, but was evident to a greater or lesser extent among groups from all Aroclors.

Discontinuing exposure to PCBs (Stop Study groups) resulted in a decrease (or lack of progression) in toxic, as well as protective, responses when compared with continued exposure groups. This was evidenced in females by the restoration of group mean body weights to control values, a decrease (or lack of progression) in the severity of hepatocellular hypertrophy, a decrease in the incidence of hepatic neoplasms (especially evident for Aroclor-1016 and Aroclor-1254 Stop Study/Core subgroup comparisons), and a lack of inhibition (i.e. derepression) of mammary gland neoplasms (which occur spontaneously at a high incidence rate).

In conclusion, treatment-related toxicity was identified for all of the Aroclors evaluated. Chronic exposure to each Aroclor induced an increased incidence and severity of neoplastic and non-neoplastic lesions, which predominantly followed the pattern: Aroclor-1254 > Aroclor-1260 > Aroclor-1242 > Aroclor-1016. It also is important to note that exposure to Aroclors increased survival and decreased the incidence of mammary gland

neoplasia, and that withdrawal from exposure was associated with decreased toxic and protective responses.

7.0 REFERENCES

Agency for Toxic Substances and Disease Registry (Draft) (1993). Toxicological Profile for Selected PCBs (Aroclor-1260, -1254, -1248, -1242, -1232, -1221, and -1016). U.S. Department of Health and Human Services, Public Health Services, Agency for Toxic Substances and Disease Registry, Atlanta, GA 30333.

Benirschke, K., Garner, F. M., and Jones, T. C. (1978). Pathology of Laboratory Animals, Volume I. Springer-Verlag.

Boorman, G. A., Eustis, S. L., Elwell, M. R., Montgomery, C. A., and MacKenzie, W. F. (1990). Pathology of the Fischer Rat, Reference and Atlas. Academic Press, Inc., San Diego, CA.

Erickson, M. D. (1985). Analytical Chemistry of PCBs. Butterworth Publishers, Boston, Massachusetts.

Hutzinger, O., Safe, S., Zitko, V., eds. (1974). The Chemistry of PCB's, CRC Press, Cleveland, Ohio.

Kimbrough, R. D., Squire, R. A., Linder, R. E., Strandberg, J. D., Montali, R. J., and Burse, V. W. (1975). Induction of Liver Tumors in Sherman Strain Female Rats by Polychlorinated Biphenyl Aroclor-1260. *J. Natl. Cancer Inst.* **55**:6, 1453-1459.

National Cancer Institute (NCI) (1978). Bioassay of Aroclor-1254 for Possible Carcinogenicity. Technical Report Series No. 38. DHEW Publication N. (NIH) 78-838. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, Bethesda, MD.

Norback, D. H. and Weltman, R. H. (1985). Polychlorinated Biphenyl Induction of Hepatocellular Carcinoma in the Sprague-Dawley Rat. *Environ. Health Perspect.* **60**, 97-105.

SANSS (1990). Structure and Nomenclature Search System. Chemical Information System (CIS) computer database.

Schaeffer, E., Greim, H., and Goessner, W. (1984). Pathology of Chronic Polychlorinated Biphenyl (PCB) Feeding in Rats. *Toxicol. Appl. Pharmacol.* **75**, 278-288.

Smith, A. G. *et al.*(1990). Sex-Linked Hepatic Uroporphyrin and the Induction of Cytochromes PP450IA in Rats Caused by Hexachlorobenzone and Polyhalogenated Biphenyls. *Biochem. Pharmacol.* **40**, 2059-2068.

Standardized System of Nomenclature and Diagnostic Criteria Guides for Toxicologic Pathology, Society of Toxicologic Pathologists/ARP/AFIP, Washington, DC.

Yuan, Yang-Dar and Carlson, Robert G. (1987). Structure, Cyclic Change, and Function, Vagina and Vulva, Rat. Genital System, one of a series of Monographs on Pathology of Laboratory Animals, sponsored by the International Life Sciences Institute, edited by T. C. Jones, Ulrich Mohr, and R. D. Hunt. Springer-Verlag, 161-168.

8.0 ACKNOWLEDGMENTS

Acknowledgment of principal contributors participating in the performance of this study is presented in the following list.

Participant	Title	Department
Michael J. Brunner, B.S.	Study Coordinator	Preclinical Drug Development
Gary E. Wilkinson, M.S., D.A.B.T.	Study Toxicologist	Preclinical Drug Development
Timothy M. Sullivan, Ph.D.,D.A.B.T.	Senior Program Manager	Preclinical Drug Development
Arthur C. Peters, D.V.M.	Study Director	Preclinical Drug Development
Laurie Goodchild, D.V.M.	Study Veterinarian	Animal Resources
Tammy O'Brien, B.S.	Primary Technician	Animal Resources
Steven Graves, B.S.	Study Chemist	Bioanalytical Chemistry
Donna Boyd-Salter, B.S.	Dose Preparation Supervisor	Bioanalytical Chemistry
Scott A. Chaffins, M.S.	Dose Preparation Supervisor	Bioanalytical Chemistry
Ronald G. Menton, Ph.D.	Statistician	Statistics and Data Analysis
Nancy Niemuth, M.S.	Statistician	Statistics and Data Analysis
Allen W. Singer, D.V.M., D.A.C.V.P.,D.A.B.T	Manager, Pathology	Pathology
Michael Ryan, D.V.M., Ph.D., D.A.C.V.P.	Associate Pathologist	Pathology
John Toft, II, D.V.M, M.S., D.A.C.V.P.	Associate Pathologist	Pathology
Stephanie Helgerman, M.S., CSP	Senior Safety Specialist	Preclinical Drug Development

9.0 FIGURES




Figure 1. Survival Curve for Aroclor-1016 Core/Interim Subgroup Male Rats




Figure 2. Survival Curve for Aroclor-1242 Core/Interim Subgroup Male Rats




Figure 3. Survival Curve for Aroclor-1254 Core/Interim Subgroup Male Rats




Figure 4. Survival Curve for Aroclor-1260 Core/Interim Subgroup Male Rats




Figure 5. Survival Curve for Aroclor-1016 Core/Interim Subgroup Female Rats




Figure 6. Survival Curve for Aroclor-1242 Core/Interim Subgroup Female Rats




Figure 7. Survival Curve Aroclor-1254 Core/Interim Subgroup Female Rats




Figure 8. Survival Curve for Aroclor-1260 Core/Interim Subgroup Female Rats




Figure 9. Survival Curve for Aroclor-1016 Stop Study Subgroup Female Rats




Figure 10. Survival Curve for Aroclor-1242 Stop Study Subgroup Female Rats




Figure 11. Survival Curve for Aroclor-1254 Stop Study Subgroup Female Rats




Figure 12. Survival Curve for Aroclor-1260 Stop Study Subgroup Female Rats




Figure 13. Group Mean Weekly Body Weights for Aroclor-1016 Core/Interim Subgroup Male Rats




Figure 14. Group Mean Weekly Body Weights for Aroclor-1242 Core/Interim Subgroup Male Rats




Figure 15. Group Mean Weekly Body Weights for Aroclor-1254 Core/Interim Subgroup Male Rats




Figure 18. Group Mean Weekly Body Weights for Aroclor-1242 Core/Interim Subgroup Female Rats[1]

1. Stop Study subgroup data are included through Week 52.




Figure 19. Group Mean Weekly Body Weights for Aroclor-1254 Core/Interim Subgroup Female Rats[1]

1. Stop Study subgroup data are included through Week 52.




Figure 20. Group Mean Weekly Body Weights for Aroclor-1260 Core/Interim Subgroup Female Rats[1]

1. Stop Study subgroup data are included through Week 52.




Figure 21. Group Mean Weekly Body Weights for Aroclor-1016 Stop Study Subgroup Female Rats




Figure 22. Group Mean Weekly Body Weights for Aroclor-1242 Stop Study Subgroup Female Rats




Figure 23. Group Mean Weekly Body Weights for Aroclor-1254 Stop Study Subgroup Female Rats




Figure 24. Group Mean Weekly Body Weights for Aroclor-1260 Stop Study Subgroup Female Rats




Figure 25. Group Mean Feed Consumption for Aroclor-1016 Core/Interim Subgroup Male Rats




Figure 26. Group Mean Feed Consumption for Aroclor-1242 Core/Interim Subgroup Male Rats




Figure 27. Group Mean Feed Consumption for Aroclor-1254 Core/Interim Subgroup Male Rats




Figure 28. Group Mean Feed Consumption for Aroclor-1260 Core/Interim Subgroup Male Rats




Figure 29. Group Mean Feed Consumption for Aroclor-1016 Core/Interim Subgroup Female Rats[1]

1. Stop Study subgroup data are included through Week 52.

802135




Figure 30. Group Mean Feed Consumption for Aroclor-1242 Core/Interim Subgroup Female Rats[1]

1. Stop Study subgroup data are included through Week 52.

802136




Figure 31. Group Mean Feed Consumption for Aroclor-1254 Core/Interim Subgroup Female Rats[1]

1. Stop Study subgroup data are included through Week 52.




Figure 32. Group Mean Feed Consumption for Aroclor-1260 Core/Interim Subgroup Female Rats[1]

1. Stop Study subgroup data are included through Week 52.

802138




Figure 33. Group Mean Feed Consumption for Aroclor-1016 Stop Study Subgroup Female Rats




Figure 34. Group Mean Feed Consumption for Aroclor-1242 Stop Study Subgroup Female Rats




Figure 35. Group Mean Feed Consumption for Aroclor-1254 Stop Study Subgroup Female Rats




Figure 36. Group Mean Feed Consumption for Aroclor-1260 Stop Study Subgroup Female Rats

10.0 TABLES

Table 1. Dose Formulation Schedule

Aroclor-1016 and Blank Batch and Dose Concentration	Aroclor-1016 and Blank Date Prepared[1]	Aroclor-1242 and Blank Batch and Dose Concentration	Aroclor-1242 and Blank Date Prepared[1]
1016-001 (50 ppm) 1016-002 (50 ppm) 1016-003 (100 ppm) 1016-004 (100 ppm) 1016-005 (200 ppm) 1016-006 (200 ppm)	1-19-93	BLANK-001 (0 ppm) BLANK-002 (0 ppm) 1242-001 (50 ppm) 1242-002 (50 ppm) 1242-003 (100 ppm) 1242-004 (100 ppm)	1-25-93
1016-007 (50 ppm) 1016-008 (50 ppm) 1016-009 (100 ppm) 1016-010 (100 ppm) 1016-011 (200 ppm) 1016-012 (200 ppm)	2-8-93	BLANK-003 (0 ppm) BLANK-004 (0 ppm) 1242-005 (50 ppm) 1242-006 (50 ppm) 1242-007 (100 ppm) 1242-008 (100 ppm)	2-15-93
1016-013 (50 ppm) 1016-014 (50 ppm) 1016-015 (100 ppm) 1016-016 (100 ppm) 1016-017 (200 ppm) 1016-018 (200 ppm)	3-8-93	BLANK-005 (0 ppm) BLANK-006 (0 ppm) 1242-009 (50 ppm) 1242-010 (50 ppm) 1242-011 (100 ppm) 1242-012 (100 ppm)	3-15-93
1016-019 (50 ppm) 1016-020 (50 ppm) 1016-021 (100 ppm) 1016-022 (100 ppm) 1016-023 (200 ppm) 1016-024 (200 ppm)	4-5-93	BLANK-007 (0 ppm) BLANK-008 (0 ppm) BLANK-009 (0 ppm) 1242-013 (50 ppm) 1242-014 (50 ppm) 1242-015 (100 ppm) 1242-016 (100 ppm)	4-5-93 4-12-93
1016-025 (50 ppm) 1016-026 (50 ppm) 1016-027 (100 ppm) 1016-028 (100 ppm) 1016-029 (200 ppm) 1016-030 (200 ppm) 1016-029A (200 ppm)	5-3-93 5-28-93	BLANK-010 (0 ppm) BLANK-011 (0 ppm) 1242-017 (50 ppm) 1242-018 (50 ppm) 1242-019 (100 ppm) 1242-020 (100 ppm)	5-10-93
1016-031 (50 ppm) 1016-032 (50 ppm) 1016-033 (100 ppm) 1016-034 (100 ppm) 1016-035 (200 ppm) 1016-036 (200 ppm)	6-1-93	BLANK-012 (0 ppm) BLANK-013 (0 ppm) 1242-021 (50 ppm) 1242-022 (50 ppm) 1242-023 (100 ppm) 1242-024 (100 ppm)	6-7-93
1016-037 (50 ppm) 1016-038 (50 ppm) 1016-039 (100 ppm) 1016-040 (100 ppm) 1016-041 (200 ppm) 1016-042 (200 ppm)	6-28-93	BLANK-014 (0 ppm) BLANK-015 (0 ppm) 1242-025 (50 ppm) 1242-026 (50 ppm) 1242-027 (100 ppm) 1242-028 (100 ppm)	7-6-93

1. Represents first day of preparation.

Table 1. Dose Formulation Schedule

Aroclor-1016 and Blank Batch and Dose Concentration	Aroclor-1016 and Blank Date Prepared[1]	Aroclor-1242 and Blank Batch and Dose Concentration	Aroclor-1242 and Blank Date Prepared[1]
1016-043 (50 ppm) 1016-044 (50 ppm) 1016-045 (100 ppm) 1016-046 (100 ppm) 1016-047 (200 ppm) 1016-048 (200 ppm)	7-27-93	BLANK-016 (0 ppm) BLANK-017 (0 ppm) 1242-029 (50 ppm) 1242-030 (50 ppm) 1242-031 (100 ppm) 1242-032 (100 ppm)	8-2-93
1016-049 (50 ppm) 1016-050 (50 ppm) 1016-051 (100 ppm) 1016-052 (100 ppm) 1016-053 (200 ppm) 1016-054 (200 ppm)	8-23-93	BLANK-018 (0 ppm) BLANK-019 (0 ppm) 1242-033 (50 ppm) 1242-034 (50 ppm) 1242-035 (100 ppm) 1242-036 (100 ppm)	8-30-93
1016-055 (50 ppm) 1016-056 (50 ppm) 1016-057 (100 ppm) 1016-058 (100 ppm) 1016-059 (200 ppm) 1016-060 (200 ppm)	9-20-93	BLANK-020 (0 ppm) BLANK-021 (0 ppm) 1242-037 (50 ppm) 1242-038 (50 ppm) 1242-039 (100 ppm) 1242-040 (100 ppm)	9-27-93
1016-061 (50 ppm) 1016-062 (50 ppm) 1016-063 (100 ppm) 1016-064 (100 ppm) 1016-065 (200 ppm) 1016-066 (200 ppm)	10-18-93	BLANK-022 (0 ppm) BLANK-023 (0 ppm) 1242-041 (50 ppm) 1242-042 (50 ppm) 1242-043 (100 ppm) 1242-044 (100 ppm)	10-25-93
1016-067 (50 ppm) 1016-068 (50 ppm) 1016-069 (100 ppm) 1016-070 (100 ppm) 1016-071 (200 ppm) 1016-072 (200 ppm)	11-15-93	BLANK-024 (0 ppm) BLANK-025 (0 ppm) 1242-045 (50 ppm) 1242-046 (50 ppm) 1242-047 (100 ppm) 1242-048 (100 ppm)	11-22-93
1016-073 (50 ppm) 1016-074 (50 ppm) 1016-075 (100 ppm) 1016-076 (100 ppm) 1016-077 (200 ppm) 1016-078 (200 ppm)	12-13-93	BLANK-026 (0 ppm) BLANK-027 (0 ppm) 1242-049 (50 ppm) 1242-050 (50 ppm) 1242-051 (100 ppm) 1242-052 (100 ppm)	12-20-93
1016-079 (50 ppm) 1016-080 (50 ppm) 1016-081 (100 ppm) 1016-082 (100 ppm) 1016-083 (200 ppm) 1016-084 (200 ppm)	1-10-94	BLANK-028 (0 ppm) BLANK-029 (0 ppm) 1242-053 (50 ppm) 1242-054 (50 ppm) 1242-055 (100 ppm) 1242-056 (100 ppm)	1-17-94

1. Represents first day of preparation.

Table 1. Dose Formulation Schedule

Aroclor-1016 and Blank Batch and Dose Concentration	Aroclor-1016 and Blank Date Prepared[1]	Aroclor-1242 and Blank Batch and Dose Concentration	Aroclor-1242 and Blank Date Prepared[1]
1016-085 (50 ppm) 1016-086 (50 ppm) 1016-087 (100 ppm) 1016-088 (100 ppm) 1016-089 (200 ppm) 1016-090 (200 ppm)	2-7-94	1242-057 (50 ppm) 1242-058 (100 ppm) BLANK-030 (0 ppm) BLANK-031 (0 ppm)	2-14-94
1016-091 (50 ppm) 1016-092 (100 ppm) 1016-093 (200 ppm) BLANK-033 (0 ppm)	3-7-94	1242-059 (50 ppm) 1242-060 (100 ppm) BLANK-034 (0 ppm) BLANK-035 (0 ppm)	3-14-94
1016-094 (50 ppm) 1016-095 (100 ppm) 1016-096 (200 ppm) BLANK-034 (0 ppm)	4-4-94	1242-061 (50 ppm) 1242-062 (100 ppm) BLANK-036 (0 ppm) BLANK-037 (0 ppm)	4-14-94
1016-097 (50 ppm) 1016-098 (100 ppm) 1016-099 (200 ppm) BLANK-035 (0 ppm)	5-2-94	1242-063 (50 ppm) 1242-064 (100 ppm) BLANK-038 (0 ppm) BLANK-039 (0 ppm)	5-9-94
1016-100 (50 ppm) 1016-101 (100 ppm) 1016-102 (200 ppm) BLANK-044 (0 ppm)	5-31-94	1242-065 (50 ppm) 1242-066 (100 ppm) BLANK-045 (0 ppm) BLANK-046 (0 ppm)	6-6-94
1016-103 (50 ppm) 1016-104 (100 ppm) 1016-105 (200 ppm) BLANK-048 (0 ppm)	6-27-94	1242-067 (50 ppm) 1242-068 (100 ppm) BLANK-049 (0 ppm) BLANK-050 (0 ppm)	7-6-94
1016-106 (50 ppm) 1016-107 (100 ppm) 1016-108 (200 ppm) BLANK-052 (0 ppm)	7-25-94	1242-069 (50 ppm) 1242-070 (100 ppm) BLANK-053 (0 ppm) BLANK-054 (0 ppm)	8-1-94
1016-109 (50 ppm) 1016-110 (100 ppm) 1016-111 (200 ppm) BLANK-056 (0 ppm)	8-22-94	1242-071 (50 ppm) 1242-072 (100 ppm) BLANK-057 (0 ppm) BLANK-058 (0 ppm)	8-29-94
1016-112 (50 ppm) 1016-113 (100 ppm) 1016-114 (200 ppm) BLANK-060 (0 ppm)	9-19-94	1242-073 (50 ppm) 1242-074 (100 ppm) BLANK-061 (0 ppm) BLANK-062 (0 ppm)	9-26-94
1016-115 (50 ppm) 1016-116 (100 ppm) 1016-117 (200 ppm) BLANK-064 (0 ppm)	10-17-94	1242-075 (50 ppm) 1242-076 (100 ppm) BLANK-065 (0 ppm)	10-24-94

1. Represents first day of preparation.

Table 1. Dose Formulation Schedule

Aroclor-1016 and Blank Batch and Dose Concentration	Aroclor-1016 and Blank Date Prepared[1]	Aroclor-1242 and Blank Batch and Dose Concentration	Aroclor-1242 and Blank Date Prepared[1]
1016-118 (50 ppm) 1016-119 (100 ppm) 1016-120 (200 ppm) BLANK-069 (0 ppm)	11-14-94	1242-077 (50 ppm) 1242-078 (100 ppm) BLANK-070 (0 ppm)	11-21-94
1016-121 (50 ppm) 1016-122 (100 ppm) 1016-123 (200 ppm) BLANK-073 (0 ppm)	12-12-94	1242-079 (50 ppm) 1242-080 (100 ppm) BLANK-074 (0 ppm)	12-19-94
1016-124 (50 ppm) 1016-125 (100 ppm) 1016-126 (200 ppm) BLANK-077 (0 ppm)	1-9-95	1242-081 (50 ppm) 1242-082 (100 ppm) BLANK-078 (0 ppm)	1-16-95
1016-127 (50 ppm) 1016-128 (100 ppm) 1016-129 (200 ppm)	2-9-95		

1. Represents first day of preparation.

Table 1. Dose Formulation Schedule

Aroclor-1254 and Blank Batch and Dose Concentration	Aroclor-1254 and Blank Date Prepared[1]	Aroclor-1260 and Blank Batch and Dose Concentration	Aroclor-1260 and Blank Date Prepared[1]
1254-001 (25 ppm) 1254-002 (25 ppm) 1254-003 (50 ppm) 1254-004 (50 ppm) 1254-005 (100 ppm) 1254-006 (100 ppm)	1-28-93	1260-001 (25 ppm) 1260-002 (25 ppm) 1260-003 (50 ppm) 1260-004 (50 ppm) 1260-005 (100 ppm) 1260-006 (100 ppm)	2-1-93
1254-007 (25 ppm) 1254-008 (25 ppm) 1254-009 (50 ppm) 1254-010 (50 ppm) 1254-011 (100 ppm) 1254-012 (100 ppm)	2-22-93	1260-007 (25 ppm) 1260-008 (25 ppm) 1260-009 (50 ppm) 1260-010 (50 ppm) 1260-011 (100 ppm) 1260-012 (100 ppm)	3-1-93
1254-013 (25 ppm) 1254-014 (25 ppm) 1254-015 (50 ppm) 1254-016 (50 ppm) 1254-017 (100 ppm) 1254-018 (100 ppm)	3-22-93	1260-013 (25 ppm) 1260-014 (25 ppm) 1260-015 (50 ppm) 1260-016 (50 ppm) 1260-017 (100 ppm) 1260-018 (100 ppm)	3-29-93
1254-019 (25 ppm) 1254-020 (25 ppm) 1254-021 (50 ppm) 1254-022 (50 ppm) 1254-023 (100 ppm) 1254-024 (100 ppm)	4-19-93	1260-019 (25 ppm) 1260-020 (25 ppm) 1260-021 (50 ppm) 1260-022 (50 ppm) 1260-023 (100 ppm) 1260-024 (100 ppm)	4-26-93
1254-025 (25 ppm) 1254-026 (25 ppm) 1254-027 (50 ppm) 1254-028 (50 ppm) 1254-029 (100 ppm) 1254-030 (100 ppm)	5-17-93	1260-025 (25 ppm) 1260-026 (25 ppm) 1260-027 (50 ppm) 1260-028 (50 ppm) 1260-029 (100 ppm) 1260-030 (100 ppm)	5-24-93
1254-031 (25 ppm) 1254-032 (25 ppm) 1254-033 (50 ppm) 1254-034 (50 ppm) 1254-035 (100 ppm) 1254-036 (100 ppm)	6-14-93	1260-031 (25 ppm) 1260-032 (25 ppm) 1260-033 (50 ppm) 1260-034 (50 ppm) 1260-035 (100 ppm) 1260-036 (100 ppm)	6-21-93
1254-037 (25 ppm) 1254-038 (25 ppm) 1254-039 (50 ppm) 1254-040 (50 ppm) 1254-041 (100 ppm) 1254-042 (100 ppm)	7-12-93	1260-037 (25 ppm) 1260-038 (25 ppm) 1260-039 (50 ppm) 1260-040 (50 ppm) 1260-041 (100 ppm) 1260-042 (100 ppm)	7-20-93

1. Represents first day of preparation.

Table 1. Dose Formulation Schedule

Aroclor-1254 and Blank Batch and Dose Concentration	Aroclor-1254 and Blank Date Prepared[1]	Aroclor-1260 and Blank Batch and Dose Concentration	Aroclor-1260 and Blank Date Prepared[1]
1254-043 (25 ppm) 1254-044 (25 ppm) 1254-045 (50 ppm) 1254-046 (50 ppm) 1254-047 (100 ppm) 1254-048 (100 ppm)	8-9-93	1260-043 (25 ppm) 1260-044 (25 ppm) 1260-045 (50 ppm) 1260-046 (50 ppm) 1260-047 (100 ppm) 1260-048 (100 ppm)	8-16-93
1254-049 (25 ppm) 1254-050 (25 ppm) 1254-051 (50 ppm) 1254-052 (50 ppm) 1254-053 (100 ppm) 1254-054 (100 ppm)	9-7-93	1260-049 (25 ppm) 1260-050 (25 ppm) 1260-051 (50 ppm) 1260-052 (50 ppm) 1260-053 (100 ppm) 1260-054 (100 ppm)	9-13-93
1254-055 (25 ppm) 1254-056 (25 ppm) 1254-057 (50 ppm) 1254-058 (50 ppm) 1254-059 (100 ppm) 1254-060 (100 ppm)	10-4-93	1260-055 (25 ppm) 1260-056 (25 ppm) 1260-057 (50 ppm) 1260-058 (50 ppm) 1260-059 (100 ppm) 1260-060 (100 ppm)	10-11-93
1254-061 (25 ppm) 1254-062 (25 ppm) 1254-063 (50 ppm) 1254-064 (50 ppm) 1254-065 (100 ppm) 1254-066 (100 ppm)	11-1-93	1260-061 (25 ppm) 1260-062 (25 ppm) 1260-063 (50 ppm) 1260-064 (50 ppm) 1260-065 (100 ppm) 1260-066 (100 ppm)	11-9-93
1254-067 (25 ppm) 1254-068 (25 ppm) 1254-069 (50 ppm) 1254-070 (50 ppm) 1254-071 (100 ppm) 1254-072 (100 ppm)	11-30-93	1260-067 (25 ppm) 1260-068 (25 ppm) 1260-069 (50 ppm) 1260-070 (50 ppm) 1260-071 (100 ppm) 1260-072 (100 ppm)	12-6-93
1254-073 (25 ppm) 1254-074 (25 ppm) 1254-075 (50 ppm) 1254-076 (50 ppm) 1254-077 (100 ppm) 1254-078 (100 ppm)	12-27-93	1260-073 (25 ppm) 1260-074 (25 ppm) 1260-075 (50 ppm) 1260-076 (50 ppm) 1260-077 (100 ppm) 1260-078 (100 ppm)	1-3-94
1254-079 (25 ppm) 1254-080 (25 ppm) 1254-081 (50 ppm) 1254-082 (50 ppm) 1254-083 (100 ppm) 1254-084 (100 ppm)	1-24-94	1260-079 (25 ppm) 1260-080 (25 ppm) 1260-081 (50 ppm) 1260-082 (50 ppm) 1260-083 (100 ppm) 1260-084 (100 ppm)	1-31-94

1. Represents first day of preparation.

Table 1. Dose Formulation Schedule

Aroclor-1254 and Blank Batch and Dose Concentration	Aroclor-1254 and Blank Date Prepared[1]	Aroclor-1260 and Blank Batch and Dose Concentration	Aroclor-1260 and Blank Date Prepared[1]
1254-085 (25 ppm) 1254-086 (50 ppm) 1254-087 (100 ppm) BLANK-032 (0 ppm)	2-21-94	1260-085 (25 ppm) 1260-086 (50 ppm) 1260-087 (100 ppm)	2-28-94
1254-088 (25 ppm) 1254-089 (50 ppm) 1254-090 (100 ppm) BLANK-036 (0 ppm)	3-21-94	1260-088 (25 ppm) 1260-089 (50 ppm) 1260-090 (100 ppm)	3-28-94
1254-091 (25 ppm) 1254-092 (50 ppm) 1254-093 (100 ppm) BLANK-037 (0 ppm)	4-18-94	1260-091 (25 ppm) 1260-092 (50 ppm) 1260-093 (100 ppm)	4-25-94
1254-094 (25 ppm) 1254-095 (50 ppm) 1254-096 (100 ppm) BLANK-038 (0 ppm)	5-16-94	1260-094 (25 ppm) 1260-095 (50 ppm) 1260-096 (100 ppm)	5-23-94
1254-097 (25 ppm) 1254-098 (50 ppm) 1254-099 (100 ppm) BLANK-047 (0 ppm)	6-13-94	1260-097 (25 ppm) 1260-098 (50 ppm) 1260-099 (100 ppm)	6-20-94
1254-100 (25 ppm) 1254-101 (50 ppm) 1254-102 (100 ppm) BLANK-051 (0 ppm)	7-11-94	1260-100 (25 ppm) 1260-101 (50 ppm) 1260-102 (100 ppm)	7-18-94
1254-103 (25 ppm) 1254-104 (50 ppm) 1254-105 (100 ppm) BLANK-055 (0 ppm)	8-8-94	1260-103 (25 ppm) 1260-104 (50 ppm) 1260-105 (100 ppm)	8-15-94
1254-106 (25 ppm) 1254-107 (50 ppm) 1254-108 (100 ppm) BLANK-059 (0 ppm)	9-6-94	1260-106 (25 ppm) 1260-107 (50 ppm) 1260-108 (100 ppm)	9-12-94
1254-109 (25 ppm) 1254-110 (50 ppm) 1254-111 (100 ppm) BLANK-063 (0 ppm)	10-3-94	1260-109 (25 ppm) 1260-110 (50 ppm) 1260-111 (100 ppm)	10-10-94
1254-112 (25 ppm) 1254-113 (50 ppm) 1254-114 (100 ppm) BLANK-067 (0 ppm)	10-31-94	1260-112 (25 ppm) 1260-113 (50 ppm) 1260-114 (100 ppm) BLANK-068 (0 ppm)	11-7-94

1. Represents first day of preparation.

Table 1. Dose Formulation Schedule

Aroclor-1254 and Blank Batch and Dose Concentration	Aroclor-1254 and Blank Date Prepared[1]	Aroclor-1260 and Blank Batch and Dose Concentration	Aroclor-1260 and Blank Date Prepared[1]
1254-115 (25 ppm) 1254-116 (50 ppm) 1254-117 (100 ppm) BLANK-071 (0 ppm)	11-28-94	1260-115 (25 ppm) 1260-116 (50 ppm) 1260-117 (100 ppm) BLANK-072 (0 ppm)	12-5-94
1254-118 (25 ppm) 1254-119 (50 ppm) 1254-120 (100 ppm) BLANK-075 (0 ppm)	12-27-94	1260-118 (25 ppm) 1260-119 (50 ppm) 1260-120 (100 ppm) BLANK-076 (0 ppm)	1-3-95
1254-121 (25 ppm) 1254-122 (50 ppm) 1254-123 (100 ppm) BLANK-079 (0 ppm)	1-23-95	1260-121 (25 ppm) 1260-122 (50 ppm) 1260-123 (100 ppm) BLANK-080 (0 ppm)	1-30-95

1. Represents first day of preparation.

Table 2. Dose Analysis Results for Aroclor-1016

Mix Date	Batch No.	Target Conc (ppm)	Actual Conc (ppm)		%E[a]	
			Preadmin	Postadmin	Preadmin	Postadmin
1/19/93	1016-001	50	47.1	53.8	-6	8
1/20/93	1016-002	50	49.7	53.9	-1	8
1/19/93	1016-003	100	96.5	111.1	-4	11
1/19/93	1016-004	100	102.8	106.3	3	6
1/19/93	1016-005	200	193.8	213.4	-3	7
1/20/93	1016-006	200	197.6	211.4	-1	6
4/5/93	1016-019	50	52.1	NA	4	NA
4/5/93	1016-020	50	55.2	NA	10	NA
4/5/93	1016-021	100	102.6	NA	3	NA
4/5/93	1016-022	100	94.0	NA	-6	NA
4/5/93	1016-023	200	197.5	NA	-1	NA
4/5/93	1016-024	200	191.2	NA	-4	NA
5/3/93	1016-029	200	149.1	133.5	-25	-33
5/28/93	1016-029A	200	182.8	NA	-9	NA
6/28/93	1016-037	50	48.6	49.6	-3	-1
6/28/93	1016-038	50	48.6	NA	-3	NA
6/28/93	1016-039	100	98.7	NA	-1	NA
6/28/93	1016-040	100	97.9	98.0	-2	-2
6/28/93	1016-041	200	193.9	196.6	-3	-2
6/28/93	1016-042	200	190.9	NA	-5	NA
9/20/93	1016-055	50	52.6	NA	5	NA
9/20/93	1016-056	50	54.7	NA	9	NA
9/20/93	1016-057	100	102.5	NA	2	NA
9/20/93	1016-058	100	103.2	NA	3	NA
9/20/93	1016-059	200	190.5	NA	-5	NA
9/20/93	1016-060	200	187.0	NA	-7	NA
12/13/93	1016-073	50	48.4	45.4	-3	-9
12/13/93	1016-074	50	52.6	NA	5	NA
12/13/93	1016-075	100	107.8	NA	7	NA
12/13/93	1016-076	100	109.8	95.8	10	-4
12/13/93	1016-077	200	218.9	191.6	9	-4

a. %E = (Actual Conc - Target Conc) × 100/Target Conc
NA = not applicable

Table 2. Dose Analysis Results for Aroclor-1016

Mix Date	Batch No.	Target Conc (ppm)	Actual Conc (ppm)		%E[a]	
			Preadmin	Postadmin	Preadmin	Postadmin
12/13/93	1016-078	200	216.7	NA	8	NA
3/07/94	1016-091	50	46.6	NA	-7	NA
3/07/94	1016-092	100	109.4	NA	9	NA
3/07/94	1016-093	200	216.6	NA	8	NA
5/31/94	1016-100	50	46.8	50.5	-6	1
5/31/94	1016-101	100	103.1	112.9	3	13
5/31/94	1016-102	200	213.7	222.8	7	11
8/22/94	1016-109	50	48.3	NA	-3	NA
8/22/94	1016-110	100	99.7	NA	0	NA
8/22/94	1016-111	200	199.0	NA	0	NA
10/17/94	1016-115	50	51.3	52.9	3	6
10/17/94	1016-116	100	96.9	100.0	-3	0
10/17/94	1016-117	200	195.4	193.2	-2	-3

a. %E = (Actual Conc - Target Conc) × 100/Target Conc
NA = not applicable

Table 3. Homogeneity Results for Aroclor-1016

Mix Date	Batch No.	Target Conc (ppm)	Actual Conc (ppm)			Mean Actual Conc (ppm)	%RSD[a]
			Top Left	Top Right	Bottom		
1/20/93	1016-002	50	51.3	48.4	49.3	49.7	3
1/20/93	1016-006	200	202.4	209.6	180.6	197.6	8
4/5/93	1016-023	200	196.4	195.8	197.2	196.5	0
6/28/93	1016-042	200	202.7	196.5	192.1	197.1	3
9/20/93	1016-060	200	186.1	203.9	196.5	195.5	5
12/13/93	1016-076	100	105.2	108.2	111.7	108.4	3
3/07/94	1016-091	50	44.8	44.7	44.8	44.8	0
5/31/94	1016-100	50	47.1	49.3	51.8	49.4	5
8/22/94	1016-111	200	192.2	201.2	203.5	199.0	3
10/17/94	1016-115	50	52.1	52.3	49.4	51.3	3
10/17/94	1016-117	200	190.7	199.9	195.4	195.4	2

a. % RSD = Relative Standard Deviation (SD * 100/Mean).

Table 4. Dose Analysis Results for Aroclor-1242

Mix Date	Batch No.	Target Conc (ppm)	Actual Conc (ppm)		%E[a]	
			Preadmin	Postadmin	Preadmin	Postadmin
1/25/93	1242-002	50	NA	51.6	NA	3
1/25/93	1242-002	50	52.0	52.7	4	5
1/25/93	1242-003	100	98.5	105.5	-2	6
1/25/93	1242-004	100	98.4	103.6	-2	4
4/12/93	1242-013	50	49.7	NA	-1	NA
4/12/93	1242-014	50	48.2	NA	-4	NA
4/12/93	1242-015	100	97.6	NA	-2	NA
4/12/93	1242-016	100	99.5	NA	-1	NA
7/6/93	1242-025	50	53.0	46.3	6	-8
7/6/93	1242-026	50	52.1	48.1	4	-4
7/6/93	1242-027	100	99.4	94.0	-1	-6
7/6/93	1242-028	100	103.8	91.0	4	-9
9/27/93	1242-037	50	50.9	NA	2	NA
9/27/93	1242-038	50	47.3	NA	-5	NA
9/27/93	1242-039	100	93.4	NA	-7	NA
9/27/93	1242-040	100	90.8	NA	-9	NA
12/20/93	1242-049	50	48.5	NA	-3	NA
12/20/93	1242-050	50	50.4	49.2	1	-2
12/20/93	1242-051	100	92.4	97.2	-8	-3
12/20/93	1242-052	100	99.5	NA	-1	NA
3/14/94	1242-059	50	45.1	NA	-10	NA
3/14/94	1242-060	100	104.0	NA	4	NA
6/06/94	1242-065	50	50.6	51.5	1	3
6/06/94	1242-066	100	100.1	97.4	0	-3
8/29/94	1242-071	50	52.7	NA	5	NA
8/29/94	1242-072	100	96.3	NA	-4	NA
10/24/94	1242-076	50	49.6	54.6	-1	9
10/24/94	1242-075	100	94.4	104.0	-6	4

a. %E = (Actual Conc - Target Conc) × 100/Target Conc
NA = not applicable

Table 5. Homogeneity Results for Aroclor-1242

Mix Date	Batch No.	Target Conc (ppm)	Actual Conc (ppm)			Mean Actual Conc (ppm)	%RSD[a]
			Top Left	Top Right	Bottom		
1/25/93	1242-002	50	48.1	49.5	49.3	48.9	4
1/25/93	1242-004	100	102.0	99.6	93.4	98.4	8
4/12/93	1242-016	100	98.2	93.4	94.4	95.3	3
7/06/93	1242-028	100	99.8	109.5	101.6	103.6	5
9/27/93	1242-039	100	89.8	96.7	96.0	94.2	4
12/20/93	1242-050	50	49.0	47.4	50.0	48.8	3
3/14/94	1242-060	100	96.5	97.1	101.7	98.4	3
6/06/94	1242-065	50	50.9	51.4	49.7	50.6	2
8/29/94	1242-072	100	95.2	96.9	97.0	96.3	1
10/24/94	1242-076	50	48.4	51.7	48.9	49.6	4
10/24/94	1242-075	100	100.0	88.7	94.7	94.4	6

a. % RSD = Relative Standard Deviation (SD * 100/Mean).

Table 6. Dose Analysis Results for Aroclor-1254

Mix Date	Batch No.	Target Conc (ppm)	Actual Conc (ppm)		%E[a]	
			Preadmin	Postadmin	Preadmin	Postadmin
1/28/93	1254-001	25	22.8	25.8	-9	3
1/28/93	1254-002	25	24.8	25.0	-1	0
1/28/93	1254-003	50	47.8	52.0	-4	4
1/28/93	1254-004	50	47.2	51.9	-6	4
1/28/93	1254-005	100	105.0	104.2	9	4
1/28/93	1254-006	100	96.2	104.4	-6	4
1/28/93	1254-005RD	100	102.0	NA	2	NA
4/19/93	1254-019	25	25.9	NA	4	NA
4/19/93	1254-020	25	24.0	NA	-4	NA
4/19/93	1254-021	50	51.4	NA	3	NA
4/19/93	1254-022	50	47.0	NA	-6	NA
4/19/93	1254-023	100	90.6	NA	-9	NA
4/19/93	1254-024	100	103.5	NA	4	NA
7/12/93	1254-037	25	27.0	23.8	10	-5
7/12/93	1254-038	25	28.0	22.9	12	-8
7/12/93	1254-039	50	45.4	44.8	-9	-10
7/12/93	1254-040	50	49.9	44.9	0	-10
7/12/93	1254-041	100	96.4	95.9	-4	-4
7/12/93	1254-042	100	102.2	92.6	2	-7
10/4/93	1254-055	25	23.5	NA	-6	NA
10/4/93	1254-056	25	23.0	NA	-8	NA
10/4/93	1254-057	50	46.0	NA	-8	NA
10/4/93	1254-058	50	48.0	NA	-4	NA
10/4/93	1254-059	100	94.4	NA	-6	NA

a. %E = (Actual Conc - Target Conc) × 100/Target Conc
NA = not applicable

Table 6. Dose Analysis Results for Aroclor-1254

Mix Date	Batch No.	Target Conc (ppm)	Actual Conc (ppm)		%E[a]	
			Preadmin	Postadmin	Preadmin	Postadmin
10/4/93	1254-060	100	91.4	NA	-9	NA
12/27/93	1254-073	25	26.4	25.8	6	3
12/27/93	1254-074	25	25.3	26.5	1	6
12/27/93	1254-075	50	47.2	51.8	-6	4
12/27/93	1254-076	50	48.0	54.5	-4	9
12/27/93	1254-077	100	101.2	101.0	1	1
12/27/93	1254-078	100	94.4	103.9	-6	4
3/21/94	1254-088	25	24.4	NA	-2	NA
3/21/94	1254-089	50	45.7	NA	-9	NA
3/21/94	1254-090	100	97.7	NA	-2	NA
6/13/94	1254-097	25	23.2	25.2	-7	1
6/13/94	1254-098	50	45.7	51.1	-9	2
6/13/94	1254-099	100	103.6	114.0	4	14
9/06/94	1254-106	25	23.3	NA	-7	NA
9/06/94	1254-107	50	47.8	NA	-4	NA
9/06/94	1254-108	100	91.8	NA	-8	NA
10/31/94	1254-112	25	26.9	25.3	7	1
10/31/94	1254-113	50	52.7	52.9	5	6
10/31/94	1254-114	100	105.0	102.8	5	3

a. %E = (Actual Conc - Target Conc) × 100/Target Conc
NA = not applicable

Table 7. Homogeneity Results for Aroclor-1254

Mix Date	Batch No.	Target Conc (ppm)	Actual Conc (ppm)			Mean Actual Conc (ppm)	%RSD[a]
			Top Left	Top Right	Bottom		
1/28/93	1254-002	25	25.0	24.8	24.6	24.8	1
1/28/93	1254-006	100	95.0	102.2	91.4	96.2	6
1/28/93	1254-006RH	100	106.4	90.2	100.0	98.9	8
4/19/93	1254-019	25	24.3	23.8	24.5	24.2	2
7/12/93	1254-042	100	97.1	98.1	93.7	96.3	2
10/4/93	1254-058	50	44.9	46.3	50.3	47.2	6
12/27/93	1254-076	50	53.6	48.8	50.8	51.1	5
3/21/94	1254-089	50	45.6	46.8	45.8	46.1	1
6/13/94	1254-097	25	22.7	24.0	23.0	23.2	3
9/06/94	1254-107	50	46.1	48.9	48.4	47.8	3
10/31/94	1254-112	25	27.4	27.4	26.1	26.9	3
10/31/94	1254-114	100	97.7	113.0	104.4	105.0	7

RH = Repeated because of poor precision between triplicate samples from each location
a. % RSD = Relative Standard Deviation (SD * 100/Mean).

Table 8. Dose Analysis Results for Aroclor-1260

Mix Date	Batch No.	Target Conc (ppm)	Actual Conc (ppm)		%E[a]	
			Preadmin	Postadmin	Preadmin	Postadmin
2/2/93	1260-001	25	25.8	27.0	3	8
2/2/93	1260-002	25	28.1	28.3	12	13
2/2/93	1260-003	50	47.4	56.2	-5	12
2/2/93	1260-004	50	48.3	53.8	-4	8
2/2/93	1260-005	100	104.1	110.4	4	10
2/2/93	1260-006	100	96.7	114.3	-3	14
4/26/93	1260-019	25	25.0	NA	0	NA
4/26/93	1260-020	25	26.0	NA	4	NA
4/26/93	1260-021	50	47.3	NA	-5	NA
4/26/93	1260-022	50	47.5	NA	-5	NA
4/26/93	1260-023	100	100.4	NA	0	NA
4/26/93	1260-024	100	105.7	NA	6	NA
7/19/93	1260-037	25	25.1	23.6	0	-6
7/19/93	1260-038	25	26.4	23.1	6	-8
7/19/93	1260-039	50	48.9	46.1	-2	-8
7/19/93	1260-040	50	53.0	49.1	6	-2
7/19/93	1260-041	100	92.8	94.1	-7	-6
7/19/93	1260-042	100	106.2	90.1	6	-10
10/11/93	1260-055	25	26.0	NA	4	NA
10/11/93	1260-056	25	23.8	NA	-5	NA
10/11/93	1260-057	50	45.5	NA	-9	NA
10/11/93	1260-058	50	47.0	NA	-6	NA
10/11/93	1260-059	100	94.8	NA	-5	NA
10/11/93	1260-060	100	91.9	NA	-8	NA

a. %E = (Actual Conc - Target Conc) × 100/Target Conc
NA = not applicable

Table 8. Dose Analysis Results for Aroclor-1260

Mix Date	Batch No.	Target Conc (ppm)	Actual Conc (ppm)		%E[a]	
			Preadmin	Postadmin	Preadmin	Postadmin
1/3/94	1260-073	25	24.0	26.0	-4	4
1/3/94	1260-074	25	24.2	26.3	-3	5
1/3/94	1260-075	50	51.6	55.1	3	10
1/3/94	1260-076	50	52.2	53.9	4	8
1/3/94	1260-077	100	109.0	103.0	9	3
1/3/94	1260-078	100	110.1	107.4	10	7
3/28/94	1260-088	25	26.9	NA	8	NA
3/28/94	1260-089	50	53.0	NA	6	NA
3/28/94	1260-090	100	96.5	NA	-4	NA
6/20/94	1260-097	25	25.1	28.4	0	14
6/20/94	1260-098	50	53.9	53.8	8	8
6/20/94	1260-099	100	105.2	118.7	5	19
9/12/94	1260-106	25	25.5	NA	2	NA
9/12/94	1260-107	50	47.9	NA	-4	NA
9/12/94	1260-108	100	101.5	NA	2	NA
11/07/94	1260-112	25	25.6	25.0	2	0
11/07/94	1260-113	50	52.8	51.9	6	4
11/07/94	1260-114	100	98.5	104.8	-2	5

a. %E = (Actual Conc - Target Conc) × 100/Target Conc
NA = not applicable

Table 9. Homogeneity Results for Aroclor-1260

Mix Date	Batch No.	Target Conc (ppm)	Actual Conc (ppm)			Mean Actual Conc (ppm)	%RSD[a]
			Top Left	Top Right	Bottom		
2/2/93	1260-001	25	25.2	25.2	27.1	25.8	4
2/2/93	1260-006	100	92.9	98.3	99.0	96.7	3
4/26/93	1260-024	100	91.0	96.7	90.2	92.8	4
7/19/93	1260-040	50	54.4	48.2	47.9	50.2	7
10/11/93	1260-060	100	100.1	96.3	86.2	94.1	8
1/3/94	1260-073	25	26.8	25.7	25.4	26.0	3
3/28/94	1260-088	25	24.9	23.9	25.7	24.8	4
6/20/94	1260-097	25	23.9	26.3	25.0	25.1	5
9/12/94	1260-108	100	104.3	98.9	101.3	101.5	3
11/07/94	1260-112	25	25.7	25.6	25.5	25.6	0
11/07/94	1260-114	100	96.6	100.6	98.3	98.5	2

a. % RSD = Relative Standard Deviation (SD * 100/Mean).

Table 10. Referee Dose Analysis Results[1]

Mix[b] Date	Batch Number	Target Concentration (ppm)	Actual Concentration (ppm)	%E[a]
6/7/93	Blank-013	0	< 0.065	NA
6/1/93	1016-034	100	102.9	3
10/18/93	1016-065 (066)[c]	200	204.2	2
5/2/94	1016-098	100	96.2	-4
1/9/95	1016-126	200	215	8
6/7/93	1242-021	50	49.6	-1
10/25/93	1242-043 (044)[c]	100	93.8	-6
4/14/94	1242-062	100	98.7	-1
1/16/95	1242-081	50	49.1	-2
1/16/95	1242-081Dup	50	49.5	-1
6/14/93	1254-036	100	102.9	3
11/1/93	1254-065 (066)[c]	100	104.8	5
4/18/94	1254-093	100	105.2	5
1/23/95	1254-122	50	56.4	13
5/24/93	1260-026	25	25.1	0
5/24/93	1260-026Dup	25	25.0	0
10/11/93	1260-059 (060)[c]	100	96.6	-3
4/25/94	1260-093	100	99.4	-1
1/30/95	1260-121	25	25.0	0

1. Analysis was performed by Northeast Analytical Environmental Lab Services, Schenectady, New York.
a. %E = (Actual Conc - Target Conc) × 100/Target Conc.
b. Represents first mix date of preparation.
c. Exact batch number unknown. Both batches in use at time of feed collection. Both batches were mixed on the same date.

Table 11. Animal Survival Probability Comparisons for Core and Interim Subgroup Male Rats

Test Substance	Description	Control	50 ppm	100 ppm	200 ppm
Aroclor-1016	Animals Initially in Study	118	68	68	68
	26-Week Interim Termination	5	6	6	6
	52-Week Interim Termination	6	6	5	6
	78-Week Interim Termination	4	5	3	4
	Found Dead	43	28	36	17
	Moribund Termination[a]	17	8	3	10
	105-Week Termination	43	14	14	25
	Survival Probability (%)[b]	42	29	27	49
	Mean Survival (days)[c]	654	623	622	653
	Survival Test (P=)[d]	0.915	0.054	0.025	0.528
Aroclor-1242	Animals Initially in Study	118	68	68	
	26-Week Interim Termination	5	6	6	
	52-Week Interim Termination	6	6	5	
	78-Week Interim Termination	4	5	4	
	Found Dead	43	17	28	
	Moribund Termination[a]	17	10	8	
	105-Week Termination	43	24	17	
	Survival Probability (%)[b]	42	48	33	
	Mean Survival (days)[c]	654	659	616	
	Survival Test (P=)[d]	0.169	0.628	0.108	

a. Accidental termination animals were censored from survival analysis and are not included with moribund termination animals.
b. Survival probability = Kaplan-Meier determinations based on the number of animals alive at the 105-Week termination.
c. Mean Survival Days = Mean of all deaths.
d. Survival Test (P=) = The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposure columns. A negative trend or a lower mortality in an exposure group is indicated by N.

Table 11. Animal Survival Probability Comparisons for Core and Interim Subgroup Male Rats

Test Substance	Description	Control	25 ppm	50 ppm	100 ppm
Aroclor-1254	Animals Initially in Study	118	68	68	68
	26-Week Interim Termination	5	5	6	6
	52-Week Interim Termination	6	6	6	6
	78-Week Interim Termination	4	5	3	4
	Found Dead	43	25	32	27
	Moribund Termination[a]	17	6	10	5
	105-Week Termination	43	21	11	20
	Survival Probability (%)[b]	42	42	21	40
	Mean Survival (days)[c]	654	637	622	640
	Survival Test (P=)[d]	0.184	0.716	0.003	0.652
Aroclor-1260	Animals Initially in Study	118	68	68	68
	26-Week Interim Termination	5	6	6	6
	52-Week Interim Termination	6	6	6	6
	78-Week Interim Termination	4	4	5	3
	Found Dead	43	19	29	34
	Moribund Termination[a]	17	9	6	3
	105-Week Termination	43	24	16	15
	Survival Probability (%)[b]	42	47	33	30
	Mean Survival (days)[c]	654	653	637	632
	Survival Test (P=)[d]	0.062	0.690	0.182	0.112

a. Accidental termination animals were censored from survival analysis and are not included with moribund termination animals.
b. Survival probability = Kaplan-Meier determinations based on the number of animals alive at the 105-Week termination.
c. Mean Survival Days = Mean of all deaths.
d. Survival Test (P=) = The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposure columns. A negative trend or a lower mortality in an exposure group is indicated by N.

Table 12. Animal Survival Probability Comparisons for Core and Interim Subgroup Female Rats

Test Substance	Description	Control	50 ppm	100 ppm	200 ppm
Aroclor-1016	Animals Initially in Study	130	80	80	80
	13-Week Interim Termination	6	6	6	6
	26-Week Interim Termination	6	6	6	6
	39-Week Interim Termination	6	6	6	6
	52-Week Interim Termination	6	6	6	6
	78-Week Interim Termination	3	5	6	6
	Found Dead	30	17	19	16
	Moribund Termination[a]	42	14	10	10
	105-Week Termination	31	20	21	24
	Survival Probability (%)[b]	31	40	43	49
	Mean Survival (days)[c]	599	657	642	671
	Survival Test (P=)[d]	0.002N	0.047N	0.047N	0.003N
Aroclor-1242	Animals Initially in Study	130	80	80	
	13-Week Interim Termination	6	6	6	
	26-Week Interim Termination	6	6	6	
	39-Week Interim Termination	6	6	6	
	52-Week Interim Termination	6	6	5	
	78-Week Interim Termination	3	5	5	
	Found Dead	30	21	18	
	Moribund Termination[a]	42	7	8	
	105-Week Termination	31	23	26	
	Survival Probability (%)[b]	31	46	51	
	Mean Survival (days)[c]	599	658	652	
	Survival Test (P=)[d]	0.002N	0.016N	0.006N	

a. Accidental termination animals were censored from survival analysis and are not included with moribund termination animals.
b. Survival probability = Kaplan-Meier determinations based on the number of animals alive at the 105-Week termination.
c. Mean Survival Days = Mean of all deaths.
d. Survival Test (P=) = The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposure columns. A negative trend or a lower mortality in an exposure group is indicated by N.

Table 12. Animal Survival Probability Comparisons for Core and Interim Subgroup Female Rats

Test Substance	Description	Control	25 ppm	50 ppm	100 ppm
Aroclor-1254	Animals Initially in Study	130	80	80	80
	13-Week Interim Termination	6	6	6	6
	26-Week Interim Termination	6	6	6	6
	39-Week Interim Termination	6	6	6	6
	52-Week Interim Termination	6	6	6	5
	78-Week Interim Termination	3	4	6	5
	Found Dead	30	10	24	25
	Moribund Termination[a]	42	9	9	7
	105-Week Termination	31	33	17	20
	Survival Probability (%)[b]	31	65	34	39
	Mean Survival (days)[c]	599	664	654	651
	Survival Test (P=)[d]	0.096	0.001N	0.103	0.067
Aroclor-1260	Animals Initially in Study	130	80	80	80
	13-Week Interim Termination	6	6	6	6
	26-Week Interim Termination	6	6	6	6
	39-Week Interim Termination	6	6	6	6
	52-Week Interim Termination	6	6	5	6
	78-Week Interim Termination	3	5	6	6
	Found Dead	30	27	17	20
	Moribund Termination[a]	42	5	13	8
	105-Week Termination	31	19	21	22
	Survival Probability (%)[b]	31	38	43	45
	Mean Survival (days)[c]	599	656	632	659
	Survival Test (P=)[d]	0.010N	0.070	0.071	0.019N

a. Accidental termination animals were censored from survival analysis and are not included with moribund termination animals.
b. Survival probability = Kaplan-Meier determinations based on the number of animals alive at the 105-Week termination.
c. Mean Survival Days = Mean of all deaths.
d. Survival Test (P=) = The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposure columns. A negative trend or a lower mortality in an exposure group is indicated by N.

Table 13. Animal Survival Probability Comparisons for Stop Study Subgroup Female Rats

Test Substance	Description	Control[a]	50 ppm	100 ppm	200 ppm
Aroclor-1016	Animals Initially in Study	130	30	30	30
	78-Week Interim Termination	27[f]	6	6	5
	Found Dead	30	3	10	14
	Moribund Termination[b]	42	11	4	4
	105-Week Termination	31	10	10	7
	Survival Probability (%)[c]	31	42	43	24
	Mean Survival (days)[d]	599	674	656	606
	Survival Test (P=)[e]	0.245	0.043N	0.082	0.677
Aroclor-1242	Animals Initially in Study	130	30	30	
	78-Week Interim Termination	27[e]	5	5	
	Found Dead	30	9	8	
	Moribund Termination[b]	42	6	6	
	105-Week Termination	31	10	11	
	Survival Probability (%)[c]	31	40	45	
	Mean Survival (days)[d]	599	649	671	
	Survival Test (P=)[e]	0.017N	0.088	0.046	

Stop Study Subgroup = Stop Study A and Stop Study B subgroup animals.

a. Core/Interim subgroup female control data used for comparison.
b. Accidental termination animals were censored from survival analysis and are not included with moribund termination animals.
c. Survival probability = Kaplan-Meier determinations based on the number of animals alive at the 105-Week termination.
d. Mean Survival Days = Mean of all deaths.
e. Survival Test (P=) = The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposure columns. A negative trend or a lower mortality in an exposure group is indicated by N.
f. Reported value for control animals is the total from the 13, 26, 39, 52, and 78 week interim termination.

Table 13. Animal Survival Probability Comparisons for Stop Study Subgroup Female Rats

Test Substance	Description	Control[a]	25 ppm	50 ppm	100 ppm
Aroclor-1254	Animals Initially in Study	130	30	30	30
	78-Week Interim Termination	27[f]	5	6	6
	Found Dead	30	5	3	7
	Moribund Termination[b]	42	9	7	4
	105-Week Termination	31	11	14	13
	Survival Probability (%)[c]	31	46	59	59
	Mean Survival (days)[d]	599	643	653	594
	Survival Test (P=)[e]	0.002N	0.092	0.004N	0.034N
Aroclor-1260	Animals Initially in Study	130	30	30	30
	78-Week Interim Termination	27[f]	6	4	5
	Found Dead	30	5	18	9
	Moribund Termination[b]	42	5	2	3
	105-Week Termination	31	14	6	13
	Survival Probability (%)[c]	31	61	24	53
	Mean Survival (days)[d]	599	663	595	666
	Survival Test (P=)[e]	0.037N	0.005N	0.776	0.012N

Stop Study Subgroup = Stop Study A and Stop Study B subgroup animals.

a. Core/Interim subgroup female control data used for comparison.
b. Accidental termination animals were censored from survival analysis and are not included with moribund termination animals.
c. Survival probability = Kaplan-Meier determinations based on the number of animals alive at the 105-Week termination.
d. Mean Survival Days = Mean of all deaths.
e. Survival Test (P=) = The result of the life table trend test (Tarone, 1975) is in the control column, and the results of the life table pairwise comparisons (Cox, 1972) with the controls are in the exposure columns. A negative trend or a lower mortality in an exposure group is indicated by N.
f. Reported value for control animals is the total from the 13, 26, 39, 52, and 78 week interim termination.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
Control	ABRASION	DORSAL - THORAX	4	404	484	23
1016/50	ABRASION	DORSAL - THORAX	2	610	642	11
1242/100	ABRASION	DORSAL - THORAX	1	484	484	1
1254/25	ABRASION	DORSAL - THORAX	3	246	283	19
1254/50	ABRASION	DORSAL - THORAX	1	253	400	22
1254/100	ABRASION	DORSAL - THORAX	3	517	531	9
1260/25	ABRASION	DORSAL - THORAX	2	439	554	12
1260/100	ABRASION	DORSAL - THORAX	1	708	722	3
1254/25	ABRASION	FRONT LIMB	1	239	246	2
1254/100	ABRASION	FRONT LIMB	1	603	603	1
Control	ABRASION	HEAD	1	43	43	1
1016/50	ABRASION	HEAD	2	435	470	11
1016/200	ABRASION	HEAD	1	463	547	13
1242/50	ABRASION	HEAD	1	15	36	4
1242/100	ABRASION	HEAD	1	393	414	4
1254/25	ABRASION	HEAD	1	477	561	13
1254/50	ABRASION	HEAD	1	456	519	10
1260/25	ABRASION	HEAD	1	673	680	2
Control	ABRASION	NECK	3	216	255	20
1016/50	ABRASION	NECK	2	351	697	79
1016/100	ABRASION	NECK	3	13	43	13
1016/200	ABRASION	NECK	3	148	202	26
1242/50	ABRASION	NECK	4	45	75	21
1242/100	ABRASION	NECK	2	36	274	68
1254/25	ABRASION	NECK	6	208	325	87
1254/100	ABRASION	NECK	1	225	253	5
1260/25	ABRASION	NECK	2	418	467	16
1260/50	ABRASION	NECK	1	533	665	20
1260/100	ABRASION	NECK	1	8	92	13

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/100	ABRASION	NOSE	1	8	15	2
1242/50	ABRASION	NOSE	1	701	730	5
1254/25	ABRASION	NOSE	1	141	155	3
Control	ABRASION	REAR LIMB	2	680	696	6
1016/100	ABRASION	REAR LIMB	1	684	684	1
1242/50	ABRASION	REAR LIMB	2	544	551	4
1254/25	ABRASION	REAR LIMB	2	372	390	7
Control	ABRASION	SHOULDER	6	131	162	33
1016/50	ABRASION	SHOULDER	5	63	138	32
1016/100	ABRASION	SHOULDER	2	89	148	14
1016/200	ABRASION	SHOULDER	2	243	316	22
1242/50	ABRASION	SHOULDER	3	43	162	33
1242/100	ABRASION	SHOULDER	4	101	166	39
1254/25	ABRASION	SHOULDER	8	45	95	42
1254/50	ABRASION	SHOULDER	3	34	59	14
1254/100	ABRASION	SHOULDER	3	76	328	89
1260/25	ABRASION	SHOULDER	1	22	43	4
1260/50	ABRASION	SHOULDER	2	29	68	13
1260/100	ABRASION	SHOULDER	3	27	52	14
Control	ABRASION	VENTRAL - ABDOMEN	1	533	533	1
1016/50	ABRASION	VENTRAL - ABDOMEN	2	551	572	8
1016/100	ABRASION	VENTRAL - ABDOMEN	2	393	404	5
1016/200	ABRASION	VENTRAL - ABDOMEN	2	232	246	6
1242/50	ABRASION	VENTRAL - ABDOMEN	1	673	673	1
1254/100	ABRASION	VENTRAL - ABDOMEN	1	680	694	3
1260/50	ABRASION	VENTRAL - ABDOMEN	1	701	722	4
1260/100	ABRASION	VENTRAL - ABDOMEN	1	337	365	5

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
Control	ALOPECIA	DORSAL	2	470	471	3
1016/50	ALOPECIA	DORSAL	1	687	729	7
1016/100	ALOPECIA	DORSAL	1	673	708	6
1016/200	ALOPECIA	DORSAL	2	547	593	15
Control	ALOPECIA	VENTRAL	2	533	554	8
1016/50	ALOPECIA	VENTRAL	2	687	729	14
1242/100	ALOPECIA	VENTRAL	1	662	662	1
1260/25	ALOPECIA	VENTRAL	1	358	407	8
Control	EYES	CORNEAL OPACITY	4	663	689	19
1016/100	EYES	CORNEAL OPACITY	1	190	190	1
1016/200	EYES	CORNEAL OPACITY	2	517	636	36
1242/50	EYES	CORNEAL OPACITY	3	682	712	16
1242/100	EYES	CORNEAL OPACITY	3	524	673	34
1254/25	EYES	CORNEAL OPACITY	4	384	473	54
1254/50	EYES	CORNEAL OPACITY	4	412	597	110
1254/100	EYES	CORNEAL OPACITY	3	465	654	85
1260/25	EYES	CORNEAL OPACITY	2	606	632	9
1260/50	EYES	CORNEAL OPACITY	1	729	729	1
1260/100	EYES	CORNEAL OPACITY	3	513	608	44
Control	EYES	DISCHARGE-RED	41	340	599	1148
1016/50	EYES	DISCHARGE-RED	22	255	591	772
1016/100	EYES	DISCHARGE-RED	15	344	510	235
1016/200	EYES	DISCHARGE-RED	15	224	486	405
1242/50	EYES	DISCHARGE-RED	13	303	600	353
1242/100	EYES	DISCHARGE-RED	19	337	554	360
1254/25	EYES	DISCHARGE-RED	14	324	536	370
1254/50	EYES	DISCHARGE-RED	17	362	507	275
1254/100	EYES	DISCHARGE-RED	18	310	523	418
1260/25	EYES	DISCHARGE-RED	21	184	563	881

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/50	EYES	DISCHARGE-RED	15	380	583	294
1260/100	EYES	DISCHARGE-RED	16	280	535	504
1016/100	EYES	ORBITAL GLOBE DEGENERATION	1	197	481	42
1242/100	EYES	ORBITAL GLOBE DEGENERATION	3	316	591	122
1254/25	EYES	ORBITAL GLOBE DEGENERATION	1	372	379	2
1254/100	EYES	ORBITAL GLOBE DEGENERATION	1	687	693	2
1260/25	EYES	ORBITAL GLOBE DEGENERATION	1	372	732	52
Control	GENERAL APPEARANCE	ABNORMAL POSTURE	2	680	683	3
1016/50	GENERAL APPEARANCE	ABNORMAL POSTURE	1	596	605	3
1016/200	GENERAL APPEARANCE	ABNORMAL POSTURE	1	708	724	4
1242/100	GENERAL APPEARANCE	ABNORMAL POSTURE	4	615	625	10
1254/25	GENERAL APPEARANCE	ABNORMAL POSTURE	1	547	568	4
1260/50	GENERAL APPEARANCE	ABNORMAL POSTURE	2	621	621	3
1260/100	GENERAL APPEARANCE	ABNORMAL POSTURE	1	701	715	3
Control	GENERAL APPEARANCE	FOOT PAD LESIONS	31	502	641	545
1016/50	GENERAL APPEARANCE	FOOT PAD LESIONS	7	563	694	141
1016/100	GENERAL APPEARANCE	FOOT PAD LESIONS	10	490	625	206
1016/200	GENERAL APPEARANCE	FOOT PAD LESIONS	11	571	649	115
1242/50	GENERAL APPEARANCE	FOOT PAD LESIONS	5	547	648	74
1242/100	GENERAL APPEARANCE	FOOT PAD LESIONS	3	666	730	30
1254/25	GENERAL APPEARANCE	FOOT PAD LESIONS	3	627	705	37
1254/50	GENERAL APPEARANCE	FOOT PAD LESIONS	2	463	690	67
1260/25	GENERAL APPEARANCE	FOOT PAD LESIONS	13	523	670	270
1260/50	GENERAL APPEARANCE	FOOT PAD LESIONS	8	588	666	89
1260/100	GENERAL APPEARANCE	FOOT PAD LESIONS	4	561	651	56

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
Control	GENERAL APPEARANCE	JAUNDICE	1	687	687	1
1016/200	GENERAL APPEARANCE	JAUNDICE	1	543	543	1
1260/100	GENERAL APPEARANCE	JAUNDICE	1	652	654	2
Control	GENERAL APPEARANCE	PALLOR	13	610	631	36
1016/50	GENERAL APPEARANCE	PALLOR	3	596	616	13
1016/100	GENERAL APPEARANCE	PALLOR	3	657	668	8
1016/200	GENERAL APPEARANCE	PALLOR	8	612	625	25
1242/50	GENERAL APPEARANCE	PALLOR	7	593	624	39
1242/100	GENERAL APPEARANCE	PALLOR	4	636	651	13
1254/25	GENERAL APPEARANCE	PALLOR	8	539	546	16
1254/50	GENERAL APPEARANCE	PALLOR	7	619	627	17
1254/100	GENERAL APPEARANCE	PALLOR	6	605	619	19
1260/25	GENERAL APPEARANCE	PALLOR	4	636	654	15
1260/50	GENERAL APPEARANCE	PALLOR	8	579	588	20
1260/100	GENERAL APPEARANCE	PALLOR	5	621	627	10
1016/200	GENERAL APPEARANCE	TAIL LESION(S)	1	568	568	1
1254/25	GENERAL APPEARANCE	TAIL LESION(S)	1	701	731	5
1260/25	GENERAL APPEARANCE	TAIL LESION(S)	1	533	535	2
Control	GENERAL APPEARANCE	THIN APPEARANCE	27	494	518	119
1016/50	GENERAL APPEARANCE	THIN APPEARANCE	6	545	564	25
1016/100	GENERAL APPEARANCE	THIN APPEARANCE	9	596	610	29
1016/200	GENERAL APPEARANCE	THIN APPEARANCE	5	547	555	12
1242/50	GENERAL APPEARANCE	THIN APPEARANCE	12	586	605	50
1242/100	GENERAL APPEARANCE	THIN APPEARANCE	11	558	570	35
1254/25	GENERAL APPEARANCE	THIN APPEARANCE	11	503	517	37
1254/50	GENERAL APPEARANCE	THIN APPEARANCE	13	585	594	37
1254/100	GENERAL APPEARANCE	THIN APPEARANCE	13	554	564	38
1260/25	GENERAL APPEARANCE	THIN APPEARANCE	10	509	541	39
1260/50	GENERAL APPEARANCE	THIN APPEARANCE	10	592	613	44

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/100	GENERAL APPEARANCE	THIN APPEARANCE	10	553	569	36
Control	GENERAL APPEARANCE	THIN COAT	3	563	590	14
1016/100	GENERAL APPEARANCE	THIN COAT	1	708	729	4
1016/200	GENERAL APPEARANCE	THIN COAT	1	554	555	2
1254/25	GENERAL APPEARANCE	THIN COAT	1	575	607	6
Control	GENERAL APPEARANCE	UNTHRIFTY	15	633	649	51
1016/50	GENERAL APPEARANCE	UNTHRIFTY	20	595	610	64
1016/100	GENERAL APPEARANCE	UNTHRIFTY	19	614	633	72
1016/200	GENERAL APPEARANCE	UNTHRIFTY	14	608	625	47
1242/50	GENERAL APPEARANCE	UNTHRIFTY	12	582	606	44
1242/100	GENERAL APPEARANCE	UNTHRIFTY	8	586	598	22
1254/25	GENERAL APPEARANCE	UNTHRIFTY	5	567	578	13
1254/50	GENERAL APPEARANCE	UNTHRIFTY	15	590	603	45
1254/100	GENERAL APPEARANCE	UNTHRIFTY	6	595	603	13
1260/25	GENERAL APPEARANCE	UNTHRIFTY	15	579	595	48
1260/50	GENERAL APPEARANCE	UNTHRIFTY	20	598	620	74
1260/100	GENERAL APPEARANCE	UNTHRIFTY	13	636	656	37
1016/50	LOCOMOTOR/BEHAVIOR	CIRCLING	1	589	591	2
1016/100	LOCOMOTOR/BEHAVIOR	CIRCLING	2	523	532	5
1260/25	LOCOMOTOR/BEHAVIOR	CIRCLING	3	499	508	7
Control	LOCOMOTOR/BEHAVIOR	HEAD TILT	4	566	586	15
1016/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	2	532	533	3
1016/100	LOCOMOTOR/BEHAVIOR	HEAD TILT	2	523	532	5
1016/200	LOCOMOTOR/BEHAVIOR	HEAD TILT	2	631	652	9
1242/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	3	582	586	6
1242/100	LOCOMOTOR/BEHAVIOR	HEAD TILT	2	659	664	4
1254/25	LOCOMOTOR/BEHAVIOR	HEAD TILT	1	624	731	16
1254/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	1	526	570	8

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/25	LOCOMOTOR/BEHAVIOR	HEAD TILT	4	500	506	8
1260/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	1	631	638	2
Control	LOCOMOTOR/BEHAVIOR	LETHARGIC	10	558	559	13
1016/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	4	586	614	22
1016/100	LOCOMOTOR/BEHAVIOR	LETHARGIC	4	612	617	7
1016/200	LOCOMOTOR/BEHAVIOR	LETHARGIC	5	617	625	11
1242/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	8	565	567	12
1242/100	LOCOMOTOR/BEHAVIOR	LETHARGIC	8	605	609	15
1254/25	LOCOMOTOR/BEHAVIOR	LETHARGIC	6	477	478	8
1254/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	9	566	566	10
1254/100	LOCOMOTOR/BEHAVIOR	LETHARGIC	2	545	545	2
1260/25	LOCOMOTOR/BEHAVIOR	LETHARGIC	6	541	550	14
1260/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	9	629	639	22
1260/100	LOCOMOTOR/BEHAVIOR	LETHARGIC	4	519	531	11
Control	LOCOMOTOR/BEHAVIOR	PARALYSIS	3	421	421	3
1016/50	LOCOMOTOR/BEHAVIOR	PARALYSIS	3	599	599	3
1016/100	LOCOMOTOR/BEHAVIOR	PARALYSIS	1	624	631	2
1016/200	LOCOMOTOR/BEHAVIOR	PARALYSIS	1	659	729	11
1242/50	LOCOMOTOR/BEHAVIOR	PARALYSIS	1	372	381	3
1242/100	LOCOMOTOR/BEHAVIOR	PARALYSIS	3	507	513	6
1254/50	LOCOMOTOR/BEHAVIOR	PARALYSIS	1	620	620	1
1260/25	LOCOMOTOR/BEHAVIOR	PARALYSIS	3	703	717	9
1260/50	LOCOMOTOR/BEHAVIOR	PARALYSIS	3	661	682	12
1260/100	LOCOMOTOR/BEHAVIOR	PARALYSIS	2	600	622	9
1016/50	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	694	694	1
1016/100	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	2	652	652	2
1016/200	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	2	607	609	3
1242/50	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	596	598	2
1260/50	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	652	652	1

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/100	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	659	659	1
Control	NOSE/MOUTH	CLEAR ORAL DISCHARGE	1	596	631	6
1242/100	NOSE/MOUTH	CLEAR ORAL DISCHARGE	2	642	648	5
1254/50	NOSE/MOUTH	CLEAR ORAL DISCHARGE	1	680	680	1
1260/50	NOSE/MOUTH	CLEAR ORAL DISCHARGE	1	524	524	1
Control	NOSE/MOUTH	CROOKED/LONG TEETH	25	137	325	430
1016/50	NOSE/MOUTH	CROOKED/LONG TEETH	9	46	158	152
1016/100	NOSE/MOUTH	CROOKED/LONG TEETH	5	54	150	73
1016/200	NOSE/MOUTH	CROOKED/LONG TEETH	7	61	134	80
1242/50	NOSE/MOUTH	CROOKED/LONG TEETH	10	86	271	253
1242/100	NOSE/MOUTH	CROOKED/LONG TEETH	14	127	278	261
1254/25	NOSE/MOUTH	CROOKED/LONG TEETH	6	43	119	71
1254/50	NOSE/MOUTH	CROOKED/LONG TEETH	7	85	245	154
1254/100	NOSE/MOUTH	CROOKED/LONG TEETH	6	64	210	131
1260/25	NOSE/MOUTH	CROOKED/LONG TEETH	13	129	361	428
1260/50	NOSE/MOUTH	CROOKED/LONG TEETH	5	142	309	124
1260/100	NOSE/MOUTH	CROOKED/LONG TEETH	9	150	360	264
1016/50	NOSE/MOUTH	MALOCCLUSION	1	43	127	13
1254/50	NOSE/MOUTH	MALOCCLUSION	2	57	61	3
1260/25	NOSE/MOUTH	MALOCCLUSION	1	162	274	17
Control	NOSE/MOUTH	ORAL LESION	4	222	414	10
1016/50	NOSE/MOUTH	ORAL LESION	2	183	183	2
1016/100	NOSE/MOUTH	ORAL LESION	1	316	481	4
1242/50	NOSE/MOUTH	ORAL LESION	1	610	620	3
1242/100	NOSE/MOUTH	ORAL LESION	1	64	64	1
1254/25	NOSE/MOUTH	ORAL LESION	1	659	662	2

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1254/50	NOSE/MOUTH	ORAL LESION	1	85	498	2
1254/100	NOSE/MOUTH	ORAL LESION	2	64	68	3
1260/25	NOSE/MOUTH	ORAL LESION	2	410	416	4
1260/50	NOSE/MOUTH	ORAL LESION	1	127	134	2
Control	NOSE/MOUTH	RED NASAL DISCHARGE	23	339	394	54
1016/50	NOSE/MOUTH	RED NASAL DISCHARGE	9	543	547	14
1016/100	NOSE/MOUTH	RED NASAL DISCHARGE	8	474	494	26
1016/200	NOSE/MOUTH	RED NASAL DISCHARGE	10	374	390	26
1242/50	NOSE/MOUTH	RED NASAL DISCHARGE	10	515	570	21
1242/100	NOSE/MOUTH	RED NASAL DISCHARGE	12	423	426	19
1254/25	NOSE/MOUTH	RED NASAL DISCHARGE	8	495	498	11
1254/50	NOSE/MOUTH	RED NASAL DISCHARGE	11	537	538	17
1254/100	NOSE/MOUTH	RED NASAL DISCHARGE	6	372	373	8
1260/25	NOSE/MOUTH	RED NASAL DISCHARGE	9	463	517	27
1260/50	NOSE/MOUTH	RED NASAL DISCHARGE	9	432	435	13
1260/100	NOSE/MOUTH	RED NASAL DISCHARGE	11	502	504	15
Control	REPRODUCTIVE[b]	PROLAPSED PENIS	1	533	733	29
1242/50	REPRODUCTIVE[b]	PROLAPSED PENIS	1	687	694	2
1254/25	REPRODUCTIVE[b]	PROLAPSED PENIS	3	661	668	6
1254/50	REPRODUCTIVE[b]	PROLAPSED PENIS	1	701	706	2
1260/25	REPRODUCTIVE[b]	PROLAPSED PENIS	1	714	714	1
1260/50	REPRODUCTIVE[b]	PROLAPSED PENIS	2	553	553	2
1260/100	REPRODUCTIVE[b]	PROLAPSED PENIS	1	692	692	1
1254/50	RESPIRATION	LABORED	2	246	264	3
1254/100	RESPIRATION	LABORED	2	375	379	3
1260/25	RESPIRATION	LABORED	2	281	285	3
1260/50	RESPIRATION	LABORED	2	521	531	5

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.
b. Listed in database as URINE/FECES.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
Control	SWELLING	ABDOMEN	17	407	476	116
1016/50	SWELLING	ABDOMEN	5	473	490	17
1016/100	SWELLING	ABDOMEN	2	376	379	3
1016/200	SWELLING	ABDOMEN	6	393	436	23
1242/50	SWELLING	ABDOMEN	7	539	603	31
1242/100	SWELLING	ABDOMEN	6	479	566	58
1254/25	SWELLING	ABDOMEN	5	416	421	9
1254/50	SWELLING	ABDOMEN	3	461	475	10
1254/100	SWELLING	ABDOMEN	8	377	516	107
1260/25	SWELLING	ABDOMEN	3	510	518	7
1260/50	SWELLING	ABDOMEN	4	519	555	24
1260/100	SWELLING	ABDOMEN	1	491	505	3
1254/100	SWELLING	HEAD	1	687	693	2
1260/25	SWELLING	HEAD	1	680	680	1
Control	SWELLING	LIMB	13	583	607	52
1016/50	SWELLING	LIMB	5	429	595	125
1016/100	SWELLING	LIMB	5	437	544	84
1016/200	SWELLING	LIMB	5	436	456	20
1242/50	SWELLING	LIMB	9	596	611	27
1242/100	SWELLING	LIMB	10	506	518	25
1254/25	SWELLING	LIMB	11	424	467	38
1254/50	SWELLING	LIMB	9	456	509	60
1254/100	SWELLING	LIMB	12	457	547	168
1260/25	SWELLING	LIMB	8	566	580	25
1260/50	SWELLING	LIMB	6	507	542	36
1260/100	SWELLING	LIMB	5	432	441	11
Control	SWELLING	MOUTH	1	211	218	2
1016/50	SWELLING	MOUTH	1	547	554	2
1016/100	SWELLING	MOUTH	2	292	327	12

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/200	SWELLING	MOUTH	3	633	652	7
1242/50	SWELLING	MOUTH	1	610	620	3
1242/100	SWELLING	MOUTH	2	376	382	4
1254/25	SWELLING	MOUTH	1	547	547	1
1254/100	SWELLING	MOUTH	1	274	548	41
1260/25	SWELLING	MOUTH	2	418	688	20
1016/50	SWELLING	NECK	1	211	211	1
Control	SWELLING	TAIL	3	379	393	9
1016/50	SWELLING	TAIL	2	481	484	3
1260/50	SWELLING	TAIL	1	435	449	3
Control	SWELLING	THORAX	9	545	608	91
1016/50	SWELLING	THORAX	1	589	729	21
1016/100	SWELLING	THORAX	2	561	641	23
1242/50	SWELLING	THORAX	1	666	701	6
1242/100	SWELLING	THORAX	2	520	545	9
1254/25	SWELLING	THORAX	1	666	731	10
1254/50	SWELLING	THORAX	2	624	714	28
1254/100	SWELLING	THORAX	3	596	652	28
1260/25	SWELLING	THORAX	4	636	678	27
1260/50	SWELLING	THORAX	2	565	720	11
1260/100	SWELLING	THORAX	4	629	673	29
Control	TISSUE MASS - DORSAL SURFACE	ABDOMEN (<1 CM)	3	414	470	27
1242/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (<1 CM)	1	638	730	14
1254/25	TISSUE MASS - DORSAL SURFACE	ABDOMEN (<1 CM)	1	344	561	26
1260/50	TISSUE MASS - DORSAL SURFACE	ABDOMEN (<1 CM)	1	330	372	7

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
Control	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	2	498	732	68
1016/50	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	2	561	614	18
1016/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	586	586	1
1016/200	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	2	645	712	21
1254/25	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	288	295	2
1254/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	295	316	4
1260/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	2	540	717	52
1254/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (>10 CM)	1	323	327	2
1260/25	TISSUE MASS - DORSAL SURFACE	HEAD (<1 CM)	1	274	732	66
1016/200	TISSUE MASS - DORSAL SURFACE	HEAD (1-10 CM)	1	561	577	4
1242/100	TISSUE MASS - DORSAL SURFACE	HEAD (1-10 CM)	1	666	730	10
1260/25	TISSUE MASS - DORSAL SURFACE	HEAD (1-10 CM)	1	697	697	1
1260/50	TISSUE MASS - DORSAL SURFACE	TAIL (1-10 CM)	1	568	653	14
Control	TISSUE MASS - DORSAL SURFACE	THORAX (<1 CM)	4	482	667	110
1242/50	TISSUE MASS - DORSAL SURFACE	THORAX (<1 CM)	1	730	730	1
1254/25	TISSUE MASS - DORSAL SURFACE	THORAX (<1 CM)	1	176	731	44

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1254/100	TISSUE MASS - DORSAL SURFACE	THORAX (<1 CM)	3	531	543	8
1016/200	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	2	435	533	30
1242/50	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	1	512	605	15
1242/100	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	1	463	477	3
1254/25	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	2	449	514	21
1254/50	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	2	488	583	29
1254/100	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	3	491	536	23
1260/25	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	3	548	714	55
1260/50	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	1	379	407	5
1260/100	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	2	552	570	7
1016/200	TISSUE MASS - DORSAL SURFACE	THORAX (>10 CM)	1	697	697	1
1254/100	TISSUE MASS - DORSAL SURFACE	THORAX (>10 CM)	1	624	633	3
1254/100	TISSUE MASS - EXTREMITIES	LEFT F LEG (<1 CM)	1	540	654	18
1254/100	TISSUE MASS - EXTREMITIES	LEFT F LEG (1-10 CM)	1	470	533	10
1016/100	TISSUE MASS - EXTREMITIES	RIGHT F LEG (1-10 CM)	1	526	557	6

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/100	TISSUE MASS - EXTREMITIES	RIGHT R LEG (1-10 CM)	1	529	529	1
Control	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	3	283	293	7
1254/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	1	197	197	1
1260/25	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	2	344	400	18
Control	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	1	659	733	11
1016/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	2	491	577	27
1016/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	1	519	663	21
1016/200	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	2	622	665	15
1242/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	1	253	519	37
1242/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	1	491	517	5
1254/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	1	659	694	6
1260/25	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	1	428	442	3
1260/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	2	523	593	22
1016/200	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	1	687	722	6
1242/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	1	302	570	10
1260/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	1	732	732	1
1016/100	TISSUE MASS - VENTRAL SURFACE	HEAD (<1 CM)	1	344	729	56

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1242/50	TISSUE MASS - VENTRAL SURFACE	HEAD (<1 CM)	1	379	631	37
1254/50	TISSUE MASS - VENTRAL SURFACE	HEAD (<1 CM)	1	526	561	6
1260/25	TISSUE MASS - VENTRAL SURFACE	HEAD (<1 CM)	1	687	694	2
1016/50	TISSUE MASS - VENTRAL SURFACE	HEAD (1-10 CM)	1	218	225	2
1254/50	TISSUE MASS - VENTRAL SURFACE	HEAD (1-10 CM)	1	568	591	5
1016/100	TISSUE MASS - VENTRAL SURFACE	TAIL (<1 CM)	1	204	260	9
1016/100	TISSUE MASS - VENTRAL SURFACE	TAIL (1-10 CM)	1	267	518	37
1260/50	TISSUE MASS - VENTRAL SURFACE	TAIL (1-10 CM)	1	456	542	14
Control	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	1	624	730	16
1254/25	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	1	498	594	15
Control	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	2	610	714	32
1016/50	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	1	526	554	5
1016/100	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	1	337	358	4
1242/50	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	1	708	727	4
1254/100	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	1	526	603	12
1260/50	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	1	484	732	36

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/100	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	2	439	609	51
Control	ULCERATION	ABDOMEN - VENTRAL	2	278	281	3
1016/50	ULCERATION	ABDOMEN - VENTRAL	1	393	414	4
1016/100	ULCERATION	ABDOMEN - VENTRAL	1	610	638	5
1016/200	ULCERATION	ABDOMEN - VENTRAL	1	687	724	7
1242/50	ULCERATION	ABDOMEN - VENTRAL	2	586	601	7
1260/25	ULCERATION	HEAD - DORSAL	1	697	697	1
1254/50	ULCERATION	HEAD - VENTRAL	1	526	591	11
1260/25	ULCERATION	HEAD - VENTRAL	1	687	694	2
1254/100	ULCERATION	LEFT F LEG	1	596	654	10
1016/100	ULCERATION	TAIL - VENTRAL	1	414	518	16
1260/50	ULCERATION	TAIL - VENTRAL	1	456	542	14
1242/50	ULCERATION	THORAX - DORSAL	1	547	605	10
1254/25	ULCERATION	THORAX - DORSAL	1	533	543	3
1254/100	ULCERATION	THORAX - DORSAL	1	596	620	5
1260/25	ULCERATION	THORAX - DORSAL	2	484	559	24
Control	ULCERATION	THORAX - VENTRAL	1	645	695	9
1254/100	ULCERATION	THORAX - VENTRAL	1	575	603	5
1260/100	ULCERATION	THORAX - VENTRAL	1	463	485	5
Control	URINE/FECES	DIARRHEA	1	288	288	1
1016/50	URINE/FECES	DIARRHEA	2	635	639	4
1016/200	URINE/FECES	DIARRHEA	1	724	724	1
1254/25	URINE/FECES	DIARRHEA	1	490	490	1
1254/50	URINE/FECES	DIARRHEA	2	558	558	2

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/25	URINE/FECES	DIARRHEA	2	561	565	3
1260/100	URINE/FECES	DIARRHEA	1	393	400	2
1254/25	URINE/FECES	DISCOLOR URINE-RED	1	610	610	1
Control	URINE/FECES	RED COLORED UROGENITAL REGION	4	137	137	4
1016/50	URINE/FECES	RED COLORED UROGENITAL REGION	1	662	662	1
1254/25	URINE/FECES	RED COLORED UROGENITAL REGION	3	400	400	3
1254/50	URINE/FECES	RED COLORED UROGENITAL REGION	1	568	596	5
1260/50	URINE/FECES	RED COLORED UROGENITAL REGION	2	302	330	10
1260/100	URINE/FECES	RED COLORED UROGENITAL REGION	1	442	442	1
Control	URINE/FECES	SOILED ANAL REGION	7	584	585	10
1016/50	URINE/FECES	SOILED ANAL REGION	1	604	604	1
1016/100	URINE/FECES	SOILED ANAL REGION	4	660	666	8
1016/200	URINE/FECES	SOILED ANAL REGION	3	629	631	4
1242/50	URINE/FECES	SOILED ANAL REGION	1	561	562	2
1242/100	URINE/FECES	SOILED ANAL REGION	2	688	688	2
1254/25	URINE/FECES	SOILED ANAL REGION	2	442	442	2
1254/50	URINE/FECES	SOILED ANAL REGION	2	702	702	2
1260/25	URINE/FECES	SOILED ANAL REGION	3	563	563	3
1260/50	URINE/FECES	SOILED ANAL REGION	1	701	701	1
1260/100	URINE/FECES	SOILED ANAL REGION	6	606	609	9
Control	URINE/FECES	UROGENITAL REGION WET	14	561	569	30
1016/50	URINE/FECES	UROGENITAL REGION WET	5	576	579	10

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 14. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Male Rats

Test Substance/ Conc. (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/100	URINE/FECES	UROGENITAL REGION WET	2	348	371	9
1016/200	URINE/FECES	UROGENITAL REGION WET	4	425	427	7
1242/50	URINE/FECES	UROGENITAL REGION WET	6	581	588	14
1242/100	URINE/FECES	UROGENITAL REGION WET	7	611	618	17
1254/25	URINE/FECES	UROGENITAL REGION WET	4	561	570	10
1254/50	URINE/FECES	UROGENITAL REGION WET	7	482	486	14
1254/100	URINE/FECES	UROGENITAL REGION WET	2	687	688	3
1260/25	URINE/FECES	UROGENITAL REGION WET	7	539	561	14
1260/50	URINE/FECES	UROGENITAL REGION WET	4	507	523	14
1260/100	URINE/FECES	UROGENITAL REGION WET	2	477	477	2

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
Control	ABRASION	DORSAL - THORAX	2	558	673	11
1016/50	ABRASION	DORSAL - THORAX	1	393	687	33
1016/100	ABRASION	DORSAL - THORAX	1	498	612	18
1016/200	ABRASION	DORSAL - THORAX	2	554	710	48
1242/50	ABRASION	DORSAL - THORAX	2	442	499	16
1254/50	ABRASION	DORSAL - THORAX	1	519	532	3
Control	ABRASION	FRONT LIMB	1	421	428	2
1016/100	ABRASION	FRONT LIMB	1	519	540	4
1016/200	ABRASION	HEAD	1	540	695	24
1242/50	ABRASION	HEAD	1	512	512	1
1242/100	ABRASION	HEAD	1	267	267	1
1254/25	ABRASION	HEAD	2	397	429	11
1254/100	ABRASION	HEAD	7	335	396	68
Control	ABRASION	NECK	2	449	488	13
1254/100	ABRASION	NECK	1	708	730	4
Control	ABRASION	NOSE	1	372	729	52
1016/200	ABRASION	NOSE	2	648	655	4
1242/50	ABRASION	NOSE	1	484	729	36
1254/25	ABRASION	NOSE	1	624	708	13
1254/50	ABRASION	NOSE	1	666	666	1
1260/25	ABRASION	NOSE	1	561	568	2
1260/100	ABRASION	NOSE	1	715	731	3
Control	ABRASION	REAR LIMB	1	617	617	1
1254/25	ABRASION	REAR LIMB	1	694	730	6
Control	ABRASION	SHOULDER	2	509	639	40
1016/50	ABRASION	SHOULDER	1	15	15	1
1016/100	ABRASION	SHOULDER	1	498	612	18
1242/50	ABRASION	SHOULDER	1	421	435	3
1254/50	ABRASION	SHOULDER	1	43	78	6

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/50	ABRASION	VENTRAL - ABDOMEN	1	666	689	5
1016/100	ABRASION	VENTRAL - ABDOMEN	1	547	612	11
1016/200	ABRASION	VENTRAL - ABDOMEN	1	694	724	6
1254/25	ABRASION	VENTRAL - ABDOMEN	1	645	652	2
1254/50	ABRASION	VENTRAL - ABDOMEN	2	600	603	3
1260/50	ABRASION	VENTRAL - ABDOMEN	1	687	701	3
Control	ALOPECIA	DORSAL	4	594	616	14
1016/50	ALOPECIA	DORSAL	2	575	657	26
1016/100	ALOPECIA	DORSAL	2	530	657	39
1016/200	ALOPECIA	DORSAL	3	535	704	77
1242/50	ALOPECIA	DORSAL	1	638	638	1
1254/25	ALOPECIA	DORSAL	1	610	610	1
1260/25	ALOPECIA	DORSAL	1	358	400	7
1260/50	ALOPECIA	DORSAL	1	351	400	8
Control	ALOPECIA	FRONT LEG(S)	1	351	400	8
1242/50	ALOPECIA	FRONT LEG(S)	1	393	407	3
1260/25	ALOPECIA	FRONT LEG(S)	1	358	407	8
1254/25	ALOPECIA	MUZZLE	1	610	610	1
1242/50	ALOPECIA	REAR LEG(S)	1	393	407	3
Control	ALOPECIA	VENTRAL	1	519	530	3
1016/50	ALOPECIA	VENTRAL	2	582	657	24
1016/100	ALOPECIA	VENTRAL	3	472	621	50
1016/200	ALOPECIA	VENTRAL	3	535	704	77
1242/50	ALOPECIA	VENTRAL	2	516	680	49
1254/25	ALOPECIA	VENTRAL	1	470	483	3
1260/25	ALOPECIA	VENTRAL	4	344	440	67
1260/50	ALOPECIA	VENTRAL	1	351	610	26
1260/100	ALOPECIA	VENTRAL	3	311	507	67

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
Control	EYES	CORNEAL OPACITY	3	423	507	40
1016/50	EYES	CORNEAL OPACITY	1	274	535	39
1016/100	EYES	CORNEAL OPACITY	1	365	645	41
1242/50	EYES	CORNEAL OPACITY	4	460	697	140
1242/100	EYES	CORNEAL OPACITY	2	502	701	59
1254/25	EYES	CORNEAL OPACITY	1	372	379	2
1254/50	EYES	CORNEAL OPACITY	2	565	604	14
1254/100	EYES	CORNEAL OPACITY	3	547	669	55
1260/25	EYES	CORNEAL OPACITY	1	519	629	17
1260/100	EYES	CORNEAL OPACITY	1	442	463	4
Control	EYES	DISCHARGE-RED	46	439	538	458
1016/50	EYES	DISCHARGE-RED	25	475	611	389
1016/100	EYES	DISCHARGE-RED	25	391	528	420
1016/200	EYES	DISCHARGE-RED	17	417	533	160
1242/50	EYES	DISCHARGE-RED	29	462	573	403
1242/100	EYES	DISCHARGE-RED	22	498	588	279
1254/25	EYES	DISCHARGE-RED	23	381	532	343
1254/50	EYES	DISCHARGE-RED	23	473	574	245
1254/100	EYES	DISCHARGE-RED	21	421	602	437
1260/25	EYES	DISCHARGE-RED	23	447	602	436
1260/50	EYES	DISCHARGE-RED	28	376	510	536
1260/100	EYES	DISCHARGE-RED	19	409	618	453
1016/50	EYES	ORBITAL GLOBE DEGENERATION	1	372	627	38
1016/100	EYES	ORBITAL GLOBE DEGENERATION	1	456	728	40
1254/25	EYES	ORBITAL GLOBE DEGENERATION	1	386	730	50
1260/50	EYES	ORBITAL GLOBE DEGENERATION	1	190	586	58
Control	GENERAL APPEARANCE	ABNORMAL POSTURE	5	646	653	10
1016/50	GENERAL APPEARANCE	ABNORMAL POSTURE	1	533	535	2
1016/100	GENERAL APPEARANCE	ABNORMAL POSTURE	1	702	702	1
1016/200	GENERAL APPEARANCE	ABNORMAL POSTURE	1	694	716	5

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1242/50	GENERAL APPEARANCE	ABNORMAL POSTURE	1	652	652	1
1242/100	GENERAL APPEARANCE	ABNORMAL POSTURE	1	540	548	3
1254/100	GENERAL APPEARANCE	ABNORMAL POSTURE	1	589	590	2
1260/25	GENERAL APPEARANCE	ABNORMAL POSTURE	3	640	652	8
1260/50	GENERAL APPEARANCE	ABNORMAL POSTURE	3	652	655	4
Control	GENERAL APPEARANCE	FOOT PAD LESIONS	9	608	701	127
1016/50	GENERAL APPEARANCE	FOOT PAD LESIONS	4	552	648	60
1016/100	GENERAL APPEARANCE	FOOT PAD LESIONS	5	589	705	88
1016/200	GENERAL APPEARANCE	FOOT PAD LESIONS	1	631	663	6
1260/25	GENERAL APPEARANCE	FOOT PAD LESIONS	3	654	681	15
1260/50	GENERAL APPEARANCE	FOOT PAD LESIONS	3	666	726	28
1254/25	GENERAL APPEARANCE	JAUNDICE	1	463	467	2
1260/100	GENERAL APPEARANCE	JAUNDICE	1	569	569	1
Control	GENERAL APPEARANCE	PALLOR	10	572	583	21
1016/50	GENERAL APPEARANCE	PALLOR	3	622	638	11
1016/100	GENERAL APPEARANCE	PALLOR	4	603	633	23
1016/200	GENERAL APPEARANCE	PALLOR	7	563	567	12
1242/50	GENERAL APPEARANCE	PALLOR	3	580	583	5
1242/100	GENERAL APPEARANCE	PALLOR	6	585	586	8
1254/25	GENERAL APPEARANCE	PALLOR	8	564	568	13
1254/50	GENERAL APPEARANCE	PALLOR	6	606	615	11
1254/100	GENERAL APPEARANCE	PALLOR	5	658	667	12
1260/25	GENERAL APPEARANCE	PALLOR	4	598	602	7
1260/50	GENERAL APPEARANCE	PALLOR	3	435	438	6
1260/100	GENERAL APPEARANCE	PALLOR	9	590	594	14
1242/50	GENERAL APPEARANCE	TAIL LESION(S)	1	659	729	11
1242/100	GENERAL APPEARANCE	TAIL LESION(S)	1	666	672	2
1254/50	GENERAL APPEARANCE	TAIL LESION(S)	1	554	554	1
Control	GENERAL APPEARANCE	THIN APPEARANCE	28	509	522	87
1016/50	GENERAL APPEARANCE	THIN APPEARANCE	8	609	617	21
1016/100	GENERAL APPEARANCE	THIN APPEARANCE	12	632	655	56

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/200	GENERAL APPEARANCE	THIN APPEARANCE	10	591	608	37
1242/50	GENERAL APPEARANCE	THIN APPEARANCE	13	525	553	52
1242/100	GENERAL APPEARANCE	THIN APPEARANCE	16	552	568	57
1254/25	GENERAL APPEARANCE	THIN APPEARANCE	9	574	590	31
1254/50	GENERAL APPEARANCE	THIN APPEARANCE	14	621	632	42
1254/100	GENERAL APPEARANCE	THIN APPEARANCE	12	615	633	48
1260/25	GENERAL APPEARANCE	THIN APPEARANCE	13	588	598	35
1260/50	GENERAL APPEARANCE	THIN APPEARANCE	4	538	548	9
1260/100	GENERAL APPEARANCE	THIN APPEARANCE	7	471	474	10
Control	GENERAL APPEARANCE	THIN COAT	4	289	356	27
1016/50	GENERAL APPEARANCE	THIN COAT	1	694	728	6
1242/50	GENERAL APPEARANCE	THIN COAT	2	302	397	29
1254/25	GENERAL APPEARANCE	THIN COAT	2	628	726	30
1254/50	GENERAL APPEARANCE	THIN COAT	3	654	720	31
1254/100	GENERAL APPEARANCE	THIN COAT	3	638	669	17
Control	GENERAL APPEARANCE	UNTHRIFTY	23	584	617	105
1016/50	GENERAL APPEARANCE	UNTHRIFTY	15	617	639	58
1016/100	GENERAL APPEARANCE	UNTHRIFTY	12	612	652	67
1016/200	GENERAL APPEARANCE	UNTHRIFTY	15	605	627	58
1242/50	GENERAL APPEARANCE	UNTHRIFTY	14	622	647	54
1242/100	GENERAL APPEARANCE	UNTHRIFTY	9	605	627	39
1254/25	GENERAL APPEARANCE	UNTHRIFTY	10	642	676	59
1254/50	GENERAL APPEARANCE	UNTHRIFTY	13	626	639	30
1254/100	GENERAL APPEARANCE	UNTHRIFTY	8	616	640	35
1260/25	GENERAL APPEARANCE	UNTHRIFTY	19	597	620	79
1260/50	GENERAL APPEARANCE	UNTHRIFTY	18	600	624	70
1260/100	GENERAL APPEARANCE	UNTHRIFTY	13	600	612	36
Control	LOCOMOTOR/BEHAVIOR	CIRCLING	14	521	539	52
1016/50	LOCOMOTOR/BEHAVIOR	CIRCLING	2	449	453	4
1016/100	LOCOMOTOR/BEHAVIOR	CIRCLING	1	456	489	6
1016/200	LOCOMOTOR/BEHAVIOR	CIRCLING	2	544	600	19
1242/50	LOCOMOTOR/BEHAVIOR	CIRCLING	2	540	549	5
1242/100	LOCOMOTOR/BEHAVIOR	CIRCLING	2	519	526	4

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1254/25	LOCOMOTOR/BEHAVIOR	CIRCLING	1	575	582	2
1260/25	LOCOMOTOR/BEHAVIOR	CIRCLING	5	560	574	15
1260/50	LOCOMOTOR/BEHAVIOR	CIRCLING	2	521	521	2
1260/100	LOCOMOTOR/BEHAVIOR	CIRCLING	1	540	569	6
Control	LOCOMOTOR/BEHAVIOR	HEAD TILT	20	560	599	136
1016/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	6	604	610	13
1016/100	LOCOMOTOR/BEHAVIOR	HEAD TILT	6	620	651	34
1016/200	LOCOMOTOR/BEHAVIOR	HEAD TILT	3	589	629	21
1242/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	11	608	659	83
1242/100	LOCOMOTOR/BEHAVIOR	HEAD TILT	7	598	642	50
1254/25	LOCOMOTOR/BEHAVIOR	HEAD TILT	7	613	639	34
1254/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	6	596	628	33
1254/100	LOCOMOTOR/BEHAVIOR	HEAD TILT	2	628	712	20
1260/25	LOCOMOTOR/BEHAVIOR	HEAD TILT	9	601	615	27
1260/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	5	554	584	27
1260/100	LOCOMOTOR/BEHAVIOR	HEAD TILT	4	624	651	20
Control	LOCOMOTOR/BEHAVIOR	LETHARGIC	14	558	560	20
1016/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	7	604	607	12
1016/100	LOCOMOTOR/BEHAVIOR	LETHARGIC	6	552	565	17
1016/200	LOCOMOTOR/BEHAVIOR	LETHARGIC	2	673	687	6
1242/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	6	593	594	7
1242/100	LOCOMOTOR/BEHAVIOR	LETHARGIC	9	549	550	12
1254/25	LOCOMOTOR/BEHAVIOR	LETHARGIC	6	557	558	7
1254/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	4	608	608	4
1254/100	LOCOMOTOR/BEHAVIOR	LETHARGIC	2	657	660	3
1260/25	LOCOMOTOR/BEHAVIOR	LETHARGIC	6	555	571	21
1260/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	6	609	616	13
1260/100	LOCOMOTOR/BEHAVIOR	LETHARGIC	3	540	542	4
1016/200	LOCOMOTOR/BEHAVIOR	PARALYSIS	2	691	694	3
1254/100	LOCOMOTOR/BEHAVIOR	PARALYSIS	4	416	418	6
Control	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	2	614	621	4
1016/50	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	416	416	1

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/100	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	554	554	1
1242/100	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	702	702	1
1254/25	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	667	667	1
Control	NOSE/MOUTH	CROOKED/LONG TEETH	12	225	342	128
1016/50	NOSE/MOUTH	CROOKED/LONG TEETH	4	130	176	31
1016/100	NOSE/MOUTH	CROOKED/LONG TEETH	5	86	143	45
1016/200	NOSE/MOUTH	CROOKED/LONG TEETH	3	57	153	45
1242/50	NOSE/MOUTH	CROOKED/LONG TEETH	9	104	223	162
1242/100	NOSE/MOUTH	CROOKED/LONG TEETH	5	107	191	65
1254/25	NOSE/MOUTH	CROOKED/LONG TEETH	6	143	185	42
1254/50	NOSE/MOUTH	CROOKED/LONG TEETH	4	136	227	56
1254/100	NOSE/MOUTH	CROOKED/LONG TEETH	4	96	166	44
1260/25	NOSE/MOUTH	CROOKED/LONG TEETH	2	176	327	45
1260/50	NOSE/MOUTH	CROOKED/LONG TEETH	3	125	363	105
1260/100	NOSE/MOUTH	CROOKED/LONG TEETH	7	162	307	152
Control	NOSE/MOUTH	MALOCCLUSION	1	176	344	25
1016/200	NOSE/MOUTH	MALOCCLUSION	1	400	400	1
1254/25	NOSE/MOUTH	MALOCCLUSION	4	206	258	35
1254/50	NOSE/MOUTH	MALOCCLUSION	1	603	611	3
1254/100	NOSE/MOUTH	MALOCCLUSION	1	372	386	3
1260/50	NOSE/MOUTH	MALOCCLUSION	1	51	51	1
Control	NOSE/MOUTH	NASAL DISCHARGE	3	500	502	4
1016/50	NOSE/MOUTH	NASAL DISCHARGE	2	540	540	2
1242/50	NOSE/MOUTH	NASAL DISCHARGE	3	514	519	5
1260/25	NOSE/MOUTH	NASAL DISCHARGE	1	538	538	1
1260/50	NOSE/MOUTH	NASAL DISCHARGE	2	584	584	2
1260/100	NOSE/MOUTH	NASAL DISCHARGE	1	672	672	1
Control	NOSE/MOUTH	ORAL LESION	4	284	292	9
1016/50	NOSE/MOUTH	ORAL LESION	3	391	395	5
1016/100	NOSE/MOUTH	ORAL LESION	4	344	344	4
1016/200	NOSE/MOUTH	ORAL LESION	1	386	386	1
1242/50	NOSE/MOUTH	ORAL LESION	1	225	239	3

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1242/100	NOSE/MOUTH	ORAL LESION	1	78	120	7
1260/50	NOSE/MOUTH	ORAL LESION	1	499	449	1
1260/100	NOSE/MOUTH	ORAL LESION	1	113	120	2
Control	NOSE/MOUTH	RED NASAL DISCHARGE	28	446	457	62
1016/50	NOSE/MOUTH	RED NASAL DISCHARGE	18	587	603	59
1016/100	NOSE/MOUTH	RED NASAL DISCHARGE	11	516	537	43
1016/200	NOSE/MOUTH	RED NASAL DISCHARGE	7	592	622	30
1242/50	NOSE/MOUTH	RED NASAL DISCHARGE	10	341	349	17
1242/100	NOSE/MOUTH	RED NASAL DISCHARGE	7	603	607	11
1254/25	NOSE/MOUTH	RED NASAL DISCHARGE	5	473	477	9
1254/50	NOSE/MOUTH	RED NASAL DISCHARGE	4	602	607	7
1260/25	NOSE/MOUTH	RED NASAL DISCHARGE	16	564	586	40
1260/50	NOSE/MOUTH	RED NASAL DISCHARGE	12	539	547	25
1260/100	NOSE/MOUTH	RED NASAL DISCHARGE	6	558	560	8
1016/50	REPRODUCTIVE[b]	PROLAPSED VAGINA	1	589	612	5
1016/200	REPRODUCTIVE[b]	PROLAPSED VAGINA	3	633	636	5
1242/100	REPRODUCTIVE[b]	PROLAPSED VAGINA	1	624	659	6
1254/25	REPRODUCTIVE[b]	PROLAPSED VAGINA	1	701	730	5
1254/50	REPRODUCTIVE[b]	PROLAPSED VAGINA	1	526	526	1
1260/25	REPRODUCTIVE[b]	PROLAPSED VAGINA	1	624	641	4
1260/100	REPRODUCTIVE[b]	PROLAPSED VAGINA	1	512	603	14
Control	RESPIRATION	LABORED	9	566	658	12
1016/50	RESPIRATION	LABORED	1	251	251	1
1016/200	RESPIRATION	LABORED	2	649	649	2
1242/50	RESPIRATION	LABORED	4	668	671	6
1242/100	RESPIRATION	LABORED	2	614	625	5
1254/25	RESPIRATION	LABORED	3	366	368	4
1254/50	RESPIRATION	LABORED	3	612	612	3
1254/100	RESPIRATION	LABORED	5	596	603	9
1260/25	RESPIRATION	LABORED	1	211	232	4
1260/50	RESPIRATION	LABORED	6	434	438	10
1260/100	RESPIRATION	LABORED	2	715	715	2

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.
b. Listed in database as URINE/FECES.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1242/50	RESPIRATION	RALES	1	652	652	1
1254/100	RESPIRATION	RALES	1	575	575	1
1260/100	RESPIRATION	RALES	1	631	631	1
Control	SWELLING	ABDOMEN	54	439	507	404
1016/50	SWELLING	ABDOMEN	15	482	572	161
1016/100	SWELLING	ABDOMEN	22	552	587	121
1016/200	SWELLING	ABDOMEN	19	543	604	158
1242/50	SWELLING	ABDOMEN	12	458	583	98
1242/100	SWELLING	ABDOMEN	20	519	596	287
1254/25	SWELLING	ABDOMEN	27	452	536	168
1254/50	SWELLING	ABDOMEN	29	487	558	183
1254/100	SWELLING	ABDOMEN	14	488	567	107
1260/25	SWELLING	ABDOMEN	13	525	569	90
1260/50	SWELLING	ABDOMEN	6	527	551	26
1260/100	SWELLING	ABDOMEN	14	549	609	127
1016/50	SWELLING	HEAD	2	652	690	13
1016/200	SWELLING	HEAD	1	652	728	12
1254/25	SWELLING	HEAD	2	603	642	13
1254/50	SWELLING	HEAD	1	561	611	9
1254/100	SWELLING	HEAD	3	561	593	18
1260/100	SWELLING	HEAD	1	631	633	2
Control	SWELLING	LIMB	3	565	578	8
1016/50	SWELLING	LIMB	4	601	627	19
1016/100	SWELLING	LIMB	4	594	687	22
1016/200	SWELLING	LIMB	2	649	722	24
1242/100	SWELLING	LIMB	2	460	470	5
1254/25	SWELLING	LIMB	3	405	591	83
1254/50	SWELLING	LIMB	3	526	710	82
1254/100	SWELLING	LIMB	4	488	526	24
1260/25	SWELLING	LIMB	4	507	595	54
1260/50	SWELLING	LIMB	3	594	631	19
1260/100	SWELLING	LIMB	2	432	460	10

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/50	SWELLING	MOUTH	3	645	657	8
1016/200	SWELLING	MOUTH	3	442	488	24
1242/50	SWELLING	MOUTH	3	283	293	7
1242/100	SWELLING	MOUTH	2	473	477	3
1254/25	SWELLING	MOUTH	1	267	267	1
1254/50	SWELLING	MOUTH	2	498	518	8
1254/100	SWELLING	MOUTH	3	661	670	7
1260/25	SWELLING	MOUTH	1	547	547	1
1260/50	SWELLING	MOUTH	2	474	485	7
1260/100	SWELLING	MOUTH	2	708	727	7
Control	SWELLING	NECK	2	414	428	6
1016/100	SWELLING	NECK	1	393	414	4
1016/200	SWELLING	NECK	4	510	558	31
1242/50	SWELLING	NECK	2	540	583	15
1242/100	SWELLING	NECK	3	517	598	38
1254/25	SWELLING	NECK	3	568	625	27
1254/50	SWELLING	NECK	3	451	544	43
1254/100	SWELLING	NECK	1	652	680	5
1260/100	SWELLING	NECK	2	551	565	6
1254/50	SWELLING	TAIL	1	722	730	2
1260/25	SWELLING	TAIL	1	477	731	37
Control	SWELLING	THORAX	30	509	569	228
1016/50	SWELLING	THORAX	10	604	647	73
1016/100	SWELLING	THORAX	11	474	573	158
1016/200	SWELLING	THORAX	11	579	630	93
1242/50	SWELLING	THORAX	16	517	548	160
1242/100	SWELLING	THORAX	12	536	625	138
1254/25	SWELLING	THORAX	21	579	640	184
1254/50	SWELLING	THORAX	18	492	571	202
1254/100	SWELLING	THORAX	10	513	585	115
1260/25	SWELLING	THORAX	15	568	629	145
1260/50	SWELLING	THORAX	13	545	595	92

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/100	SWELLING	THORAX	11	550	585	67
1254/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (<1 CM)	1	512	512	1
Control	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	561	637	12
1016/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	337	428	14
1242/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	358	366	3
1254/50	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	617	631	3
1260/50	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	624	722	15
1260/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	731	731	1
Control	TISSUE MASS - DORSAL SURFACE	HEAD (<1 CM)	1	652	700	8
1242/100	TISSUE MASS - DORSAL SURFACE	HEAD (<1 CM)	1	288	729	64
1254/25	TISSUE MASS - DORSAL SURFACE	HEAD (<1 CM)	1	673	715	7
1254/100	TISSUE MASS - DORSAL SURFACE	HEAD (<1 CM)	1	477	547	11
1260/25	TISSUE MASS - DORSAL SURFACE	HEAD (<1 CM)	1	561	597	7
1016/50	TISSUE MASS - DORSAL SURFACE	HEAD (1-10 CM)	2	624	652	10
1016/100	TISSUE MASS - DORSAL SURFACE	HEAD (1-10 CM)	1	547	569	5
1016/200	TISSUE MASS - DORSAL SURFACE	HEAD (1-10 CM)	1	561	567	2
1260/100	TISSUE MASS - DORSAL SURFACE	HEAD (1-10 CM)	1	533	569	7
1254/25	TISSUE MASS - DORSAL SURFACE	THORAX (<1 CM)	1	288	302	3

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1254/50	TISSUE MASS - DORSAL SURFACE	THORAX (<1 CM)	3	325	328	4
Control	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	3	659	730	33
1016/200	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	1	575	622	8
1242/50	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	1	547	589	3
1242/100	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	2	313	327	6
1254/25	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	1	645	645	1
1254/50	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	2	341	533	57
Control	TISSUE MASS - EXTREMITIES	RIGHT F LEG (<1 CM)	1	218	288	11
1260/100	TISSUE MASS - EXTREMITIES	RIGHT F LEG (<1 CM)	1	456	463	2
Control	TISSUE MASS - EXTREMITIES	RIGHT F LEG (1-10 CM)	2	386	445	20
1260/100	TISSUE MASS - EXTREMITIES	RIGHT F LEG (1-10 CM)	1	470	536	11
1016/50	TISSUE MASS - EXTREMITIES	RIGHT R LEG (1-10 CM)	1	624	626	2
1242/100	TISSUE MASS - EXTREMITIES	RIGHT R LEG (1-10 CM)	1	666	687	4
1254/50	TISSUE MASS - EXTREMITIES	RIGHT R LEG (1-10 CM)	1	610	711	16
1254/100	TISSUE MASS - EXTREMITIES	RIGHT R LEG (1-10 CM)	1	624	730	16
1260/25	TISSUE MASS - EXTREMITIES	RIGHT R LEG (1-10 CM)	1	587	587	1
Control	TISSUE MASS - EXTREMITIES	TAIL	1	218	407	28

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
Control	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	3	421	445	14
1016/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	14	317	343	68
1016/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	7	310	319	16
1016/200	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	8	301	329	38
1242/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	1	316	407	14
1254/25	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	1	687	708	4
1254/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	2	246	260	6
1254/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	4	360	370	10
1260/25	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	3	314	351	19
1260/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	4	302	335	23
1260/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	4	444	478	23
Control	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	30	489	578	407
1016/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	15	396	517	182
1016/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	21	465	548	260
1016/200	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	14	497	588	201
1242/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	5	519	705	138
1242/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	8	600	687	109
1254/25	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	10	583	636	86
1254/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	10	540	618	121
1254/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	5	554	638	66

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/25	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	13	528	637	216
1260/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	10	442	503	87
1260/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	7	535	581	54
Control	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	3	554	566	10
1016/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	1	728	728	1
1016/200	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	1	443	443	1
1242/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	1	708	725	4
1254/25	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	1	295	295	1
1260/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	1	204	212	3
Control	TISSUE MASS - VENTRAL SURFACE	HEAD (<1 CM)	1	190	281	14
1016/50	TISSUE MASS - VENTRAL SURFACE	HEAD (<1 CM)	1	645	666	4
1242/50	TISSUE MASS - VENTRAL SURFACE	HEAD (<1 CM)	2	327	649	49
1260/25	TISSUE MASS - VENTRAL SURFACE	HEAD (<1 CM)	1	694	731	6
1260/50	TISSUE MASS - VENTRAL SURFACE	HEAD (<1 CM)	1	721	721	1
1016/50	TISSUE MASS - VENTRAL SURFACE	HEAD (1-10 CM)	2	551	580	11
1242/100	TISSUE MASS - VENTRAL SURFACE	TAIL (<1 CM)	1	115	120	2
1254/50	TISSUE MASS - VENTRAL SURFACE	TAIL (<1 CM)	1	670	670	1

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1242/100	TISSUE MASS - VENTRAL SURFACE	TAIL (1-10 CM)	1	127	611	71
Control	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	3	241	272	16
1016/50	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	10	276	322	75
1016/100	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	10	334	371	64
1016/200	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	8	274	327	70
1242/50	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	2	264	320	18
1242/100	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	1	337	379	7
1254/25	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	1	260	281	4
1254/50	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	1	337	456	18
1254/100	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	2	253	264	5
1260/25	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	3	358	402	22
1260/50	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	5	358	373	16
1260/100	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	3	363	402	20
Control	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	23	513	648	464
1016/50	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	14	512	618	231
1016/100	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	18	456	591	338
1016/200	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	20	509	615	329
1242/50	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	8	548	614	86
1242/100	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	9	552	646	133

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1254/25	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	15	632	705	169
1254/50	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	16	548	641	230
1254/100	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	6	471	611	127
1260/25	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	15	517	628	257
1260/50	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	11	525	628	173
1260/100	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	12	581	679	178
1016/200	TISSUE MASS - VENTRAL SURFACE	THORAX (>10 CM)	1	716	716	1
1254/25	TISSUE MASS - VENTRAL SURFACE	THORAX (>10 CM)	1	721	721	1
Control	ULCERATION	ABDOMEN - DORSAL	1	624	637	3
1016/100	ULCERATION	ABDOMEN - DORSAL	1	421	428	2
1254/50	ULCERATION	ABDOMEN - DORSAL	1	617	631	3
Control	ULCERATION	ABDOMEN - VENTRAL	8	530	546	29
1016/50	ULCERATION	ABDOMEN - VENTRAL	4	642	651	10
1016/100	ULCERATION	ABDOMEN - VENTRAL	2	512	584	27
1016/200	ULCERATION	ABDOMEN - VENTRAL	3	573	654	40
1242/100	ULCERATION	ABDOMEN - VENTRAL	1	554	569	4
1254/25	ULCERATION	ABDOMEN - VENTRAL	1	687	708	4
1254/50	ULCERATION	ABDOMEN - VENTRAL	1	533	533	1
1254/100	ULCERATION	ABDOMEN - VENTRAL	3	517	554	20
1260/25	ULCERATION	ABDOMEN - VENTRAL	3	675	686	8
1260/50	ULCERATION	ABDOMEN - VENTRAL	2	407	411	4
1016/200	ULCERATION	HEAD - DORSAL	1	561	567	2
1242/50	ULCERATION	HEAD - DORSAL	1	190	239	8
1254/100	ULCERATION	HEAD - DORSAL	2	565	575	5
1016/50	ULCERATION	HEAD - VENTRAL	2	568	580	6

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1242/50	ULCERATION	HEAD - VENTRAL	1	540	569	6
Control	ULCERATION	RIGHT F LEG	2	430	445	7
1242/100	ULCERATION	TAIL - VENTRAL	1	554	611	10
Control	ULCERATION	THORAX - DORSAL	1	554	554	1
1242/50	ULCERATION	THORAX - DORSAL	1	582	589	2
1254/25	ULCERATION	THORAX - DORSAL	1	645	645	1
Control	ULCERATION	THORAX - VENTRAL	9	511	576	86
1016/50	ULCERATION	THORAX - VENTRAL	1	666	689	5
1016/100	ULCERATION	THORAX - VENTRAL	4	589	601	12
1016/200	ULCERATION	THORAX - VENTRAL	4	543	586	30
1242/100	ULCERATION	THORAX - VENTRAL	2	449	471	9
1254/25	ULCERATION	THORAX - VENTRAL	3	547	617	33
1254/50	ULCERATION	THORAX - VENTRAL	5	635	643	11
1254/100	ULCERATION	THORAX - VENTRAL	1	652	663	3
1260/25	ULCERATION	THORAX - VENTRAL	1	645	708	10
1260/50	ULCERATION	THORAX - VENTRAL	1	590	590	1
1260/100	ULCERATION	THORAX - VENTRAL	3	626	626	3
Control	URINE/FECES	DIARRHEA	3	372	372	3
1016/50	URINE/FECES	DIARRHEA	1	659	670	3
1016/100	URINE/FECES	DIARRHEA	3	711	713	4
1242/50	URINE/FECES	DIARRHEA	1	602	602	1
1260/50	URINE/FECES	DIARRHEA	2	642	646	3
Control	URINE/FECES	DISCOLOR URINE-RED	1	456	456	1
1254/100	URINE/FECES	DISCOLOR URINE-RED	2	465	466	3
1260/50	URINE/FECES	DISCOLOR URINE-RED	1	547	547	1
Control	URINE/FECES	SOILED ANAL REGION	5	490	504	9
1016/50	URINE/FECES	SOILED ANAL REGION	3	567	572	7
1016/100	URINE/FECES	SOILED ANAL REGION	5	686	698	15
1016/200	URINE/FECES	SOILED ANAL REGION	1	687	694	2

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 15. Combined Incidence Summary of Clinical Observations for Core and Interim Subgroup Female Rats

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1242/50	URINE/FECES	SOILED ANAL REGION	1	602	602	1
1242/100	URINE/FECES	SOILED ANAL REGION	1	659	677	4
1254/25	URINE/FECES	SOILED ANAL REGION	1	687	687	1
1260/25	URINE/FECES	SOILED ANAL REGION	2	627	627	2
1260/50	URINE/FECES	SOILED ANAL REGION	3	634	636	4
1260/100	URINE/FECES	SOILED ANAL REGION	1	681	681	1
Control	URINE/FECES	UROGENITAL REGION WET	22	531	542	43
1016/50	URINE/FECES	UROGENITAL REGION WET	11	571	575	21
1016/100	URINE/FECES	UROGENITAL REGION WET	8	518	534	22
1016/200	URINE/FECES	UROGENITAL REGION WET	4	625	628	6
1242/50	URINE/FECES	UROGENITAL REGION WET	5	493	541	14
1242/100	URINE/FECES	UROGENITAL REGION WET	8	604	609	16
1254/25	URINE/FECES	UROGENITAL REGION WET	2	492	495	3
1254/50	URINE/FECES	UROGENITAL REGION WET	6	623	629	10
1254/100	URINE/FECES	UROGENITAL REGION WET	4	573	575	6
1260/25	URINE/FECES	UROGENITAL REGION WET	4	544	557	10
1260/50	URINE/FECES	UROGENITAL REGION WET	13	535	539	23
1260/100	URINE/FECES	UROGENITAL REGION WET	2	516	516	2

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1254/100	ABRASION	DORSAL - ABDOMEN	1	729	732	2
Control	ABRASION	DORSAL - THORAX	2	558	673	11
1260/25	ABRASION	DORSAL - THORAX	1	190	190	1
1016/50	ABRASION	HEAD	1	701	722	4
1254/25	ABRASION	HEAD	1	582	732	15
1260/100	ABRASION	HEAD	1	729	735	2
Control	ABRASION	SHOULDER	2	509	639	40
1016/200	ABRASION	SHOULDER	1	85	92	2
1260/100	ABRASION	SHOULDER	1	8	15	2
Control	ALOPECIA	VENTRAL	1	519	530	3
1016/50	ALOPECIA	VENTRAL	1	351	582	27
1016/200	ALOPECIA	VENTRAL	1	211	407	29
Control	EYES	CORNEAL OPACITY	3	423	507	40
1016/50	EYES	CORNEAL OPACITY	1	735	735	1
1016/200	EYES	CORNEAL OPACITY	1	213	213	1
1254/25	EYES	CORNEAL OPACITY	2	568	590	9
Control	EYES	DISCHARGE-RED	46	439	538	458
1016/50	EYES	DISCHARGE-RED	12	402	625	243
1016/100	EYES	DISCHARGE-RED	9	452	603	180
1016/200	EYES	DISCHARGE-RED	12	437	533	90
1242/50	EYES	DISCHARGE-RED	8	407	624	174
1242/100	EYES	DISCHARGE-RED	15	372	602	305
1254/25	EYES	DISCHARGE-RED	10	362	573	221

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1254/50	EYES	DISCHARGE-RED	6	487	580	86
1254/100	EYES	DISCHARGE-RED	4	520	567	10
1260/25	EYES	DISCHARGE-RED	11	375	508	85
1260/50	EYES	DISCHARGE-RED	11	448	590	46
1260/100	EYES	DISCHARGE-RED	11	378	462	101
Control	GENERAL APPEARANCE	ABNORMAL POSTURE	5	646	653	10
1016/50	GENERAL APPEARANCE	ABNORMAL POSTURE	1	680	680	1
1016/200	GENERAL APPEARANCE	ABNORMAL POSTURE	2	579	579	2
1242/50	GENERAL APPEARANCE	ABNORMAL POSTURE	1	659	689	6
1242/100	GENERAL APPEARANCE	ABNORMAL POSTURE	1	729	729	1
1260/50	GENERAL APPEARANCE	ABNORMAL POSTURE	1	687	687	1
1260/100	GENERAL APPEARANCE	ABNORMAL POSTURE	2	569	569	2
Control	GENERAL APPEARANCE	FOOT PAD LESIONS	9	608	701	127
1016/50	GENERAL APPEARANCE	FOOT PAD LESIONS	3	666	728	31
1016/200	GENERAL APPEARANCE	FOOT PAD LESIONS	1	512	736	33
1242/50	GENERAL APPEARANCE	FOOT PAD LESIONS	1	547	734	28
1254/100	GENERAL APPEARANCE	FOOT PAD LESIONS	1	529	529	1
1260/50	GENERAL APPEARANCE	FOOT PAD LESIONS	1	715	735	4
1242/100	GENERAL APPEARANCE	JAUNDICE	1	687	689	2
1254/25	GENERAL APPEARANCE	JAUNDICE	1	687	687	1
1254/50	GENERAL APPEARANCE	JAUNDICE	1	554	557	2
1254/100	GENERAL APPEARANCE	JAUNDICE	1	498	501	2
Control	GENERAL APPEARANCE	PALLOR	10	572	583	21
1016/50	GENERAL APPEARANCE	PALLOR	2	673	667	3
1016/100	GENERAL APPEARANCE	PALLOR	1	444	444	1

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/200	GENERAL APPEARANCE	PALLOR	3	673	681	7
1242/50	GENERAL APPEARANCE	PALLOR	7	638	648	19
1242/100	GENERAL APPEARANCE	PALLOR	3	624	627	5
1254/25	GENERAL APPEARANCE	PALLOR	3	468	468	3
1254/50	GENERAL APPEARANCE	PALLOR	2	558	593	12
1254/100	GENERAL APPEARANCE	PALLOR	1	560	560	1
1260/25	GENERAL APPEARANCE	PALLOR	3	539	540	4
1260/50	GENERAL APPEARANCE	PALLOR	6	589	595	10
1016/200	GENERAL APPEARANCE	TAIL LESION(S)	1	666	688	5
Control	GENERAL APPEARANCE	THIN APPEARANCE	28	509	522	87
1016/50	GENERAL APPEARANCE	THIN APPEARANCE	7	636	642	15
1016/100	GENERAL APPEARANCE	THIN APPEARANCE	5	529	552	24
1016/200	GENERAL APPEARANCE	THIN APPEARANCE	8	539	547	20
1242/50	GENERAL APPEARANCE	THIN APPEARANCE	5	554	571	21
1242/100	GENERAL APPEARANCE	THIN APPEARANCE	6	510	516	13
1254/25	GENERAL APPEARANCE	THIN APPEARANCE	5	602	606	10
1254/50	GENERAL APPEARANCE	THIN APPEARANCE	8	549	571	31
1254/100	GENERAL APPEARANCE	THIN APPEARANCE	3	442	448	7
1260/25	GENERAL APPEARANCE	THIN APPEARANCE	3	520	537	12
1260/50	GENERAL APPEARANCE	THIN APPEARANCE	7	343	352	19
1260/100	GENERAL APPEARANCE	THIN APPEARANCE	6	520	639	28
Control	GENERAL APPEARANCE	THIN COAT	4	289	356	27
1016/50	GENERAL APPEARANCE	THIN COAT	1	624	724	16
1242/50	GENERAL APPEARANCE	THIN COAT	1	386	421	6
1242/100	GENERAL APPEARANCE	THIN COAT	1	722	735	3

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
Control	GENERAL APPEARANCE	UNTHRIFTY	23	584	617	105
1016/50	GENERAL APPEARANCE	UNTHRIFTY	11	608	619	25
1016/100	GENERAL APPEARANCE	UNTHRIFTY	3	617	638	12
1016/200	GENERAL APPEARANCE	UNTHRIFTY	4	575	605	21
1242/50	GENERAL APPEARANCE	UNTHRIFTY	8	608	632	32
1242/100	GENERAL APPEARANCE	UNTHRIFTY	6	614	621	12
1254/25	GENERAL APPEARANCE	UNTHRIFTY	3	626	633	6
1254/50	GENERAL APPEARANCE	UNTHRIFTY	5	568	601	23
1254/100	GENERAL APPEARANCE	UNTHRIFTY	1	582	582	1
1260/50	GENERAL APPEARANCE	UNTHRIFTY	2	614	631	7
1260/100	GENERAL APPEARANCE	UNTHRIFTY	1	561	603	7
Control	LOCOMOTOR/BEHAVIOR	CIRCLING	14	521	539	52
1016/200	LOCOMOTOR/BEHAVIOR	CIRCLING	1	624	652	5
1242/50	LOCOMOTOR/BEHAVIOR	CIRCLING	1	589	603	2
1242/100	LOCOMOTOR/BEHAVIOR	CIRCLING	2	519	527	5
1254/25	LOCOMOTOR/BEHAVIOR	CIRCLING	1	689	689	1
1260/100	LOCOMOTOR/BEHAVIOR	CIRCLING	2	552	552	2
Control	LOCOMOTOR/BEHAVIOR	HEAD TILT	20	560	599	136
1016/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	7	583	613	34
1016/100	LOCOMOTOR/BEHAVIOR	HEAD TILT	2	628	632	4
1016/200	LOCOMOTOR/BEHAVIOR	HEAD TILT	5	592	631	33
1242/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	3	559	613	27
1242/100	LOCOMOTOR/BEHAVIOR	HEAD TILT	7	575	611	44
1254/25	LOCOMOTOR/BEHAVIOR	HEAD TILT	1	631	689	10
1254/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	3	503	587	35
1254/100	LOCOMOTOR/BEHAVIOR	HEAD TILT	2	495	499	4
1260/25	LOCOMOTOR/BEHAVIOR	HEAD TILT	1	554	557	2

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/50	LOCOMOTOR/BEHAVIOR	HEAD TILT	1	645	659	3
1260/100	LOCOMOTOR/BEHAVIOR	HEAD TILT	6	584	637	51
Control	LOCOMOTOR/BEHAVIOR	LETHARGIC	14	558	560	20
1016/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	7	603	610	17
1016/100	LOCOMOTOR/BEHAVIOR	LETHARGIC	2	547	555	5
1016/200	LOCOMOTOR/BEHAVIOR	LETHARGIC	3	506	513	7
1242/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	3	640	664	11
1242/100	LOCOMOTOR/BEHAVIOR	LETHARGIC	7	612	622	10
1254/25	LOCOMOTOR/BEHAVIOR	LETHARGIC	4	545	553	9
1254/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	2	512	519	4
1260/25	LOCOMOTOR/BEHAVIOR	LETHARGIC	2	512	512	2
1260/50	LOCOMOTOR/BEHAVIOR	LETHARGIC	2	516	516	2
1260/100	LOCOMOTOR/BEHAVIOR	LETHARGIC	2	547	552	5
Control	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	2	614	621	4
1016/50	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	611	611	1
1016/200	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	456	456	1
1242/100	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	638	638	1
1254/25	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	659	659	1
1260/25	LOCOMOTOR/BEHAVIOR	UNRESPONSIVE	1	449	449	1
Control	NOSE/MOUTH	CROOKED/LONG TEETH	12	225	342	128
1016/50	NOSE/MOUTH	CROOKED/LONG TEETH	4	165	204	27
1016/100	NOSE/MOUTH	CROOKED/LONG TEETH	2	50	155	32
1242/50	NOSE/MOUTH	CROOKED/LONG TEETH	4	62	218	92
1242/100	NOSE/MOUTH	CROOKED/LONG TEETH	7	91	250	141
1254/25	NOSE/MOUTH	CROOKED/LONG TEETH	2	127	187	19
1260/25	NOSE/MOUTH	CROOKED/LONG TEETH	1	113	309	29

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/50	NOSE/MOUTH	CROOKED/LONG TEETH	2	166	302	41
1260/100	NOSE/MOUTH	CROOKED/LONG TEETH	3	192	302	50
Control	NOSE/MOUTH	MALOCCLUSION	1	176	344	25
1016/200	NOSE/MOUTH	MALOCCLUSION	1	470	512	3
1254/25	NOSE/MOUTH	MALOCCLUSION	2	208	253	15
Control	NOSE/MOUTH	NASAL DISCHARGE	3	500	502	4
1016/50	NOSE/MOUTH	NASAL DISCHARGE	1	463	466	2
1016/100	NOSE/MOUTH	NASAL DISCHARGE	1	470	470	1
1260/25	NOSE/MOUTH	NASAL DISCHARGE	1	253	253	1
Control	NOSE/MOUTH	ORAL LESION	4	284	292	9
1016/50	NOSE/MOUTH	ORAL LESION	2	278	404	5
1016/100	NOSE/MOUTH	ORAL LESION	2	250	513	7
1016/200	NOSE/MOUTH	ORAL LESION	2	470	533	3
1242/50	NOSE/MOUTH	ORAL LESION	3	316	316	3
1242/100	NOSE/MOUTH	ORAL LESION	3	251	265	9
1254/25	NOSE/MOUTH	ORAL LESION	1	274	344	6
1260/25	NOSE/MOUTH	ORAL LESION	1	113	120	2
1260/50	NOSE/MOUTH	ORAL LESION	3	365	420	5
1260/100	NOSE/MOUTH	ORAL LESION	2	334	491	7

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
Control	NOSE/MOUTH	RED NASAL DISCHARGE	28	446	457	62
1016/50	NOSE/MOUTH	RED NASAL DISCHARGE	4	494	539	10
1016/100	NOSE/MOUTH	RED NASAL DISCHARGE	6	568	576	15
1016/200	NOSE/MOUTH	RED NASAL DISCHARGE	8	370	389	19
1242/50	NOSE/MOUTH	RED NASAL DISCHARGE	5	570	580	10
1242/100	NOSE/MOUTH	RED NASAL DISCHARGE	7	360	379	23
1254/25	NOSE/MOUTH	RED NASAL DISCHARGE	3	529	535	6
1254/50	NOSE/MOUTH	RED NASAL DISCHARGE	3	563	566	4
1254/100	NOSE/MOUTH	RED NASAL DISCHARGE	2	582	585	3
1260/25	NOSE/MOUTH	RED NASAL DISCHARGE	2	697	697	2
1260/50	NOSE/MOUTH	RED NASAL DISCHARGE	7	544	546	10
1260/100	NOSE/MOUTH	RED NASAL DISCHARGE	2	358	358	2
1016/50	REPRODUCTIVE[b]	PROLAPSED VAGINA	1	463	680	27
1260/50	REPRODUCTIVE[b]	PROLAPSED VAGINA	1	554	554	1
Control	RESPIRATION	LABORED	9	566	568	12
1016/50	RESPIRATION	LABORED	3	607	607	4
1016/100	RESPIRATION	LABORED	2	530	532	4
1016/200	RESPIRATION	LABORED	3	493	449	6
1242/50	RESPIRATION	LABORED	1	568	568	1
1242/100	RESPIRATION	LABORED	1	568	569	2
1254/25	RESPIRATION	LABORED	3	501	501	3
1254/100	RESPIRATION	LABORED	3	447	447	4
1260/25	RESPIRATION	LABORED	1	239	253	3
1260/50	RESPIRATION	LABORED	2	428	428	2

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.
b. Listed in database as URINE/FECES.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/100	RESPIRATION	RALES	1	596	597	2
1242/100	RESPIRATION	RALES	1	113	120	2
1254/100	RESPIRATION	RALES	1	582	582	1
1260/25	RESPIRATION	RALES	1	239	253	3
Control	SWELLING	ABDOMEN	54	439	507	404
1016/50	SWELLING	ABDOMEN	14	484	543	111
1016/100	SWELLING	ABDOMEN	13	513	569	105
1016/200	SWELLING	ABDOMEN	11	493	560	114
1242/50	SWELLING	ABDOMEN	12	570	621	96
1242/100	SWELLING	ABDOMEN	11	558	592	62
1254/25	SWELLING	ABDOMEN	16	497	572	156
1254/50	SWELLING	ABDOMEN	13	543	594	94
1254/100	SWELLING	ABDOMEN	9	549	633	78
1260/25	SWELLING	ABDOMEN	13	535	593	90
1260/50	SWELLING	ABDOMEN	10	523	578	52
1260/100	SWELLING	ABDOMEN	10	542	607	68
1016/50	SWELLING	HEAD	1	708	724	4
1242/50	SWELLING	HEAD	2	603	681	25
Control	SWELLING	LIMB	3	565	578	8
1016/50	SWELLING	LIMB	1	645	732	14
1016/100	SWELLING	LIMB	1	582	582	1
1242/50	SWELLING	LIMB	1	302	302	1
1254/100	SWELLING	LIMB	1	211	529	47
1260/50	SWELLING	LIMB	1	526	547	2
1016/50	SWELLING	MOUTH	1	323	323	1

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/100	SWELLING	MOUTH	1	596	597	2
1254/25	SWELLING	MOUTH	1	393	393	1
Control	SWELLING	NECK	2	414	428	6
1016/50	SWELLING	NECK	2	481	512	9
1016/200	SWELLING	NECK	1	456	540	13
1242/50	SWELLING	NECK	1	589	603	3
1242/100	SWELLING	NECK	2	442	490	14
1254/25	SWELLING	NECK	3	547	591	13
1254/50	SWELLING	NECK	2	460	540	25
1260/50	SWELLING	NECK	1	512	533	4
1260/50	SWELLING	TAIL	1	687	735	8
Control	SWELLING	THORAX	30	509	569	228
1016/50	SWELLING	THORAX	10	611	661	81
1016/100	SWELLING	THORAX	6	534	579	38
1016/200	SWELLING	THORAX	5	550	606	41
1242/50	SWELLING	THORAX	7	583	626	51
1242/100	SWELLING	THORAX	10	595	648	85
1254/25	SWELLING	THORAX	13	557	629	131
1254/50	SWELLING	THORAX	15	574	609	93
1254/100	SWELLING	THORAX	11	543	620	124
1260/25	SWELLING	THORAX	9	633	700	96
1260/50	SWELLING	THORAX	7	572	592	25
1260/100	SWELLING	THORAX	10	544	629	117
Control	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	561	637	12

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	2	460	589	40
1242/50	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	652	689	7
1254/25	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	687	687	1
1254/50	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	3	601	667	33
1254/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	659	722	10
1260/50	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	652	736	13
1260/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (1-10 CM)	1	554	695	22
1016/100	TISSUE MASS - DORSAL SURFACE	ABDOMEN (>10 CM)	1	498	557	10
Control	TISSUE MASS - DORSAL SURFACE	HEAD (<1 CM)	1	652	700	8
1254/100	TISSUE MASS - DORSAL SURFACE	HEAD (<1 CM)	1	638	708	11
1242/50	TISSUE MASS - DORSAL SURFACE	HEAD (1-10 CM)	1	659	668	3
1254/100	TISSUE MASS - DORSAL SURFACE	HEAD (1-10 CM)	1	715	736	4
1016/100	TISSUE MASS - DORSAL SURFACE	THORAX (<1 CM)	1	316	330	3
1254/25	TISSUE MASS - DORSAL SURFACE	THORAX (<1 CM)	1	197	274	12
1254/100	TISSUE MASS - DORSAL SURFACE	THORAX (<1 CM)	1	183	190	2

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/100	TISSUE MASS - DORSAL SURFACE	THORAX (<1 CM)	1	582	582	1
Control	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	3	659	730	33
1016/200	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	1	596	732	21
1254/25	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	1	281	443	25
1254/50	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	1	617	668	9
1254/100	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	1	197	332	21
1260/100	TISSUE MASS - DORSAL SURFACE	THORAX (1-10 CM)	1	666	735	11
Control	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	3	421	445	14
1016/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	4	295	311	8
1016/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	1	302	309	2
1016/200	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	5	246	294	33
1254/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	1	554	732	15
1260/25	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	1	582	582	1
1260/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (<1 CM)	3	444	494	25
Control	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	30	489	578	407
1016/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	8	556	655	94

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1016/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	10	499	597	152
1016/200	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	9	475	580	122
1242/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	9	540	635	133
1242/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	7	639	678	46
1254/25	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	8	575	696	149
1254/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	6	603	707	76
1254/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	6	631	696	63
1260/25	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	12	587	656	134
1260/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	6	507	593	75
1260/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (1-10 CM)	5	649	718	56
Control	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	3	554	566	10
1016/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	3	638	663	16
1016/100	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	1	631	683	9
1016/200	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	1	715	736	4
1242/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	1	428	443	4
1254/50	TISSUE MASS - VENTRAL SURFACE	ABDOMEN (>10 CM)	2	659	677	8

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
Control	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	3	241	272	16
1016/50	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	3	279	307	15
1016/100	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	4	251	415	45
1016/200	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	4	218	269	30
1242/100	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	1	260	260	1
1254/50	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	1	120	127	2
1254/100	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	2	397	397	2
1260/25	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	4	363	397	21
1260/50	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	4	360	397	21
1260/100	TISSUE MASS - VENTRAL SURFACE	THORAX (<1 CM)	2	379	386	4
Control	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	23	513	648	464
1016/50	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	6	555	692	103
1016/100	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	4	624	675	35
1016/200	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	7	435	566	104
1242/50	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	3	653	692	20
1242/100	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	4	628	694	44
1254/25	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	10	622	683	95

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1254/50	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	11	557	653	164
1254/100	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	6	535	645	101
1260/25	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	7	561	713	122
1260/50	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	8	478	609	156
1260/100	TISSUE MASS - VENTRAL SURFACE	THORAX (1-10 CM)	5	632	725	73
1254/100	TISSUE MASS - VENTRAL SURFACE	THORAX (>10 CM)	1	379	392	3
1260/25	TISSUE MASS - VENTRAL SURFACE	THORAX (>10 CM)	1	589	597	3
Control	ULCERATION	ABDOMEN - DORSAL	1	624	637	3
1242/50	ULCERATION	ABDOMEN - DORSAL	1	680	689	3
1254/50	ULCERATION	ABDOMEN - DORSAL	1	582	597	4
Control	ULCERATION	ABDOMEN - VENTRAL	8	530	546	29
1016/100	ULCERATION	ABDOMEN - VENTRAL	1	715	722	2
1242/100	ULCERATION	ABDOMEN - VENTRAL	2	596	600	4
1260/25	ULCERATION	ABDOMEN - VENTRAL	3	521	540	13
1260/50	ULCERATION	ABDOMEN - VENTRAL	2	561	569	5
1260/100	ULCERATION	ABDOMEN - VENTRAL	1	694	695	2
1242/50	ULCERATION	HEAD - DORSAL	1	659	668	3
Control	ULCERATION	THORAX - DORSAL	1	554	554	1
1016/200	ULCERATION	THORAX - DORSAL	1	708	732	5

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1254/25	ULCERATION	THORAX - DORSAL	1	428	443	4
1254/50	ULCERATION	THORAX - DORSAL	1	617	668	9
Control	ULCERATION	THORAX - VENTRAL	9	511	576	86
1016/200	ULCERATION	THORAX - VENTRAL	1	563	563	1
1242/50	ULCERATION	THORAX - VENTRAL	1	606	606	1
1254/25	ULCERATION	THORAX - VENTRAL	2	589	592	3
1254/100	ULCERATION	THORAX - VENTRAL	2	589	648	19
1260/50	ULCERATION	THORAX - VENTRAL	1	414	447	4
1260/100	ULCERATION	THORAX - VENTRAL	1	722	736	3
Control	URINE/FECES	DIARRHEA	3	372	372	3
1254/25	URINE/FECES	DIARRHEA	1	725	725	1
1260/50	URINE/FECES	DIARRHEA	1	358	358	1
Control	URINE/FECES	DISCOLOR URINE-RED	1	456	456	1
1016/50	URINE/FECES	DISCOLOR URINE-RED	1	722	729	2
1242/50	URINE/FECES	DISCOLOR URINE-RED	2	656	659	3
1254/25	URINE/FECES	DISCOLOR URINE-RED	1	190	218	5
1254/100	URINE/FECES	DISCOLOR URINE-RED	1	330	332	2
1260/50	URINE/FECES	DISCOLOR URINE-RED	1	225	225	1
Control	URINE/FECES	SOILED ANAL REGION	5	490	504	9
1016/50	URINE/FECES	SOILED ANAL REGION	1	631	646	4
1016/100	URINE/FECES	SOILED ANAL REGION	2	595	595	2
1016/200	URINE/FECES	SOILED ANAL REGION	2	406	407	3
1242/50	URINE/FECES	SOILED ANAL REGION	2	610	611	3
1254/25	URINE/FECES	SOILED ANAL REGION	2	689	689	2
1254/100	URINE/FECES	SOILED ANAL REGION	1	587	587	1

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 16. Combined Incidence Summary of Clinical Observations for Stop Study Subgroup Female Rats[1]

Test Substance/ Conc (ppm)	Observation		Number of Animals Affected	Mean[a] First Day of Finding	Mean[a] Last Day of Finding	Total Incidence
1260/25	URINE/FECES	SOILED ANAL REGION	1	708	708	1
1260/50	URINE/FECES	SOILED ANAL REGION	2	488	524	10
Control	URINE/FECES	UROGENITAL REGION WET	22	531	542	43
1016/50	URINE/FECES	UROGENITAL REGION WET	7	624	627	11
1016/100	URINE/FECES	UROGENITAL REGION WET	4	551	561	11
1016/200	URINE/FECES	UROGENITAL REGION WET	5	529	537	12
1242/50	URINE/FECES	UROGENITAL REGION WET	7	577	606	23
1242/100	URINE/FECES	UROGENITAL REGION WET	5	666	668	8
1254/25	URINE/FECES	UROGENITAL REGION WET	4	656	661	7
1254/50	URINE/FECES	UROGENITAL REGION WET	4	535	548	10
1254/100	URINE/FECES	UROGENITAL REGION WET	3	451	457	7
1260/25	URINE/FECES	UROGENITAL REGION WET	2	344	351	4
1260/50	URINE/FECES	UROGENITAL REGION WET	5	545	560	12
1260/100	URINE/FECES	UROGENITAL REGION WET	3	526	530	5

1. Core/Interim subgroup female control findings reported for comparison.

a. The mean day is calculated by taking an average of all first (or last) occurrences of a finding for affected animals within a dose group.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			-5	1	8	15	22	29
Control	0	Mean	212	251	303	345	382	413
		STD	6	9	16	18	21	26
		N	118	118	118	118	118	118
Aroclor-1016	50	Mean	213	250	304	349	385	413
		STD	7	11	16	18	23	26
		N	68	68	68	68	68	68
	100	Mean	213	249	305	348	382	409
		STD	6	10	15	20	23	24
		N	68	68	68	68	68	68
	200	Mean	213	250	305	350	387	417
		STD	6	9	15	18	22	25
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	213	252	308	347	385	416
		STD	6	9	15	19	24	28
		N	68	68	68	68	68	68
	100	Mean	213	250	303	348	384	414
		STD	7	8	14	17	20	22
		N	68	68	68	68	68	68
Aroclor-1254	25	Mean	213	251	306	353	385	416
		STD	6	9	14	20	24	28
		N	68	68	68	68	68	68
	50	Mean	213	252	309	353	386	416
		STD	7	9	14	20	23	31
		N	68	68	68	68	68	68
	100	Mean	212	250	305	344	374	403
		STD	7	10	13	17	19	22
		N	68	68	68	68	68	68
Aroclor-1260	25	Mean	213	251	308	350	388	419
		STD	7	9	14	17	21	25
		N	68	68	68	68	68	68
	50	Mean	213	249	305	350	387	417
		STD	7	10	15	19	24	28
		N	68	68	68	68	68	68
	100	Mean	213	248	307	351	388	419
		STD	7	9	15	20	24	28
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			36	43	50	57	64	71
Control	0	Mean	437	459	479	497	514	529
		STD	27	30	33	34	36	37
		N	118	118	118	118	118	118
Aroclor-1016	50	Mean	439	466	488	512	522	541
		STD	30	35	37	40	42	46
		N	68	68	68	68	68	68
	100	Mean	434	461	482	505	514	532
		STD	27	30	33	36	38	41
		N	68	68	68	68	68	68
	200	Mean	441	466	487	509	519	536
		STD	28	33	35	37	39	41
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	441	463	489	510	525	535
		STD	30	34	37	40	41	45
		N	68	68	68	68	68	68
	100	Mean	438	458	485	506	522	533
		STD	26	31	33	34	36	38
		N	68	68	68	68	68	68
Aroclor-1254	25	Mean	440	464	482	508	522	533
		STD	31	34	36	39	42	44
		N	67	67	67	67	67	67
	50	Mean	440	463	477	500	515	527
		STD	32	33	36	40	41	42
		N	68	68	68	68	68	68
	100	Mean	**422[b]**	**444[a]**	**456[b]**	**476[b]**	**488[b]**	**494[b]**
		STD	25	28	31	35	35	38
		N	68	68	68	68	67	67
Aroclor-1260	25	Mean	443	466	483	504	522	536
		STD	30	35	41	43	43	43
		N	68	68	68	68	68	68
	50	Mean	446	470	489	510	526	541
		STD	32	35	38	42	44	46
		N	68	68	68	68	68	68
	100	Mean	448	471	493	**514[a]**	529	540
		STD	31	35	38	42	46	45
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			78	85	92	99	106	114
Control	0	Mean	538	550	559	568	576	584
		STD	39	42	43	44	44	47
		N	118	117	117	117	117	117
Aroclor-1016	50	Mean	552	566	579	589	596	607[a]
		STD	47	49	51	52	53	55
		N	68	68	68	67	67	67
	100	Mean	543	555	567	575	584	594
		STD	44	50	49	51	51	56
		N	68	68	68	68	68	68
	200	Mean	549	563	577	584	590	604
		STD	44	44	48	50	52	54
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	551	563	576	586	595	605
		STD	45	48	48	50	51	53
		N	68	68	68	68	68	68
	100	Mean	546	557	568	579	586	594
		STD	41	43	45	47	48	50
		N	68	68	68	68	68	68
Aroclor-1254	25	Mean	547	557	570	579	589	595
		STD	45	47	49	50	52	53
		N	67	67	67	67	67	67
	50	Mean	542	548	562	570	575	583
		STD	43	45	46	48	48	47
		N	68	68	68	68	68	68
	100	Mean	505[b]	509[b]	518[b]	526[b]	531[b]	535[b]
		STD	38	39	44	42	41	42
		N	67	67	67	66	66	66
Aroclor-1260	25	Mean	549	559	568	575	586	594
		STD	46	48	51	51	53	54
		N	68	68	68	68	68	68
	50	Mean	555	567	578	586	596	605
		STD	47	50	52	54	55	53
		N	68	68	68	68	68	68
	100	Mean	553	561	574	580	592	599
		STD	49	52	56	57	57	56
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			120	127	134	141	149	155
Control	0	Mean	592	600	611	614	616	628
		STD	49	50	51	51	51	54
		N	117	117	117	117	117	117
Aroclor-1016	50	Mean	**615[a]**	623	630	**642[a]**	**647[b]**	**660[b]**
		STD	56	58	60	63	62	65
		N	67	67	67	67	67	67
	100	Mean	602	610	617	625	626	641
		STD	57	57	58	59	59	62
		N	68	68	68	68	68	68
	200	Mean	610	615	625	633	636	650
		STD	56	58	59	60	61	62
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	610	618	627	634	639	649
		STD	54	56	57	58	56	58
		N	68	68	68	68	68	68
	100	Mean	599	602	615	620	625	634
		STD	50	54	55	56	55	57
		N	68	67	67	67	67	67
Aroclor-1254	25	Mean	604	613	618	629	627	643
		STD	56	57	59	60	57	61
		N	67	67	67	67	67	67
	50	Mean	590	598	602	612	611	624
		STD	48	50	51	52	51	54
		N	68	68	68	68	68	68
	100	Mean	**541[b]**	**547[b]**	**549[b]**	**556[b]**	**558[b]**	**567[b]**
		STD	44	46	46	48	48	52
		N	66	66	66	66	66	66
Aroclor-1260	25	Mean	605	612	619	626	634	645
		STD	60	60	58	60	59	62
		N	68	68	68	68	68	68
	50	Mean	**618[a]**	622	627	632	638	648
		STD	60	60	61	62	62	65
		N	68	68	68	68	68	68
	100	Mean	612	618	624	628	637	648
		STD	60	59	60	61	61	64
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			162	169	176	183	190	197
Control	0	Mean	633	637	634	638	644	649
		STD	54	56	56	57	59	60
		N	117	117	117	117	112	112
Aroclor-1016	50	Mean	**664[b]**	**670[b]**	**672[b]**	**676[b]**	**682[b]**	**688[b]**
		STD	66	70	71	74	75	76
		N	67	67	67	67	61	61
	100	Mean	647	653	655	659	663	666
		STD	63	62	63	65	65	64
		N	68	68	68	68	62	61
	200	Mean	651	660	**664[a]**	663	669	676
		STD	64	65	66	68	66	68
		N	68	68	68	68	62	61
Aroclor-1242	50	Mean	655	661	**668[b]**	**670[a]**	**673[a]**	673
		STD	60	61	63	64	67	68
		N	68	68	68	68	62	62
	100	Mean	639	644	653	655	666	667
		STD	58	62	61	62	61	63
		N	67	67	66	66	60	60
Aroclor-1254	25	Mean	643	655	658	663	664	671
		STD	62	64	65	65	67	69
		N	67	67	66	66	61	61
	50	Mean	621	631	634	639	640	648
		STD	56	56	56	58	59	61
		N	68	68	68	68	62	62
	100	Mean	**566[b]**	**572[b]**	**579[b]**	**582[b]**	**580[b]**	**586[b]**
		STD	55	59	50	52	56	57
		N	66	66	65	65	59	59
Aroclor-1260	25	Mean	651	654	660	**667[a]**	667	671
		STD	65	65	68	68	70	75
		N	68	68	68	68	62	62
	50	Mean	654	658	**666[b]**	**674[b]**	672	**680[a]**
		STD	66	68	69	71	72	74
		N	68	68	68	68	62	62
	100	Mean	651	656	**663[a]**	**669[a]**	667	674
		STD	64	65	66	67	69	70
		N	68	68	68	68	62	62

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			204	211	218	225	232	239
Control	0	Mean	650	662	664	672	677	682
		STD	62	63	63	63	63	66
		N	112	112	112	112	112	112
Aroclor-1016	50	Mean	**696[b]**	**705[b]**	**704[b]**	702	**712[a]**	**717[a]**
		STD	78	78	80	84	82	83
		N	61	61	61	61	60	60
	100	Mean	674	684	684	684	690	695
		STD	67	67	68	68	69	71
		N	61	61	61	61	61	61
	200	Mean	**686[b]**	**694[a]**	**696[a]**	696	704	708
		STD	70	71	71	72	73	75
		N	61	61	61	61	61	61
Aroclor-1242	50	Mean	678	**693[a]**	**695[a]**	700	706	706
		STD	69	70	71	71	72	72
		N	62	62	62	62	62	62
	100	Mean	669	681	681	683	689	692
		STD	64	65	65	66	66	66
		N	60	60	59	59	59	59
Aroclor-1254	25	Mean	674	681	683	692	693	698
		STD	70	71	72	74	73	79
		N	61	61	61	61	61	61
	50	Mean	653	659	661	667	667	674
		STD	61	61	61	63	63	66
		N	62	62	62	62	62	62
	100	Mean	**589[b]**	**597[b]**	**595[b]**	**601[b]**	**600[b]**	**602[b]**
		STD	57	58	59	61	62	62
		N	59	59	59	59	59	59
Aroclor-1260	25	Mean	678	685	692	693	701	702
		STD	78	78	77	76	78	81
		N	62	62	62	62	62	62
	50	Mean	**687[b]**	**695[a]**	**699[a]**	702	**708[a]**	712
		STD	76	76	77	77	79	79
		N	62	61	61	61	61	61
	100	Mean	679	688	688	690	698	701
		STD	71	72	73	73	74	74
		N	62	62	62	62	62	62

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			246	253	260	267	274	281
Control	0	Mean	688	698	699	697	707	711
		STD	66	70	71	72	73	74
		N	112	112	112	112	112	112
Aroclor-1016	50	Mean	718	718	725	731[a]	733	735
		STD	84	85	86	87	86	87
		N	59	59	59	59	59	59
	100	Mean	695	698	703	709	711	714
		STD	72	72	74	74	74	75
		N	61	61	61	61	61	61
	200	Mean	710	713	718	721	726	728
		STD	75	75	76	77	79	80
		N	60	60	60	60	60	60
Aroclor-1242	50	Mean	710	719	719	715	726	726
		STD	73	73	73	75	76	78
		N	62	62	62	62	62	62
	100	Mean	696	705	708	707	715	719
		STD	66	67	67	69	71	70
		N	59	59	59	59	59	59
Aroclor-1254	25	Mean	701	702	710	712	713	722
		STD	79	79	78	79	79	80
		N	61	61	61	61	61	61
	50	Mean	674	677	683	685	687	694
		STD	63	64	64	66	67	67
		N	62	62	62	62	62	62
	100	Mean	603[b]	606[b]	610[b]	615[b]	616[b]	623[b]
		STD	62	63	63	65	64	66
		N	59	59	59	59	59	59
Aroclor-1260	25	Mean	703	705	716	716	722	718
		STD	81	80	83	85	86	87
		N	62	62	62	62	62	62
	50	Mean	710	712	725	727	732	728
		STD	81	80	81	82	83	82
		N	61	61	61	60	61	61
	100	Mean	700	704	715	716	717	719
		STD	77	77	77	79	82	81
		N	62	62	61	61	61	61

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			288	295	302	309	316	323
Control	0	Mean	712	710	719	725	723	729
		STD	74	75	75	79	79	79
		N	112	112	112	112	111	110
Aroclor-1016	50	Mean	734	**746**[a]	750	753	**760**[a]	759
		STD	89	90	90	91	93	94
		N	59	59	59	59	59	59
	100	Mean	719	727	729	732	737	740
		STD	76	77	79	80	81	81
		N	61	61	61	61	61	61
	200	Mean	733	738	744	748	753	756
		STD	82	81	83	86	86	87
		N	60	60	60	60	60	60
Aroclor-1242	50	Mean	730	734	736	741	746	750
		STD	77	77	80	80	81	83
		N	62	62	62	62	62	62
	100	Mean	724	726	726	725	733	736
		STD	71	71	70	69	68	69
		N	59	59	59	58	58	57
Aroclor-1254	25	Mean	722	732	731	730	737	745
		STD	81	82	84	85	87	87
		N	61	61	61	61	60	60
	50	Mean	694	699	696	701	706	712
		STD	68	68	69	68	70	70
		N	62	62	62	62	62	61
	100	Mean	**621**[b]	**628**[b]	**627**[b]	**629**[b]	**633**[b]	**639**[b]
		STD	66	68	67	67	67	72
		N	59	59	59	59	59	59
Aroclor-1260	25	Mean	728	730	734	736	746	742
		STD	88	90	89	93	93	93
		N	62	62	62	62	61	62
	50	Mean	739	741	743	747	756	753
		STD	84	85	85	87	88	89
		N	61	61	61	61	61	61
	100	Mean	726	723	729	731	739	740
		STD	84	86	85	89	89	92
		N	61	61	61	61	61	61

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			330	337	344	351	358	365
Control	0	Mean	736	738	742	744	745	746
		STD	79	82	85	87	86	88
		N	110	110	110	110	110	110
Aroclor-1016	50	Mean	772	770	775	782	776	779
		STD	94	95	96	98	97	98
		N	59	59	59	59	59	59
	100	Mean	748	743	747	753	752	752
		STD	82	83	83	84	86	87
		N	61	61	61	61	61	61
	200	Mean	765	764	770	770	773	776
		STD	87	89	90	89	89	87
		N	60	60	60	60	60	60
Aroclor-1242	50	Mean	757	758	758	760	766	767
		STD	83	85	86	89	88	92
		N	62	62	62	62	62	62
	100	Mean	742	742	741	742	753	753
		STD	69	71	70	71	73	73
		N	57	57	57	57	57	57
Aroclor-1254	25	Mean	748	747	750	755	754	756
		STD	90	89	90	91	92	92
		N	60	60	60	60	60	60
	50	Mean	715	714	718	722	720	720
		STD	71	72	73	74	75	75
		N	61	61	61	61	61	61
	100	Mean	**641[b]**	**639[b]**	**643[b]**	**647[b]**	**646[b]**	**647[b]**
		STD	71	72	73	74	74	75
		N	58	58	58	58	58	58
Aroclor-1260	25	Mean	745	752	748	760	756	762
		STD	94	95	98	97	98	99
		N	62	62	62	61	61	61
	50	Mean	759	760	763	769	767	768
		STD	89	90	88	91	90	90
		N	61	61	61	61	61	60
	100	Mean	740	739	743	747	744	747
		STD	93	94	95	97	91	96
		N	61	61	61	61	60	59

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			372	379	386	393	400	407
Control	0	Mean	754	755	761	761	763	770
		STD	88	91	93	97	101	98
		N	110	104	104	104	104	103
Aroclor-1016	50	Mean	784	782	792	790	791	794
		STD	99	104	106	110	112	113
		N	58	52	52	52	52	52
	100	Mean	764	768	776	779	781	781
		STD	87	91	91	91	94	96
		N	60	55	55	55	55	55
	200	Mean	785	780	788	795	791	794
		STD	89	84	86	86	88	93
		N	60	54	54	54	54	54
Aroclor-1242	50	Mean	766	765	779	780	778	780
		STD	95	102	88	88	88	89
		N	62	56	54	54	54	54
	100	Mean	754	749	755	756	754	756
		STD	74	72	76	74	74	74
		N	57	52	51	51	51	51
Aroclor-1254	25	Mean	756	751	753	756	769	765
		STD	93	98	100	104	102	102
		N	60	54	54	54	53	53
	50	Mean	719	**710[a]**	**710[b]**	**716[a]**	723	**718[a]**
		STD	74	74	73	73	74	77
		N	61	55	55	55	55	55
	100	Mean	**649[b]**	**643[b]**	**644[b]**	**648[b]**	**654[b]**	**650[b]**
		STD	75	78	78	79	81	80
		N	58	52	52	52	52	52
Aroclor-1260	25	Mean	760	760	766	765	772	768
		STD	103	102	101	101	100	102
		N	61	55	55	55	55	55
	50	Mean	766	770	777	779	785	785
		STD	92	92	94	93	94	95
		N	60	54	54	53	53	53
	100	Mean	750	754	761	757	758	759
		STD	98	93	102	102	106	108
		N	59	53	53	53	53	52

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			414	421	428	435	442	449
Control	0	Mean	776	777	779	783	777	789
		STD	97	99	96	97	95	96
		N	102	102	101	101	101	101
Aroclor-1016	50	Mean	799	798	805	806	812	810
		STD	113	115	114	115	117	123
		N	52	52	52	52	52	52
	100	Mean	783	782	796	795	803	801
		STD	97	102	95	93	93	95
		N	54	54	53	53	52	52
	200	Mean	795	803	809	807	810	811
		STD	98	89	91	94	101	88
		N	54	53	53	53	53	52
Aroclor-1242	50	Mean	786	783	791	783	785	784
		STD	89	91	90	91	88	89
		N	54	54	54	53	53	53
	100	Mean	759	756	764	760	766	766
		STD	74	75	74	76	76	75
		N	51	51	51	51	51	51
Aroclor-1254	25	Mean	764	773	773	771	781	777
		STD	102	98	98	98	98	98
		N	53	52	52	52	52	52
	50	Mean	**719[b]**	**723[b]**	**726[b]**	**721[b]**	732	**729[b]**
		STD	73	76	72	75	74	74
		N	54	54	53	53	52	52
	100	Mean	**649[b]**	**652[b]**	**653[b]**	**648[b]**	**658[b]**	**658[b]**
		STD	80	80	80	78	79	77
		N	52	52	52	52	52	52
Aroclor-1260	25	Mean	768	777	770	772	775	783
		STD	105	106	109	108	109	113
		N	55	55	55	55	55	55
	50	Mean	784	793	782	786	788	797
		STD	96	97	96	101	107	109
		N	53	53	53	52	52	52
	100	Mean	761	772	764	761	766	772
		STD	113	95	100	103	106	107
		N	51	49	49	49	48	48

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			456	463	470	477	484	491
Control	0	Mean	787	783	791	792	783	786
		STD	96	97	97	99	103	104
		N	100	100	100	100	100	99
Aroclor-1016	50	Mean	810	809	815	823	**825[a]**	834
		STD	126	132	137	129	122	124
		N	52	52	52	51	50	50
	100	Mean	801	801	807	805	804	814
		STD	96	96	101	104	103	108
		N	51	51	51	51	50	49
	200	Mean	808	809	811	810	808	819
		STD	90	93	96	102	104	107
		N	52	52	52	52	52	52
Aroclor-1242	50	Mean	784	782	784	787	788	795
		STD	91	92	93	93	92	97
		N	53	53	53	52	51	51
	100	Mean	766	757	759	756	759	765
		STD	73	71	73	79	74	75
		N	51	51	51	51	50	50
Aroclor-1254	25	Mean	778	780	777	783	780	786
		STD	97	98	100	103	110	117
		N	52	51	51	51	51	50
	50	Mean	**729[b]**	**730[b]**	**731[b]**	**736[b]**	743	744
		STD	75	79	81	86	82	84
		N	52	52	52	52	51	50
	100	Mean	**660[b]**	**664[b]**	**667[b]**	**670[b]**	**675[b]**	**678[b]**
		STD	78	79	78	81	82	82
		N	52	52	52	52	51	51
Aroclor-1260	25	Mean	780	774	767	772	780	777
		STD	116	120	127	126	134	141
		N	55	55	55	54	51	51
	50	Mean	795	791	801	804	807	807
		STD	113	114	95	97	98	100
		N	52	52	49	49	49	49
	100	Mean	769	764	755	762	775	775
		STD	109	112	116	122	111	115
		N	48	48	48	46	45	44

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			498	505	512	519	526	533
Control	0	Mean	798	789	797	792	800	796
		STD	101	102	109	110	115	120
		N	97	97	97	95	94	93
Aroclor-1016	50	Mean	833	830	831	833	830	834
		STD	125	128	134	135	142	140
		N	50	50	50	49	48	47
	100	Mean	812	812	811	820	821	829
		STD	109	113	121	115	118	122
		N	49	49	49	47	47	47
	200	Mean	814	820	824	826	827	831
		STD	109	103	102	101	102	103
		N	52	51	51	50	50	50
Aroclor-1242	50	Mean	798	794	797	795	802	807
		STD	105	111	123	132	130	116
		N	51	51	51	51	50	49
	100	Mean	770	768	769	770	766	759
		STD	81	78	82	88	95	109
		N	49	48	48	47	46	45
Aroclor-1254	25	Mean	785	788	791	785	786	784
		STD	111	113	120	124	121	129
		N	49	49	49	49	48	48
	50	Mean	732[b]	737[a]	734[a]	730[a]	737[a]	741
		STD	94	94	104	111	105	98
		N	50	49	49	48	46	45
	100	Mean	676[b]	678[b]	681[b]	680[b]	674[b]	677[b]
		STD	80	80	79	83	84	74
		N	51	51	51	50	50	49
Aroclor-1260	25	Mean	780	791	794	789	792	793
		STD	145	122	127	126	126	124
		N	50	47	47	47	47	46
	50	Mean	805	804	808	807	807	803
		STD	103	106	111	109	112	113
		N	49	49	49	48	47	47
	100	Mean	776	787	785	787	785	788
		STD	120	104	106	106	103	107
		N	44	43	43	43	43	42

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			540	547	554	561	568	575
Control	0	Mean	802	804	802	798	810	810
		STD	111	113	113	116	111	111
		N	91	91	90	86	84	84
Aroclor-1016	50	Mean	831	827	819	836	832	829
		STD	146	148	157	146	156	162
		N	45	43	43	36	36	35
	100	Mean	823	815	827	827	836	825
		STD	126	134	115	108	85	93
		N	47	46	44	39	38	38
	200	Mean	828	826	823	833	833	827
		STD	106	116	105	88	96	103
		N	50	48	46	41	41	41
Aroclor-1242	50	Mean	803	811	811	812	814	811
		STD	123	112	110	122	127	128
		N	49	48	48	43	42	40
	100	Mean	761	766	772	764	771	770
		STD	106	97	99	110	97	104
		N	44	43	42	38	37	37
Aroclor-1254	25	Mean	781	787	786	781	780	786
		STD	133	133	144	135	140	130
		N	48	46	46	41	41	40
	50	Mean	**741[a]**	**739[a]**	750	741	**736[a]**	**744[a]**
		STD	102	109	102	111	120	105
		N	43	42	39	35	35	34
	100	Mean	**674[b]**	**673[b]**	**683[b]**	**682[b]**	**680[b]**	**681[b]**
		STD	77	81	66	68	68	67
		N	49	49	47	43	42	40
Aroclor-1260	25	Mean	796	794	793	774	787	785
		STD	118	122	124	132	118	118
		N	45	45	45	41	40	40
	50	Mean	794	789	801	788	789	780
		STD	117	123	108	114	100	99
		N	45	44	42	37	36	36
	100	Mean	785	789	794	796	793	788
		STD	107	105	105	97	98	100
		N	42	40	40	37	37	37

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			582	589	596	603	610	617
Control	0	Mean	808	797	802	800	797	791
		STD	104	105	112	115	119	123
		N	82	81	79	79	78	77
Aroclor-1016	50	Mean	829	824	845	844	844	861
		STD	168	183	156	162	134	111
		N	35	35	33	32	29	27
	100	Mean	818	817	819	825	818	812
		STD	104	108	113	85	86	90
		N	38	35	33	32	32	31
	200	Mean	834	834	835	834	817	814
		STD	99	106	110	113	106	114
		N	40	40	39	39	38	37
Aroclor-1242	50	Mean	808	796	794	795	798	794
		STD	135	135	145	142	153	163
		N	40	40	40	38	37	37
	100	Mean	772	759	758	754	750	754
		STD	106	112	120	102	116	104
		N	36	36	36	34	34	33
Aroclor-1254	25	Mean	789	781	777	779	783	782
		STD	117	122	124	119	111	109
		N	39	39	38	36	35	33
	50	Mean	**738[a]**	733	**732[a]**	**724[a]**	736	731
		STD	112	121	107	118	101	104
		N	34	34	32	32	30	30
	100	Mean	**674[b]**	**667[b]**	**661[b]**	**658[b]**	**657[b]**	**651[b]**
		STD	63	62	63	65	68	72
		N	39	39	39	38	38	38
Aroclor-1260	25	Mean	782	795	793	792	793	792
		STD	121	107	111	113	112	116
		N	40	39	39	38	38	38
	50	Mean	772	765	766	756	758	754
		STD	102	108	108	114	112	115
		N	36	36	35	35	34	34
	100	Mean	786	787	789	779	776	776
		STD	99	92	97	92	92	94
		N	37	36	36	35	35	35

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			624	631	638	645	652	659
Control	0	Mean	791	784	786	787	774	769
		STD	129	131	134	142	148	147
		N	76	76	73	70	70	66
Aroclor-1016	50	Mean	854	851	842	852	847	826
		STD	107	116	119	111	119	127
		N	26	25	25	23	23	23
	100	Mean	812	803	797	782	780	771
		STD	80	81	81	88	104	102
		N	30	28	27	27	26	25
	200	Mean	818	813	817	805	805	796
		STD	116	122	110	117	124	135
		N	35	35	34	34	34	34
Aroclor-1242	50	Mean	794	806	800	800	804	794
		STD	157	151	158	145	132	137
		N	35	34	34	33	32	32
	100	Mean	746	737	743	723	723	728
		STD	118	133	130	138	138	137
		N	30	29	28	28	27	24
Aroclor-1254	25	Mean	786	780	774	764	755	738
		STD	102	102	106	109	113	125
		N	32	32	31	31	31	30
	50	Mean	737	733	725	717	708	695
		STD	100	97	95	93	95	99
		N	29	29	28	28	26	25
	100	Mean	650[b]	644[b]	625[b]	615[b]	613[b]	613[b]
		STD	77	85	81	89	74	72
		N	37	36	35	35	34	32
Aroclor-1260	25	Mean	782	777	778	785	772	758
		STD	120	118	120	118	120	130
		N	38	38	37	36	35	35
	50	Mean	744	730	722	733	723	717
		STD	124	133	144	146	150	156
		N	33	33	32	31	30	28
	100	Mean	774	765	758	760	740	706
		STD	96	100	104	111	113	127
		N	34	34	34	33	33	31

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study				
			666	673	680	687	694
Control	0	Mean	767	781	771	765	762
		STD	151	127	129	136	137
		N	65	60	60	60	57
Aroclor-1016	50	Mean	827	812	816	805	795
		STD	117	136	139	147	155
		N	21	21	20	20	20
	100	Mean	751	739	732	747	730
		STD	109	123	141	115	131
		N	23	23	21	19	19
	200	Mean	794	801	803	792	785
		STD	135	116	118	124	130
		N	33	31	31	31	31
Aroclor-1242	50	Mean	782	776	771	755	780
		STD	147	162	158	171	144
		N	32	32	31	29	27
	100	Mean	732	721	725	715	704
		STD	118	132	121	129	135
		N	23	23	22	22	22
Aroclor-1254	25	Mean	747	735	747	745	732
		STD	115	122	112	116	124
		N	28	28	26	26	25
	50	Mean	**676[a]**	**662[b]**	**645[b]**	**636[b]**	**628[b]**
		STD	92	95	113	125	136
		N	24	24	22	21	18
	100	Mean	**601[b]**	**591[b]**	**586[b]**	**589[b]**	**612[b]**
		STD	76	80	92	101	90
		N	32	32	31	29	24
Aroclor-1260	25	Mean	743	751	744	745	744
		STD	137	138	122	125	133
		N	35	33	31	30	30
	50	Mean	732	737	736	740	735
		STD	145	156	139	142	151
		N	26	24	23	23	23
	100	Mean	701	725	706	711	717
		STD	134	118	124	118	115
		N	29	26	26	24	23

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 17. Group Mean Body Weights (g) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study			
			701	708	715	722
Control	0	Mean	761	757	765	754
		STD	144	140	122	120
		N	54	52	50	46
Aroclor-1016	50	Mean	794	801	803	776
		STD	159	167	174	169
		N	19	18	17	15
	100	Mean	705	695	724	731
		STD	150	172	155	149
		N	19	17	15	14
	200	Mean	767	765	758	754
		STD	142	151	156	158
		N	30	29	29	27
Aroclor-1242	50	Mean	786	775	769	775
		STD	125	132	144	131
		N	26	26	26	25
	100	Mean	705	700	707	714
		STD	129	137	127	125
		N	21	20	19	18
Aroclor-1254	25	Mean	721	716	717	707
		STD	136	135	127	133
		N	25	25	24	23
	50	Mean	**637[a]**	641	**627[a]**	667
		STD	127	119	131	74
		N	14	13	13	11
	100	Mean	**627[b]**	**633[b]**	**624[b]**	**617[b]**
		STD	63	56	56	52
		N	22	21	21	20
Aroclor-1260	25	Mean	739	722	721	714
		STD	136	151	134	138
		N	27	25	24	24
	50	Mean	737	756	734	745
		STD	143	129	135	100
		N	22	19	19	17
	100	Mean	717	708	676	683
		STD	116	119	128	111
		N	22	20	19	17

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			-5	1	8	15	22	29
Control	0	Mean	194	198	220	238	252	265
		STD	11	12	15	17	20	22
		N	130	130	130	130	130	130
Aroclor-1016	50	Mean	195	203	224	241	255	265
		STD	12	12	15	18	19	20
		N	110	110	110	110	110	110
	100	Mean	196	203	224	240	253	263
		STD	12	13	16	19	20	22
		N	110	110	110	110	110	110
	200	Mean	196	201	222	235	248	259
		STD	13	13	15	17	19	19
		N	110	110	110	110	110	110
Aroclor-1242	50	Mean	196	202	222	238	250	259
		STD	12	15	17	20	20	22
		N	110	110	110	110	110	110
	100	Mean	196	202	223	237	249	**258[a]**
		STD	12	13	16	18	20	20
		N	110	110	110	110	110	110
Aroclor-1254	25	Mean	196	201	222	238	251	**257[a]**
		STD	12	13	16	19	21	20
		N	110	110	110	110	110	110
	50	Mean	196	200	221	234	247	**254[b]**
		STD	12	13	17	18	20	21
		N	110	110	110	110	110	110
	100	Mean	196	200	222	235	247	**251[b]**
		STD	12	13	16	17	20	21
		N	110	110	110	110	110	110
Aroclor-1260	25	Mean	196	202	223	240	253	263
		STD	12	14	18	21	23	24
		N	110	110	110	110	110	110
	50	Mean	195	199	221	237	249	259
		STD	12	14	16	19	21	23
		N	110	110	110	110	110	110
	100	Mean	196	200	224	241	252	262
		STD	12	13	15	17	20	21
		N	110	110	110	110	110	110

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			36	43	50	57	64	71
Control	0	Mean	270	277	284	288	294	299
		STD	23	22	23	25	25	26
		N	130	130	130	129	129	129
Aroclor-1016	50	Mean	275	283	292	294	300	305
		STD	22	23	24	24	25	26
		N	110	110	110	110	110	110
	100	Mean	273	281	288	293	299	303
		STD	24	26	26	27	29	28
		N	110	110	110	110	110	110
	200	Mean	270	276	282	287	292	295
		STD	22	23	24	24	27	27
		N	110	110	110	110	110	110
Aroclor-1242	50	Mean	267	274	283	289	292	299
		STD	24	26	27	28	28	29
		N	110	110	110	110	110	110
	100	Mean	266	275	281	287	288	292
		STD	22	24	25	25	24	25
		N	110	110	110	110	110	110
Aroclor-1254	25	Mean	267	275	282	285	289	293
		STD	21	23	24	24	25	25
		N	110	110	110	110	110	110
	50	Mean	264	271	277	282	287	**290[a]**
		STD	23	24	25	25	25	26
		N	110	110	110	110	110	110
	100	Mean	**261[a]**	**265[b]**	**270[b]**	**273[b]**	**276[b]**	**279[b]**
		STD	22	23	23	24	24	25
		N	110	110	110	110	110	110
Aroclor-1260	25	Mean	270	277	285	290	293	298
		STD	24	25	27	28	28	28
		N	110	110	110	110	110	110
	50	Mean	267	273	279	287	291	296
		STD	23	24	26	27	27	27
		N	110	110	110	109	109	109
	100	Mean	270	276	281	289	293	296
		STD	22	23	24	26	25	26
		N	110	109	110	110	110	110

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			78	85	92	99	107	113
Control	0	Mean	301	308	311	316	317	320
		STD	27	28	28	28	29	30
		N	129	129	129	123	123	123
Aroclor-1016	50	Mean	**311[a]**	314	314	319	323	326
		STD	26	27	26	29	28	30
		N	110	110	110	104	104	104
	100	Mean	309	313	314	318	322	325
		STD	29	30	30	31	31	33
		N	110	110	110	104	104	104
	200	Mean	301	304	306	309	313	317
		STD	28	28	27	29	29	31
		N	110	110	110	104	104	104
Aroclor-1242	50	Mean	303	308	310	313	318	322
		STD	30	31	30	30	32	32
		N	110	110	110	104	104	104
	100	Mean	294	302	305	**305[a]**	308	312
		STD	25	25	27	28	28	28
		N	110	110	110	104	104	104
Aroclor-1254	25	Mean	297	300	304	307	309	312
		STD	26	26	26	28	29	29
		N	110	110	110	104	104	104
	50	Mean	293	**295[b]**	**298[b]**	**297[b]**	**299[b]**	**301[b]**
		STD	27	28	28	29	30	31
		N	110	110	110	104	104	104
	100	Mean	**280[b]**	**281[b]**	**282[b]**	**282[b]**	**283[b]**	**283[b]**
		STD	25	27	27	27	28	27
		N	110	110	110	104	104	104
Aroclor-1260	25	Mean	304	308	310	313	317	323
		STD	29	28	29	29	29	31
		N	110	110	110	104	104	104
	50	Mean	302	306	308	311	315	321
		STD	28	28	28	28	29	29
		N	108	108	108	102	102	102
	100	Mean	302	306	306	310	314	317
		STD	27	28	28	29	30	31
		N	110	110	110	104	104	104

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			120	127	134	142	148	155
Control	0	Mean	323	329	331	333	335	337
		STD	31	32	33	34	34	35
		N	123	123	123	123	123	123
Aroclor-1016	50	Mean	328	331	329	331	338	343
		STD	30	31	31	32	32	33
		N	104	104	104	104	104	104
	100	Mean	327	332	333	334	342	347
		STD	34	34	35	36	36	38
		N	104	104	104	104	104	104
	200	Mean	319	322	322	325	330	333
		STD	31	31	31	32	33	34
		N	104	104	104	104	104	104
Aroclor-1242	50	Mean	325	329	334	337	337	343
		STD	32	34	35	37	36	38
		N	104	104	104	104	104	104
	100	Mean	312	**316[a]**	**319[a]**	**320[a]**	**320[b]**	**324[a]**
		STD	29	29	31	30	30	32
		N	104	104	104	104	104	104
Aroclor-1254	25	Mean	314	**317[a]**	320	324	326	326
		STD	30	32	32	34	34	35
		N	104	104	104	104	104	104
	50	Mean	**302[b]**	**305[b]**	**307[b]**	**311[b]**	**313[b]**	**314[b]**
		STD	31	32	32	33	33	33
		N	104	104	104	104	104	104
	100	Mean	**283[b]**	**285[b]**	**287[b]**	**290[b]**	**293[b]**	**293[b]**
		STD	27	26	27	28	28	28
		N	104	104	104	104	104	104
Aroclor-1260	25	Mean	325	328	331	336	339	341
		STD	32	33	34	35	36	36
		N	104	104	104	104	104	104
	50	Mean	322	325	328	333	335	337
		STD	29	31	31	33	33	34
		N	102	102	102	102	102	102
	100	Mean	317	321	322	327	330	331
		STD	32	32	33	35	35	35
		N	104	104	104	104	104	104

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			162	169	176	183	190	197
Control	0	Mean	342	343	341	348	352	350
		STD	36	37	36	38	38	39
		N	123	123	123	123	117	117
Aroclor-1016	50	Mean	346	349	351	350	355	357
		STD	35	36	36	38	38	40
		N	104	104	104	104	98	98
	100	Mean	[illegible]	354	**357[a]**	356	361	364
		STD	[illegible]	41	42	41	41	42
		N	104	104	104	104	98	98
	200	Mean	[illegible]	341	343	343	350	351
		STD	[illegible]	36	36	36	39	40
		N	104	104	104	104	98	98
Aroclor-1242	50	Mean	347	347	351	355	357	361
		STD	38	39	41	42	42	43
		N	104	104	104	103	98	98
	100	Mean	**328[a]**	**328[a]**	331	**333[a]**	**334[b]**	**335[a]**
		STD	32	32	32	33	33	33
		N	104	104	104	104	98	98
Aroclor-1254	25	Mean	**329[a]**	332	335	**333[a]**	**337[a]**	340
		STD	36	37	38	38	38	39
		N	104	104	104	104	97	97
	50	Mean	**315[b]**	**317[b]**	**320[b]**	**320[b]**	**322[b]**	**324[b]**
		STD	33	34	35	35	35	35
		N	104	104	104	104	98	98
	100	Mean	**295[b]**	**297[b]**	**300[b]**	**299[b]**	**300[b]**	**303[b]**
		STD	29	29	29	29	30	31
		N	104	104	104	104	98	98
Aroclor-1260	25	Mean	345	347	352	353	356	360
		STD	37	38	39	39	40	41
		N	104	104	104	104	98	98
	50	Mean	340	344	348	350	351	355
		STD	35	35	36	36	37	39
		N	102	101	101	101	95	95
	100	Mean	333	336	340	341	343	346
		STD	37	38	40	41	40	40
		N	104	104	104	104	98	98

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			204	211	218	225	232	239
Control	0	Mean	356	360	365	369	369	372
		STD	40	42	44	45	46	47
		N	117	117	117	117	117	116
Aroclor-1016	50	Mean	362	364	366	367	369	373
		STD	41	41	42	42	43	45
		N	98	98	98	98	98	98
	100	Mean	370	373	375	377	378	385
		STD	43	44	46	46	47	49
		N	98	98	98	98	98	98
	200	Mean	356	359	362	361	363	370
		STD	41	41	42	42	43	45
		N	98	98	97	97	97	97
Aroclor-1242	50	Mean	367	370	371	377	378	383
		STD	45	46	47	49	49	50
		N	98	98	98	98	98	98
	100	Mean	**341[a]**	**342[a]**	**343[b]**	**346[b]**	**347[b]**	**353[a]**
		STD	34	36	34	34	35	37
		N	98	98	97	97	97	96
Aroclor-1254	25	Mean	342	346	349	**351[a]**	353	354
		STD	39	41	43	44	45	45
		N	97	97	97	97	97	97
	50	Mean	**325[b]**	**328[b]**	**330[b]**	**332[b]**	**334[b]**	**334[b]**
		STD	35	36	36	37	38	38
		N	98	98	98	98	98	98
	100	Mean	**304[b]**	**306[b]**	**307[b]**	**309[b]**	**310[b]**	**311[b]**
		STD	31	32	32	31	32	32
		N	98	98	98	98	98	98
Aroclor-1260	25	Mean	362	366	368	370	374	371
		STD	42	44	46	46	48	48
		N	98	98	98	98	98	98
	50	Mean	359	361	364	366	367	368
		STD	39	40	42	43	44	43
		N	95	95	94	94	94	94
	100	Mean	349	350	352	354	356	358
		STD	40	41	43	43	44	45
		N	98	98	98	98	98	98

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			246	253	260	267	274	281
Control	0	Mean	378	376	376	383	385	392
		STD	48	48	50	50	51	52
		N	116	116	116	116	116	110
Aroclor-1016	50	Mean	378	379	383	386	387	394
		STD	46	46	48	49	50	51
		N	98	98	98	98	98	92
	100	Mean	388	391	394	395	398	405
		STD	50	51	51	53	54	55
		N	98	98	9[a]	98	98	92
	200	Mean	372	372	378	377	381	387
		STD	46	46	48	48	50	53
		N	97	96	96	96	96	90
Aroclor-1242	50	Mean	380	382	382	387	387	394
		STD	52	51	52	53	54	55
		N	98	98	98	98	98	92
	100	Mean	**351[b]**	**352[b]**	**354[b]**	**357[b]**	**357[b]**	**364[b]**
		STD	36	37	38	40	40	41
		N	96	96	96	96	96	90
Aroclor-1254	25	Mean	**355[b]**	359	362	**363[a]**	**365[a]**	**367[b]**
		STD	47	47	48	49	50	50
		N	97	97	97	97	97	91
	50	Mean	**335[b]**	**338[b]**	**339[b]**	**341[b]**	**343[b]**	**347[b]**
		STD	39	40	41	41	43	42
		N	98	98	98	98	98	92
	100	Mean	**312[b]**	**312[b]**	**313[b]**	**316[b]**	**317[b]**	**319[b]**
		STD	32	33	33	34	34	34
		N	97	97	97	97	97	91
Aroclor-1260	25	Mean	374	382	383	385	387	390
		STD	49	51	52	53	54	52
		N	98	97	97	97	97	91
	50	Mean	370	376	379	379	381	384
		STD	45	47	47	49	50	52
		N	94	94	94	94	94	88
	100	Mean	360	363	367	369	369	371
		STD	45	47	48	49	49	48
		N	98	98	98	98	98	92

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			288	295	302	309	316	323
Control	0	Mean	389	398	405	405	408	408
		STD	52	53	55	56	56	58
		N	109	109	109	109	109	109
Aroclor-1016	50	Mean	394	399	404	407	411	411
		STD	51	54	53	56	55	57
		N	92	92	92	92	92	92
	100	Mean	408	411	415	418	421	421
		STD	57	58	57	59	59	60
		N	92	92	92	92	91	91
	200	Mean	388	392	397	400	402	402
		STD	52	53	54	56	57	57
		N	90	90	90	90	90	90
Aroclor-1242	50	Mean	393	393	398	408	406	411
		STD	56	57	60	62	61	63
		N	92	92	91	91	91	90
	100	Mean	**363[b]**	**364[b]**	**367[b]**	**374[b]**	**371[b]**	**377[b]**
		STD	42	44	45	47	48	47
		N	90	90	90	90	90	89
Aroclor-1254	25	Mean	369	**372[b]**	**372[b]**	**377[b]**	**378[b]**	**381[b]**
		STD	51	54	52	53	55	57
		N	91	91	90	90	90	90
	50	Mean	**349[b]**	**352[b]**	**354[b]**	**356[b]**	**359[b]**	**362[b]**
		STD	43	44	45	46	47	46
		N	92	92	92	92	92	92
	100	Mean	**322[b]**	**325[b]**	**325[b]**	**327[b]**	**328[b]**	**330[b]**
		STD	35	36	38	39	40	40
		N	91	91	91	91	91	91
Aroclor-1260	25	Mean	392	398	399	401	402	406
		STD	53	55	56	58	58	58
		N	91	91	91	91	91	91
	50	Mean	385	389	391	393	396	400
		STD	53	53	55	55	56	57
		N	88	88	88	88	88	88
	100	Mean	372	**377[a]**	**377[b]**	**381[a]**	**383[a]**	386
		STD	48	49	50	51	52	53
		N	92	92	92	92	92	92

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			330	337	344	351	358	365
Control	0	Mean	414	414	423	420	423	426
		STD	59	59	60	61	62	62
		N	109	108	108	108	108	108
Aroclor-1016	50	Mean	414	417	423	423	423	422
		STD	58	59	61	62	62	63
		N	92	92	92	92	92	92
	100	Mean	424	428	434	434	433	433
		STD	61	62	64	65	64	66
		N	91	91	91	91	90	90
	200	Mean	405	408	415	414	414	415
		STD	57	59	60	61	63	64
		N	90	90	90	90	90	90
Aroclor-1242	50	Mean	414	414	418	424	424	426
		STD	64	65	66	67	68	69
		N	90	90	90	90	90	90
	100	Mean	**379[b]**	**378[b]**	**380[b]**	**384[b]**	**385[b]**	**384[b]**
		STD	48	48	49	50	51	52
		N	89	89	89	89	89	89
Aroclor-1254	25	Mean	**383[b]**	**386[b]**	**385[b]**	**381[b]**	**388[b]**	**392[b]**
		STD	57	57	57	58	60	62
		N	90	90	90	89	88	88
	50	Mean	**365[b]**	**366[b]**	**367[b]**	**361[b]**	**367[b]**	**371[b]**
		STD	49	49	50	48	51	52
		N	92	92	92	91	91	91
	100	Mean	**330[b]**	**333[b]**	**334[b]**	**331[b]**	**334[b]**	**338[b]**
		STD	43	42	44	43	44	47
		N	91	90	90	90	90	89
Aroclor-1260	25	Mean	409	411	417	418	420	424
		STD	60	61	62	64	64	66
		N	91	91	91	91	91	91
	50	Mean	400	402	408	408	411	414
		STD	57	60	59	60	61	61
		N	88	88	88	88	88	86
	100	Mean	**389[a]**	**387[a]**	**393[b]**	**393[a]**	**396[a]**	**398[a]**
		STD	54	55	56	57	58	61
		N	92	92	92	92	92	92

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			372	379	386	393	400	407
Control	0	Mean	428	438	439	441	448	447
		STD	64	66	66	68	71	72
		N	101	101	98	98	98	98
Aroclor-1016	50	Mean	427	436	439	440	441	443
		STD	61	64	65	65	66	65
		N	56	56	56	56	56	56
	100	Mean	446	452	457	460	455	459
		STD	74	77	79	80	76	74
		N	53	53	53	53	52	52
	200	Mean	417	424	426	430	432	437
		STD	63	65	66	66	67	67
		N	56	56	56	56	56	56
Aroclor-1242	50	Mean	420	426	426	428	427	430
		STD	65	68	68	67	67	65
		N	55	55	55	55	55	55
	100	Mean	384[b]	391[b]	389[b]	390[b]	392[b]	394[b]
		STD	49	49	50	51	50	51
		N	53	53	52	52	52	52
Aroclor-1254	25	Mean	384[b]	391[b]	392[b]	394[b]	391[b]	390[b]
		STD	59	62	63	66	64	66
		N	54	54	54	53	53	53
	50	Mean	372[b]	377[b]	379[b]	382[b]	378[b]	374[b]
		STD	53	55	55	58	55	54
		N	55	55	55	55	55	55
	100	Mean	330[b]	332[b]	334[b]	336[b]	335[b]	333[b]
		STD	38	40	40	41	41	41
		N	55	55	55	55	54	54
Aroclor-1260	25	Mean	433	432	430	436	441	441
		STD	66	66	66	66	68	68
		N	56	55	55	55	55	55
	50	Mean	418	419	423	425	427	427
		STD	58	58	59	59	60	60
		N	53	53	53	53	53	53
	100	Mean	406	411	412	415	422	420
		STD	61	63	63	65	67	68
		N	56	56	56	56	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			414	421	428	435	442	449
Control	0	Mean	444	447	456	460	465	466
		STD	71	68	69	67	64	67
		N	97	96	95	94	91	91
Aroclor-1016	50	Mean	450	445	450	458	455	458
		STD	65	64	66	68	67	65
		N	55	55	55	55	54	53
	100	Mean	462	458	461	468	473	475
		STD	74	77	78	84	82	88
		N	52	52	51	51	51	51
	200	Mean	440	438	441	446	448	450
		STD	67	71	72	75	76	78
		N	56	56	56	56	56	55
Aroclor-1242	50	Mean	439	440	440	441	446	445
		STD	67	68	69	70	71	71
		N	55	55	55	55	55	54
	100	Mean	**402[b]**	**401[b]**	**403[b]**	**397[b]**	**404[b]**	**401[b]**
		STD	51	54	57	58	59	59
		N	52	52	52	51	51	51
Aroclor-1254	25	Mean	**394[b]**	**403[b]**	**407[b]**	**410[b]**	**421[b]**	**420[b]**
		STD	67	71	71	71	75	76
		N	52	52	51	51	50	50
	50	Mean	**379[b]**	**387[b]**	**390[b]**	**395[b]**	**403[b]**	**403[b]**
		STD	56	60	60	62	63	64
		N	55	55	55	55	55	55
	100	Mean	**335[b]**	**339[b]**	**340[b]**	**344[b]**	**349[b]**	**349[b]**
		STD	39	42	41	42	43	43
		N	54	54	54	54	54	54
Aroclor-1260	25	Mean	444	445	449	457	460	457
		STD	68	69	70	71	74	75
		N	55	55	55	55	55	55
	50	Mean	428	433	434	444	445	442
		STD	61	60	63	62	64	62
		N	52	52	52	51	51	50
	100	Mean	423	428	427	433	**431[a]**	**431[a]**
		STD	67	69	68	70	72	72
		N	56	56	56	56	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			456	463	470	477	484	491
Control	0	Mean	470	469	467	471	476	472
		STD	70	74	73	75	77	79
		N	89	88	88	87	87	85
Aroclor-1016	50	Mean	459	456	463	471	478	474
		STD	68	69	69	71	74	74
		N	53	53	52	51	51	51
	100	Mean	477	477	482	486	493	493
		STD	88	91	93	96	101	99
		N	51	51	51	51	51	49
	200	Mean	450	450	456	460	466	460
		STD	79	81	81	82	85	87
		N	55	54	54	54	54	52
Aroclor-1242	50	Mean	454	453	451	465	466	465
		STD	74	75	78	76	81	79
		N	54	53	53	52	52	52
	100	Mean	**406[b]**	**406[b]**	**404[b]**	**414[b]**	**412[b]**	**414[b]**
		STD	62	60	62	64	66	69
		N	51	51	51	51	51	51
Aroclor-1254	25	Mean	**418[b]**	**426[a]**	**425[a]**	433	437	437
		STD	74	75	76	79	80	83
		N	50	50	49	49	48	48
	50	Mean	**404[b]**	**410[b]**	**408[b]**	**413[b]**	**416[b]**	**414[b]**
		STD	66	65	67	66	69	70
		N	55	55	55	55	55	55
	100	Mean	**350[b]**	**354[b]**	**350[b]**	**356[b]**	**358[b]**	**358[b]**
		STD	46	46	47	48	49	50
		N	54	54	53	53	53	52
Aroclor-1260	25	Mean	458	466	472	472	479	483
		STD	75	76	78	80	81	82
		N	55	54	54	54	54	54
	50	Mean	443	446	448	449	459	461
		STD	61	64	68	69	71	75
		N	50	50	50	49	49	49
	100	Mean	**429[b]**	438	439	437	442	446
		STD	72	73	74	76	79	81
		N	56	56	55	55	54	53

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			498	505	512	519	526	533
Control	0	Mean	466	471	471	470	470	464
		STD	80	85	88	91	91	97
		N	82	82	81	78	75	72
Aroclor-1016	50	Mean	482	482	479	481	476	477
		STD	79	79	82	84	90	97
		N	51	51	51	51	51	50
	100	Mean	**509[a]**	508	507	509	506	508
		STD	96	97	98	99	100	101
		N	48	48	48	48	48	48
	200	Mean	473	472	474	473	472	473
		STD	84	87	90	95	95	96
		N	51	51	51	51	51	51
Aroclor-1242	50	Mean	466	476	475	475	475	475
		STD	83	83	83	83	87	84
		N	52	51	50	50	50	50
	100	Mean	**416[b]**	**423[b]**	430	428	429	430
		STD	70	70	69	70	73	75
		N	51	50	48	48	48	48
Aroclor-1254	25	Mean	438	443	445	449	448	451
		STD	83	84	87	89	91	92
		N	48	48	48	48	48	48
	50	Mean	**412[b]**	**417[b]**	**418[b]**	**420[a]**	**423[a]**	421
		STD	72	74	72	73	72	74
		N	55	54	53	53	53	52
	100	Mean	**359[b]**	**361[b]**	**363[b]**	**362[b]**	**362[b]**	**362[b]**
		STD	49	51	52	54	56	60
		N	52	52	52	52	52	52
Aroclor-1260	25	Mean	481	486	484	482	488	485
		STD	84	86	90	93	93	95
		N	53	53	53	53	52	51
	50	Mean	465	475	471	476	479	477
		STD	73	71	72	73	75	76
		N	48	47	47	47	47	47
	100	Mean	447	451	450	461	464	462
		STD	78	83	89	81	85	87
		N	51	51	51	49	49	49

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			540	547	554	561	568	575
Control	0	Mean	476	478	471	477	477	479
		STD	89	91	86	88	88	89
		N	69	67	64	60	60	59
Aroclor-1016	50	Mean	485	485	497	497	500	504
		STD	89	92	97	96	99	102
		N	48	48	42	41	40	40
	100	Mean	505	501	501	505	503	506
		STD	101	101	106	103	105	106
		N	48	48	42	40	39	38
	200	Mean	473	469	466	465	458	458
		STD	98	99	93	94	87	90
		N	51	51	45	44	42	41
Aroclor-1242	50	Mean	474	475	467	465	465	464
		STD	86	91	97	96	99	101
		N	49	49	44	44	44	43
	100	Mean	**425[a]**	**431[a]**	434	433	435	433
		STD	76	80	73	72	75	76
		N	48	48	42	42	42	41
Aroclor-1254	25	Mean	449	445	442	441	438	437
		STD	92	94	98	101	102	103
		N	48	48	44	44	44	44
	50	Mean	**419[b]**	**422[b]**	**415[b]**	**416[b]**	**411[b]**	**408[b]**
		STD	75	75	75	75	77	76
		N	51	51	45	44	42	42
	100	Mean	**365[b]**	**371[b]**	**367[b]**	**363[b]**	**361[b]**	**359[b]**
		STD	59	55	55	53	53	55
		N	51	50	45	44	44	43
Aroclor-1260	25	Mean	485	491	485	479	487	491
		STD	101	106	109	113	117	116
		N	50	50	45	45	43	42
	50	Mean	476	482	480	482	486	484
		STD	74	71	68	68	72	74
		N	47	46	40	39	39	39
	100	Mean	451	459	454	453	460	464
		STD	79	82	88	88	89	87
		N	46	46	39	39	39	37

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			582	589	596	603	610	617
Control	0	Mean	465	466	468	478	474	475
		STD	84	84	85	74	76	82
		N	59	57	57	53	53	53
Aroclor-1016	50	Mean	505	504	504	492	495	496
		STD	103	107	107	108	110	111
		N	40	40	40	38	38	36
	100	Mean	505	504	505	502	512	504
		STD	108	108	114	119	117	117
		N	38	38	37	37	36	34
	200	Mean	454	463	460	461	466	464
		STD	94	92	90	92	89	92
		N	41	39	39	39	38	38
Aroclor-1242	50	Mean	466	458	458	462	460	460
		STD	100	102	98	96	101	105
		N	42	42	41	39	39	39
	100	Mean	436	435	435	436	438	440
		STD	78	76	80	84	88	86
		N	41	41	41	41	41	40
Aroclor-1254	25	Mean	435	438	435	439	435	438
		STD	106	105	105	108	110	107
		N	44	44	44	42	42	42
	50	Mean	**406[b]**	**406[b]**	**403[b]**	**398[b]**	**390[b]**	**395[b]**
		STD	75	77	79	80	79	78
		N	42	42	42	40	40	36
	100	Mean	**359[b]**	**358[b]**	**360[b]**	**358[b]**	**352[b]**	**350[b]**
		STD	54	57	49	51	50	49
		N	42	42	41	40	38	37
Aroclor-1260	25	Mean	497	500	499	509	520	524
		STD	125	125	120	118	126	117
		N	40	39	38	36	35	33
	50	Mean	488	484	476	474	472	476
		STD	79	83	89	87	85	82
		N	39	38	37	36	34	31
	100	Mean	471	468	459	460	470	466
		STD	86	92	97	99	96	99
		N	37	37	37	37	36	36

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			624	631	638	645	652	659
Control	0	Mean	472	468	481	472	470	472
		STD	89	95	93	98	94	91
		N	53	51	48	48	47	47
Aroclor-1016	50	Mean	499	502	502	497	495	495
		STD	114	111	115	117	120	122
		N	35	33	33	33	33	32
	100	Mean	504	497	496	491	486	491
		STD	119	121	121	121	122	126
		N	33	30	30	30	30	29
	200	Mean	467	460	459	457	459	457
		STD	94	93	97	98	100	100
		N	37	37	37	37	36	35
Aroclor-1242	50	Mean	463	468	469	466	469	468
		STD	101	101	105	106	115	112
		N	37	36	35	35	35	31
	100	Mean	441	441	441	444	445	432
		STD	84	87	89	80	85	86
		N	40	40	40	38	38	37
Aroclor-1254	25	Mean	438	436	440	436	433	433
		STD	110	108	105	102	97	94
		N	42	42	41	41	41	40
	50	Mean	**394[b]**	**390[b]**	**385[b]**	**390[b]**	**388[b]**	**391[b]**
		STD	83	83	84	78	79	79
		N	35	35	33	30	30	29
	100	Mean	**349[b]**	**348[b]**	**350[b]**	**352[b]**	**352[b]**	**346[b]**
		STD	51	53	54	47	46	48
		N	37	34	31	29	29	29
Aroclor-1260	25	Mean	522	510	512	512	506	511
		STD	117	119	121	127	133	126
		N	33	32	30	29	28	27
	50	Mean	469	467	477	476	469	468
		STD	85	85	82	87	92	91
		N	31	29	28	28	28	28
	100	Mean	456	456	460	458	452	448
		STD	102	102	101	105	105	106
		N	36	35	33	32	31	31

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			666	673	680	687	694	701
Control	0	Mean	467	467	463	466	467	465
		STD	95	96	94	93	93	99
		N	45	43	41	40	39	36
Aroclor-1016	50	Mean	490	498	497	503	518	513
		STD	125	125	124	118	117	121
		N	32	30	29	28	26	25
	100	Mean	488	483	478	498	496	489
		STD	129	129	128	110	109	117
		N	29	29	29	26	26	25
	200	Mean	450	456	447	450	456	456
		STD	105	109	117	119	116	119
		N	34	34	33	32	31	30
Aroclor-1242	50	Mean	480	474	475	480	477	479
		STD	110	113	116	118	122	113
		N	30	30	29	26	26	25
	100	Mean	421	423	435	427	429	419
		STD	89	90	76	81	81	83
		N	34	32	30	29	28	28
Aroclor-1254	25	Mean	435	437	432	429	422	420
		STD	96	89	92	93	97	99
		N	39	38	37	36	36	35
	50	Mean	**392[a]**	**387[a]**	395	394	**385[a]**	**376[a]**
		STD	86	94	88	85	89	100
		N	29	27	25	23	23	21
	100	Mean	**345[b]**	**347[b]**	**344[b]**	**343[b]**	**340[b]**	**348[b]**
		STD	50	51	59	59	62	55
		N	28	28	28	26	26	24
Aroclor-1260	25	Mean	513	508	507	503	502	496
		STD	124	126	124	130	130	126
		N	25	25	25	25	25	25
	50	Mean	468	471	464	467	475	470
		STD	90	89	96	102	91	96
		N	28	28	28	27	26	26
	100	Mean	465	459	452	455	455	454
		STD	101	103	108	102	102	100
		N	29	28	28	27	27	27

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 18. Group Mean Body Weights (g) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study		
			708	715	722
Control	0	Mean	472	477	468
		STD	91	93	94
		N	34	32	32
Aroclor-1016	50	Mean	502	514	510
		STD	132	130	135
		N	25	23	21
	100	Mean	498	494	492
		STD	96	102	109
		N	23	23	21
	200	Mean	469	482	481
		STD	113	108	96
		N	28	27	25
Aroclor-1242	50	Mean	473	467	465
		STD	117	122	135
		N	25	25	23
	100	Mean	422	422	419
		STD	77	79	86
		N	27	27	27
Aroclor-1254	25	Mean	414	414	400[a]
		STD	97	95	89
		N	35	34	33
	50	Mean	390[a]	400	396
		STD	92	89	92
		N	18	17	17
	100	Mean	340[b]	347[b]	336[b]
		STD	54	51	51
		N	24	22	21
Aroclor-1260	25	Mean	485	501	498
		STD	134	116	116
		N	24	22	21
	50	Mean	476	468	486
		STD	94	102	88
		N	24	24	22
	100	Mean	451	448	437
		STD	93	90	98
		N	26	25	24

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 19. Group Mean Body Weights (g) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			365	372	379	386	393	400
Control[1]	0	Mean	426	428	438	439	441	448
		STD	62	64	66	66	68	71
		N	108	101	101	98	98	98
Aroclor-1016	50	Mean	435	437	439	436	439	444
		STD	66	67	70	71	69	67
		N	30	30	30	30	30	30
	100	Mean	433	436	441	438	441	445
		STD	59	58	62	64	63	63
		N	30	29	29	29	29	29
	200	Mean	421	422	428	427	431	436
		STD	65	64	63	63	66	64
		N	28	27	27	27	27	27
Aroclor-1242	50	Mean	427	432	431	431	435	435
		STD	74	76	75	79	77	78
		N	29	29	29	29	29	29
	100	Mean	**381[b]**	**383[b]**	**382[b]**	**383[b]**	**387[b]**	**390[b]**
		STD	57	58	56	57	57	54
		N	30	30	30	30	30	30
Aroclor-1254	25	Mean	**389[a]**	396	**398[a]**	**398[a]**	**397[a]**	**396[b]**
		STD	54	55	56	57	60	58
		N	28	28	28	28	28	28
	50	Mean	**368[b]**	**370[b]**	**376[b]**	**375[b]**	**376[b]**	**373[b]**
		STD	48	48	50	50	52	49
		N	30	30	30	30	30	30
	100	Mean	**351[b]**	**356[b]**	**361[b]**	**366[b]**	**357[b]**	**357[b]**
		STD	59	62	65	71	57	57
		N	29	29	29	29	28	28
Aroclor-1260	25	Mean	415	419	424	426	425	430
		STD	67	68	72	71	73	71
		N	29	29	29	29	29	29
	50	Mean	419	420	432	432	432	438
		STD	72	73	74	72	73	73
		N	28	28	28	28	28	28
	100	Mean	**380[b]**	**382[b]**	**393[a]**	**391[b]**	**392[b]**	**398[b]**
		STD	54	55	55	56	57	60
		N	30	30	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 19. Group Mean Body Weights (g) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			407	414	421	428	435	442
Control[1]	0	Mean	447	444	447	456	460	465
		STD	72	71	68	69	67	64
		N	98	97	96	95	94	91
Aroclor-1016	50	Mean	443	452	445	444	458	452
		STD	68	69	75	76	75	78
		N	30	30	30	30	30	30
	100	Mean	446	453	455	457	463	461
		STD	65	67	69	68	73	72
		N	29	29	29	29	29	29
	200	Mean	437	445	445	449	455	450
		STD	63	65	64	69	68	71
		N	27	26	26	26	26	26
Aroclor-1242	50	Mean	443	455	449	450	458	454
		STD	81	84	83	86	89	89
		N	29	29	29	29	29	29
	100	Mean	**392[b]**	**401[a]**	**402[a]**	**401[b]**	**402[b]**	**404[b]**
		STD	55	55	58	59	59	64
		N	30	30	30	30	30	30
Aroclor-1254	25	Mean	**397[b]**	**403[a]**	**405[a]**	**406[b]**	**417[a]**	**415[b]**
		STD	60	61	63	65	69	75
		N	28	28	28	28	28	28
	50	Mean	**373[b]**	**377[b]**	**384[b]**	**381[b]**	**386[b]**	**387[b]**
		STD	51	51	52	53	53	56
		N	30	30	30	30	30	30
	100	Mean	**356[b]**	**360[b]**	**367[b]**	**363[b]**	**371[b]**	**372[b]**
		STD	56	58	59	62	66	68
		N	28	28	28	28	27	27
Aroclor-1260	25	Mean	428	432	439	436	443	443
		STD	71	72	72	74	70	71
		N	29	29	29	29	29	29
	50	Mean	438	442	448	441	450	446
		STD	75	76	75	71	70	71
		N	28	28	28	28	28	28
	100	Mean	**399[b]**	**402[a]**	**405[a]**	**404[b]**	**414[a]**	**412[b]**
		STD	60	63	63	65	65	67
		N	29	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 19. Group Mean Body Weights (g) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			449	456	463	470	477	484
Control[1]	0	Mean	466	470	469	467	471	476
		STD	67	70	74	73	75	77
		N	91	89	88	88	87	87
Aroclor-1016	50	Mean	457	455	455	**417[a]**	434	448
		STD	74	77	77	74	69	71
		N	30	30	30	29	29	29
	100	Mean	464	471	469	441	452	468
		STD	60	65	69	60	68	69
		N	28	28	28	27	27	27
	200	Mean	446	443	443	448	439	439
		STD	71	75	78	89	95	97
		N	24	24	24	24	24	24
Aroclor-1242	50	Mean	442	448	446	470	460	464
		STD	88	92	96	91	92	93
		N	28	28	28	27	27	27
	100	Mean	**401[b]**	**401[b]**	**402[b]**	**407[b]**	**403[b]**	**412[b]**
		STD	66	68	71	73	76	73
		N	30	30	30	30	30	29
Aroclor-1254	25	Mean	424	430	431	441	434	439
		STD	68	72	71	74	76	78
		N	26	26	26	26	26	26
	50	Mean	**389[b]**	**389[b]**	**391[b]**	**398[b]**	**395[b]**	**404[b]**
		STD	56	60	65	66	65	62
		N	30	30	30	30	30	29
	100	Mean	**378[b]**	**388[b]**	**393[b]**	**407[b]**	**401[b]**	**408[b]**
		STD	64	62	64	63	65	68
		N	27	26	26	26	26	26
Aroclor-1260	25	Mean	443	446	454	470	462	469
		STD	69	68	70	73	71	70
		N	29	29	27	26	26	26
	50	Mean	442	453	453	467	458	466
		STD	74	69	67	67	69	70
		N	26	26	25	25	24	24
	100	Mean	**413[b]**	**418[b]**	**421[a]**	433	**422[a]**	**426[a]**
		STD	66	66	67	71	70	73
		N	29	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 19. Group Mean Body Weights (g) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			491	498	505	512	519	526
Control[1]	0	Mean	472	466	471	471	470	470
		STD	79	80	85	88	91	91
		N	85	82	82	81	78	75
Aroclor-1016	50	Mean	449	464	466	465	464	470
		STD	74	78	81	86	89	91
		N	29	28	28	28	28	28
	100	Mean	477	486	500	497	501	504
		STD	75	82	72	77	76	76
		N	27	27	26	26	26	26
	200	Mean	452	456	459	466	465	465
		STD	89	93	95	86	86	86
		N	22	22	22	21	21	20
Aroclor-1242	50	Mean	465	473	469	465	470	468
		STD	97	99	100	103	101	101
		N	27	27	27	27	26	26
	100	Mean	**413[b]**	**417[a]**	**422[a]**	421	426	431
		STD	76	80	82	86	88	81
		N	29	29	28	28	28	27
Aroclor-1254	25	Mean	444	457	456	453	461	465
		STD	79	82	84	88	82	82
		N	26	26	26	26	25	25
	50	Mean	**408[b]**	**415[a]**	**418[a]**	**417[a]**	**419[a]**	421
		STD	63	66	66	68	69	76
		N	29	29	29	29	29	29
	100	Mean	**411[b]**	**416[a]**	425	421	426	427
		STD	70	72	76	76	78	80
		N	26	26	25	25	25	25
Aroclor-1260	25	Mean	471	481	482	482	478	482
		STD	70	71	71	69	73	73
		N	26	26	26	26	26	26
	50	Mean	470	479	475	473	468	461
		STD	71	70	62	69	68	66
		N	24	24	24	24	23	23
	100	Mean	**424[a]**	433	431	427	425	425
		STD	76	79	79	84	80	84
		N	29	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 19. Group Mean Body Weights (g) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			533	540	547	554	561	568
Control[1]	0	Mean	464	476	478	471	477	477
		STD	97	89	91	86	88	88
		N	72	69	67	64	60	60
Aroclor-1016	50	Mean	469	465	469	471	486	487
		STD	93	99	102	105	102	98
		N	28	28	28	22	21	21
	100	Mean	513	511	516	507	506	507
		STD	75	73	74	85	75	78
		N	26	26	26	20	19	19
	200	Mean	466	465	470	465	464	472
		STD	81	85	83	97	98	91
		N	20	20	20	15	15	14
Aroclor-1242	50	Mean	473	465	465	445	446	443
		STD	110	108	112	80	83	87
		N	26	26	26	19	19	19
	100	Mean	441	436	438	436	443	443
		STD	83	88	86	72	74	77
		N	27	27	27	22	22	22
Aroclor-1254	25	Mean	475	470	471	481	478	485
		STD	84	85	93	99	97	92
		N	25	25	25	20	19	19
	50	Mean	427	429	437	437	432	442
		STD	80	73	74	72	73	67
		N	29	28	28	22	20	20
	100	Mean	444	437	445	427	420	420
		STD	81	82	83	81	74	73
		N	24	24	24	17	16	16
Aroclor-1260	25	Mean	493	491	494	470	486	493
		STD	75	79	82	82	65	64
		N	26	26	26	20	19	19
	50	Mean	476	465	469	461	464	486
		STD	71	76	78	80	86	61
		N	23	22	22	18	17	15
	100	Mean	427	429	434	421	**414[a]**	**414[a]**
		STD	86	89	88	81	80	84
		N	29	28	28	23	22	22

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 19. Group Mean Body Weights (g) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			575	582	589	596	603	610
Control[1]	0	Mean	479	465	466	468	478	474
		STD	89	84	84	85	74	76
		N	59	59	57	57	53	53
Aroclor-1016	50	Mean	483	495	481	481	487	478
		STD	107	97	117	113	101	113
		N	21	20	21	21	20	20
	100	Mean	498	503	497	491	499	495
		STD	78	78	81	81	73	79
		N	19	19	19	19	18	18
	200	Mean	466	462	463	458	476	470
		STD	95	98	104	109	97	97
		N	14	14	14	14	13	13
Aroclor-1242	50	Mean	443	449	455	450	451	464
		STD	84	87	90	93	96	89
		N	18	18	18	17	17	15
	100	Mean	441	450	455	449	451	450
		STD	77	74	77	80	79	77
		N	21	20	20	20	20	20
Aroclor-1254	25	Mean	486	481	481	480	482	479
		STD	95	87	89	91	93	92
		N	19	19	18	17	17	17
	50	Mean	438	439	443	435	443	435
		STD	69	66	66	67	70	74
		N	20	20	20	20	19	19
	100	Mean	420	423	431	433	436	434
		STD	81	85	91	80	81	80
		N	16	15	14	14	14	14
Aroclor-1260	25	Mean	495	498	501	499	495	495
		STD	65	69	70	70	64	65
		N	19	19	19	19	18	18
	50	Mean	484	474	471	474	485	500
		STD	65	81	89	82	81	56
		N	15	14	14	13	12	11
	100	Mean	425	427	428	423	425	433
		STD	78	77	82	83	80	74
		N	20	20	19	19	19	18

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 19. Group Mean Body Weights (g) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			617	624	631	638	645	652
Control[1]	0	Mean	475	472	468	481	472	470
		STD	82	89	95	93	98	94
		N	53	53	51	48	48	47
Aroclor-1016	50	Mean	479	479	478	475	469	462
		STD	95	92	99	111	114	123
		N	18	18	18	18	18	17
	100	Mean	510	514	515	523	518	515
		STD	76	79	83	86	86	90
		N	16	16	16	16	16	16
	200	Mean	476	475	477	485	480	478
		STD	101	100	108	106	105	110
		N	13	13	13	13	13	13
Aroclor-1242	50	Mean	464	472	470	473	471	456
		STD	93	93	97	99	102	101
		N	15	15	15	15	15	15
	100	Mean	451	454	456	463	464	457
		STD	82	81	90	89	90	92
		N	19	19	19	18	17	16
Aroclor-1254	25	Mean	480	481	482	488	485	476
		STD	94	94	99	103	104	105
		N	16	16	16	15	15	15
	50	Mean	436	437	438	453	456	456
		STD	80	85	91	85	93	90
		N	19	19	19	18	17	17
	100	Mean	440	444	444	449	444	443
		STD	77	78	72	74	73	78
		N	14	14	14	14	14	13
Aroclor-1260	25	Mean	504	511	510	520	515	511
		STD	70	73	73	74	73	73
		N	18	18	18	18	18	18
	50	Mean	501	506	504	508	492	486
		STD	50	50	48	46	43	48
		N	11	11	11	11	11	10
	100	Mean	441	442	443	451	449	446
		STD	79	78	77	78	77	81
		N	18	18	18	18	18	18

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 19. Group Mean Body Weights (g) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			659	666	673	680	687	694
Control[1]	0	Mean	472	467	467	463	466	467
		STD	91	95	96	94	93	93
		N	47	45	43	41	40	39
Aroclor-1016	50	Mean	470	466	455	471	477	490
		STD	127	128	117	104	105	99
		N	17	17	16	14	13	13
	100	Mean	530	525	532	526	513	516
		STD	96	100	104	110	111	126
		N	15	15	15	15	13	12
	200	Mean	478	473	472	464	472	514
		STD	114	118	127	142	134	119
		N	13	13	13	12	11	9
Aroclor-1242	50	Mean	464	455	468	459	455	479
		STD	102	106	112	113	114	95
		N	15	15	14	14	14	12
	100	Mean	466	458	470	476	477	470
		STD	92	94	100	98	101	96
		N	16	16	16	15	15	14
Aroclor-1254	25	Mean	477	477	486	486	477	488
		STD	106	109	111	111	111	93
		N	15	15	15	15	15	13
	50	Mean	460	459	466	465	453	454
		STD	94	97	86	84	79	78
		N	17	17	15	15	14	14
	100	Mean	447	448	460	457	453	461
		STD	77	80	82	83	81	84
		N	13	13	13	13	13	13
Aroclor-1260	25	Mean	517	519	527	525	525	531
		STD	73	78	82	77	81	85
		N	18	18	18	18	17	17
	50	Mean	488	492	497	488	478	472
		STD	53	56	60	64	73	93
		N	10	9	9	9	9	8
	100	Mean	449	446	443	442	443	466
		STD	83	84	88	93	96	84
		N	18	18	18	17	17	15

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 19. Group Mean Body Weights (g) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study			
			701	708	715	722
Control[1]	0	Mean	465	472	477	468
		STD	99	91	93	94
		N	36	34	32	32
Aroclor-1016	50	Mean	489	487	468	454
		STD	102	108	120	127
		N	13	13	12	12
	100	Mean	533	533	538	515
		STD	109	111	125	142
		N	11	11	11	11
	200	Mean	503	499	503	492
		STD	123	136	152	144
		N	9	9	9	9
Aroclor-1242	50	Mean	471	472	489	473
		STD	95	88	95	95
		N	12	12	11	11
	100	Mean	466	479	485	474
		STD	101	95	102	104
		N	13	12	12	12
Aroclor-1254	25	Mean	476	474	473	458
		STD	90	95	93	100
		N	12	12	12	12
	50	Mean	454	452	463	457
		STD	78	79	85	82
		N	14	14	14	14
	100	Mean	464	465	470	461
		STD	84	86	87	90
		N	13	13	13	13
Aroclor-1260	25	Mean	523	514	521	517
		STD	88	92	92	93
		N	15	15	15	14
	50	Mean	487	488	492	499
		STD	82	80	70	60
		N	7	7	7	6
	100	Mean	454	459	468	463
		STD	85	84	85	82
		N	14	14	13	13

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 20. Significant Body Weight Differences Between Aroclor Test Substances for Core/Interim and Stop Study Subgroup Male and Female Rats

Time Interval[1]	Concentration (ppm)	Test Substance	Core/Interim Subgroups				Stop Study Subgroups	
			Male Group Comparisons		Female Group Comparisons		Female Group Comparisons	
			$p<0.05$	$p<0.01$	$p<0.05$	$p<0.01$	$p<0.05$	$p<0.01$
Week 26	50	1016	A	A	A	A	A	A
		1242	A	A	A	A	A	A
		1254	B	A	B	B	B	B
		1260	A	A	A	A	A	A
	100	1016	A	A	A	A	A	A
		1242	A	A	B	B	AC	A
		1254	B	B	C	C	B	B
		1260	A	A	B	B	C	A
Week 52	50	1016	A	A	A	A	A	A
		1242	A	A	A	A	A	A
		1254	B	B	B	B	B	B
		1260	A	A	A	A	A	A
	100	1016	A	A	A	A	A	A
		1242	A	A	B	B	B	B
		1254	B	B	C	C	C	B
		1260	A	A	B	B	B	B

1. Smoothed body weights were calculated as the average of up to 9 weekly body weights centered at 26, 52, 78, and 100 weeks.

2. The footnote (2) indicates comparisons of the Stop Study subgroup (A and B) females with the Core/Interim subgroup females for which the average body weights of Core/Interim females were statistically less than those of Stop Study females.

The letter legends indicate comparisons between the four Aroclor test substances. If at least one letter is common to any pair of [both] compared Aroclor test substances (example: 1016A, 1242A), no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 20. Significant Body Weight Differences Between Aroclor Test Substances for Core/Interim and Stop Study Subgroup Male and Female Rats

Time Interval[1]	Concentration (ppm)	Test Substance	Core/Interim Subgroups				Stop Study Subgroups	
			Male Group Comparisons		Female Group Comparisons		Female Group Comparisons	
			$p<0.05$	$p<0.01$	$p<0.05$	$p<0.01$	$p<0.05$	$p<0.01$
Week 78	50	1016	A	A	A	A	A	A
		1242	A	A	A	A	A	A
		1254	B	B	B	B	A	A
		1260	A	AB	A	A	A	A
	100	1016	A	A	A	A	A	A
		1242	B	A	B	B	B	B
		1254	C	B	C	C	B[2]	B[2]
		1260	AB	A	B	AB	B	B
Week 100	50	1016	A	A	A	A	A	A
		1242	A	A	A	A	A	A
		1254	B	B	B	B	A[2]	A
		1260	A	AB	A	A	A	A
	100	1016	A	A	A	A	A	A
		1242	A	A	B	A	A	A
		1254	B	B	C	B	A[2]	A[2]
		1260	A	A	AB	A	A	A

1. Smoothed body weights were calculated as the average of up to 9 weekly body weights centered at 26, 52, 78, and 100 weeks.

2. The footnote (2) indicates comparisons of the Stop Study subgroup (A and B) females with the Core/Interim subgroup females for which the average body weights of Core/Interim females were statistically less than those of Stop Study females.

The letter legends indicate comparisons between the four Aroclor test substances. If at least one letter is common to any pair of [both] compared Aroclor test substances (example: 1016A, 1242A), no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			8	15	22	29	36	43
Control	0	Mean	7.4	6.0	5.3	4.4	3.5	3.2
		STD	1.4	0.9	0.9	1.1	1.0	1.2
		N	118	118	118	118	118	118
Aroclor-1016	50	Mean	7.8	6.5	5.1	4.1	3.6	3.9
		STD	1.7	1.6	1.1	1.2	1.5	2.1
		N	68	68	68	68	68	68
	100	Mean	7.9	6.2	5.0	**3.8[b]**	3.6	**3.8[b]**
		STD	1.0	1.1	1.0	1.1	1.4	1.0
		N	68	68	68	68	68	68
	200	Mean	7.9	6.4	5.3	4.2	3.5	3.5
		STD	1.3	1.1	0.9	0.9	1.3	1.2
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	8.0	5.7	5.3	4.5	3.5	3.1
		STD	1.1	1.0	1.0	1.0	0.9	0.9
		N	68	68	68	68	68	68
	100	Mean	7.7	6.3	5.1	4.4	3.3	2.9
		STD	1.2	1.0	1.4	1.4	1.9	1.4
		N	68	68	68	68	68	68
Aroclor-1254	25	Mean	7.9	**6.6[b]**	**4.6[b]**	4.4	3.3	3.4
		STD	1.0	1.1	1.0	0.9	0.9	1.2
		N	68	68	68	68	67	67
	50	Mean	**8.2[b]**	6.2	4.8	4.2	3.4	3.3
		STD	1.0	1.2	1.2	2.6	1.3	1.0
		N	68	68	68	68	68	68
	100	Mean	7.9	5.6	**4.2[b]**	4.2	**2.7[b]**	3.2
		STD	1.4	1.1	1.0	0.9	0.8	0.9
		N	68	68	68	68	68	68
Aroclor-1260	25	Mean	**8.1[b]**	5.9	5.4	4.5	3.4	3.3
		STD	0.9	0.9	1.2	1.1	1.3	2.0
		N	68	68	68	68	68	68
	50	Mean	8.0	6.4	5.3	4.3	**4.1[b]**	3.4
		STD	1.4	1.5	1.1	0.9	0.9	0.8
		N	68	68	68	68	68	68
	100	Mean	**8.4[b]**	6.3	5.2	4.5	**4.1[b]**	3.4
		STD	1.2	1.0	1.0	0.9	0.9	1.2
		N	68	68	68	68	68	68

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			50	57	64	71	78	85
Control	0	Mean	2.8	2.6	2.5	2.1	1.4	1.7
		STD	1.1	1.0	1.0	0.8	0.8	0.8
		N	118	118	118	118	118	117
Aroclor-1016	50	Mean	3.2	**3.5[b]**	**1.4[b]**	2.6	1.6	2.0
		STD	1.6	1.0	0.9	1.3	1.0	1.0
		N	68	68	68	68	68	68
	100	Mean	3.0	3.2	**1.4[b]**	**2.5[b]**	1.6	1.6
		STD	1.0	1.7	1.0	1.0	1.8	1.8
		N	68	68	68	68	68	68
	200	Mean	3.1	**3.1[b]**	**1.4[b]**	2.5	1.8	2.0
		STD	1.1	0.9	1.5	1.0	1.2	0.8
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	**3.8[b]**	3.0	2.2	**1.4[b]**	**2.3[b]**	1.8
		STD	0.9	0.7	0.6	1.5	0.7	0.8
		N	68	68	68	68	68	68
	100	Mean	**3.9[b]**	3.0	2.2	**1.6[b]**	**1.9[b]**	1.5
		STD	1.8	1.1	0.7	0.8	0.8	0.9
		N	68	68	68	68	68	68
Aroclor-1254	25	Mean	2.6	**3.7[b]**	**2.0[b]**	**1.6[b]**	**2.0[b]**	1.4
		STD	0.9	1.0	0.9	0.8	1.2	1.0
		N	67	67	67	67	67	67
	50	Mean	**2.1[b]**	3.2	2.1	1.8	**2.1[b]**	**0.9[b]**
		STD	0.9	1.6	0.9	0.8	0.9	1.4
		N	68	68	68	68	68	68
	100	Mean	**1.7[b]**	2.9	**1.8[b]**	**0.8[b]**	1.6	**0.6[b]**
		STD	1.0	1.3	0.8	1.6	1.0	1.1
		N	68	68	67	67	67	67
Aroclor-1260	25	Mean	2.4	3.1	2.6	2.0	1.8	1.5
		STD	1.7	1.3	1.1	0.9	1.3	1.1
		N	68	68	68	68	68	68
	50	Mean	2.7	3.0	2.4	2.1	**2.0[b]**	1.7
		STD	1.2	0.9	0.7	1.1	0.9	1.2
		N	68	68	68	68	68	68
	100	Mean	3.0	3.0	2.2	**1.4[b]**	**2.0[b]**	**1.1[b]**
		STD	1.2	1.1	1.3	1.3	1.2	1.2
		N	68	68	68	68	68	68

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			92	99	106	114	120	127
Control	0	Mean	1.3	1.3	1.1	1.1	1.3	1.2
		STD	0.8	0.8	1.0	1.3	1.3	0.9
		N	117	117	117	117	117	117
Aroclor-1016	50	Mean	**1.9[b]**	1.2	1.1	1.3	1.4	1.1
		STD	1.0	0.9	1.1	1.1	1.4	0.9
		N	68	67	67	67	67	67
	100	Mean	1.8	1.1	1.3	1.2	1.5	1.1
		STD	1.2	1.3	1.2	1.5	1.2	1.1
		N	68	68	68	68	68	68
	200	Mean	**2.0[b]**	1.1	0.9	**1.7[b]**	0.9	0.8
		STD	0.9	0.9	1.1	1.0	1.4	1.1
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	**1.8[b]**	1.4	1.3	1.3	0.9	1.0
		STD	0.7	1.0	0.8	0.7	1.0	1.0
		N	68	68	68	68	68	68
	100	Mean	1.6	1.5	1.0	1.1	**0.7[b]**	**0.5[b]**
		STD	0.8	0.8	0.8	0.8	0.9	1.3
		N	68	68	68	68	68	67
Aroclor-1254	25	Mean	**1.8[b]**	1.4	1.4	0.7	1.5	1.4
		STD	0.9	0.7	1.1	0.9	1.2	0.9
		N	67	67	67	67	67	67
	50	Mean	**2.0[b]**	1.1	0.8	1.0	1.1	1.2
		STD	0.8	1.0	0.9	0.8	1.1	1.0
		N	68	68	68	68	68	68
	100	Mean	1.3	**0.7[b]**	0.8	**0.4[b]**	1.0	0.9
		STD	1.8	0.9	0.8	0.9	1.0	0.9
		N	67	66	66	66	66	66
Aroclor-1260	25	Mean	1.2	1.1	1.5	1.0	1.8	1.1
		STD	1.6	1.3	1.4	1.1	2.0	1.0
		N	68	68	68	68	68	68
	50	Mean	1.6	1.2	1.4	1.1	2.1	**0.7[b]**
		STD	1.2	0.8	0.7	1.1	1.9	0.9
		N	68	68	68	68	68	68
	100	Mean	1.8	0.9	**1.8[b]**	0.9	**2.1[b]**	0.8
		STD	1.4	1.0	1.1	1.0	1.4	0.9
		N	68	68	68	68	68	68

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			134	141	149	155	162	169
Control	0	Mean	1.5	0.5	0.2	1.9	0.8	0.5
		STD	0.9	0.9	1.1	1.3	1.0	0.9
		N	117	117	117	117	117	117
Aroclor-1016	50	Mean	1.1	**1.6[b]**	0.6	2.2	0.6	0.9
		STD	1.0	1.1	1.0	1.4	0.9	1.1
		N	67	67	67	67	67	67
	100	Mean	1.0	**1.1[b]**	0.2	2.5	0.7	0.9
		STD	1.2	1.0	0.8	1.4	0.9	0.9
		N	68	68	68	68	68	68
	200	Mean	1.4	**1.1[b]**	0.5	2.3	**0.2[b]**	**1.2[b]**
		STD	0.9	1.0	1.0	1.0	1.0	0.9
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	1.4	**1.0[b]**	0.6	1.7	0.9	1.0
		STD	1.0	1.0	0.8	0.9	1.2	1.0
		N	68	68	68	68	68	68
	100	Mean	1.8	0.8	0.5	1.6	0.7	0.6
		STD	0.8	0.7	0.7	0.9	1.0	1.8
		N	67	67	67	67	67	67
Aroclor-1254	25	Mean	**0.7[b]**	**1.5[b]**	-0.2	**2.7[b]**	**-0.1[b]**	**1.7[b]**
		STD	0.8	0.9	1.2	1.5	1.0	1.0
		N	67	67	67	67	67	67
	50	Mean	**0.6[b]**	**1.4[b]**	-0.1	2.2	**-0.4[b]**	**1.4[b]**
		STD	0.8	0.8	0.9	1.3	1.0	1.0
		N	68	68	68	68	68	68
	100	Mean	**0.3[b]**	**1.0[b]**	0.2	1.5	**-0.1[b]**	0.8
		STD	0.8	0.8	1.1	1.3	1.2	1.1
		N	66	66	66	66	66	66
Aroclor-1260	25	Mean	**1.0[b]**	0.9	**1.0[b]**	1.9	0.8	0.4
		STD	1.0	0.9	1.0	1.2	1.2	1.1
		N	68	68	68	68	68	68
	50	Mean	**0.7[b]**	0.7	0.7	1.8	0.7	0.6
		STD	0.7	0.8	0.8	1.3	0.7	0.8
		N	68	68	68	68	68	68
	100	Mean	**0.9[b]**	0.5	**1.2[b]**	1.8	0.5	0.7
		STD	1.0	0.7	0.9	1.0	0.8	0.8
		N	68	68	68	68	68	68

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			176	183	190	197	204	211
Control	0	Mean	-0.4	0.6	1.0	0.7	0.2	1.7
		STD	1.2	1.6	1.2	1.1	1.0	0.9
		N	117	117	112	112	112	112
Aroclor-1016	50	Mean	**0.2**[b]	0.6	1.3	0.8	**1.2**[b]	1.3
		STD	1.2	1.6	1.2	0.9	1.0	1.1
		N	67	67	61	61	61	61
	100	Mean	**0.4**[b]	0.4	0.9	0.6	**1.1**[b]	1.4
		STD	1.3	1.8	2.3	1.0	1.0	0.9
		N	68	68	62	61	61	61
	200	Mean	**0.6**[b]	0.0	0.6	1.0	**1.4**[b]	**1.2**[b]
		STD	0.8	1.4	1.6	1.0	0.9	0.9
		N	68	68	62	61	61	61
Aroclor-1242	50	Mean	**0.9**[b]	0.2	1.1	**0.1**[b]	0.6	2.2
		STD	1.1	0.9	1.0	1.0	0.9	0.8
		N	68	68	62	62	62	62
	100	Mean	**1.1**[b]	0.3	1.3	0.2	0.2	1.8
		STD	0.9	1.0	1.0	0.8	1.1	1.0
		N	66	66	60	60	60	60
Aroclor-1254	25	Mean	**0.6**[b]	0.7	**0.3**[b]	1.0	0.4	**1.0**[b]
		STD	0.9	0.8	1.1	0.9	1.0	1.0
		N	66	66	61	61	61	61
	50	Mean	**0.4**[b]	0.7	**0.1**[b]	1.1	**0.7**[b]	**0.9**[b]
		STD	0.8	0.9	1.0	0.8	0.8	0.8
		N	68	68	62	62	62	62
	100	Mean	**0.5**[b]	0.3	**-0.1**[b]	0.9	0.5	**1.0**[b]
		STD	0.9	1.2	1.2	0.7	0.8	0.9
		N	65	65	59	59	59	59
Aroclor-1260	25	Mean	**0.8**[b]	1.1	**0.3**[b]	0.6	**0.9**[b]	**1.0**[b]
		STD	0.9	0.9	1.1	1.7	1.2	1.3
		N	68	68	62	62	62	62
	50	Mean	**1.1**[b]	1.1	**-0.1**[b]	1.1	**1.1**[b]	1.3
		STD	0.7	0.8	1.2	0.9	0.8	0.9
		N	68	68	62	62	62	61
	100	Mean	**1.0**[b]	0.9	**0.0**[b]	1.0	0.7	1.3
		STD	0.7	1.0	1.7	1.1	1.5	1.1
		N	68	68	62	62	62	62

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			218	225	232	239	246	253
Control	0	Mean	0.3	1.2	0.7	0.7	0.9	1.4
		STD	0.9	1.1	1.3	0.9	0.7	1.0
		N	112	112	112	112	112	112
Aroclor-1016	50	Mean	0.0	**-0.4[b]**	1.0	0.7	**0.4[b]**	**0.1[b]**
		STD	1.1	2.4	0.9	1.0	0.9	1.1
		N	61	61	60	60	59	59
	100	Mean	0.1	**0.0[b]**	0.9	0.7	**0.0[b]**	**0.5[b]**
		STD	1.1	1.0	0.8	0.7	0.9	0.8
		N	61	61	61	61	61	61
	200	Mean	0.3	**0.0[b]**	1.1	0.5	**0.1[b]**	**0.5[b]**
		STD	0.9	1.0	0.9	1.5	0.8	0.9
		N	61	61	61	61	60	60
Aroclor-1242	50	Mean	0.3	0.7	0.8	**0.0[b]**	0.6	1.4
		STD	0.8	0.8	0.8	1.1	0.9	1.4
		N	62	62	62	62	62	62
	100	Mean	0.0	**0.3[b]**	0.9	0.5	**0.4[b]**	1.4
		STD	1.1	1.1	0.9	0.8	0.8	0.9
		N	59	59	59	59	59	59
Aroclor-1254	25	Mean	0.4	1.3	0.2	0.6	0.5	**0.2[b]**
		STD	0.9	1.0	0.9	1.7	1.1	1.2
		N	61	61	61	61	61	61
	50	Mean	0.2	0.8	**0.0[b]**	1.1	**-0.1[b]**	**0.4[b]**
		STD	0.9	1.1	0.8	1.0	1.1	0.8
		N	62	62	62	62	62	62
	100	Mean	**-0.2[b]**	0.8	**-0.2[b]**	0.4	**0.1[b]**	**0.4[b]**
		STD	0.8	1.0	0.9	1.0	1.0	1.0
		N	59	59	59	59	59	59
Aroclor-1260	25	Mean	**0.9[b]**	**0.2[b]**	1.1	0.2	**0.1[b]**	**0.3[b]**
		STD	0.9	1.1	1.0	1.3	1.2	1.5
		N	62	62	62	62	62	62
	50	Mean	0.6	**0.4[b]**	0.9	0.6	**-0.4[b]**	**0.4[b]**
		STD	0.9	0.8	0.9	0.9	0.8	1.0
		N	61	61	61	61	61	61
	100	Mean	0.1	**0.2[b]**	1.2	0.5	**-0.1[b]**	**0.6[b]**
		STD	1.2	0.8	0.9	0.9	1.3	1.1
		N	62	62	62	62	62	62

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			260	267	274	281	288	295
Control	0	Mean	0.1	-0.2	1.4	0.6	0.2	-0.3
		STD	1.3	1.2	1.2	1.5	1.1	1.4
		N	112	112	112	112	112	112
Aroclor-1016	50	Mean	**1.0[b]**	**0.8[b]**	**0.3[b]**	0.3	-0.2	**1.7[b]**
		STD	0.9	0.9	1.0	0.8	0.9	1.1
		N	59	59	59	59	59	59
	100	Mean	0.7	**0.9[b]**	**0.3[b]**	0.3	0.7	**1.1[b]**
		STD	0.9	0.8	0.9	1.2	1.1	1.1
		N	61	61	61	61	61	61
	200	Mean	**0.8[b]**	**0.4[b]**	**0.7[b]**	0.2	0.7	**0.7[b]**
		STD	0.9	0.7	1.1	1.0	1.3	0.8
		N	60	60	60	60	60	60
Aroclor-1242	50	Mean	0.0	-0.6	1.6	**0.0[b]**	0.6	**0.4[b]**
		STD	0.8	1.3	0.9	0.8	1.1	1.0
		N	62	62	62	62	62	62
	100	Mean	0.4	-0.2	1.2	0.6	0.6	0.3
		STD	1.0	1.5	1.6	1.1	1.1	1.7
		N	59	59	59	59	59	59
Aroclor-1254	25	Mean	**1.1[b]**	0.2	**0.2[b]**	**1.3[b]**	0.0	**1.4[b]**
		STD	0.8	1.1	0.9	0.9	1.0	1.0
		N	61	61	61	61	61	61
	50	Mean	**0.8[b]**	**0.4[b]**	**0.3[b]**	0.9	-0.1	**0.8[b]**
		STD	1.0	1.1	1.0	0.9	1.0	1.4
		N	62	62	62	62	62	62
	100	Mean	0.6	**0.6[b]**	**0.1[b]**	1.0	-0.3	**1.1[b]**
		STD	0.9	0.8	0.9	1.2	0.9	0.8
		N	59	59	59	59	59	59
Aroclor-1260	25	Mean	**1.5[b]**	0.0	0.9	**-0.6[b]**	**1.5[b]**	0.2
		STD	1.2	1.0	1.0	1.3	1.2	1.5
		N	62	62	62	62	62	62
	50	Mean	**1.8[b]**	0.1	1.0	**-0.6[b]**	**1.6[b]**	0.2
		STD	0.9	1.0	0.9	1.3	0.9	1.0
		N	61	60	60	61	61	61
	100	Mean	**1.5[b]**	0.2	**0.1[b]**	0.2	**1.1[b]**	-0.4
		STD	1.1	1.1	1.3	1.1	1.4	1.5
		N	61	61	61	61	61	61

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			302	309	316	323	330	337
Control	0	Mean	1.3	0.8	0.0	0.7	1.0	0.3
		STD	1.4	1.7	2.4	1.2	0.9	1.1
		N	112	112	111	110	110	110
Aroclor-1016	50	Mean	**0.6**[b]	0.4	**1.1**[b]	**-0.2**[b]	**1.8**[b]	-0.3
		STD	0.9	1.1	1.0	1.1	1.0	1.1
		N	59	59	59	59	59	59
	100	Mean	**0.4**[b]	0.4	0.8	0.3	1.1	**-0.7**[b]
		STD	1.1	1.2	1.2	1.1	1.0	1.2
		N	61	61	61	61	61	61
	200	Mean	0.8	0.6	0.8	0.3	1.3	-0.2
		STD	1.0	1.1	1.0	0.8	1.0	1.3
		N	60	60	60	60	60	60
Aroclor-1242	50	Mean	**0.3**[b]	0.7	0.8	0.6	1.0	0.1
		STD	1.3	1.1	0.9	1.0	0.9	1.0
		N	62	62	62	62	62	62
	100	Mean	**0.1**[b]	0.2	**1.1**[b]	0.7	0.7	0.0
		STD	1.3	1.3	1.0	1.2	1.1	0.8
		N	59	58	58	57	57	57
Aroclor-1254	25	Mean	**-0.1**[b]	0.0	0.8	1.1	**0.4**[b]	-0.2
		STD	1.2	2.0	1.1	0.9	1.1	1.2
		N	61	61	60	60	60	60
	50	Mean	**-0.4**[b]	0.7	0.7	0.6	**0.4**[b]	-0.2
		STD	1.5	0.8	0.8	1.0	0.9	0.9
		N	62	62	62	61	61	61
	100	Mean	**-0.2**[b]	0.4	0.5	0.8	0.6	-0.2
		STD	1.1	0.9	1.3	1.9	0.7	0.9
		N	59	59	59	59	58	58
Aroclor-1260	25	Mean	0.7	0.3	**1.2**[b]	**-0.2**[b]	**0.4**[b]	**0.9**[b]
		STD	1.1	1.4	1.3	1.3	1.2	1.3
		N	62	62	61	61	62	62
	50	Mean	**0.3**[b]	0.6	**1.3**[b]	**-0.4**[b]	0.8	0.2
		STD	1.0	1.0	1.0	1.2	1.0	1.0
		N	61	61	61	61	61	61
	100	Mean	0.8	0.3	**1.1**[b]	0.1	**0.1**[b]	-0.1
		STD	1.0	1.2	1.1	1.6	1.0	1.7
		N	61	61	61	61	61	61

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			344	351	358	365	372	379
Control	0	Mean	0.6	0.2	0.2	0.2	1.1	0.3
		STD	1.3	1.5	1.5	1.1	1.4	1.4
		N	110	110	110	110	110	104
Aroclor-1016	50	Mean	0.7	**1.0[b]**	**-0.8[b]**	0.4	0.7	0.3
		STD	1.0	1.0	1.2	1.9	1.4	1.1
		N	59	59	59	59	58	52
	100	Mean	0.6	0.9	-0.1	0.0	1.5	0.2
		STD	1.2	1.3	1.2	1.8	1.3	1.5
		N	61	61	61	61	60	55
	200	Mean	0.8	0.1	0.5	0.3	1.3	0.3
		STD	1.0	1.1	1.2	1.6	1.0	1.0
		N	60	60	60	60	60	54
Aroclor-1242	50	Mean	0.0	0.2	1.0	0.0	**-0.1[b]**	0.2
		STD	1.5	1.3	1.6	1.4	2.3	2.0
		N	62	62	62	62	62	56
	100	Mean	-0.1	0.2	**1.5[b]**	0.1	**0.1[b]**	0.0
		STD	1.4	0.8	0.9	1.1	1.8	1.2
		N	57	57	57	57	57	52
Aroclor-1254	25	Mean	0.4	0.8	-0.2	0.3	**-0.1[b]**	**-0.6[b]**
		STD	1.1	1.1	1.0	1.0	1.5	1.4
		N	60	60	60	60	60	54
	50	Mean	0.6	0.7	-0.4	0.1	**-0.2[b]**	**-0.6[b]**
		STD	1.0	1.0	1.0	1.3	1.5	1.1
		N	61	61	61	61	61	55
	100	Mean	0.5	0.7	-0.3	0.2	**0.3[b]**	**-0.5[b]**
		STD	0.8	0.9	1.0	1.0	1.1	0.8
		N	58	58	58	58	58	52
Aroclor-1260	25	Mean	**-0.5[b]**	**1.2[b]**	-0.5	**0.9[b]**	**-0.3[b]**	0.5
		STD	1.6	1.1	1.5	1.1	1.7	1.4
		N	62	61	61	61	61	55
	50	Mean	0.4	0.8	-0.2	0.5	**-0.4[b]**	0.1
		STD	1.3	1.4	1.3	1.5	1.4	1.4
		N	61	61	61	60	60	54
	100	Mean	0.6	0.5	-0.4	0.3	0.3	0.4
		STD	1.1	1.4	2.3	2.6	1.5	2.3
		N	61	61	60	59	59	53

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			386	393	400	407	414	421
Control	0	Mean	0.8	0.0	0.3	0.5	0.6	0.0
		STD	1.2	1.2	1.7	1.8	1.1	1.5
		N	104	104	104	103	102	102
Aroclor-1016	50	Mean	1.4	-0.3	0.2	0.3	0.7	-0.2
		STD	1.2	1.9	1.6	1.3	1.3	2.1
		N	52	52	52	52	52	52
	100	Mean	1.1	0.5	0.3	-0.1	0.7	-0.1
		STD	1.8	2.0	1.6	1.6	1.3	2.1
		N	55	55	55	55	54	54
	200	Mean	1.0	**1.0[b]**	-0.5	0.4	0.2	0.2
		STD	1.0	0.9	1.3	1.8	1.9	1.1
		N	54	54	54	54	54	53
Aroclor-1242	50	Mean	0.6	0.1	-0.2	0.3	0.8	-0.4
		STD	1.1	0.9	1.1	0.8	0.8	1.0
		N	54	54	54	54	54	54
	100	Mean	1.0	0.1	-0.3	0.3	0.5	-0.4
		STD	1.8	1.2	0.9	0.9	1.1	1.1
		N	51	51	51	51	51	51
Aroclor-1254	25	Mean	0.3	0.4	**1.3[b]**	**-0.5[b]**	**-0.2[b]**	0.7
		STD	1.8	2.5	1.6	1.2	0.9	1.2
		N	54	54	53	53	53	52
	50	Mean	**0.0[b]**	**0.9[b]**	1.0	**-0.8[b]**	**-0.3[b]**	0.6
		STD	1.2	0.9	1.0	1.7	1.2	1.5
		N	55	55	55	55	54	54
	100	Mean	**0.0[b]**	**0.7[b]**	0.9	**-0.6[b]**	**-0.1[b]**	0.4
		STD	0.9	1.0	1.4	1.0	0.9	1.0
		N	52	52	52	52	52	52
Aroclor-1260	25	Mean	0.8	-0.1	1.0	**-0.5[b]**	0.0	**1.2[b]**
		STD	1.8	2.5	1.5	1.4	1.2	1.5
		N	55	55	55	55	55	55
	50	Mean	0.9	-0.1	0.9	0.0	**-0.1[b]**	**1.3[b]**
		STD	2.2	2.1	1.5	1.4	1.3	1.2
		N	54	53	53	53	53	53
	100	Mean	1.0	-0.5	0.0	0.1	0.0	0.7
		STD	2.5	1.8	2.2	2.0	1.4	1.6
		N	53	53	53	52	51	49

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			428	435	442	449	456	463
Control	0	Mean	0.0	0.5	-0.9	1.8	-0.2	-0.6
		STD	1.4	1.1	1.6	1.5	1.5	1.7
		N	101	101	101	101	100	100
Aroclor-1016	50	Mean	**1.1**[b]	0.1	**0.9**[b]	**-0.4**[b]	0.1	-0.1
		STD	1.3	1.4	1.5	2.0	1.5	2.0
		N	52	52	52	52	52	52
	100	Mean	**1.1**[b]	-0.1	**0.8**[b]	**-0.2**[b]	0.0	0.1
		STD	1.1	1.3	1.0	1.0	1.3	1.3
		N	53	53	52	52	51	51
	200	Mean	**1.0**[b]	**-0.4**[b]	**0.4**[b]	**-0.8**[b]	-0.4	0.1
		STD	1.4	1.7	2.0	1.5	2.0	1.6
		N	53	53	53	52	52	52
Aroclor-1242	50	Mean	**1.1**[b]	**-0.9**[b]	**0.3**[b]	**0.0**[b]	0.0	-0.4
		STD	1.0	1.3	1.1	0.9	1.9	1.1
		N	54	53	53	53	53	53
	100	Mean	**1.2**[b]	**-0.6**[b]	**0.9**[b]	**0.0**[b]	0.0	-1.4
		STD	1.1	1.0	0.8	0.8	1.5	2.6
		N	51	51	51	51	51	51
Aroclor-1254	25	Mean	0.1	**-0.4**[b]	**1.5**[b]	**-0.7**[b]	0.2	**0.6**[b]
		STD	1.2	1.4	1.2	1.1	1.5	1.6
		N	52	52	52	52	52	51
	50	Mean	0.0	-0.8	**1.2**[b]	**-0.4**[b]	0.0	0.1
		STD	1.1	3.8	1.1	0.8	1.2	2.5
		N	53	53	52	52	52	52
	100	Mean	0.1	**-0.7**[b]	**1.4**[b]	**0.0**[b]	0.3	**0.6**[b]
		STD	1.3	1.3	1.0	0.9	1.0	1.0
		N	52	52	52	52	52	52
Aroclor-1260	25	Mean	**-1.0**[b]	0.3	**0.4**[b]	1.1	-0.4	-0.7
		STD	1.6	1.4	1.3	1.5	1.2	2.0
		N	55	55	55	55	55	55
	50	Mean	**-1.5**[b]	0.4	**0.3**[b]	1.3	-0.3	-0.5
		STD	1.9	2.3	1.6	1.4	1.4	1.7
		N	53	52	52	52	52	52
	100	Mean	**-1.3**[b]	-0.4	**0.7**[b]	**0.8**[b]	-0.3	-0.8
		STD	2.0	2.3	2.0	1.6	2.2	1.7
		N	49	49	48	48	48	48

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			470	477	484	491	498	505
Control	0	Mean	1.1	0.2	-1.3	0.1	1.4	-1.4
		STD	1.8	2.1	2.4	1.8	1.6	1.6
		N	100	100	100	99	97	97
Aroclor-1016	50	Mean	0.9	0.0	-0.7	**1.3[b]**	**-0.2[b]**	**-0.4[b]**
		STD	1.7	1.7	1.2	1.4	1.5	1.7
		N	52	51	50	50	50	50
	100	Mean	0.8	-0.2	-0.8	**1.3[b]**	**-0.4[b]**	**0.1[b]**
		STD	1.9	2.0	1.5	1.5	1.3	1.5
		N	51	51	50	49	49	49
	200	Mean	0.3	-0.1	-0.2	**1.5[b]**	**-0.6[b]**	**0.2[b]**
		STD	1.8	1.6	1.6	1.2	2.1	1.8
		N	52	52	52	52	52	51
Aroclor-1242	50	Mean	0.3	0.1	-0.4	1.0	0.4	-0.5
		STD	1.0	1.3	1.7	2.4	2.0	2.0
		N	53	52	51	51	51	51
	100	Mean	0.3	-0.4	-0.2	0.9	0.5	-0.7
		STD	2.0	2.2	1.7	1.2	2.0	1.4
		N	51	51	50	50	49	48
Aroclor-1254	25	Mean	-0.4	0.8	-0.4	0.4	**-1.1[b]**	**0.3[b]**
		STD	2.7	1.9	2.6	2.1	1.7	1.3
		N	51	51	51	50	49	49
	50	Mean	0.1	0.8	**0.3[b]**	0.0	**-1.7[b]**	**0.1[b]**
		STD	1.8	1.9	1.6	1.9	2.8	2.2
		N	52	52	51	50	50	49
	100	Mean	0.4	0.5	**0.3[b]**	0.4	**-0.4[b]**	**0.3[b]**
		STD	1.1	1.4	1.3	1.0	1.1	1.1
		N	52	52	51	51	51	51
Aroclor-1260	25	Mean	**-1.1[b]**	-0.2	**0.3[b]**	-0.5	**-0.1[b]**	-0.3
		STD	2.1	2.7	2.4	2.1	2.2	2.5
		N	55	54	51	51	50	47
	50	Mean	**-0.6[b]**	0.5	**0.4[b]**	-0.1	**-0.2[b]**	**-0.1[b]**
		STD	1.6	1.6	1.4	1.7	1.9	1.8
		N	49	49	49	49	49	49
	100	Mean	**-1.3[b]**	0.3	**0.8[b]**	-0.1	**0.1[b]**	**0.3[b]**
		STD	3.2	1.9	1.5	1.3	2.1	1.4
		N	48	46	45	44	44	43

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			512	519	526	533	540	547
Control	0	Mean	1.3	-1.3	0.9	-0.4	-0.2	0.2
		STD	2.5	1.6	2.1	2.6	1.2	1.4
		N	97	95	94	93	91	91
Aroclor-1016	50	Mean	0.1	**0.1**[b]	-0.1	-0.2	-1.2	**-1.7**[b]
		STD	1.9	1.6	2.6	2.4	2.5	2.6
		N	50	49	48	47	45	43
	100	Mean	-0.2	**-0.1**[b]	0.1	**1.2**[b]	-0.9	-0.8
		STD	2.5	1.6	1.5	1.5	1.9	2.0
		N	49	47	47	47	47	46
	200	Mean	0.5	**0.3**[b]	0.1	0.7	-0.5	-0.8
		STD	2.0	1.4	1.6	1.5	1.7	3.2
		N	51	50	50	50	50	48
Aroclor-1242	50	Mean	0.3	-0.2	-0.2	-0.6	-0.6	-0.1
		STD	3.1	2.3	2.5	1.9	2.3	1.8
		N	51	51	50	49	49	48
	100	Mean	**0.1**[b]	**0.4**[b]	**-0.6**[b]	-0.9	-1.0	-0.3
		STD	1.6	1.7	1.9	3.0	2.3	1.7
		N	48	47	46	45	44	43
Aroclor-1254	25	Mean	0.5	-1.0	**-0.7**[b]	-0.4	-0.4	-0.4
		STD	1.8	1.9	2.0	2.3	1.9	1.3
		N	49	49	48	48	48	46
	50	Mean	**-0.5**[b]	-1.3	**-0.7**[b]	-0.5	-0.1	-0.8
		STD	2.6	3.3	2.3	1.7	1.6	1.9
		N	49	48	46	45	43	42
	100	Mean	0.4	**-0.1**[b]	**-0.9**[b]	-0.4	-0.3	-0.2
		STD	1.1	1.5	1.9	1.7	2.0	1.7
		N	51	50	50	49	49	49
Aroclor-1260	25	Mean	0.3	-0.7	0.5	0.1	-0.3	-0.4
		STD	2.0	2.2	2.0	2.1	2.0	2.3
		N	47	47	47	46	45	45
	50	Mean	0.5	-0.8	-0.2	-0.6	-1.5	-1.3
		STD	2.0	1.5	1.6	3.1	2.9	2.8
		N	49	48	47	47	45	44
	100	Mean	**-0.3**[b]	**0.2**[b]	-0.2	0.1	-0.3	-0.4
		STD	1.9	1.4	2.7	1.4	1.2	1.3
		N	43	43	43	42	42	40

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

802281

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			554	561	568	575	582	589
Control	0	Mean	-0.5	-0.9	1.0	0.0	-0.9	-1.4
		STD	1.6	2.3	1.6	1.8	2.0	2.1
		N	90	86	84	84	82	81
Aroclor-1016	50	Mean	-1.1	0.5	-0.5	-1.5	0.0	-0.6
		STD	2.9	2.7	2.7	3.0	2.3	3.5
		N	43	36	36	35	35	35
	100	Mean	-0.1	**0.9[b]**	**-0.4[b]**	-1.5	-1.1	-0.8
		STD	1.6	1.5	1.8	2.9	3.0	2.5
		N	44	39	38	38	38	35
	200	Mean	0.2	**1.1[b]**	-0.1	-0.8	0.1	0.0
		STD	1.8	1.6	3.2	2.4	1.3	2.7
		N	46	41	41	41	40	40
Aroclor-1242	50	Mean	0.1	-0.7	0.1	0.3	-0.4	-1.7
		STD	2.4	2.8	1.3	1.7	2.3	3.2
		N	48	43	42	40	40	40
	100	Mean	0.1	-1.3	-0.3	-0.2	-0.6	-1.8
		STD	2.1	2.6	2.4	1.8	2.0	2.4
		N	42	38	37	37	36	36
Aroclor-1254	25	Mean	-0.1	-1.1	**-0.1[b]**	-0.5	-1.0	-1.1
		STD	2.8	2.0	1.8	1.8	1.6	4.4
		N	46	41	41	40	39	39
	50	Mean	0.2	-1.3	-0.7	-0.5	-0.8	-0.8
		STD	2.8	2.7	2.8	2.1	2.2	2.0
		N	39	35	35	34	34	34
	100	Mean	0.2	-0.8	**-0.5[b]**	-0.2	-1.3	-1.1
		STD	2.1	2.1	2.4	1.0	1.9	3.6
		N	47	43	42	40	39	39
Aroclor-1260	25	Mean	-0.1	-1.7	0.5	-0.2	-0.4	**0.7[b]**
		STD	2.3	2.4	1.8	1.1	1.6	1.7
		N	45	41	40	40	40	39
	50	Mean	0.1	-1.9	**-1.1[b]**	-1.2	-1.2	-1.0
		STD	2.4	2.7	3.2	2.7	3.0	2.7
		N	42	37	36	36	36	36
	100	Mean	**0.7[b]**	-1.1	**-0.4[b]**	-0.8	-0.3	-0.8
		STD	1.8	1.5	1.8	1.8	2.1	1.7
		N	40	37	37	37	37	36

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			596	603	610	617	624	631
Control	0	Mean	0.4	-0.2	-0.6	-1.0	-0.3	-1.0
		STD	2.0	2.0	1.8	2.0	2.4	2.2
		N	79	79	78	77	76	76
Aroclor-1016	50	Mean	-0.8	-0.8	-1.3	-0.1	0.1	-0.5
		STD	2.3	4.3	3.1	1.7	1.3	2.2
		N	33	32	29	27	26	25
	100	Mean	-0.4	-0.9	-1.0	-0.9	-1.1	-1.6
		STD	3.2	3.5	2.2	2.7	4.1	2.6
		N	33	32	32	31	30	28
	200	Mean	0.0	-0.1	-1.2	-0.7	-0.5	-0.7
		STD	1.3	1.9	2.3	2.2	1.5	1.7
		N	39	39	38	37	35	35
Aroclor-1242	50	Mean	-0.3	-1.6	-0.4	-0.5	-1.9	0.0
		STD	3.1	2.5	2.9	2.7	1.9	2.0
		N	40	38	37	37	35	34
	100	Mean	-0.2	**-1.8[b]**	-0.5	-1.1	-1.8	-1.1
		STD	2.2	2.0	2.8	2.5	2.6	3.0
		N	36	34	34	33	30	29
Aroclor-1254	25	Mean	-0.2	-1.1	-1.0	-1.3	-0.4	-0.8
		STD	2.9	1.6	3.3	2.6	1.7	1.8
		N	38	36	35	33	32	32
	50	Mean	**-2.1[b]**	-1.1	-0.6	-0.8	0.1	-0.6
		STD	2.0	3.3	2.7	2.9	1.3	1.4
		N	32	32	30	30	29	29
	100	Mean	-0.8	-0.4	-0.2	-0.9	-0.4	-0.6
		STD	3.1	1.9	1.6	1.7	1.5	2.5
		N	39	38	38	38	37	36
Aroclor-1260	25	Mean	-0.3	-0.6	0.2	-0.2	-1.4	-0.8
		STD	1.3	1.7	2.0	1.7	3.7	2.4
		N	39	38	38	38	38	38
	50	Mean	-0.8	-1.5	-0.9	-0.7	-1.3	-2.0
		STD	3.5	2.6	2.7	2.0	2.8	3.2
		N	35	35	34	34	33	33
	100	Mean	0.3	-0.6	-0.5	-0.1	-0.4	-1.3
		STD	1.9	1.6	1.9	2.2	2.5	1.6
		N	36	35	35	35	34	34

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			638	645	652	659	666	673
Control	0	Mean	-0.3	-0.5	-1.8	-2.1	-0.9	-0.8
		STD	2.6	2.8	2.7	2.3	2.4	2.3
		N	73	70	70	66	65	60
Aroclor-1016	50	Mean	-1.3	-0.3	-0.7	-3.0	-3.0	-2.2
		STD	2.0	2.5	1.9	3.4	4.5	4.5
		N	25	23	23	23	21	21
	100	Mean	-1.5	-2.2	-0.5	-2.6	-1.7	-1.8
		STD	2.4	2.5	3.8	2.5	2.1	3.0
		N	27	27	26	25	23	23
	200	Mean	-0.9	-1.7	0.0	-1.3	-1.5	0.0
		STD	3.3	3.2	2.6	2.9	2.7	2.0
		N	34	34	34	34	33	31
Aroclor-1242	50	Mean	-0.9	-2.1	-1.3	-1.4	-1.8	-0.9
		STD	2.1	3.3	3.2	2.4	2.9	2.8
		N	34	33	32	32	32	32
	100	Mean	-0.9	-2.8[b]	-1.4	-1.9	-2.0	-1.6
		STD	2.5	2.6	3.3	3.1	2.7	3.1
		N	28	28	27	24	23	23
Aroclor-1254	25	Mean	-0.9	-1.4	-1.3	-2.0	-1.3	-1.6
		STD	1.6	2.8	2.4	3.4	2.9	2.9
		N	31	31	31	30	28	28
	50	Mean	-1.2	-1.1	-1.4	-1.6	-3.1[b]	-2.1
		STD	1.9	1.9	2.5	2.6	3.2	2.9
		N	28	28	26	25	24	24
	100	Mean	-1.7	-1.4	-1.8	-1.2	-1.7	-1.5
		STD	2.2	2.5	2.5	2.1	2.2	2.6
		N	35	35	34	32	32	32
Aroclor-1260	25	Mean	-0.5	0.9	-1.7	-2.0	-2.1	-0.3
		STD	1.6	2.1	1.6	3.8	3.8	2.9
		N	37	36	35	35	35	33
	50	Mean	-2.1	-0.1	-3.2	-1.7	-1.1	-0.8
		STD	3.5	3.7	3.4	2.7	2.1	3.0
		N	32	31	30	28	26	24
	100	Mean	-0.9	0.2	-2.8	-3.5	-2.9	-0.4
		STD	1.8	2.1	4.6	5.1	5.6	2.4
		N	34	33	33	31	29	26

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 21. Group Mean Body Weight Gains (g/day) by Week for Core and Interim Subgroup Male Rats[a]

Test Substance	Conc. (ppm)		Day of Study						
			680	687	694	701	708	715	722
Control	0	Mean	-1.4	-0.9	-1.3	-1.1	-1.7	-1.2	-1.7
		STD	2.4	3.2	2.4	2.0	2.3	2.4	2.2
		N	60	60	57	54	52	50	46
Aroclor-1016	50	Mean	-0.5	-1.5	-1.5	-1.1	-0.4	-0.5	-1.9
		STD	3.1	4.9	2.7	1.9	3.0	2.3	3.3
		N	20	20	20	19	18	17	15
	100	Mean	-0.8	-2.4	-2.4	-3.6	-2.9	-1.3	-1.8
		STD	4.0	2.4	3.5	4.3	5.1	3.6	2.6
		N	21	19	19	19	17	15	14
	200	Mean	0.2	-1.5	-1.0	-2.2	-0.8	-1.0	-2.1
		STD	1.7	2.6	2.2	2.7	2.5	2.2	2.2
		N	31	31	31	30	29	29	27
Aroclor-1242	50	Mean	-2.1	-1.0	-0.1	-1.3	-1.6	-0.8	-1.2
		STD	2.1	3.1	2.0	1.5	2.0	2.9	1.9
		N	31	29	27	26	26	26	25
	100	Mean	-1.5	-1.3	-1.7	-1.9	-2.1	-1.2	-0.7
		STD	2.3	2.0	2.8	3.5	2.7	2.8	1.6
		N	22	22	22	21	20	19	18
Aroclor-1254	25	Mean	-0.6	-0.3	-1.2	-1.6	-0.7	-1.6	-1.3
		STD	1.7	2.1	2.4	3.0	1.8	1.7	1.6
		N	26	26	25	25	25	24	23
	50	Mean	-2.5	-2.1	-3.1	-2.4	-2.0	-1.9	-0.7
		STD	4.2	4.5	4.3	4.3	1.7	2.9	1.6
		N	22	21	18	14	13	13	11
	100	Mean	-0.9	-0.9	-0.7	-0.7	**-0.1[b]**	-1.3	**-0.2[b]**
		STD	2.8	3.4	2.2	1.0	1.2	1.4	1.0
		N	31	29	24	22	21	21	20
Aroclor-1260	25	Mean	-2.1	0.6	-0.2	-1.0	-2.4	-2.1	-1.0
		STD	2.1	2.3	2.5	2.7	3.2	1.8	2.4
		N	31	30	30	27	25	24	24
	50	Mean	-2.5	0.5	-0.7	-2.3	-0.8	-3.1	-2.0
		STD	1.6	1.4	1.9	5.0	2.0	1.9	3.8
		N	23	23	23	22	19	19	17
	100	Mean	-2.7	-0.4	-0.4	-0.9	-1.1	-3.5	-2.0
		STD	1.9	2.3	2.3	2.1	2.0	2.9	3.4
		N	26	24	23	22	20	19	17

a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			8	15	22	29	36	43
Control	0	Mean	3.2	2.6	1.9	1.9	0.6	1.0
		STD	0.9	0.9	1.0	1.0	1.0	0.9
		N	130	130	130	130	130	130
Aroclor-1016	50	Mean	2.9	2.5	2.0	**1.5[b]**	**1.4[b]**	1.2
		STD	1.2	1.2	1.1	1.0	0.9	1.1
		N	110	110	110	110	110	110
	100	Mean	3.0	2.2	1.9	**1.4[b]**	**1.4[b]**	1.2
		STD	0.9	1.0	1.0	0.9	0.9	0.9
		N	110	110	110	110	110	110
	200	Mean	3.1	**1.9[b]**	1.8	1.6	**1.5[b]**	1.0
		STD	1.0	1.1	1.3	1.2	1.2	1.2
		N	110	110	110	110	110	110
Aroclor-1242	50	Mean	2.8	2.3	1.8	**1.2[b]**	**1.2[b]**	1.0
		STD	0.9	1.1	1.2	1.0	1.1	1.2
		N	110	110	110	110	110	110
	100	Mean	3.0	**2.0[b]**	1.8	**1.2[b]**	**1.3[b]**	1.2
		STD	1.0	0.9	1.0	0.8	0.8	0.7
		N	110	110	110	110	110	110
Aroclor-1254	25	Mean	3.1	2.3	1.8	**0.9[b]**	**1.4[b]**	1.2
		STD	0.9	0.9	1.0	0.8	0.8	0.9
		N	110	110	110	110	110	110
	50	Mean	3.0	**1.8[b]**	1.9	**1.0[b]**	**1.4[b]**	0.9
		STD	1.0	0.7	0.8	0.7	0.7	0.8
		N	110	110	110	110	110	110
	100	Mean	3.1	**1.8[b]**	1.7	**0.6[b]**	**1.4[b]**	0.7
		STD	0.9	0.8	0.9	0.8	0.8	0.9
		N	110	110	110	110	110	110
Aroclor-1260	25	Mean	3.0	2.5	1.9	**1.4[b]**	1.0	1.0
		STD	1.3	1.1	1.0	1.0	1.0	1.1
		N	110	110	110	110	110	110
	50	Mean	3.0	2.3	1.7	**1.4[b]**	**1.1[b]**	0.9
		STD	1.1	0.9	0.9	1.0	1.1	1.1
		N	110	110	110	110	110	110
	100	Mean	3.3	2.4	1.7	**1.4[b]**	**1.2[b]**	0.7
		STD	1.6	1.7	1.0	0.9	0.9	1.0
		N	110	110	110	110	110	109

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			50	57	64	71	78	85
Control	0	Mean	1.1	0.5	0.8	0.7	0.3	0.9
		STD	1.0	1.2	1.2	1.2	1.1	1.5
		N	130	129	129	129	129	129
Aroclor-1016	50	Mean	1.2	0.3	0.9	0.6	**0.9[b]**	**0.4[b]**
		STD	0.9	1.0	0.9	1.0	0.8	0.7
		N	110	110	110	110	110	110
	100	Mean	1.0	0.6	0.9	0.5	**1.0[b]**	0.5
		STD	1.0	0.9	1.0	1.0	0.9	1.0
		N	110	110	110	110	110	110
	200	Mean	0.9	0.6	0.7	0.4	**0.9[b]**	**0.3[b]**
		STD	1.0	1.0	1.1	0.9	0.9	0.7
		N	110	110	110	110	110	110
Aroclor-1242	50	Mean	1.3	0.8	0.5	0.9	0.7	0.7
		STD	1.0	1.2	0.9	1.0	0.9	1.0
		N	110	110	110	110	110	110
	100	Mean	0.9	0.9	**0.1[b]**	0.5	0.4	1.1
		STD	0.8	1.1	1.0	1.1	1.0	1.0
		N	110	110	110	110	110	110
Aroclor-1254	25	Mean	1.0	0.4	0.6	0.5	0.6	**0.3[b]**
		STD	1.0	0.9	0.8	0.8	0.9	0.9
		N	110	110	110	110	110	110
	50	Mean	1.0	0.7	0.7	0.4	0.5	**0.3[b]**
		STD	0.7	0.7	0.7	0.6	0.8	0.7
		N	110	110	110	110	110	110
	100	Mean	0.7	0.4	**0.4[b]**	0.3	0.2	**0.1[b]**
		STD	1.0	0.7	0.7	0.8	0.7	0.7
		N	110	110	110	110	110	110
Aroclor-1260	25	Mean	1.1	0.8	**0.4[b]**	0.7	**0.8[b]**	0.6
		STD	1.2	1.2	0.9	0.9	0.9	0.9
		N	110	110	110	110	110	110
	50	Mean	0.9	1.0	0.6	0.8	**0.8[b]**	0.5
		STD	1.4	1.1	1.0	0.9	0.8	0.8
		N	110	109	109	109	108	108
	100	Mean	0.8	**1.1[b]**	0.5	0.5	**0.8[b]**	0.6
		STD	1.0	1.1	0.8	0.8	0.8	0.7
		N	109	110	110	110	110	110

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			92	99	107	113	120	127
Control	0	Mean	0.5	0.7	0.2	0.4	0.4	0.9
		STD	1.2	1.0	0.9	0.9	0.7	0.7
		N	129	123	123	123	123	123
Aroclor-1016	50	Mean	**0.0[b]**	0.7	0.5	0.5	0.3	**0.5[b]**
		STD	0.8	1.0	1.0	1.2	0.9	0.9
		N	110	104	104	104	104	104
	100	Mean	0.1	0.6	0.5	0.5	0.3	0.8
		STD	1.0	1.0	0.7	1.1	0.9	0.9
		N	110	104	104	104	104	104
	200	Mean	0.3	0.5	0.5	0.6	0.3	**0.4[b]**
		STD	0.8	1.0	0.9	1.0	0.8	0.8
		N	110	104	104	104	104	104
Aroclor-1242	50	Mean	0.3	**0.1[b]**	**0.6[b]**	0.7	0.5	0.6
		STD	0.7	1.1	0.7	1.1	0.8	0.9
		N	110	104	104	104	104	104
	100	Mean	0.3	**0.0[b]**	0.5	0.5	0.0	0.6
		STD	0.9	0.9	1.0	1.3	1.0	1.1
		N	110	104	104	104	104	104
Aroclor-1254	25	Mean	0.7	**0.2[b]**	0.3	0.5	0.3	**0.3[b]**
		STD	0.9	0.8	0.6	0.9	0.6	0.9
		N	110	104	104	104	104	104
	50	Mean	0.3	**0.0[b]**	0.2	0.3	0.2	**0.4[b]**
		STD	0.6	0.7	0.9	1.2	0.7	0.5
		N	110	104	104	104	104	104
	100	Mean	0.1	**0.0[b]**	0.1	**0.0[b]**	**0.0[b]**	**0.3[b]**
		STD	0.6	0.7	0.6	0.8	0.6	0.6
		N	110	104	104	104	104	104
Aroclor-1260	25	Mean	0.4	0.5	0.4	**1.0[b]**	0.3	**0.5[b]**
		STD	0.9	0.8	0.7	1.2	0.8	0.9
		N	110	104	104	104	104	104
	50	Mean	0.4	0.4	**0.5[b]**	**1.0[b]**	**0.1[b]**	**0.4[b]**
		STD	0.9	0.9	0.7	1.2	0.9	0.9
		N	108	102	102	102	102	102
	100	Mean	**0.1[b]**	0.5	0.5	0.5	0.1	0.5
		STD	0.8	1.0	0.7	1.0	1.1	1.1
		N	110	104	104	104	104	104

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			134	142	148	155	162	169
Control	0	Mean	0.3	0.3	0.2	0.3	0.7	0.2
		STD	0.8	0.8	1.2	1.1	0.9	0.9
		N	123	123	123	123	123	123
Aroclor-1016	50	Mean	**-0.3[b]**	0.2	**1.2[b]**	0.7	0.5	0.4
		STD	0.7	0.6	0.9	0.9	1.0	0.9
		N	104	104	104	104	104	104
	100	Mean	0.1	0.2	**1.2[b]**	**0.8[b]**	0.6	0.4
		STD	0.9	0.7	1.1	1.0	0.9	0.9
		N	104	104	104	104	104	104
	200	Mean	0.0	0.4	**0.9[b]**	0.4	0.7	0.4
		STD	0.8	0.6	0.9	0.9	0.9	0.8
		N	104	104	104	104	104	104
Aroclor-1242	50	Mean	0.7	0.4	-0.1	**0.9[b]**	0.5	0.0
		STD	1.0	0.8	1.0	0.9	0.9	0.9
		N	104	104	104	104	104	104
	100	Mean	0.3	0.2	-0.1	0.7	0.5	0.1
		STD	1.2	1.1	1.4	0.9	1.1	0.9
		N	104	104	104	104	104	104
Aroclor-1254	25	Mean	0.5	0.5	0.4	0.0	0.3	0.5
		STD	0.9	0.5	1.2	0.7	0.8	0.8
		N	104	104	104	104	104	104
	50	Mean	0.2	0.5	0.4	0.1	**0.2[b]**	0.3
		STD	0.6	0.6	0.7	0.6	0.6	0.8
		N	104	104	104	104	104	104
	100	Mean	0.2	0.4	0.5	0.1	**0.3[b]**	0.3
		STD	0.7	0.6	0.7	0.7	0.6	0.7
		N	104	104	104	104	104	104
Aroclor-1260	25	Mean	0.4	**0.7[b]**	0.4	0.4	0.6	0.3
		STD	0.8	0.6	1.0	0.7	0.7	0.8
		N	104	104	104	104	104	104
	50	Mean	0.5	0.6	0.4	0.3	0.4	0.5
		STD	1.1	0.7	1.0	0.8	0.7	0.9
		N	102	102	102	102	102	101
	100	Mean	0.1	**0.6[b]**	0.6	0.1	0.4	0.3
		STD	0.8	0.7	1.0	0.8	0.8	1.0
		N	104	104	104	104	104	104

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			176	183	190	197	204	211
Control	0	Mean	-0.3	0.9	0.3	-0.2	0.8	0.5
		STD	0.8	0.9	1.0	1.2	1.0	1.0
		N	123	123	117	117	117	117
Aroclor-1016	50	Mean	**0.3[b]**	**-0.1[b]**	**0.9[b]**	**0.4[b]**	0.7	0.3
		STD	0.8	1.1	1.0	0.8	0.9	0.9
		N	104	104	98	98	98	98
	100	Mean	**0.4[b]**	**-0.2[b]**	**0.8[b]**	**0.3[b]**	0.9	0.5
		STD	0.8	1.1	1.0	0.8	0.9	1.0
		N	104	104	98	98	98	98
	200	Mean	**0.3[b]**	**-0.1[b]**	**0.9[b]**	0.1	0.7	0.4
		STD	0.7	1.0	0.8	0.9	1.1	1.0
		N	104	104	98	98	98	98
Aroclor-1242	50	Mean	**0.6[b]**	**0.5[b]**	0.1	**0.5[b]**	0.9	0.4
		STD	0.8	0.8	1.1	1.1	0.9	0.8
		N	104	103	97	98	98	98
	100	Mean	**0.4[b]**	**0.2[b]**	0.1	0.1	0.8	0.2
		STD	0.8	0.8	0.7	1.0	0.7	1.0
		N	104	104	98	98	98	98
Aroclor-1254	25	Mean	**0.5[b]**	**-0.3[b]**	0.2	**0.4[b]**	**0.4[b]**	0.5
		STD	0.8	0.8	0.8	0.8	0.8	0.8
		N	104	104	97	97	97	97
	50	Mean	**0.4[b]**	**0.0[b]**	0.1	**0.3[b]**	**0.2[b]**	0.4
		STD	0.7	0.7	0.8	0.7	0.9	0.6
		N	104	104	98	98	98	98
	100	Mean	**0.4[b]**	**-0.2[b]**	0.1	**0.4[b]**	**0.0[b]**	0.3
		STD	0.6	0.6	0.6	0.7	0.6	0.6
		N	104	104	98	98	98	98
Aroclor-1260	25	Mean	**0.7[b]**	**0.1[b]**	0.5	**0.5[b]**	**0.4[b]**	0.4
		STD	0.9	0.8	0.8	0.8	0.8	1.6
		N	104	104	98	98	98	98
	50	Mean	**0.5[b]**	**0.3[b]**	0.3	**0.6[b]**	0.5	0.3
		STD	0.8	0.8	0.9	0.7	0.9	1.0
		N	101	101	95	95	95	95
	100	Mean	**0.6[b]**	**0.2[b]**	0.3	**0.6[b]**	0.4	0.1
		STD	0.9	0.9	1.2	0.9	0.9	1.2
		N	104	104	98	98	98	98

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			218	225	232	239	246	253
Control	0	Mean	0.7	0.5	0.1	0.4	0.8	-0.3
		STD	0.9	0.8	0.9	0.8	1.1	0.8
		N	117	117	117	116	116	116
Aroclor-1016	50	Mean	0.4	**0.1**[b]	0.3	0.7	0.6	0.1
		STD	1.0	1.0	1.1	1.1	1.0	1.1
		N	98	98	98	98	98	98
	100	Mean	**0.2**[b]	0.2	0.3	**1.0**[b]	0.4	**0.4**[b]
		STD	0.9	0.9	1.1	1.2	0.8	1.0
		N	98	98	98	98	98	98
	200	Mean	0.4	**-0.1**[b]	0.3	**1.0**[b]	**0.2**[b]	-0.1
		STD	0.8	0.9	1.1	1.0	0.9	1.0
		N	97	97	97	97	97	96
Aroclor-1242	50	Mean	**0.2**[b]	0.8	0.2	0.8	**-0.4**[b]	**0.2**[b]
		STD	0.8	0.9	1.0	1.0	1.0	1.0
		N	98	98	98	98	98	98
	100	Mean	**-0.1**[b]	0.4	0.3	**0.8**[b]	**-0.4**[b]	**0.2**[b]
		STD	0.8	0.6	0.9	0.9	0.8	0.7
		N	97	97	97	96	96	96
Aroclor-1254	25	Mean	0.4	0.3	0.3	0.1	**0.2**[b]	**0.5**[b]
		STD	0.9	0.7	0.8	0.7	0.8	0.7
		N	97	97	97	97	97	97
	50	Mean	**0.2**[b]	0.3	0.3	**-0.1**[b]	**0.3**[b]	**0.3**[b]
		STD	0.6	0.6	0.6	0.7	0.8	0.6
		N	98	98	98	98	98	98
	100	Mean	**0.2**[b]	0.3	0.2	**0.0**[b]	**0.1**[b]	0.0
		STD	0.6	0.5	0.6	0.5	0.6	0.7
		N	98	98	98	98	97	97
Aroclor-1260	25	Mean	0.3	0.4	0.5	**-0.4**[b]	0.4	**1.0**[b]
		STD	1.0	0.9	0.8	1.2	1.2	0.8
		N	98	98	98	98	98	97
	50	Mean	0.4	0.3	0.2	0.1	0.2	**0.9**[b]
		STD	0.8	1.3	0.9	1.0	0.9	0.9
		N	94	94	94	94	94	94
	100	Mean	0.3	0.2	0.4	0.2	**0.3**[b]	**0.5**[b]
		STD	1.1	0.8	0.9	1.0	1.0	1.0
		N	98	98	98	98	98	98

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			260	267	274	281	288	295
Control	0	Mean	0.1	0.9	0.3	0.6	-0.4	1.3
		STD	1.0	1.0	1.4	1.0	1.1	1.0
		N	116	116	116	110	109	109
Aroclor-1016	50	Mean	**0.6[b]**	**0.3[b]**	0.3	0.8	-0.1	**0.8[b]**
		STD	1.0	0.9	1.1	1.0	1.0	1.1
		N	98	98	98	92	92	92
	100	Mean	0.4	**0.2[b]**	0.4	0.7	**0.4[b]**	**0.4[b]**
		STD	1.3	1.1	1.0	1.2	1.1	1.1
		N	98	98	98	92	92	92
	200	Mean	**0.8[b]**	**-0.1[b]**	0.6	0.8	**0.1[b]**	**0.5[b]**
		STD	0.8	0.8	0.8	1.0	0.9	0.8
		N	96	96	96	90	90	90
Aroclor-1242	50	Mean	0.1	0.7	-0.1	**1.2[b]**	0.0	**0.0[b]**
		STD	0.8	0.8	0.8	1.0	1.3	1.2
		N	98	98	98	92	92	92
	100	Mean	0.2	**0.5[b]**	-0.1	**1.2[b]**	-0.2	**0.2[b]**
		STD	0.9	0.9	0.7	0.9	0.8	1.0
		N	96	96	96	90	90	90
Aroclor-1254	25	Mean	0.4	**0.1[b]**	0.3	0.3	**0.2[b]**	**0.5[b]**
		STD	0.8	0.9	0.7	0.7	0.9	0.8
		N	97	97	97	91	91	91
	50	Mean	0.2	**0.4[b]**	0.2	0.3	**0.3[b]**	**0.4[b]**
		STD	0.6	0.7	0.8	0.8	0.7	0.8
		N	98	98	98	92	92	92
	100	Mean	0.2	**0.3[b]**	0.2	0.3	**0.4[b]**	**0.4[b]**
		STD	0.7	0.7	0.7	0.6	0.7	0.8
		N	97	97	97	91	91	91
Aroclor-1260	25	Mean	0.2	**0.2[b]**	0.3	0.5	**0.4[b]**	**0.8[b]**
		STD	1.1	0.8	1.0	1.0	0.9	1.0
		N	97	97	97	91	91	91
	50	Mean	0.4	**0.1[b]**	0.2	0.5	**0.2[b]**	**0.5[b]**
		STD	0.9	1.0	1.0	1.0	1.0	1.0
		N	94	94	94	88	88	88
	100	Mean	0.5	**0.3[b]**	0.1	0.4	**0.1[b]**	**0.6[b]**
		STD	1.2	1.0	1.0	0.9	0.8	1.2
		N	98	98	98	92	92	92

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			302	309	316	323	330	337
Control	0	Mean	1.0	-0.1	0.5	0.0	0.8	-0.1
		STD	1.1	1.1	1.0	1.0	1.2	0.9
		N	109	109	109	109	109	108
Aroclor-1016	50	Mean	0.6	**0.5**[b]	0.5	0.1	0.4	**0.5**[b]
		STD	1.1	1.1	1.0	0.9	0.9	1.0
		N	92	92	92	92	92	92
	100	Mean	0.6	0.5	0.3	0.0	0.5	**0.6**[b]
		STD	1.1	1.1	0.9	1.1	1.1	1.2
		N	92	92	91	91	91	91
	200	Mean	0.7	0.4	0.3	0.0	0.5	**0.5**[b]
		STD	0.8	0.9	0.8	0.8	0.8	0.8
		N	90	90	90	90	90	90
Aroclor-1242	50	Mean	0.6	**1.4**[b]	-0.2	**0.7**[b]	0.4	0.0
		STD	1.1	0.9	1.9	0.9	0.8	0.9
		N	91	91	91	90	90	90
	100	Mean	**0.3**[b]	**1.0**[b]	**-0.5**[b]	**0.7**[b]	**0.2**[b]	-0.1
		STD	1.0	0.7	0.9	0.8	0.8	0.7
		N	90	90	90	89	89	89
Aroclor-1254	25	Mean	**0.3**[b]	**0.7**[b]	0.2	**0.5**[b]	**0.3**[b]	**0.5**[b]
		STD	0.7	0.7	1.5	0.8	0.9	0.9
		N	90	90	90	90	90	90
	50	Mean	**0.4**[b]	0.3	0.4	**0.4**[b]	0.4	0.2
		STD	0.7	0.6	0.7	0.8	0.9	0.9
		N	92	92	92	92	92	92
	100	Mean	**0.0**[b]	0.3	**0.1**[b]	0.3	**0.0**[b]	0.3
		STD	0.9	0.8	0.7	0.8	1.5	0.7
		N	91	91	91	91	91	90
Aroclor-1260	25	Mean	**0.0**[b]	0.3	0.1	**0.6**[b]	0.4	0.3
		STD	0.8	1.0	1.0	0.8	1.2	1.0
		N	91	91	91	91	91	91
	50	Mean	**0.3**[b]	0.3	0.3	**0.6**[b]	**0.1**[b]	0.2
		STD	1.0	1.0	1.1	0.8	1.4	1.1
		N	88	88	88	88	88	88
	100	Mean	**0.1**[b]	**0.5**[b]	0.3	0.4	0.4	-0.2
		STD	0.9	0.9	0.9	1.1	1.2	1.1
		N	92	92	92	92	92	92

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			344	351	358	365	372	379
Control	0	Mean	1.2	-0.3	0.3	0.4	0.5	1.3
		STD	1.1	1.1	1.1	1.0	1.1	1.2
		N	108	108	108	108	101	101
Aroclor-1016	50	Mean	0.8	0.0	0.0	-0.1	**1.3[b]**	1.3
		STD	1.1	1.1	1.0	1.4	1.2	1.0
		N	92	92	92	92	56	56
	100	Mean	[illegible].0	0.0	**-0.3[b]**	0.0	**1.4[b]**	0.8
		STD	[illegible]	1.9	1.2	1.8	1.5	1.1
		N	91	91	90	90	53	53
	200	Mean	0.[illegible]	-0.2	0.0	0.2	**1.1[b]**	0.9
		STD	[illegible].9	1.0	0.9	1.3	1.1	0.9
		N	90	90	90	90	56	56
Aroclor-1242	50	Mean	**0.6[b]**	**0.8[b]**	0.0	0.4	**-0.6[b]**	0.9
		STD	1.1	1.0	0.9	1.0	1.1	1.1
		N	90	90	90	90	55	55
	100	Mean	**0.3[b]**	**0.5[b]**	0.1	-0.1	**-0.4[b]**	0.9
		STD	1.0	1.1	1.3	1.2	0.9	0.7
		N	89	89	89	89	53	53
Aroclor-1254	25	Mean	**-0.2[b]**	-0.4	**0.9[b]**	0.6	**-0.5[b]**	1.0
		STD	1.0	1.1	1.1	1.2	1.1	1.1
		N	90	89	88	88	54	54
	50	Mean	**0.2[b]**	-0.8	0.8	0.7	**-0.4[b]**	0.7
		STD	1.0	1.1	1.1	1.0	1.0	1.0
		N	92	91	91	91	55	55
	100	Mean	**0.2[b]**	-0.6	0.4	0.4	**-0.3[b]**	**0.4[b]**
		STD	1.0	0.8	1.1	1.1	1.3	0.9
		N	90	90	90	89	55	55
Aroclor-1260	25	Mean	1.0	0.1	0.2	0.6	0.6	**-0.1[b]**
		STD	1.0	1.0	1.0	1.2	1.2	1.4
		N	91	91	91	91	56	55
	50	Mean	0.9	-0.1	0.4	0.5	0.3	**0.1[b]**
		STD	1.0	1.2	1.1	0.9	1.0	1.2
		N	88	88	88	86	53	53
	100	Mean	0.8	-0.1	0.5	0.4	0.2	0.7
		STD	1.0	1.1	1.0	1.2	1.1	1.4
		N	92	92	92	92	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			386	393	400	407	414	421
Control	0	Mean	0.2	0.2	1.0	-0.1	-0.5	0.0
		STD	1.2	1.4	1.4	1.5	1.4	1.5
		N	98	98	98	98	97	96
Aroclor-1016	50	Mean	0.3	0.2	**0.2[b]**	0.3	**0.7[b]**	-0.7
		STD	1.0	1.0	1.5	1.1	1.2	1.1
		N	56	56	56	56	55	55
	100	Mean	0.7	0.4	**-0.2[b]**	0.7	**0.4[b]**	-0.7
		STD	1.3	1.0	1.6	1.3	1.4	1.4
		N	53	53	52	52	52	52
	200	Mean	0.4	0.5	**0.3[b]**	**0.8[b]**	**0.3[b]**	-0.3
		STD	1.0	1.0	1.0	1.0	1.0	1.1
		N	56	56	56	56	56	56
Aroclor-1242	50	Mean	0.0	0.2	-0.1	0.4	**1.2[b]**	0.2
		STD	0.9	1.1	2.2	1.4	1.2	1.4
		N	55	55	55	55	55	55
	100	Mean	-0.2	0.1	**0.3[b]**	0.3	**1.0[b]**	-0.1
		STD	0.7	0.8	0.9	1.2	1.0	1.4
		N	52	52	52	52	52	52
Aroclor-1254	25	Mean	0.2	0.4	**-0.4[b]**	-0.2	**0.5[b]**	**1.2[b]**
		STD	1.4	1.1	1.2	0.9	1.3	1.1
		N	54	53	53	53	52	52
	50	Mean	0.3	0.5	**-0.6[b]**	-0.6	**0.8[b]**	**1.0[b]**
		STD	1.0	1.2	1.3	1.0	0.9	1.0
		N	55	55	55	55	55	55
	100	Mean	0.2	0.4	**-0.4[b]**	-0.2	**0.2[b]**	0.6
		STD	0.9	1.1	1.0	0.9	1.0	1.1
		N	55	55	54	54	54	54
Aroclor-1260	25	Mean	-0.3	**0.9[b]**	0.7	0.0	**0.5[b]**	0.1
		STD	1.1	0.9	1.1	1.2	0.9	1.8
		N	55	55	55	55	55	55
	50	Mean	0.5	0.4	0.3	0.0	**0.2[b]**	0.7
		STD	1.4	1.3	1.2	1.0	1.3	1.0
		N	53	53	53	53	52	52
	100	Mean	0.2	0.4	1.0	-0.3	**0.4[b]**	0.7
		STD	1.2	1.0	1.1	1.2	1.0	1.4
		N	56	56	56	56	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			428	435	442	449	456	463
Control	0	Mean	1.1	0.3	0.4	0.2	0.3	-0.2
		STD	1.5	1.7	1.9	2.2	1.7	2.0
		N	95	94	91	91	89	88
Aroclor-1016	50	Mean	0.7	**1.2**[b]	-0.3	0.1	0.0	-0.4
		STD	1.3	1.2	2.0	1.6	2.2	1.7
		N	55	55	54	53	53	53
	100	Mean	0.5	1.0	0.7	0.4	0.2	0.1
		STD	1.3	2.3	1.7	1.8	1.5	1.5
		N	51	51	51	51	51	51
	200	Mean	0.4	0.8	0.2	0.4	0.0	0.0
		STD	1.1	1.1	1.0	1.2	1.5	1.3
		N	56	56	56	55	55	54
Aroclor-1242	50	Mean	**0.1**[b]	0.1	0.7	-0.2	1.2	-0.1
		STD	1.1	1.2	1.1	1.0	1.8	1.3
		N	55	55	55	54	54	53
	100	Mean	**0.3**[b]	**-0.8**[b]	0.9	-0.4	0.7	0.1
		STD	1.1	1.0	1.0	1.1	1.5	0.8
		N	52	51	51	51	51	51
Aroclor-1254	25	Mean	**0.2**[b]	0.4	**1.5**[b]	-0.2	-0.2	**1.1**[b]
		STD	1.7	0.9	1.3	1.9	1.9	1.5
		N	51	51	50	50	50	50
	50	Mean	0.5	0.6	**1.3**[b]	0.0	0.1	**0.9**[b]
		STD	1.2	0.9	1.0	1.0	0.9	1.1
		N	55	55	55	55	55	55
	100	Mean	**0.1**[b]	0.5	0.8	-0.1	0.1	0.6
		STD	0.9	0.9	0.9	0.9	1.0	1.1
		N	54	54	54	54	54	54
Aroclor-1260	25	Mean	0.5	**1.2**[b]	0.3	-0.3	0.0	**1.0**[b]
		STD	1.3	0.9	1.1	1.3	1.1	1.1
		N	55	55	55	55	55	54
	50	Mean	**0.2**[b]	1.0	0.2	0.1	0.0	0.4
		STD	1.4	1.0	1.2	1.2	1.0	2.5
		N	52	51	51	50	50	50
	100	Mean	**-0.2**[b]	1.0	-0.4	0.0	-0.3	**1.3**[b]
		STD	1.4	1.2	1.3	1.1	1.5	1.4
		N	56	56	56	56	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			470	477	484	491	498	505
Control	0	Mean	-0.3	0.9	0.6	-0.8	-0.8	0.8
		STD	1.9	1.5	1.7	2.2	2.0	2.6
		N	88	87	87	85	82	82
Aroclor-1016	50	Mean	**0.9[b]**	0.7	1.0	-0.6	**1.1[b]**	0.0
		STD	1.5	1.3	1.1	1.3	1.6	1.4
		N	52	51	51	51	51	51
	100	Mean	**0.7[b]**	0.7	0.9	-0.7	**1.6[b]**	-0.2
		STD	1.3	1.3	1.8	1.2	1.3	1.3
		N	51	51	51	49	48	48
	200	Mean	**0.9[b]**	0.6	0.9	-0.7	**1.3[b]**	-0.1
		STD	1.3	1.0	1.2	1.5	1.3	1.2
		N	54	54	54	52	51	51
Aroclor-1242	50	Mean	-0.3	1.5	0.2	-0.1	0.1	1.2
		STD	2.1	1.8	1.4	1.3	1.4	1.7
		N	53	52	52	52	52	51
	100	Mean	-0.3	1.4	-0.3	**0.3[b]**	**0.3[b]**	0.4
		STD	1.2	1.4	1.4	1.2	1.2	1.4
		N	51	51	51	51	51	50
Aroclor-1254	25	Mean	-0.4	1.2	0.4	0.0	0.1	0.8
		STD	1.4	1.5	0.9	0.9	0.8	1.0
		N	49	49	48	48	48	48
	50	Mean	-0.3	0.8	0.4	-0.3	-0.3	0.4
		STD	1.2	1.2	1.3	1.4	1.8	1.7
		N	55	55	55	55	55	54
	100	Mean	-0.3	0.8	0.3	0.0	**0.2[b]**	0.2
		STD	1.2	0.9	1.0	0.8	0.9	0.8
		N	53	53	53	52	52	52
Aroclor-1260	25	Mean	**0.8[b]**	**-0.1[b]**	1.1	**0.6[b]**	-0.4	0.8
		STD	1.2	1.4	1.1	1.5	1.1	1.4
		N	54	54	54	54	53	53
	50	Mean	0.3	**-0.2[b]**	1.4	0.3	0.2	0.9
		STD	2.0	1.6	2.1	1.5	1.2	1.4
		N	50	49	49	49	48	47
	100	Mean	0.4	**-0.3[b]**	0.3	0.2	-0.1	0.5
		STD	1.4	2.2	1.5	1.3	1.1	1.9
		N	55	55	54	53	51	51

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			512	519	526	533	540	547
Control	0	Mean	-0.2	-0.5	-0.4	-1.0	0.4	0.8
		STD	3.6	2.4	2.1	2.1	1.5	2.3
		N	81	78	75	72	69	67
Aroclor-1016	50	Mean	-0.3	0.2	-0.6	0.1	-0.1	0.0
		STD	1.7	1.8	1.9	2.1	1.3	1.8
		N	51	51	51	50	48	48
	100	Mean	-0.1	0.3	-0.5	**0.3**[b]	-0.4	-0.6
		STD	1.1	1.6	1.6	1.7	1.7	2.2
		N	48	48	48	48	48	48
	200	Mean	0.2	-0.1	-0.1	0.1	0.0	**-0.6**[b]
		STD	1.5	1.9	1.2	2.2	1.8	2.0
		N	51	51	51	51	51	51
Aroclor-1242	50	Mean	0.3	0.1	0.0	-0.1	-0.4	0.2
		STD	1.4	1.3	1.8	1.9	2	2.3
		N	50	50	50	50	49	49
	100	Mean	0.4	-0.2	0.1	0.2	**-0.7**[b]	0.7
		STD	1.1	1.5	1.1	1.5	1.7	1.5
		N	48	48	48	48	48	48
Aroclor-1254	25	Mean	0.3	**0.6**[b]	-0.1	**0.4**[b]	-0.3	**-0.5**[b]
		STD	1.0	1.2	1.0	1.2	1.4	1.3
		N	48	48	48	48	48	48
	50	Mean	0.1	0.3	0.3	0.0	-0.1	0.4
		STD	1.3	1.9	1.2	1.5	1.7	1.5
		N	53	53	53	52	51	51
	100	Mean	0.3	0.0	0.0	-0.1	0.1	0.3
		STD	1.0	1.2	1.2	1.7	1.4	1.2
		N	52	52	52	52	51	50
Aroclor-1260	25	Mean	-0.3	-0.3	0.4	-0.2	-0.3	0.9
		STD	1.6	1.6	2.1	1.6	1.9	1.5
		N	53	53	52	51	50	50
	50	Mean	-0.5	0.8	0.3	-0.3	-0.1	0.4
		STD	1.4	1.8	1.6	1.7	1.3	1.4
		N	47	47	47	47	47	46
	100	Mean	-0.2	0.4	0.5	-0.4	-0.5	1.2
		STD	2.0	1.3	1.5	1.3	1.1	1.5
		N	51	49	49	49	46	46

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			554	561	568	575	582	589
Control	0	Mean	-0.5	0.0	0.0	0.3	-1.9	0.1
		STD	2.3	1.9	2.4	2.6	2.2	1.8
		N	64	60	60	59	59	57
Aroclor-1016	50	Mean	**1.1**[b]	-0.4	0.4	0.6	**0.1**[b]	-0.1
		STD	1.5	1.3	1.2	1.3	1.3	1.7
		N	42	41	40	40	40	40
	100	Mean	0.5	-0.6	-0.6	0.4	**-0.1**[b]	-0.2
		STD	2.1	2.1	2.3	2.3	2.0	2.5
		N	42	40	39	38	38	38
	200	Mean	**1.1**[b]	-0.7	-0.2	0.2	-0.5	0.3
		STD	2.1	1.7	1.1	1.6	2.4	1.2
		N	45	44	42	41	41	39
Aroclor-1242	50	Mean	-0.6	-0.2	0.0	-0.6	**-0.2**[b]	-1.0
		STD	2.2	2.1	2.4	2.1	2.1	2.4
		N	44	44	44	43	42	42
	100	Mean	-0.6	-0.3	0.4	-0.2	**0.3**[b]	-0.1
		STD	1.6	1.6	2.0	1.2	1.7	1.2
		N	42	42	42	41	41	41
Aroclor-1254	25	Mean	-0.8	-0.2	-0.4	-0.1	**-0.3**[b]	0.4
		STD	1.3	1.5	1.3	1.5	1.3	1.5
		N	44	44	44	44	44	44
	50	Mean	-1.0	0.2	-0.5	-0.3	**-0.3**[b]	0.0
		STD	1.7	1.2	1.1	1.5	1.6	1.5
		N	45	44	42	42	42	42
	100	Mean	-0.6	-0.2	-0.4	-0.5	**-0.4**[b]	-0.2
		STD	1.5	1.2	1.3	1.6	1.2	1.5
		N	45	44	44	43	42	42
Aroclor-1260	25	Mean	-1.2	-0.9	0.0	-0.4	**0.1**[b]	-0.3
		STD	2.2	2.6	2.6	2.3	2.8	2.8
		N	45	45	43	42	40	39
	50	Mean	-0.6	-0.1	0.5	-0.3	**0.7**[b]	-1.0
		STD	2.7	1.7	2.1	1.9	2.0	2.5
		N	40	39	39	39	39	38
	100	Mean	-1.0	-0.1	0.9	-0.7	**1.0**[b]	-0.4
		STD	1.8	1.6	1.6	1.5	1.5	1.9
		N	39	39	39	37	37	37

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			596	603	610	617	624	631
Control	0	Mean	0.3	0.4	-0.7	0.3	-0.5	-0.5
		STD	2.6	1.6	1.8	2.3	2.5	2.8
		N	57	53	53	53	53	51
Aroclor-1016	50	Mean	0.0	-0.4	0.3	-0.9	-0.3	-0.7
		STD	2.0	2.9	2.2	2.4	1.8	2.4
		N	40	38	38	36	35	33
	100	Mean	0.1	-0.4	0.2	-1.2	-0.7	-0.5
		STD	2.2	2.3	2.4	2.3	2.7	1.4
		N	37	37	36	34	33	30
	200	Mean	-0.5	0.2	0.2	-0.3	-0.1	-1.0
		STD	2.3	1.5	1.4	1.8	1.9	1.6
		N	39	39	38	38	37	37
Aroclor-1242	50	Mean	-0.7	0.6	-0.3	-0.1	-0.4	0.1
		STD	2.3	2.1	2.4	2.4	2.0	1.9
		N	41	39	39	39	37	36
	100	Mean	0.1	0.0	0.3	-0.4	0.1	0.0
		STD	1.4	1.6	2.2	1.6	1.8	1.5
		N	41	41	41	40	40	40
Aroclor-1254	25	Mean	-0.3	0.5	-0.6	0.4	0.0	-0.4
		STD	1.2	1.3	1.4	2.1	1.9	1.6
		N	44	42	42	42	42	42
	50	Mean	-0.5	-0.7	-1.2	0.2	0.0	-0.6
		STD	2.2	2.0	2.4	1.8	1.9	2.4
		N	42	40	40	36	35	35
	100	Mean	-0.3	-0.3	-0.6	-0.2	-0.1	-0.9
		STD	1.5	1.8	1.4	1.2	1.8	2.2
		N	41	40	38	37	37	34
Aroclor-1260	25	Mean	-0.9	-0.3	1.3[b]	-0.6	-0.2	-1.3
		STD	2.2	2.4	2.0	2.2	2.1	1.4
		N	38	36	35	33	33	32
	50	Mean	-1.0	-0.9	0.2	-0.9	-1.1	-1.3
		STD	3.1	4.3	3.9	3.0	2.8	2.5
		N	37	36	34	31	31	29
	100	Mean	-1.3	0.2	0.5	-0.5	-1.4	-0.4
		STD	2.0	1.8	1.6	1.7	3.2	2.0
		N	37	37	36	36	36	35

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study					
			638	645	652	659	666	673
Control	0	Mean	0.3	-1.3	-0.9	0.2	-0.7	0.0
		STD	2.8	1.7	3.0	2.0	2.6	3.2
		N	48	48	47	47	45	43
Aroclor-1016	50	Mean	0.0	-0.8	-0.2	-0.3	-0.7	-0.1
		STD	2.1	1.6	2.4	2.0	2.2	1.9
		N	33	33	33	32	32	30
	100	Mean	-0.2	-0.7	-0.7	0.0	-0.4	-0.7
		STD	1.9	2.1	2.3	2.6	2.1	3.0
		N	30	30	30	29	29	29
	200	Mean	-0.1	-0.3	0.1	-0.4	-0.6	0.8
		STD	1.6	1.8	1.9	2.7	1.9	2.0
		N	37	37	36	35	34	34
Aroclor-1242	50	Mean	-0.1	-0.4	0.4	**-1.7[b]**	0.8	-0.9
		STD	1.7	1.3	2.8	2.3	3.2	2.7
		N	35	35	35	31	30	30
	100	Mean	0.0	-0.7	0.0	**-2.4[b]**	-0.6	-0.9
		STD	1.8	1.6	2.4	2.7	2.4	1.8
		N	40	38	38	37	34	32
Aroclor-1254	25	Mean	-0.1	-0.5	-0.5	-0.5	-0.2	-0.6
		STD	1.8	1.8	2.3	2.4	1.9	2.5
		N	41	41	41	40	39	38
	50	Mean	-0.4	0.0	-0.2	0.0	0.1	-0.4
		STD	1.5	1.9	1.5	1.5	3.3	2.4
		N	33	30	30	29	29	27
	100	Mean	-0.6	-0.8	0.1	-0.8	0.1	0.2
		STD	2.4	1.6	1.1	1.4	1.3	1.3
		N	31	29	29	29	28	28
Aroclor-1260	25	Mean	-0.7	-0.4	-0.3	-0.8	-0.2	-0.8
		STD	2.8	2.3	1.9	2.6	2.6	2.7
		N	30	29	28	27	25	25
	50	Mean	0.7	-0.1	-1.1	0.0	0.0	0.3
		STD	1.7	2.4	3.0	1.8	1.8	2.4
		N	28	28	28	28	28	28
	100	Mean	-0.3	0.1	-1.7	-0.7	**0.9[b]**	-0.5
		STD	2.3	1.5	2.0	2.0	1.1	2.2
		N	33	32	31	31	29	28

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 22. Group Mean Body Weight Gains (g/day) by Week for Core, Interim, and Stop Study[1] Subgroup Female Rats[a]

Test Substance	Conc. (ppm)		Day of Study						
			680	687	694	701	708	715	722
Control	0	Mean	-1.6	-0.1	-0.6	-0.3	-0.4	0.4	-1.3
		STD	1.6	2.0	1.8	2.4	2.3	2.0	3.2
		N	41	40	39	36	34	32	32
Aroclor-1016	50	Mean	-1.5	-0.6	0.4	-0.4	-1.5	-0.7	-0.1
		STD	2.1	1.7	2.4	3.1	3.5	3.0	1.9
		N	29	28	26	25	25	23	21
	100	Mean	-0.8	-0.4	-0.4	-1.6	-1.3	-0.6	-1.5
		STD	3.1	1.8	2.9	4.4	2.8	3.3	2.7
		N	29	26	26	25	23	23	21
	200	Mean	-1.9	-0.4	-0.2	-0.5	-0.1	0.6	-0.8
		STD	2.4	2.0	2.0	2.6	1.4	2.5	1.3
		N	33	32	31	30	28	27	25
Aroclor-1242	50	Mean	-0.5	-0.6	-0.4	-1.3	-0.9	-0.9	-0.6
		STD	2.1	1.2	1.3	1.9	2.9	2.1	3.3
		N	29	26	26	25	25	25	23
	100	Mean	**-0.1[b]**	-1.6	-0.4	-1.4	-0.6	0.0	-0.5
		STD	2.0	2.4	2.2	2.8	2.0	1.1	2.9
		N	30	29	28	28	27	27	27
Aroclor-1254	25	Mean	-0.9	-0.9	-1.0	-0.5	-0.9	-0.7	-1.2
		STD	2.0	1.9	2.7	3.0	2.4	1.7	2.3
		N	37	36	36	35	35	34	33
	50	Mean	-0.3	-0.3	-1.2	-1.7	-1.0	0.3	-0.6
		STD	1.7	2.0	2.9	2.8	2.3	1.3	1.2
		N	25	23	23	21	18	17	17
	100	Mean	-0.4	-0.7	-0.5	0.1	-1.2	0.3	-1.0
		STD	2.4	1.4	1.5	1.3	1.5	2.0	2.5
		N	28	26	26	24	24	22	21
Aroclor-1260	25	Mean	-0.2	-0.6	0.0	-0.9	-1.5	-0.9	-0.8
		STD	1.8	3.0	1.9	2.8	2.9	1.5	3.4
		N	25	25	25	25	24	22	21
	50	Mean	-0.9	-0.4	-0.3	-0.6	-1.2	-1.1	0.1
		STD	3.1	2.4	1.6	2.4	2.2	3.0	1.5
		N	28	27	26	26	24	24	22
	100	Mean	-1.0	-0.7	0.0	-0.2	-1.3	-0.9	-0.8
		STD	2.1	1.7	1.7	2.2	2.9	2.9	2.8
		N	28	27	27	27	26	25	24

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 23. Group Mean Body Weight Gains (g/day) by Week for Stop Study Subgroup Female Rats Following Treatment Cessation[a]

Test Substance	Conc. (ppm)		Day of Study					
			365	372	379	386	393	400
Control[1]	0	Mean	0.4	0.5	1.3	0.2	0.2	1.0
		STD	1.0	1.1	1.2	1.2	1.4	1.4
		N	108	101	101	98	98	98
Aroclor-1016	50	Mean	0.5	0.2	**0.4[b]**	-0.4	0.4	0.6
		STD	1.0	1.0	1.4	1.2	1.1	1.0
		N	30	30	30	30	30	30
	100	Mean	0.3	0.2	0.6	-0.4	0.5	0.6
		STD	2.1	1.0	1.6	0.9	1.0	1.1
		N	30	29	29	29	29	29
	200	Mean	1.1	**-0.4[b]**	0.9	-0.1	0.5	0.7
		STD	0.9	1.0	0.7	1.1	1.0	0.8
		N	28	27	27	27	27	27
Aroclor-1242	50	Mean	0.2	0.8	**-0.1[b]**	0.0	0.5	0.0
		STD	1.1	0.8	1.0	1.4	1.3	1.6
		N	29	29	29	29	29	29
	100	Mean	-0.3	0.3	**-0.1[b]**	0.0	0.6	0.4
		STD	1.1	1.3	1.1	0.8	1.2	1.0
		N	30	30	30	30	30	30
Aroclor-1254	25	Mean	0.2	0.9	**0.3[b]**	0.0	0.0	**-0.3[b]**
		STD	0.9	0.8	0.8	0.8	1.0	0.9
		N	28	28	28	28	28	28
	50	Mean	0.5	0.4	0.8	0.0	0.1	**-0.4[b]**
		STD	0.9	0.8	0.9	0.9	1.1	1.2
		N	30	30	30	30	30	30
	100	Mean	0.4	0.6	0.7	0.7	0.1	**0.0[b]**
		STD	1.2	0.9	1.2	1.5	1.2	1.0
		N	29	29	29	29	28	28
Aroclor-1260	25	Mean	0.3	0.5	0.7	0.4	-0.1	0.7
		STD	0.8	0.7	1.5	1.5	0.9	1.0
		N	29	29	29	29	29	29
	50	Mean	0.3	0.2	1.8	0.0	0.0	0.9
		STD	0.9	1.0	1.2	0.9	0.8	0.9
		N	28	28	28	28	28	28
	100	Mean	0.1	0.3	1.6	-0.4	0.2	0.8
		STD	1.0	1.5	1.4	1.2	1.0	1.1
		N	30	30	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 23. Group Mean Body Weight Gains (g/day) by Week for Stop Study Subgroup Female Rats Following Treatment Cessation[a]

Test Substance	Conc. (ppm)		Day of Study					
			407	414	421	428	435	442
Control[1]	0	Mean	-0.1	-0.5	0.0	1.1	0.3	0.4
		STD	1.5	1.4	1.5	1.5	1.7	1.9
		N	98	97	96	95	94	91
Aroclor-1016	50	Mean	-0.1	**1.3[b]**	-0.9	**-0.1[b]**	**1.9[b]**	**-0.8[b]**
		STD	1.3	1.1	2.7	1.8	1.3	1.2
		N	30	30	30	30	30	30
	100	Mean	0.2	**1.0[b]**	0.3	0.2	0.9	-0.3
		STD	1.1	1.2	1.5	1.3	1.8	1.2
		N	29	29	29	29	29	29
	200	Mean	0.1	**1.4[b]**	-0.1	0.6	0.9	-0.6
		STD	1.3	0.8	0.8	1.1	1.4	2.4
		N	27	26	26	26	26	26
Aroclor-1242	50	Mean	**1.1[b]**	**1.8[b]**	-0.8	0.1	1.1	-0.6
		STD	1.6	1.3	1.1	1.4	2.5	1.8
		N	29	29	29	29	29	29
	100	Mean	0.3	**1.1[b]**	0.2	**-0.2[b]**	0.2	0.2
		STD	1.0	1.4	1.3	1.4	1.3	1.4
		N	30	30	30	30	30	30
Aroclor-1254	25	Mean	0.2	**0.9[b]**	0.2	0.2	**1.6[b]**	-0.3
		STD	0.9	1.1	1.4	1.2	1.3	2.1
		N	28	28	28	28	28	28
	50	Mean	-0.1	**0.6[b]**	1.0	**-0.4[b]**	0.7	0.2
		STD	0.8	0.9	1.1	1.2	1.4	0.9
		N	30	30	30	30	30	30
	100	Mean	-0.1	**0.5[b]**	1.0	**-0.7[b]**	0.9	0.1
		STD	0.9	1.0	1.2	2.0	1.4	0.9
		N	28	28	28	28	27	27
Aroclor-1260	25	Mean	-0.3	**0.6[b]**	1.0	**-0.4[b]**	1.0	-0.1
		STD	1.0	1.0	1.4	1.2	1.3	1.4
		N	29	29	29	29	29	29
	50	Mean	-0.1	**0.7[b]**	0.9	**-1.1[b]**	1.2	-0.5
		STD	1.0	1.3	1.3	2.2	2.0	2.2
		N	28	28	28	28	28	28
	100	Mean	0.2	**0.4[b]**	0.5	**-0.2[b]**	1.5	-0.3
		STD	1.1	1.1	1.2	1.0	1.3	1.4
		N	29	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 23. Group Mean Body Weight Gains (g/day) by Week for Stop Study Subgroup Female Rats Following Treatment Cessation[a]

Test Substance	Conc. (ppm)		Day of Study					
			449	456	463	470	477	484
Control[1]	0	Mean	0.2	0.3	-0.2	-0.3	0.9	0.6
		STD	2.2	1.7	2.0	1.9	1.5	1.7
		N	91	89	88	88	87	87
Aroclor-1016	50	Mean	0.6	-0.2	0.0	**-5.9[b]**	**2.5[b]**	**2.1[b]**
		STD	1.7	1.0	1.5	2.3	1.9	2.3
		N	30	30	30	29	29	29
	100	Mean	-0.7	0.9	-0.2	**-5.0[b]**	1.6	2.3
		STD	1.8	1.9	1.6	1.6	2.8	2.7
		N	28	28	28	27	27	27
	200	Mean	-0.8	-0.4	0.0	0.6	**-1.3[b]**	0.1
		STD	2.8	2.7	1.7	3.4	2.0	3.3
		N	24	24	24	24	24	24
Aroclor-1242	50	Mean	-0.8	0.9	-0.4	**2.4[b]**	**-1.4[b]**	0.6
		STD	1.7	1.8	1.7	1.0	0.9	1.3
		N	28	28	28	27	27	27
	100	Mean	-0.5	0.1	0.1	**0.7[b]**	**-0.5[b]**	0.7
		STD	1.5	1.3	1.1	1.0	1.4	1.2
		N	30	30	30	30	30	29
Aroclor-1254	25	Mean	0.0	0.9	0.1	**1.4[b]**	**-1.0[b]**	0.8
		STD	0.9	0.7	1.0	1.0	1.0	0.9
		N	26	26	26	26	26	26
	50	Mean	0.3	0.0	0.2	**1.0[b]**	**-0.4[b]**	0.8
		STD	1.2	1.6	1.9	1.1	0.9	1.5
		N	30	30	30	30	30	29
	100	Mean	0.9	0.7	0.6	**2.1[b]**	**-0.9[b]**	1.0
		STD	1.4	1.1	1.1	1.0	1.2	1.3
		N	27	26	26	26	26	26
Aroclor-1260	25	Mean	0.0	0.5	0.3	**2.1[b]**	**-1.2[b]**	1.1
		STD	2.4	2.1	1.6	0.9	0.9	0.8
		N	29	29	27	26	26	26
	50	Mean	-1.4	1.6	0.3	**2.1[b]**	**-1.5[b]**	1.2
		STD	3.8	2.7	1.3	1.2	1.0	1.1
		N	26	26	25	25	24	24
	100	Mean	0.1	0.7	0.4	**1.8[b]**	**-1.6[b]**	0.5
		STD	1.7	1.2	1.1	1.1	1.2	1.6
		N	29	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 23. Group Mean Body Weight Gains (g/day) by Week for Stop Study Subgroup Female Rats Following Treatment Cessation[a]

Test Substance	Conc. (ppm)		Day of Study					
			491	498	505	512	519	526
Control[1]	0	Mean	-0.8	-0.8	0.8	-0.2	-0.5	-0.4
		STD	2.2	2.0	2.6	3.6	2.4	2.1
		N	85	82	82	81	78	75
Aroclor-1016	50	Mean	0.1	**1.9[b]**	0.3	-0.2	-0.1	0.8
		STD	1.9	1.6	1.3	1.6	1.7	1.3
		N	29	28	28	28	28	28
	100	Mean	**1.3[b]**	**1.3[b]**	0.8	-0.4	0.6	0.5
		STD	1.9	2.3	2.2	1.6	1.2	1.3
		N	27	27	26	26	26	26
	200	Mean	-0.2	0.6	0.4	-0.2	-0.2	**0.7[b]**
		STD	1.0	2.0	1.4	1.4	1.1	1.0
		N	22	22	22	21	21	20
Aroclor-1242	50	Mean	0.2	**1.1[b]**	**-0.6[b]**	-0.6	0.0	-0.4
		STD	1.1	1.6	1.1	1.4	1.6	2.0
		N	27	27	27	27	26	26
	100	Mean	0.2	0.5	0.3	-0.2	0.6	-0.1
		STD	1.3	2.7	1.1	1.2	1.4	1.3
		N	29	29	28	28	28	27
Aroclor-1254	25	Mean	**0.7[b]**	**1.8[b]**	-0.2	-0.5	0.2	0.6
		STD	1.0	1.1	1.3	2.0	0.7	0.8
		N	26	26	26	26	25	25
	50	Mean	**0.7[b]**	**1.0[b]**	0.4	-0.1	0.2	0.3
		STD	1.0	1.6	1.0	1.1	1.3	1.8
		N	29	29	29	29	29	29
	100	Mean	**0.4[b]**	0.6	0.9	-0.6	0.7	0.2
		STD	1.2	2.5	1.7	1.7	1.4	1.3
		N	26	26	25	25	25	25
Aroclor-1260	25	Mean	0.3	**1.3[b]**	0.2	0.0	-0.5	0.5
		STD	1.2	1.0	1.1	1.4	1.1	1.4
		N	26	26	26	26	26	26
	50	Mean	0.4	**1.3[b]**	-0.5	-0.4	0.0	-1.0
		STD	1.3	1.3	2.4	1.8	1.3	1.0
		N	24	24	24	24	23	23
	100	Mean	-0.1	**1.2[b]**	-0.3	-0.6	-0.2	0.0
		STD	1.2	1.5	1.2	1.8	1.8	1.7
		N	29	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 23. Group Mean Body Weight Gains (g/day) by Week for Stop Study Subgroup Female Rats Following Treatment Cessation[a]

Test Substance	Conc. (ppm)		Day of Study					
			533	540	547	554	561	568
Control[1]	0	Mean	-1.0	0.4	0.8	-0.5	0.0	0.0
		STD	2.1	1.5	2.3	2.3	1.9	2.4
		N	72	69	67	64	60	60
Aroclor-1016	50	Mean	-0.2	-0.4	0.4	-0.8	1.0	0.1
		STD	3.4	2.2	2.3	2.3	1.9	0.9
		N	28	28	28	22	21	21
	100	Mean	**1.2[b]**	-0.3	0.7	-0.5	1.2	0.1
		STD	1.7	1.7	1.9	1.5	1.9	2.2
		N	26	26	26	20	19	19
	200	Mean	0.3	-0.2	0.7	-1.0	-0.2	-0.1
		STD	1.5	1.3	1.6	1.7	3.4	2.0
		N	20	20	20	15	15	14
Aroclor-1242	50	Mean	0.7	**-1.1[b]**	0.0	0.1	0.1	-0.4
		STD	2.5	1.9	2.0	2.9	1.6	4.0
		N	26	26	26	19	19	19
	100	Mean	**1.5[b]**	-0.6	0.2	-0.8	1.0	0.0
		STD	1.3	1.3	1.5	2.5	1.2	2.4
		N	27	27	27	22	22	22
Aroclor-1254	25	Mean	**1.4[b]**	-0.7	0.2	0.5	-0.1	1.1
		STD	0.9	1.6	2.8	2.4	1.1	1.1
		N	25	25	25	20	19	19
	50	Mean	**0.9[b]**	-0.6	1.1	-1.3	0.0	1.3
		STD	1.2	1.2	1.8	1.7	1.4	1.8
		N	29	28	28	22	20	20
	100	Mean	**1.8[b]**	**-0.9[b]**	1.1	-0.8	0.2	0.1
		STD	1.3	0.9	1.2	1.3	1.3	1.4
		N	24	24	24	17	16	16
Aroclor-1260	25	Mean	**1.7[b]**	-0.4	0.5	-0.5	0.7	1.0
		STD	1.3	1.8	1.4	1.5	1.5	1.4
		N	26	26	26	20	19	19
	50	Mean	**2.1[b]**	**-1.3[b]**	0.5	-0.5	-0.3	0.5
		STD	2.0	1.4	1.9	1.5	1.7	1.6
		N	23	22	22	18	17	15
	100	Mean	0.3	-0.4	0.7	-0.6	0.1	-0.1
		STD	1.8	1.3	1.0	1.8	2.1	1.9
		N	29	28	28	23	22	22

1. Core/Interim subgroup female control data reported for comparison.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 23. Group Mean Body Weight Gains (g/day) by Week for Stop Study Subgroup Female Rats Following Treatment Cessation[a]

Test Substance	Conc. (ppm)		Day of Study					
			575	582	589	596	603	610
Control[1]	0	Mean	0.3	-1.9	0.1	0.3	0.4	-0.7
		STD	2.6	2.2	1.8	2.6	1.6	1.8
		N	59	59	57	57	53	53
Aroclor-1016	50	Mean	-0.5	**0.5**[b]	-0.1	-0.1	-0.9	-1.3
		STD	2.0	1.6	1.1	1.4	1.7	3.9
		N	21	20	20	21	20	20
	100	Mean	-1.2	**0.6**[b]	-0.8	-0.8	-0.4	-0.6
		STD	2.3	1.4	2.8	1.7	2.4	2.3
		N	19	19	19	19	18	18
	200	Mean	-0.8	-0.5	0.1	-0.7	0.2	-0.8
		STD	2.2	2.6	2.5	1.9	1.2	1.7
		N	14	14	14	14	13	13
Aroclor-1242	50	Mean	-1.1	**0.8**[b]	0.9	-0.7	0.1	-0.1
		STD	1.5	1.4	1.6	1.0	1.7	1.4
		N	18	18	18	17	17	15
	100	Mean	-1.3	**0.3**[b]	0.7	-0.8	0.2	-0.1
		STD	2.3	1.8	1.2	1.2	1.1	1.7
		N	21	20	20	20	20	20
Aroclor-1254	25	Mean	0.1	-0.6	0.7	-0.6	0.3	-0.3
		STD	1.0	3.4	1.4	1.0	1.3	1.3
		N	19	19	18	17	17	17
	50	Mean	-0.5	**0.1**[b]	0.6	-1.2	0.5	-1.2
		STD	1.3	1.7	1.6	1.7	2.7	2.6
		N	20	20	20	20	19	19
	100	Mean	0.0	-0.6	-0.3	0.3	0.5	-0.3
		STD	2.3	4.3	2.6	3.1	1.4	1.2
		N	16	15	14	14	14	14
Aroclor-1260	25	Mean	0.3	**0.5**[b]	0.4	-0.3	0.2	0.0
		STD	1.2	1.8	1.6	1.3	1.3	1.3
		N	19	19	19	19	18	18
	50	Mean	-0.3	-1.2	-0.5	-1.3	0.1	-0.4
		STD	2.2	3.3	2.0	1.5	1.1	1.2
		N	15	14	14	13	12	11
	100	Mean	0.0	**0.2**[b]	0.2	-0.7	0.3	-0.3
		STD	1.0	1.1	1.3	1.2	1.0	0.9
		N	20	20	19	19	19	18

1. Core/Interim subgroup female control data reported for comparison.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 23. Group Mean Body Weight Gains (g/day) by Week for Stop Study Subgroup Female Rats Following Treatment Cessation[a]

Test Substance	Conc. (ppm)		Day of Study					
			617	624	631	638	645	652
Control[1]	0	Mean	0.3	-0.5	-0.5	0.3	-1.3	-0.9
		STD	2.3	2.5	2.8	2.8	1.7	3.0
		N	53	53	51	48	48	47
Aroclor-1016	50	Mean	0.6	-0.1	-0.1	-0.4	-0.8	-1.6
		STD	4.1	2.9	3.7	4.1	3.2	2.7
		N	18	18	18	18	18	17
	100	Mean	0.5	0.5	0.1	1.2	-0.8	-0.4
		STD	1.9	1.5	1.9	1.7	1.3	2.0
		N	16	16	16	16	16	16
	200	Mean	0.8	-0.2	0.3	1.2	-0.7	-0.3
		STD	1.6	2.0	2.1	2.1	1.5	1.8
		N	13	13	13	13	13	13
Aroclor-1242	50	Mean	0.1	**1.2**[b]	-0.4	0.5	-0.3	-2.1
		STD	1.1	1.2	2.2	1.5	1.7	3.3
		N	15	15	15	15	15	15
	100	Mean	0.6	0.4	0.3	0.2	**0.7**[b]	-1.3
		STD	1.5	2.2	2.1	1.5	1.7	2.1
		N	19	19	19	18	17	16
Aroclor-1254	25	Mean	1.1	0.2	0.2	-0.3	-0.5	-1.2
		STD	2.3	1.6	1.7	2.7	1.4	1.6
		N	16	16	16	15	15	15
	50	Mean	0.2	0.1	0.1	0.7	0.2	0.1
		STD	3.2	1.3	2.3	1.6	2.5	2.1
		N	19	19	19	18	17	17
	100	Mean	0.8	0.5	0.0	0.8	-0.7	-0.5
		STD	1.4	1.2	1.9	2.0	2.5	1.3
		N	14	14	14	14	14	13
Aroclor-1260	25	Mean	1.3	**1.1**[b]	-0.1	1.4	-0.8	-0.6
		STD	1.3	1.0	1.3	1.4	1.5	1.3
		N	18	18	18	18	18	18
	50	Mean	0.2	0.7	-0.3	0.5	-2.2	-1.1
		STD	2.6	1.2	1.0	1.4	3.5	1.7
		N	11	11	11	11	11	10
	100	Mean	1.2	0.2	0.1	1.2	-0.4	-0.4
		STD	1.5	1.2	1.5	1.4	1.0	1.4
		N	18	18	18	18	18	18

1. Core/Interim subgroup female control data reported for comparison.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 23. Group Mean Body Weight Gains (g/day) by Week for Stop Study Subgroup Female Rats Following Treatment Cessation[a]

Test Substance	Conc. (ppm)		Day of Study					
			659	666	673	680	687	694
Control[1]	0	Mean	0.2	-0.7	0.0	-1.6	-0.1	-0.6
		STD	2.0	2.6	3.2	1.6	2.0	1.8
		N	47	45	43	41	40	39
Aroclor-1016	50	Mean	1.1	-0.7	1.0	-1.0	-0.8	1.8[b]
		STD	2.3	2.4	2.5	3.3	1.8	2.5
		N	17	17	16	14	13	13
	100	Mean	1.4	-0.7	0.9	-0.8	-0.7	0.3
		STD	2.2	2.5	2.0	2.1	1.8	2.7
		N	15	15	15	15	13	12
	200	Mean	-0.1	-0.6	-0.2	-1.8	-1.5	0.4
		STD	2.3	1.9	2.3	3.1	2.0	1.9
		N	13	13	13	12	11	9
Aroclor-1242	50	Mean	1.2	-1.3	1.3	-1.3	-0.6	0.6
		STD	2.1	2.3	1.8	2.8	1.4	1.1
		N	15	15	14	14	14	12
	100	Mean	1.2	-1.2	1.8	-0.5	0.1	0.2
		STD	1.5	2.5	2.9	4.2	3.0	1.6
		N	16	16	16	15	15	14
Aroclor-1254	25	Mean	0.1	0.0	1.3	-0.1	-1.3	-0.8
		STD	2.0	1.4	1.7	1.6	2.6	3.1
		N	15	15	15	15	15	13
	50	Mean	0.4	-0.1	1.4	-0.2	-0.2	0.1
		STD	1.5	2.2	2.0	2.0	1.6	0.9
		N	17	17	15	15	14	14
	100	Mean	0.6	0.2	1.7	-0.4	-0.5	1.0
		STD	1.3	1.1	1.1	1.4	0.8	1.1
		N	13	13	13	13	13	13
Aroclor-1260	25	Mean	0.9	0.3	1.2	-0.3	0.0	0.8
		STD	1.1	1.8	1.4	1.4	1.9	1.9
		N	18	18	18	18	17	17
	50	Mean	0.2	-0.1	0.7	-1.4	-1.4	-0.9
		STD	1.3	0.9	1.6	1.1	2.8	3.0
		N	10	9	9	9	9	8
	100	Mean	0.4	-0.4	-0.5	-0.1	0.1	1.0
		STD	1.5	1.8	3.0	2.4	2.2	2.1
		N	18	18	18	17	17	15

1. Core/Interim subgroup female control data reported for comparison.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 23. Group Mean Body Weight Gains (g/day) by Week for Stop Study Subgroup Female Rats Following Treatment Cessation[a]

Test Substance	Conc. (ppm)		Day of Study			
			701	708	715	722
Control[1]	0	Mean	-0.3	-0.4	0.4	-1.3
		STD	2.4	2.3	2.0	3.2
		N	36	34	32	32
Aroclor-1016	50	Mean	-0.2	-0.2	-1.3	-2.0
		STD	2.8	2.3	5.4	3.6
		N	13	13	12	12
	100	Mean	-1.0	0.0	0.7	-3.3
		STD	2.3	1.5	2.7	4.3
		N	11	11	11	11
	200	Mean	-1.6	-0.5	0.6	-1.6
		STD	2.4	2.7	3.1	1.9
		N	9	9	9	9
Aroclor-1242	50	Mean	-1.1	0.1	1.7	-2.3
		STD	2.1	2.3	1.4	2.9
		N	12	12	11	11
	100	Mean	-0.9	0.4	0.8	-1.6
		STD	2.6	1.8	3.1	1.4
		N	13	12	12	12
Aroclor-1254	25	Mean	-0.7	-0.2	-0.1	-2.2
		STD	2.0	2.0	2.3	3.2
		N	12	12	12	12
	50	Mean	-0.1	-0.3	1.7	-0.9
		STD	1.3	1.3	1.3	1.3
		N	14	14	14	14
	100	Mean	0.4	0.1	0.7	-1.3
		STD	1.2	1.1	2.0	1.3
		N	13	13	13	13
Aroclor-1260	25	Mean	-0.5	-1.3	1.0	-1.4
		STD	2.5	2.9	1.2	1.3
		N	15	15	15	14
	50	Mean	-0.1	0.1	0.6	-1.7
		STD	1.3	2.0	2.1	1.3
		N	7	7	7	6
	100	Mean	-0.8	0.7	0.5	-0.8
		STD	1.5	1.0	1.0	1.3
		N	14	14	13	13

1. Core/Interim subgroup female control data reported for comparison.
a. Statistical difference from control at $p \leq 0.05$ not reported for body weight gains.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			8	15	22	29	36	43
Control	0	Mean	27	26	27	27	27	27
		STD	2	2	2	2	2	2
		N	118	118	118	118	118	118
Aroclor-1016	50	Mean	27	27[a]	28	28	28[a]	28
		STD	2	2	2	2	2	3
		N	68	68	68	68	68	68
	100	Mean	27	27[a]	28	28	28[b]	28[b]
		STD	2	2	2	2	2	2
		N	68	68	68	68	68	67
	200	Mean	27	27	28	28	28[a]	28[b]
		STD	2	2	2	3	2	2
		N	68	68	68	67	68	68
Aroclor-1242	50	Mean	26	27	27	28	28[b]	28[b]
		STD	2	2	3	2	2	2
		N	68	68	68	68	68	68
	100	Mean	26	27	27	28	28	28
		STD	3	2	2	3	3	3
		N	68	68	68	68	68	67
Aroclor-1254	25	Mean	26	27	27	27	27	28[b]
		STD	2	2	2	3	2	3
		N	68	68	68	68	67	67
	50	Mean	26	27[a]	27	27	28	28[b]
		STD	2	2	2	3	2	2
		N	68	68	68	68	67	68
	100	Mean	25[b]	26	26[b]	26[b]	26[a]	26
		STD	2	2	2	2	2	2
		N	68	68	68	68	68	68
Aroclor-1260	25	Mean	26	28[b]	28	28	28	29[b]
		STD	2	2	2	2	3	3
		N	68	68	68	68	68	68
	50	Mean	26	28[b]	27	28	29[b]	29[b]
		STD	2	2	2	2	3	3
		N	68	68	68	68	68	68
	100	Mean	26	27[a]	28	28	29[b]	29[b]
		STD	2	2	2	2	2	3
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			50	57	64	71	78	85
Control	0	Mean	27	26	27	27	27	26
		STD	2	2	2	2	2	2
		N	118	118	118	118	118	117
Aroclor-1016	50	Mean	29[b]	30[b]	29[b]	29[b]	29[b]	29[b]
		STD	3	3	3	3	3	3
		N	68	68	68	68	68	68
	100	Mean	29[b]	29[b]	29[b]	28[a]	28[a]	28
		STD	3	3	3	2	3	4
		N	68	68	68	68	68	68
	200	Mean	28[b]	29[b]	28[b]	28	28[a]	28[b]
		STD	2	2	3	2	3	2
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	27	28[b]	27	27	27	27
		STD	3	3	2	3	2	3
		N	68	68	68	68	68	68
	100	Mean	28	28[b]	27	28[a]	27	27[b]
		STD	3	2	2	2	2	2
		N	68	68	68	68	68	68
Aroclor-1254	25	Mean	28[b]	28[b]	29[b]	28[b]	28[b]	27[a]
		STD	2	2	3	2	3	2
		N	67	67	67	67	67	67
	50	Mean	27	27	27	27	27	26
		STD	2	2	3	2	2	3
		N	68	68	68	68	68	68
	100	Mean	26	26	26	25[b]	25[b]	25
		STD	2	2	2	3	2	2
		N	68	68	67	67	67	67
Aroclor-1260	25	Mean	28[a]	29[b]	28[b]	28[b]	28[a]	28[b]
		STD	4	3	3	3	3	3
		N	68	68	68	68	68	68
	50	Mean	29[b]	29[b]	28[b]	28[b]	28[a]	28[b]
		STD	3	3	3	3	3	2
		N	68	68	68	68	68	68
	100	Mean	29[b]	29[b]	28[b]	28[b]	28[b]	29[b]
		STD	3	3	3	3	3	3
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			92	99	106	114	120	127
Control	0	Mean	27	26	26	26	26	26
		STD	2	2	2	2	3	2
		N	117	117	117	117	117	117
Aroclor-1016	50	Mean	**28[b]**	**27[b]**	27	27	**28[b]**	27
		STD	3	2	3	2	3	2
		N	68	67	67	67	67	67
	100	Mean	27	26	26	26	**27[a]**	26
		STD	3	3	2	3	2	3
		N	68	68	68	63	68	68
	200	Mean	27	26	26	**27[b]**	**27[a]**	27
		STD	2	2	2	3	2	3
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	26	26	27	27	**28[b]**	**27[a]**
		STD	2	2	2	2	3	3
		N	68	68	68	68	68	68
	100	Mean	27	26	**27[a]**	27	**27[b]**	27
		STD	2	2	2	2	2	2
		N	68	68	67	68	68	67
Aroclor-1254	25	Mean	27	27	27	**27[a]**	**27[b]**	**28[a]**
		STD	2	2	2	2	2	3
		N	67	67	67	67	67	67
	50	Mean	26	26	26	27	**27[a]**	**27[a]**
		STD	2	2	2	2	2	2
		N	68	68	68	68	68	68
	100	Mean	**25[a]**	25	26	26	25	26
		STD	3	3	2	2	3	3
		N	67	66	66	66	66	66
Aroclor-1260	25	Mean	26	26	27	26	**28[b]**	27
		STD	3	3	3	3	3	3
		N	68	68	68	68	68	68
	50	Mean	26	27	27	26	**28[b]**	27
		STD	3	2	3	2	3	2
		N	68	68	68	68	68	68
	100	Mean	27	27	**27[a]**	**27[a]**	**29[b]**	**27[a]**
		STD	3	3	3	2	3	3
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			134	141	149	155	162	169
Control	0	Mean	27	25	25	26	26	26
		STD	2	2	2	2	3	3
		N	117	117	117	117	116	117
Aroclor-1016	50	Mean	27	28[b]	27[b]	28[b]	27[b]	28[a]
		STD	3	2	2	3	3	3
		N	67	67	67	67	67	67
	100	Mean	26[a]	27[b]	27[b]	28[b]	27	27
		STD	2	2	3	3	3	3
		N	68	68	68	68	68	68
	200	Mean	27	27[a]	27[b]	28[b]	27	27
		STD	2	2	3	3	3	3
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	27	27[b]	27[b]	27	27[b]	27[a]
		STD	2	2	2	2	2	2
		N	68	68	68	68	68	68
	100	Mean	27	27[b]	27[b]	27	27[a]	27
		STD	2	2	2	2	2	3
		N	67	67	67	67	67	67
Aroclor-1254	25	Mean	28	28[b]	27[b]	28[b]	27[b]	27
		STD	2	3	2	3	2	2
		N	67	67	67	67	67	67
	50	Mean	27	27[b]	27[b]	27[a]	27	26
		STD	2	2	2	2	2	2
		N	68	68	68	68	68	68
	100	Mean	26[b]	26	25	26	26	25
		STD	2	2	2	3	3	3
		N	66	66	66	66	66	66
Aroclor-1260	25	Mean	27	28[b]	27[b]	28[b]	28[b]	27
		STD	3	3	2	3	3	3
		N	68	68	68	68	68	68
	50	Mean	26[a]	27[b]	27[b]	27[a]	27[b]	27
		STD	2	2	2	2	2	2
		N	68	68	68	68	68	68
	100	Mean	27	28[b]	27[b]	28[b]	28[b]	28[b]
		STD	3	3	2	3	3	2
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			176	183	190	197	204	211
Control	0	Mean	25	27	26	26	26	27
		STD	3	3	3	3	3	2
		N	117	117	112	112	112	112
Aroclor-1016	50	Mean	28[b]	27	27	28[b]	28[b]	28[a]
		STD	3	3	3	3	3	3
		N	67	67	61	61	61	61
	100	Mean	27[b]	26	26	27[a]	27[b]	27
		STD	3	3	3	3	3	3
		N	68	68	62	61	61	61
	200	Mean	27[b]	27	27	28[b]	28[b]	28[b]
		STD	2	3	3	3	3	3
		N	68	68	62	61	61	61
Aroclor-1242	50	Mean	27[b]	27	26	26	27[a]	27
		STD	2	2	3	3	2	2
		N	68	68	62	62	62	62
	100	Mean	27[b]	27	26	27	27[a]	27
		STD	2	3	3	3	3	2
		N	66	66	60	60	60	60
Aroclor-1254	25	Mean	27[b]	28	27	27[b]	27[b]	27
		STD	2	2	3	2	2	2
		N	66	66	61	61	61	61
	50	Mean	26[b]	27	26	26	26	26
		STD	2	2	2	2	2	2
		N	68	68	62	62	62	62
	100	Mean	25	25[b]	25[b]	25	25	25[b]
		STD	3	2	3	2	2	2
		N	66	65	59	59	59	59
Aroclor-1260	25	Mean	27[b]	27	26	27[a]	27[b]	27
		STD	3	2	3	3	3	3
		N	68	68	62	62	62	62
	50	Mean	27[b]	27	26	27	27[b]	28
		STD	2	2	3	3	3	2
		N	68	68	62	62	62	61
	100	Mean	26[b]	27	26	27	27[b]	28[a]
		STD	2	3	3	2	3	3
		N	68	68	62	62	62	62

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			218	225	232	239	246	253
Control	0	Mean	27	28	27	28	28	29
		STD	2	3	2	3	2	3
		N	112	112	112	112	112	112
Aroclor-1016	50	Mean	28	27	**28[b]**	28	29	29
		STD	3	4	3	3	3	3
		N	61	61	60	60	59	59
	100	Mean	28	27	27	28	29	27
		STD	3	3	3	3	3	3
		N	61	61	61	61	61	61
	200	Mean	28	28	27	28	29	28
		STD	3	2	2	3	2	2
		N	61	61	61	61	60	60
Aroclor-1242	50	Mean	27	**27[a]**	26	**26[b]**	27	**27[b]**
		STD	2	2	2	2	2	2
		N	62	62	62	62	62	62
	100	Mean	27	27	27	28	28	**27[b]**
		STD	2	2	3	2	2	2
		N	59	59	59	59	59	59
Aroclor-1254	25	Mean	27	27	27	27	27	**27[b]**
		STD	2	2	2	3	3	3
		N	61	61	61	61	61	61
	50	Mean	27	**26[b]**	26	**27[b]**	**26[b]**	**27[b]**
		STD	2	2	2	2	2	2
		N	62	62	62	62	62	62
	100	Mean	**26[b]**	**25[b]**	25	**26[b]**	**25[b]**	**25[b]**
		STD	2	2	2	2	2	2
		N	59	59	59	59	59	59
Aroclor-1260	25	Mean	28	28	28	28	29	**27[a]**
		STD	3	3	3	3	3	3
		N	62	62	62	62	62	62
	50	Mean	27	28	27	28	28	**26[b]**
		STD	2	2	2	2	2	2
		N	61	61	61	61	61	61
	100	Mean	27	28	27	28	28	**27[b]**
		STD	3	2	3	3	3	3
		N	62	62	62	62	62	62

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			260	267	274	281	288	295
Control	0	Mean	28	27	27	27	27	27
		STD	3	3	2	3	2	3
		N	111	112	112	112	111	112
Aroclor-1016	50	Mean	28	29[b]	29[b]	28	29[b]	28
		STD	2	3	3	3	3	3
		N	59	59	59	59	59	59
	100	Mean	27[b]	28	28[b]	27	28	27
		STD	3	3	3	3	3	3
		N	61	61	61	61	61	61
	200	Mean	27[a]	28	28	27	28	28
		STD	3	3	3	2	3	2
		N	60	60	60	60	60	60
Aroclor-1242	50	Mean	27	28	28	27	27	28
		STD	2	3	2	3	2	2
		N	62	62	62	62	62	62
	100	Mean	27	28	27	28	27	27
		STD	2	2	3	2	2	3
		N	59	59	58	58	58	59
Aroclor-1254	25	Mean	27[a]	27	27	27	27	27
		STD	3	2	3	2	3	3
		N	61	61	61	61	61	61
	50	Mean	27[a]	27	27	26	27	26
		STD	2	2	2	2	2	3
		N	62	62	62	62	62	62
	100	Mean	26[b]	27	26	26	27	27
		STD	2	2	2	2	2	2
		N	59	59	59	59	59	59
Aroclor-1260	25	Mean	28	29[a]	29[b]	28[b]	28[a]	28
		STD	3	3	3	3	3	3
		N	62	62	62	62	61	62
	50	Mean	28	29[a]	28	28	28	28
		STD	2	2	3	3	3	3
		N	61	60	61	61	61	61
	100	Mean	28	28	27	28[a]	28	28
		STD	3	3	3	3	3	3
		N	61	61	61	61	61	61

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

802318

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			302	309	316	323	330	337
Control	0	Mean	27	27	27	28	28	27
		STD	3	3	3	3	3	3
		N	112	112	111	110	110	110
Aroclor-1016	50	Mean	**28[a]**	28	28	28	28	**28[a]**
		STD	2	3	2	3	2	3
		N	59	59	59	59	59	59
	100	Mean	27	28	27	28	27	28
		STD	3	3	3	3	3	3
		N	61	61	61	61	61	61
	200	Mean	**29[b]**	28	28	29	28	**28[a]**
		STD	2	3	3	3	2	3
		N	60	60	60	60	60	60
Aroclor-1242	50	Mean	27	27	27	27	28	28
		STD	2	3	2	2	3	3
		N	62	62	62	62	62	62
	100	Mean	27	27	27	27	28	27
		STD	2	3	2	2	3	3
		N	59	58	58	57	57	57
Aroclor-1254	25	Mean	28	27	28	28	28	28
		STD	3	3	3	3	3	3
		N	61	61	60	60	60	60
	50	Mean	26	27	28	27	28	28
		STD	4	3	3	3	3	3
		N	62	62	62	61	61	61
	100	Mean	27	27	27	**26[b]**	27	27
		STD	2	2	2	2	2	2
		N	59	59	59	59	58	57
Aroclor-1260	25	Mean	**28[a]**	**29[b]**	28	28	28	28
		STD	3	3	3	3	3	3
		N	62	62	62	62	62	62
	50	Mean	**28[a]**	28	28	27	28	**28[b]**
		STD	3	3	3	3	2	2
		N	61	61	61	60	61	61
	100	Mean	28	28	28	28	28	28
		STD	3	3	4	3	3	4
		N	61	61	61	61	61	61

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			344	351	358	365	372	379
Control	0	Mean	26	28	27	28	27	28
		STD	3	3	3	3	3	3
		N	110	110	110	110	110	104
Aroclor-1016	50	Mean	28[a]	28	28	27	28	29
		STD	3	3	3	3	3	3
		N	59	59	59	59	58	52
	100	Mean	27	28	28	28	28	29
		STD	3	3	3	3	3	3
		N	61	61	61	61	60	55
	200	Mean	28[a]	28	28	28	28	29
		STD	3	2	3	3	3	3
		N	60	60	60	60	60	54
Aroclor-1242	50	Mean	27	27	27	28	26	27
		STD	3	3	4	4	5	5
		N	62	62	62	62	62	56
	100	Mean	27	28	27	28	26	26
		STD	3	3	3	3	4	3
		N	57	57	57	57	57	52
Aroclor-1254	25	Mean	27	27	28	28	27	28
		STD	3	3	3	3	4	4
		N	60	60	60	60	60	54
	50	Mean	28[a]	27	27	27	26	27
		STD	3	3	2	2	3	2
		N	61	61	61	61	61	55
	100	Mean	26	25[b]	25[b]	26[b]	25[b]	26[a]
		STD	2	3	3	2	3	2
		N	58	58	58	58	58	52
Aroclor-1260	25	Mean	29[b]	28	27	28	28	27
		STD	4	3	3	3	3	4
		N	62	61	61	61	61	55
	50	Mean	29[b]	28	28	28	27	27
		STD	2	2	2	3	3	3
		N	61	61	61	60	60	54
	100	Mean	29[b]	28	27	28	28	28
		STD	3	3	3	3	3	3
		N	61	61	58	59	59	52

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			386	393	400	407	414	421
Control	0	Mean	28	28	28	27	28	28
		STD	3	3	4	4	3	3
		N	104	104	104	103	102	102
Aroclor-1016	50	Mean	28	29	28	29	27	27
		STD	4	4	4	3	3	4
		N	52	52	52	52	52	52
	100	Mean	28	28	28	28	27[b]	27
		STD	3	3	3	3	3	4
		N	55	55	55	55	54	54
	200	Mean	28	29	28	28	27	28
		STD	3	2	3	4	5	3
		N	54	54	54	54	54	53
Aroclor-1242	50	Mean	28	28	27	27	27[b]	27
		STD	3	3	3	3	2	2
		N	54	54	54	54	54	54
	100	Mean	28	28	27	27	27[b]	27
		STD	5	3	3	3	2	3
		N	51	51	51	51	51	51
Aroclor-1254	25	Mean	28	28	27	26	26[b]	27
		STD	4	4	3	3	3	3
		N	54	53	53	53	53	52
	50	Mean	27	27	26[a]	25[b]	25[b]	25[b]
		STD	2	3	3	3	2	3
		N	55	55	55	55	54	54
	100	Mean	26	26	25[b]	24[b]	24[b]	25[b]
		STD	2	2	3	2	2	2
		N	52	52	52	52	52	52
Aroclor-1260	25	Mean	28	27	28	28	28	26
		STD	4	4	4	4	3	3
		N	55	55	55	55	55	55
	50	Mean	27	27	28	29	28	27
		STD	3	3	2	3	3	3
		N	54	53	53	53	53	53
	100	Mean	28	26	29	29	28	27
		STD	4	4	5	4	4	4
		N	53	53	53	52	51	49

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			428	435	442	449	456	463
Control	0	Mean	27	26	26	28	28	28
		STD	3	3	3	3	3	3
		N	101	101	101	101	100	100
Aroclor-1016	50	Mean	28	**29[b]**	28	28	29	29
		STD	3	3	4	4	4	4
		N	52	52	52	52	52	52
	100	Mean	27	**28[a]**	27	28	28	28
		STD	3	3	3	3	3	3
		N	53	53	52	52	51	51
	200	Mean	28	28	28	28	29	29
		STD	4	4	5	4	4	4
		N	53	53	53	52	52	52
Aroclor-1242	50	Mean	27	**28[a]**	**28[b]**	28	29	30
		STD	2	2	2	2	3	3
		N	54	53	53	53	53	53
	100	Mean	27	**28[b]**	**28[b]**	29	29	29
		STD	3	3	2	2	2	4
		N	51	51	51	51	51	51
Aroclor-1254	25	Mean	28	**28[b]**	**28[b]**	**29[a]**	29	28
		STD	3	3	3	3	4	3
		N	52	52	52	52	52	51
	50	Mean	27	27	27	28	28	27
		STD	2	3	3	2	2	4
		N	53	53	52	52	52	52
	100	Mean	26	26	26	28	28	27
		STD	2	3	3	2	3	3
		N	52	52	52	52	52	52
Aroclor-1260	25	Mean	27	27	28	28	28	27
		STD	3	3	4	4	4	5
		N	55	55	55	55	55	55
	50	Mean	27	28	**28[a]**	29	29	29
		STD	2	4	4	2	3	3
		N	53	53	52	52	52	52
	100	Mean	27	27	28	28	29	28
		STD	4	5	5	4	4	4
		N	49	49	48	48	48	47

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			470	477	484	491	498	505
Control	0	Mean	27	27	27	27	27	26
		STD	4	3	5	4	3	3
		N	100	100	100	99	97	97
Aroclor-1016	50	Mean	28	29	29	28	28	27
		STD	4	5	3	3	4	5
		N	52	51	50	50	50	50
	100	Mean	28	28	28	28	28	28
		STD	4	4	4	4	4	5
		N	51	51	50	49	49	49
	200	Mean	28	**29[b]**	**30[b]**	**29[b]**	**29[a]**	**29[b]**
		STD	4	4	4	4	4	4
		N	52	52	52	52	52	51
Aroclor-1242	50	Mean	28	**30[b]**	**30[b]**	28	28	28
		STD	3	3	3	4	5	5
		N	53	52	51	51	51	51
	100	Mean	28	29	**29[b]**	28	29	**28[a]**
		STD	4	5	3	3	5	2
		N	51	51	50	50	49	48
Aroclor-1254	25	Mean	**29[a]**	28	27	28	28	27
		STD	5	3	6	5	4	4
		N	51	50	51	50	48	49
	50	Mean	28	28	28	27	26	25
		STD	3	3	3	3	6	4
		N	52	52	51	50	50	49
	100	Mean	**29[a]**	27	27	27	28	27
		STD	3	3	3	3	2	2
		N	52	52	51	51	51	51
Aroclor-1260	25	Mean	28	27	28	27	28	27
		STD	6	6	6	5	6	5
		N	55	54	51	51	50	47
	50	Mean	**29[b]**	28	28	28	28	27
		STD	3	3	3	4	4	4
		N	49	49	49	49	49	49
	100	Mean	28	28	29	29	28	28
		STD	6	5	3	3	4	4
		N	48	46	45	44	44	43

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			512	519	526	533	540	547
Control	0	Mean	26	28	27	27	27	28
		STD	4	4	4	5	3	3
		N	97	95	94	93	91	91
Aroclor-1016	50	Mean	27	27	27	27	28	26
		STD	5	4	4	5	7	6
		N	50	49	48	47	45	43
	100	Mean	27	27	27	28	29	28
		STD	6	4	4	4	4	4
		N	49	46	47	47	47	46
	200	Mean	28	28	28	27	28	27
		STD	4	2	3	3	4	4
		N	51	50	50	50	50	48
Aroclor-1242	50	Mean	28	26	27	28	28	27
		STD	7	7	6	5	5	5
		N	51	51	50	49	49	48
	100	Mean	28	27	27	27	28	27
		STD	3	4	5	7	6	4
		N	48	47	46	45	44	43
Aroclor-1254	25	Mean	28	27	28	27	28	28
		STD	4	4	4	5	5	4
		N	49	49	48	48	48	46
	50	Mean	25	25	26	26	27	27
		STD	6	6	5	4	3	4
		N	49	48	46	45	43	42
	100	Mean	27	26	26	26	26	26
		STD	3	4	4	3	4	4
		N	51	50	50	49	49	49
Aroclor-1260	25	Mean	27	27	28	28	28	28
		STD	4	5	4	5	4	5
		N	47	47	47	46	45	44
	50	Mean	27	27	28	27	26	27
		STD	4	3	3	3	4	5
		N	49	48	47	47	45	44
	100	Mean	28	28	28	29	27	29
		STD	4	3	4	4	3	3
		N	43	43	43	42	42	40

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			554	561	568	575	582	589
Control	0	Mean	27	28	27	28	27	27
		STD	3	4	3	4	3	4
		N	90	86	84	84	82	81
Aroclor-1016	50	Mean	25	27	28	28	28	26
		STD	8	7	7	7	6	8
		N	43	36	36	35	35	35
	100	Mean	27	28	28	28	26	26
		STD	5	4	4	6	7	7
		N	44	39	38	37	38	35
	200	Mean	27	28	28	27	28	27
		STD	3	2	5	5	3	4
		N	46	41	41	41	40	40
Aroclor-1242	50	Mean	27	28	28	28	27	27
		STD	5	7	5	4	5	6
		N	48	43	42	40	40	40
	100	Mean	27	28	27	27	27	26
		STD	4	4	4	5	5	6
		N	42	38	37	37	36	36
Aroclor-1254	25	Mean	25	26	26	26	27	24
		STD	6	4	4	3	3	5
		N	46	41	41	40	39	39
	50	Mean	**25[a]**	**24[a]**	26	**25[b]**	26	24
		STD	4	5	5	5	6	6
		N	39	35	35	34	34	34
	100	Mean	**25[a]**	**25[a]**	26	**25[b]**	26	**23[b]**
		STD	4	5	4	2	3	3
		N	47	43	42	40	39	39
Aroclor-1260	25	Mean	27	28	**29[a]**	30	**30[b]**	**30[b]**
		STD	5	5	4	4	4	4
		N	45	41	40	40	39	39
	50	Mean	25	26	27	27	26	26
		STD	5	6	5	7	7	6
		N	42	37	36	36	36	36
	100	Mean	27	28	29	29	29	**29[a]**
		STD	4	4	5	4	5	5
		N	40	37	37	37	37	36

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			596	603	610	617	624	631
Control	0	Mean	26	29	27	27	27	27
		STD	3	4	4	4	5	5
		N	79	79	78	77	76	76
Aroclor-1016	50	Mean	28	28	28	29[b]	28	29
		STD	5	7	7	2	3	4
		N	33	32	29	27	26	25
	100	Mean	27	29	29	26	26	27
		STD	5	6	5	4	5	5
		N	33	32	32	31	30	28
	200	Mean	27	29	28	26	27	28
		STD	3	4	5	5	4	5
		N	39	39	38	37	35	35
Aroclor-1242	50	Mean	25	27	25	26	27	27
		STD	7	5	6	7	5	5
		N	40	38	37	37	35	34
	100	Mean	26	26	25	26	26	24
		STD	5	6	6	6	7	7
		N	36	34	34	33	30	29
Aroclor-1254	25	Mean	26	25[b]	26	25	26	27
		STD	4	4	6	6	3	4
		N	38	35	34	33	32	32
	50	Mean	25	24[b]	26	25	27	27
		STD	5	6	6	6	3	3
		N	31	32	30	30	29	29
	100	Mean	25	24[b]	25	23[b]	24[b]	25
		STD	3	3	3	3	3	4
		N	39	38	38	38	37	36
Aroclor-1260	25	Mean	30[b]	29	30[b]	30[b]	29	28
		STD	4	4	4	4	6	6
		N	38	38	38	38	38	38
	50	Mean	27	26	27	27	28	27
		STD	6	6	6	5	6	7
		N	35	35	34	34	33	33
	100	Mean	30[b]	29	29	28	29	28
		STD	4	4	5	5	5	5
		N	36	35	35	35	34	34

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			638	645	652	659	666	673
Control	0	Mean	27	26	25	25	25	27
		STD	5	7	6	5	5	4
		N	73	70	70	66	65	60
Aroclor-1016	50	Mean	27	28	27	26	24	25
		STD	3	3	4	6	8	10
		N	25	23	23	23	21	21
	100	Mean	26	25	27	25	25	26
		STD	5	6	18	7	7	8
		N	27	27	27	25	23	23
	200	Mean	26	27	26	27	26	28
		STD	5	6	7	7	6	4
		N	34	34	34	34	33	31
Aroclor-1242	50	Mean	27	26	25	25	24	26
		STD	5	6	6	6	7	9
		N	34	33	32	32	32	32
	100	Mean	25	24	24	24	24	25
		STD	7	6	6	7	7	7
		N	28	28	27	24	23	23
Aroclor-1254	25	Mean	25	25	24	24	24	26
		STD	4	5	5	7	4	5
		N	31	31	31	30	28	28
	50	Mean	25	26	24	24	22	24
		STD	3	5	6	5	7	8
		N	28	28	26	25	24	24
	100	Mean	23[b]	24	23	22	23	24
		STD	4	5	5	5	5	5
		N	35	34	34	32	32	32
Aroclor-1260	25	Mean	29	29	30[b]	28	26	28
		STD	4	5	5	5	7	7
		N	37	36	35	35	35	34
	50	Mean	26	26	27	26	27	28
		STD	7	9	8	7	5	5
		N	32	31	30	28	26	24
	100	Mean	28	27	26	25	24	28
		STD	5	5	7	8	8	5
		N	34	33	33	31	29	26

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 24. Group Mean Feed Consumption (g/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study						
			680	687	694	701	708	715	722
Control	0	Mean	26	24	25	26	25	25	25
		STD	5	6	5	5	6	6	6
		N	60	60	57	54	52	50	46
Aroclor-1016	50	Mean	25	26	26	28	27	27	26
		STD	7	6	8	4	5	5	7
		N	20	20	20	19	18	17	15
	100	Mean	24	24	24	23	21	23	25
		STD	8	7	8	9	9	8	7
		N	21	19	19	19	17	15	14
	200	Mean	26	26	26	26	24	25	26
		STD	4	5	6	6	7	6	6
		N	31	31	31	30	29	29	27
Aroclor-1242	50	Mean	25	25	27	27	26	25	26
		STD	6	8	3	3	4	5	4
		N	31	29	27	26	26	26	25
	100	Mean	26	26	25	24	25	25	26
		STD	6	5	6	7	6	6	5
		N	22	22	22	21	20	19	18
Aroclor-1254	25	Mean	26	27	26	26	25	27	26
		STD	4	4	4	5	3	3	3
		N	26	26	25	25	25	24	23
	50	Mean	22	21	20	24	23	24	25
		STD	9	9	10	8	4	6	4
		N	22	21	18	14	13	13	11
	100	Mean	22[a]	24	24	26	25	26	25
		STD	5	6	4	4	2	2	3
		N	31	29	24	22	21	21	20
Aroclor-1260	25	Mean	27	29[a]	28	27	25	27	27
		STD	4	4	5	5	7	6	6
		N	31	30	30	27	25	24	24
	50	Mean	26	28	28	27	28	28	27
		STD	4	5	5	5	3	3	5
		N	23	23	23	22	19	19	17
	100	Mean	26	27	26	27	27	26	25
		STD	5	5	6	6	6	5	6
		N	26	24	23	22	20	19	17

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			8	15	22	29	36	43
Control	0	Mean	19	21	21	22	22	21
		STD	2	3	3	4	4	4
		N	130	130	130	130	130	130
Aroclor-1016	50	Mean	19	21	21	**21[a]**	23	**23[a]**
		STD	2	3	3	2	4	4
		N	110	110	110	110	110	110
	100	Mean	20	21	22	22	23	**23[b]**
		STD	2	3	3	3	4	4
		N	110	110	110	110	110	110
	200	Mean	**20[b]**	**22[a]**	22	23	**25[b]**	**24[b]**
		STD	3	4	4	5	5	5
		N	110	110	110	110	110	110
Aroclor-1242	50	Mean	20	21	**23[b]**	22	22	21
		STD	3	5	5	4	4	4
		N	110	110	110	110	110	110
	100	Mean	20	21	22	22	22	**22[a]**
		STD	3	4	4	5	5	5
		N	110	110	110	110	110	110
Aroclor-1254	25	Mean	19	20	21	21	**21[b]**	20
		STD	3	3	3	4	3	2
		N	110	110	110	110	109	108
	50	Mean	20	20	21	**21[b]**	**20[b]**	20
		STD	3	3	4	3	2	2
		N	110	110	109	109	108	110
	100	Mean	20	20	**20[b]**	**20[b]**	**20[b]**	**19[b]**
		STD	2	3	3	3	2	3
		N	110	110	110	109	110	110
Aroclor-1260	25	Mean	20	21	22	23	23	22
		STD	3	3	4	5	5	5
		N	110	110	110	110	110	110
	50	Mean	20	21	22	**24[a]**	24	22
		STD	3	3	4	6	6	5
		N	110	110	110	110	110	110
	100	Mean	**21[b]**	21	22	23	24	22
		STD	3	3	4	5	5	4
		N	109	110	110	110	110	109

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			50	57	64	71	78	85
Control	0	Mean	21	21	21	20	21	20
		STD	4	4	4	3	4	3
		N	130	129	129	129	129	128
Aroclor-1016	50	Mean	22	21	21	21	21	20
		STD	4	3	3	3	2	2
		N	110	110	110	110	110	110
	100	Mean	**23[a]**	22	22	21	21	20
		STD	4	4	3	3	2	3
		N	110	110	110	110	110	110
	200	Mean	23	22	21	21	20	20
		STD	4	4	4	4	3	3
		N	110	110	110	110	110	110
Aroclor-1242	50	Mean	**23[b]**	22	21	21	20	19
		STD	5	5	4	4	3	3
		N	110	110	110	110	110	110
	100	Mean	23	21	21	22	20	19
		STD	5	4	5	6	5	2
		N	110	108	110	110	110	110
Aroclor-1254	25	Mean	21	21	20	20	20	20
		STD	3	3	3	4	4	3
		N	109	107	108	110	109	106
	50	Mean	20	20	**20[b]**	19	19	19
		STD	3	3	3	3	3	3
		N	109	109	108	110	110	110
	100	Mean	**19[b]**	**19[b]**	**19[b]**	**19[b]**	**18[b]**	**18[a]**
		STD	3	3	3	3	3	3
		N	109	110	109	110	110	110
Aroclor-1260	25	Mean	23	21	**20[a]**	21	20	20
		STD	5	3	3	4	4	4
		N	110	110	110	110	110	110
	50	Mean	23	22	22	21	21	21
		STD	5	5	5	5	4	4
		N	110	109	109	109	108	108
	100	Mean	22	22	21	21	21	20
		STD	5	4	4	4	4	4
		N	109	110	110	110	110	110

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			92	99	107	113	120	127
Control	0	Mean	19	20	21	20	19	20
		STD	3	3	4	4	3	3
		N	129	122	122	123	122	122
Aroclor-1016	50	Mean	20	20	20	20	21	20
		STD	2	3	3	4	3	3
		N	110	104	104	104	104	104
	100	Mean	20	20	20	20	20	20
		STD	3	3	2	3	3	3
		N	110	103	103	104	104	104
	200	Mean	20	19	21	20	20	20
		STD	3	2	4	2	3	3
		N	110	102	104	104	104	104
Aroclor-1242	50	Mean	19	21	20	21	20	21
		STD	3	5	4	4	3	4
		N	110	104	104	104	104	104
	100	Mean	19	21	20	20	20	20
		STD	3	5	3	4	3	3
		N	110	104	104	104	104	104
Aroclor-1254	25	Mean	20	19	20	19	19	**19[b]**
		STD	3	3	3	3	3	3
		N	108	104	102	102	104	104
	50	Mean	19	**18[b]**	20	19	19	**19[b]**
		STD	3	3	4	3	3	2
		N	110	104	104	104	104	104
	100	Mean	**18[b]**	**18[b]**	**19[b]**	**18[b]**	**18[b]**	**18[b]**
		STD	3	2	3	4	2	2
		N	110	104	104	104	104	104
Aroclor-1260	25	Mean	20	19	**19[a]**	21	19	20
		STD	5	3	3	4	2	3
		N	110	104	104	104	104	104
	50	Mean	20	20	19	22	20	20
		STD	5	5	3	4	3	3
		N	108	102	102	102	102	102
	100	Mean	20	21	19	21	19	20
		STD	4	5	3	4	3	3
		N	110	104	104	104	103	104

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			134	142	148	155	162	169
Control	0	Mean	19	20	19	20	21	20
		STD	3	3	3	3	3	3
		N	123	122	123	122	123	121
Aroclor-1016	50	Mean	**20[a]**	20	**21[b]**	20	21	**21[a]**
		STD	3	2	3	3	3	3
		N	104	104	104	104	104	104
	100	Mean	**21[b]**	20	**21[b]**	20	21	20
		STD	3	2	3	3	3	3
		N	104	104	104	104	104	104
	200	Mean	**20[b]**	**21[a]**	**21[b]**	20	20	20
		STD	3	3	3	3	3	3
		N	103	104	103	104	104	104
Aroclor-1242	50	Mean	**21[b]**	20	20	20	21	20
		STD	3	3	3	4	3	3
		N	101	104	104	104	104	104
	100	Mean	20	20	19	19	20	20
		STD	3	3	3	4	3	3
		N	104	104	104	104	104	104
Aroclor-1254	25	Mean	19	19	19	19	**19[a]**	19
		STD	3	3	3	3	3	3
		N	104	104	104	103	104	104
	50	Mean	19	19	19	19	**19[a]**	20
		STD	3	3	2	2	3	3
		N	104	104	104	104	104	104
	100	Mean	18	**18[b]**	**18[b]**	**18[b]**	**19[b]**	19
		STD	2	2	2	2	2	2
		N	104	104	104	104	104	104
Aroclor-1260	25	Mean	20	20	20	20	**19[b]**	20
		STD	2	3	3	3	3	3
		N	104	104	104	104	104	104
	50	Mean	20	20	21	20	20	20
		STD	3	3	4	3	3	3
		N	102	102	102	102	102	101
	100	Mean	20	20	20	20	20	20
		STD	3	3	3	3	3	4
		N	104	104	104	104	104	104

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			176	183	190	197	204	211
Control	0	Mean	21	20	20	20	20	21
		STD	3	3	3	3	3	3
		N	123	123	117	117	117	117
Aroclor-1016	50	Mean	21	20	20	21	21	21
		STD	3	3	3	3	3	3
		N	104	104	98	98	98	98
	100	Mean	20	20	20	20	21	21
		STD	3	3	2	3	3	2
		N	104	104	98	98	98	98
	200	Mean	20	20	20	21	20	20
		STD	3	3	3	3	3	3
		N	104	104	98	98	98	98
Aroclor-1242	50	Mean	20	21	20	21	21	21
		STD	3	3	3	3	3	3
		N	104	104	98	98	98	98
	100	Mean	20	20	19	20	20	20
		STD	3	3	3	3	3	3
		N	104	104	98	98	98	98
Aroclor-1254	25	Mean	20	19	20	20	20	20
		STD	3	3	3	3	3	3
		N	103	104	97	97	97	97
	50	Mean	20	20	19	20	20	20
		STD	3	3	3	3	3	3
		N	104	104	98	98	98	98
	100	Mean	**19[b]**	19	**19[b]**	19	**19[a]**	**19[b]**
		STD	2	2	2	2	2	2
		N	104	104	98	98	98	98
Aroclor-1260	25	Mean	**19[b]**	19	**19[a]**	20	20	20
		STD	2	3	3	2	3	3
		N	104	104	98	98	98	98
	50	Mean	20	20	20	20	20	20
		STD	3	3	3	3	3	3
		N	101	101	95	95	95	95
	100	Mean	20	20	20	21	20	20
		STD	3	3	3	3	3	3
		N	104	104	98	98	98	97

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			218	225	232	239	246	253
Control	0	Mean	21	21	21	22	20	21
		STD	3	3	3	3	3	3
		N	117	117	117	116	116	115
Aroclor-1016	50	Mean	21	21	22	21	21	21
		STD	2	2	3	3	3	3
		N	97	97	98	97	98	98
	100	Mean	21	21	22[b]	22	22[b]	21
		STD	3	3	3	3	3	3
		N	98	97	98	98	98	97
	200	Mean	21	20	22	21	21	21
		STD	3	3	3	3	3	3
		N	97	97	97	97	97	94
Aroclor-1242	50	Mean	21	21	21	22	21	21
		STD	3	3	3	3	4	3
		N	98	98	98	98	98	96
	100	Mean	20	20[a]	21	21	20	20
		STD	2	3	3	3	3	3
		N	97	97	96	96	96	96
Aroclor-1254	25	Mean	20	20	20	20[b]	21	21
		STD	3	3	3	3	2	2
		N	97	97	97	97	97	97
	50	Mean	20	20	21	20[b]	20	20
		STD	3	3	3	3	3	3
		N	98	97	98	98	98	98
	100	Mean	19[b]	20[b]	20[a]	19[b]	19[a]	19[b]
		STD	2	2	2	3	2	2
		N	98	98	97	98	97	97
Aroclor-1260	25	Mean	20	21	21	21	20	22[b]
		STD	3	3	3	3	4	3
		N	98	98	98	98	98	97
	50	Mean	21	21	21	21	21	22
		STD	3	3	3	3	4	4
		N	94	93	93	94	94	94
	100	Mean	21	20	21	21	21	22
		STD	4	3	3	3	3	3
		N	98	98	98	98	98	98

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			260	267	274	281	288	295
Control	0	Mean	20	20	21	22	21	22
		STD	3	3	3	3	3	3
		N	115	116	116	108	108	109
Aroclor-1016	50	Mean	**22[a]**	**22[b]**	21	21	22	21
		STD	3	3	3	3	3	3
		N	98	98	98	92	92	92
	100	Mean	**23[b]**	**23[b]**	22	23	22	23
		STD	3	3	3	3	3	4
		N	98	98	98	92	92	92
	200	Mean	**22[a]**	**22[b]**	21	22	22	22
		STD	3	3	3	3	3	3
		N	96	96	96	90	90	90
Aroclor-1242	50	Mean	21	**22[b]**	21	21	22	21
		STD	4	4	3	3	4	3
		N	98	98	98	92	92	92
	100	Mean	21	21	20	**20[a]**	22	21
		STD	3	3	3	3	4	3
		N	96	96	96	90	90	90
Aroclor-1254	25	Mean	**22[a]**	21	21	21	21	21
		STD	3	2	3	3	3	3
		N	97	97	97	91	91	91
	50	Mean	21	21	21	21	21	**21[b]**
		STD	3	3	3	3	3	3
		N	98	98	98	92	92	91
	100	Mean	20	20	**20[a]**	**20[b]**	**20[b]**	**20[b]**
		STD	2	3	2	2	2	2
		N	97	97	97	91	91	91
Aroclor-1260	25	Mean	**22[b]**	**22[b]**	21	22	22	22
		STD	3	3	3	3	3	3
		N	97	97	97	91	91	91
	50	Mean	**22[b]**	**22[b]**	22	22	22	22
		STD	3	3	3	3	3	4
		N	94	94	94	86	88	88
	100	Mean	22	21	21	21	21	22
		STD	3	3	3	3	3	3
		N	98	98	98	92	92	92

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			302	309	316	323	330	337
Control	0	Mean	22	23	21	23	21	22
		STD	3	3	3	4	3	3
		N	109	109	109	109	109	108
Aroclor-1016	50	Mean	22	22	22	21[b]	21	22
		STD	2	3	3	3	3	3
		N	92	92	92	92	92	92
	100	Mean	22	22	25	22[a]	21	22
		STD	3	3	20	3	3	3
		N	92	92	92	91	91	91
	200	Mean	21	22	22	22[a]	21	22
		STD	3	3	3	3	3	3
		N	90	90	90	90	90	90
Aroclor-1242	50	Mean	22	22	22	23	22	23
		STD	4	4	3	4	3	4
		N	91	91	91	90	90	90
	100	Mean	21	21[b]	21	22[b]	21	22
		STD	3	3	3	3	3	3
		N	90	90	90	89	89	89
Aroclor-1254	25	Mean	22	22[a]	21	21[b]	22	21[a]
		STD	3	2	3	3	3	3
		N	90	90	90	90	90	90
	50	Mean	22	21[b]	21	21[b]	21	21[a]
		STD	3	3	3	3	3	3
		N	92	92	91	92	92	92
	100	Mean	20[b]	20[b]	20[b]	20[b]	20[a]	20[b]
		STD	3	2	2	2	3	2
		N	91	90	91	91	91	90
Aroclor-1260	25	Mean	23	22	21	21[b]	22	22
		STD	3	3	3	3	3	3
		N	91	91	91	91	91	91
	50	Mean	22	22	21	22[a]	22	23
		STD	3	4	4	3	4	4
		N	88	88	88	88	88	87
	100	Mean	21	22	21	21[b]	22	22
		STD	3	3	3	3	3	3
		N	92	92	92	92	91	92

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			344	351	358	365	372	379
Control	0	Mean	22	23	23	22	22	22
		STD	3	4	3	3	3	3
		N	108	108	108	108	101	101
Aroclor-1016	50	Mean	22	21	**21[b]**	22	21	22
		STD	3	3	3	3	2	3
		N	92	92	92	92	56	56
	100	Mean	22	21	**21[b]**	21	22	22
		STD	3	3	3	4	3	3
		N	91	91	90	90	53	53
	200	Mean	23	22	**21[b]**	22	22	22
		STD	3	3	3	3	3	3
		N	90	90	90	90	56	56
Aroclor-1242	50	Mean	22	21	22	22	21	23
		STD	4	3	3	4	4	4
		N	90	90	90	90	55	55
	100	Mean	**21[a]**	**20[b]**	**21[b]**	**21[a]**	**20[a]**	22
		STD	3	3	3	3	2	3
		N	89	89	89	89	53	53
Aroclor-1254	25	Mean	**20[b]**	**19[b]**	22	22	21	**21[a]**
		STD	3	3	3	3	3	3
		N	90	89	88	88	54	54
	50	Mean	**20[b]**	**19[b]**	**21[a]**	22	21	21
		STD	3	3	3	3	3	3
		N	92	91	91	91	55	55
	100	Mean	**19[b]**	**17[b]**	**20[b]**	**20[b]**	**20[b]**	**20[b]**
		STD	3	2	3	3	2	3
		N	90	90	90	89	55	55
Aroclor-1260	25	Mean	22	21	22	22	21	21
		STD	3	3	3	3	3	3
		N	91	91	91	91	56	55
	50	Mean	22	21	22	22	21	22
		STD	3	4	3	3	3	3
		N	88	88	88	86	53	53
	100	Mean	22	**21[b]**	22	22	21	23
		STD	3	3	3	3	3	3
		N	91	92	92	92	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			386	393	400	407	414	421
Control	0	Mean	22	22	21	22	22	21
		STD	3	3	4	4	4	4
		N	98	98	98	97	97	96
Aroclor-1016	50	Mean	22	22	21	21	22	21
		STD	3	2	3	3	3	3
		N	56	56	56	56	55	55
	100	Mean	23	23	22	22	22	22
		STD	4	3	4	2	3	4
		N	53	53	52	52	52	52
	200	Mean	22	23	**23[a]**	22	23	22
		STD	3	3	2	3	3	3
		N	56	56	56	56	56	56
Aroclor-1242	50	Mean	23	21	21	21	21	23
		STD	3	3	4	3	3	4
		N	55	55	55	55	54	55
	100	Mean	22	21	20	**20[a]**	21	21
		STD	2	2	2	2	2	3
		N	52	52	52	52	52	52
Aroclor-1254	25	Mean	21	**19[b]**	**19[b]**	**19[b]**	**20[a]**	22
		STD	3	4	2	2	3	3
		N	54	53	53	53	52	52
	50	Mean	22	**20[a]**	**19[b]**	**18[b]**	**20[b]**	22
		STD	3	3	3	3	2	3
		N	55	55	55	55	55	55
	100	Mean	**20[a]**	**19[b]**	**18[b]**	**18[b]**	**18[b]**	21
		STD	2	3	2	2	2	3
		N	55	55	54	54	54	54
Aroclor-1260	25	Mean	**20[b]**	**23[a]**	23	23	22	21
		STD	3	3	3	3	3	3
		N	55	55	55	55	55	55
	50	Mean	22	22	22	22	21	21
		STD	2	3	3	3	3	2
		N	53	53	53	53	52	52
	100	Mean	23	23	23	22	21	21
		STD	3	3	3	3	3	3
		N	56	56	56	56	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			428	435	442	449	456	463
Control	0	Mean	22	21	23	22	23	22
		STD	4	3	4	5	3	4
		N	95	94	91	91	89	88
Aroclor-1016	50	Mean	23	23	22	23	23	23
		STD	3	3	4	4	4	5
		N	55	55	54	53	53	52
	100	Mean	23	23	23	23	23	23
		STD	3	4	4	3	3	4
		N	51	51	51	51	51	51
	200	Mean	22	22	21	22	22	23
		STD	3	3	3	3	3	4
		N	56	56	56	55	55	54
Aroclor-1242	50	Mean	**24[b]**	**24[b]**	23	**24[b]**	24	**24[a]**
		STD	3	3	3	3	5	4
		N	54	55	54	54	54	53
	100	Mean	23	**23[a]**	22	**24[a]**	23	23
		STD	3	3	3	3	3	3
		N	52	51	51	51	51	51
Aroclor-1254	25	Mean	22	22	22	22	22	22
		STD	4	3	3	4	4	3
		N	51	51	50	50	50	50
	50	Mean	22	22	22	22	23	22
		STD	3	3	3	3	2	3
		N	55	55	55	55	55	55
	100	Mean	21	21	**20[b]**	21	22	22
		STD	2	2	2	2	2	3
		N	54	54	54	54	54	53
Aroclor-1260	25	Mean	21	22	23	23	22	23
		STD	3	3	3	3	3	3
		N	55	55	55	55	55	54
	50	Mean	21	21	22	22	22	22
		STD	3	2	2	3	2	4
		N	52	51	51	50	50	50
	100	Mean	22	22	23	23	22	23
		STD	3	3	4	3	4	3
		N	56	56	56	56	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			470	477	484	491	498	505
Control	0	Mean	23	22	22	21	21	20
		STD	4	4	4	5	5	6
		N	88	87	87	85	82	82
Aroclor-1016	50	Mean	24	24[a]	24	22	22	22
		STD	3	3	3	3	4	4
		N	52	51	50	50	51	51
	100	Mean	23	23	23	23	23	23[b]
		STD	3	4	4	3	3	3
		N	51	51	51	49	48	48
	200	Mean	23	23	24	22	22	22
		STD	3	4	5	4	4	4
		N	54	54	54	52	51	51
Aroclor-1242	50	Mean	25	23	24[a]	25[b]	23	24[b]
		STD	5	4	4	4	4	4
		N	53	52	51	52	52	51
	100	Mean	25	22	23	23	22	22
		STD	4	4	4	4	4	4
		N	51	51	51	51	51	50
Aroclor-1254	25	Mean	23	22	22	22	22	22
		STD	3	3	3	3	3	3
		N	49	49	48	48	48	48
	50	Mean	23	21	22	21	22	21
		STD	3	3	3	3	4	4
		N	55	55	55	55	55	54
	100	Mean	22	21	21	21	22	21
		STD	3	2	2	3	3	2
		N	52	52	53	52	52	52
Aroclor-1260	25	Mean	23	23	23	22	22	22
		STD	4	3	3	4	4	4
		N	54	54	54	54	53	53
	50	Mean	21	22	22	21	22	22
		STD	5	4	3	4	3	3
		N	50	49	49	49	48	47
	100	Mean	23	23	22	21	21	22
		STD	3	5	4	3	3	4
		N	55	55	54	53	51	51

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			512	519	526	533	540	547
Control	0	Mean	20	21	21	22	21	21
		STD	5	5	5	5	4	5
		N	81	78	75	72	69	67
Aroclor-1016	50	Mean	21	21	21	21	22	20
		STD	5	5	5	5	4	4
		N	51	51	51	50	46	48
	100	Mean	23[a]	22	22	23	22	21
		STD	3	4	4	4	4	4
		N	48	48	47	48	48	48
	200	Mean	22	21	22	23	21	21
		STD	3	4	4	5	4	4
		N	51	50	50	51	51	51
Aroclor-1242	50	Mean	24[b]	25[b]	24[b]	25[b]	22	22
		STD	4	4	3	4	4	5
		N	49	50	50	50	48	49
	100	Mean	22	22	21	22	21	21
		STD	3	4	3	3	4	4
		N	48	48	48	48	48	48
Aroclor-1254	25	Mean	22	22	23	23	21	20
		STD	3	4	4	4	4	4
		N	48	48	48	48	48	48
	50	Mean	22	21	22	22	21	21
		STD	3	3	3	4	3	3
		N	53	53	53	52	51	51
	100	Mean	21	21	21	21	20	20
		STD	3	2	3	4	4	3
		N	52	52	52	52	51	50
Aroclor-1260	25	Mean	21	21	21	22	21	21
		STD	4	4	4	4	5	5
		N	53	53	52	51	50	50
	50	Mean	21	22	21	22	22	22
		STD	3	4	4	4	3	2
		N	47	47	47	47	47	46
	100	Mean	21	22	22	21	22	21
		STD	4	3	3	4	3	4
		N	51	49	49	49	46	46

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			554	561	568	575	582	589
Control	0	Mean	21	22	22	21	21	21
		STD	4	3	4	5	5	5
		N	64	60	60	59	59	57
Aroclor-1016	50	Mean	23	**24[a]**	23	23	23	22
		STD	4	5	4	4	3	4
		N	42	41	40	40	40	40
	100	Mean	21	23	23	22	23	23
		STD	4	5	4	4	5	5
		N	41	38	39	38	38	38
	200	Mean	22	**24[a]**	24	23	23	**24[a]**
		STD	4	4	4	4	5	5
		N	44	44	42	41	41	39
Aroclor-1242	50	Mean	21	23	22	23	22	23
		STD	6	6	6	6	5	6
		N	44	44	44	42	42	41
	100	Mean	21	22	21	22	22	22
		STD	4	4	4	3	4	3
		N	42	42	42	41	41	41
Aroclor-1254	25	Mean	19	19	20	20	20	21
		STD	4	5	4	4	4	3
		N	44	44	44	44	44	44
	50	Mean	19	20	**20[a]**	19	20	20
		STD	4	3	3	4	4	4
		N	45	44	41	42	42	42
	100	Mean	**19[a]**	**19[b]**	**19[b]**	19	19	19
		STD	3	3	3	3	3	3
		N	45	44	44	43	42	42
Aroclor-1260	25	Mean	20	22	22	23	22	23
		STD	5	6	6	6	7	6
		N	45	45	43	42	40	39
	50	Mean	21	23	22	23	22	22
		STD	5	4	5	5	5	6
		N	40	39	39	39	39	38
	100	Mean	21	23	23	23	24	**24[a]**
		STD	5	5	4	4	4	4
		N	39	39	39	35	37	37

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			596	603	610	617	624	631
Control	0	Mean	21	21	21	21	20	21
		STD	5	4	5	6	6	6
		N	57	53	53	53	53	51
Aroclor-1016	50	Mean	23	22	21	21	23	22
		STD	4	6	5	5	5	6
		N	40	38	38	36	35	33
	100	Mean	23	24	23	22	23	22
		STD	6	6	6	6	7	5
		N	37	37	36	34	33	30
	200	Mean	24	23	23	23	23	22
		STD	5	6	4	5	4	5
		N	39	39	38	38	37	37
Aroclor-1242	50	Mean	22	23	23	22	**24[a]**	23
		STD	5	4	5	4	5	5
		N	41	39	39	39	37	36
	100	Mean	22	21	21	22	**23[a]**	22
		STD	3	4	5	3	3	3
		N	41	41	41	40	40	40
Aroclor-1254	25	Mean	20	20	19	20	21	20
		STD	3	4	3	4	4	4
		N	44	42	42	42	42	42
	50	Mean	20	19	**18[a]**	20	20	19
		STD	5	5	5	3	4	5
		N	42	40	40	36	35	35
	100	Mean	20	**18[b]**	20	20	20	20
		STD	3	3	4	3	5	3
		N	41	40	38	37	37	34
Aroclor-1260	25	Mean	23	23	23	23	21	22
		STD	6	5	5	6	6	6
		N	38	36	35	33	33	32
	50	Mean	21	21	21	22	20	21
		STD	6	6	7	6	7	7
		N	37	36	34	31	31	29
	100	Mean	22	23	23	24	22	23
		STD	5	5	4	4	5	6
		N	36	37	36	35	36	35

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			638	645	652	659	666	673
Control	0	Mean	21	21	19	19	21	20
		STD	6	5	5	4	6	5
		N	48	48	47	47	45	43
Aroclor-1016	50	Mean	21	21	20	21	21	21
		STD	6	5	5	6	6	5
		N	33	33	33	32	32	30
	100	Mean	22	23	21	21	23	19
		STD	5	6	5	6	6	6
		N	30	30	30	29	29	29
	200	Mean	22	22	22	20	22	22
		STD	5	5	6	6	6	6
		N	37	37	36	35	34	34
Aroclor-1242	50	Mean	23	23	22	22	24	22
		STD	5	5	6	6	5	4
		N	35	35	35	31	30	30
	100	Mean	21	21	19	19	19	19
		STD	3	4	5	6	6	5
		N	40	38	38	37	34	32
Aroclor-1254	25	Mean	21	20	20	19	21	20
		STD	4	5	4	5	6	5
		N	41	41	41	40	39	38
	50	Mean	20	21	21	20	21	20
		STD	4	4	4	3	5	6
		N	33	30	30	29	29	27
	100	Mean	19	20	20	20	21	21
		STD	5	3	3	3	5	4
		N	31	29	29	29	28	28
Aroclor-1260	25	Mean	21	22	22	21	23	20
		STD	7	5	5	6	6	6
		N	30	29	28	27	25	25
	50	Mean	22	21	22	21	23	21
		STD	5	5	6	5	5	5
		N	28	28	28	28	28	28
	100	Mean	22	23	21	21	23	22
		STD	5	5	5	5	4	5
		N	33	32	31	31	29	28

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study				
			680	687	694	701	708
Control	0	Mean	20	20	21	20	20
		STD	5	5	5	5	5
		N	41	40	39	36	34
Aroclor-1016	50	Mean	20	21	19	20	18
		STD	5	6	5	7	8
		N	29	28	26	25	25
	100	Mean	21	22	21	20	21
		STD	6	5	5	7	4
		N	29	26	26	25	23
	200	Mean	21	22	21	22	22
		STD	6	6	6	5	6
		N	33	32	31	30	28
Aroclor-1242	50	Mean	21	22	21	21	20
		STD	5	4	4	5	6
		N	29	26	26	25	25
	100	Mean	20	20	19	19	19
		STD	4	6	8	7	6
		N	30	29	28	28	27
Aroclor-1254	25	Mean	21	20	20	19	20
		STD	6	5	6	6	5
		N	37	36	36	35	35
	50	Mean	21	21	20	17	20
		STD	5	4	5	6	4
		N	25	23	23	21	18
	100	Mean	21	21	20	20	20
		STD	5	4	4	4	3
		N	28	26	26	24	24
Aroclor-1260	25	Mean	23	23	23	23	21
		STD	5	6	6	7	6
		N	25	25	25	25	24
	50	Mean	23	23[a]	23	21	22
		STD	6	5	4	5	6
		N	28	27	26	26	24
	100	Mean	23	24[b]	23	22	22
		STD	6	5	6	6	5
		N	28	27	27	27	26

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 25. Group Mean Feed Consumption (g/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study	
			715	722
Control	0	Mean	21	21
		STD	4	5
		N	32	26
Aroclor-1016	50	Mean	20	23
		STD	6	5
		N	23	15
	100	Mean	21	22
		STD	7	5
		N	23	15
	200	Mean	22	22
		STD	4	4
		N	27	19
Aroclor-1242	50	Mean	19	19
		STD	7	8
		N	25	17
	100	Mean	19	20
		STD	5	4
		N	27	21
Aroclor-1254	25	Mean	19	17
		STD	4	5
		N	34	27
	50	Mean	19	19
		STD	3	4
		N	17	11
	100	Mean	19	19
		STD	4	5
		N	22	16
Aroclor-1260	25	Mean	22	21
		STD	6	6
		N	22	15
	50	Mean	21	22
		STD	5	3
		N	24	16
	100	Mean	22	22
		STD	6	6
		N	25	18

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 26. Group Mean Feed Consumption (g/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			365	372	379	386	393	400
Control[1]	0	Mean	22	22	22	22	22	21
		STD	3	3	3	3	3	4
		N	108	101	101	98	98	98
Aroclor-1016	50	Mean	23	**24[a]**	23	**24[a]**	23	22
		STD	3	3	3	3	3	2
		N	30	30	30	30	30	30
	100	Mean	21	22	22	21	22	22
		STD	5	4	4	4	4	3
		N	30	29	29	29	29	29
	200	Mean	22	21	22	22	23	22
		STD	4	3	4	4	4	3
		N	28	27	27	27	27	27
Aroclor-1242	50	Mean	22	22	21	23	22	21
		STD	3	3	3	4	4	3
		N	29	29	29	29	29	29
	100	Mean	21	20	21	21	21	21
		STD	4	3	3	2	3	3
		N	30	30	30	30	30	30
Aroclor-1254	25	Mean	23	23	22	22	20	21
		STD	3	3	2	2	2	2
		N	28	28	28	28	28	28
	50	Mean	21	21	21	21	**20[a]**	**19[b]**
		STD	3	3	4	3	4	3
		N	30	30	30	30	30	30
	100	Mean	21	21	21	22	**20[a]**	20
		STD	3	3	3	3	3	3
		N	29	29	29	29	28	28
Aroclor-1260	25	Mean	23	22	21	23	23	23
		STD	3	3	4	3	4	4
		N	29	29	29	29	29	29
	50	Mean	23	23	23	**24[a]**	23	**23[a]**
		STD	4	3	4	3	3	3
		N	28	28	28	28	28	28
	100	Mean	22	22	**20[b]**	22	22	**23[a]**
		STD	3	3	3	4	3	3
		N	30	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 26. Group Mean Feed Consumption (g/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			407	414	421	428	435	442
Control[1]	0	Mean	22	22	21	22	21	23
		STD	4	4	4	4	3	4
		N	97	97	96	95	94	91
Aroclor-1016	50	Mean	22	23	21	21	23	24
		STD	2	3	4	3	3	3
		N	30	30	30	30	30	30
	100	Mean	21	23	22	22	22	23
		STD	2	3	3	4	3	3
		N	28	29	29	29	29	29
	200	Mean	22	23	22	22	21	23
		STD	4	4	3	3	3	5
		N	27	26	26	26	26	26
Aroclor-1242	50	Mean	23	23	22	22	23	22
		STD	4	4	3	4	5	6
		N	29	29	29	29	29	29
	100	Mean	22	21	21	20	20	22
		STD	3	3	3	3	4	4
		N	30	30	30	30	30	30
Aroclor-1254	25	Mean	**20[b]**	21	23	23	23	23
		STD	2	2	3	3	3	4
		N	28	28	27	28	28	28
	50	Mean	**19[b]**	20	22	22	21	22
		STD	3	2	3	3	3	3
		N	30	30	30	30	30	30
	100	Mean	**19[b]**	20	21	21	21	23
		STD	2	3	3	4	3	3
		N	28	28	28	28	27	27
Aroclor-1260	25	Mean	23	22	21	22	22	23
		STD	3	3	3	4	4	4
		N	29	29	29	29	29	29
	50	Mean	23	22	21	21	22	22
		STD	3	2	3	4	5	5
		N	28	28	28	28	28	28
	100	Mean	23	21	20	21	22	24
		STD	3	3	3	4	3	3
		N	29	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 26. Group Mean Feed Consumption (g/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			449	456	463	470	477	484
Control[1]	0	Mean	22	23	22	23	22	22
		STD	5	3	4	4	4	4
		N	91	89	88	88	87	87
Aroclor-1016	50	Mean	23	23	23	**7[b]**	**26[b]**	25
		STD	3	4	3	2	4	5
		N	30	30	30	29	29	29
	100	Mean	21	23	23	**8[b]**	24	24
		STD	3	4	5	5	6	7
		N	28	28	28	27	27	27
	200	Mean	20	20	22	**20[a]**	21	21
		STD	5	5	5	5	5	5
		N	24	24	24	24	24	24
Aroclor-1242	50	Mean	22	23	22	23	22	23
		STD	5	5	5	3	3	3
		N	28	28	28	27	27	27
	100	Mean	20	22	22	22	20	21
		STD	4	4	3	3	3	3
		N	30	30	30	30	30	29
Aroclor-1254	25	Mean	23	24	24	23	22	22
		STD	2	3	3	2	2	3
		N	26	26	26	26	26	26
	50	Mean	21	21	21	21	21	21
		STD	3	4	4	3	3	3
		N	30	30	30	30	30	29
	100	Mean	22	23	24	22	22	22
		STD	3	3	4	3	3	3
		N	26	26	26	26	26	26
Aroclor-1260	25	Mean	22	23	23	23	23	23
		STD	4	3	4	3	3	3
		N	29	29	27	26	26	26
	50	Mean	21	23	24	23	23	23
		STD	6	4	3	4	4	3
		N	26	26	25	25	24	23
	100	Mean	21	23	23	23	22	21
		STD	3	3	4	4	3	4
		N	28	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 26. Group Mean Feed Consumption (g/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			491	498	505	512	519	526
Control[1]	0	Mean	21	21	20	20	21	21
		STD	5	5	6	5	5	5
		N	85	82	82	81	78	75
Aroclor-1016	50	Mean	23	23	23	23	22	23
		STD	6	4	3	5	3	4
		N	29	28	28	28	28	28
	100	Mean	24	23	24	23[a]	23	23
		STD	6	5	4	3	4	4
		N	27	27	26	26	26	26
	200	Mean	21	21	21	21	21	21
		STD	4	4	3	3	3	2
		N	22	22	22	21	21	20
Aroclor-1242	50	Mean	22	21	22	21	22	20
		STD	3	3	4	5	4	4
		N	27	27	27	27	26	26
	100	Mean	21	20	21	21	21	20
		STD	3	3	3	3	3	2
		N	29	29	28	28	28	27
Aroclor-1254	25	Mean	22	22	22	22	22	22
		STD	3	2	3	4	2	3
		N	26	26	26	26	25	25
	50	Mean	20	20	20	21	20	21
		STD	3	3	4	4	4	5
		N	29	29	29	28	29	29
	100	Mean	21	20	22	21	22	21
		STD	3	4	3	3	3	4
		N	26	26	25	25	25	25
Aroclor-1260	25	Mean	21	22	22	21	22	22
		STD	3	3	3	3	4	4
		N	26	26	26	26	26	26
	50	Mean	22	22	21	21	22	22
		STD	3	3	4	4	4	3
		N	24	24	24	24	23	23
	100	Mean	20	20	21	21	21	20
		STD	3	3	3	4	5	4
		N	29	29	29	28	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 26. Group Mean Feed Consumption (g/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			533	540	547	554	561	568
Control[1]	0	Mean	22	21	21	21	22	22
		STD	5	4	5	4	3	4
		N	72	69	67	64	60	60
Aroclor-1016	50	Mean	22	22	21	22	23	25
		STD	3	6	4	6	4	3
		N	27	28	28	22	21	21
	100	Mean	23	24[a]	23	24	23	24
		STD	4	5	4	5	3	3
		N	26	26	26	20	19	19
	200	Mean	20	21	20	21	20	22
		STD	3	4	3	4	6	4
		N	20	20	20	14	15	14
Aroclor-1242	50	Mean	21	22	21	22	22	22
		STD	5	5	5	6	5	7
		N	26	26	26	19	19	19
	100	Mean	21	21	19	20	21	21
		STD	2	3	3	6	4	5
		N	27	27	27	22	22	22
Aroclor-1254	25	Mean	22	22	21	24	23	23
		STD	2	3	4	4	3	2
		N	25	25	25	20	19	19
	50	Mean	20	21	20	20	21	21
		STD	3	3	3	5	2	3
		N	29	28	28	22	20	20
	100	Mean	21	21	21	22	21	21
		STD	3	3	4	3	3	4
		N	24	24	24	17	16	16
Aroclor-1260	25	Mean	22	23	21	22	23	24[a]
		STD	3	4	3	3	4	2
		N	26	26	26	20	19	19
	50	Mean	22	22	22	22	21	22
		STD	3	4	4	5	5	5
		N	23	22	22	18	17	15
	100	Mean	20	22	21	22	21	22
		STD	4	5	4	5	4	4
		N	29	28	28	23	22	22

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 26. Group Mean Feed Consumption (g/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			575	582	589	596	603	610
Control[1]	0	Mean	21	21	21	21	21	21
		STD	5	5	5	5	4	5
		N	59	59	57	57	53	53
Aroclor-1016	50	Mean	23	23	22	23	23	20
		STD	4	4	4	5	4	7
		N	21	20	20	21	20	20
	100	Mean	23	21	21	22	21	19
		STD	3	4	4	5	5	5
		N	18	19	19	19	18	18
	200	Mean	22	20	20	21	22	20
		STD	5	6	6	7	4	4
		N	14	14	14	14	13	13
Aroclor-1242	50	Mean	22	21	22	22	21	22
		STD	4	3	4	4	5	3
		N	18	18	18	17	17	15
	100	Mean	20	20	21	22	20	22
		STD	5	4	4	3	4	3
		N	21	20	20	20	20	20
Aroclor-1254	25	Mean	23	21	22	25	23	22
		STD	3	5	4	3	3	4
		N	19	19	18	17	17	17
	50	Mean	21	21	21	22	20	19
		STD	3	3	4	4	4	5
		N	20	20	20	20	19	19
	100	Mean	21	20	21	25	23	23
		STD	5	7	4	3	3	3
		N	16	15	14	14	14	14
Aroclor-1260	25	Mean	23	23	23	23	23	23
		STD	3	3	4	3	3	3
		N	19	19	19	19	18	18
	50	Mean	21	20	21	23	24	23
		STD	5	6	6	5	4	3
		N	15	14	14	13	12	11
	100	Mean	22	21	22	23	22	21
		STD	3	3	4	3	3	2
		N	20	20	18	19	19	18

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 26. Group Mean Feed Consumption (g/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			617	624	631	638	645	652
Control[1]	0	Mean	21	20	21	21	21	19
		STD	6	6	6	6	5	5
		N	53	53	51	48	48	47
Aroclor-1016	50	Mean	23	22	22	21	22	22
		STD	6	6	7	10	8	7
		N	18	18	18	18	18	17
	100	Mean	22	20	22	21	22	22
		STD	3	4	4	4	4	3
		N	16	16	16	16	16	16
	200	Mean	22	20	22	22	22	21
		STD	4	4	4	4	4	5
		N	13	13	13	13	13	13
Aroclor-1242	50	Mean	23	21	22	23	22	20
		STD	4	3	4	4	4	4
		N	15	15	15	15	15	15
	100	Mean	23	21	22	22	23	22
		STD	4	3	4	3	2	3
		N	19	19	19	18	17	16
Aroclor-1254	25	Mean	24	22	24	22	22	20
		STD	6	5	6	7	6	6
		N	16	16	16	15	15	15
	50	Mean	20	20	21	22	21	23
		STD	5	4	4	3	5	4
		N	19	19	19	18	17	17
	100	Mean	23	22	22	22	22	22
		STD	3	4	3	4	5	2
		N	14	14	14	14	14	13
Aroclor-1260	25	Mean	24	24	24	24	23	22
		STD	4	3	4	5	3	3
		N	18	18	18	18	18	18
	50	Mean	23	21	24	22	19	21
		STD	5	5	4	3	8	4
		N	11	11	11	11	11	10
	100	Mean	23	21	23	21	22	20
		STD	5	4	5	4	4	4
		N	18	18	18	18	18	18

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 26. Group Mean Feed Consumption (g/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			659	666	673	680	687	694
Control[1]	0	Mean	19	21	20	20	20	21
		STD	4	6	5	5	5	5
		N	47	45	43	41	40	39
Aroclor-1016	50	Mean	23	24	23	24	24	25
		STD	7	5	6	7	5	7
		N	17	17	16	14	13	13
	100	Mean	21	22	22	21	21	20
		STD	3	5	6	6	4	6
		N	15	15	15	15	13	12
	200	Mean	20	21	19	18	19	19
		STD	5	7	5	8	6	5
		N	13	13	13	12	11	9
Aroclor-1242	50	Mean	21	21	21	20	20	20
		STD	3	4	5	4	4	5
		N	15	15	14	14	14	12
	100	Mean	22	22	20	21	21	20
		STD	3	3	4	3	3	4
		N	16	16	16	15	15	14
Aroclor-1254	25	Mean	20	20	22	22	21	19
		STD	5	3	3	3	5	6
		N	15	15	15	15	15	13
	50	Mean	22	23	21	22	21	20
		STD	4	5	4	3	3	3
		N	17	17	15	15	14	14
	100	Mean	22	21	21	21	21	21
		STD	2	3	3	2	3	3
		N	13	13	13	13	13	13
Aroclor-1260	25	Mean	22	23	23	23	22	20
		STD	3	4	5	3	3	4
		N	18	18	18	18	17	17
	50	Mean	20	21	21	21	19	16
		STD	6	4	5	6	6	7
		N	10	9	9	9	9	8
	100	Mean	20	20	19	22	21	22
		STD	4	4	6	5	6	5
		N	18	18	18	17	17	15

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 26. Group Mean Feed Consumption (g/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study			
			701	708	715	722
Control[1]	0	Mean	20	20	21	21
		STD	5	5	4	5
		N	36	34	32	26
Aroclor-1016	50	Mean	23	23	22	21
		STD	4	7	10	9
		N	13	13	12	12
	100	Mean	21	22	23	19
		STD	6	3	3	7
		N	11	11	11	11
	200	Mean	19	19	21	20
		STD	4	6	5	5
		N	9	9	9	9
Aroclor-1242	50	Mean	20	20	22	20
		STD	5	5	5	5
		N	12	12	11	11
	100	Mean	20	21	21	20
		STD	5	4	7	4
		N	13	12	12	12
Aroclor-1254	25	Mean	20	21	22	19
		STD	5	7	5	9
		N	12	12	12	12
	50	Mean	20	21	22	21
		STD	3	4	4	3
		N	14	14	14	14
	100	Mean	21	22	21	22
		STD	4	4	3	4
		N	13	13	13	13
Aroclor-1260	25	Mean	21	19	22	21
		STD	4	7	4	5
		N	15	15	15	14
	50	Mean	20	20	21	19
		STD	3	3	3	1
		N	7	7	7	6
	100	Mean	22	22	23	22
		STD	4	4	4	2
		N	14	14	13	13

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			8	15	22	29	36	43
Control	0	Mean	88	77	71	66	62	58
		STD	10	4	5	4	4	3
		N	118	118	118	118	118	118
Aroclor-1016	50	Mean	88	78	72	67	64[b]	60[a]
		STD	7	4	5	3	4	4
		N	68	68	68	68	68	68
	100	Mean	88	79	72	68	65[b]	61[b]
		STD	5	4	4	4	4	4
		N	68	68	68	68	68	67
	200	Mean	87	78	72	66	64[a]	60[a]
		STD	4	4	4	6	4	4
		N	68	68	68	67	68	68
Aroclor-1242	50	Mean	85	77	70	67	64[b]	61[b]
		STD	5	5	7	5	4	3
		N	68	68	68	68	68	68
	100	Mean	87	77	70	68	63	60[b]
		STD	11	5	4	6	6	5
		N	68	68	68	68	68	67
Aroclor-1254	25	Mean	86	77	69	64[b]	62	61[b]
		STD	4	4	4	4	3	4
		N	68	68	68	68	67	67
	50	Mean	85	78	71	65	63	60[b]
		STD	4	5	5	5	4	4
		N	68	68	68	68	67	68
	100	Mean	83[b]	75	69	64[b]	62	59
		STD	4	4	3	4	3	3
		N	68	68	68	68	68	68
Aroclor-1260	25	Mean	86	79[b]	71	67	63	61[b]
		STD	4	4	4	4	5	5
		N	68	68	68	68	68	68
	50	Mean	86	79[b]	71	67	65[b]	62[b]
		STD	6	4	4	3	5	4
		N	68	68	68	68	68	68
	100	Mean	85	78	71	67	64[a]	62[b]
		STD	6	4	4	4	5	6
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			50	57	64	71	78	85
Control	0	Mean	56	53	52	50	49	48
		STD	4	3	3	3	3	3
		N	118	118	118	118	118	117
Aroclor-1016	50	Mean	60[b]	58[b]	56[b]	53[b]	52[b]	51[b]
		STD	5	4	4	4	4	4
		N	68	68	68	68	68	68
	100	Mean	60[b]	58[b]	55[b]	52[b]	51[b]	50
		STD	4	5	3	3	3	6
		N	68	68	68	68	68	68
	200	Mean	58[b]	57[b]	54[b]	52	50	50[b]
		STD	4	3	4	4	4	3
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	56	55[b]	52	51	49	48
		STD	3	3	3	3	3	3
		N	68	68	68	68	68	68
	100	Mean	57	55[b]	52	52[a]	50	49[a]
		STD	6	4	3	4	4	4
		N	68	68	68	68	68	68
Aroclor-1254	25	Mean	59[b]	56[b]	55[b]	52[b]	51[b]	49[a]
		STD	3	3	3	3	3	3
		N	67	67	67	67	67	67
	50	Mean	58[a]	54	53	51	50	48
		STD	3	3	3	3	3	4
		N	68	68	68	68	68	68
	100	Mean	57	54	53	50	50	50[b]
		STD	3	3	3	4	4	4
		N	68	68	67	67	67	67
Aroclor-1260	25	Mean	59[a]	58[b]	54[b]	52	51	50[a]
		STD	6	6	4	5	4	5
		N	68	68	68	68	68	68
	50	Mean	58[b]	57[b]	54[b]	52	50	49
		STD	4	3	3	3	3	3
		N	68	68	68	68	68	68
	100	Mean	59[b]	57[b]	54	53[a]	52[b]	51[b]
		STD	5	5	5	5	4	4
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			92	99	106	114	120	127
Control	0	Mean	48	46	46	44	43	44
		STD	3	3	3	3	4	3
		N	117	117	117	117	117	117
Aroclor-1016	50	Mean	49	47	45	44	45[a]	43
		STD	4	3	3	3	4	3
		N	68	67	67	67	67	67
	100	Mean	48	46	45	44	44	43
		STD	3	4	2	3	2	2
		N	68	68	68	63	68	68
	200	Mean	47	45[a]	44[b]	45	44	44
		STD	3	3	2	4	3	5
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	45[b]	44[b]	45	44	46[b]	45
		STD	3	3	3	3	3	2
		N	68	68	68	68	68	68
	100	Mean	47	46	47	45	46[b]	45
		STD	3	3	4	3	4	5
		N	68	68	67	68	68	67
Aroclor-1254	25	Mean	48	47	46	45	45[b]	45
		STD	3	3	2	3	2	3
		N	67	67	67	67	67	67
	50	Mean	46[a]	46	45	46[b]	46[b]	45[a]
		STD	3	3	2	3	3	3
		N	68	68	68	68	68	68
	100	Mean	49	49[b]	48[b]	48[b]	47[b]	47[b]
		STD	6	4	4	4	4	4
		N	67	66	66	66	66	66
Aroclor-1260	25	Mean	46	46	46	44	47[b]	44
		STD	4	5	5	5	6	6
		N	68	68	68	68	68	68
	50	Mean	45[b]	45	45	44	45	43
		STD	3	3	3	3	3	3
		N	68	68	68	68	68	68
	100	Mean	48	47	46	45	47[b]	44
		STD	4	4	4	3	3	3
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			134	141	149	155	162	169
Control	0	Mean	45	41	46	36	41	41
		STD	3	3	3	2	4	4
		N	117	117	117	117	116	117
Aroclor-1016	50	Mean	**44[a]**	**43[b]**	**49[b]**	**37[a]**	41	41
		STD	3	3	3	3	3	3
		N	67	67	67	67	67	67
	100	Mean	**43[b]**	**43[b]**	**49[b]**	**37[a]**	41	42
		STD	3	2	3	3	2	3
		N	68	68	68	68	68	68
	200	Mean	**43[b]**	**43[b]**	**49[b]**	**38[b]**	42	41
		STD	3	3	4	3	4	4
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	**43[b]**	**43[b]**	**48[b]**	36	42	41
		STD	3	2	3	2	2	2
		N	68	68	68	68	68	68
	100	Mean	44	**44[b]**	**49[b]**	36	43	42
		STD	4	5	4	3	3	4
		N	67	67	67	67	67	67
Aroclor-1254	25	Mean	45	**44[b]**	**49[b]**	**37[a]**	43	41
		STD	3	3	3	2	2	3
		N	67	67	67	67	67	67
	50	Mean	45	**45[b]**	**50[b]**	**37[b]**	**43[a]**	41
		STD	3	3	3	2	3	3
		N	68	68	68	68	68	68
	100	Mean	**47[a]**	**46[b]**	**52[b]**	**39[b]**	**45[b]**	**44[b]**
		STD	4	4	4	3	4	3
		N	66	66	66	66	66	66
Aroclor-1260	25	Mean	44	**44[b]**	**50[b]**	**38[b]**	43	42
		STD	5	5	5	4	4	5
		N	68	68	68	68	68	68
	50	Mean	**42[b]**	43	**48[b]**	36	42	41
		STD	3	3	3	2	3	3
		N	68	68	68	68	68	68
	100	Mean	**44[a]**	**44[b]**	**49[b]**	**37[b]**	**43[a]**	42
		STD	4	3	3	2	2	3
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			176	183	190	197	204	211
Control	0	Mean	39	42	41	40	39	40
		STD	4	4	4	4	4	4
		N	117	117	112	112	112	112
Aroclor-1016	50	Mean	**41[b]**	**40[a]**	40	41	41	40
		STD	3	3	3	3	4	3
		N	67	67	61	61	61	61
	100	Mean	**42[b]**	**40[a]**	40	41	41	40
		STD	2	3	4	3	3	2
		N	68	68	62	61	61	61
	200	Mean	**41[b]**	40	40	**42[a]**	**42[b]**	40
		STD	3	3	4	3	3	2
		N	68	68	62	61	61	61
Aroclor-1242	50	Mean	**41[b]**	41	**39[a]**	39	40	**39[b]**
		STD	2	2	3	2	2	2
		N	68	68	62	62	62	62
	100	Mean	**42[b]**	42	40	40	40	40
		STD	4	4	4	3	3	3
		N	66	66	60	60	60	60
Aroclor-1254	25	Mean	**42[b]**	42	40	41	40	40
		STD	3	3	4	3	3	2
		N	66	66	61	61	61	61
	50	Mean	**42[b]**	42	40	41	40	40
		STD	3	3	3	3	2	3
		N	68	68	62	62	62	62
	100	Mean	**43[b]**	43	**43[a]**	**42[b]**	**42[b]**	**42[b]**
		STD	3	3	4	3	3	3
		N	65	65	59	59	59	59
Aroclor-1260	25	Mean	**42[b]**	41	40	41	40	40
		STD	5	5	6	5	4	5
		N	68	68	62	62	62	62
	50	Mean	**41[a]**	40	**39[b]**	40	40	40
		STD	2	2	3	3	2	3
		N	68	68	62	62	62	61
	100	Mean	40	**40[b]**	**39[a]**	40	40	40
		STD	2	3	3	3	3	3
		N	68	68	62	62	62	62

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			218	225	232	239	246	253
Control	0	Mean	41	42	39	42	41	41
		STD	4	6	6	5	4	5
		N	112	112	112	112	112	112
Aroclor-1016	50	Mean	40	39[b]	39	40[b]	40	41
		STD	4	5	3	3	3	3
		N	61	61	60	60	59	59
	100	Mean	40	40[b]	40	41	41	39[b]
		STD	2	3	3	2	3	3
		N	61	61	61	61	61	61
	200	Mean	40	41	39	40	41	39[b]
		STD	3	2	3	3	3	3
		N	61	61	61	61	60	60
Aroclor-1242	50	Mean	39[b]	38[b]	37	37[b]	38[b]	37[b]
		STD	2	2	2	3	2	3
		N	62	62	62	62	62	62
	100	Mean	40	40[b]	39	40	40	38[b]
		STD	3	3	4	3	3	3
		N	59	59	59	59	59	59
Aroclor-1254	25	Mean	40	39[b]	39	39[b]	39[b]	39[b]
		STD	2	2	3	3	3	3
		N	61	61	61	61	61	61
	50	Mean	40	39[b]	40	40[b]	39[a]	39[a]
		STD	3	3	3	3	3	3
		N	62	62	62	62	62	62
	100	Mean	43[b]	42	42[b]	43	42	42
		STD	3	3	3	3	4	3
		N	59	59	59	59	59	59
Aroclor-1260	25	Mean	41	41	40	41	41	39
		STD	7	6	6	5	6	7
		N	62	62	62	62	62	62
	50	Mean	39[b]	39[b]	39	39[b]	39[b]	37[b]
		STD	2	2	2	2	2	3
		N	61	61	61	61	61	61
	100	Mean	39[a]	41	39	40	40	39[b]
		STD	3	3	3	3	3	4
		N	62	62	62	62	62	62

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			260	267	274	281	288	295
Control	0	Mean	40	39	39	38	38	38
		STD	4	4	4	4	4	4
		N	111	112	112	112	111	112
Aroclor-1016	50	Mean	39[a]	40	40	38	39	38
		STD	3	3	4	4	3	3
		N	59	59	59	59	59	59
	100	Mean	38[b]	39	40[a]	38	39	38
		STD	2	3	3	3	2	3
		N	61	61	61	61	61	61
	200	Mean	37[b]	39	38	38	38	39
		STD	3	3	3	2	2	3
		N	60	60	60	60	60	60
Aroclor-1242	50	Mean	38[b]	39	38	38	37	38
		STD	3	4	3	4	3	2
		N	62	62	62	62	62	62
	100	Mean	39[a]	40	38	38	38	37
		STD	3	3	3	3	3	5
		N	59	59	58	58	58	59
Aroclor-1254	25	Mean	38[b]	39	38	37	38	37
		STD	3	3	3	2	2	2
		N	61	61	61	61	61	61
	50	Mean	39	40	39	38	39	38
		STD	3	3	3	3	3	4
		N	62	62	62	62	62	62
	100	Mean	43[b]	43[b]	43[b]	42[b]	43[b]	43[b]
		STD	3	3	3	3	3	3
		N	59	59	59	59	59	59
Aroclor-1260	25	Mean	39	40	40	40	39	39
		STD	5	5	7	5	6	6
		N	62	62	62	62	61	62
	50	Mean	38[b]	39	39	39	37	37
		STD	2	2	3	3	3	3
		N	61	60	61	61	61	61
	100	Mean	39	40	38	39	39	39
		STD	4	5	4	3	5	5
		N	61	61	61	61	61	61

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			302	309	316	323	330	337
Control	0	Mean	38	38	38	38	39	37
		STD	5	5	4	4	5	4
		N	112	112	111	110	110	110
Aroclor-1016	50	Mean	38	38	37	37	36[b]	37
		STD	3	4	3	3	3	4
		N	59	59	59	59	59	59
	100	Mean	38	38	37[a]	37	36[b]	37
		STD	3	3	3	3	3	3
		N	61	61	61	61	61	61
	200	Mean	39	38	38	38	36[b]	37
		STD	3	3	3	4	3	3
		N	60	60	60	60	60	60
Aroclor-1242	50	Mean	37	37	37	36[a]	37	37
		STD	3	4	3	3	3	4
		N	62	62	62	62	62	62
	100	Mean	38	37	37	37	37	37
		STD	3	3	4	4	5	3
		N	59	58	58	57	57	57
Aroclor-1254	25	Mean	38	37	38	37	37	37
		STD	3	3	3	2	2	3
		N	61	61	60	60	60	60
	50	Mean	38	38	39	38	39	40[b]
		STD	5	4	4	3	3	3
		N	62	62	62	61	61	61
	100	Mean	43[b]	43[b]	42[b]	41[b]	42[b]	42[b]
		STD	3	3	3	3	4	4
		N	59	59	59	59	58	57
Aroclor-1260	25	Mean	39	40[b]	39	38	38	38
		STD	6	5	6	6	5	5
		N	62	62	61	62	62	62
	50	Mean	38	38	37	36[b]	37	38
		STD	3	2	3	3	3	3
		N	61	61	61	60	61	61
	100	Mean	39	39	39	38	39	39
		STD	6	6	6	7	7	9
		N	61	61	61	61	61	61

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			344	351	358	365	372	379
Control	0	Mean	35	38	37	38	36	37
		STD	4	4	4	3	4	4
		N	110	110	110	110	110	104
Aroclor-1016	50	Mean	36	36	36	35[b]	35	37
		STD	3	3	4	4	5	4
		N	59	59	59	59	58	52
	100	Mean	37	38	37	37	36	37
		STD	3	2	3	3	2	2
		N	61	61	61	61	60	55
	200	Mean	36	37	36	36[a]	35	37
		STD	3	3	4	4	4	3
		N	60	60	60	60	60	54
Aroclor-1242	50	Mean	36	36	35	36	34	35
		STD	3	4	5	5	6	6
		N	62	62	62	62	62	56
	100	Mean	37	37	36	37	35	36
		STD	4	3	4	5	5	5
		N	57	57	57	57	57	52
Aroclor-1254	25	Mean	37	36[b]	37	38	35	38
		STD	3	3	3	3	4	4
		N	60	60	60	60	60	54
	50	Mean	39[b]	38	38	37	36	38
		STD	3	3	3	3	5	3
		N	61	61	61	61	61	55
	100	Mean	41[b]	38	39[b]	40[b]	38[b]	41[b]
		STD	3	3	3	4	4	4
		N	58	58	58	58	58	52
Aroclor-1260	25	Mean	40[b]	37	37	37	37	37
		STD	7	5	5	6	6	7
		N	62	61	61	61	61	55
	50	Mean	38[b]	37	36	37	36	36
		STD	4	3	3	3	4	3
		N	61	61	61	60	60	54
	100	Mean	40[b]	39	37	38	38	37
		STD	9	8	4	9	9	4
		N	61	61	58	59	59	52

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			386	393	400	407	414	421
Control	0	Mean	36	37	36	36	37	36
		STD	4	4	4	5	5	4
		N	104	104	104	103	102	102
Aroclor-1016	50	Mean	36	36	36	37	35[a]	35
		STD	5	6	5	4	4	5
		N	52	52	52	52	52	52
	100	Mean	36	36	36	36	34[b]	35
		STD	4	4	3	2	4	4
		N	55	55	55	55	54	54
	200	Mean	35	36	35	35	34[b]	35
		STD	3	3	2	3	6	4
		N	54	54	54	54	54	53
Aroclor-1242	50	Mean	36	36	35	35	34[b]	35
		STD	3	3	3	4	3	3
		N	54	54	54	54	54	54
	100	Mean	38	37	36	35	35	36
		STD	7	5	4	4	4	4
		N	51	51	51	51	51	51
Aroclor-1254	25	Mean	38	38	35	35	34[b]	35
		STD	4	5	3	3	3	3
		N	54	53	53	53	53	52
	50	Mean	38[a]	38	36	35	35	35
		STD	4	4	3	4	3	3
		N	55	55	55	55	54	54
	100	Mean	41[b]	41[b]	38[a]	38[a]	38	38[b]
		STD	4	3	3	3	3	3
		N	52	52	52	52	52	52
Aroclor-1260	25	Mean	37	36	36	37	36	35
		STD	5	7	6	6	6	5
		N	55	55	55	55	55	55
	50	Mean	35	35	37	37	36	35
		STD	4	3	3	3	3	3
		N	54	53	53	53	53	53
	100	Mean	37	35	39	39	38	35
		STD	10	9	11	12	10	5
		N	53	53	53	52	51	49

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			428	435	442	449	456	463
Control	0	Mean	36	34	34	35	36	36
		STD	5	5	4	5	6	5
		N	101	101	101	101	100	100
Aroclor-1016	50	Mean	35	36	35	35	36	37
		STD	5	5	5	5	5	7
		N	52	52	52	52	52	52
	100	Mean	34	35	34	35	35	35
		STD	3	3	3	3	3	3
		N	53	53	52	52	51	51
	200	Mean	34	34	34	34	36	36
		STD	4	5	5	4	5	5
		N	53	53	53	52	52	52
Aroclor-1242	50	Mean	35	36	36	36	37	38
		STD	3	4	4	4	5	5
		N	54	53	53	53	53	53
	100	Mean	36	**37[b]**	**37[b]**	**38[b]**	**38[a]**	38
		STD	4	4	3	3	4	5
		N	51	51	51	51	51	51
Aroclor-1254	25	Mean	37	**37[b]**	**37[b]**	**38[b]**	37	37
		STD	3	3	3	3	4	4
		N	52	52	52	52	52	51
	50	Mean	37	**37[b]**	**37[b]**	**39[b]**	**39[b]**	37
		STD	3	4	3	3	4	6
		N	53	53	52	52	52	52
	100	Mean	**41[b]**	**41[b]**	**40[b]**	**43[b]**	**42[b]**	**41[b]**
		STD	4	4	4	3	3	3
		N	52	52	52	52	52	52
Aroclor-1260	25	Mean	36	36	36	36	37	36
		STD	6	6	6	7	5	6
		N	55	55	55	55	55	55
	50	Mean	35	35	36	36	37	37
		STD	4	6	5	4	5	5
		N	53	52	52	52	52	52
	100	Mean	36	36	36	37	38	37
		STD	6	6	7	7	6	6
		N	49	49	48	48	48	47

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			470	477	484	491	498	505
Control	0	Mean	34	34	35	34	34	34
		STD	6	6	7	6	5	5
		N	100	100	100	99	97	97
Aroclor-1016	50	Mean	35	35	36	34	34	33
		STD	7	7	4	4	5	6
		N	52	51	50	50	50	50
	100	Mean	34	35	35	34	34	35
		STD	4	3	3	3	3	4
		N	51	51	50	49	49	49
	200	Mean	35	37	38	36	36	36
		STD	6	6	9	8	8	8
		N	52	52	52	52	52	51
Aroclor-1242	50	Mean	36	39[b]	38[b]	35	35	35
		STD	4	4	4	6	6	6
		N	53	52	51	51	51	51
	100	Mean	36	38[b]	39[b]	36	37[b]	37[b]
		STD	5	6	4	4	5	3
		N	51	51	50	50	49	48
Aroclor-1254	25	Mean	38[a]	36	35	35	36	35
		STD	6	3	6	6	4	3
		N	51	50	51	50	48	49
	50	Mean	39[b]	38[b]	38[b]	36	36	34
		STD	4	4	3	3	7	5
		N	52	52	51	50	50	49
	100	Mean	43[b]	41[b]	41[b]	40[b]	42[b]	40[b]
		STD	4	3	3	3	4	4
		N	52	52	51	51	51	51
Aroclor-1260	25	Mean	36	35	35	35	35	34
		STD	7	7	8	7	8	8
		N	55	54	51	51	50	47
	50	Mean	37[a]	35	35	35	34	33
		STD	4	4	4	4	5	5
		N	49	49	49	49	49	49
	100	Mean	38	37	38	37	36	36
		STD	8	8	6	6	7	7
		N	48	46	45	44	44	43

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			512	519	526	533	540	547
Control	0	Mean	33	35	34	34	34	36
		STD	6	5	5	7	5	4
		N	97	95	94	93	91	91
Aroclor-1016	50	Mean	33	33	33	33	33	32
		STD	7	5	6	7	8	8
		N	50	49	48	47	45	43
	100	Mean	33	33[a]	33	33	35	34
		STD	6	3	3	3	4	5
		N	49	46	47	47	47	46
	200	Mean	35	35	34	33	34	33
		STD	7	4	5	4	5	5
		N	51	50	50	50	50	48
Aroclor-1242	50	Mean	34	33	34	35	35	34
		STD	8	9	8	7	7	6
		N	51	51	50	49	49	48
	100	Mean	37[b]	35	36	35	36	35
		STD	4	4	6	8	7	5
		N	48	47	46	45	44	43
Aroclor-1254	25	Mean	36[a]	35	35	35	36	36
		STD	3	3	4	5	4	5
		N	49	49	48	48	48	46
	50	Mean	34	34	35	36	37[a]	36
		STD	6	8	5	3	4	4
		N	49	48	46	45	43	42
	100	Mean	39[b]	39[b]	39[b]	39[b]	39[b]	39[b]
		STD	4	5	6	5	5	6
		N	51	50	50	49	49	49
Aroclor-1260	25	Mean	35	34	36	37	36	36
		STD	6	8	8	9	8	9
		N	47	47	47	46	45	44
	50	Mean	34	34	35	34	33	35
		STD	4	3	3	4	7	7
		N	49	48	47	47	45	44
	100	Mean	36[a]	36	37	37	35	37
		STD	7	6	8	7	5	7
		N	43	43	43	42	42	40

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			554	561	568	575	582	589
Control	0	Mean	34	35	34	35	34	34
		STD	5	6	6	5	5	5
		N	90	86	84	84	82	81
Aroclor-1016	50	Mean	31	33	34	33	34	32
		STD	9	8	8	8	10	9
		N	43	36	36	35	35	35
	100	Mean	33	34	34	34	32	32
		STD	5	4	3	6	7	8
		N	44	39	38	37	38	35
	200	Mean	33	33	34	33	33	32
		STD	4	3	6	7	4	5
		N	46	41	41	41	40	40
Aroclor-1242	50	Mean	34	35	34	35	34	33
		STD	6	7	5	4	6	8
		N	48	43	42	40	40	40
	100	Mean	34	37	35	35	34	34
		STD	4	4	6	6	6	7
		N	42	38	37	37	36	36
Aroclor-1254	25	Mean	31	34	34	34	35	32
		STD	7	6	4	5	5	6
		N	46	41	41	40	39	39
	50	Mean	33	33	35	33	35	33
		STD	5	6	9	7	8	7
		N	39	35	35	34	34	34
	100	Mean	36	36	**38[a]**	37	**39[b]**	35
		STD	5	6	5	3	4	5
		N	47	43	42	40	39	39
Aroclor-1260	25	Mean	35	38	38	39	**40[a]**	**39[a]**
		STD	9	10	10	11	12	8
		N	45	41	40	40	39	39
	50	Mean	32	33	34	35	34	35
		STD	6	7	6	8	8	8
		N	42	37	36	36	36	36
	100	Mean	34	36	36	37	38	**37[a]**
		STD	6	6	7	6	7	7
		N	40	37	37	37	37	36

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			596	603	610	617	624	631
Control	0	Mean	33	37	35	34	35	36
		STD	5	7	7	7	9	10
		N	79	79	78	77	76	76
Aroclor-1016	50	Mean	35	35	33	34	34	35
		STD	10	13	8	5	6	6
		N	33	32	29	27	26	25
	100	Mean	33	35	35	32	32	33
		STD	6	7	6	5	7	5
		N	33	32	32	31	30	28
	200	Mean	33	35	34	32	33	34
		STD	5	5	7	6	5	7
		N	39	39	38	37	35	35
Aroclor-1242	50	Mean	31	35	32	33	34	33
		STD	8	6	6	8	5	5
		N	40	38	37	37	35	34
	100	Mean	34	35	33	34	34	33
		STD	8	8	8	7	9	9
		N	36	34	34	33	30	29
Aroclor-1254	25	Mean	33	33[a]	33	31	34	35
		STD	5	5	7	7	4	5
		N	38	35	34	33	32	32
	50	Mean	34	32[a]	36	34	37	37
		STD	5	8	8	8	6	6
		N	31	32	30	30	29	29
	100	Mean	38[b]	37	39[a]	36	37	39
		STD	4	4	4	4	5	5
		N	39	38	38	38	37	36
Aroclor-1260	25	Mean	38[b]	37	39[a]	38	38	37
		STD	9	8	9	9	10	11
		N	38	38	38	38	38	38
	50	Mean	35	35	36	36	38	37
		STD	7	8	7	7	8	11
		N	35	35	34	34	33	33
	100	Mean	38[b]	37	38	36	38	37
		STD	6	6	8	7	7	7
		N	36	35	35	35	34	34

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			638	645	652	659	666	673
Control	0	Mean	35	33	33	33	33	35
		STD	9	9	9	8	7	9
		N	73	70	70	66	65	60
Aroclor-1016	50	Mean	33	33	32	31	29	31
		STD	5	5	6	8	11	12
		N	25	23	23	23	21	21
	100	Mean	32	31	31	33	33	34
		STD	6	7	8	8	8	8
		N	27	27	26	25	23	23
	200	Mean	33	33	33	34	33	35
		STD	8	9	9	10	9	6
		N	34	34	34	34	33	31
Aroclor-1242	50	Mean	34	32	32	31	31	32
		STD	4	7	7	7	8	10
		N	34	33	32	32	32	32
	100	Mean	33	34	34	34	32	35
		STD	10	8	9	13	9	11
		N	28	28	27	24	23	23
Aroclor-1254	25	Mean	33	33	32	32	32	35
		STD	5	6	6	8	5	7
		N	31	31	31	30	28	28
	50	Mean	35	36	34	35	32	37
		STD	5	8	10	9	10	13
		N	28	28	26	25	24	24
	100	Mean	37	**39[a]**	38	37	**38[a]**	**41[a]**
		STD	6	7	7	7	7	6
		N	35	34	34	32	32	32
Aroclor-1260	25	Mean	39	38	**39[b]**	37	35	36
		STD	9	10	10	8	10	11
		N	37	36	35	35	35	33
	50	Mean	37	35	38	37	38	39
		STD	11	12	12	10	9	9
		N	32	31	30	28	26	24
	100	Mean	37	36	36	34	33	39
		STD	7	7	10	11	12	8
		N	34	33	33	31	29	26

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study						
			680	687	694	701	708	715	722
Control	0	Mean	35	32	33	35	33	33	33
		STD	9	10	8	6	7	8	8
		N	60	60	57	54	52	50	46
Aroclor-1016	50	Mean	31	33	33	37	35	35	35
		STD	10	9	12	9	9	8	12
		N	20	20	20	19	18	17	15
	100	Mean	32	32	32	33	30	30	35
		STD	9	8	9	12	12	11	9
		N	21	19	19	19	17	15	14
	200	Mean	33	34	33	34	32	33	34
		STD	6	7	7	7	7	6	6
		N	31	31	31	30	29	29	27
Aroclor-1242	50	Mean	32	32	35	35	34	33	34
		STD	6	9	9	5	6	6	5
		N	31	29	27	26	26	26	25
	100	Mean	36	36	35	34	36	35	37
		STD	9	9	9	11	9	11	9
		N	22	22	22	21	20	19	18
Aroclor-1254	25	Mean	35	37	36	36	36	39[a]	37
		STD	4	4	5	6	5	8	8
		N	26	26	25	25	25	24	23
	50	Mean	33	32	31	36	36	39	38
		STD	14	12	13	11	3	6	6
		N	22	21	18	14	13	13	11
	100	Mean	38	41[b]	40[b]	41[b]	40[b]	42[b]	40[b]
		STD	7	7	5	6	3	4	5
		N	31	29	24	22	21	21	20
Aroclor-1260	25	Mean	38	39[a]	39[a]	38	35	39	39
		STD	8	10	9	9	11	11	12
		N	31	30	30	27	25	24	24
	50	Mean	37	39	39	37	38	40	36
		STD	9	12	11	10	9	13	6
		N	23	23	23	22	19	19	17
	100	Mean	37	38	37	38	39	40[a]	37
		STD	9	9	8	9	8	10	8
		N	26	24	23	22	20	19	17

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			8	15	22	29	36	43
Aroclor-1016	50	Mean	4.4	3.9	3.6	3.4	**3.2**[b]	**3.0**[a]
		STD	0.4	0.2	0.3	0.2	0.2	0.2
		N	68	68	68	68	68	68
	100	Mean	8.8	7.9	7.2	6.8	**6.5**[b]	**6.1**[b]
		STD	0.5	0.4	0.4	0.4	0.4	0.4
		N	68	68	68	68	68	67
	200	Mean	17.4	15.6	14.4	13.2	**12.8**[a]	**12.0**[a]
		STD	0.8	0.8	0.8	1.2	0.8	0.8
		N	68	68	68	67	68	68
Aroclor-1242	50	Mean	4.3	3.9	3.5	3.4	**3.2**[b]	**3.1**[b]
		STD	0.3	0.3	0.4	0.3	0.2	0.2
		N	68	68	68	68	68	68
	100	Mean	8.7	7.7	7.0	6.8	6.3	**6.0**[b]
		STD	1.1	0.5	0.4	0.6	0.6	0.5
		N	68	68	68	68	68	67
Aroclor-1254	25	Mean	2.2	1.9	1.7	**1.6**[b]	1.6	**1.5**[b]
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	68	68	68	68	67	67
	50	Mean	4.3	3.9	3.6	3.3	3.2	**3.0**[b]
		STD	0.2	0.3	0.3	0.3	0.2	0.2
		N	68	68	68	68	67	68
	100	Mean	**8.3**[b]	7.5	6.9	**6.4**[b]	6.2	5.9
		STD	0.4	0.4	0.3	0.4	0.3	0.3
		N	68	68	68	68	68	68
Aroclor-1260	25	Mean	2.2	**2.0**[b]	1.8	1.7	1.6	**1.5**[b]
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	68	68	68	68	68	68
	50	Mean	4.3	**4.0**[b]	3.6	3.4	**3.3**[b]	**3.1**[b]
		STD	0.3	0.2	0.2	0.2	0.3	0.2
		N	68	68	68	68	68	68
	100	Mean	8.5	7.8	7.1	6.7	**6.4**[a]	**6.2**[b]
		STD	0.6	0.4	0.4	0.4	0.5	0.6
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			50	57	64	71	78	85
Aroclor-1016	50	Mean	**3.0[b]**	**2.9[b]**	**2.8[b]**	**2.7[b]**	**2.6[b]**	**2.6[b]**
		STD	0.3	0.2	0.2	0.2	0.2	0.2
		N	68	68	68	68	68	68
	100	Mean	**6.0[b]**	**5.8[b]**	**5.5[b]**	**5.2[b]**	**5.1[b]**	5.0
		STD	0.4	0.5	0.3	0.3	0.3	0.6
		N	68	68	68	68	68	68
	200	Mean	**11.6[b]**	**11.4[b]**	**10.8[b]**	10.4	10.0	**10.0[b]**
		STD	0.8	0.6	0.8	0.8	0.8	0.6
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	2.8	**2.8[b]**	2.6	2.6	2.5	2.4
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	68	68	68	68	68	68
	100	Mean	5.7	**5.5[b]**	5.2	**5.2[a]**	5.0	**4.9[a]**
		STD	0.6	0.4	0.3	0.4	0.4	0.4
		N	68	68	68	68	68	68
Aroclor-1254	25	Mean	**1.5[b]**	**1.4[b]**	**1.4[b]**	**1.3[b]**	**1.3[b]**	**1.2[a]**
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	67	67	67	67	67	67
	50	Mean	**2.9[a]**	2.7	2.7	2.6	2.5	2.4
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	68	68	68	68	68	68
	100	Mean	5.7	5.4	5.3	5.0	5.0	**5.0[b]**
		STD	0.3	0.3	0.3	0.4	0.4	0.4
		N	68	68	67	67	67	67
Aroclor-1260	25	Mean	**1.5[a]**	**1.5[b]**	**1.4[b]**	1.3	1.3	**1.3[a]**
		STD	0.2	0.2	0.1	0.1	0.1	0.1
		N	68	68	68	68	68	68
	50	Mean	**2.9[b]**	**2.9[b]**	**2.7[b]**	2.6	2.5	2.5
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	68	68	68	68	68	68
	100	Mean	**5.9[b]**	**5.7[b]**	5.4	**5.3[a]**	**5.2[b]**	**5.1[b]**
		STD	0.5	0.5	0.5	0.5	0.4	0.4
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			92	99	106	114	120	127
Aroclor-1016	50	Mean	2.5	2.4	2.3	2.2	**2.3[a]**	2.2
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	68	67	67	67	67	67
	100	Mean	4.8	4.6	4.5	4.4	4.4	4.3
		STD	0.3	0.4	0.2	0.3	0.2	0.2
		N	68	68	68	63	68	68
	200	Mean	9.4	**9.0[a]**	**8.8[b]**	9.0	8.8	8.8
		STD	0.6	0.6	0.4	0.8	0.6	1.0
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	**2.3[b]**	**2.2[b]**	2.3	2.2	**2.3[b]**	2.3
		STD	0.2	0.2	0.2	0.2	0.2	0.1
		N	68	68	68	68	68	68
	100	Mean	4.7	4.6	4.7	4.5	**4.6[b]**	4.5
		STD	0.3	0.3	0.4	0.3	0.4	0.5
		N	68	68	67	68	68	67
Aroclor-1254	25	Mean	1.2	1.2	1.2	1.1	**1.1[b]**	1.1
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	67	67	67	67	67	67
	50	Mean	**2.3[a]**	2.3	2.3	**2.3[b]**	**2.3[b]**	**2.3[a]**
		STD	0.2	0.2	0.1	0.2	0.2	0.2
		N	68	68	68	68	68	68
	100	Mean	4.9	**4.9[b]**	**4.8[b]**	**4.8[b]**	**4.7[b]**	**4.7[b]**
		STD	0.6	0.4	0.4	0.4	0.4	0.4
		N	67	66	66	66	66	66
Aroclor-1260	25	Mean	1.2	1.2	1.2	1.1	**1.2[b]**	1.1
		STD	0.1	0.1	0.1	0.1	0.2	0.2
		N	68	68	68	68	68	68
	50	Mean	**2.3[b]**	2.3	2.3	2.2	2.3	2.2
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	68	68	68	68	68	68
	100	Mean	4.8	4.7	4.6	4.5	**4.7[b]**	4.4
		STD	0.4	0.4	0.4	0.3	0.3	0.3
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			134	141	149	155	162	169
Aroclor-1016	50	Mean	2.2[a]	2.2[b]	2.5[b]	1.9[a]	2.1	2.1
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	67	67	67	67	67	67
	100	Mean	4.3[b]	4.3[b]	4.9[b]	3.7[a]	4.1	4.2
		STD	0.3	0.2	0.3	0.3	0.2	0.3
		N	68	68	68	68	68	68
	200	Mean	8.6[b]	8.6[b]	9.8[b]	7.6[b]	8.4	8.2
		STD	0.6	0.6	0.8	0.6	0.8	0.8
		N	68	68	68	68	68	68
Aroclor-1242	50	Mean	2.2[b]	2.2[b]	2.4[b]	1.8	2.1	2.1
		STD	0.2	0.1	0.2	0.1	0.1	0.1
		N	68	68	68	68	68	68
	100	Mean	4.4	4.4[b]	4.9[b]	3.6	4.3	4.2
		STD	0.4	0.5	0.4	0.3	0.3	0.4
		N	67	67	67	67	67	67
Aroclor-1254	25	Mean	1.1	1.1[b]	1.2[b]	0.9[a]	1.1	1.0
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	67	67	67	67	67	67
	50	Mean	2.3	2.3[b]	2.5[b]	1.9[b]	2.2[a]	2.1
		STD	0.2	0.2	0.2	0.1	0.2	0.2
		N	68	68	68	68	68	68
	100	Mean	4.7[a]	4.6[b]	5.2[b]	3.9[b]	4.5[b]	4.4[b]
		STD	0.4	0.4	0.4	0.3	0.4	0.3
		N	66	66	66	66	66	66
Aroclor-1260	25	Mean	1.1	1.1[b]	1.3[b]	1.0[b]	1.1	1.1
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	68	68	68	68	68	68
	50	Mean	2.1[b]	2.2	2.4[b]	1.8	2.1	2.1
		STD	0.2	0.2	0.2	0.1	0.2	0.2
		N	68	68	68	68	68	68
	100	Mean	4.4[a]	4.4[b]	4.9[b]	3.7[b]	4.3[a]	4.2
		STD	0.4	0.3	0.3	0.2	0.2	0.3
		N	68	68	68	68	68	68

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			176	183	190	197	204	211
Aroclor-1016	50	Mean	**2.1[b]**	**2.0[a]**	2.0	2.1	2.1	2.0
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	67	67	61	61	61	61
	100	Mean	**4.2[b]**	**4.0[a]**	4.0	4.1	4.1	4.0
		STD	0.2	0.3	0.4	0.3	0.3	0.2
		N	68	68	62	61	61	61
	200	Mean	**8.2[b]**	8.0	8.0	**8.4[a]**	**8.4[b]**	8.0
		STD	0.6	0.6	0.8	0.6	0.6	0.4
		N	68	68	62	61	61	61
Aroclor-1242	50	Mean	**2.1[b]**	2.1	**2.0[a]**	2.0	2.0	**2.0[b]**
		STD	0.1	0.1	0.2	0.1	0.1	0.1
		N	68	68	62	62	62	62
	100	Mean	**4.2[b]**	4.2	4.0	4.0	4.0	4.0
		STD	0.4	0.4	0.4	0.3	0.3	0.3
		N	66	66	60	60	60	60
Aroclor-1254	25	Mean	**1.1[b]**	1.1	1.0	1.0	1.0	1.0
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	66	66	61	61	61	61
	50	Mean	**2.1[b]**	2.1	2.0	2.1	2.0	2.0
		STD	0.2	0.2	0.2	0.2	0.1	0.2
		N	68	68	62	62	62	62
	100	Mean	**4.3[b]**	4.3	**4.3[a]**	**4.2[b]**	**4.2[b]**	**4.2[b]**
		STD	0.3	0.3	0.4	0.3	0.3	0.3
		N	65	65	59	59	59	59
Aroclor-1260	25	Mean	**1.1[b]**	1.0	1.0	1.0	1.0	1.0
		STD	0.1	0.1	0.2	0.1	0.1	0.1
		N	68	68	62	62	62	62
	50	Mean	**2.1[a]**	2.0	**2.0[b]**	2.0	2.0	2.0
		STD	0.1	0.1	0.2	0.2	0.1	0.2
		N	68	68	62	62	62	61
	100	Mean	4.0	**4.0[b]**	**3.9[a]**	4.0	4.0	4.0
		STD	0.2	0.3	0.3	0.3	0.3	0.3
		N	68	68	62	62	62	62

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			218	225	232	239	246	253
Aroclor-1016	50	Mean	2.0	**2.0**[b]	2.0	**2.0**[b]	2.0	2.1
		STD	0.2	0.3	0.2	0.2	0.2	0.2
		N	61	61	60	60	59	59
	100	Mean	4.0	4.0	**4.0**[b]	4.1	4.1	**3.9**[b]
		STD	0.2	0.3	0.3	0.2	0.3	0.3
		N	61	61	61	61	61	61
	200	Mean	8.0	8.2	7.8	8.0	8.2	**7.8**[b]
		STD	0.6	0.4	0.6	0.6	0.6	0.6
		N	61	61	61	61	60	60
Aroclor-1242	50	Mean	**2.0**[b]	**1.9**[b]	1.9	**1.9**[b]	**1.9**[b]	**1.9**[b]
		STD	0.1	0.1	0.1	0.2	0.1	0.2
		N	62	62	62	62	62	62
	100	Mean	4.0	**4.0**[b]	3.9	4.0	4.0	**3.8**[b]
		STD	0.3	0.3	0.4	0.3	0.3	0.3
		N	59	59	59	59	59	59
Aroclor-1254	25	Mean	1.0	**1.0**[b]	1.0	**1.0**[b]	**1.0**[b]	**1.0**[b]
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	61	61	61	61	61	61
	50	Mean	2.0	**2.0**[b]	2.0	**2.0**[b]	**2.0**[a]	**2.0**[a]
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	62	62	62	62	62	62
	100	Mean	**4.3**[b]	4.2	**4.2**[b]	4.3	4.2	4.2
		STD	0.3	0.3	0.3	0.3	0.4	0.3
		N	59	59	59	59	59	59
Aroclor-1260	25	Mean	1.0	1.0	1.0	1.0	1.0	1.0
		STD	0.2	0.2	0.2	0.1	0.2	0.2
		N	62	62	62	62	62	62
	50	Mean	**2.0**[b]	**2.0**[b]	2.0	**2.0**[b]	**2.0**[b]	**1.9**[b]
		STD	0.1	0.1	0.1	0.1	0.1	0.2
		N	61	61	61	61	61	61
	100	Mean	**3.9**[a]	4.1	3.9	4.0	4.0	**3.9**[b]
		STD	0.3	0.3	0.3	0.3	0.3	0.4
		N	62	62	62	62	62	62

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			260	267	274	281	288	295
Aroclor-1016	50	Mean	**2.0**[a]	2.0	2.0	1.9	2.0	1.9
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	59	59	59	59	59	59
	100	Mean	**3.8**[b]	3.9	**4.0**[a]	3.8	3.9	3.8
		STD	0.2	0.3	0.3	0.3	0.2	0.3
		N	61	61	61	61	61	61
	200	Mean	**7.4**[b]	7.8	7.6	7.6	7.6	7.8
		STD	0.6	0.6	0.6	0.4	0.4	0.6
		N	60	60	60	60	60	60
Aroclor-1242	50	Mean	**1.9**[b]	2.0	1.9	1.9	1.9	1.9
		STD	0.2	0.2	0.2	0.2	0.2	0.1
		N	62	62	62	62	62	62
	100	Mean	**3.9**[a]	4.0	3.8	3.8	3.8	3.7
		STD	0.3	0.3	0.3	0.3	0.3	0.5
		N	59	59	58	58	58	59
Aroclor-1254	25	Mean	**1.0**[b]	1.0	1.0	0.9	1.0	0.9
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	61	61	61	61	61	61
	50	Mean	2.0	2.0	2.0	1.9	2.0	1.9
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	62	62	62	62	62	62
	100	Mean	**4.3**[b]	**4.3**[b]	**4.3**[b]	**4.2**[b]	**4.3**[b]	**4.3**[b]
		STD	0.3	0.3	0.3	0.3	0.3	0.3
		N	59	59	59	59	59	59
Aroclor-1260	25	Mean	1.0	1.0	1.0	1.0	1.0	1.0
		STD	0.1	0.1	0.2	0.1	0.2	0.2
		N	62	62	62	62	61	62
	50	Mean	**1.9**[b]	2.0	2.0	2.0	1.9	1.9
		STD	0.1	0.1	0.2	0.2	0.2	0.2
		N	61	60	61	61	61	61
	100	Mean	3.9	4.0	3.8	3.9	3.9	3.9
		STD	0.4	0.5	0.4	0.3	0.5	0.5
		N	61	61	61	61	61	61

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			302	309	316	323	330	337
Aroclor-1016	50	Mean	1.9	1.9	1.9	1.9	**1.8[b]**	1.9
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	59	59	59	59	59	59
	100	Mean	3.8	3.8	**3.7[a]**	3.7	**3.6[b]**	3.7
		STD	0.3	0.3	0.3	0.3	0.3	0.3
		N	61	61	61	61	61	61
	200	Mean	7.8	7.6	7.6	7.6	**7.2[b]**	7.4
		STD	0.6	0.6	0.6	0.8	0.6	0.6
		N	60	60	60	60	60	60
Aroclor-1242	50	Mean	1.9	1.9	1.9	**1.8[a]**	1.9	1.9
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	62	62	62	62	62	62
	100	Mean	3.8	3.7	3.7	3.7	3.7	3.7
		STD	0.3	0.3	0.4	0.4	0.5	0.3
		N	59	58	58	57	57	57
Aroclor-1254	25	Mean	1.0	0.9	1.0	0.9	0.9	0.9
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	61	61	60	60	60	60
	50	Mean	1.9	1.9	2.0	1.9	2.0	**2.0[b]**
		STD	0.3	0.2	0.2	0.2	0.2	0.2
		N	62	62	62	61	61	61
	100	Mean	**4.3[b]**	**4.3[b]**	**4.2[b]**	**4.1[b]**	**4.2[b]**	**4.2[b]**
		STD	0.3	0.3	0.3	0.3	0.4	0.4
		N	59	59	59	59	58	57
Aroclor-1260	25	Mean	1.0	**1.0[b]**	1.0	1.0	1.0	1.0
		STD	0.2	0.1	0.2	0.2	0.1	0.1
		N	62	62	61	62	62	62
	50	Mean	1.9	1.9	1.9	**1.8[b]**	1.9	1.9
		STD	0.2	0.1	0.2	0.2	0.2	0.2
		N	61	61	61	60	61	61
	100	Mean	3.9	3.9	3.9	3.8	3.9	3.9
		STD	0.6	0.6	0.6	0.7	0.7	0.9
		N	61	61	61	61	61	61

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			344	351	358	365	372	379
Aroclor-1016	50	Mean	1.8	1.8	1.8	**1.8**[b]	1.8	1.9
		STD	0.2	0.2	0.2	0.2	0.3	0.2
		N	59	59	59	59	58	52
	100	Mean	3.7	3.8	3.7	3.7	3.6	3.7
		STD	0.3	0.2	0.3	0.3	0.2	0.2
		N	61	61	61	61	60	55
	200	Mean	7.2	7.4	7.2	**7.2**[a]	7.0	7.4
		STD	0.6	0.6	0.8	0.8	0.8	0.6
		N	60	60	60	60	60	54
Aroclor-1242	50	Mean	1.8	1.8	1.8	1.8	1.7	1.8
		STD	0.2	0.2	0.3	0.3	0.3	0.3
		N	62	62	62	62	62	56
	100	Mean	3.7	3.7	3.6	3.7	3.5	3.6
		STD	0.4	0.3	0.4	0.5	0.5	0.5
		N	57	57	57	57	57	52
Aroclor-1254	25	Mean	0.9	**0.9**[b]	0.9	1.0	0.9	1.0
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	60	60	60	60	60	54
	50	Mean	**2.0**[b]	1.9	1.9	1.9	1.8	1.9
		STD	0.2	0.2	0.2	0.2	0.3	0.2
		N	61	61	61	61	61	55
	100	Mean	**4.1**[b]	3.8	**3.9**[b]	**4.0**[b]	**3.8**[b]	**4.1**[b]
		STD	0.3	0.3	0.3	0.4	0.4	0.4
		N	58	58	58	58	58	52
Aroclor-1260	25	Mean	**1.0**[b]	0.9	0.9	0.9	0.9	0.9
		STD	0.2	0.1	0.1	0.2	0.2	0.2
		N	62	61	61	61	61	55
	50	Mean	**1.9**[b]	1.9	1.8	1.9	1.8	1.8
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	61	61	61	60	60	54
	100	Mean	**4.0**[b]	3.9	3.7	3.8	3.8	3.7
		STD	0.9	0.8	0.4	0.9	0.9	0.4
		N	61	61	58	59	59	52

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			386	393	400	407	414	421
Aroclor-1016	50	Mean	1.8	1.8	1.8	1.9	**1.8[a]**	1.8
		STD	0.3	0.3	0.3	0.2	0.2	0.3
		N	52	52	52	52	52	52
	100	Mean	3.6	3.6	3.6	3.6	**3.4[b]**	3.5
		STD	0.4	0.4	0.3	0.2	0.4	0.4
		N	55	55	55	55	54	54
	200	Mean	7.0	7.2	7.0	7.0	**6.8[b]**	7.0
		STD	0.6	0.6	0.4	0.6	1.2	0.8
		N	54	54	54	54	54	53
Aroclor-1242	50	Mean	1.8	1.8	1.8	1.8	**1.7[b]**	1.8
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	54	54	54	54	54	54
	100	Mean	3.8	3.7	3.6	3.5	3.5	3.6
		STD	0.7	0.5	0.4	0.4	0.4	0.4
		N	51	51	51	51	51	51
Aroclor-1254	25	Mean	1.0	1.0	0.9	0.9	**0.9[b]**	0.9
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	54	53	53	53	53	52
	50	Mean	**1.9[a]**	1.9	1.8	1.8	1.8	1.8
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	55	55	55	55	54	54
	100	Mean	**4.1[b]**	**4.1[b]**	**3.8[a]**	**3.8[a]**	3.8	**3.8[b]**
		STD	0.4	0.3	0.3	0.3	0.3	0.3
		N	52	52	52	52	52	52
Aroclor-1260	25	Mean	0.9	0.9	0.9	0.9	0.9	0.9
		STD	0.1	0.2	0.2	0.2	0.2	0.1
		N	55	55	55	55	55	55
	50	Mean	1.8	1.8	1.9	1.9	1.8	1.8
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	54	53	53	53	53	53
	100	Mean	3.7	3.5	3.9	3.9	3.8	3.5
		STD	1.0	0.9	1.1	1.2	1.0	0.5
		N	53	53	53	52	51	49

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			428	435	442	449	456	463
Aroclor-1016	50	Mean	1.8	1.8	1.8	1.8	1.8	1.9
		STD	0.3	0.3	0.3	0.3	0.3	0.4
		N	52	52	52	52	52	52
	100	Mean	3.4	3.5	3.4	3.5	3.5	3.5
		STD	0.3	0.3	0.3	0.3	0.3	0.3
		N	53	53	52	52	51	51
	200	Mean	6.8	6.8	6.8	6.8	7.2	7.2
		STD	0.8	1.0	1.0	0.8	1.0	1.0
		N	53	53	53	52	52	52
Aroclor-1242	50	Mean	1.8	1.8	1.8	1.8	1.9	1.9
		STD	0.2	0.2	0.2	0.2	0.3	0.3
		N	54	53	53	53	53	53
	100	Mean	3.6	**3.7[b]**	**3.7[b]**	**3.8[b]**	**3.8[a]**	3.8
		STD	0.4	0.4	0.3	0.3	0.4	0.5
		N	51	51	51	51	51	51
Aroclor-1254	25	Mean	0.9	**0.9[b]**	**0.9[b]**	**1.0[b]**	0.9	0.9
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	52	52	52	52	52	51
	50	Mean	1.9	**1.9[b]**	**1.9[b]**	**2.0[b]**	**2.0[b]**	1.9
		STD	0.2	0.2	0.2	0.2	0.2	0.3
		N	53	53	52	52	52	52
	100	Mean	**4.1[b]**	**4.1[b]**	**4.0[b]**	**4.3[b]**	**4.2[b]**	**4.1[b]**
		STD	0.4	0.4	0.4	0.3	0.3	0.3
		N	52	52	52	52	52	52
Aroclor-1260	25	Mean	0.9	0.9	0.9	0.9	0.9	0.9
		STD	0.2	0.2	0.2	0.2	0.1	0.2
		N	55	55	55	55	55	55
	50	Mean	1.8	1.8	1.8	1.8	1.9	1.9
		STD	0.2	0.3	0.3	0.2	0.3	0.3
		N	53	52	52	52	52	52
	100	Mean	3.6	3.6	3.6	3.7	3.8	3.7
		STD	0.6	0.6	0.7	0.7	0.6	0.6
		N	49	49	48	48	48	47

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			470	477	484	491	498	505
Aroclor-1016	50	Mean	1.8	1.8	1.8	1.7	1.7	1.7
		STD	0.4	0.4	0.2	0.2	0.3	0.3
		N	52	51	50	50	50	50
	100	Mean	3.4	3.5	3.5	3.4	3.4	3.5
		STD	0.4	0.3	0.3	0.3	0.3	0.4
		N	51	51	50	49	49	49
	200	Mean	7.0	7.4	7.6	7.2	7.2	7.2
		STD	1.2	1.2	1.8	1.6	1.6	1.6
		N	52	52	52	52	52	51
Aroclor-1242	50	Mean	1.8	**2.0[b]**	**1.9[b]**	1.8	1.8	1.8
		STD	0.2	0.2	0.2	0.3	0.3	0.3
		N	53	52	51	51	51	51
	100	Mean	3.6	**3.8[b]**	**3.9[b]**	3.6	**3.7[b]**	**3.7[b]**
		STD	0.5	0.6	0.4	0.4	0.5	0.3
		N	51	51	50	50	49	48
Aroclor-1254	25	Mean	**1.0[a]**	0.9	0.9	0.9	0.9	0.9
		STD	0.2	0.1	0.2	0.2	0.1	0.1
		N	51	50	51	50	48	49
	50	Mean	**2.0[b]**	**1.9[b]**	**1.9[b]**	1.8	1.8	1.7
		STD	0.2	0.2	0.2	0.2	0.4	0.3
		N	52	52	51	50	50	49
	100	Mean	**4.3[b]**	**4.1[b]**	**4.1[b]**	**4.0[b]**	**4.2[b]**	**4.0[b]**
		STD	0.4	0.3	0.3	0.3	0.4	0.4
		N	52	52	51	51	51	51
Aroclor-1260	25	Mean	0.9	0.9	0.9	0.9	0.9	0.9
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	55	54	51	51	50	47
	50	Mean	**1.9[a]**	1.8	1.8	1.8	1.7	1.7
		STD	0.2	0.2	0.2	0.2	0.3	0.3
		N	49	49	49	49	49	49
	100	Mean	3.8	3.7	3.8	3.7	3.6	3.6
		STD	0.8	0.8	0.6	0.6	0.7	0.7
		N	48	46	45	44	44	43

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			512	519	526	533	540	547
Aroclor-1016	50	Mean	1.7	1.7	1.7	1.7	1.7	1.6
		STD	0.4	0.3	0.3	0.4	0.4	0.4
		N	50	49	48	47	45	43
	100	Mean	3.3	**3.3[a]**	3.3	3.3	3.5	3.4
		STD	0.6	0.3	0.3	0.3	0.4	0.5
		N	49	46	47	47	47	46
	200	Mean	7.0	7.0	6.8	6.6	6.8	6.6
		STD	1.4	0.8	1.0	0.8	1.0	1.0
		N	51	50	50	50	50	48
Aroclor-1242	50	Mean	1.7	1.7	1.7	1.8	1.8	1.7
		STD	0.4	0.5	0.4	0.4	0.4	0.3
		N	51	51	50	49	49	48
	100	Mean	**3.7[b]**	3.5	3.6	3.5	3.6	3.5
		STD	0.4	0.4	0.6	0.8	0.7	0.5
		N	48	47	46	45	44	43
Aroclor-1254	25	Mean	**0.9[a]**	0.9	0.9	0.9	0.9	0.9
		STD	0.1	0.1	0.1	0.1	0.1	0.1
		N	49	49	48	48	48	46
	50	Mean	1.7	1.7	1.8	1.8	**1.9[a]**	1.8
		STD	0.3	0.4	0.3	0.2	0.2	0.2
		N	49	48	46	45	43	42
	100	Mean	**3.9[b]**	**3.9[b]**	**3.9[b]**	**3.9[b]**	**3.9[b]**	**3.9[b]**
		STD	0.4	0.5	0.6	0.5	0.5	0.6
		N	51	50	50	49	49	49
Aroclor-1260	25	Mean	0.9	0.9	0.9	0.9	0.9	0.9
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	47	47	47	46	45	44
	50	Mean	1.7	1.7	1.8	1.7	1.7	1.8
		STD	0.2	0.2	0.2	0.2	0.4	0.4
		N	49	48	47	47	45	44
	100	Mean	**3.6[a]**	3.6	3.7	3.7	3.5	3.7
		STD	0.7	0.6	0.8	0.7	0.5	0.7
		N	43	43	43	42	42	40

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			554	561	568	575	582	589
Aroclor-1016	50	Mean	1.6	1.7	1.7	1.7	1.7	1.6
		STD	0.5	0.4	0.4	0.4	0.5	0.5
		N	43	36	36	35	35	35
	100	Mean	3.3	3.4	3.4	3.4	3.2	3.2
		STD	0.5	0.4	0.3	0.6	0.7	0.8
		N	44	39	38	37	38	35
	200	Mean	6.6	6.6	6.8	6.6	6.6	6.4
		STD	0.8	0.6	1.2	1.4	0.8	1.0
		N	46	41	41	41	40	40
Aroclor-1242	50	Mean	1.7	1.8	1.7	1.8	1.7	1.7
		STD	0.3	0.4	0.3	0.2	0.3	0.4
		N	48	43	42	40	40	40
	100	Mean	3.4	3.7	3.5	3.5	3.4	3.4
		STD	0.4	0.4	0.6	0.6	0.6	0.7
		N	42	38	37	37	36	36
Aroclor-1254	25	Mean	0.8	0.9	0.9	0.9	0.9	0.8
		STD	0.2	0.2	0.1	0.1	0.1	0.2
		N	46	41	41	40	39	39
	50	Mean	1.7	1.7	1.8	1.7	1.8	1.7
		STD	0.3	0.3	0.5	0.4	0.4	0.4
		N	39	35	35	34	34	34
	100	Mean	3.6	3.6	**3.8[a]**	3.7	**3.9[b]**	3.5
		STD	0.5	0.6	0.5	0.3	0.4	0.5
		N	47	43	42	40	39	39
Aroclor-1260	25	Mean	0.9	1.0	1.0	1.0	**1.0[a]**	**1.0[a]**
		STD	0.2	0.3	0.3	0.3	0.3	0.2
		N	45	41	40	40	39	39
	50	Mean	1.6	1.7	1.7	1.8	1.7	1.8
		STD	0.3	0.4	0.3	0.4	0.4	0.4
		N	42	37	36	36	36	36
	100	Mean	3.4	3.6	3.6	3.7	3.8	**3.7[a]**
		STD	0.6	0.6	0.7	0.6	0.7	0.7
		N	40	37	37	37	37	36

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			596	603	610	617	624	631
Aroclor-1016	50	Mean	1.8	1.8	1.7	1.7	1.7	1.8
		STD	0.5	0.7	0.4	0.3	0.3	0.3
		N	33	32	29	27	26	25
	100	Mean	3.3	3.5	3.5	3.2	3.2	3.3
		STD	0.6	0.7	0.6	0.5	0.7	0.5
		N	33	32	32	31	30	28
	200	Mean	6.6	7.0	6.8	6.4	6.6	6.8
		STD	1.0	1.0	1.4	1.2	1.0	1.4
		N	39	39	38	37	35	35
Aroclor-1242	50	Mean	1.6	1.3	1.6	1.7	1.7	1.7
		STD	0.4	0.3	0.3	0.4	0.3	0.3
		N	40	38	37	37	35	34
	100	Mean	3.4	3.5	3.3	3.4	3.4	3.3
		STD	0.8	0.8	0.8	0.7	0.9	0.9
		N	36	34	34	33	30	29
Aroclor-1254	25	Mean	0.8	**0.8**[a]	0.8	0.8	0.9	0.9
		STD	0.1	0.1	0.2	0.2	0.1	0.1
		N	38	35	34	33	32	32
	50	Mean	1.7	**1.6**[a]	1.8	1.7	1.9	1.9
		STD	0.3	0.4	0.4	0.4	0.3	0.3
		N	31	32	30	30	29	29
	100	Mean	**3.8**[b]	3.7	**3.9**[a]	3.6	3.7	3.9
		STD	0.4	0.4	0.4	0.4	0.5	0.5
		N	39	38	38	38	37	36
Aroclor-1260	25	Mean	**1.0**[b]	0.9	**1.0**[a]	1.0	1.0	0.9
		STD	0.2	0.2	0.2	0.2	0.3	0.3
		N	38	38	38	38	38	38
	50	Mean	1.8	1.8	1.8	1.8	1.9	1.9
		STD	0.4	0.4	0.4	0.4	0.4	0.6
		N	35	35	34	34	33	33
	100	Mean	**3.8**[b]	3.7	3.8	3.6	3.8	3.7
		STD	0.6	0.6	0.8	0.7	0.7	0.7
		N	36	35	35	35	34	34

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study					
			638	645	652	659	666	673
Aroclor-1016	50	Mean	1.7	1.7	1.6	1.6	1.5	1.6
		STD	0.3	0.3	0.3	0.4	0.6	0.6
		N	25	23	23	23	21	21
	100	Mean	3.2	3.1	3.1	3.3	3.3	3.4
		STD	0.6	0.7	0.8	0.8	0.8	0.8
		N	27	27	26	25	23	23
	200	Mean	6.6	6.6	6.6	6.8	6.6	7.0
		STD	1.6	1.8	1.8	2.0	1.8	1.2
		N	34	34	34	34	33	31
Aroclor-1242	50	Mean	1.7	1.6	1.6	1.6	1.6	1.6
		STD	0.2	0.4	0.4	0.4	0.4	0.5
		N	34	33	32	32	32	32
	100	Mean	3.3	3.4	3.4	3.4	3.2	3.5
		STD	1.0	0.8	0.9	1.3	0.9	1.1
		N	28	28	27	24	23	23
Aroclor-1254	25	Mean	0.8	0.8	0.8	0.8	0.8	0.9
		STD	0.1	0.2	0.2	0.2	0.1	0.2
		N	31	31	31	30	28	28
	50	Mean	1.8	1.8	1.7	1.8	1.6	1.9
		STD	0.3	0.4	0.5	0.5	0.5	0.7
		N	28	28	26	25	24	24
	100	Mean	3.7	**3.9[a]**	3.8	3.7	**3.8[a]**	**4.1[a]**
		STD	0.6	0.7	0.7	0.7	0.7	0.6
		N	35	34	34	32	32	32
Aroclor-1260	25	Mean	1.0	1.0	**1.0[b]**	0.9	0.9	0.9
		STD	0.2	0.3	0.3	0.2	0.3	0.3
		N	37	36	35	35	35	33
	50	Mean	1.9	1.8	1.9	1.9	1.9	2.0
		STD	0.6	0.6	0.6	0.5	0.5	0.5
		N	32	31	30	28	26	24
	100	Mean	3.7	3.6	3.6	3.4	3.3	3.9
		STD	0.7	0.7	1.0	1.1	1.2	0.8
		N	34	33	33	31	29	26

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 27A. Group Mean Test Article Consumption (mg/kg/day) for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Day of Study						
			680	687	694	701	708	715	722
Aroclor-1016	50	Mean	1.6	1.7	1.7	1.9	1.8	1.8	1.8
		STD	0.5	0.5	0.6	0.5	0.5	0.4	0.6
		N	20	20	20	19	18	17	15
	100	Mean	3.2	3.2	3.2	3.3	3.0	3.0	3.5
		STD	0.9	0.8	0.9	1.2	1.2	1.1	0.9
		N	21	19	19	19	17	15	14
	200	Mean	6.6	6.8	6.6	6.8	6.4	6.6	6.8
		STD	1.2	1.4	1.4	1.4	1.4	1.2	1.2
		N	31	31	31	30	29	29	27
Aroclor-1242	50	Mean	1.6	1.6	1.8	1.8	1.7	1.7	1.7
		STD	0.3	0.5	0.3	0.3	0.3	0.3	0.3
		N	31	29	27	26	26	26	25
	100	Mean	3.6	3.6	3.5	3.4	3.6	3.5	3.7
		STD	0.9	0.9	0.9	1.1	0.9	1.1	0.9
		N	22	22	22	21	20	19	18
Aroclor-1254	25	Mean	0.9	0.9	0.9	0.9	0.9	**1.0[a]**	0.9
		STD	0.1	0.1	0.1	0.2	0.1	0.2	0.2
		N	26	26	25	25	25	24	23
	50	Mean	1.7	1.6	1.6	1.8	1.8	2.0	1.9
		STD	0.7	0.6	0.7	0.6	0.2	0.3	0.3
		N	22	21	18	14	13	13	11
	100	Mean	3.8	**4.1[b]**	**4.0[b]**	**4.1[b]**	**4.0[b]**	**4.2[b]**	**4.0[b]**
		STD	0.7	0.7	0.5	0.6	0.3	0.4	0.5
		N	31	29	24	22	21	21	20
Aroclor-1260	25	Mean	1.0	**1.0[a]**	**1.0[a]**	1.0	0.9	1.0	1.0
		STD	0.2	0.3	0.2	0.2	0.3	0.3	0.3
		N	31	30	30	27	25	24	24
	50	Mean	1.9	2.0	2.0	1.9	1.9	2.0	1.8
		STD	0.5	0.6	0.6	0.5	0.5	0.7	0.3
		N	23	23	23	22	19	19	17
	100	Mean	3.7	3.8	3.7	3.8	3.9	**4.0[a]**	3.7
		STD	0.9	0.9	0.8	0.9	0.8	1.0	0.8
		N	26	24	23	22	20	19	17

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			8	15	22	29	36	43
Control	0	Mean	87	87	85	84	83	76
		STD	9	11	10	17	14	12
		N	130	130	130	130	130	130
Aroclor-1016	50	Mean	85	86	83	79[a]	84	80
		STD	9	11	12	9	15	15
		N	110	110	110	110	110	110
	100	Mean	88	88	87	84	87	81
		STD	9	11	13	13	15	16
		N	110	110	110	110	110	110
	200	Mean	92[b]	95[b]	89	89	92[b]	87[b]
		STD	11	18	15	18	20	20
		N	110	110	110	110	110	110
Aroclor-1242	50	Mean	91	91	94[b]	85	82	78
		STD	17	22	20	17	15	16
		N	110	110	110	110	110	110
	100	Mean	90	90	90	86	82	82
		STD	15	16	18	18	19	20
		N	110	110	110	110	110	110
Aroclor-1254	25	Mean	87	85	84	83	77[b]	73
		STD	11	12	13	14	11	10
		N	110	110	110	110	109	108
	50	Mean	90	86	86	82	77[b]	74
		STD	11	11	15	10	8	9
		N	110	110	109	109	108	110
	100	Mean	90	85	80[b]	81	77[b]	73
		STD	12	11	11	12	9	10
		N	110	110	110	109	110	110
Aroclor-1260	25	Mean	90	85	86	90	84	80
		STD	13	11	13	21	18	16
		N	110	110	110	110	110	110
	50	Mean	91	88	87	95[b]	89	82[a]
		STD	14	13	14	22	21	17
		N	110	110	110	110	110	110
	100	Mean	93[b]	89	88	88	88	82[a]
		STD	14	14	14	18	21	15
		N	109	110	110	110	110	109

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			50	57	64	71	78	85
Control	0	Mean	75	73	72	68	69	64
		STD	14	15	15	12	13	10
		N	130	129	129	129	129	128
Aroclor-1016	50	Mean	76	71	69	68	66	63
		STD	12	11	9	9	7	7
		N	110	110	110	110	110	110
	100	Mean	80	76	73	70	68	64
		STD	14	15	12	12	10	9
		N	110	110	110	110	110	110
	200	Mean	81[a]	76	73	71	68	66
		STD	15	13	11	12	9	9
		N	110	110	110	110	110	110
Aroclor-1242	50	Mean	83[b]	76	73	70	66	63
		STD	20	19	15	12	9	9
		N	110	110	110	110	110	110
	100	Mean	81	74	74	75[a]	70	63
		STD	21	16	18	22	19	8
		N	110	108	110	110	110	110
Aroclor-1254	25	Mean	76	73	70	70	69	66
		STD	13	12	11	13	13	12
		N	109	107	108	110	109	106
	50	Mean	73	71	68	68	67	66
		STD	11	10	9	10	10	11
		N	109	109	108	110	110	110
	100	Mean	72	71	67[a]	68	66	65
		STD	12	11	9	11	11	12
		N	109	110	109	110	110	110
Aroclor-1260	25	Mean	80	72	68[a]	69	67	67
		STD	19	12	11	15	13	17
		N	110	110	110	110	110	110
	50	Mean	81	78	75	72	69	68
		STD	18	16	19	18	14	16
		N	110	109	109	109	108	108
	100	Mean	80	77	74	71	69	67
		STD	17	13	13	12	12	11
		N	109	110	110	110	110	110

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			92	99	107	113	120	127
Control	0	Mean	63	64	65	63	60	62
		STD	8	9	11	13	8	9
		N	129	122	122	123	122	122
Aroclor-1016	50	Mean	63	62	62	62	63	60
		STD	8	9	8	12	8	7
		N	110	104	104	104	104	104
	100	Mean	63	62	62[a]	61	62	61
		STD	9	9	7	8	10	10
		N	110	103	103	104	104	104
	200	Mean	64	62	66	63	63	63
		STD	8	7	14	8	10	7
		N	110	102	104	104	104	104
Aroclor-1242	50	Mean	62	68	65	64	63	63
		STD	9	17	12	12	10	11
		N	110	104	104	104	104	104
	100	Mean	63	68	66	64	65[b]	64
		STD	11	17	13	13	11	9
		N	110	104	104	104	104	104
Aroclor-1254	25	Mean	64	62	64	62	62	60
		STD	12	10	10	9	11	9
		N	108	104	102	102	104	104
	50	Mean	64	62	67	64	63	62
		STD	11	8	14	10	8	7
		N	110	104	104	104	104	104
	100	Mean	64	63	68	66	64[a]	63
		STD	10	8	11	14	8	7
		N	110	104	104	104	104	104
Aroclor-1260	25	Mean	65	62	61[a]	65	60	60
		STD	16	12	10	11	7	8
		N	110	104	104	104	104	104
	50	Mean	66	65	62	68	61	62
		STD	16	16	10	14	9	9
		N	108	102	102	102	102	102
	100	Mean	64	67	62	67	61	61
		STD	12	16	10	14	9	8
		N	110	104	104	104	103	104

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			134	142	148	155	162	169
Control	0	Mean	58	59	58	58	61	57
		STD	8	9	7	8	7	8
		N	123	122	123	122	123	121
Aroclor-1016	50	Mean	**61[b]**	61	**62[b]**	59	60	59
		STD	7	6	7	7	7	6
		N	104	104	104	104	104	104
	100	Mean	**63[b]**	62	**62[a]**	59	59	58
		STD	10	8	9	9	9	8
		N	104	104	104	104	104	104
	200	Mean	**64[b]**	**64[b]**	**64[b]**	60	60	60
		STD	7	8	11	9	7	7
		N	103	104	103	104	104	104
Aroclor-1242	50	Mean	**61[b]**	61	61	59	60	58
		STD	8	7	10	10	8	8
		N	101	104	104	104	104	104
	100	Mean	**63[b]**	**63[a]**	**62[a]**	58	61	**61[a]**
		STD	10	11	7	12	8	8
		N	104	104	104	104	104	104
Aroclor-1254	25	Mean	**61[a]**	59	59	59	60	59
		STD	8	8	9	9	8	8
		N	104	104	104	103	104	104
	50	Mean	**64[b]**	61	**62[a]**	61	62	**62[b]**
		STD	9	7	7	7	8	7
		N	104	104	104	104	104	104
	100	Mean	**64[b]**	**63[b]**	**62[b]**	**63[b]**	**64[b]**	**64[b]**
		STD	6	6	5	5	6	6
		N	104	104	104	104	104	104
Aroclor-1260	25	Mean	59	60	59	58	**56[b]**	57
		STD	5	7	6	7	6	9
		N	104	104	104	104	104	104
	50	Mean	61	60	62	59	58	57
		STD	8	7	11	8	8	7
		N	102	102	102	102	102	101
	100	Mean	**61[b]**	62	**61[a]**	60	60	60
		STD	8	8	9	8	8	10
		N	104	104	104	104	104	104

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			176	183	190	197	204	211
Control	0	Mean	61	57	58	57	57	59
		STD	7	7	7	10	8	8
		N	123	123	117	117	117	117
Aroclor-1016	50	Mean	59	57	57	58	57	57
		STD	7	6	6	7	7	6
		N	104	104	98	98	98	98
	100	Mean	57[b]	55	55	56	56	55[b]
		STD	8	8	6	6	8	5
		N	104	104	98	98	98	98
	200	Mean	60	58	58	59	57	57
		STD	8	8	7	7	7	7
		N	104	104	98	98	98	98
Aroclor-1242	50	Mean	58[b]	59	55	58	57	57
		STD	6	6	7	7	6	7
		N	104	103	98	98	98	98
	100	Mean	60	59	58	59	59	59
		STD	6	7	7	8	6	8
		N	104	104	98	98	98	98
Aroclor-1254	25	Mean	59	58	58	58	58	59
		STD	8	8	8	7	8	7
		N	103	104	97	97	97	97
	50	Mean	61	61[b]	61[a]	61[a]	61[b]	62[a]
		STD	7	7	8	7	7	7
		N	104	104	98	98	98	98
	100	Mean	65[b]	64[b]	63[b]	63[b]	63[b]	62[b]
		STD	6	7	6	5	6	5
		N	104	104	98	98	98	98
Aroclor-1260	25	Mean	55[b]	55	54[b]	55	55	55[b]
		STD	6	6	6	5	5	9
		N	104	104	98	98	98	98
	50	Mean	58[a]	58	56	58	57	56
		STD	7	7	7	7	7	7
		N	101	101	95	95	95	95
	100	Mean	60	59	58	60	59	58
		STD	8	7	8	8	8	7
		N	104	104	98	98	98	97

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			218	225	232	239	246	253
Control	0	Mean	57	57	58	58	54	56
		STD	7	9	6	8	6	7
		N	117	117	117	116	116	115
Aroclor-1016	50	Mean	56	57	59	57	56	55
		STD	6	6	8	8	7	7
		N	97	97	98	97	98	98
	100	Mean	55	55	60	57	56	54
		STD	6	7	8	8	8	7
		N	98	97	98	98	98	97
	200	Mean	57	57	61	58	57	57
		STD	6	10	10	7	7	7
		N	97	97	97	97	97	94
Aroclor-1242	50	Mean	56	55	57	56	55	55
		STD	7	6	8	7	9	8
		N	98	98	98	98	98	96
	100	Mean	57	57	59	58	**58[b]**	57
		STD	6	6	10	6	6	8
		N	97	97	96	96	96	96
Aroclor-1254	25	Mean	58	58	58	57	**59[b]**	**59[b]**
		STD	6	6	6	6	6	6
		N	97	97	97	97	97	97
	50	Mean	**62[b]**	**61[b]**	**63[b]**	61	**61[b]**	**61[b]**
		STD	8	7	8	11	7	8
		N	98	97	98	98	98	98
	100	Mean	**62[b]**	**64[b]**	**65[b]**	**63[b]**	**62[b]**	**62[b]**
		STD	6	8	6	9	6	6
		N	98	98	97	98	97	97
Aroclor-1260	25	Mean	55	56	57	56	55	**59[a]**
		STD	8	7	7	7	10	8
		N	98	98	98	98	98	97
	50	Mean	57	57	58	58	57	**59[a]**
		STD	7	8	7	8	9	7
		N	94	93	93	94	94	94
	100	Mean	58	58	59	59	**57[b]**	**60[b]**
		STD	8	7	8	8	7	9
		N	98	98	98	98	98	98

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			260	267	274	281	288	295
Control	0	Mean	55	54	55	56	55	56
		STD	10	7	10	8	7	7
		N	115	116	116	108	107	109
Aroclor-1016	50	Mean	57	58[b]	55	54	56	54
		STD	7	7	7	7	8	9
		N	98	98	98	92	92	92
	100	Mean	59[a]	58[b]	56	56	55	55
		STD	9	9	9	9	9	10
		N	98	98	98	92	92	92
	200	Mean	58	58[b]	56	57	58	57
		STD	8	6	8	7	8	8
		N	96	96	96	90	90	90
Aroclor-1242	50	Mean	56	57[a]	54	54	56	55
		STD	9	9	7	6	8	7
		N	98	98	98	92	92	92
	100	Mean	59[a]	59[b]	58	57	62[b]	59
		STD	9	8	8	7	13	8
		N	96	96	96	90	90	90
Aroclor-1254	25	Mean	61[b]	57[b]	57	58	57	57
		STD	7	6	7	7	7	7
		N	97	97	97	91	91	91
	50	Mean	63[b]	62[b]	60[b]	60[a]	59[b]	59[a]
		STD	10	11	8	7	7	8
		N	98	98	98	92	92	91
	100	Mean	64[b]	62[b]	62[b]	62[b]	61[b]	62[b]
		STD	7	7	7	7	6	7
		N	97	97	97	91	91	91
Aroclor-1260	25	Mean	58	58[b]	56	56	56	56
		STD	7	7	8	7	7	8
		N	97	97	97	91	91	91
	50	Mean	59[a]	58[b]	57	56	56	58
		STD	7	6	6	7	8	10
		N	94	94	94	86	88	88
	100	Mean	59[a]	58[b]	57	57	57	58
		STD	9	8	7	9	9	8
		N	98	98	98	92	92	92

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			302	309	316	323	330	337
Control	0	Mean	56	57	52	58	52	54
		STD	9	8	7	10	7	6
		N	109	109	109	109	109	108
Aroclor-1016	50	Mean	54	54	54	53[b]	51	52
		STD	7	7	8	6	7	6
		N	92	92	92	92	92	92
	100	Mean	54	54	55	53[b]	50	52[a]
		STD	8	8	10	8	6	6
		N	92	92	91	91	91	91
	200	Mean	54	55	55[a]	55	53	55
		STD	6	7	8	7	6	7
		N	90	90	90	90	90	90
Aroclor-1242	50	Mean	56	56	54	57	54	57
		STD	9	9	8	9	7	9
		N	91	91	91	90	90	90
	100	Mean	58	57	57[b]	58	56[b]	58[b]
		STD	9	9	8	8	7	8
		N	90	90	90	89	89	89
Aroclor-1254	25	Mean	59[a]	58	57[b]	55	57[b]	55
		STD	7	7	10	7	9	7
		N	90	90	90	90	90	90
	50	Mean	61[b]	59	60[b]	59	59[b]	58[a]
		STD	8	7	8	9	9	9
		N	92	92	91	92	92	92
	100	Mean	63[b]	61[b]	61[b]	61	61[b]	60[b]
		STD	8	6	6	7	9	7
		N	91	90	91	91	91	90
Aroclor-1260	25	Mean	57	56	52	53[b]	53	55
		STD	9	8	8	7	7	7
		N	91	91	91	91	91	91
	50	Mean	58	57	55	55	55	57
		STD	9	10	11	9	9	11
		N	88	88	88	88	88	87
	100	Mean	57	59	55	56	56[b]	58[b]
		STD	7	8	9	7	9	8
		N	92	92	92	92	91	92

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			344	351	358	365	372	379
Control	0	Mean	54	54	54	53	51	51
		STD	7	10	6	7	7	6
		N	108	108	108	108	101	101
Aroclor-1016	50	Mean	53	**51[a]**	**50[b]**	52	50	51
		STD	6	6	7	7	6	5
		N	92	92	92	92	56	56
	100	Mean	52	**49[b]**	**48[b]**	**50[a]**	50	50
		STD	6	7	7	8	6	5
		N	91	91	90	90	53	53
	200	Mean	56	54	**51[b]**	52	53	53
		STD	7	6	6	7	6	6
		N	90	90	90	90	56	56
Aroclor-1242	50	Mean	53	**50[a]**	53	52	50	54
		STD	8	6	7	9	10	9
		N	90	90	90	90	55	55
	100	Mean	56	54	56	55	53	**57[b]**
		STD	9	7	7	8	7	9
		N	89	89	89	89	53	53
Aroclor-1254	25	Mean	51	**50[a]**	**58[a]**	**57[b]**	**55[a]**	54
		STD	7	9	9	8	9	9
		N	90	89	88	88	54	54
	50	Mean	56	52	**59[b]**	**58[b]**	**58[b]**	**56[b]**
		STD	8	9	8	8	7	7
		N	92	91	91	91	55	55
	100	Mean	**57[b]**	53	**61[b]**	**61[b]**	**61[b]**	**61[b]**
		STD	6	5	6	6	7	9
		N	90	90	90	89	55	55
Aroclor-1260	25	Mean	53	52	52	53	50	50
		STD	7	6	8	8	8	8
		N	91	91	91	91	56	55
	50	Mean	55	53	53	53	51	53
		STD	9	12	8	8	8	9
		N	88	88	88	86	53	53
	100	Mean	57	54	56	**57[b]**	53	**56[a]**
		STD	8	7	8	7	7	9
		N	91	92	92	92	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			386	393	400	407	414	421
Control	0	Mean	50	50	48	50	49	48
		STD	6	5	7	8	8	7
		N	98	98	98	97	97	96
Aroclor-1016	50	Mean	50	49	49	47	49	48
		STD	6	6	8	7	8	8
		N	56	56	56	56	55	55
	100	Mean	52	52	48	49	49	49
		STD	7	7	8	8	8	7
		N	53	53	52	52	52	52
	200	Mean	52	**55[b]**	**54[b]**	52	52	50
		STD	7	8	7	6	6	6
		N	56	56	56	56	56	56
Aroclor-1242	50	Mean	54	51	50	50	49	52
		STD	9	8	9	7	7	8
		N	55	55	55	55	54	55
	100	Mean	**55[b]**	**55[b]**	**52[b]**	52	52	**53[b]**
		STD	6	7	7	5	6	7
		N	52	52	52	52	52	52
Aroclor-1254	25	Mean	**54[b]**	50	49	49	51	**55[b]**
		STD	8	10	6	6	6	6
		N	54	53	53	53	52	52
	50	Mean	**59[b]**	**54[b]**	50	49	**53[a]**	**59[b]**
		STD	7	7	8	7	7	7
		N	55	55	55	55	55	55
	100	Mean	**61[b]**	**55[b]**	**53[b]**	**54[b]**	**55[b]**	**62[b]**
		STD	8	7	6	5	8	11
		N	55	55	54	54	54	54
Aroclor-1260	25	Mean	47	**54[b]**	**52[b]**	52	50	47
		STD	8	6	7	6	7	7
		N	55	55	55	55	55	55
	50	Mean	53	53	**52[a]**	51	50	48
		STD	7	8	8	8	8	7
		N	53	53	53	53	52	52
	100	Mean	**56[b]**	**56[b]**	**55[b]**	**53[a]**	51	49
		STD	9	6	9	6	8	5
		N	56	56	56	56	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			428	435	442	449	456	463
Control	0	Mean	48	47	49	47	48	47
		STD	8	7	8	9	7	7
		N	95	94	91	91	89	88
Aroclor-1016	50	Mean	52[a]	50	48	50	51	52[a]
		STD	8	8	11	8	10	12
		N	55	55	54	53	53	52
	100	Mean	51	49	49	50	49	50
		STD	6	9	[illegible]	7	8	10
		N	51	51	51	51	51	51
	200	Mean	50	50	48	51	50	52[b]
		STD	6	6	7	8	8	8
		N	56	56	56	55	55	54
Aroclor-1242	50	Mean	55[b]	55[b]	51	55[b]	54[b]	53[b]
		STD	7	7	7	7	9	8
		N	54	55	54	54	54	53
	100	Mean	56[b]	58[b]	55[b]	60[b]	58[b]	58[b]
		STD	7	7	6	9	11	9
		N	52	51	51	51	51	51
Aroclor-1254	25	Mean	54[b]	54[b]	53	53[b]	53	52[b]
		STD	8	8	7	9	10	7
		N	51	51	50	50	50	50
	50	Mean	58[b]	57[b]	56[b]	56[b]	58[b]	54[b]
		STD	8	7	9	8	8	11
		N	55	55	55	55	55	55
	100	Mean	61[b]	61[b]	59[b]	60[b]	63[b]	62[b]
		STD	8	8	7	8	9	10
		N	54	54	54	54	54	53
Aroclor-1260	25	Mean	48	49	51	50	48	49
		STD	6	6	7	8	7	7
		N	55	55	55	55	55	54
	50	Mean	48	49	51	51	49	49
		STD	7	7	8	8	6	10
		N	52	51	51	50	50	50
	100	Mean	51[a]	51[b]	54	55[b]	52	54[b]
		STD	9	7	13	13	11	8
		N	56	56	56	56	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			470	477	484	491	498	505
Control	0	Mean	50	46	47	46	46	43
		STD	9	9	9	11	10	12
		N	88	87	87	85	82	82
Aroclor-1016	50	Mean	52	51[a]	50	48	46	47
		STD	8	6	6	7	8	8
		N	52	51	50	50	51	51
	100	Mean	49	48	48	48	46	46
		STD	8	9	8	9	8	9
		N	51	51	51	49	48	48
	200	Mean	51	51[a]	52	48	48	48
		STD	7	9	13	10	10	10
		N	54	54	54	52	51	51
Aroclor-1242	50	Mean	56[b]	51[a]	52[b]	53[b]	50	52[b]
		STD	10	8	9	10	8	10
		N	53	52	51	52	52	51
	100	Mean	62[b]	55[b]	58[b]	56[b]	53[b]	53[b]
		STD	15	12	16	15	13	7
		N	51	51	51	51	51	50
Aroclor-1254	25	Mean	55[a]	51[a]	52[a]	50	52[b]	50[b]
		STD	9	7	9	8	8	6
		N	49	49	48	48	48	48
	50	Mean	57[b]	52[b]	53[b]	52[b]	54[b]	51[b]
		STD	9	8	8	9	11	9
		N	55	55	55	55	55	54
	100	Mean	63[b]	59[b]	60[b]	61[b]	61[b]	58[b]
		STD	8	7	7	9	8	6
		N	52	52	53	52	52	52
Aroclor-1260	25	Mean	50	50	49	46	46	46
		STD	7	7	9	8	8	8
		N	54	54	54	54	53	53
	50	Mean	48	50	49	47	50	46
		STD	12	8	8	8	12	8
		N	50	49	49	49	48	47
	100	Mean	52	52[b]	49	47	49	49[b]
		STD	7	10	10	7	8	9
		N	55	55	54	53	51	51

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			512	519	526	533	540	547
Control	0	Mean	43	45	45	47	45	44
		STD	10	10	11	12	9	11
		N	81	78	75	72	69	67
Aroclor-1016	50	Mean	45	44	44	45	45	43
		STD	9	10	11	11	8	7
		N	51	51	51	50	46	48
	100	Mean	46	45	45	47	45	44
		STD	9	10	10	13	12	12
		N	48	48	47	48	48	48
	200	Mean	47	46	47	48	46	45
		STD	6	9	8	11	9	10
		N	51	50	50	51	51	51
Aroclor-1242	50	Mean	**51[b]**	**53[b]**	**51[b]**	53	47	47
		STD	10	11	10	13	10	14
		N	49	50	50	50	48	49
	100	Mean	**51[b]**	**53[b]**	**50[b]**	52	49	**50[b]**
		STD	7	8	7	8	10	10
		N	48	48	48	48	48	48
Aroclor-1254	25	Mean	**51[b]**	49	**52[b]**	51	48	46
		STD	9	10	11	10	9	9
		N	48	48	48	48	48	48
	50	Mean	**54[b]**	**52[b]**	**53[b]**	**54[a]**	**51[b]**	**50[b]**
		STD	9	7	9	9	9	8
		N	53	53	53	52	51	51
	100	Mean	**59[b]**	**59[b]**	**59[b]**	**59[b]**	**56[b]**	**56[b]**
		STD	9	8	10	14	11	11
		N	52	52	52	52	51	50
Aroclor-1260	25	Mean	45	45	43	45	44	42
		STD	9	10	8	8	10	9
		N	53	53	52	51	50	50
	50	Mean	46	46	45	46	46	46
		STD	7	9	9	9	7	6
		N	47	47	47	47	47	46
	100	Mean	48	48	48	46	49	45
		STD	9	8	9	9	8	7
		N	51	49	49	49	46	46

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			554	561	568	575	582	589
Control	0	Mean	46	46	47	45	46	45
		STD	11	10	11	12	15	12
		N	64	60	60	59	59	57
Aroclor-1016	50	Mean	47	50	47	47	46	46
		STD	11	13	12	11	8	10
		N	42	41	40	40	40	40
	100	Mean	43	46	47	45	46	46
		STD	11	11	13	11	12	13
		N	41	38	39	38	38	38
	200	Mean	49	52[a]	53	51	52	52[a]
		STD	13	10	12	13	14	11
		N	44	44	42	41	41	39
Aroclor-1242	50	Mean	47	50	48	51	48	52
		STD	16	15	17	17	14	16
		N	44	44	44	42	42	41
	100	Mean	49	52[a]	50	53[a]	50	53[a]
		STD	8	9	11	10	11	11
		N	42	42	42	41	41	41
Aroclor-1254	25	Mean	44	44	46	47	47	50
		STD	9	10	8	8	8	9
		N	44	44	44	44	44	44
	50	Mean	47	49	49	48	49	51
		STD	10	9	9	10	11	11
		N	45	44	41	42	42	42
	100	Mean	53[b]	52[b]	53[a]	54[b]	54[a]	54[b]
		STD	9	8	9	10	10	9
		N	45	44	44	43	42	42
Aroclor-1260	25	Mean	42	46	46	47	44	46
		STD	8	13	12	12	13	11
		N	45	45	43	42	40	39
	50	Mean	44	47	45	48	46	46
		STD	11	8	9	9	11	13
		N	40	39	39	39	39	38
	100	Mean	47	52	51	49	51	51
		STD	10	14	8	8	9	8
		N	39	39	39	35	37	37

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			596	603	610	617	624	631
Control	0	Mean	47	45	46	45	43	45
		STD	15	10	11	13	13	13
		N	57	53	53	53	53	51
Aroclor-1016	50	Mean	46	45	44	44	47	45
		STD	13	13	13	12	13	12
		N	40	38	38	36	35	33
	100	Mean	48	50	46	46	47	47
		STD	14	17	15	15	18	17
		N	37	37	36	34	33	30
	200	Mean	53	52	51	51	**50[a]**	49
		STD	11	16	11	16	10	17
		N	39	39	38	38	37	37
Aroclor-1242	50	Mean	49	51	52	49	**53[b]**	52
		STD	13	16	17	11	16	15
		N	41	39	39	39	37	36
	100	Mean	51	50	49	**52[a]**	**54[b]**	52
		STD	8	12	15	15	13	14
		N	41	41	41	40	40	40
Aroclor-1254	25	Mean	48	47	45	48	**51[a]**	48
		STD	9	7	8	10	12	13
		N	44	42	42	42	42	42
	50	Mean	50	48	47	51	**52[a]**	50
		STD	13	14	15	11	13	16
		N	42	40	40	36	35	35
	100	Mean	**55[a]**	51	**57[b]**	**57[b]**	**59[b]**	**58[b]**
		STD	10	10	14	10	18	13
		N	41	40	38	37	37	34
Aroclor-1260	25	Mean	48	45	45	45	41	43
		STD	13	9	9	10	11	10
		N	38	36	35	33	33	32
	50	Mean	46	44	46	48	44	46
		STD	16	16	20	12	16	17
		N	37	36	34	31	31	29
	100	Mean	49	51	51	52	51	52
		STD	10	13	11	12	17	20
		N	36	37	36	35	36	35

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			638	645	652	659	666	673
Control	0	Mean	44	44	41	42	44	44
		STD	13	9	10	10	14	10
		N	48	48	47	47	45	43
Aroclor-1016	50	Mean	43	44	42	43	44	44
		STD	13	10	11	16	14	13
		N	33	33	33	32	32	30
	100	Mean	48	50	46	45	50	42
		STD	17	20	16	14	19	18
		N	30	30	30	29	29	29
	200	Mean	48	50	49	46	49	49
		STD	14	17	17	17	15	14
		N	37	37	36	35	34	34
Aroclor-1242	50	Mean	50	51	47	48	52	47
		STD	14	15	15	15	19	11
		N	35	35	35	31	30	30
	100	Mean	50	49	44	44	47	46
		STD	12	12	11	15	17	13
		N	40	38	38	37	34	32
Aroclor-1254	25	Mean	49	47	47	46	49	46
		STD	13	12	13	12	13	11
		N	41	41	41	40	39	38
	50	Mean	52	**55[b]**	**54[b]**	**52[b]**	**55[a]**	51
		STD	14	14	15	8	11	14
		N	33	30	30	29	29	27
	100	Mean	**55[b]**	**57[b]**	**57[b]**	**58[b]**	**62[b]**	**61[b]**
		STD	14	9	11	10	14	12
		N	31	29	29	29	28	28
Aroclor-1260	25	Mean	42	44	45	42	46	40
		STD	11	10	11	12	11	12
		N	30	29	28	27	25	25
	50	Mean	46	45	46	45	50	45
		STD	11	10	13	13	15	13
		N	28	28	28	28	28	28
	100	Mean	49	53	47	49	52	50
		STD	15	17	14	15	16	16
		N	33	32	31	31	29	28

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study				
			680	687	694	701	708
Control	0	Mean	45	42	46	44	43
		STD	11	11	11	13	12
		N	41	40	39	36	34
Aroclor-1016	50	Mean	42	43	38	39	37
		STD	11	17	10	13	15
		N	29	28	26	25	25
	100	Mean	46	46	43	43	42
		STD	17	13	12	15	11
		N	29	26	26	25	23
	200	Mean	49	50	47	51	48
		STD	15	12	15	16	12
		N	33	32	31	30	28
Aroclor-1242	50	Mean	46	48	46	46	43
		STD	12	13	16	17	14
		N	29	26	26	25	25
	100	Mean	47	47	45	47	47
		STD	13	15	22	22	20
		N	30	29	28	28	27
Aroclor-1254	25	Mean	49	47	47	46	49
		STD	14	11	14	14	13
		N	37	36	36	35	35
	50	Mean	53	54[a]	52	45	52
		STD	11	10	13	16	11
		N	25	23	23	21	18
	100	Mean	61[b]	62[b]	61[b]	60[b]	60[b]
		STD	13	15	15	19	14
		N	28	26	26	24	24
Aroclor-1260	25	Mean	48	47	47	48	46
		STD	13	15	13	17	13
		N	25	25	25	25	24
	50	Mean	51	50	50	46	47
		STD	13	12	10	10	13
		N	28	27	26	26	24
	100	Mean	52	55[b]	54	50	51
		STD	21	20	22	19	19
		N	28	27	27	27	26

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)		Day of Study	
			715	722
Control	0	Mean	45	47
		STD	9	14
		N	32	26
Aroclor-1016	50	Mean	39	47
		STD	12	12
		N	23	15
	100	Mean	42	45
		STD	17	14
		N	23	15
	200	Mean	47	47
		STD	11	9
		N	27	19
Aroclor-1242	50	Mean	42	42
		STD	17	19
		N	25	17
	100	Mean	47	50
		STD	18	18
		N	27	21
Aroclor-1254	25	Mean	46	44
		STD	12	14
		N	34	27
	50	Mean	48	50
		STD	8	6
		N	17	11
	100	Mean	57[b]	57
		STD	13	16
		N	22	16
Aroclor-1260	25	Mean	46	44
		STD	16	17
		N	22	15
	50	Mean	46	48
		STD	11	7
		N	24	16
	100	Mean	51	53
		STD	18	16
		N	25	18

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			8	15	22	29	36	43
Aroclor-1016	50	Mean	4.3	4.3	4.2	**4.0[a]**	4.2	4.0
		STD	0.5	0.6	0.6	0.5	0.8	0.8
		N	110	110	110	110	110	110
	100	Mean	8.8	8.8	8.7	8.4	8.7	8.1
		STD	0.9	1.1	1.3	1.3	1.5	1.6
		N	110	110	110	110	110	110
	200	Mean	**18.4[b]**	**19.0[b]**	17.8	17.8	**18.4[b]**	**17.4[b]**
		STD	2.2	3.6	3.0	3.6	4.0	4.0
		N	110	110	110	110	110	110
Aroclor-1242	50	Mean	4.6	4.6	**4.7[b]**	4.3	4.1	3.9
		STD	0.9	1.1	1.0	0.9	0.8	0.8
		N	110	110	110	110	110	110
	100	Mean	9.0	9.0	9.0	8.6	8.2	8.2
		STD	1.5	1.6	1.8	1.8	1.9	2.0
		N	110	110	110	110	110	110
Aroclor-1254	25	Mean	2.2	2.1	2.1	2.1	**1.9[b]**	1.8
		STD	0.3	0.3	0.3	0.4	0.3	0.3
		N	110	110	110	110	109	108
	50	Mean	4.5	4.3	4.3	4.1	**3.9[b]**	3.7
		STD	0.6	0.6	0.8	0.5	0.4	0.5
		N	110	110	109	109	108	110
	100	Mean	9.0	8.5	**8.0[b]**	8.1	**7.7[b]**	7.3
		STD	1.2	1.1	1.1	1.2	0.9	1.0
		N	110	110	110	109	110	110
Aroclor-1260	25	Mean	2.3	2.1	2.2	2.3	2.1	2.0
		STD	0.3	0.3	0.3	0.5	0.5	0.4
		N	110	110	110	110	110	110
	50	Mean	4.6	4.4	4.4	**4.8[b]**	4.5	**4.1[a]**
		STD	0.7	0.7	0.7	1.1	1.1	0.9
		N	110	110	110	110	110	110
	100	Mean	**9.3[b]**	8.9	8.8	8.8	8.8	**8.2[a]**
		STD	1.4	1.4	1.4	1.8	2.1	1.5
		N	109	110	110	110	110	109

1. *Stop Study subgroup rats represented in treatment through Day 365.*
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			50	57	64	71	78	85
Aroclor-1016	50	Mean	3.8	3.6	3.5	3.4	3.3	3.2
		STD	0.6	0.6	0.5	0.5	0.4	0.4
		N	110	110	110	110	110	110
	100	Mean	8.0	7.6	7.3	7.0	6.8	6.4
		STD	1.4	1.5	1.2	1.2	1.0	0.9
		N	110	110	110	110	110	110
	200	Mean	**16.2[a]**	15.2	14.6	14.2	13.6	13.2
		STD	3.0	2.6	2.2	2.4	1.8	1.8
		N	110	110	110	110	110	110
Aroclor-1242	50	Mean	**4.2[b]**	3.8	3.7	3.5	3.3	3.2
		STD	1.0	1.0	0.8	0.6	0.5	0.5
		N	110	110	110	110	110	110
	100	Mean	8.1	7.4	7.4	**7.5[a]**	7.0	6.3
		STD	2.1	1.6	1.8	2.2	1.9	0.8
		N	110	108	110	110	110	110
Aroclor-1254	25	Mean	1.9	1.8	1.8	1.8	1.7	1.7
		STD	0.3	0.3	0.3	0.3	0.3	0.3
		N	109	107	108	110	109	106
	50	Mean	3.7	3.6	3.4	3.4	3.4	3.3
		STD	0.6	0.5	0.5	0.5	0.5	0.6
		N	109	109	108	110	110	110
	100	Mean	7.2	7.1	**6.7[a]**	6.8	6.6	6.5
		STD	1.2	1.1	0.9	1.1	1.1	1.2
		N	109	110	109	110	110	110
Aroclor-1260	25	Mean	2.0	1.8	**1.7[a]**	1.7	1.7	1.7
		STD	0.5	0.3	0.3	0.4	0.3	0.4
		N	110	110	110	110	110	110
	50	Mean	4.1	3.9	3.8	3.6	3.5	3.4
		STD	0.9	0.8	1.0	0.9	0.7	0.8
		N	110	109	109	109	108	108
	100	Mean	8.0	7.7	7.4	7.1	6.9	6.7
		STD	1.7	1.3	1.3	1.2	1.2	1.1
		N	109	110	110	110	110	110

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			92	99	106	114	120	127
Aroclor-1016	50	Mean	3.2	3.1	3.1	3.1	3.2	3.0
		STD	0.4	0.5	0.4	0.6	0.4	0.4
		N	110	104	104	104	104	104
	100	Mean	6.3	6.2	**6.2[a]**	6.1	6.2	6.1
		STD	0.9	0.9	0.7	0.8	1.0	1.0
		N	110	103	103	104	104	104
	200	Mean	12.8	12.4	13.2	12.6	12.6	12.6
		STD	1.6	1.4	2.8	1.6	2.0	1.4
		N	110	102	104	104	104	104
Aroclor-1242	50	Mean	3.1	3.4	3.3	3.2	3.2	3.2
		STD	0.5	0.9	0.6	0.6	0.5	0.6
		N	110	104	104	104	104	104
	100	Mean	6.3	6.8	6.6	6.4	**6.5[b]**	6.4
		STD	1.1	1.7	1.3	1.3	1.1	0.9
		N	110	104	104	104	104	104
Aroclor-1254	25	Mean	1.6	1.6	1.6	1.6	1.6	1.5
		STD	0.3	0.3	0.3	0.2	0.3	0.2
		N	108	104	102	102	104	104
	50	Mean	3.2	3.1	3.4	3.2	3.2	3.1
		STD	0.6	0.4	0.7	0.5	0.4	0.4
		N	110	104	104	104	104	104
	100	Mean	6.4	6.3	6.8	6.6	**6.4[a]**	6.3
		STD	1.0	0.8	1.1	1.4	0.8	0.7
		N	110	104	104	104	104	104
Aroclor-1260	25	Mean	1.6	1.6	**1.5[a]**	1.6	1.5	1.5
		STD	0.4	0.3	0.3	0.3	0.2	0.2
		N	110	104	104	104	104	104
	50	Mean	3.3	3.3	3.1	3.4	3.1	3.1
		STD	0.8	0.8	0.5	0.7	0.5	0.5
		N	108	102	102	102	102	102
	100	Mean	6.4	6.7	6.2	6.7	6.1	6.1
		STD	1.2	1.6	1.0	1.4	0.9	0.8
		N	110	104	104	104	103	104

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			134	141	149	155	162	169
Aroclor-1016	50	Mean	**3.1**[b]	3.1	**3.1**[b]	3.0	3.0	3.0
		STD	0.4	0.3	0.4	0.4	0.4	0.3
		N	104	104	104	104	104	104
	100	Mean	**6.3**[b]	6.2	**6.2**[a]	5.9	5.9	5.8
		STD	1.0	0.8	0.9	0.9	0.9	0.8
		N	104	104	104	104	104	104
	200	Mean	**12.8**[b]	**12.8**[b]	**12.8**[b]	12.0	12.0	12.0
		STD	1.4	1.6	2.2	1.8	1.4	1.4
		N	103	104	103	104	104	104
Aroclor-1242	50	Mean	**3.1**[b]	3.1	3.1	3.0	3.0	2.9
		STD	0.4	0.4	0.5	0.5	0.4	0.4
		N	101	104	104	104	104	104
	100	Mean	**6.3**[b]	**6.3**[a]	**6.2**[a]	5.8	6.1	**6.1**[a]
		STD	1.0	1.1	0.7	1.2	0.8	0.8
		N	104	104	104	104	104	104
Aroclor-1254	25	Mean	**1.5**[a]	1.5	1.5	1.5	1.5	1.5
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	104	104	104	103	104	104
	50	Mean	**3.2**[b]	3.1	**3.1**[a]	3.1	3.1	**3.1**[b]
		STD	0.5	0.4	0.4	0.4	0.4	0.4
		N	104	104	104	104	104	104
	100	Mean	**6.4**[b]	**6.3**[b]	**6.2**[b]	**6.3**[b]	**6.4**[b]	**6.4**[b]
		STD	0.6	0.6	0.5	0.5	0.6	0.6
		N	104	104	104	104	104	104
Aroclor-1260	25	Mean	1.5	1.5	1.5	1.5	**1.4**[b]	1.4
		STD	0.1	0.2	0.2	0.2	0.2	0.2
		N	104	104	104	104	104	104
	50	Mean	3.1	3.0	3.1	3.0	2.9	2.9
		STD	0.4	0.4	0.6	0.4	0.4	0.4
		N	102	102	102	102	102	101
	100	Mean	**6.1**[b]	6.2	**6.1**[a]	6.0	6.0	6.0
		STD	0.8	0.8	0.9	0.8	0.8	1.0
		N	104	104	104	104	104	104

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			176	183	190	197	204	211
Aroclor-1016	50	Mean	3.0	2.9	2.9	2.9	2.9	2.9
		STD	0.4	0.3	0.3	0.4	0.4	0.3
		N	104	104	98	98	98	98
	100	Mean	**5.7[b]**	5.5	5.5	5.6	5.6	**5.5[b]**
		STD	0.8	0.8	0.6	0.6	0.8	0.5
		N	104	104	98	98	98	98
	200	Mean	12.0	11.6	11.6	11.8	11.4	11.4
		STD	1.6	1.6	1.4	1.4	1.4	1.4
		N	104	104	98	98	98	98
Aroclor-1242	50	Mean	**2.9[b]**	3.0	2.8	2.9	2.9	2.9
		STD	0.3	0.3	0.4	0.4	0.3	0.4
		N	104	103	98	98	98	98
	100	Mean	6.0	5.9	5.8	5.9	5.9	5.9
		STD	0.6	0.7	0.7	0.8	0.6	0.8
		N	104	104	98	98	98	98
Aroclor-1254	25	Mean	1.5	1.5	1.5	1.5	1.5	1.5
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	103	104	97	97	97	97
	50	Mean	3.1	**3.1[b]**	**3.1[a]**	**3.1[a]**	**3.1[b]**	**3.1[a]**
		STD	0.4	0.4	0.4	0.4	0.4	0.4
		N	104	104	98	98	98	98
	100	Mean	**6.5[b]**	**6.4[b]**	**6.3[b]**	**6.3[b]**	**6.3[b]**	**6.2[b]**
		STD	0.6	0.7	0.6	0.5	0.6	0.5
		N	104	104	98	98	98	98
Aroclor-1260	25	Mean	**1.4[b]**	1.4	**1.4[b]**	1.4	1.4	**1.4[b]**
		STD	0.2	0.2	0.2	0.1	0.1	0.2
		N	104	104	98	98	98	98
	50	Mean	**2.9[a]**	2.9	2.8	2.9	2.9	2.8
		STD	0.4	0.4	0.4	0.4	0.4	0.4
		N	101	101	95	95	95	95
	100	Mean	6.0	5.9	5.8	6.0	5.9	5.8
		STD	0.8	0.7	0.8	0.8	0.8	0.7
		N	104	104	98	98	98	97

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			218	225	232	239	246	253
Aroclor-1016	50	Mean	2.8	2.9	3.0	2.9	2.8	2.8
		STD	0.3	0.3	0.4	0.4	0.4	0.4
		N	97	97	98	97	98	98
	100	Mean	5.5	5.5	6.0	5.7	5.6	5.4
		STD	0.6	0.7	0.8	0.8	0.8	0.7
		N	98	97	98	98	98	97
	200	Mean	11.4	11.4	12.2	11.6	11.4	11.4
		STD	1.2	2.0	2.0	1.4	1.4	1.4
		N	97	97	97	97	97	94
Aroclor-1242	50	Mean	2.8	2.8	2.9	2.8	2.8	2.8
		STD	0.4	0.3	0.4	0.4	0.5	0.4
		N	98	98	98	98	98	96
	100	Mean	5.7	5.7	5.9	5.8	**5.8[b]**	5.7
		STD	0.6	0.6	1.0	0.6	0.6	0.8
		N	97	97	96	96	96	96
Aroclor-1254	25	Mean	1.5	1.5	1.5	1.4	**1.5[b]**	**1.5[b]**
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	97	97	97	97	97	97
	50	Mean	**3.1[b]**	**3.1[b]**	**3.2[b]**	3.1	**3.1[b]**	**3.1[b]**
		STD	0.4	0.4	0.4	0.6	0.4	0.4
		N	98	97	98	98	98	98
	100	Mean	**6.2[b]**	**6.4[b]**	**6.5[b]**	**6.3[b]**	**6.2[b]**	**6.2[b]**
		STD	0.6	0.8	0.6	0.9	0.6	0.6
		N	98	98	97	98	97	97
Aroclor-1260	25	Mean	1.4	1.4	1.4	1.4	1.4	**1.5[a]**
		STD	0.2	0.2	0.2	0.2	0.3	0.2
		N	98	98	98	98	98	97
	50	Mean	2.9	2.9	2.9	2.9	2.9	**3.0[a]**
		STD	0.4	0.4	0.4	0.4	0.5	0.4
		N	94	93	93	94	94	94
	100	Mean	5.8	5.8	5.9	5.9	**5.7[b]**	**6.0[b]**
		STD	0.8	0.7	0.8	0.8	0.7	0.9
		N	98	98	98	98	98	98

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			260	267	274	281	288	295
Aroclor-1016	50	Mean	2.9	**2.9[b]**	2.8	2.7	2.8	2.7
		STD	0.4	0.4	0.4	0.4	0.4	0.5
		N	98	98	98	92	92	92
	100	Mean	**5.9[a]**	**5.8[b]**	5.6	5.6	5.5	5.5
		STD	0.9	0.9	0.9	0.9	0.9	1.0
		N	98	98	98	92	92	92
	200	Mean	11.6	**11.6[b]**	11.2	11.4	11.6	11.4
		STD	1.6	1.2	1.6	1.4	1.6	1.6
		N	96	96	96	90	90	90
Aroclor-1242	50	Mean	2.8	**2.9[a]**	2.7	2.7	2.8	2.8
		STD	0.5	0.5	0.4	0.3	0.4	0.4
		N	98	98	98	92	92	92
	100	Mean	**5.9[a]**	**5.9[b]**	5.8	5.7	**6.2[b]**	5.9
		STD	0.9	0.8	0.8	0.7	1.3	0.8
		N	96	96	96	90	90	90
Aroclor-1254	25	Mean	**1.5[b]**	**1.4[b]**	1.4	1.5	1.4	1.4
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	97	97	97	91	91	91
	50	Mean	**3.2[b]**	**3.1[b]**	**3.0[b]**	**3.0[a]**	**3.0[b]**	**3.0[a]**
		STD	0.5	0.6	0.4	0.4	0.4	0.4
		N	98	98	98	92	92	91
	100	Mean	**6.4[b]**	**6.2[b]**	**6.2[b]**	**6.2[b]**	**6.1[b]**	**6.2[b]**
		STD	0.7	0.7	0.7	0.7	0.6	0.7
		N	97	97	97	91	91	91
Aroclor-1260	25	Mean	1.5	**1.5[b]**	1.4	1.4	1.4	1.4
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	97	97	97	91	91	91
	50	Mean	**3.0[a]**	**2.9[b]**	2.9	2.8	2.8	2.9
		STD	0.4	0.3	0.3	0.4	0.4	0.5
		N	94	94	94	86	88	88
	100	Mean	**5.9[a]**	**5.8[b]**	5.7	5.7	5.7	5.8
		STD	0.9	0.8	0.7	0.9	0.9	0.8
		N	98	98	98	92	92	92

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			302	309	316	323	330	337
Aroclor-1016	50	Mean	2.7	2.7	2.7	**2.7[b]**	2.6	2.6
		STD	0.4	0.4	0.4	0.3	0.4	0.3
		N	92	92	92	92	92	92
	100	Mean	5.4	5.4	5.5	**5.3[b]**	5.0	**5.2[a]**
		STD	0.8	0.8	1.0	0.8	0.6	0.6
		N	92	92	91	91	91	91
	200	Mean	10.8	11.0	**11.0[a]**	11.0	10.6	11.0
		STD	1.2	1.4	1.6	1.4	1.2	1.4
		N	90	90	90	90	90	90
Aroclor-1242	50	Mean	2.8	2.8	2.7	2.9	2.7	2.9
		STD	0.5	0.5	0.4	0.5	0.4	0.5
		N	91	91	91	90	90	90
	100	Mean	5.8	5.7	**5.7[b]**	5.8	**5.6[b]**	**5.8[b]**
		STD	0.9	0.9	0.8	0.8	0.7	0.8
		N	90	90	90	89	89	89
Aroclor-1254	25	Mean	**1.5[a]**	1.5	**1.4[b]**	1.4	**1.4[b]**	1.4
		STD	0.2	0.2	0.3	0.2	0.2	0.2
		N	90	90	90	90	90	90
	50	Mean	**3.1[b]**	3.0	**3.0[b]**	3.0	**3.0[b]**	**2.9[a]**
		STD	0.4	0.4	0.4	0.5	0.5	0.5
		N	92	92	91	92	92	92
	100	Mean	**6.3[b]**	**6.1[b]**	**6.1[b]**	6.1	**6.1[b]**	**6.0[b]**
		STD	0.8	0.6	0.6	0.7	0.9	0.7
		N	91	90	91	91	91	90
Aroclor-1260	25	Mean	1.4	1.4	1.3	**1.3[b]**	1.3	1.4
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	91	91	91	91	91	91
	50	Mean	2.9	2.9	2.8	2.8	2.8	2.9
		STD	0.5	0.5	0.6	0.5	0.5	0.6
		N	88	88	88	88	88	87
	100	Mean	5.7	5.9	5.5	5.6	**5.6[b]**	**5.8[b]**
		STD	0.7	0.8	0.9	0.7	0.9	0.8
		N	92	92	92	92	91	92

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			344	351	358	365	372	379
Aroclor-1016	50	Mean	2.7	**2.6[a]**	**2.5[b]**	2.6	2.5	2.6
		STD	0.3	0.3	0.4	0.4	0.3	0.3
		N	92	92	92	92	56	56
	100	Mean	5.2	**4.9[b]**	**4.8[b]**	**5.0[a]**	5.0	5.0
		STD	0.6	0.7	0.7	0.8	0.6	0.5
		N	91	91	90	90	53	53
	200	Mean	11.2	10.8	**10.2[b]**	10.4	10.6	10.6
		STD	1.4	1.2	1.2	1.4	1.2	1.2
		N	90	90	90	90	56	56
Aroclor-1242	50	Mean	2.7	**2.5[a]**	2.7	2.6	2.5	2.7
		STD	0.4	0.3	0.4	0.5	0.5	0.5
		N	90	90	90	90	55	55
	100	Mean	5.6	5.4	5.6	5.5	5.3	**5.7[b]**
		STD	0.9	0.7	0.7	0.8	0.7	0.9
		N	89	89	89	89	53	53
Aroclor-1254	25	Mean	1.3	**1.3[a]**	**1.5[a]**	**1.4[b]**	**1.4[a]**	1.4
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	90	89	88	88	54	54
	50	Mean	2.8	2.6	**3.0[b]**	**2.9[b]**	**2.9[b]**	**2.8[b]**
		STD	0.4	0.5	0.4	0.4	0.4	0.4
		N	92	91	91	91	55	55
	100	Mean	**5.7[b]**	5.3	**6.1[b]**	**6.1[b]**	**6.1[b]**	**6.1[b]**
		STD	0.6	0.5	0.6	0.6	0.7	0.9
		N	90	90	90	89	55	55
Aroclor-1260	25	Mean	1.3	1.3	1.3	1.3	1.3	1.3
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	91	91	91	91	56	55
	50	Mean	2.8	2.7	2.7	2.7	2.6	2.7
		STD	0.5	0.6	0.4	0.4	0.4	0.5
		N	88	88	88	86	53	53
	100	Mean	5.7	5.4	5.6	**5.7[b]**	5.3	**5.6[a]**
		STD	0.8	0.7	0.8	0.7	0.7	0.9
		N	91	92	92	92	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			386	393	400	407	414	421
Aroclor-1016	50	Mean	2.5	2.5	2.5	2.4	2.5	2.4
		STD	0.3	0.3	0.4	0.4	0.4	0.4
		N	56	56	56	56	55	55
	100	Mean	5.2	5.2	4.8	4.9	4.9	4.9
		STD	0.7	0.7	0.8	0.8	0.8	0.7
		N	53	53	52	52	52	52
	200	Mean	10.4	**11.0[b]**	**10.8[b]**	10.4	10.4	10.0
		STD	1.4	1.6	1.4	1.2	1.2	1.2
		N	56	56	56	56	56	56
Aroclor-1242	50	Mean	2.7	2.6	2.5	2.5	2.5	2.6
		STD	0.5	0.4	0.5	0.4	0.4	0.4
		N	55	55	55	55	54	55
	100	Mean	**5.5[b]**	**5.5[b]**	**5.2[b]**	5.2	5.2	**5.3[b]**
		STD	0.6	0.7	0.7	0.5	0.6	0.7
		N	52	52	52	52	52	52
Aroclor-1254	25	Mean	**1.4[b]**	1.3	1.2	1.2	1.3	**1.4[b]**
		STD	0.2	0.3	0.2	0.2	0.2	0.2
		N	54	53	53	53	52	52
	50	Mean	**3.0[b]**	**2.7[b]**	2.5	2.5	**2.7[a]**	**3.0[b]**
		STD	0.4	0.4	0.4	0.4	0.4	0.4
		N	55	55	55	55	55	55
	100	Mean	**6.1[b]**	**5.5[b]**	**5.3[b]**	**5.4[b]**	**5.5[b]**	**6.2[b]**
		STD	0.8	0.7	0.6	0.5	0.8	1.1
		N	55	55	54	54	54	54
Aroclor-1260	25	Mean	1.2	**1.4[b]**	**1.3[b]**	1.3	1.3	1.2
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	55	55	55	55	55	55
	50	Mean	2.7	2.7	**2.6[a]**	2.6	2.5	2.4
		STD	0.4	0.4	0.4	0.4	0.4	0.4
		N	53	53	53	53	52	52
	100	Mean	**5.6[b]**	**5.6[b]**	**5.5[b]**	**5.3[a]**	5.1	4.9
		STD	0.9	0.6	0.9	0.6	0.8	0.5
		N	56	56	56	56	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			428	435	442	449	456	463
Aroclor-1016	50	Mean	**2.6[a]**	2.5	2.4	2.5	2.6	**2.6[a]**
		STD	0.4	0.4	0.6	0.4	0.5	0.6
		N	55	55	54	53	53	52
	100	Mean	5.1	4.9	4.9	5.0	4.9	5.0
		STD	0.6	0.9	0.9	0.7	0.8	1.0
		N	51	51	51	51	51	51
	200	Mean	10.0	10.0	9.6	10.2	10.0	**10.4[b]**
		STD	1.2	1.2	1.4	1.6	1.6	1.6
		N	56	56	56	55	55	54
Aroclor-1242	50	Mean	**2.8[b]**	**2.8[b]**	2.6	**2.8[b]**	**2.7[b]**	**2.7[b]**
		STD	0.4	0.4	0.4	0.4	0.5	0.4
		N	54	55	54	54	54	53
	100	Mean	**5.6[b]**	**5.8[b]**	**5.5[b]**	**6.0[b]**	**5.8[b]**	**5.8[b]**
		STD	0.7	0.7	0.6	0.9	1.1	0.9
		N	52	51	51	51	51	51
Aroclor-1254	25	Mean	**1.4[b]**	**1.4[b]**	1.3	**1.3[b]**	1.3	**1.3[b]**
		STD	0.2	0.2	0.2	0.2	0.3	0.2
		N	51	51	50	50	50	50
	50	Mean	**2.9[b]**	**2.9[b]**	**2.8[b]**	**2.8[b]**	**2.9[b]**	**2.7[b]**
		STD	0.4	0.4	0.5	0.4	0.4	0.6
		N	55	55	55	55	55	55
	100	Mean	**6.1[b]**	**6.1[b]**	**5.9[b]**	**6.0[b]**	**6.3[b]**	**6.2[b]**
		STD	0.8	0.8	0.7	0.8	0.9	1.0
		N	54	54	54	54	54	53
Aroclor-1260	25	Mean	1.2	1.2	1.3	1.3	1.2	1.2
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	55	55	55	55	55	54
	50	Mean	2.4	2.5	2.6	2.6	2.5	2.5
		STD	0.4	0.4	0.4	0.4	0.3	0.5
		N	52	51	51	50	50	50
	100	Mean	**5.1[a]**	**5.1[b]**	5.4	**5.5[b]**	5.2	**5.4[b]**
		STD	0.9	0.7	1.3	1.3	1.1	0.8
		N	56	56	56	56	56	56

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			470	477	484	491	498	505
Aroclor-1016	50	Mean	2.6	**2.6[a]**	2.5	2.4	2.3	2.4
		STD	0.4	0.3	0.3	0.4	0.4	0.4
		N	52	51	50	50	51	51
	100	Mean	4.9	4.8	4.8	4.8	4.6	4.6
		STD	0.8	0.9	0.8	0.9	0.8	0.9
		N	51	51	51	49	48	48
	200	Mean	10.2	**10.2[a]**	10.4	9.6	9.6	9.6
		STD	1.4	1.8	2.6	2.0	2.0	2.0
		N	54	54	54	52	51	51
Aroclor-1242	50	Mean	**2.8[b]**	**2.6[a]**	**2.6[b]**	**2.7[b]**	2.5	**2.6[b]**
		STD	0.5	0.4	0.5	0.5	0.4	0.5
		N	53	52	51	52	52	51
	100	Mean	**6.2[b]**	**5.5[b]**	**5.8[b]**	**5.6[b]**	**5.3[b]**	**5.3[b]**
		STD	1.5	1.2	1.6	1.5	1.3	0.7
		N	51	51	51	51	51	50
Aroclor-1254	25	Mean	**1.4[a]**	**1.3[a]**	**1.3[a]**	1.3	**1.3[b]**	**1.3[b]**
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	49	49	48	48	48	48
	50	Mean	**2.9[b]**	**2.6[b]**	**2.7[b]**	**2.6[b]**	**2.7[b]**	**2.6[b]**
		STD	0.5	0.4	0.4	0.5	0.6	0.5
		N	55	55	55	55	55	54
	100	Mean	**6.3[b]**	**5.9[b]**	**6.0[b]**	**6.1[b]**	**6.1[b]**	**5.8[b]**
		STD	0.8	0.7	0.7	0.9	0.8	0.6
		N	52	52	53	52	52	52
Aroclor-1260	25	Mean	1.3	1.3	1.2	1.2	1.2	1.2
		STD	0.2	0.2	0.2	0.2	0.2	0.2
		N	54	54	54	54	53	53
	50	Mean	2.4	2.5	2.5	2.4	2.5	2.3
		STD	0.6	0.4	0.4	0.4	0.6	0.4
		N	50	49	49	49	48	47
	100	Mean	5.2	**5.2[b]**	4.9	4.7	4.9	**4.9[b]**
		STD	0.7	1.0	1.0	0.7	0.8	0.9
		N	55	55	54	53	51	51

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			512	519	526	533	540	547
Aroclor-1016	50	Mean	2.3	2.2	2.2	2.3	2.3	2.2
		STD	0.5	0.5	0.6	0.6	0.4	0.4
		N	51	51	51	50	46	48
	100	Mean	4.6	4.5	4.5	4.7	4.5	4.4
		STD	0.9	1.0	1.0	1.3	1.2	1.2
		N	48	48	47	48	48	48
	200	Mean	9.4	9.2	9.4	9.6	9.2	9.0
		STD	1.2	1.8	1.6	2.2	1.8	2.0
		N	51	50	50	51	51	51
Aroclor-1242	50	Mean	**2.6[b]**	**2.7[b]**	**2.6[b]**	2.7	2.4	2.4
		STD	0.5	0.6	0.5	0.7	0.5	0.7
		N	49	50	50	50	48	49
	100	Mean	**5.1[b]**	**5.3[b]**	**5.0[b]**	5.2	4.9	**5.0[b]**
		STD	0.7	0.8	0.7	0.8	1.0	1.0
		N	48	48	48	48	48	48
Aroclor-1254	25	Mean	**1.3[b]**	1.2	**1.3[b]**	1.3	1.2	1.2
		STD	0.2	0.3	0.3	0.3	0.2	0.2
		N	48	48	48	48	48	48
	50	Mean	**2.7[b]**	**2.6[b]**	**2.7[b]**	**2.7[a]**	**2.6[b]**	**2.5[b]**
		STD	0.5	0.4	0.5	0.5	0.5	0.4
		N	53	53	53	52	51	51
	100	Mean	**5.9[b]**	**5.9[b]**	**5.9[b]**	**5.9[b]**	**5.6[b]**	**5.6[b]**
		STD	0.9	0.8	1.0	1.4	1.1	1.1
		N	52	52	52	52	51	50
Aroclor-1260	25	Mean	1.1	1.1	1.1	1.1	1.1	1.1
		STD	0.2	0.3	0.2	0.2	0.3	0.2
		N	53	53	52	51	50	50
	50	Mean	2.3	2.3	2.3	2.3	2.3	2.3
		STD	0.4	0.5	0.5	0.5	0.4	0.3
		N	47	47	47	47	47	46
	100	Mean	4.8	4.8	4.8	4.6	4.9	4.5
		STD	0.9	0.8	0.9	0.9	0.8	0.7
		N	51	49	49	49	46	46

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			554	561	568	575	582	589
Aroclor-1016	50	Mean	2.4	2.5	2.4	2.4	2.3	2.3
		STD	0.6	0.7	0.6	0.6	0.4	0.5
		N	42	41	40	40	40	40
	100	Mean	4.3	4.6	4.7	4.5	4.6	4.6
		STD	1.1	1.1	1.3	1.1	1.2	1.3
		N	41	38	39	38	38	38
	200	Mean	9.8	**10.4[a]**	10.6	10.2	10.4	**10.4[a]**
		STD	2.6	2.0	2.4	2.6	2.8	2.2
		N	44	44	42	41	41	39
Aroclor-1242	50	Mean	2.4	2.5	2.4	2.6	2.4	2.6
		STD	0.8	0.8	0.9	0.9	0.7	0.8
		N	44	44	44	42	42	41
	100	Mean	4.9	**5.2[a]**	5.0	**5.3[a]**	5.0	**5.3[a]**
		STD	0.8	0.9	1.1	1.0	1.1	1.1
		N	42	42	42	41	41	41
Aroclor-1254	25	Mean	1.1	1.1	1.2	1.2	1.2	1.3
		STD	0.2	0.3	0.2	0.2	0.2	0.2
		N	44	44	44	44	44	44
	50	Mean	2.4	2.5	2.5	2.4	2.5	2.6
		STD	0.5	0.5	0.5	0.5	0.6	0.6
		N	45	44	41	42	42	42
	100	Mean	**5.3[b]**	**5.2[b]**	**5.3[a]**	**5.4[b]**	**5.4[a]**	**5.4[b]**
		STD	0.9	0.8	0.9	1.0	1.0	0.9
		N	45	44	44	43	42	42
Aroclor-1260	25	Mean	1.1	1.2	1.2	1.2	1.1	1.2
		STD	0.2	0.3	0.3	0.3	0.3	0.3
		N	45	45	43	42	40	39
	50	Mean	2.2	2.4	2.3	2.4	2.3	2.3
		STD	0.6	0.4	0.5	0.5	0.6	0.7
		N	40	39	39	39	39	38
	100	Mean	4.7	5.2	5.1	4.9	5.1	5.1
		STD	1.0	1.4	0.8	0.8	0.9	0.8
		N	39	39	39	35	37	37

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			596	603	610	617	624	631
Aroclor-1016	50	Mean	2.3	2.3	2.2	2.2	2.4	2.3
		STD	0.7	0.7	0.7	0.6	0.7	0.6
		N	40	38	38	36	35	33
	100	Mean	4.8	5.0	4.6	4.6	4.7	4.7
		STD	1.4	1.7	1.5	1.5	1.8	1.7
		N	37	37	36	34	33	30
	200	Mean	10.6	10.4	10.2	10.2	**10.0[a]**	9.8
		STD	2.2	3.2	2.2	3.2	2.0	3.4
		N	39	39	38	38	37	37
Aroclor-1242	50	Mean	2.5	2.6	2.6	2.5	**2.7[b]**	2.6
		STD	0.7	0.8	0.9	0.6	0.8	0.8
		N	41	39	39	39	37	36
	100	Mean	5.1	5.0	4.9	**5.2[a]**	**5.4[b]**	5.2
		STD	0.8	1.2	1.5	1.5	1.3	1.4
		N	41	41	41	40	40	40
Aroclor-1254	25	Mean	1.2	1.2	1.1	1.2	**1.3[a]**	1.2
		STD	0.2	0.2	0.2	0.3	0.3	0.3
		N	44	42	42	42	42	42
	50	Mean	2.5	2.4	2.4	2.6	**2.6[a]**	2.5
		STD	0.7	0.7	0.8	0.6	0.7	0.8
		N	42	40	40	36	35	35
	100	Mean	**5.5[a]**	5.1	**5.7[b]**	**5.7[b]**	**5.9[b]**	**5.8[b]**
		STD	1.0	1.0	1.4	1.0	1.8	1.3
		N	41	40	38	37	37	34
Aroclor-1260	25	Mean	1.2	1.1	1.1	1.1	1.0	1.1
		STD	0.3	0.2	0.2	0.3	0.3	0.3
		N	38	36	35	33	33	32
	50	Mean	2.3	2.2	2.3	2.4	2.2	2.3
		STD	0.8	0.8	1.0	0.6	0.8	0.9
		N	37	36	34	31	31	29
	100	Mean	4.9	5.1	5.1	5.2	5.1	5.2
		STD	1.0	1.3	1.1	1.2	1.7	2.0
		N	36	37	36	35	36	35

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study					
			638	645	652	659	666	673
Aroclor-1016	50	Mean	2.2	2.2	2.1	2.2	2.2	2.2
		STD	0.7	0.5	0.6	0.8	0.7	0.7
		N	33	33	33	32	32	30
	100	Mean	4.8	5.0	4.6	4.5	5.0	4.2
		STD	1.7	2.0	1.6	1.4	1.9	1.8
		N	30	30	30	29	29	29
	200	Mean	9.6	10.0	9.8	9.2	9.8	9.8
		STD	2.8	3.4	3.4	3.4	3.0	2.8
		N	37	37	36	35	34	34
Aroclor-1242	50	Mean	2.5	2.6	2.4	2.4	2.6	2.4
		STD	0.7	0.8	0.8	0.8	1.0	0.6
		N	35	35	35	31	30	30
	100	Mean	5.0	4.9	4.4	4.4	4.7	4.6
		STD	1.2	1.2	1.1	1.5	1.7	1.3
		N	40	38	38	37	34	32
Aroclor-1254	25	Mean	1.2	1.2	1.2	1.2	1.2	1.2
		STD	0.3	0.3	0.3	0.3	0.3	0.3
		N	41	41	41	40	39	38
	50	Mean	2.6	**2.8[b]**	**2.7[b]**	**2.6[b]**	**2.8[a]**	2.6
		STD	0.7	0.7	0.8	0.4	0.6	0.7
		N	33	30	30	29	29	27
	100	Mean	**5.5[b]**	**5.7[b]**	**5.7[b]**	**5.8[b]**	**6.2[b]**	**6.1[b]**
		STD	1.4	0.9	1.1	1.0	1.4	1.2
		N	31	29	29	29	28	28
Aroclor-1260	25	Mean	1.1	1.1	1.1	1.1	1.2	1.0
		STD	0.3	0.3	0.3	0.3	0.3	0.3
		N	30	29	28	27	25	25
	50	Mean	2.3	2.3	2.3	2.3	2.5	2.3
		STD	0.6	0.5	0.7	0.7	0.8	0.7
		N	28	28	28	28	28	28
	100	Mean	4.9	5.3	4.7	4.9	5.2	5.0
		STD	1.5	1.7	1.4	1.5	1.6	1.6
		N	33	32	31	31	29	28

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 28A. Group Mean Test Article Consumption (mg/kg/day) for Core, Interim, and Stop Study Subgroup[1] Female Rats

Test Substance	Conc. (ppm)		Day of Study						
			680	687	694	701	708	715	722
Aroclor-1016	50	Mean	2.1	2.2	1.9	2.0	1.9	2.0	2.4
		STD	0.6	0.9	0.5	0.7	0.8	0.6	0.6
		N	29	28	26	25	25	23	15
	100	Mean	4.6	4.6	4.3	4.3	4.2	4.2	4.5
		STD	1.7	1.3	1.2	1.5	1.1	1.7	1.4
		N	29	26	26	25	23	23	15
	200	Mean	9.8	10.0	9.4	10.2	9.6	9.4	9.4
		STD	3.0	2.4	3.0	3.2	2.4	2.2	1.8
		N	33	32	31	30	28	27	19
Aroclor-1242	50	Mean	2.3	2.4	2.3	2.3	2.2	2.1	2.1
		STD	0.6	0.7	0.8	0.9	0.7	0.9	1.0
		N	29	26	26	25	25	25	17
	100	Mean	4.7	4.7	4.5	4.7	4.7	4.7	5.0
		STD	1.3	1.5	2.2	2.2	2.0	1.8	1.8
		N	30	29	28	28	27	27	21
Aroclor-1254	25	Mean	1.2	1.2	1.2	1.2	1.2	1.2	1.1
		STD	0.4	0.3	0.4	0.4	0.3	0.3	0.4
		N	37	36	36	35	35	34	27
	50	Mean	2.7	**2.7[a]**	2.6	2.3	2.6	2.4	2.5
		STD	0.6	0.5	0.7	0.8	0.6	0.4	0.3
		N	25	23	23	21	18	17	11
	100	Mean	**6.1[b]**	**6.2[b]**	**6.1[b]**	**6.0[b]**	**6.0[b]**	**5.7[b]**	5.7
		STD	1.3	1.5	1.5	1.9	1.4	1.3	1.6
		N	28	26	26	24	24	22	16
Aroclor-1260	25	Mean	1.2	1.2	1.2	1.2	1.2	1.2	1.1
		STD	0.3	0.4	0.3	0.4	0.3	0.4	0.4
		N	25	25	25	25	24	22	15
	50	Mean	2.6	2.5	2.5	2.3	2.4	2.3	2.4
		STD	0.7	0.6	0.5	0.5	0.7	0.6	0.4
		N	28	27	26	26	24	24	16
	100	Mean	5.2	**5.5[b]**	5.4	5.0	5.1	5.1	5.3
		STD	2.1	2.0	2.2	1.9	1.9	1.8	1.6
		N	28	27	27	27	26	25	18

1. Stop Study subgroup rats represented in treatment through Day 365.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 29. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			365	372	379	386	393	400
Control[1]	0	Mean	53	51	51	50	50	48
		STD	7	7	6	6	5	7
		N	108	101	101	98	98	98
Aroclor-1016	50	Mean	53	**56[a]**	54	**55[b]**	53	51
		STD	8	9	8	7	9	7
		N	30	30	30	30	30	30
	100	Mean	48	51	50	48	49	49
		STD	10	7	8	8	6	5
		N	30	29	29	29	29	29
	200	Mean	52	51	52	52	54	50
		STD	7	7	7	8	8	7
		N	28	27	27	27	27	27
Aroclor-1242	50	Mean	53	51	50	54	52	50
		STD	7	5	6	11	8	9
		N	29	29	29	29	29	29
	100	Mean	55	54	54	**55[b]**	**57[a]**	**54[b]**
		STD	10	8	8	6	9	9
		N	30	30	30	30	30	30
Aroclor-1254	2z5	Mean	**59[a]**	**58[b]**	**57[b]**	**57[b]**	51	**53[b]**
		STD	10	10	7	7	7	6
		N	28	28	28	28	28	28
	50	Mean	59	56	56	**56[b]**	54	52
		STD	10	10	11	6	12	9
		N	30	30	30	30	30	30
	100	Mean	**60[b]**	**59[b]**	**58[b]**	**60[b]**	**56[b]**	**56[b]**
		STD	6	5	5	5	6	7
		N	29	29	29	29	28	28
Aroclor-1260	25	Mean	55	53	51	56	55	**54[a]**
		STD	9	7	8	14	10	10
		N	29	29	29	29	29	29
	50	Mean	56	**56[a]**	53	**56[b]**	55	**54[b]**
		STD	11	8	10	9	8	7
		N	28	28	28	28	28	28
	100	Mean	**57[a]**	**57[b]**	51	56	**57[b]**	**59[b]**
		STD	8	9	8	11	7	11
		N	30	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 29. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			407	414	421	428	435	442
Control[1]	0	Mean	50	49	48	48	47	49
		STD	8	8	7	8	7	8
		N	97	97	96	95	94	91
Aroclor-1016	50	Mean	51	52	47	49	50	53
		STD	8	6	10	6	8	10
		N	30	30	30	30	30	30
	100	Mean	48	51	48	48	48	50
		STD	5	5	6	7	7	7
		N	28	29	29	29	29	29
	200	Mean	50	52	49	50	46	51
		STD	8	7	5	6	6	9
		N	27	26	26	26	26	26
Aroclor-1242	50	Mean	53	51	50	49	50	49
		STD	10	7	9	8	10	12
		N	29	29	29	29	29	29
	100	Mean	**55[b]**	53	52	51	**51[a]**	**56[b]**
		STD	7	7	8	8	8	9
		N	30	30	30	30	30	30
Aroclor-1254	25	Mean	51	**53[a]**	**57[b]**	**57[b]**	**57[b]**	**56[b]**
		STD	6	6	10	8	10	11
		N	28	28	27	28	28	28
	50	Mean	52	**53[a]**	**57[b]**	**57[b]**	**55[b]**	**58[b]**
		STD	7	7	8	8	7	9
		N	30	30	30	30	30	30
	100	Mean	**54[a]**	**56[b]**	**59[b]**	**59[b]**	**58[b]**	**62[b]**
		STD	6	6	8	9	5	6
		N	28	28	28	28	27	27
Aroclor-1260	25	Mean	53	51	49	52	51	52
		STD	7	8	8	11	11	9
		N	29	29	29	29	29	29
	50	Mean	**54[a]**	50	47	47	50	50
		STD	7	7	9	9	13	12
		N	28	28	28	28	28	28
	100	Mean	**57[b]**	**53[a]**	51	54	**53[b]**	**59[b]**
		STD	7	8	9	12	9	10
		N	29	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 29. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			449	456	463	470	477	484
Control[1]	0	Mean	47	48	47	50	46	47
		STD	9	7	7	9	9	9
		N	91	89	88	88	87	87
Aroclor-1016	50	Mean	51	53	**52[a]**	**18[b]**	**61[b]**	**55[a]**
		STD	8	12	9	7	14	13
		N	30	30	30	29	29	29
	100	Mean	46	50	49	**18[b]**	53	52
		STD	6	7	8	11	13	13
		N	28	28	28	27	27	27
	200	Mean	46	46	50	44	49	49
		STD	11	10	9	10	16	17
		N	24	24	24	24	24	24
Aroclor-1242	50	Mean	50	51	49	50	48	50
		STD	12	9	12	5	6	6
		N	28	28	28	27	27	27
	100	Mean	49	**56[b]**	**57[b]**	54	53	**53[a]**
		STD	10	9	13	12	14	7
		N	30	30	30	30	30	29
Aroclor-1254	25	Mean	**55[b]**	**56[b]**	**57[b]**	54	**52[a]**	51
		STD	6	9	8	6	7	6
		N	26	26	26	26	26	26
	50	Mean	**53[a]**	**54[a]**	**55[b]**	54	**53[b]**	**53[a]**
		STD	7	10	10	9	9	10
		N	30	30	30	30	30	29
	100	Mean	**58[b]**	**61[b]**	**61[b]**	56	**55[b]**	**54[b]**
		STD	7	9	7	7	6	6
		N	26	26	26	26	26	26
Aroclor-1260	25	Mean	50	52	51	50	50	49
		STD	12	9	8	8	8	7
		N	29	29	27	26	26	26
	50	Mean	47	52	**53[b]**	50	50	49
		STD	13	10	9	9	7	9
		N	26	26	25	25	24	23
	100	Mean	52	**57[b]**	**56[b]**	53	**52[a]**	49
		STD	8	11	11	9	9	9
		N	28	29	29	29	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 29. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			491	498	505	512	519	526
Control[1]	0	Mean	46	46	43	43	45	45
		STD	11	10	12	10	10	11
		N	85	82	82	81	78	75
Aroclor-1016	50	Mean	51	50	49	**50[a]**	48	49
		STD	14	8	8	9	8	8
		N	29	28	28	28	28	28
	100	Mean	51	47	47	47	46	46
		STD	12	10	6	6	9	8
		N	27	27	26	26	26	26
	200	Mean	47	46	46	45	46	46
		STD	10	10	9	6	8	7
		N	22	22	22	21	21	20
Aroclor-1242	50	Mean	47	46	47	46	47	43
		STD	5	8	8	8	10	7
		N	27	27	27	27	26	26
	100	Mean	51	48	**50[b]**	**51[b]**	**51[a]**	48
		STD	8	7	7	7	10	8
		N	29	29	28	28	28	27
Aroclor-1254	25	Mean	**51[a]**	49	**50[b]**	50	49	49
		STD	6	7	6	10	8	7
		N	26	26	26	26	25	25
	50	Mean	50	49	**48[a]**	**51[a]**	47	49
		STD	8	8	7	9	7	8
		N	29	29	29	28	29	29
	100	Mean	**52[b]**	49	**52[b]**	**51[a]**	**51[a]**	**50[a]**
		STD	5	8	7	7	7	6
		N	26	26	25	25	25	25
Aroclor-1260	25	Mean	46	46	46	45	46	46
		STD	7	6	6	6	10	8
		N	26	26	26	26	26	26
	50	Mean	48	46	45	46	48	48
		STD	6	7	10	8	8	8
		N	24	24	24	24	23	23
	100	Mean	49	48	**50[a]**	50	52	49
		STD	9	9	9	11	15	10
		N	29	29	29	28	29	29

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 29. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			533	540	547	554	561	568
Control[1]	0	Mean	47	45	44	46	46	47
		STD	12	9	11	11	10	11
		N	72	69	67	64	60	60
Aroclor-1016	50	Mean	48	49	46	48	49	51
		STD	7	11	10	14	11	8
		N	27	28	28	22	21	21
	100	Mean	46	47	44	47	46	48
		STD	9	10	9	10	9	7
		N	26	26	26	20	19	19
	200	Mean	43	46	43	46	45	49
		STD	5	11	7	10	16	11
		N	20	20	20	14	15	14
Aroclor-1242	50	Mean	45	50	48	49	48	48
		STD	10	17	19	13	10	15
		N	26	26	26	19	19	19
	100	Mean	49	50	45	47	47	48
		STD	8	9	8	14	10	10
		N	27	27	27	22	22	22
Aroclor-1254	25	Mean	47	48	46	51	49	49
		STD	6	7	8	10	10	8
		N	25	25	25	20	19	19
	50	Mean	48	49	46	48	49	49
		STD	8	7	7	12	9	10
		N	29	28	28	22	20	20
	100	Mean	48	48	48	51	50	50
		STD	4	6	7	8	7	9
		N	24	24	24	17	16	16
Aroclor-1260	25	Mean	45	46	43	48	48	50
		STD	7	6	5	9	8	6
		N	26	26	26	20	19	19
	50	Mean	46	47	47	49	46	46
		STD	7	8	8	10	10	11
		N	23	22	22	18	17	15
	100	Mean	49	53[b]	51	53	52	53
		STD	12	13	12	14	11	12
		N	29	28	28	23	22	22

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 29. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			575	582	589	596	603	610
Control[1]	0	Mean	45	46	45	47	45	46
		STD	12	15	12	15	10	11
		N	59	59	57	57	53	53
Aroclor-1016	50	Mean	49	46	46	49	48	43
		STD	9	8	8	10	8	13
		N	21	20	20	21	20	20
	100	Mean	46	43	44	46	41	39
		STD	9	12	14	16	11	12
		N	18	19	19	19	18	18
	200	Mean	48	43	43	45	47	43
		STD	12	15	16	17	12	9
		N	14	14	14	14	13	13
Aroclor-1242	50	Mean	51	48	50	51	48	49
		STD	8	7	9	11	10	8
		N	18	18	18	17	17	15
	100	Mean	47	45	46	49	46	50
		STD	10	10	7	9	9	9
		N	21	20	20	20	20	20
Aroclor-1254	25	Mean	48	44	48	53	49	48
		STD	8	12	11	12	10	10
		N	19	19	18	17	17	17
	50	Mean	48	48	49	52	46	45
		STD	9	12	11	15	11	13
		N	20	20	20	20	19	19
	100	Mean	49	47	51	**60[a]**	53	**54[a]**
		STD	8	15	8	15	10	9
		N	16	15	14	14	14	14
Aroclor-1260	25	Mean	48	46	46	46	47	46
		STD	8	5	8	6	6	5
		N	19	19	19	19	18	18
	50	Mean	44	40	45	48	50	46
		STD	9	10	9	8	9	7
		N	15	14	14	13	12	11
	100	Mean	55	51	53	57	**54[a]**	49
		STD	16	13	20	18	16	9
		N	20	20	18	19	19	18

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 29. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			617	624	631	638	645	652
Control[1]	0	Mean	45	43	45	44	44	41
		STD	13	13	13	13	9	10
		N	53	53	51	48	48	47
Aroclor-1016	50	Mean	50	46	47	44	48	47
		STD	18	14	17	20	18	13
		N	18	18	18	18	18	17
	100	Mean	44	40	43	41	43	43
		STD	8	7	10	8	7	7
		N	16	16	16	16	16	16
	200	Mean	47	43	47	45	46	44
		STD	9	9	6	10	11	6
		N	13	13	13	13	13	13
Aroclor-1242	50	Mean	51	44	48	49	48	45
		STD	10	5	12	8	8	9
		N	15	15	15	15	15	15
	100	Mean	52	47	49	49	51	**50[a]**
		STD	13	9	9	9	9	8
		N	19	19	19	18	17	16
Aroclor-1254	25	Mean	53	46	50	45	45	43
		STD	17	14	16	14	14	14
		N	16	16	16	15	15	15
	50	Mean	47	47	49	50	46	**50[a]**
		STD	12	9	12	8	10	7
		N	19	19	19	18	17	17
	100	Mean	54	51	52	50	50	**51[a]**
		STD	10	10	10	10	11	6
		N	14	14	14	14	14	13
Aroclor-1260	25	Mean	49	48	48	46	44	45
		STD	8	6	8	9	7	8
		N	18	18	18	18	18	18
	50	Mean	47	43	47	43	38	44
		STD	11	11	8	6	15	7
		N	11	11	11	11	11	10
	100	Mean	54	49	53	48	50	47
		STD	20	14	16	10	12	11
		N	18	18	18	18	18	18

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 29. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study					
			659	666	673	680	687	694
Control[1]	0	Mean	42	44	44	45	42	46
		STD	10	14	10	11	11	11
		N	47	45	43	41	40	39
Aroclor-1016	50	Mean	51	56	53	51	51	53
		STD	13	19	18	16	15	19
		N	17	17	16	14	13	13
	100	Mean	40	41	41	39	42	38
		STD	7	10	10	8	8	11
		N	15	15	15	15	13	12
	200	Mean	42	45	42	38	40	37
		STD	10	17	13	14	12	12
		N	13	13	13	12	11	9
Aroclor-1242	50	Mean	47	47	45	46	46	43
		STD	10	12	9	11	15	11
		N	15	15	14	14	14	12
	100	Mean	47	49	45	44	45	45
		STD	10	12	13	9	14	15
		N	16	16	16	15	15	14
Aroclor-1254	25	Mean	42	43	46	49	47	39
		STD	12	8	10	15	20	12
		N	15	15	15	15	15	13
	50	Mean	49	51	46	47	48	46
		STD	6	14	10	8	9	6
		N	17	17	15	15	14	14
	100	Mean	50	47	47	47	47	45
		STD	7	7	6	6	7	6
		N	13	13	13	13	13	13
Aroclor-1260	25	Mean	43	46	46	44	42	38
		STD	5	13	17	8	8	8
		N	18	18	18	18	17	17
	50	Mean	41	43	42	44	40	33
		STD	12	7	8	9	10	13
		N	10	9	9	9	9	8
	100	Mean	46	47	45	50	47	47
		STD	13	12	17	13	13	14
		N	18	18	18	17	17	15

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 29. Group Mean Feed Consumption Per Body Weight (g/kg/day) for Stop Study Subgroup Female Rats Following Treatment Cessation

Test Substance	Conc. (ppm)		Day of Study			
			701	708	715	722
Control[1]	0	Mean	44	43	45	47
		STD	13	12	9	14
		N	36	34	32	26
Aroclor-1016	50	Mean	48	48	48	46
		STD	9	16	22	21
		N	13	13	12	12
	100	Mean	38	43	46	39
		STD	11	11	13	19
		N	11	11	11	11
	200	Mean	39	38	43	43
		STD	11	12	13	20
		N	9	9	9	9
Aroclor-1242	50	Mean	44	44	46	44
		STD	13	12	11	10
		N	12	12	11	11
	100	Mean	44	45	43	42
		STD	15	12	15	9
		N	13	12	12	12
Aroclor-1254	25	Mean	44	45	47	43
		STD	13	16	15	20
		N	12	12	12	12
	50	Mean	44	48	49	47
		STD	8	8	9	9
		N	14	14	14	14
	100	Mean	46	47	45	48
		STD	8	8	6	10
		N	13	13	13	13
Aroclor-1260	25	Mean	40	38	42	40
		STD	9	13	9	8
		N	15	15	15	14
	50	Mean	41	42	42	39
		STD	4	6	4	3
		N	7	7	7	6
	100	Mean	50	49	51	50
		STD	13	13	15	11
		N	14	14	13	13

1. Core/Interim subgroup female control data reported for comparison.

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 30. Group Mean Total Feed and Test Substance Consumption for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)	Cumulative Mean Weekly Feed Consumption (g)	Cumulative Mean Weekly Total Feed[a] Consumption (g/kg)	Test Substance[b] Consumption (mg)	Test Substance[a] Consumption (mg/kg)
Control	0	19300	28769	0	0
Aroclor-1016	50	19985	28694	999	1435
	100	19520	28651	1952	2865
	200	19872	28720	3974	5744
Aroclor-1242	50	19525	28467	976	1423
	100	19365	29170	1937	2917
Aroclor-1254	25	19488	28993	487	725
	50	18852	29343	943	1467
	100	18425	31272	1843	3127
Aroclor-1260	25	20085	29881	502	747
	50	19761	29158	988	1458
	100	20009	29872	2001	2987

a. Summation of weekly calculated values.

b. Total test substance consumption (mg) = $\frac{\text{Total feed consumed (g)} * \text{Target concentration in feed } (\mu g/g)}{1000}$

Table 31. Group Mean Total Feed and Test Substance Consumption for Core, Interim, and Stop Study[1] Subgroup Female Rats

Test Substance	Conc. (ppm)	Cumulative Mean Weekly Feed Consumption (g)	Cumulative Mean Weekly Total Feed[a] Consumption (g/kg)	Test Substance[b] Consumption (mg)	Test Substance[a] Consumption (mg/kg)
Control	0	15149	38929	0	0
Aroclor-1016	50	15487	39237	774	1962
	100	15637	38983	1564	3898
	200	15531	40594	3106	8119
Aroclor-1242	50	15640	40405	782	2020
	100	15076	41552	1508	4155
Aroclor-1254	25	14903	40426	373	1011
	50	14699	41823	735	2091
	100	14326	43831	1433	4383
Aroclor-1260	25	15481	39101	387	978
	50	15462	40034	773	2002
	100	15504	41580	1550	4158

a. Summation of weekly calculated values.

b. Total test substance consumption (mg) = $\frac{\text{Total feed consumed (g)} * \text{Target concentration in feed } (\mu g/g)}{1000}$

1. Stop Study females were not included after Week 52.

Table 32. Summary of Ophthalmic Examinations for Core and Interim Subgroup Male Rats

Test Substance	Conc. (ppm)		Examination Period (Week)				
			Pretest[a]	26	52	78	105
Control	0	Corneal Lesion(s)[b]	1/118	0/5	2/6	1/4	17/46
Aroclor-1016	200	Corneal Lesion(s)[b]	1/68	0/6	0/6	0/4	7/27
Aroclor-1242	100	Corneal Lesion(s)[b]	2/68	0/6	1/5	2/4	9/18
Aroclor-1254	100	Corneal Lesion(s)[b]	0/68	0/6	1/6	1/4	12/20
Aroclor-1260	100	Corneal Lesion(s)[b]	0/68	1/6	1/6	0/3	7/17
Control	0	Hemorrhage	0/118	0/5	0/6	0/4	1/46
Aroclor-1016	200	Hemorrhage	1/68	0/6	0/6	0/4	0/27
Control	0	Lens Lesion(s)[c]	0/118	0/6	0/6	0/4	4/46
Aroclor-1016	200	Lens Lesion(s)[c]	0/68	0/6	0/6	1/4	2/27
Aroclor-1242	100	Lens Lesion(s)[c]	0/68	0/6	0/5	0/4	1/18
Aroclor-1254	100	Lens Lesion(s)[c]	0/68	0/6	0/6	0/4	1/20
Aroclor-1260	100	Lens Lesion(s)[c]	0/68	0/6	1/6	0/3	1/17
Aroclor-1016	200	Persistent Pupillary Membranes	1/68	0/6	0/6	0/4	0/27
Control	0	Periocular Discharge	0/118	0/5	1/6	1/4	8/46
Aroclor-1016	200	Periocular Discharge	0/68	1/6	1/6	0/4	3/27
Aroclor-1242	100	Periocular Discharge	0/68	0/6	0/5	1/4	3/18
Aroclor-1254	100	Periocular Discharge	0/68	0/6	0/6	0/4	1/20
Aroclor-1260	100	Periocular Discharge	0/68	1/6	0/6	1/3	2/17
Control	0	Synechia	0/118	0/5	0/6	0/4	1/46
Aroclor-1260	100	Synechia	0/68	0/6	0/6	1/3	0/17
Control	0	Will not Dilate-Iris/Pupil	0/118	0/5	0/6	0/4	1/46
Aroclor-1016	200	Will not Dilate-Iris/Pupil	1/68	0/6	0/6	0/4	0/27
Aroclor-1254	100	Will not Dilate-Iris/Pupil	1/68	0/6	0/6	0/4	0/20

a. All Core and Interim subgroup animals examined (only high and control Core and Interim subgroup animals reported).
b. Summarization of Corneal Lesion(s) include: abrasions, scratches, opacities, cataracts, ulcerations, drying, hazy and translucent appearance, and vascularization associated with the cornea.
c. Summarization of Lens Lesion(s) include: cataracts, opacities, and hazy appearance.

Table 33. Summary of Ophthalmic Examinations for Core and Interim Subgroup Female Rats

Test Substance	Conc. (ppm)		Examination Period						
			Pretest[a]	13	26	39	52	78	105
Control	0	Corneal Lesion(s)[b]	0/130	0/6	0/6	0/6	0/6	0/3	13/32
Aroclor-1016	200	Corneal Lesion(s)[b]	0/80	0/6	0/6	0/6	0/6	1/6	2/25
Aroclor-1242	100	Corneal Lesion(s)[b]	0/80	0/6	0/6	0/6	1/5	1/5	6/27
Aroclor-1254	100	Corneal Lesion(s)[b]	0/80	0/6	0/6	0/6	2/6	1/5	6/21
Aroclor-1260	100	Corneal Lesion(s)[b]	1/80	0/6	0/6	1/6	0/6	0/6	3/22
Aroclor-1016	200	Hemorrhage	0/80	0/6	0/6	0/6	0/6	0/6	1/25
Aroclor-1242	100	Hemorrhage	0/80	0/6	0/6	0/6	0/5	0/5	1/27
Aroclor-1016	200	Lens Lesion(s)[c]	0/80	0/6	0/6	0/6	0/6	0/6	1/25
Aroclor-1242	100	Lens Lesion(s)[c]	0/80	0/6	0/6	0/6	0/5	0/5	1/27
Aroclor-1254	100	Lens Lesion(s)[c]	0/80	0/6	0/6	0/6	0/6	0/5	1/21
Aroclor-1254	100	Persistent Vasculature	0/80	1/6	0/6	0/6	0/6	0/5	0/21
Control	0	Periocular Discharge	0/130	0/6	0/6	0/6	0/6	0/3	5/32
Aroclor-1016	200	Periocular Discharge	0/80	0/6	0/6	0/6	0/6	0/6	2/25
Aroclor-1242	100	Periocular Discharge	0/80	0/6	0/6	0/6	1/5	1/5	4/27
Aroclor-1254	100	Periocular Discharge	0/80	0/6	1/6	0/6	0/6	0/5	0/21
Aroclor-1260	100	Periocular Discharge	0/80	0/6	0/6	0/6	0/6	0/6	4/22
Aroclor-1254	100	Will not Dilate-Iris/Pupil	0/80	0/6	0/6	0/6	0/6	0/5	2/21
Aroclor-1260	100	Will not Dilate-Iris/Pupil	0/80	0/6	0/6	0/6	0/6	1/6	0/22

a. All Core and Interim subgroup animals examined (only high and control Core and Interim subgroup animals reported).
b. Summarization of Corneal Lesion(s) include: abrasions, scratches, opacities, cataracts, ulcerations, drying, hazy and translucent appearance, and vascularization associated with the cornea.
c. Summarization of Lens Lesion(s) include: cataracts, opacities, and hazy appearance.

Table 34. Group Mean Hematology Values for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Red Blood Cells ($10^6/\mu L$)				Hemoglobin (g/dL)				Hematocrit (%)			
Control	0	Mean	7.94	7.78	7.42	6.92	15.1	15.4	14.8	13.2	45.5	43.8	41.2	39.7
		STD	0.34	0.49	0.68	1.53	0.6	0.9	0.9	3.3	1.5	2.3	3.0	9.8
Aroclor-1016	50	Mean	8.32	7.95	7.66	6.66	15.4	15.1	14.5	12.2	45.4	44.0	41.9	36.7
		STD	0.33	0.50	0.71	1.62	0.7	0.8	1.0	3.3	1.9	2.1	3.4	9.9
	100	Mean	**8.47[a]**	8.16	7.26	7.31	15.7	15.4	14.1	13.8	45.8	44.7	40.9	41.4
		STD	0.48	0.85	1.34	1.15	0.6	1.1	2.0	2.5	1.9	3.2	7.1	7.2
	200	Mean	8.09	7.90	7.27	6.97	15.4	15.2	14.3	13.4	45.4	44.3	41.0	40.2
		STD	0.36	0.30	0.94	1.20	0.6	0.7	1.3	2.2	1.5	1.7	3.7	6.5
Aroclor-1242	50	Mean	8.16	**8.48[a]**	7.81	7.22	15.1	15.8	14.6	13.6	45.4	46.4	43.4	41.1
		STD	0.38	0.56	0.51	0.70	0.6	1.0	0.9	1.7	2.2	2.5	2.3	5.0
	100	Mean	7.85	7.99†	7.27	7.26	14.8	15.3†	14.0	13.8	44.9	45.5†	41.2	41.9
		STD	0.31	0.46	0.74	1.40	0.5	0.5	1.7	1.6	1.6	1.3	4.7	5.2
Aroclor-1254	25	Mean	8.18	8.09	7.57	7.05	14.7	14.8	14.1	13.1	45.0	44.4	41.0	40.3
		STD	0.47	0.62	0.48	0.75	0.5	0.7	0.8	1.5	1.7	2.3	2.2	4.1
	50	Mean	8.03	8.20	7.14	6.65	14.8	15.1	13.5	11.8	45.3	45.8	39.3	36.8
		STD	0.35	0.52	0.91	0.86	0.7	1.1	1.6	1.2	1.9	3.1	4.6	3.9
	100	Mean	8.04	7.98	7.26	6.82	14.6	**14.3[a]**	**13.2[b]**	11.8	44.6	43.3	39.0	36.8
		STD	0.56	0.66	0.57	0.61	0.6	1.0	0.9	1.0	2.2	2.5	2.3	3.2
Aroclor-1260	25	Mean	8.12	7.74	7.63	6.85†	15.3	14.8	15.1	12.5†	45.9	43.1	43.0	38.4†
		STD	0.64	0.44	0.42	1.00	1.0	0.5	0.7	1.7	3.2	1.5	2.2	5.5
	50	Mean	8.27	8.03	7.74	6.80	15.2	15.4	14.9	12.7	45.6	44.5	42.7	38.9
		STD	0.26	0.37	0.51	0.92	0.4	0.9	0.7	1.8	1.2	2.1	2.3	5.3
	100	Mean	8.29	7.93	7.82	6.96	15.1	14.7	14.7	12.4	45.8	43.1	42.8	38.3
		STD	0.39	0.62	0.79	0.64	0.4	0.8	1.2	1.0	1.1	2.3	3.9	3.0

N = 10 unless otherwise noted; † N = 9
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 34. Group Mean Hematology Values for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Mean Corpuscular Volume (fL)				Mean Corpuscular Hemoglobin (pg)				Mean Corpuscular Hemoglobin Conc. (g/dL)			
Control	0	Mean	57	56	56	57	19.1	19.8	19.9	19.1	33.3	35.0	35.8	33.4
		STD	2	3	2	5	0.5	1.0	0.9	1.8	0.5	0.8	1.0	1.1
Aroclor-1016	50	Mean	**55[a]**	55	55	55	18.6	19.0	19.0	18.2	34.0	34.3	**34.6[a]**	33.1
		STD	2	2	3	4	0.8	0.7	1.1	1.3	0.5	0.7	1.2	1.1
	100	Mean	**54[a]**	55	56	56	18.6	18.9	19.6	18.8	**34.3[a]**	34.4	**34.6[a]**	33.3
		STD	2	3	3	2	0.5	0.9	1.1	0.7	0.9	0.5	0.6	0.9
	200	Mean	56	56	57	58	19.1	19.3	19.8	19.3	34.0	34.4	34.9	33.3
		STD	2	2	3	3	1.1	0.9	1.1	1.2	0.7	1.0	0.6	0.7
Aroclor-1242	50	Mean	56	55	56	57	18.5	18.7	18.8	18.8	33.3	**34.1[a]**	**33.7[b]**	33.0
		STD	3	3	3	3	1.0	1.1	1.1	0.9	1.0	1.1	0.7	0.8
	100	Mean	57	57[†]	57	59	18.9	19.2[†]	19.2	19.4	33.0	**33.8[b†]**	**33.8[b]**	33.1
		STD	2	2	2	7	0.6	0.8	1.1	2.4	0.8	0.7	0.7	1.0
Aroclor-1254	25	Mean	55	55	54	57	**18.0[a]**	**18.3[b]**	18.7	18.5	32.7	**33.3[b]**	**34.4[b]**	**32.3[a]**
		STD	2	3	3	2	0.9	0.9	1.1	0.5	0.9	0.5	0.8	0.9
	50	Mean	57	56	55	56	18.4	**18.4[b]**	18.9	17.8	32.5	**33.0[b]**	**34.3[b]**	**32.1[a]**
		STD	2	2	2	3	0.6	0.7	1.2	1.2	0.7	0.6	1.0	0.8
	100	Mean	56	54	54	54	18.1	**17.9[b]**	**18.3[b]**	**17.2[a]**	32.7	**32.9[b]**	**34.0[b]**	**31.9[b]**
		STD	2	2	3	3	1.0	1.0	1.2	0.9	0.8	0.6	1.1	0.4
Aroclor-1260	25	Mean	57	56	56	56[†]	18.8	19.2	19.9	18.2[†]	33.3	34.4	35.2	**32.5[a†]**
		STD	2	2	2	3	0.8	0.8	0.8	0.7	0.4	0.4	0.9	0.7
	50	Mean	55	55	55	57	18.4	19.1	19.3	18.8	33.4	34.6	35.0	32.8
		STD	2	2	3	4	0.6	0.8	0.9	1.4	0.5	0.5	0.5	0.3
	100	Mean	55	55	55	55	18.2	**18.6[b]**	18.8	17.9	32.9	**34.1[a]**	**34.3[b]**	32.5
		STD	2	3	2	2	0.7	0.8	0.9	0.7	0.5	0.6	0.6	1.0

N = 10 unless otherwise noted; † N = 9
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 34. Group Mean Hematology Values for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study			
			26	52	78	105	26	52	78	105
			Platelets ($10^3/\mu L$)				Reticulocytes (%)			
Control	0	Mean	1131	1065	1107	1107	1.5	2.1	1.5	6.6
		STD	101	132	214	394	0.7	0.6	1.2	13.4
Aroclor-1016	50	Mean	1113	1127	1062	1213	1.5	1.7	2.6	4.9
		STD	152	172	249	367	0.4	0.8	3.5	6.8
	100	Mean	1146	1134	1246	1236	1.2	1.6	1.8	2.0
		STD	113	122	187	291	0.4	1.0	1.8	1.4
	200	Mean	1102	1034	1120	1115	1.2	1.6	1.9	2.7
		STD	106	143	124	363	0.4	0.6	1.9	1.4
Aroclor-1242	50	Mean	1097	1125	1190	1206	1.6	1.9	1.4	1.9
		STD	253	245	188	296	0.5	0.8	0.8	1.1
	100	Mean	1108	933†	1069	1034	1.7	2.0	1.4	2.7
		STD	123	201	154	202	0.8	0.6	1.1	3.1
Aroclor-1254	25	Mean	**980[b]**	1011	1047	1083	1.3	2.6	1.5	2.2
		STD	72	78	157	264	0.5	0.6	0.6	1.1
	50	Mean	**979[b]**	1021	1029	1167	1.5	2.0	1.8	2.4
		STD	101	223	251	147	0.5	0.9	1.1	1.0
	100	Mean	1046	1020	1031	1015	1.7	2.1	1.3	2.7
		STD	124	163	201	350	0.6	1.1	0.6	0.9
Aroclor-1260	25	Mean	1063	1001	1054	1205†	1.4	**1.2[b]**	1.1	1.9†
		STD	116	69	67	125	0.3	0.5	0.4	0.5
	50	Mean	1088	1116	1137	1138	1.2	**1.0[b]**	1.3	2.0
		STD	124	103	163	285	0.3	0.5	0.7	1.8
	100	Mean	1106	1021	1125	1290	1.1	**0.9[b]**	1.6	2.1
		STD	181	129	161	202	0.4	0.3	0.8	0.9

N = 10 unless otherwise noted; † N = 9
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 35. Group Mean Hematology Values for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Red Blood Cells ($10^6/\mu L$)				Hemoglobin (g/dL)				Hematocrit (%)			
Control	0	Mean	7.17	7.14	7.28	7.36	14.7	15.0	15.5	15.3	42.7	42.0	43.8	45.4
		STD	0.55	0.46	0.72	0.81	1.1	0.9	1.1	1.5	3.1	2.9	3.5	4.5
Aroclor-1016	50	Mean	7.28	7.14	7.08	**6.37[a]**	14.6	15.1	15.1	**13.3[a]**	43.9	42.8	43.8	40.0
		STD	0.42	0.44	0.41	1.05	0.7	0.7	0.8	2.0	2.1	1.9	2.4	6.6
	100	Mean	7.12	7.02	**6.36[a]**	**5.94[a]**	14.2	14.6	**13.4[b]**	**12.5[a]**	42.9	41.5	**38.9[a]**	**37.0[a]**
		STD	0.58	0.44	1.00	1.54	0.8	0.6	1.5	2.5	2.6	1.9	5.2	7.8
	200	Mean	7.07	7.05	6.71	**6.56[a]**	14.2	14.4	**13.9[b]**	**13.3[b]**	42.0	41.1	40.7	**40.3[b]**
		STD	0.70	0.30	0.58	0.40	1.3	0.5	0.9	0.5	4.0	1.5	2.9	1.9
Aroclor-1242	50	Mean	7.08	7.11	7.48	6.54	14.3	14.5	15.1	13.4	41.5	41.2	42.6	39.6
		STD	0.41	0.40	0.37	1.43	1.0	1.0	0.6	2.7	2.9	2.7	1.7	8.3
	100	Mean	7.49	7.03	7.21	6.30	14.4	**13.9[b]**	**14.3[a]**	**12.1[a]**	42.5	40.6	**40.6[a]**	**35.7[b]**
		STD	0.60	0.37	0.47	1.45	1.1	0.7	0.6	2.7	3.2	1.8	1.9	8.2
Aroclor-1254	25	Mean	7.40	7.29	7.25	6.77	14.2	14.5	14.7	**12.5[b]**	42.8	41.6	42.7	**36.8[b]**
		STD	0.33	0.42	0.44	0.55	0.5	0.7	1.0	1.3	1.6	2.3	2.9	3.6
	50	Mean	7.24	6.70	6.73	**6.19[b]**	**13.6[a]**	**13.3[b]**	**13.4[b]**	**11.0[b]**	41.0	**38.1[b]**	**39.5[a]**	**32.8[b]**
		STD	0.39	0.32	0.48	0.66	0.7	0.5	0.8	1.6	2.4	2.1	2.5	4.0
	100	Mean	7.21	6.93	6.65	**5.95[b]**	**12.9[b]**	**13.1[b]**	**12.8[b]**	**10.9[b]**	**38.8[b]**	**37.9[b]**	**37.8[b]**	**32.2[b]**
		STD	0.50	0.38	0.71	0.66	0.8	0.8	1.1	0.9	2.6	2.1	3.4	2.5
Aroclor-1260	25	Mean	7.31	7.08	7.10	**6.30[a]**	14.5	14.4	14.9	**12.9[b]**	43.2	41.7	43.3	**38.1[b]**
		STD	0.43	0.38	0.66	0.97	0.4	0.6	1.0	1.5	2.1	1.8	2.7	5.1
	50	Mean	7.23	7.20	7.41	**6.30[a]**	14.3	14.6	15.1	**12.3[b]**	42.5	42.0	44.5	**36.7[b]**
		STD	0.34	0.43	0.33	1.04	0.7	0.6	0.7	2.0	2.2	2.2	1.7	5.9
	100	Mean	7.35	7.28	6.99	**5.76[a]**	14.1	14.4	**13.9[a]**	**11.4[b]**	41.6	41.6	40.9	**33.6[b]**
		STD	0.26	0.34	0.84	1.84	0.7	0.5	1.8	2.6	1.9	1.9	5.5	8.1

N = 10 unless otherwise noted; † N = 9
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 35. Group Mean Hematology Values for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Mean Corpuscular Volume (fL)				Mean Corpuscular Hemoglobin (pg)				Mean Corpuscular Hemoglobin Conc. (g/dL)			
Control	0	Mean	60	59	60	62	20.6	21.0	21.4	20.8	34.5	35.8	35.4	33.6
		STD	2	2	2	3	0.8	0.6	0.9	1.0	0.5	0.9	0.8	0.5
Aroclor-1016	50	Mean	60	60	62	63	20.1	21.1	21.4	21.0	**33.4[a]**	35.2	**34.6[a]**	33.5
		STD	2	2	3	4	0.7	0.8	0.9	1.1	0.5	0.6	0.3	1.1
	100	Mean	60	59	61	64	20.0	20.8	21.3	21.6	**33.1[b]**	35.2	34.6	33.8
		STD	3	2	3	9	1.1	0.9	1.5	3.6	0.8	0.6	1.1	1.0
	200	Mean	59	58	61	62	20.1	20.5	20.9	20.2	33.8	35.2	**34.3[b]**	32.9
		STD	3	3	3	3	0.9	1.1	1.1	0.8	0.6	0.6	0.5	0.7
Aroclor-1242	50	Mean	59	58	57	61	20.2	20.3	20.2	20.6	34.4	35.2	35.5	33.9
		STD	2	3	2	3	0.7	0.9	0.8	0.6	0.6	0.6	0.4	1.0
	100	Mean	57	58	**56[a]**	**57[a]**	**19.2[b]**	**19.9[a]**	**19.8[b]**	**19.3[a]**	33.9	**34.3[b]**	35.2	34.1
		STD	2	2	3	4	0.6	0.8	0.9	1.2	0.6	0.5	0.5	0.9
Aroclor-1254	25	Mean	58	57	59	**54[b]**	**19.2[b]**	**19.9[a]**	20.3	**18.5[b]**	**33.2[b]**	**34.9[a]**	**34.5[b]**	34.0
		STD	2	2	2	3	0.7	0.6	0.8	1.2	0.8	0.8	0.5	0.7
	50	Mean	**57[a]**	57	59	**53[b]**	**18.7[b]**	**19.9[a]**	**19.9[a]**	**17.7[b]**	**33.1[b]**	35.1	**33.9[b]**	33.3
		STD	2	2	2	4	0.6	0.7	0.8	1.7	0.8	0.8	0.8	0.9
	100	Mean	**54[b]**	**55[b]**	57	**54[b]**	**18.0[b]**	**18.9[b]**	**19.3[b]**	**18.5[b]**	**33.4[a]**	**34.5[b]**	**33.9[b]**	33.9
		STD	2	2	4	4	0.7	1.0	1.2	1.4	0.6	0.7	0.9	0.7
Aroclor-1260	25	Mean	59	59	61	61	19.9	20.4	21.1	20.7	33.6	**34.6[b]**	**34.5[a]**	34.0
		STD	2	2	3	3	0.9	0.8	1.1	1.5	1.1	0.4	0.6	1.1
	50	Mean	59	58	60	**58[a]**	19.8	20.4	20.3	**19.6[a]**	33.6	**34.8[a]**	**33.9[b]**	33.6
		STD	3	3	2	3	1.0	0.9	1.0	1.2	0.8	0.9	0.6	0.5
	100	Mean	**57[a]**	57	59	61	**19.2[b]**	**19.8[a]**	**19.9[a]**	20.9	33.9	**34.5[b]**	**33.9[b]**	33.9
		STD	3	3	3	11	1.2	1.0	0.9	4.3	0.9	0.7	0.8	1.0

N = 10 unless otherwise noted; † N = 9
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 35. Group Mean Hematology Values for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study			
			26	52	78	105	26	52	78	105
			Platelets ($10^3/\mu L$)				Reticulocytes (%)			
Control	0	Mean	904	922	899	857	1.3	1.4	1.3	1.7
		STD	174	162	141	243	0.3	0.4	0.8	0.4
Aroclor-1016	50	Mean	883	852	914	969	1.2	1.4	1.3	2.9
		STD	209	103	98	246	0.2	0.3	0.4	2.0
	100	Mean	914	914	997	914	1.1	1.4	1.5	3.3
		STD	119	162	253	288	0.3	0.5	0.7	3.1
	200	Mean	938	885	924	963	1.3	1.4	1.5	1.9
		STD	130	137	172	222	0.4	0.4	1.2	0.7
Aroclor-1242	50	Mean	943	823	927	827	1.3	1.3	1.1	2.9
		STD	91	156	63	295	0.3	0.4	0.4	3.4
	100	Mean	880	842	865	954	1.5	1.4	1.3	3.8
		STD	97	84	119	146	0.3	0.3	0.6	5.6
Aroclor-1254	25	Mean	864	802	881	765	1.1	1.4	1.2	1.9
		STD	157	76	72	299	0.2	0.3	0.6	0.8
	50	Mean	921	833	945	960	1.5	1.5	1.6	**3.0[b]**
		STD	90	79	126	182	0.3	0.5	0.8	0.9
	100	Mean	954	908	908	1127	1.9	1.8	**2.3[a]**	**4.0[b]**
		STD	156	121	143	328	0.8	0.5	1.2	1.5
Aroclor-1260	25	Mean	941	910	921	1052	1.3	1.5	2.1	2.5
		STD	85	73	130	287	0.3	0.3	1.0	1.7
	50	Mean	913	900	939	947	1.2	1.4	1.7	1.8
		STD	110	87	94	151	0.3	0.5	0.4	0.8
	100	Mean	889	859	944	919	1.2	1.4	1.9	5.5
		STD	108	133	98	199	0.4	0.4	0.5	11.6

N = 10 unless otherwise noted; † N = 9
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 36. Group Mean Cell Differential Counts for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			White Blood Cells ($10^3/\mu L$)				Segmented Neutrophils (%)				Band Neutrophils (%)			
Control	0	Mean	12.1	14.0	11.2	12.1	12	18	31	42	0	0	0	0
		STD	3.5	2.8	3.3	3.9	7	5	12	16	0	0	0	0
Aroclor-1016	50	Mean	**17.3[b]**	**19.5[b]**	**15.8[a]**	20.1	9	19	29	47	0	0	0	0
		STD	2.9	5.7	3.5	18.4	5	6	17	13	0	0	0	0
	100	Mean	**16.4[a]**	16.9	15.1	12.6	10	23	34	51	0	0	0	0
		STD	5.0	3.0	4.9	2.4	7	7	21	17	0	0	0	0
	200	Mean	15.5	15.7	**15.6[a]**	14.6	9	24	27	45	0	0	0	0
		STD	3.3	2.1	2.8	2.0	5	11	11	13	0	0	0	0
Aroclor-1242	50	Mean	12.7	14.8	15.0	14.1	13	25	29	38	0	0	0	0
		STD	1.6	3.0	3.1	6.6	6	10	9	12	0	0	0	0
	100	Mean	13.0	14.5†	14.5	14.0	10	24†	23	38	0	0†	0	0
		STD	2.1	5.3	4.7	6.9	7	8	6	11	0	0	0	0
Aroclor-1254	25	Mean	14.0	15.7	14.5	11.9	10	22	26	40	0	0	0	0
		STD	3.4	4.0	3.3	2.2	5	11	6	11	0	0	0	0
	50	Mean	14.2	14.6	14.3	11.4	10	20	30	38	0	0	0	0
		STD	2.0	2.7	1.8	3.6	7	9	14	13	0	0	0	0
	100	Mean	14.0	16.5	**15.5[a]**	9.7	9	16	24	40	0	0	0	0
		STD	4.4	3.6	2.8	3.6	5	7	8	13	0	0	0	0
Aroclor-1260	25	Mean	14.7	14.5	15.1	15.2†	14	17	23	51†	0	0	0	0†
		STD	2.8	2.3	2.3	5.3	6	6	8	11	0	0	0	0
	50	Mean	15.3	16.3	**16.9[b]**	12.0	14	26	24	39	0	0	0	0
		STD	3.1	4.3	4.0	4.1	9	9	14	16	0	0	0	0
	100	Mean	**18.4[b]**	**18.9[a]**	**16.5[b]**	15.5	13	19	23	49	0	0	0	0
		STD	2.9	2.9	2.5	7.0	8	7	5	11	0	0	0	0

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 36. Group Mean Cell Differential Counts for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Lymphocytes (%)				Monocytes (%)				Eosinophils (%)			
Control	0	Mean	87	80	65	50	1	1	3	7	1	1	2	1
		STD	8	7	10	18	1	1	2	4	1	2	2	1
Aroclor-1016	50	Mean	89	78	67	50	0	2	3	3[a]	1	1	1	1
		STD	5	6	17	14	0	2	2	2	1	1	1	1
	100	Mean	89	72	63	47	1	4[b]	3	2[b]	1	1	1	1
		STD	8	6	20	18	1	2	2	2	1	1	1	1
	200	Mean	89	72	70	52	1	3	2	3[a]	1	1	1	0
		STD	5	12	11	13	1	3	3	2	1	1	1	0
Aroclor-1242	50	Mean	85	73	68	55	1	1	1	7	1	1	1	1
		STD	7	10	9	12	2	1	1	3	1	1	1	1
	100	Mean	89	74†	73	56	1	1†	3	6	1	1†	1	1
		STD	7	8	7	12	1	1	2	2	1	1	1	1
Aroclor-1254	25	Mean	90	76	71	57	0	1	2	3[a]	0	1	1	1
		STD	5	10	7	10	0	2	1	2	1	1	1	1
	50	Mean	89	77	68	58	1	2	2	3	1	1	1	1
		STD	8	9	15	14	1	2	1	2	1	1	1	1
	100	Mean	90	81	73	56	0	2	2	3	0	1	1	1
		STD	6	7	7	12	0	3	1	2	1	1	1	1
Aroclor-1260	25	Mean	85	80	74	43†	0	2[a]	2	6†	1	1	1	1†
		STD	8	7	9	9	1	2	2	3	1	2	0	1
	50	Mean	85	69	73	56	1	3	2	5	0	2	1	1
		STD	9	10	14	17	1	3	1	3	1	1	1	1
	100	Mean	86	76	75[a]	45	1	3[a]	1	5	0	2	1	1
		STD	9	8	6	11	1	2	1	3	0	2	1	1

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 36. Group Mean Cell Differential Counts for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study			
			26	52	78	105	26	52	78	105
			Basophils (%)				Nucleated Red Blood Cells (#/100 WBC)			
Control	0	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
Aroclor-1016	50	Mean	0	0	0	0	0	0	3	0
		STD	0	0	0	0	0	0	9	0
	100	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
	200	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
Aroclor-1242	50	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
	100	Mean	0	0†	0	0	0	0†	0	0
		STD	0	0	0	0	0	0	0	0
Aroclor-1254	25	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
	50	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
	100	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
Aroclor-1260	25	Mean	0	0	0	0†	0	0	0	0†
		STD	0	0	0	0	0	0	0	0
	50	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	1	0	0
	100	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 37. Group Mean Cell Differential Counts for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			White Blood Cells ($10^3/\mu L$)				Segmented Neutrophils (%)				Band Neutrophils (%)			
Control	0	Mean	8.6	11.6	11.2	9.9	21	27	41	46	0	0	0	0
		STD	2.3	3.2	3.8	3.5	16	10	17	14	0	0	0	0
Aroclor-1016	50	Mean	9.7	10.2	9.3	11.1	15	23	27	52	0	0	0	0
		STD	2.9	2.8	2.2	3.8	7	6	13	17	0	0	0	0
	100	Mean	9.6	11.3	12.6	12.4	14	29	36	53	0	0	0	0
		STD	2.4	2.8	4.0	4.8	8	13	14	12	0	0	0	0
	200	Mean	**11.0[a]**	**9.0[a]**	10.5	10.6	17	23	**24[a]**	50	0	0	0	0
		STD	1.7	1.3	1.4	3.8	8	7	8	11	0	0	0	0
Aroclor-1242	50	Mean	9.2	10.4	11.2	**6.9[a]**	10	26	27	47	0	0	0	0
		STD	2.1	2.7	3.8	2.3	6	9	11	12	0	0	0	0
	100	Mean	**14.7[a]**	11.2	10.5	**6.6[a]**	19	27	27	50	0	0	0	0
		STD	6.9	1.7	3.6	1.5	20	6	16	15	0	0	0	0
Aroclor-1254	25	Mean	**12.0[a]**	10.8	9.1	9.5	12	21	**25[a]**	52	0	0	0	0
		STD	2.8	2.1	1.1	5.7	5	5	4	16	0	0	0	0
	50	Mean	11.6	9.7	**7.9[a]**	11.3	12	25	31	47	0	0	0	1
		STD	3.9	2.4	2.0	5.6	6	8	11	13	0	0	0	4
	100	Mean	**15.7[b]**	12.2	10.8	10.6	12	23	**24[a]**	46	0	0	0	0
		STD	5.0	4.0	2.5	4.5	7	7	9	17	0	0	0	0
Aroclor-1260	25	Mean	10.6	9.8	10.7	14.0	12	29	**26[a]**	52	0	0	0	0
		STD	3.2	2.3	3.0	10.9	4	11	10	20	0	0	0	0
	50	Mean	10.5	9.5	10.1	11.3	11	23	**27[a]**	45	0	0	0	0
		STD	2.8	1.9	3.0	4.0	4	8	5	13	0	0	0	0
	100	Mean	**11.5[a]**	9.3	10.3	8.2	**8[a]**	19	**22[a]**	44	0	0	0	0
		STD	1.8	1.3	2.8	2.5	2	8	12	11	0	0	0	0

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 37. Group Mean Cell Differential Counts for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Lymphocytes (%)				Monocytes (%)				Eosinophils (%)			
Control	0	Mean	78	70	57	51	0	1	1	1	1	1	1	2
		STD	15	9	16	15	1	1	1	1	1	2	1	1
Aroclor-1016	50	Mean	83	73	**71[a]**	46	0	1	1	1	2	3	1	**1[b]**
		STD	7	6	13	16	0	1	1	1	1	2	1	1
	100	Mean	85	68	62	45	0	1	1	2	1	2	1	**1[a]**
		STD	7	13	14	12	1	1	1	1	1	1	1	1
	200	Mean	82	74	**73[a]**	48	0	1	2	1	1	2	1	**1[b]**
		STD	3	6	8	10	0	1	1	1	1	2	1	1
Aroclor-1242	50	Mean	88	72	**72[a]**	53	0	1	1	1	1	2	1	**1[b]**
		STD	7	9	12	12	1	1	1	1	1	1	1	1
	100	Mean	79	71	72	48	1	1	1	2	2	1	0	**0[b]**
		STD	19	7	16	15	1	1	1	2	1	1	1	0
Aroclor-1254	25	Mean	87	76	**74[b]**	47	1	1	1	1	1	1	1	**1[b]**
		STD	6	5	4	16	1	1	1	1	1	1	1	1
	50	Mean	87	74	67	51	1	1	1	1	1	1	1	**0[b]**
		STD	6	8	11	15	1	1	1	2	1	0	1	0
	100	Mean	86	76	**75[b]**	53	1	1	1	2	1	1	0	**0[b]**
		STD	8	6	8	19	1	1	1	2	1	1	1	0
Aroclor-1260	25	Mean	85	68	**71[a]**	41	1	1	1	**6[b]**	2	2	2	**0[b]**
		STD	4	11	10	20	1	1	1	3	2	2	1	1
	50	Mean	87	74	**71[a]**	50	1	1	1	**5[b]**	2	2	2	1
		STD	4	8	6	15	1	1	1	2	1	2	1	1
	100	Mean	**91[a]**	78	**75[a]**	51	1	2	2	**5[a]**	1	2	1	**1[b]**
		STD	3	8	14	10	1	1	1	4	1	1	1	1

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 37. Group Mean Cell Differential Counts for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study			
			26	52	78	105	26	52	78	105
			Basophils (%)				Nucleated Red Blood Cells (#/100WBC)			
Control	0	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
Aroclor-1016	50	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
	100	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
	200	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
Aroclor-1242	50	Mean	0	0	0	0	0	0	0	4
		STD	0	0	0	0	0	0	0	11
	100	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	1
Aroclor-1254	25	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
	50	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
	100	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
Aroclor-1260	25	Mean	0	0	0	0	0	0	0	2
		STD	0	0	0	0	0	0	0	5
	50	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	0
	100	Mean	0	0	0	0	0	0	0	0
		STD	0	0	0	0	0	0	0	1

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 38. Group Mean Serum Chemistry Values for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Albumin (g/dL)				Blood Urea Nitrogen (mg/dL)				Cholesterol (mg/dL)			
Control	0	Mean	4.5	4.3	4.1	3.5	18	13	12	15	96	110	173	157
		STD	0.3	0.3	0.3	0.6	2	2	3	3	18	24	73	84
Aroclor-1016	50	Mean	4.4	4.2	4.3	3.6	17	14	23	16	123	**168[a]**	167	176
		STD	0.3	0.3	0.5	0.7	2	3	29	4	34	60	29	91
	100	Mean	4.4	4.3	4.1	3.7	16	14	37	23	117	**153[a]**	209	217
		STD	0.4	0.4	0.7	0.4	3	3	62	14	33	37	38	94
	200	Mean	4.4	4.4	4.3	4.0	**15[b]**	13	**15[b]**	18	114	**136[a]**	184	210
		STD	0.3	0.4	0.5	0.6	2	2	2	11	22	26	48	71
Aroclor-1242	50	Mean	4.7	4.6	4.4	4.0	18	12	**14[a]**	21	108	125	181	208
		STD	0.3	0.2	0.3	0.7	2	1	2	16	22	41	64	94
	100	Mean	4.5	4.4	4.1	3.9	18	13	16	16	127	142	209	166
		STD	0.4	0.3	0.6	0.4	2	2	9	10	37	50	89	34
Aroclor-1254	25	Mean	4.4	4.3	4.2	4.0	19	14	14	23	123	**160[a]**	203	**262[a]**
		STD	0.2	0.4	0.4	0.5	2	2	6	19	33	56	67	75
	50	Mean	4.5	4.6	4.1	3.5	17	13	14	25	128	**151[b]**	193	222
		STD	0.4	0.5	0.4	0.8	2	2	4	31	25	30	46	84
	100	Mean	4.6	4.6	4.2	3.9	16	14	**18[a]**	19	**164[b]**	**194[b]**	241	**259[a]**
		STD	0.3	0.4	0.4	0.5	2	2	7	15	30	44	67	81
Aroclor-1260	25	Mean	4.5	4.2	4.1	3.2†	18	12	**14[a]**	**26[a]†**	98	119	169	226†
		STD	0.5	0.2	0.4	0.6	2	2	2	13	23	40	73	139
	50	Mean	4.5	4.4	4.2	3.5	18	13	16	16	111	160	189	207
		STD	0.4	0.2	0.3	0.3	2	3	6	5	19	70	62	55
	100	Mean	4.3	4.0	4.2	3.4	18	14	**15[a]**	18	120	**143[a]**	197	207
		STD	0.4	0.4	0.3	0.6	1	2	3	9	21	27	40	50

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 38. Group Mean Serum Chemistry Values for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Creatinine (mg/dL)				Glucose (mg/dL)				Total Bilirubin (mg/dL)			
Control	0	Mean	0.7	0.6	0.6	0.7	102	138	108	100	0.1	0.2	0.2	0.1
		STD	0.0	0.1	0.1	0.1	9	27	22	32	0.0	0.0	0.0	0.1
Aroclor-1016	50	Mean	0.7	0.7	0.8	0.8	**113[a]**	131	**142[b]**	95	**0.2[b]**	0.1	0.2	0.1
		STD	0.1	0.1	0.2	0.2	10	25	20	30	0.0	0.1	0.1	0.0
	100	Mean	0.7	0.7	1.1	1.1	113	148	**138[a]**	85	**0.2[b]**	0.1	0.1	0.1
		STD	0.1	0.2	0.9	0.7	17	47	33	26	0.0	0.1	0.1	0.1
	200	Mean	0.7	0.7	**0.7[a]**	1.0	116	134	149	103	**0.2[b]**	0.1	0.2	0.1
		STD	0.0	0.1	0.0	0.8	21	27	57	39	0.0	0.0	0.1	0.0
Aroclor-1242	50	Mean	0.7	**0.7[a]**	0.7	1.1	108	134	**138[b]**	103	**0.2[b]**	0.1	0.3	0.1
		STD	0.1	0.0	0.1	0.6	10	19	8	48	0.0	0.1	0.2	0.1
	100	Mean	0.7	0.7	0.7	0.8	**114[a]**	119	**130[a]**	102	**0.2[b]**	0.1	0.2	0.1
		STD	0.1	0.1	0.2	0.4	8	16	20	13	0.0	0.0	0.1	0.0
Aroclor-1254	25	Mean	0.7	**0.7[b]**	**0.8[a]**	1.1	101	124	**129[a]**	99	0.1	0.1	0.2	0.1
		STD	0.1	0.1	0.2	0.6	7	20	12	16	0.0	0.1	0.0	0.0
	50	Mean	0.7	**0.8[b]**	**0.7[a]**	1.0	104	125	**133[a]**	106	0.1	0.1	0.3	0.1
		STD	0.1	0.1	0.1	0.8	12	19	14	16	0.1	0.1	0.3	0.1
	100	Mean	0.7	**0.8[b]**	**0.8[b]**	0.9	101	**108[b]**	**130[a]**	106	**0.2[a]**	0.2	0.2	0.1
		STD	0.1	0.1	0.1	0.4	9	8	14	18	0.0	0.0	0.1	0.0
Aroclor-1260	25	Mean	0.7	**0.7[b]**	**0.8[b]**	1.2†	**113[a]**	**110[a]**	**143[a]**	69†	**0.2[b]**	0.2	0.2	**0.1[a†]**
		STD	0.1	0.1	0.1	0.8	9	16	35	28	0.0	0.0	0.1	0.1
	50	Mean	0.7	**0.7[b]**	**0.9[a]**	0.7	112	**110[a]**	**135[a]**	74	**0.2[b]**	0.2	0.2	**0.1[a]**
		STD	0.0	0.1	0.3	0.1	12	7	18	20	0.0	0.1	0.2	0.0
	100	Mean	0.7	**0.7[a]**	**0.8[b]**	0.8	107	112	124	**72[a]**	0.2	0.2	0.2	0.1
		STD	0.0	0.0	0.1	0.4	8	27	33	14	0.2	0.0	0.1	0.1

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 38. Group Mean Serum Chemistry Values for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study			
			26	52	78	105
			Total Protein (g/dL)			
Control	0	Mean	7.0	6.9	6.8	6.8
		STD	0.4	0.5	0.4	0.6
Aroclor-1016	50	Mean	6.9	7.0	7.1	6.9
		STD	0.4	0.5	0.7	0.7
	100	Mean	7.0	7.4	7.1	7.0
		STD	0.2	0.5	0.7	0.3
	200	Mean	7.1	7.2	7.1	7.1
		STD	0.3	0.4	0.4	0.5
Aroclor-1242	50	Mean	7.3	7.3	7.0	7.2
		STD	0.4	0.3	0.3	0.9
	100	Mean	7.2	7.3	6.9	7.0
		STD	0.3	0.4	0.4	0.3
Aroclor-1254	25	Mean	6.9	7.2	7.0	7.2
		STD	0.3	0.5	0.5	0.7
	50	Mean	7.0	7.5[a]	6.9	6.9
		STD	0.5	0.6	0.5	0.7
	100	Mean	7.1	7.4	6.8	7.0
		STD	0.3	0.4	0.5	0.4
Aroclor-1260	25	Mean	7.0	7.2	7.1	6.9†
		STD	0.5	0.4	0.6	0.4
	50	Mean	7.0	7.3	7.0	6.6
		STD	0.4	0.3	0.3	0.3
	100	Mean	7.1	7.0	7.3	6.9
		STD	0.5	0.5	0.6	0.6

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 39. Group Mean Serum Chemistry Values for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Albumin (g/dL)				Blood Urea Nitrogen (mg/dL)				Cholesterol (mg/dL)			
Control	0	Mean	5.6	5.2	5.6	5.0	19	15	14	14	118	180	146	136
		STD	0.5	0.8	0.5	0.7	3	5	1	3	30	149	26	35
Aroclor-1016	50	Mean	5.3	5.2	5.0	**4.0[a]**	**16[a]**	14	**17[a]**	23	106	136	197	162
		STD	0.4	0.3	0.6	1.0	1	2	3	16	28	43	124	87
	100	Mean	5.5	5.2	**4.6[b]**	**4.1[a]**	**15[a]**	12	16	16	123	153	168	167
		STD	0.6	0.6	0.7	1.0	3	2	4	6	24	39	84	59
	200	Mean	5.4	5.3	4.9	4.4	**14[b]**	13	14	14	127	167	214	180
		STD	0.4	0.4	0.4	0.5	2	2	3	3	39	47	112	56
Aroclor-1242	50	Mean	5.6	5.6	5.6	4.6	18	13	13	24	110	146	184	225
		STD	0.4	0.4	0.5	0.9	3	3	2	38	24	36	55	146
	100	Mean	**4.9[a]**	5.3	4.9	4.5	19	14	17	15	128	211	**240[b]**	**277[b]**
		STD	0.5	0.6	0.9	0.6	7	4	8	4	25	53	74	84
Aroclor-1254	25	Mean	5.4	5.4	5.3	4.1	**16[a]**	13	**11[a]**	15	145	176	**225[a]**	**254[b]**
		STD	0.6	0.4	0.4	0.7	2	3	2	6	29	21	82	83
	50	Mean	5.3	5.2	5.1	**3.7[b]**	**16[a]**	13	12	16	**191[b]**	223	**265[b]**	**360[b]**
		STD	0.5	0.6	0.6	0.5	1	2	3	3	32	43	50	139
	100	Mean	**4.8[b]**	4.6	**4.6[b]**	**3.8[b]**	**15[b]**	14	15	**20[a]**	**193[b]**	226	**255[a]**	**287[b]**
		STD	0.5	0.6	0.4	0.4	1	3	2	5	50	64	105	71
Aroclor-1260	25	Mean	5.6	5.2	5.1	**3.9[a]**	17	12	14	37	127	157	162	147
		STD	0.4	0.2	0.3	0.8	1	1	3	75	25	28	30	56
	50	Mean	5.9	5.4	5.2	4.4	17	13	12	15	151	200	**233[b]**	**237[a]**
		STD	0.4	0.3	0.6	0.5	2	3	2	5	25	25	58	99
	100	Mean	5.4	5.3	4.9	4.4	18	13	13	15	**161[a]**	244	**260[b]**	**273[b]**
		STD	0.5	0.4	0.6	0.5	3	2	2	5	27	46	76	110

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 39. Group Mean Serum Chemistry Values for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Creatinine (mg/dL)				Glucose (mg/dL)				Total Bilirubin (mg/dL)			
Control	0	Mean	0.7	0.8	0.8	0.8	118	106	119	81	0.2	0.2	0.2	0.1
		STD	0.1	0.2	0.0	0.1	13	22	11	16	0.0	0.1	0.0	0.1
Aroclor-1016	50	Mean	0.7	0.7	**0.7[a]**	0.8	113	114	115	78	0.1	0.1	0.2	0.1
		STD	0.0	0.1	0.1	0.5	6	8	19	36	0.0	0.1	0.1	0.0
	100	Mean	0.7	0.7	0.7	0.7	113	118	113	83	0.2	0.2	0.1	0.1
		STD	0.0	0.1	0.1	0.1	8	20	14	22	0.0	0.1	0.0	0.1
	200	Mean	**0.7[a]**	0.7	**0.7[b]**	0.7	119	115	111	87	0.2	0.2	0.2	0.1
		STD	0.0	0.1	0.1	0.1	7	18	14	16	0.0	0.1	0.1	0.1
Aroclor-1242	50	Mean	0.7	0.7	0.8	1.0	108	101	112	86	0.2	0.2	0.2	0.1
		STD	0.0	0.1	0.1	0.9	9	10	17	38	0.0	0.1	0.1	0.1
	100	Mean	0.7	0.7	0.8	0.7	113	102	105	83	0.2	0.2	0.2	**0.2[a]**
		STD	0.1	0.1	0.1	0.1	8	8	45	14	0.1	0.1	0.1	0.1
Aroclor-1254	25	Mean	0.7	0.7	**0.7[b]**	0.7	110	106	**102[b]**	89	0.2	0.2	**0.3[b]**	0.2
		STD	0.0	0.1	0.0	0.1	7	10	11	23	0.1	0.1	0.1	0.1
	50	Mean	**0.7[a]**	0.7	**0.7[b]**	0.7	**106[a]**	106	**98[b]**	88	0.2	0.2	**0.3[a]**	**0.2[b]**
		STD	0.1	0.1	0.1	0.1	10	10	11	6	0.1	0.1	0.2	0.1
	100	Mean	**0.6[b]**	0.7	**0.7[b]**	0.8	112	105	**96[b]**	78	**0.3[b]**	0.2	**0.3[b]**	**0.4[b]**
		STD	0.0	0.1	0.0	0.1	8	6	9	23	0.1	0.1	0.1	0.2
Aroclor-1260	25	Mean	0.7	0.7	**0.7[b]**	0.9	**106[a]**	105	128	82	0.2	0.2	0.1	0.1
		STD	0.0	0.1	0.1	0.7	9	12	20	23	0.0	0.1	0.0	0.1
	50	Mean	0.7	0.7	**0.7[b]**	0.7	108	107	120	77	0.2	0.2	0.2	0.1
		STD	0.0	0.1	0.1	0.1	10	11	15	16	0.0	0.1	0.1	0.0
	100	Mean	0.7	0.7	**0.7[b]**	0.7	110	103	111	77	**0.2[a]**	0.2	0.2	**0.1[a]**
		STD	0.1	0.1	0.1	0.1	12	10	18	12	0.0	0.1	0.1	0.0

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 39. Group Mean Serum Chemistry Values for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study			
			26	52	78	105
			Total Protein (g/dL)			
Control	0	Mean	7.8	7.9	8.6	8.1
		STD	0.6	0.7	0.6	0.7
Aroclor-1016	50	Mean	7.5	7.8	7.9	7.2[a]
		STD	0.5	0.5	0.6	0.9
	100	Mean	7.7	7.9	7.6[b]	7.3
		STD	0.7	0.8	0.7	0.9
	200	Mean	7.8	8.0	7.9	7.5
		STD	0.6	0.6	0.4	0.5
Aroclor-1242	50	Mean	7.8	8.1	8.1	7.6
		STD	0.4	0.4	0.5	1.0
	100	Mean	7.3	8.3	8.2	8.1
		STD	0.7	0.3	0.8	0.8
Aroclor-1254	25	Mean	7.6	8.1	8.2	7.5
		STD	0.6	0.5	0.3	0.4
	50	Mean	7.8	8.0	8.2	7.5
		STD	0.5	0.7	0.8	0.5
	100	Mean	7.4	7.9	8.3	8.1
		STD	0.5	0.6	0.4	0.8
Aroclor-1260	25	Mean	7.8	8.1	7.9	7.6
		STD	0.3	0.4	0.6	0.8
	50	Mean	8.2	8.2	7.9	7.6
		STD	0.3	0.4	0.6	0.6
	100	Mean	7.8	8.3	8.0	7.9
		STD	0.5	0.5	0.6	0.7

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 40. Group Mean Serum Enzyme Values for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Alanine Aminotransferase (IU/L)				Alkaline Phosphatase (IU/L)				Aspartate Aminotransferase (IU/L)			
Control	0	Mean	43	45	39	33	317	177	143	138	90	90	91	86
		STD	10	16	11	12	47	32	55	78	17	22	28	35
Aroclor-1016	50	Mean	39	36	118	30	306	166	161	123	**71[a]**	77	184	93
		STD	14	12	271	9	99	35	58	69	14	17	359	33
	100	Mean	56	40	43	37	315	176	141	120	101	98	80	81
		STD	55	7	26	13	92	42	42	41	73	33	36	25
	200	Mean	41	42	35	36	308	196	178	106	86	93	72	81
		STD	12	13	7	19	111	55	63	54	15	22	10	21
Aroclor-1242	50	Mean	48	48	35	37	333	169	145	120	90	117	**67[a]**	85
		STD	13	18	7	14	77	39	45	34	15	38	12	25
	100	Mean	44	49	36	35	349	198	156	118	80	98	**70[a]**	94
		STD	17	34	9	7	95	51	50	22	27	34	8	23
Aroclor-1254	25	Mean	42	47	49	37	371	189	167	132	112	119	82	73
		STD	11	28	29	14	111	74	54	47	41	72	17	23
	50	Mean	85	48	251	45	374	224	167	194	137	**112[a]**	565	126
		STD	140	14	667	34	115	71	45	104	125	22	1548	74
	100	Mean	49	45	43	37	373	222	203	176	128	**138[b]**	98	116
		STD	27	12	18	18	97	64	70	77	68	30	32	42
Aroclor-1260	25	Mean	41	41	59	49†	386	179	181	117†	79	100	107	118†
		STD	4	8	43	28	102	37	46	51	18	26	73	60
	50	Mean	41	41	38	33	386	164	184	130	**72[a]**	82	87	90
		STD	9	7	8	9	77	67	53	43	17	16	44	15
	100	Mean	42	49	43	51	355	169	169	135	87	107	87	108
		STD	8	37	14	38	90	45	68	49	25	50	29	31

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 40. Group Mean Serum Enzyme Values for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Creatine Kinase (IU/L)				Gamma-Glutamyltransferase (IU/L)				Lactate Dehydrogenase (IU/L)			
Control	0	Mean	435	289	334	165	0	1	3	1	818	360	675	333
		STD	186	117	164	81	0	2	6	3	511	207	363	252
Aroclor-1016	50	Mean	363	423	**163[a]**	257	0	0	3	2	423	503	**148[b]**	474
		STD	195	327	118	215	0	1	5	2	263	218	111	519
	100	Mean	566	661	**99[b]**	230	1	1	1	1	665	730	**137[b]**	314
		STD	299	639	32	104	3	4	2	3	578	573	67	144
	200	Mean	614	492	**136[b]**	260	0	1	2	2	526	606	**136[b]**	364
		STD	456	603	99	170	0	2	2	3	360	567	54	427
Aroclor-1242	50	Mean	306	516	**74[b]**	233	0	0	0	0	712	**762[a]**	**116[b]**	372
		STD	120	337	13	136	0	0	0	0	253	338	27	297
	100	Mean	**173[b]**	354	**112[b]**	264	0	0	1	1	**395[a]**	588	**110[b]**	443
		STD	96	220	61	214	0	0	2	1	249	340	36	448
Aroclor-1254	25	Mean	814	635	**108[b]**	185	**7[a]**	1	3	4	1082	812	**99[b]**	289
		STD	573	826	52	90	10	1	2	6	554	748	24	204
	50	Mean	732	643	**137[b]**	273	**8[a]**	1	5	2	1075	710	1255	473
		STD	511	568	74	289	10	1	9	1	593	513	3608	548
	100	Mean	656	**646[a]**	**109[b]**	248	**1[b]**	2	3	3	1157	**1130[a]**	**125[b]**	422
		STD	451	420	24	157	1	1	3	2	661	789	32	399
Aroclor-1260	25	Mean	464	**769[a]**	374	**387[a†]**	**1[a]**	1	2	2[†]	517	**985[a]**	**163[b]**	529[†]
		STD	250	600	251	257	1	1	3	2	406	689	60	451
	50	Mean	468	364	341	**377[a]**	5	0	1	4	436	445	**128[b]**	673
		STD	309	260	245	227	7	1	1	4	389	325	43	435
	100	Mean	743	777	273	308	3	1	2	**11[a]**	660	752	**146[b]**	562
		STD	697	1002	330	270	4	2	3	12	681	569	107	555

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 41. Group Mean Serum Enzyme Values for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Alanine Aminotransferase (IU/L)				Alkaline Phosphatase (IU/L)				Aspartate Aminotransferase (IU/L)			
Control	0	Mean	81	48	63	53	318	80	90	96	117	88	136	132
		STD	52	19	32	20	126	44	34	68	68	35	64	46
Aroclor-1016	50	Mean	52	42	**32[a]**	34	271	78	90	92	85	84	**61[b]**	98
		STD	34	24	8	24	110	26	30	31	26	29	13	52
	100	Mean	**42[a]**	41	38	36	**175[a]**	75	115	128	72	99	93	102
		STD	15	21	18	16	90	76	133	140	10	61	47	41
	200	Mean	73	35	**32[a]**	35	**167[a]**	57	69	61	90	73	**64[b]**	95
		STD	71	7	10	18	68	27	29	27	60	16	12	32
Aroclor-1242	50	Mean	49	53	41	50	283	98	92	103	83	126	102	108
		STD	14	24	10	22	90	46	35	66	19	47	27	25
	100	Mean	61	88	95	63	266	85	128	85	104	**178[a]**	244	212
		STD	13	54	105	27	80	37	113	60	21	89	293	148
Aroclor-1254	25	Mean	88	73	47	60	251	75	71	117	163	195	105	209
		STD	54	44	17	38	107	40	25	117	87	217	43	146
	50	Mean	74	58	45	**175[a]**	293	90	88	134	**194[a]**	**197[a]**	142	**250[b]**
		STD	37	34	18	161	142	35	50	138	82	130	87	104
	100	Mean	67	62	72	**259[a]**	363	**131[a]**	129	**164[a]**	**244[a]**	**334[b]**	238	**305[b]**
		STD	24	16	40	275	132	35	45	59	116	162	130	103
Aroclor-1260	25	Mean	51	35	**37[a]**	**37[a]**	277	73	72	319	76	77	**75[a]**	141
		STD	16	9	6	11	111	24	12	561	19	15	12	75
	50	Mean	65	43	39	49	245	76	65	62	87	96	**81[a]**	126
		STD	43	26	13	21	107	32	33	16	29	38	20	64
	100	Mean	66	51	40	64	192	57	90	67	96	97	100	273
		STD	26	20	7	44	84	21	43	14	31	29	45	434

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 41. Group Mean Serum Enzyme Values for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Creatine Kinase (IU/L)				Gamma-Glutamyltransferase (IU/L)				Lactate Dehydrogenase (IU/L)			
Control	0	Mean	351	332	320	523	0	1	1	1	459	280	174	637
		STD	154	195	115	456	1	1	1	1	196	242	128	665
Aroclor-1016	50	Mean	365	441	**105[b]**	454	1	0	0	0	637	407	107	591
		STD	147	351	81	559	3	0	1	1	202	328	35	562
	100	Mean	273	378	**120[b]**	347	4	0	1	2	500	219	145	579
		STD	118	525	70	296	9	0	1	2	229	163	67	507
	200	Mean	297	394	**119[b]**	334	3	0	0	2	421	419	123	503
		STD	173	288	56	186	6	0	0	4	236	318	36	195
Aroclor-1242	50	Mean	290	770	**818[b]**	303	1	1	1	2	377	535	192	537
		STD	158	958	379	211	1	1	1	3	188	421	59	436
	100	Mean	255	322	**917[a]**	321	1	1	**8[a]**	27	306	457	470	615
		STD	119	166	743	156	1	1	7	41	192	189	755	384
Aroclor-1254	25	Mean	290	327	207	259	5	0	7	26	436	338	122	229
		STD	155	193	134	236	7	0	12	38	269	212	31	107
	50	Mean	197	430	**214[a]**	264	**9[a]**	1	10	**62[b]**	344	609	202	265
		STD	118	389	88	209	10	1	14	51	184	622	99	268
	100	Mean	184	510	**184[a]**	225	7	1	**15[a]**	**57[b]**	**201[b]**	442	158	359
		STD	138	654	110	71	10	1	15	49	97	250	95	210
Aroclor-1260	25	Mean	252	390	226	461	3	1	1	6	436	247	233	605
		STD	126	297	158	188	4	1	1	8	266	183	293	422
	50	Mean	274	491	249	348	1	1	2	**8[b]**	436	294	236	379
		STD	247	709	328	142	1	1	2	6	575	393	318	135
	100	Mean	271	212	**205[a]**	325	1	1	7	29	306	181	254	1190
		STD	238	141	97	146	2	1	11	43	321	78	250	2086

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 42. Group Mean Serum Electrolyte Values for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Calcium (mg/dL)				Chloride (mEq/L)				Phosphorus (mg/dL)			
Control	0	Mean	10.0	10.6	10.5	10.4	97	102	101	103	7.6	7.7	5.9	7.4
		STD	0.8	0.3	0.3	0.5	2	1	2	3	1.3	0.6	0.4	1.1
Aroclor-1016	50	Mean	10.0	10.8	10.6	10.8	96	100†	102	103	8.2	8.3	6.2	7.6
		STD	0.8	0.6	0.3	0.7	3	4	4	5	1.0	2.1	1.1	0.9
	100	Mean	9.7	10.9	10.8	**11.5[a]**	96	99	99	101	7.6	8.0	7.4	8.7
		STD	0.6	0.3	0.9	1.4	2	4	5	2	0.6	1.6	4.9	2.4
	200	Mean	9.8	10.7	10.5	**11.6[a]**	97	**97[a]**	100	**99[a]**	7.9	7.2	5.6	8.6
		STD	0.9	0.4	0.4	1.2	2	4	3	3	0.6	0.7	0.6	1.9
Aroclor-1242	50	Mean	10.1	10.5	10.6	**11.5[a]**	**101[a]**	**100[a]**	**93[b]**	102	7.9	7.4	**4.9[b]**	8.8
		STD	0.9	0.4	0.4	1.2	1	1	2	4	0.6	0.7	0.5	2.9
	100	Mean	9.7	10.5	10.5	10.7	100	101	**95[b]**	104	7.4	7.2	5.3	7.3
		STD	1.0	0.3	0.2	0.4	2	2	3	2	1.0	0.7	1.1	0.8
Aroclor-1254	25	Mean	10.4	**11.5[a]**	10.5	**11.4[a]**	97	101	**95[b]**	104	7.8	7.6	5.7	8.0
		STD	0.7	1.0	0.2	1.0	2	2	2	2	0.8	1.4	0.4	2.4
	50	Mean	10.5	**11.5[b]**	10.2	10.7	98	101	**96[b]**	104	7.5	7.8	**5.3[b]**	8.0
		STD	1.1	0.7	0.4	0.6	2	2	2	3	1.0	1.3	0.5	2.8
	100	Mean	10.3	**11.6[b]**	10.4	10.8	98	101	**96[b]**	**107[b]**	7.6	8.3	5.9	7.7
		STD	0.7	0.6	0.3	0.5	3	2	1	2	1.1	0.9	0.4	1.5
Aroclor-1260	25	Mean	**11.4[b]**	**11.1[a]**	**10.9[a]**	10.9†	99	**98[a]**	**95[b]**	101†	7.8	**8.3[a]**	6.0	9.0†
		STD	0.9	0.4	0.5	1.9	2	3	2	4	0.9	0.6	0.7	3.2
	50	Mean	**11.4[b]**	**11.1[a]**	**10.9[b]**	**9.9[a]**	97	**97[a]**	**94[b]**	103	7.4	7.6	5.8	6.7
		STD	0.3	0.6	0.2	0.3	2	5	1	2	0.5	0.9	1.1	1.0
	100	Mean	**11.1[a]**	10.8	**10.9[b]**	10.2	97	**100[a]**	**95[b]**	101	7.6	8.1	5.8	7.7
		STD	0.4	0.6	0.3	0.6	3	2	3	3	0.7	1.3	0.4	1.6

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 42. Group Mean Serum Electrolyte Values for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study			
			26	52	78	105	26	52	78	105
			Potassium (mEq/L)				Sodium (mEq/L)			
Control	0	Mean	6.4	5.6	5.8	5.5	148	147	148	151
		STD	0.3	0.5	0.3	0.5	2	2	1	1
Aroclor-1016	50	Mean	6.9	**6.6[b†]**	**6.3[a]**	5.8	148	150[†]	**153[b]**	150
		STD	0.6	0.9	0.5	0.7	1	1	4	1
	100	Mean	6.8	**6.3[a]**	6.1	5.7	149	150	**152[b]**	151
		STD	0.4	0.4	0.7	0.5	2	3	2	4
	200	Mean	6.7	6.1	6.1	5.7	148	**151[b]**	**152[b]**	150
		STD	0.3	0.5	0.4	1.0	2	2	2	2
Aroclor-1242	50	Mean	6.7	5.9	**6.2[b]**	5.9	**155[b]**	149	**151[b]**	151
		STD	0.4	0.6	0.3	1.0	3	2	2	3
	100	Mean	6.8	5.8	**6.3[a]**	5.5	**153[b]**	148	**151[b]**	152
		STD	0.5	0.5	0.3	0.4	5	2	1	2
Aroclor-1254	25	Mean	6.7	**6.4[a]**	5.8	5.8	148	149	**150[b]**	151
		STD	0.4	0.6	0.2	0.3	2	2	1	2
	50	Mean	6.8	**6.6[b]**	6.0	6.0	148	**151[a]**	148	151
		STD	0.7	0.7	0.3	0.6	2	3	1	3
	100	Mean	6.5	**6.5[b]**	**6.3[b]**	**6.1[a]**	148	148	148	151
		STD	0.5	0.7	0.4	0.4	2	3	1	2
Aroclor-1260	25	Mean	**7.1[b]**	**6.5[b]**	**6.4[b]**	5.9[†]	150	150	**152[b]**	151[†]
		STD	0.6	0.4	0.3	0.6	4	2	2	3
	50	Mean	**7.3[b]**	**6.4[a]**	6.1	5.6	**149[a]**	**154[b]**	**151[b]**	150
		STD	0.3	0.5	0.3	0.5	2	3	2	2
	100	Mean	**7.2[b]**	6.0	5.9	5.7	**149[a]**	**151[b]**	**152[b]**	150
		STD	0.3	0.5	0.4	0.5	2	2	2	3

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 43. Group Mean Serum Electrolyte Values for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Calcium (mg/dL)				Chloride (mEq/L)				Phosphorus (mg/dL)			
Control	0	Mean	11.3	11.1	11.2	10.9	100	94	90	99	6.0	6.7	4.9	7.5
		STD	0.5	0.4	0.4	0.5	3	4	3	4	1.0	1.5	1.2	2.2
Aroclor-1016	50	Mean	11.0	11.2	10.9	10.7	99	98	92	99	6.4	6.0	5.6	7.2
		STD	0.3	0.2	0.5	1.0	2	4	4	4	0.8	1.0	0.8	1.5
	100	Mean	11.3	11.2	10.7	10.7	98	96	93	98	6.7	6.0	5.7	7.2
		STD	0.5	0.6	0.4	0.6	3	5	6	5	0.7	0.4	0.7	1.6
	200	Mean	11.3	11.0	10.8	10.8	98	97	93	100	6.3	5.6	5.2	6.0
		STD	0.3	0.2	0.4	0.2	3	3	4	3	0.5	1.0	0.4	0.5
Aroclor-1242	50	Mean	**10.8[a]**	10.8	10.8	11.0	100	94	92	97	5.9	6.5	5.2	7.7
		STD	0.3	0.3	0.4	0.9	2	4	4	5	0.7	0.8	0.5	3.9
	100	Mean	11.1	10.7	10.7	10.9	101	97	94	102	**6.9[a]**	6.3	5.7	6.2
		STD	0.9	0.4	0.6	0.4	2	3	6	4	0.9	0.6	1.4	1.3
Aroclor-1254	25	Mean	11.5	11.2	10.9	10.3	97	97	94	99	6.2	6.3	5.7	7.1
		STD	0.5	0.4	0.3	0.7	3	5	4	4	0.3	0.8	0.5	1.7
	50	Mean	11.6	11.2	10.9	**10.4[a]**	**96[a]**	**99[a]**	**97[a]**	100	6.3	6.4	**6.0[a]**	6.9
		STD	0.4	0.6	0.4	0.4	3	2	5	2	0.8	0.8	0.7	1.5
	100	Mean	11.3	10.9	10.8	10.6	98	99	**96[a]**	101	6.5	7.1	**6.2[a]**	8.7
		STD	0.4	0.6	0.5	0.4	2	4	5	4	0.5	1.4	0.7	1.2
Aroclor-1260	25	Mean	10.7	11.0	**10.6[a]**	11.0	**94[b]**	94	94	101	6.1	5.7	4.8	8.8
		STD	0.7	0.3	0.3	1.1	2	4	3	8	0.4	0.5	0.6	4.2
	50	Mean	11.1	11.3	10.9	10.7	**94[b]**	91	91	95	6.4	6.1	5.1	6.7
		STD	0.7	0.3	0.4	0.3	2	3	5	4	0.8	1.0	0.7	0.9
	100	Mean	11.4	11.2	**10.6[a]**	10.6	**94[b]**	93	93	99	6.7	**5.5[a]**	4.9	6.7
		STD	2.1	0.5	0.5	0.5	4	4	7	3	0.9	0.5	0.8	0.6

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 43. Group Mean Serum Electrolyte Values for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study			
			26	52	78	105	26	52	78	105
			Potassium (mEq/L)				Sodium (mEq/L)			
Control	0	Mean	5.6	5.6	5.5	5.1	145	146	149	152
		STD	0.6	0.8	0.5	0.4	2	3	2	6
Aroclor-1016	50	Mean	6.1	5.6	5.6	5.0	**147[b]**	149	148	148
		STD	0.5	0.7	0.9	0.7	1	2	2	4
	100	Mean	**6.2[b]**	5.4	5.6	5.1	147	148	147	**148[a]**
		STD	0.5	0.5	0.6	0.8	2	3	1	3
	200	Mean	**6.1[a]**	5.5	5.5	5.2	146	148	147	**146[a]**
		STD	0.2	0.4	0.4	0.4	1	2	1	2
Aroclor-1242	50	Mean	6.0	5.7	5.5	5.0	145	148	148	149
		STD	0.6	0.5	0.3	0.4	1	1	1	4
	100	Mean	**6.6[b]**	5.9	5.5	5.3	144	146	148	149
		STD	0.4	0.2	0.8	0.5	2	2	2	5
Aroclor-1254	25	Mean	**6.3[b]**	5.7	5.2	5.0	145	147	148	**148[a]**
		STD	0.3	0.5	0.5	0.4	2	3	2	3
	50	Mean	**6.4[b]**	5.9	5.8	5.2	145	147	148	**146[a]**
		STD	0.4	0.5	0.3	0.6	3	3	2	3
	100	Mean	**6.2[a]**	6.1	5.8	**5.8[b]**	143	147	147	148
		STD	0.3	0.6	0.2	0.5	1	3	2	3
Aroclor-1260	25	Mean	5.8	5.8	5.4	5.7	**142[a]**	149	148	152
		STD	0.4	0.3	0.6	2.1	2	3	3	4
	50	Mean	5.8	5.7	5.4	4.7	142	**150[a]**	148	149
		STD	0.5	0.4	0.5	0.4	2	2	2	2
	100	Mean	5.8	5.9	5.1	5.2	**142[b]**	**150[b]**	149	**147[a]**
		STD	0.3	0.7	0.3	0.5	3	2	3	2

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 44. Group Mean Urinalysis Values for Core Subgroup Male Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Volume (mL)				pH				Specific Gravity (g/mL)			
Control	0	Mean	7.9	20.1	16.4	15.5	7.0	6.7	6.4	5.4	1.037	1.035	1.034	1.031
		STD	2.6	25.0	11.8	6.7	0.8	0.7	0.7	0.7	0.014	0.018	0.013	0.009
Aroclor-1016	50	Mean	10.8	11.3	9.5	12.7	6.9	6.2	6.2	5.7	1.038	1.038	1.042	1.030
		STD	4.5	6.2	3.0	8.0	0.7	0.4	0.6	0.8	0.013	0.014	0.014	0.007
	100	Mean	10.1	14.3	11.3	15.5	7.1	6.6	6.1	5.2	1.035	1.036	1.034	1.032
		STD	4.0	10.0	4.3	5.1	0.3	0.7	0.3	0.4	0.012	0.014	0.012	0.006
	200	Mean	10.5	11.3	11.3	17.3	7.0	6.3	6.1	5.3	1.035	1.032	1.035	1.030
		STD	3.1	4.7	4.4	6.2	0.5	0.5	0.3	0.5	0.009	0.010	0.015	0.007
Aroclor-1242	50	Mean	10.1	11.7	9.9	23.0	7.0	6.8	6.1	5.9	1.036	1.031	1.046	1.028
		STD	2.1	4.9	3.8	22.2	0.5	0.6	0.3	0.9	0.008	0.008	0.011	0.014
	100	Mean	12.2	13.9	10.1	11.7†	7.2	6.8	6.0	6.0†	1.033	1.028	1.044	1.038†
		STD	6.5	5.5	5.3	8.2	0.4	0.6	0.5	0.7	0.013	0.009	0.011	0.013
Aroclor-1254	25	Mean	**12.0[a]**	12.1	11.9	18.8	7.3	6.7	6.4	5.4	1.033	1.030	1.031	1.027
		STD	4.3	3.3	4.0	10.3	0.5	0.8	0.5	0.7	0.009	0.010	0.008	0.009
	50	Mean	20.7	13.0	12.8	13.8	7.2	7.0	6.0	5.4	1.031	1.029	1.033	1.033
		STD	24.8	4.7	4.1	7.4	0.8	0.7	0.5	0.5	0.010	0.012	0.011	0.009
	100	Mean	**13.8[b]**	14.5	13.9	15.7	7.4	6.7	6.2	5.6	1.029	1.029	1.028	1.030
		STD	4.7	5.8	5.2	9.9	0.5	0.5	0.6	0.5	0.006	0.007	0.008	0.010
Aroclor-1260	25	Mean	**11.6[a]**	17.8	14.7	16.8	7.0	6.8	6.3	5.7	1.034	1.023	1.034	1.031
		STD	2.6	5.8	6.3	7.5	0.5	0.6	0.5	1.3	0.011	0.005	0.010	0.007
	50	Mean	**12.6[b]**	23.3	16.0	14.9	7.4	7.1	6.6	5.1	1.030	**1.021[a]**	1.031	1.032
		STD	2.5	6.6	7.1	6.5	0.5	0.7	0.7	0.3	0.005	0.005	0.007	0.007
	100	Mean	**13.7[b]**	21.6	11.6	17.5	7.5	6.9	6.2	5.0	1.030	**1.020[a]**	1.035	1.033
		STD	1.7	7.1	3.5	20.4	0.5	0.9	0.4	0.0	0.004	0.006	0.007	0.010

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 45. Group Mean Urinalysis Values for Core Subgroup Female Rats

Test Substance	Conc. (ppm)		Week of Study				Week of Study				Week of Study			
			26	52	78	105	26	52	78	105	26	52	78	105
			Volume (mL)				pH				Specific Gravity (g/mL)			
Control	0	Mean	8.4	8.6	11.2	11.5	6.2	5.8	6.1	5.8	1.022	1.027	1.026	1.026
		STD	2.8	2.7	4.5	5.1	0.4	0.4	0.6	0.8	0.004	0.007	0.004	0.006
Aroclor-1016	50	Mean	6.5	7.3	9.2	12.6	6.0	5.5	**5.5[b]**	5.6	**1.035[b]**	1.033	1.029	1.026
		STD	2.2	2.7	3.2	5.8	0.0	0.5	0.5	0.7	0.009	0.008	0.009	0.005
	100	Mean	8.8	10.0	10.7	13.7	6.5	5.8	**5.6[a]**	6.0	1.028	1.029	1.030	1.027
		STD	2.9	4.4	7.0	4.9	0.5	0.6	0.5	0.7	0.007	0.008	0.011	0.007
	200	Mean	7.7	9.5	9.7	10.2	6.2	5.5	**5.6[a]**	5.9	**1.031[a]**	1.028	1.034	1.029
		STD	3.1	3.2	6.4	3.6	0.4	0.5	0.7	0.6	0.008	0.011	0.012	0.009
Aroclor-1242	50	Mean	**12.5[a]**	8.4	11.0	13.6	**6.8[a]**	6.1	6.0	5.7	1.019	1.026	1.029	1.026
		STD	3.3	3.3	4.3	8.8	0.6	0.3	0.0	0.7	0.005	0.007	0.007	0.008
	100	Mean	**14.5[b]**	8.9	9.3	9.8	6.3	6.0	6.0	5.7	1.018	1.023	**1.032[a]**	1.033
		STD	3.1	3.0	3.3	3.7	0.5	0.5	0.0	0.5	0.003	0.005	0.007	0.011
Aroclor-1254	25	Mean	9.3	9.5	13.1	10.4	6.3	5.8	6.2	5.7	1.024	1.027	1.026	1.031
		STD	2.6	4.1	4.7	4.1	0.7	0.4	0.4	0.7	0.007	0.010	0.006	0.012
	50	Mean	9.8	15.7	13.0	12.9	6.2	6.0	6.0	5.5	1.023	1.017	1.032	1.030
		STD	4.2	10.5	7.8	4.7	0.4	0.5	0.0	0.7	0.009	0.008	0.010	0.006
	100	Mean	9.6	**11.9[a]**	12.9	13.3	6.2	5.7	6.2	5.3	1.026	1.022	1.029	1.030
		STD	4.1	2.4	5.7	4.5	0.4	0.5	0.4	0.5	0.008	0.006	0.007	0.008
Aroclor-1260	25	Mean	7.3	11.1	11.4	14.3†	5.6	6.0	6.0	5.6†	1.028	1.027	**1.030[a]**	1.035†
		STD	2.9	3.3	3.5	11.9	2.0	0.5	0.0	0.7	0.005	0.010	0.005	0.020
	50	Mean	9.2	**12.2[b]**	10.9	15.6	6.0	5.6	5.9	5.5	1.025	1.024	1.031	1.025
		STD	2.6	2.1	2.8	3.2	0.0	0.5	0.3	0.5	0.008	0.007	0.007	0.004
	100	Mean	8.7	10.6	10.7	15.3	6.2	5.5	5.9	5.4	1.028	1.028	1.033	1.026
		STD	2.5	2.9	4.9	10.3	0.4	0.5	0.3	0.5	0.008	0.006	0.012	0.005

N = 10 unless otherwise noted; † N = 9.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			$p<0.05$	$p<0.01$	$p<0.05$	$p<0.01$
Red Blood Cells (Erythrocyte Count) ($10^6/\mu L$)						
Week 78	50	1016	A	A	AB	AB
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	AB
	100	1016	A	A	A	A
		1242	A	A	B	B
		1254	A	A	AC	AB
		1260	A	A	BC	AB
Hemoglobin (g/dL)						
Week 26	50	1016	A	A	A	A
		1242	AB	A	AB	AB
		1254	B	A	B	B
		1260	AB	A	AB	AB
	100	1016	A	A	A	A
		1242	B	B	A	A
		1254	B	B	B	B
		1260	B	AB	A	A
Week 52	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	A
	100	1016	A	A	A	A
		1242	A	A	B	A
		1254	B	B	C	B
		1260	AB	AB	AB	A
Week 78	50	1016	AB	A	A	A
		1242	A	A	A	A
		1254	B	A	B	B
		1260	A	A	A	A

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			p<0.05	p<0.01	p<0.05	p<0.01
Hemoglobin (g/dL)						
	100	1016	AB	A	AB	AB
		1242	AB	A	A	A
		1254	A	A	B	B
		1260	B	A	A	AB
Week 104	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	AB	AB
Hematocrit (%)						
Week 26	50	1016	A	A	A	A
		1242	A	A	B	A
		1254	A	A	B	A
		1260	A	A	AB	A
	100	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	AB
Week 52	50	1016	A	A	A	A
		1242	B	A	A	A
		1254	AB	A	B	B
		1260	AB	A	A	A
	100	1016	AB	A	A	A
		1242	B	A	A	A
		1254	A	A	B	B
		1260	A	A	A	A
Week 78	50	1016	A	A	A	A
		1242	A	A	A	AB
		1254	A	A	B	B
		1260	A	A	A	A

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			p<0.05	p<0.01	p<0.05	p<0.01
Hematocrit (%)						
	100	1016	A	A	AB	A
		1242	A	A	AB	A
		1254	A	A	A	A
		1260	A	A	B	A
Week 104	50	1016	A	A	A	A
		1242	A	A	A	AB
		1254	A	A	B	B
		1260	A	A	AB	AB
Mean Corpuscular Volume (fL)						
Week 26	50	1016	A	A	A	A
		1242	AB	A	AB	AB
		1254	B	A	B	B
		1260	AB	A	A	AB
	100	1016	A	A	A	A
		1242	B	B	B	B
		1254	AB	AB	C	C
		1260	AB	AB	B	B
Week 52	50	1016	A	A	A	A
		1242	A	A	AB	AB
		1254	A	A	B	B
		1260	A	A	AB	AB
	100	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	AB
Week 78	50	1016	A	A	A	A
		1242	A	A	B	B
		1254	A	A	BC	AB
		1260	A	A	AC	A

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			p<0.05	p<0.01	p<0.05	p<0.01
Mean Corpuscular Volume (fL)						
	100	1016	A	A	A	A
		1242	A	A	B	B
		1254	A	A	B	B
		1260	A	A	B	AB
Week 104	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	AB
	100	1016	A	A	A	A
		1242	A	A	B	BC
		1254	A	A	B	C
		1260	A	A	A	AB
Mean Corpuscular Hemoglobin (pg)						
Week 26	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	A
	100	1016	AB	A	A	A
		1242	A	A	B	A
		1254	B	A	C	B
		1260	AB	A	B	A
Week 52	50	1016	A	A	A	A
		1242	A	A	B	AB
		1254	A	A	B	B
		1260	A	A	B	AB
	100	1016	A	AB	A	A
		1242	A	A	B	AB
		1254	B	B	C	B
		1260	AB	AB	B	B

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			$p<0.05$	$p<0.01$	$p<0.05$	$p<0.01$
Mean Corpuscular Hemoglobin (pg)						
Week 78	50	1016	A	A	A	A
		1242	A	A	B	AB
		1254	A	A	B	B
		1260	A	A	B	AB
	100	1016	A	A	A	A
		1242	AB	AB	B	B
		1254	B	B	B	B
		1260	AB	AB	B	B
Week 104	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	AB
	100	1016	AB	AB	A	A
		1242	A	A	BC	AB
		1254	C	C	C	B
		1260	BC	BC	AB	A
Mean Corpuscular Hemoglobin Concentration (g/dL)						
Week 26	50	1016	A	A	A	A
		1242	B	AB	B	B
		1254	C	B	A	A
		1260	B	A	A	AB
	100	1016	A	A	A	A
		1242	B	B	B	A
		1254	B	B	AB	A
		1260	B	B	B	A
Week 52	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	B	B	A	A
		1260	A	A	A	A

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			$p<0.05$	$p<0.01$	$p<0.05$	$p<0.01$
Mean Corpuscular Hemoglobin Concentration (g/dL)						
	100	1016	A	A	A	A
		1242	A	AB	B	B
		1254	B	B	B	AB
		1260	A	A	B	AB
Week 78	50	1016	A	AB	A	A
		1242	B	A	B	B
		1254	AB	AB	C	A
		1260	A	B	C	A
	100	1016	A	A	A	AB
		1242	B	A	A	A
		1254	AB	A	B	C
		1260	AB	A	B	BC
Week 104	50	1016	A	A	A	A
		1242	A	AB	A	A
		1254	B	B	A	A
		1260	AB	AB	A	A
	100	1016	A	A	A	A
		1242	AC	A	A	A
		1254	B	B	A	A
		1260	BC	AB	A	A
Reticulocytes (%)						
Week 26	100	1016	A	A	A	A
		1242	A	A	B	AB
		1254	A	A	C	B
		1260	A	A	AB	A
Week 52	50	1016	AB	AB	A	A
		1242	A	AB	A	A
		1254	A	A	A	A
		1260	B	B	A	A

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			p<0.05	p<0.01	p<0.05	p<0.01
Reticulocytes (%)						
	100	1016	AB	AB	A	A
		1242	A	A	A	A
		1254	A	A	A	A
		1260	B	B	A	A
Week 78	100	1016	A	A	A	AB
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	AB	AB
Albumin (g/dL)						
Week 26	50	1016	A	A	A	A
		1242	A	A	AB	AB
		1254	A	A	A	A
		1260	A	A	B	B
	100	1016	A	A	A	A
		1242	A	A	B	BC
		1254	A	A	B	C
		1260	A	A	A	AB
Week 52	50	1016	A	A	A	A
		1242	B	A	A	A
		1254	B	A	A	A
		1260	AB	A	A	A
	100	1016	A	AB	A	AB
		1242	A	A	A	A
		1254	A	A	B	B
		1260	B	B	A	A
Week 78	50	1016	A	A	A	A
		1242	A	A	B	A
		1254	A	A	AB	A
		1260	A	A	AB	A

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			p<0.05	p<0.01	p<0.05	p<0.01
Albumin (g/dL)						
Week 104	50	1016	A	A	A	AB
		1242	A	A	B	A
		1254	A	A	A	B
		1260	A	A	AB	AB
	100	1016	A	A	AB	A
		1242	A	A	A	A
		1254	A	A	B	A
		1260	A	A	AB	A
Cholesterol (mg/dL)						
Week 26	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	C	C
	100	1016	A	A	A	A
		1242	A	A	A	AC
		1254	B	B	B	B
		1260	A	A	C	BC
Week 52	50	1016	A	A	A	A
		1242	B	A	A	A
		1254	AB	A	B	B
		1260	AB	A	B	AB
	100	1016	A	AB	A	A
		1242	A	A	B	AB
		1254	B	B	B	B
		1260	A	AB	B	B
Week 78	50	1016	A	A	AB	A
		1242	A	A	A	A
		1254	A	A	B	A
		1260	A	A	AB	A

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			$p<0.05$	$p<0.01$	$p<0.05$	$p<0.01$
Cholesterol (mg/dL)						
	100	1016	A	A	A	A
		1242	A	A	B	AB
		1254	A	A	B	AB
		1260	A	A	B	B
Week 104	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	A
Week 104	100	1016	A	A	A	A
		1242	A	A	B	B
		1254	A	A	B	B
		1260	A	A	B	AB
Total Bilirubin (mg/dL)						
Week 26	50	1016	A	A	A	A
		1242	AB	AB	B	AB
		1254	B	B	B	B
		1260	A	AB	AB	AB
	100	1016	A	A	AC	A
		1242	AB	A	A	A
		1254	B	A	B	B
		1260	AB	A	C	A
Week 52	50	1016	A	A	A	A
		1242	AB	AB	A	A
		1254	A	A	A	A
		1260	B	B	A	A
	100	1016	A	A	A	A
		1242	AB	A	A	A
		1254	B	A	A	A
		1260	AB	A	A	A

1. *Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.*

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			p<0.05	p<0.01	p<0.05	p<0.01
Total Bilirubin (mg/dL)						
Week 78	50	1016	A	A	AC	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	C	A
	100	1016	A	A	A	A
		1242	A	A	AC	AB
		1254	A	A	B	B
		1260	A	A	C	AB
Week 104	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	A
		1260	A	A	AB	A
	100	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	A
Total Protein (g/dL)						
Week 26	50	1016	A	A	A	A
		1242	A	A	AB	AB
		1254	A	A	AB	AB
		1260	A	A	B	B
	100	1016	A	A	AB	A
		1242	A	A	A	A
		1254	A	A	AB	A
		1260	A	A	B	A
Alanine Aminotransferase (IU/L)						
Week 52	100	1016	A	A	A	A
		1242	A	A	B	B
		1254	A	A	BC	AB
		1260	A	A	AC	AB

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			p<0.05	p<0.01	p<0.05	p<0.01
Alanine Aminotransferase (IU/L)						
Week 78	100	1016	A	A	A	A
		1242	A	A	B	B
		1254	A	A	B	B
		1260	A	A	A	A
Week 104	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	A
	100	1016	A	A	A	A
		1242	A	A	B	A
		1254	A	A	C	B
		1260	A	A	AB	A
Alkaline Phosphatase (IU/L)						
Week 26	100	1016	A	A	A	A
		1242	A	A	A	AB
		1254	A	A	B	B
		1260	A	A	A	A
Aspartate Aminotransferase (IU/L)						
Week 26	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	A
	100	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	A
Week 52	50	1016	A	A	A	A
		1242	B	A	AB	AB
		1254	BC	A	B	B
		1260	AC	A	A	AB

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			p<0.05	p<0.01	p<0.05	p<0.01
Aspartate Aminotransferase (IU/L)						
	100	1016	A	A	A	A
		1242	A	A	A	A
		1254	B	A	B	B
		1260	AB	A	A	A
Week 78	100	1016	A	A	A	A
		1242	A	A	B	B
		1254	A	A	B	B
		1260	A	A	A	A
Week 104	50	1016	AB	A	A	A
		1242	A	A	A	A
		1254	B	A	B	A
		1260	A	A	AB	A
	100	1016	A	A	A	A
		1242	AB	A	AB	AB
		1254	B	A	B	B
		1260	AB	A	B	AB
Creatine Kinase (IU/L)						
Week 26	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	B	A	A	A
		1260	AB	A	A	A
	100	1016	A	A	A	A
		1242	B	B	A	A
		1254	A	A	A	A
		1260	A	A	A	A
Week 78	50	1016	A	A	A	A
		1242	B	A	B	B
		1254	A	A	C	C
		1260	C	B	C	AC

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			p<0.05	p<0.01	p<0.05	p<0.01
Creatine Kinase (IU/L)						
	100	1016	A	A	A	A
		1242	A	A	B	B
		1254	A	AB	AC	A
		1260	B	B	C	A
Gamma Glutamyl Transferase (IU/L)						
Week 26	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	B	B	B	B
		1260	B	AB	A	A
	100	1016	A	A	AB	A
		1242	A	A	A	A
		1254	A	A	B	A
		1260	A	A	A	A
Week 78	50	1016	A	A	A	A
		1242	A	A	A	AB
		1254	A	A	B	B
		1260	A	A	A	AB
	100	1016	A	A	A	A
		1242	A	A	A	AB
		1254	A	A	B	B
		1260	A	A	A	AB
Week 104	50	1016	A	A	A	A
		1242	A	A	A	A
		1254	A	A	B	B
		1260	A	A	A	A
	100	1016	A	A	A	A
		1242	A	A	AC	AB
		1254	A	A	B	B
		1260	B	B	C	AB

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 46. Significant Differences Between Aroclor Test Substances for Hematology, Serum Chemistry, and Serum Electrolyte Values for Core Subgroup Male and Female Rats

Time Interval	Concentration (ppm)	Test Substance	Male Group Comparisons		Female Group Comparisons	
			$p<0.05$	$p<0.01$	$p<0.05$	$p<0.01$
Lactate Dehydrogenase (IU/L)						
Week 26	50	1016	A	A	A	A
		1242	B	AB	B	AB
		1254	B	B	B	AB
		1260	A	A	B	B
	100	1016	A	AB	A	A
		1242	A	A	AB	AB
		1254	B	B	B	B
		1260	A	AB	B	B
Week 52	50	1016	A	A	AB	A
		1242	A	A	A	A
		1254	A	A	A	A
		1260	A	A	B	A
	100	1016	A	A	A	AB
		1242	A	A	B	A
		1254	A	A	B	AB
		1260	A	A	A	B
Week 104	50	1016	A	A	A	A
		1242	A	A	AB	A
		1254	A	A	B	A
		1260	A	A	AB	A
	100	1016	A	A	AB	A
		1242	A	A	AB	A
		1254	A	A	A	A
		1260	A	A	B	A

1. Only those parameters deemed significant by the study director are being reported in Table 43. Additional parameter comparisons can be found in the study file.

If at least one letter is common to both compared Aroclor test substances (example: 1016A, 1242A) no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.

Table 47. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)						
			Adrenal Glands	Brain	Heart	Kidneys	Liver	Lungs	Pituitary Gland
Control	0	Mean[1]	0.053	2.238	1.907	4.799	25.090	2.246	0.016
		STD	0.005	0.066	0.180	0.509	4.287	0.130	0.003
Aroclor-1016	50	Mean	0.063	2.162	1.787	4.828	29.912	2.625	0.015
		STD	0.014	0.092	0.178	0.435	3.729	0.328	0.002
	100	Mean	0.063	2.088	1.769	4.702	25.402	2.436	0.017
		STD	0.009	0.032	0.149	0.451	2.846	0.321	0.003
	200	Mean	0.073	2.178	1.994	4.445	27.146	2.437	0.016
		STD	0.026	0.145	0.265	0.343	5.413	0.467	0.002
Aroclor-1242	50	Mean[2]	0.070	2.122	1.951	4.933	29.281	2.622	0.017
		STD	0.012	0.186	0.256	0.642	6.684	0.376	0.002
	100	Mean	0.064	2.243	1.738	4.441	26.200	2.280	0.019
		STD	0.005	0.148	0.237	0.445	4.403	0.170	0.005
Aroclor-1254	25	Mean[1]	0.068	2.168	1.775	4.727	29.165	2.394	0.016
		STD	0.014	0.093	0.149	0.609	4.115	0.297	0.002
	50	Mean	0.054	2.168	1.610	4.404	28.362	2.202	0.016
		STD	0.011	0.230	0.117	0.509	4.521	0.192	0.002
	100	Mean	0.057	2.108	1.744	4.715	32.615	2.170	0.015
		STD	0.009	0.066	0.298	0.461	4.813	0.363	0.001
Aroclor-1260	25	Mean	0.055	2.204	1.787	4.648	27.008	2.389	0.017
		STD	0.011	0.131	0.172	0.605	3.876	0.390	0.004
	50	Mean	0.052	2.277	1.687	4.784	31.284	2.384	0.017
		STD	0.011	0.121	0.175	0.611	3.138	0.372	0.002
	100	Mean	0.063	2.236	1.715	4.667	32.635	2.324	0.017
		STD	0.009	0.115	0.171	0.574	5.105	0.326	0.004

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 5 for lungs only.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 47. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)						
			Salivary Glands	Thymus	Thyroid Gland	Epididymides	Prostate	Seminal Vesicles	Testes
Control	0	Mean[1]	0.646	0.439	0.029	1.474	1.648	1.536	3.652
		STD	0.131	0.152	0.003	0.093	0.666	0.652	0.163
Aroclor-1016	50	Mean	0.738	0.487	0.030	1.562	1.160	1.514	3.790
		STD	0.142	0.103	0.007	0.141	0.661	0.305	0.471
	100	Mean	0.830	0.480	0.037	1.524	1.004	1.554	3.721
		STD	0.130	0.108	0.004	0.179	0.374	0.222	0.205
	200	Mean	0.769	0.489	0.034	1.559	1.241	1.736	3.635
		STD	0.097	0.174	0.008	0.086	0.393	0.456	0.236
Aroclor-1242	50	Mean	0.791	0.552	0.034	1.595	1.518	1.310	3.466
		STD	0.123	0.113	0.009	0.135	0.507	0.264	0.150
	100	Mean	0.759	0.370	**0.044**[a]	1.629	1.007	1.852	3.619
		STD	0.122	0.089	0.012	0.237	0.460	0.484	0.290
Aroclor-1254	25	Mean[1]	0.801	0.410	0.042	1.619	1.187	1.615	3.594
		STD	0.115	0.100	0.008	0.094	0.364	0.478	0.122
	50	Mean	0.651	0.362	0.034	1.415	1.394	1.708	3.391
		STD	0.138	0.139	0.007	0.114	0.503	0.680	0.330
	100	Mean	0.723	0.339	**0.045**[a]	1.517	1.223	1.520	3.642
		STD	0.159	0.073	0.013	0.095	0.274	0.295	0.389
Aroclor-1260	25	Mean	0.762	0.435	0.035	1.479	1.221	1.494	3.602
		STD	0.099	0.225	0.004	0.099	0.321	0.298	0.330
	50	Mean	0.702	0.406	0.034	1.608	1.135	1.880	3.797
		STD	0.089	0.166	0.005	0.070	0.459	0.757	0.143
	100	Mean	0.627	0.313	0.039	1.476	1.697	1.678	3.763
		STD	0.122	0.135	0.008	0.100	0.561	0.339	0.279

N = 6 unless otherwise noted.
1. N = 5 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 47. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)						
			Adrenal Glands	Brain	Heart	Kidneys	Liver	Lungs	Pituitary Gland
Control	0	Mean[1]	0.008	0.344	0.295	0.735	3.825	0.346	0.002
		STD	0.001	0.026	0.055	0.072	0.473	0.042	0.001
Aroclor-1016	50	Mean	0.009	0.305	0.251	0.678	4.190	0.373	0.002
		STD	0.002	0.028	0.016	0.027	0.296	0.069	0.000
	100	Mean	0.009	0.310	0.262	0.696	3.753	0.360	0.002
		STD	0.002	0.030	0.032	0.083	0.426	0.048	0.000
	200	Mean	0.011	0.340	0.308	0.690	4.164	0.375	0.003
		STD	0.004	0.049	0.024	0.059	0.448	0.047	0.001
Aroclor-1242	50	Mean	0.010	0.300	0.273	0.692	4.098	0.368	0.002
		STD	0.001	0.045	0.024	0.074	0.802	0.042	0.000
	100	Mean[2]	0.010	0.356	0.275	0.703	4.111	0.357	0.003
		STD	0.001	0.035	0.029	0.061	0.378	0.039	0.001
Aroclor-1254	25	Mean[1]	0.010	0.322	0.263	0.699	4.317	0.356	0.002
		STD	0.002	0.016	0.009	0.055	0.499	0.056	0.000
	50	Mean	0.008	0.341	0.254	0.691	4.427	0.346	0.003
		STD	0.002	0.038	0.025	0.065	0.447	0.029	0.001
	100	Mean	0.010	0.358	0.295	0.801	**5.545**[a]	0.367	0.003
		STD	0.001	0.016	0.037	0.069	0.824	0.046	0.000
Aroclor-1260	25	Mean	0.008	0.328	0.263	0.682	3.966	0.351	0.003
		STD	0.001	0.047	0.013	0.050	0.413	0.041	0.000
	50	Mean	0.008	0.338	0.250	0.707	4.653	0.355	0.003
		STD	0.001	0.021	0.026	0.052	0.562	0.059	0.000
	100	Mean	0.009	0.327	0.250	0.681	4.772	0.338	0.002
		STD	0.001	0.023	0.020	0.076	0.797	0.030	0.001

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 5 for lungs only.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 47. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)						
			Salivary Glands	Thymus	Thyroid Gland	Epididymides	Prostate	Seminal Vesicles	Testes
Control	0	Mean[1]	0.098	0.067	0.004	0.226	0.247	0.235	0.561
		STD	0.016	0.021	0.001	0.010	0.090	0.097	0.045
Aroclor-1016	50	Mean	0.104	0.069	0.004	0.220	0.158	0.213	0.533
		STD	0.022	0.016	0.001	0.018	0.081	0.042	0.061
	100	Mean	0.123	0.071	0.005	0.227	0.146	0.230	0.552
		STD	0.025	0.014	0.001	0.038	0.047	0.036	0.059
	200	Mean	0.119	0.074	0.005	0.243	0.199	0.272	0.569
		STD	0.017	0.019	0.002	0.032	0.083	0.082	0.092
Aroclor-1242	50	Mean	0.111	0.077	0.005	0.224	0.215	0.183	0.489
		STD	0.012	0.015	0.001	0.012	0.075	0.031	0.050
	100	Mean	0.123	0.058	**0.007**[a]	0.260	0.159	0.289	0.576
		STD	0.036	0.010	0.002	0.050	0.066	0.051	0.075
Aroclor-1254	25	Mean[1]	0.120	0.061	0.006	0.241	0.177	0.240	0.534
		STD	0.023	0.016	0.001	0.031	0.058	0.071	0.036
	50	Mean	0.103	0.056	0.005	0.223	0.218	0.276	0.534
		STD	0.023	0.019	0.001	0.021	0.071	0.132	0.065
	100	Mean	0.122	0.057	**0.008**[a]	**0.258**[b]	0.210	0.259	0.617
		STD	0.020	0.012	0.002	0.006	0.058	0.052	0.040
Aroclor-1260	25	Mean	0.113	0.062	0.005	0.218	0.179	0.218	0.535
		STD	0.020	0.027	0.001	0.015	0.041	0.031	0.085
	50	Mean	0.104	0.059	0.005	0.240	0.167	0.280	0.565
		STD	0.014	0.020	0.001	0.024	0.063	0.113	0.050
	100	Mean	0.091	0.045	0.006	0.216	0.253	0.244	0.549
		STD	0.010	0.018	0.001	0.018	0.101	0.044	0.028

N = 6 unless otherwise noted.
1. N = 5 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 47. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)						
			Adrenal Glands	Heart	Kidneys	Liver	Lungs	Pituitary Gland	Salivary Gland
Control	0	Mean[3]	2.379	81.905	219.239	1182.211	99.851	0.691	30.411
		STD	0.229	4.616	24.605	193.687	7.873	0.155	5.538
Aroclor-1016	50	Mean	2.909	82.875	223.670	1387.194	121.594	0.681	33.986
		STD	0.602	10.488	24.201	200.194	16.172	0.125	5.673
	100	Mean	2.983	83.872	222.653	1200.693	115.478	0.790	39.289
		STD	0.435	9.032	23.845	123.197	16.863	0.138	6.535
	200	Mean	3.311	90.996	203.316	1243.767	111.391	0.729	35.094
		STD	1.026	12.910	23.297	287.515	22.897	0.073	4.660
Aroclor-1242	50	Mean	3.302	91.881	232.640	1377.099	123.485	0.794	37.330
		STD	0.520	9.965	27.460	278.881	15.708	0.101	6.136
	100	Mean[2]	2.893	79.293	202.297	1201.714	104.801	0.860	34.557
		STD	0.222	12.966	24.776	270.381	16.228	0.236	5.666
Aroclor-1254	25	Mean[1]	3.117	81.406	216.999	1340.575	109.804	0.734	36.785
		STD	0.649	8.453	33.177	229.564	15.258	0.101	6.028
	50	Mean	2.523	75.421	205.950	1332.450	103.474	0.763	29.965
		STD	0.641	11.304	32.900	304.056	18.911	0.136	4.480
	100	Mean	2.717	83.202	225.212	1551.599	103.724	0.709	34.513
		STD	0.477	14.539	26.648	198.352	19.416	0.084	7.755
Aroclor-1260	25	Mean	2.529	82.128	214.068	1241.851	109.576	0.795	34.983
		STD	0.591	10.557	36.227	205.802	17.943	0.220	5.114
	50	Mean	2.268	73.695	209.730	1372.768	104.537	0.750	30.700
		STD	0.553	5.900	30.040	169.273	18.236	0.075	3.605
	100	Mean	2.796	75.931	207.092	1447.900	102.842	0.737	27.703
		STD	0.372	6.950	28.946	243.011	13.213	0.155	4.821

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 5 for lungs only.
3. N = 4 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 47. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)					
			Thymus	Thyroid Gland	Epididymides	Prostate	Seminal Vesicles	Testes
Control	0	Mean[2]	21.180	1.289	67.718	84.975	72.875	164.978
		STD	6.648	0.179	1.657	21.419	28.057	10.300
Aroclor-1016	50	Mean	22.608	1.405	72.439	53.876	70.071	175.780
		STD	5.214	0.366	8.372	30.625	14.124	25.678
	100	Mean	22.680	1.726	72.203	47.559	73.627	176.224
		STD	4.922	0.186	9.407	18.071	11.195	13.567
	200	Mean	22.420	1.555	71.054	56.859	79.113	165.918
		STD	8.545	0.410	3.258	19.035	20.390	13.559
Aroclor-1242	50	Mean	25.989	1.604	75.389	71.913	61.760	164.470
		STD	5.080	0.451	7.934	24.266	12.940	20.107
	100	Mean	16.954	**1.996[a]**	74.587	44.887	84.728	165.772
		STD	4.485	0.512	14.800	17.252	24.666	27.034
Aroclor-1254	25	Mean[1]	18.663	1.917	74.174	54.366	73.378	164.572
		STD	4.014	0.346	5.054	16.593	18.938	6.430
	50	Mean	17.300	1.552	65.930	66.570	78.342	158.335
		STD	7.650	0.306	7.218	27.748	27.733	22.509
	100	Mean	16.129	**2.158[a]**	72.407	58.371	72.488	173.847
		STD	3.298	0.624	5.864	13.488	14.342	20.726
Aroclor-1260	25	Mean	20.024	1.613	67.854	55.863	68.726	164.884
		STD	10.591	0.189	5.636	14.114	15.044	11.932
	50	Mean	17.866	1.507	70.442	50.036	83.324	166.342
		STD	7.954	0.272	3.801	20.821	36.663	9.173
	100	Mean	13.813	1.701	65.411	75.514	74.539	166.744
		STD	5.740	0.317	4.863	25.778	16.495	13.216

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 4 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 48. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)							
			Adrenal Glands	Brain	Heart	Kidney	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean	0.097	2.265	2.252	4.934	25.203	2.624	0.029	0.678
		STD	0.078	0.080	0.466	0.903	2.028	0.496	0.030	0.121
Aroclor-1016	50	Mean	0.067	2.278	2.100	5.680	31.920	2.686	0.021	0.737
		STD	0.022	0.094	0.236	0.563	4.607	0.462	0.005	0.057
	100	Mean[1]	0.060	2.158	1.906	5.246	28.314	2.709	0.019	0.792
		STD	0.010	0.086	0.146	0.398	3.048	0.333	0.003	0.191
	200	Mean	0.079	2.165	2.075	5.960	32.771	2.629	0.040	0.664
		STD	0.016	0.171	0.217	0.738	5.986	0.302	0.053	0.099
Aroclor-1242	50	Mean	0.063	2.255	2.035	5.303	36.811	2.757	0.018	0.713
		STD	0.011	0.038	0.164	0.784	11.146	0.418	0.004	0.102
	100	Mean[1]	0.066	2.292	2.140	5.951	**34.770[b]**	2.508	0.022	0.774
		STD	0.005	0.141	0.116	0.908	2.891	0.323	0.006	0.113
Aroclor-1254	25	Mean	0.066	2.248	2.047	5.746	**32.223[b]**	2.860	0.018	0.722
		STD	0.012	0.143	0.299	0.720	3.963	0.406	0.004	0.141
	50	Mean	0.060	2.152	2.081	5.099	**33.229[b]**	2.796	0.017	0.657
		STD	0.007	0.115	0.279	0.245	2.598	0.559	0.003	0.114
	100	Mean	0.055	2.146	1.883	5.088	**34.592[b]**	2.816	0.018	0.635
		STD	0.012	0.095	0.210	0.603	2.991	0.699	0.004	0.141
Aroclor-1260	25	Mean	0.065	2.206	1.975	5.629	30.226	2.496	0.019	0.759
		STD	0.005	0.141	0.233	0.420	2.797	0.159	0.004	0.093
	50	Mean	0.067	2.219	1.947	5.201	**32.542[b]**	2.642	0.018	0.642
		STD	0.006	0.105	0.232	0.478	4.273	0.207	0.003	0.131
	100	Mean	0.074	2.227	2.069	6.749	**40.983[b]**	2.494	0.018	0.804
		STD	0.014	0.171	0.373	2.009	3.793	0.218	0.002	0.092

N = 6 unless otherwise noted.
1. N = 5 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 48. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)						
			Spleen	Thymus	Thyroid Gland	Epididymides	Prostate	Seminal Vesicles	Testes
Control	0	Mean	1.039	0.451	0.045	1.444	1.448	1.416	3.597
		STD	0.420	0.114	0.007	0.094	0.894	0.243	0.165
Aroclor-1016	50	Mean	1.071	0.430	0.049	1.490	1.379	1.495	3.586
		STD	0.169	0.150	0.007	0.150	0.165	0.264	0.323
	100	Mean[1]	1.007	0.430	0.051	1.485	1.652	1.481	3.650
		STD	0.127	0.208	0.013	0.157	0.251	0.237	0.258
	200	Mean	1.118	0.537	0.055	1.486	2.003	1.765	3.583
		STD	0.277	0.279	0.010	0.167	0.908	0.632	0.460
Aroclor-1242	50	Mean[2]	1.399	0.422	0.051	1.440	1.393	1.418	3.623
		STD	0.808	0.107	0.009	0.117	0.189	0.350	0.382
	100	Mean[1]	1.089	0.454	0.055	1.701	1.455	2.077	3.755
		STD	0.074	0.221	0.011	0.179	0.407	0.552	0.203
Aroclor-1254	25	Mean	1.150	0.404	0.050	1.502	1.513	1.661	3.832
		STD	0.227	0.160	0.008	0.075	0.279	0.360	0.237
	50	Mean	1.070	0.546	**0.066[a]**	1.537	1.451	1.287	3.819
		STD	0.205	0.216	0.006	0.066	0.419	0.261	0.207
	100	Mean	1.066	0.366	0.052	1.481	1.944	1.743	3.721
		STD	0.103	0.157	0.007	0.166	0.498	0.435	0.150
Aroclor-1260	25	Mean	0.870	0.491	0.050	1.467	1.232	1.595	3.577
		STD	0.138	0.352	0.006	0.121	0.441	0.498	0.174
	50	Mean	1.013	0.392	**0.063[a]**	1.550	1.636	1.388	3.736
		STD	0.160	0.174	0.016	0.090	0.286	0.320	0.385
	100	Mean	1.190	0.324	**0.067[a]**	1.481	1.193	1.437	3.699
		STD	0.345	0.154	0.015	0.187	0.411	0.202	0.420

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 5 for thyroid gland only.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 48. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)							
			Adrenal Glands	Brain	Heart	Kidney	Liver	Lung	Pituitary Gland	Salivary Glands
Control	0	Mean	0.013	0.300	0.297	0.646	3.325	0.345	0.004	0.090
		STD	0.009	0.028	0.054	0.063	0.115	0.051	0.005	0.019
Aroclor-1016	50	Mean	0.008	0.279	0.255	0.692	3.892	0.327	0.003	0.090
		STD	0.003	0.029	0.018	0.067	0.595	0.055	0.001	0.005
	100	Mean[1]	0.008	0.300	0.264	0.728	3.923	0.375	0.003	0.110
		STD	0.001	0.022	0.020	0.066	0.416	0.039	0.000	0.025
	200	Mean	0.009	0.261	0.249	0.712	3.908	0.318	0.004	0.080
		STD	0.001	0.037	0.033	0.072	0.582	0.060	0.005	0.013
Aroclor-1242	50	Mean	0.008	0.287	0.258	0.669	4.602	0.353	0.002	0.091
		STD	0.001	0.027	0.023	0.071	1.030	0.079	0.000	0.020
	100	Mean[1]	0.008	0.284	0.265	0.733	**4.282**[b]	0.309	0.003	0.095
		STD	0.001	0.028	0.029	0.104	0.198	0.041	0.001	0.013
Aroclor-1254	25	Mean	0.009	0.297	0.270	0.759	4.260	0.377	0.002	0.095
		STD	0.001	0.021	0.037	0.080	0.496	0.044	0.000	0.018
	50	Mean	0.008	0.287	0.275	0.677	**4.398**[b]	0.370	0.002	0.087
		STD	0.001	0.038	0.034	0.059	0.342	0.073	0.000	0.016
	100	Mean	0.008	0.324	0.286	0.769	**5.232**[b]	0.429	0.003	0.096
		STD	0.002	0.017	0.045	0.100	0.582	0.127	0.001	0.023
Aroclor-1260	25	Mean	0.008	0.287	0.253	0.727	**3.871**[b]	0.323	0.002	0.098
		STD	0.001	0.057	0.029	0.106	0.220	0.051	0.001	0.015
	50	Mean	0.009	0.308	0.268	0.717	**4.474**[b]	0.365	0.003	0.090
		STD	0.002	0.036	0.029	0.056	0.439	0.036	0.001	0.024
	100	Mean	0.010	0.305	0.281	0.925	**5.636**[b]	0.343	0.003	0.110
		STD	0.002	0.036	0.044	0.281	0.967	0.062	0.000	0.019

N = 6 unless otherwise noted.
1. N = 5 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 48. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)						
			Spleen	Thymus	Thyroid Gland	Epididymides	Prostate	Seminal Vesicles	Testes
Control	0	Mean	0.135	0.061	0.006	0.192	0.189	0.189	0.477
		STD	0.043	0.019	0.001	0.020	0.112	0.042	0.044
Aroclor-1016	50	Mean	0.130	0.053	0.006	0.182	0.169	0.183	0.438
		STD	0.020	0.019	0.001	0.026	0.027	0.038	0.058
	100	Mean[1]	0.140	0.059	0.007	0.206	0.229	0.206	0.507
		STD	0.020	0.026	0.002	0.025	0.035	0.034	0.054
	200	Mean	0.133	0.063	0.007	0.178	0.239	0.211	0.437
		STD	0.026	0.029	0.002	0.024	0.101	0.072	0.106
Aroclor-1242	50	Mean[2]	0.172	0.053	0.007	0.183	0.176	0.181	0.462
		STD	0.085	0.011	0.001	0.017	0.021	0.050	0.081
	100	Mean[1]	0.135	0.056	0.007	0.210	0.180	0.255	0.464
		STD	0.013	0.027	0.001	0.027	0.055	0.057	0.040
Aroclor-1254	25	Mean	0.152	0.053	0.007	0.199	0.201	0.219	0.507
		STD	0.026	0.020	0.001	0.013	0.043	0.044	0.037
	50	Mean	0.141	0.075	**0.009[a]**	0.205	0.192	0.172	0.507
		STD	0.022	0.035	0.001	0.027	0.055	0.043	0.053
	100	Mean	0.161	0.055	0.008	0.225	**0.293[a]**	0.265	0.563
		STD	0.021	0.024	0.001	0.036	0.071	0.078	0.046
Aroclor-1260	25	Mean	0.111	0.062	0.006	0.188	0.161	0.206	0.463
		STD	0.011	0.041	0.001	0.014	0.060	0.062	0.074
	50	Mean	0.139	0.052	**0.009[a]**	0.215	0.229	0.191	0.520
		STD	0.015	0.017	0.002	0.026	0.060	0.042	0.086
	100	Mean	0.160	0.043	**0.009[a]**	0.203	0.160	0.197	0.509
		STD	0.037	0.016	0.002	0.030	0.040	0.039	0.090

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 5 for thyroid gland only.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 48. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)						
			Adrenal Glands	Heart	Kidney	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean	4.243	99.017	217.491	1112.285	115.886	1.289	29.938
		STD	3.216	17.342	36.247	77.350	22.181	1.378	5.060
Aroclor-1016	50	Mean	2.930	92.554	249.751	1401.356	118.485	0.918	32.427
		STD	0.957	13.683	28.192	193.765	23.077	0.209	3.386
	100	Mean[1]	2.787	88.384	243.343	1317.303	125.582	0.894	36.809
		STD	0.402	7.254	20.399	184.421	15.306	0.170	9.332
	200	Mean	3.653	95.754	276.286	**1515.794[a]**	121.853	1.920	30.979
		STD	0.859	5.145	37.362	260.656	14.561	2.656	5.834
Aroclor-1242	50	Mean	2.809	90.234	235.596	**1636.026[a]**	122.205	0.813	31.625
		STD	0.483	7.369	38.715	511.974	17.851	0.177	4.480
	100	Mean[1]	2.873	93.776	258.811	1518.392	109.227	0.954	33.712
		STD	0.197	9.850	30.311	116.794	10.376	0.305	4.041
Aroclor-1254	25	Mean	2.967	91.379	257.463	1442.881	127.675	0.818	32.180
		STD	0.604	14.586	44.012	239.232	20.235	0.169	6.343
	50	Mean	2.785	96.779	237.681	**1549.959[a]**	129.970	0.764	30.577
		STD	0.397	12.682	19.123	168.580	25.537	0.113	5.213
	100	Mean	2.576	87.936	237.743	**1614.967[a]**	131.337	0.824	29.763
		STD	0.566	10.846	32.051	158.440	31.800	0.201	7.621
Aroclor-1260	25	Mean	2.963	89.895	256.591	1380.451	113.359	0.843	34.635
		STD	0.287	12.616	31.802	204.911	6.959	0.131	5.773
	50	Mean	3.024	87.854	235.095	1471.868	119.136	0.814	29.113
		STD	0.286	10.633	26.254	222.379	8.232	0.155	6.749
	100	Mean	3.348	93.225	304.606	**1850.180[a]**	112.359	0.828	36.268
		STD	0.614	17.500	92.229	229.608	11.077	0.126	4.932

N = 6 unless otherwise noted.
1. N = 5 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 48. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)						
			Spleen	Thymus	Thyroid Gland	Epididymides	Prostate	Seminal Vesicles	Testes
Control	0	Mean	45.595	19.996	1.989	63.869	63.745	62.422	158.940
		STD	16.922	5.186	0.364	5.440	38.332	10.245	9.209
Aroclor-1016	50	Mean	47.121	18.898	2.135	65.394	60.535	65.642	157.358
		STD	8.194	6.781	0.350	5.629	6.698	11.441	12.067
	100	Mean[1]	46.557	20.141	2.384	68.740	76.582	68.646	169.143
		STD	4.517	10.292	0.668	5.467	11.345	11.060	10.226
	200	Mean	51.124	24.598	2.557	68.577	91.049	81.449	165.602
		STD	8.883	12.180	0.503	4.531	33.373	28.627	19.153
Aroclor-1242	50	Mean[2]	62.377	18.721	2.242	63.874	61.837	62.860	160.673
		STD	36.756	4.845	0.429	5.734	9.036	15.243	17.159
	100	Mean[1]	47.695	19.561	2.409	74.162	63.707	91.449	164.359
		STD	4.767	9.085	0.493	5.768	17.680	27.282	14.446
Aroclor-1254	25	Mean	51.521	18.034	2.222	66.908	67.550	74.670	170.643
		STD	12.033	7.523	0.431	2.467	13.405	19.017	8.249
	50	Mean	49.983	25.167	**3.069[a]**	71.529	67.147	59.814	177.913
		STD	10.749	9.117	0.359	3.638	18.276	11.561	13.920
	100	Mean	49.770	16.931	2.429	69.293	90.459	81.425	173.757
		STD	5.530	6.909	0.359	9.919	22.385	21.043	12.025
Aroclor-1260	25	Mean	39.871	22.166	2.257	66.874	55.512	72.112	162.698
		STD	8.846	15.361	0.358	8.327	19.937	21.297	12.610
	50	Mean	45.637	17.550	2.801	69.912	73.579	63.066	168.563
		STD	6.692	7.382	0.603	4.056	10.939	16.209	17.602
	100	Mean	53.337	14.342	**3.046[a]**	66.699	52.938	64.906	166.249
		STD	14.579	6.136	0.821	8.596	14.956	10.778	15.671

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 5 for thyroid gland only.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 49. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)							
			Adrenal Glands	Brain	Heart	Kidney	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean[2]	0.138	2.175	1.845	4.415	22.990	2.541	0.051	0.679
		STD	0.111	0.046	0.080	0.390	5.080	0.301	0.040	0.053
Aroclor-1016	50	Mean[1]	0.091	**2.339[a]**	2.114	5.103	28.043	3.283	0.026	0.882
		STD	0.030	0.090	0.228	0.483	6.978	0.827	0.005	0.136
	100	Mean[3]	0.088	2.281	2.284	6.215	36.144	3.031	0.090	0.756
		STD	0.026	0.083	0.259	1.192	3.826	0.399	0.108	0.047
	200	Mean[2]	0.122	2.171	2.353	5.727	30.874	2.778	0.027	0.872
		STD	0.048	0.097	0.293	0.858	7.623	0.260	0.002	0.211
Aroclor-1242	50	Mean[1]	0.078	2.257	2.276	5.218	29.144	2.699	0.035	0.858
		STD	0.011	0.119	0.252	0.645	4.300	0.389	0.012	0.109
	100	Mean[2]	0.077	2.239	1.988	4.701	26.874	2.299	0.028	0.851
		STD	0.015	0.064	0.063	0.291	2.366	0.095	0.007	0.144
Aroclor-1254	25	Mean[1]	0.081	2.183	**2.345[a]**	5.598	32.840	2.454	0.025	0.740
		STD	0.033	0.093	0.113	1.001	3.856	0.311	0.008	0.198
	50	Mean[3]	0.061	2.323	1.949	4.237	29.890	2.440	0.023	0.774
		STD	0.003	0.026	0.116	0.462	2.525	0.137	0.003	0.009
	100	Mean[2]	0.061	2.230	2.010	4.695	35.716	2.548	0.024	0.772
		STD	0.010	0.060	0.392	0.385	1.793	0.414	0.002	0.040
Aroclor-1260	25	Mean[2]	0.078	2.333	**2.731[a]**	5.354	32.067	2.894	0.137	0.773
		STD	0.015	0.106	0.312	1.189	9.842	0.668	0.194	0.210
	50	Mean[1]	0.072	**2.340[a]**	2.175	5.167	34.211	2.333	0.027	0.743
		STD	0.012	0.084	0.386	0.544	5.629	0.233	0.006	0.089
	100	Mean[3]	0.071	2.254	1.729	5.167	33.237	2.350	0.026	0.811
		STD	0.010	0.062	0.178	1.275	2.868	0.396	0.006	0.107

1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 49. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)						
			Spleen	Thymus	Thyroid Gland	Epididymides	Prostate	Seminal Vesicles	Testes
Control	0	Mean[2]	1.095	0.556	0.050	1.459	1.990	1.786	3.193
		STD	0.141	0.215	0.013	0.250	0.819	0.285	0.348
Aroclor-1016	50	Mean[1]	1.533	0.495	0.057	1.511	2.570	3.473	3.530
		STD	0.793	0.289	0.011	0.152	3.296	4.376	0.485
	100	Mean[3]	1.219	0.553	0.067	1.586	1.845	1.613	3.779
		STD	0.179	0.054	0.007	0.029	0.139	0.357	0.658
	200	Mean[2]	1.401	0.789	0.075	1.435	1.249	1.523	3.549
		STD	0.243	0.314	0.021	0.249	0.342	0.322	0.647
Aroclor-1242	50	Mean[1]	1.283	0.301	0.056	1.573	1.283	1.874	3.650
		STD	0.117	0.097	0.008	0.133	0.568	0.198	0.130
	100	Mean[2]	1.164	0.490	0.062	1.508	1.079	1.490	3.744
		STD	0.181	0.337	0.006	0.150	0.368	0.061	0.259
Aroclor-1254	25	Mean[1]	1.302	0.483	0.072	1.316	1.113	1.822	3.161
		STD	0.298	0.178	0.011	0.493	0.392	0.822	1.264
	50	Mean[3]	1.194	0.469	0.049	1.378	1.326	1.554	3.489
		STD	0.124	0.214	0.012	0.228	0.191	0.314	0.698
	100	Mean[2]	1.275	0.502	0.062	1.709	1.113	1.541	4.114
		STD	0.134	0.126	0.015	0.157	0.497	0.321	0.472
Aroclor-1260	25	Mean[2]	1.215	0.495	0.063	1.479	1.304	1.834	3.378
		STD	0.190	0.157	0.014	0.147	0.643	1.018	0.540
	50	Mean[1]	1.621	0.419	0.067	1.577	1.130	2.131	3.524
		STD	0.672	0.190	0.015	0.396	0.355	0.448	1.335
	100	Mean[3]	1.030	0.435	0.073	1.392	1.335	1.743	3.458
		STD	0.085	0.231	0.008	0.139	0.180	0.246	0.346

1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 49. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)							
			Adrenal Glands	Brain	Heart	Kidney	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean[2]	0.018	0.296	0.250	0.599	3.098	0.344	0.007	0.093
		STD	0.013	0.055	0.034	0.096	0.652	0.057	0.005	0.020
Aroclor-1016	50	Mean[1]	0.013	0.307	0.273	0.660	3.471	0.410	0.003	0.116
		STD	0.008	0.093	0.068	0.173	0.233	0.070	0.001	0.036
	100	Mean[3]	0.009	0.237	0.237	0.642	3.748	0.317	0.009	0.079
		STD	0.002	0.014	0.015	0.083	0.233	0.058	0.010	0.009
	200	Mean[2]	0.013	0.244	0.263	0.643	3.454	0.311	0.003	0.097
		STD	0.004	0.024	0.024	0.105	0.843	0.028	0	0.015
Aroclor-1242	50	Mean[1]	0.010	0.299	0.302	0.690	3.851	0.357	0.005	0.114
		STD	0.002	0.027	0.045	0.092	0.579	0.051	0.002	0.024
	100	Mean[2]	0.010	0.295	0.262	0.619	3.542	0.303	0.004	0.114
		STD	0.002	0.038	0.036	0.075	0.534	0.041	0.001	0.033
Aroclor-1254	25	Mean[1]	0.014	0.325	0.351	0.880	4.704	0.363	0.004	0.100
		STD	0.013	0.162	0.183	0.625	1.720	0.179	0.002	0.015
	50	Mean[3]	0.008	0.316	0.265	0.574	4.046	0.331	0.003	0.105
		STD	0.001	0.019	0.032	0.054	0.058	0.015	0.001	0.007
	100	Mean[2]	0.009	0.350	0.312	0.736	**5.590[b]**	0.396	0.004	0.121
		STD	0.001	0.041	0.042	0.087	0.358	0.030	0.001	0.016
Aroclor-1260	25	Mean[2]	0.009	0.273	0.325	0.614	3.642	0.338	0.018	0.088
		STD	0.001	0.034	0.085	0.036	0.593	0.083	0.028	0.011
	50	Mean[1]	0.009	0.297	0.277	0.655	4.292	0.295	0.003	0.095
		STD	0.002	0.035	0.067	0.089	0.389	0.033	0.001	0.017
	100	Mean[3]	0.011	0.338	0.257	0.797	4.950	0.348	0.004	0.124
		STD	0.003	0.056	0.031	0.335	0.550	0.051	0.001	0.039

1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 49. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)						
			Spleen	Thymus	Thyroid Gland	Epididymides	Prostate	Seminal Vesicles	Testes
Control	0	Mean[2]	0.150	0.072	0.007	0.198	0.274	0.246	0.436
		STD	0.036	0.022	0.002	0.046	0.124	0.073	0.098
Aroclor-1016	50	Mean[1]	0.221	0.057	0.008	0.198	0.421	0.574	0.473
		STD	0.191	0.023	0.004	0.060	0.675	0.903	0.183
	100	Mean[3]	0.126	0.057	0.007	0.165	0.192	0.166	0.396
		STD	0.013	0.003	0.001	0.010	0.014	0.026	0.090
	200	Mean[2]	0.157	0.087	0.009	0.161	0.139	0.172	0.396
		STD	0.029	0.032	0.003	0.027	0.027	0.043	0.057
Aroclor-1242	50	Mean[1]	0.170	0.039	0.007	0.209	0.172	0.248	0.483
		STD	0.024	0.011	0.002	0.029	0.085	0.036	0.040
	100	Mean[2]	0.155	0.063	0.008	0.200	0.141	0.196	0.495
		STD	0.042	0.040	0.001	0.039	0.046	0.020	0.086
Aroclor-1254	25	Mean[1]	0.177	0.062	0.010	0.168	0.145	0.224	0.399
		STD	0.029	0.008	0.004	0.028	0.024	0.066	0.078
	50	Mean[3]	0.163	0.063	0.007	0.187	0.181	0.212	0.473
		STD	0.026	0.028	0.002	0.033	0.036	0.050	0.096
	100	Mean[2]	0.200	0.078	0.010	0.267	0.174	0.238	0.644
		STD	0.025	0.015	0.002	0.022	0.080	0.029	0.075
Aroclor-1260	25	Mean[2]	0.140	0.060	0.007	0.172	0.146	0.202	0.391
		STD	0.007	0.027	0	0.016	0.061	0.088	0.042
	50	Mean[1]	0.210	0.052	0.008	0.197	0.142	0.267	0.438
		STD	0.103	0.021	0.002	0.040	0.042	0.037	0.155
	100	Mean[3]	0.156	0.061	0.011	0.212	0.198	0.266	0.527
		STD	0.041	0.021	0.001	0.060	0.026	0.086	0.145

1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 49. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)						
			Adrenal Glands	Heart	Kidney	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean[2]	6.383	84.847	202.999	1058.565	116.836	2.377	31.206
		STD	5.257	4.431	17.747	243.820	13.710	1.870	2.102
Aroclor-1016	50	Mean[1]	3.904	90.613	218.568	1200.817	139.856	1.127	37.669
		STD	1.340	11.887	24.515	313.411	32.081	0.235	5.296
	100	Mean[3]	3.870	100.045	272.484	1583.107	132.891	3.911	33.235
		STD	1.073	9.199	50.207	129.488	16.512	4.622	3.169
	200	Mean[2]	5.619	108.653	264.233	1421.761	128.460	1.246	40.375
		STD	2.233	15.346	40.664	340.971	16.836	0.113	10.786
Aroclor-1242	50	Mean[1]	3.428	100.746	231.283	1297.491	119.559	1.530	38.128
		STD	0.352	8.323	27.378	234.451	15.676	0.516	5.550
	100	Mean[2]	3.428	88.840	210.167	1200.054	102.814	1.264	38.013
		STD	0.752	2.895	15.682	93.543	6.833	0.325	6.346
Aroclor-1254	25	Mean[1]	3.682	107.613	256.404	1507.814	112.125	1.154	33.864
		STD	1.429	7.178	43.838	201.451	9.928	0.306	8.621
	50	Mean[3]	2.612	83.904	182.261	1286.125	105.002	0.977	33.307
		STD	0.145	5.336	18.158	96.528	4.747	0.134	0.459
	100	Mean[2]	2.742	90.461	210.546	1603.516	114.633	1.053	34.621
		STD	0.519	19.441	17.259	115.142	21.178	0.095	1.417
Aroclor-1260	25	Mean[2]	3.311	**117.521**[a]	228.674	1365.321	123.618	6.158	32.942
		STD	0.546	17.499	45.058	381.394	25.023	9.001	8.056
	50	Mean[1]	3.073	92.865	220.518	1462.040	99.593	1.167	31.749
		STD	0.621	15.395	18.140	229.883	7.831	0.215	3.679
	100	Mean[3]	3.141	76.656	230.117	1473.267	104.125	1.168	36.101
		STD	0.501	6.433	61.788	87.220	16.043	0.242	5.681

1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 49. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)						
			Spleen	Thymus	Thyroid Gland	Epididymides	Prostate	Seminal Vesicles	Testes
Control	0	Mean[2]	50.321	25.677	2.298	67.115	91.180	82.092	146.749
		STD	6.059	10.101	0.594	11.666	36.812	12.774	15.364
Aroclor-1016	50	Mean[1]	65.637	21.039	2.453	64.724	111.351	149.546	151.245
		STD	34.464	11.829	0.506	7.746	143.347	190.276	22.560
	100	Mean[3]	53.532	24.228	2.961	69.553	80.837	70.703	166.072
		STD	8.303	1.853	0.384	1.394	3.341	14.982	30.892
	200	Mean[2]	64.954	36.082	3.461	66.358	57.915	70.168	163.990
		STD	13.683	14.053	1.024	12.976	17.521	14.348	32.909
Aroclor-1242	50	Mean[1]	57.007	13.451	2.475	69.752	57.101	83.028	162.098
		STD	6.534	4.679	0.402	5.114	25.986	7.847	11.170
	100	Mean[2]	52.019	21.661	2.749	67.314	48.037	66.534	167.204
		STD	8.221	14.529	0.297	6.046	15.651	1.999	9.998
Aroclor-1254	25	Mean[1]	59.689	22.204	3.301	60.354	51.231	83.782	144.893
		STD	13.435	8.244	0.663	22.328	18.583	38.129	56.888
	50	Mean[3]	51.413	20.209	2.113	59.298	57.125	66.894	150.038
		STD	5.499	9.245	0.546	9.483	8.480	13.400	29.109
	100	Mean[2]	57.229	22.592	2.795	76.784	49.814	69.360	184.727
		STD	6.793	6.043	0.672	8.582	22.021	15.954	23.670
Aroclor-1260	25	Mean[2]	52.003	21.373	2.683	63.262	55.110	77.546	144.342
		STD	7.162	7.565	0.526	3.759	25.887	41.930	18.719
	50	Mean[1]	69.018	17.781	2.852	67.339	48.013	91.308	150.670
		STD	28.052	7.696	0.578	16.256	13.992	20.278	56.705
	100	Mean[3]	45.772	19.127	3.234	61.923	59.149	77.549	153.787
		STD	4.751	9.646	0.271	7.780	7.041	12.709	19.213

1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 50. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Male Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)							
			Adrenal Gland	Brain	Heart	Kidneys	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean	0.164	2.252	2.335	5.894	26.438	2.932	0.040	0.839
		STD	0.158	0.104	0.325	0.987	6.613	0.930	0.039	0.222
		N	10	42	10	10	42	10	10	10
Aroclor-1016	50	Mean	0.173	2.193	2.381	5.525	23.508	2.523	0.096	0.647
		STD	0.227	0.107	0.529	1.182	9.976	0.388	0.139	0.071
		N	10	14	10	10	14	10	10	10
	100	Mean	0.102	2.220	2.389	6.636	27.295	2.855	0.051	0.707
		STD	0.045	0.122	0.719	2.305	9.595	1.219	0.038	0.232
		N	10	14	10	10	14	10	10	10
	200	Mean	0.097	2.252	2.264	6.620	27.386	2.619	0.038	0.669
		STD	0.038	0.113	0.375	1.849	5.557	0.469	0.040	0.107
		N	10	25	10	10	25	10	10	10
Aroclor-1242	50	Mean	0.095	2.218	2.473	6.498	26.019	2.707	0.053	0.741
		STD	0.022	0.092	0.431	2.663	4.119	0.434	0.047	0.084
		N	10	24	10	10	24	10	10	10
	100	Mean	0.077	2.223	2.478	5.844	28.363	2.826	0.026	0.779
		STD	0.025	0.081	0.275	0.899	9.396	0.367	0.007	0.143
		N	10	17	10	10	17	10	10	10
Aroclor-1254	25	Mean	0.096	2.207	2.261	6.082	29.766	2.904	0.040	0.659
		STD	0.031	0.119	0.293	1.607	6.279	0.700	0.026	0.064
		N	10	21	10	10	21	10	10	10
	50	Mean	0.087	2.200	2.224	5.671	28.623	2.958	0.030	0.719
		STD	0.020	0.099	0.549	1.791	4.874	0.632	0.030	0.159
		N	10	11	10	10	11	10	10	10
	100	Mean	0.073	2.188	2.035	4.996	30.922	2.495	0.024	0.647
		STD	0.012	0.095	0.178	0.704	7.487	0.248	0.010	0.094
		N	10	20	10	10	20	10	10	10
Aroclor-1260	25	Mean	0.103	2.221	2.483	7.964	29.281	2.559	0.077	0.810
		STD	0.029	0.098	0.704	3.561	8.725	0.473	0.085	0.193
		N	10	24	10	10	24	10	10	10
	50	Mean	0.110	2.208	2.519	6.242	29.475	2.895	0.088	0.691
		STD	0.055	0.100	0.382	0.852	5.395	0.995	0.098	0.093
		N	10	16	10	10	16	10	10	10
	100	Mean	0.083	2.241	1.995	6.151	29.560	2.547	0.190	0.667
		STD	0.022	0.071	0.280	1.929	8.626	0.272	0.222	0.142
		N	10	15	10	10	15	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 50. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Male Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)						
			Spleen	Thymus	Thyroid Gland	Epididymides	Prostate	Seminal Vesicles	Testes
Control	0	Mean	1.602	0.332	0.048	1.422	1.114	1.487	3.511
		STD	1.058	0.176	0.011	0.191	0.289	0.544	0.374
		N	10	10	10	10	10	10	10
Aroclor-1016	50	Mean	1.933	0.407	0.046	1.315	0.991	1.359	3.325
		STD	2.306	0.164	0.013	0.186	0.409	0.460	0.913
		N	10	10	10	10	10	10	10
	100	Mean	1.015	0.425	0.061	1.269	1.295	1.545	3.091
		STD	0.190	0.236	0.034	0.266	0.632	0.579	0.722
		N	10	10	10	10	10	10	10
	200	Mean	1.131	0.348	0.053	1.313	1.101	1.433	3.276
		STD	0.218	0.118	0.012	0.365	0.445	0.715	1.216
		N	10	10	10	10	10	10	10
Aroclor-1242	50	Mean	1.272	0.521	0.111	1.475	1.653	1.544	3.515
		STD	0.267	0.220	0.104	0.253	1.002	0.672	0.633
		N	10	10	10	10	10	10	10
	100	Mean	1.172	0.364	0.058	1.507	1.367	1.636	3.748
		STD	0.328	0.139	0.015	0.189	0.481	0.488	0.611
		N	10	10	10	10	10	10	10
Aroclor-1254	25	Mean	1.321	0.455	0.063	1.480	1.360	1.751	3.581
		STD	0.341	0.204	0.011	0.197	0.880	1.084	0.787
		N	10	10	10	10	10	10	10
	50	Mean	1.219	0.459	0.183	1.535	0.892	1.343	3.682
		STD	0.281	0.199	0.370	0.239	0.370	0.279	0.484
		N	10	10	10	10	10	10	10
	100	Mean	1.208	0.295	0.135	1.504	1.268	1.160	3.652
		STD	0.566	0.117	0.256	0.187	0.457	0.241	0.192
		N	10	10	10	10	10	10	10
Aroclor-1260	25	Mean	1.233	0.341	0.067	1.347	1.419	1.009	3.355
		STD	0.325	0.190	0.017	0.319	0.923	0.298	1.269
		N	10	10	10	10	10	10	10
	50	Mean	1.196	0.364	0.058	1.472	1.650	1.492	3.662
		STD	0.153	0.086	0.013	0.503	0.623	0.666	1.412
		N	10	10	10	10	10	10	10
	100	Mean	1.104	0.434	0.060	1.248	1.412	1.321	3.520
		STD	0.286	0.151	0.013	0.206	0.616	0.318	0.686
		N	10	10	10	10	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 50. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)							
			Adrenal Glands	Brain	Heart	Kidneys	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean	0.024	0.311	0.356	0.888	3.598	0.454	0.006	0.127
		STD	0.022	0.058	0.103	0.241	0.968	0.219	0.004	0.040
		N	10	42	10	10	42	10	10	10
Aroclor-1016	50	Mean	0.022	0.319	0.311	0.747	3.352	0.343	0.016	**0.088[a]**
		STD	0.026	0.088	0.046	0.233	1.680	0.105	0.029	0.025
		N	10	14	10	10	14	10	10	10
	100	Mean	0.017	0.332	0.382	1.071	4.244	0.459	0.008	0.104
		STD	0.013	0.077	0.223	0.720	2.396	0.350	0.008	0.033
		N	10	14	10	10	14	10	10	10
	200	Mean	0.014	0.305	0.329	0.999	3.640	0.381	0.006	0.098
		STD	0.006	0.060	0.064	0.460	0.738	0.082	0.006	0.021
		N	10	25	10	10	25	10	10	10
Aroclor-1242	50	Mean	0.013	0.306	0.340	0.916	3.551	0.384	0.008	0.102
		STD	0.003	0.069	0.094	0.498	0.790	0.161	0.010	0.024
		N	10	24	10	10	24	10	10	10
	100	Mean	0.011	0.327	0.341	0.808	4.360	0.390	0.004	0.107
		STD	0.005	0.069	0.067	0.207	2.690	0.086	0.001	0.028
		N	10	17	10	10	17	10	10	10
Aroclor-1254	25	Mean	0.013	0.318	0.318	0.865	4.234	0.407	0.006	**0.092[a]**
		STD	0.005	0.054	0.078	0.349	0.957	0.120	0.004	0.018
		N	10	21	10	10	21	10	10	10
	50	Mean	0.014	0.350	0.350	0.877	4.518	0.466	0.005	0.113
		STD	0.003	0.042	0.097	0.254	0.745	0.120	0.005	0.027
		N	10	11	10	10	11	10	10	10
	100	Mean	0.013	**0.375[b]**	0.359	0.877	**5.289[b]**	0.439	0.004	0.114
		STD	0.003	0.034	0.041	0.119	1.326	0.042	0.002	0.019
		N	10	20	10	10	20	10	10	10
Aroclor-1260	25	Mean	0.018	0.337	0.425	1.375	4.285	0.434	0.014	0.138
		STD	0.008	0.080	0.149	0.709	1.099	0.099	0.016	0.043
		N	10	24	10	10	24	10	10	10
	50	Mean	0.015	0.305	0.356	0.883	4.047	0.414	0.013	0.097
		STD	0.007	0.043	0.072	0.165	0.832	0.179	0.015	0.013
		N	10	16	10	10	16	10	10	10
	100	Mean	0.013	0.347	0.326	1.004	4.440	0.419	0.036	0.108
		STD	0.003	0.057	0.044	0.332	1.004	0.066	0.045	0.022
		N	10	15	10	10	15	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 50. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)						
			Spleen	Thymus	Thyroid Gland	Epididymis	Prostate	Seminal Vesicles	Testes
Control	0	Mean	0.257	0.047	0.007	0.211	0.164	0.215	0.524
		STD	0.217	0.018	0.002	0.027	0.034	0.070	0.083
		N	10	10	10	10	10	10	10
Aroclor-1016	50	Mean	0.235	0.054	0.006	**0.173[a]**	0.130	0.175	0.426
		STD	0.231	0.022	0.001	0.022	0.051	0.048	0.096
		N	10	10	10	10	10	10	10
	100	Mean	0.151	0.060	0.009	0.185	0.184	0.221	0.453
		STD	0.034	0.026	0.006	0.038	0.077	0.065	0.114
		N	10	10	10	10	10	10	10
	200	Mean	0.167	0.052	0.008	0.186	0.157	0.200	0.464
		STD	0.051	0.022	0.003	0.034	0.061	0.084	0.165
		N	10	10	10	10	10	10	10
Aroclor-1242	50	Mean	0.176	0.067	0.014	0.202	0.229	0.211	0.480
		STD	0.059	0.018	0.011	0.058	0.156	0.104	0.115
		N	10	10	10	10	10	10	10
	100	Mean	0.165	0.050	0.008	0.205	0.186	0.221	0.508
		STD	0.067	0.021	0.002	0.022	0.071	0.062	0.070
		N	10	10	10	10	10	10	10
Aroclor-1254	25	Mean	0.183	0.062	0.009	0.206	0.190	0.243	0.499
		STD	0.048	0.025	0.002	0.031	0.132	0.162	0.123
		N	10	10	10	10	10	10	10
	50	Mean	0.189	0.071	0.033	0.239	0.138	0.209	0.574
		STD	0.037	0.029	0.074	0.035	0.053	0.038	0.068
		N	10	10	10	10	10	10	10
	100	Mean	0.211	0.051	0.024	**0.265[a]**	0.222	0.204	**0.643[a]**
		STD	0.089	0.017	0.046	0.037	0.075	0.043	0.056
		N	10	10	10	10	10	10	10
Aroclor-1260	25	Mean	0.206	0.053	0.012	0.229	0.259	0.175	0.562
		STD	0.051	0.018	0.004	0.068	0.240	0.073	0.188
		N	10	10	10	10	10	10	10
	50	Mean	0.169	0.051	0.008	0.204	0.230	0.207	0.509
		STD	0.027	0.013	0.002	0.068	0.084	0.091	0.196
		N	10	10	10	10	10	10	10
	100	Mean	0.178	0.071	0.010	0.205	0.233	0.218	0.577
		STD	0.035	0.023	0.002	0.041	0.111	0.068	0.132
		N	10	10	10	10	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 50. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Male Rats

Test Substance	Conc. (ppm)	Organ-to-Brain Weight Ratios (%)							
			Adrenal Glands	Heart	Kidneys	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean	7.034	101.666	255.994	1177.426	127.577	1.728	36.510
		STD	6.455	14.728	40.468	298.679	40.686	1.641	9.648
		N	10	10	10	42	10	10	10
Aroclor-1016	50	Mean	7.728	106.755	248.732	1070.493	113.579	4.356	29.156
		STD	10.017	22.007	54.388	440.908	17.824	6.384	3.604
		N	10	10	10	14	10	10	10
	100	Mean	4.680	108.856	302.457	1237.166	130.099	2.370	31.522
		STD	2.298	36.985	118.449	466.484	61.494	1.807	8.430
		N	10	10	10	14	10	10	10
	200	Mean	4.315	100.930	293.774	1216.452	116.242	1.714	29.807
		STD	1.695	18.197	77.007	239.423	18.769	1.813	5.061
		N	10	10	10	25	10	10	10
Aroclor-1242	50	Mean	4.293	111.006	292.736	1174.813	121.843	2.353	33.400
		STD	1.043	19.403	123.972	192.215	20.927	2.076	4.761
		N	10	10	10	24	10	10	10
	100	Mean	3.456	112.058	263.928	1278.957	127.562	1.176	35.192
		STD	1.127	13.881	40.505	432.040	15.876	0.287	6.482
		N	10	10	10	17	10	10	10
Aroclor-1254	25	Mean	4.423	103.911	279.687	1346.206	134.261	1.875	30.257
		STD	1.493	15.457	78.239	272.972	37.741	1.269	3.533
		N	10	10	10	21	10	10	10
	50	Mean	3.955	101.928	259.934	1304.289	135.420	1.386	32.712
		STD	0.959	28.730	90.152	239.604	33.493	1.445	7.305
		N	10	10	10	11	10	10	10
	100	Mean	3.407	94.643	232.465	1410.953	116.083	1.132	30.197
		STD	0.681	7.621	32.789	327.323	10.925	0.480	4.970
		N	10	10	10	20	10	10	10
Aroclor-1260	25	Mean	4.642	111.892	357.511	1316.223	115.497	3.449	36.778
		STD	1.290	28.770	149.948	374.804	17.934	3.805	8.953
		N	10	10	10	24	10	10	10
	50	Mean	4.978	113.735	281.502	1336.094	129.948	3.972	31.222
		STD	2.609	16.739	36.001	247.565	40.931	4.402	4.435
		N	10	10	10	16	10	10	10
	100	Mean	3.687	89.263	274.742	1315.422	113.983	8.685	29.771
		STD	0.959	12.241	84.723	372.486	11.980	10.192	5.959
		N	10	10	10	15	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 50. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Male Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)						
			Spleen	Thymus	Thyroid Gland	Epididymides	Prostate	Seminal Vesicles	Testes
Control	0	Mean	69.913	14.393	2.099	61.816	48.581	64.478	152.576
		STD	46.399	7.521	0.458	7.968	12.980	23.313	14.540
		N	10	10	10	10	10	10	10
Aroclor-1016	50	Mean	86.602	18.344	2.068	59.168	44.436	60.934	149.045
		STD	103.019	7.353	0.543	8.628	17.777	20.502	39.879
		N	10	10	10	10	10	10	10
	100	Mean	45.693	19.117	2.749	57.093	58.271	69.346	139.868
		STD	7.311	10.320	1.394	11.091	28.507	25.223	34.80
		N	10	10	10	10	10	10	10
	200	Mean	50.210	15.496	2.350	58.502	49.262	63.360	146.751
		STD	9.282	5.216	0.556	16.419	20.765	31.181	55.466
		N	10	10	10	10	10	10	10
Aroclor-1242	50	Mean	57.521	23.283	4.927	66.091	74.501	69.368	157.431
		STD	13.971	9.144	4.424	10.298	46.896	30.919	24.767
		N	10	10	10	10	10	10	10
	100	Mean	53.001	16.443	2.618	68.047	61.544	74.191	168.914
		STD	14.939	6.248	0.680	8.475	21.067	23.350	24.582
		N	10	10	10	10	10	10	10
Aroclor-1254	25	Mean	60.685	20.843	**2.871**[a]	67.854	62.061	80.502	163.581
		STD	16.481	9.295	0.462	8.878	40.138	50.214	31.389
		N	10	10	10	10	10	10	10
	50	Mean	55.693	21.039	8.386	69.724	40.816	61.149	167.500
		STD	13.723	9.644	16.958	9.743	17.463	12.778	21.512
		N	10	10	10	10	10	10	10
	100	Mean	56.092	13.614	6.400	69.908	59.060	54.197	170.013
		STD	25.389	4.957	12.391	7.830	21.004	12.278	10.046
		N	10	10	10	10	10	10	10
Aroclor-1260	25	Mean	55.657	15.407	**3.004**[a]	61.203	65.519	45.866	152.962
		STD	13.420	8.586	0.731	15.044	45.316	13.969	59.349
		N	10	10	10	10	10	10	10
	50	Mean	54.138	16.528	2.611	66.802	74.737	67.464	165.715
		STD	7.969	4.468	0.529	23.711	28.770	29.851	64.299
		N	10	10	10	10	10	10	10
	100	Mean	49.172	19.446	2.665	55.760	63.256	59.044	157.329
		STD	11.650	6.741	0.595	8.781	27.802	14.102	29.767
		N	10	10	10	10	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 51. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 13-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)					
			Adrenal Glands	Brain	Heart	Kidneys	Liver	Lungs
Control	0	Mean	0.075	1.917	0.954	2.534	11.957	1.628
		STD	0.007	0.031	0.106	0.322	2.052	0.235
Aroclor-1016	50	Mean	0.074	1.944	1.125	2.576	12.225	1.726
		STD	0.018	0.091	0.118	0.144	1.364	0.165
	100	Mean	0.077	1.999	1.065	2.606	13.118	1.646
		STD	0.018	0.096	0.111	0.268	2.118	0.167
	200	Mean	0.083	1.963	1.118	2.610	12.824	1.589
		STD	0.012	0.078	0.105	0.210	2.612	0.246
Aroclor-1242	50	Mean	0.065	1.963	0.963	2 306	11.095	1.564
		STD	0.012	0.099	0.103	0.337	1.713	0.327
	100	Mean	0.061	1.916	1.076	2.383	12.921	1.576
		STD	0.007	0.046	0.054	0.192	1.433	0.185
Aroclor-1254	25	Mean	0.057	1.936	1.006	2.263	11.113	1.627
		STD	0.009	0.136	0.108	0.260	0.837	0.301
	50	Mean	0.066	1.909	1.114	2.460	13.430	1.785
		STD	0.011	0.070	0.171	0.199	1.805	0.255
	100	Mean	0.067	1.896	0.969	2.475	**15.691**[a]	1.573
		STD	0.013	0.072	0.067	0.185	2.531	0.283
Aroclor-1260	25	Mean	0.073	1.905	1.057	2.422	13.325	1.542
		STD	0.009	0.123	0.098	0.288	2.519	0.254
	50	Mean	0.071	1.910	1.057	2.474	12.342	1.507
		STD	0.014	0.024	0.188	0.278	2.665	0.161
	100	Mean	0.068	1.910	0.998	2.482	11.958	1.652
		STD	0.010	0.093	0.086	0.168	1.394	0.182

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 51. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 13-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)					
			Pituitary Gland	Salivary Glands	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean	0.023	0.395	0.286	0.019	0.123	0.503
		STD	0.005	0.052	0.061	0.003	0.026	0.113
Aroclor-1016	50	Mean	0.022	0.500	0.316	0.019	0.123	0.570
		STD	0.003	0.064	0.097	0.005	0.019	0.131
	100	Mean	0.024	0.425	0.355	0.024	0.118	0.547
		STD	0.006	0.081	0.137	0.006	0.020	0.101
	200	Mean	0.022	0.503	0.289	0.022	0.138	0.544
		STD	0.006	0.044	0.094	0.004	0.026	0.103
Aroclor-1242	50	Mean	0.016	0.395	0.257	0.021	0.138	0.508
		STD	0.004	0.052	0.065	0.005	0.017	0.134
	100	Mean	0.017	0.438	0.281	0.023	0.132	0.482
		STD	0.003	0.057	0.061	0.006	0.023	0.088
Aroclor-1254	25	Mean	0.016	0.417	0.226	0.025	0.131	0.474
		STD	0.004	0.043	0.045	0.005	0.016	0.119
	50	Mean	0.017	0.451	0.283	0.025	0.129	0.559
		STD	0.008	0.092	0.082	0.005	0.020	0.126
	100	Mean	0.017	0.372	0.227	0.030	0.112	0.622
		STD	0.006	0.042	0.035	0.005	0.021	0.232
Aroclor-1260	25	Mean	0.020	0.449	0.316	0.022	0.139	0.532
		STD	0.006	0.073	0.056	0.006	0.018	0.115
	50	Mean	0.021	0.454	0.284	0.024	0.122	0.655
		STD	0.005	0.099	0.048	0.008	0.022	0.278
	100	Mean	0.024	0.453	0.271	0.023	0.118	0.486
		STD	0.007	0.076	0.045	0.008	0.021	0.121

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 51. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 13-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)					
			Adrenal Glands	Brain	Heart	Kidney	Liver	Lungs
Control	0	Mean	0.024	0.625	0.309	0.817	3.850	0.525
		STD	0.003	0.067	0.025	0.031	0.366	0.037
Aroclor-1016	50	Mean	0.023	0.609	0.351	0.807	3.818	0.538
		STD	0.006	0.063	0.034	0.075	0.433	0.044
	100	Mean	0.025	0.656	0.347	0.852	4.268	0.541
		STD	0.004	0.062	0.018	0.076	0.455	0.080
	200	Mean	0.028	0.668	**0.380[a]**	0.885	4.299	0.540
		STD	0.004	0.063	0.033	0.057	0.415	0.082
Aroclor-1242	50	Mean	0.023	0.704	0.344	0.823	3.955	0.556
		STD	0.003	0.049	0.025	0.083	0.418	0.084
	100	Mean	0.020	0.639	**0.358[a]**	0.791	4.299	0.524
		STD	0.003	0.061	0.032	0.059	0.559	0.071
Aroclor-1254	25	Mean	0.020	0.694	**0.359[a]**	0.808	3.984	0.585
		STD	0.004	0.068	0.028	0.072	0.406	0.125
	50	Mean	0.022	0.641	**0.371[a]**	0.824	4.476	0.595
		STD	0.003	0.044	0.030	0.047	0.286	0.051
	100	Mean	0.024	0.693	0.353	0.903	**5.725[a]**	0.571
		STD	0.004	0.052	0.021	0.065	0.937	0.073
Aroclor-1260	25	Mean	0.023	0.601	0.333	0.761	4.182	0.483
		STD	0.003	0.050	0.024	0.043	0.665	0.052
	50	Mean	0.023	0.640	0.350	0.820	4.051	0.502
		STD	0.003	0.072	0.041	0.033	0.339	0.061
	100	Mean	0.023	0.649	0.338	0.844	4.059	0.560
		STD	0.003	0.046	0.019	0.074	0.455	0.044

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 51. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 13-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)					
			Pituitary Gland	Salivary Glands	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean	0.007	0.128	0.092	0.006	0.040	0.162
		STD	0.001	0.021	0.010	0.001	0.008	0.025
Aroclor-1016	50	Mean	0.007	0.157	0.099	0.006	0.039	0.180
		STD	0.001	0.027	0.032	0.002	0.008	0.051
	100	Mean	0.008	0.139	0.114	0.008	0.039	0.179
		STD	0.002	0.024	0.030	0.003	0.006	0.034
	200	Mean	0.008	0.171	0.096	0.007	0.047	0.186
		STD	0.002	0.016	0.021	0.002	0.010	0.036
Aroclor-1242	50	Mean	0.006	0.141	0.091	0.007	0.049	0.180
		STD	0.002	0.014	0.017	0.001	0.005	0.038
	100	Mean	0.006	0.146	0.094	0.008	0.044	0.160
		STD	0.001	0.019	0.021	0.002	0.005	0.025
Aroclor-1254	25	Mean	0.006	0.149	0.081	0.009	0.047	0.171
		STD	0.001	0.018	0.017	0.001	0.005	0.050
	50	Mean	0.005	0.151	0.093	0.008	0.044	0.185
		STD	0.002	0.030	0.019	0.002	0.009	0.029
	100	Mean	0.006	0.136	0.083	**0.011**[a]	0.041	0.226
		STD	0.002	0.015	0.011	0.002	0.008	0.081
Aroclor-1260	25	Mean	0.006	0.143	0.099	0.007	0.044	0.170
		STD	0.002	0.032	0.014	0.002	0.008	0.050
	50	Mean	0.007	0.152	0.095	0.008	0.041	0.217
		STD	0.001	0.040	0.017	0.003	0.010	0.088
	100	Mean	0.008	0.154	0.092	0.008	0.040	0.164
		STD	0.003	0.026	0.012	0.002	0.006	0.034

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 51. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 13-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)					
			Adrenal Glands	Heart	Kidney	Liver	Lungs	Pituitary Gland
Control	0	Mean	3.913	49.741	132.159	623.870	84.981	1.175
		STD	0.378	5.493	16.560	108.120	12.525	0.248
Aroclor-1016	50	Mean	3.800	57.893	132.691	628.334	88.926	1.136
		STD	0.935	5.623	7.695	55.129	8.924	0.172
	100	Mean	3.853	53.269	130.525	656.654	82.584	1.218
		STD	0.793	4.444	13.095	101.145	10.316	0.308
	200	Mean	4.248	57.100	133.049	652.972	81.125	1.122
		STD	0.669	6.328	10.714	126.398	13.724	0.313
Aroclor-1242	50	Mean	3.310	48.971	117.263	564.701	79.668	0.799
		STD	0.520	3.512	13.772	76.773	15.297	0.238
	100	Mean	3.181	56.157	124.377	673.474	82.173	0.877
		STD	0.295	2.554	9.606	62.204	8.583	0.133
Aroclor-1254	25	Mean	2.956	51.982	116.922	577.237	84.337	0.800
		STD	0.460	4.433	10.869	69.701	16.244	0.178
	50	Mean	3.419	58.230	128.814	701.815	93.549	0.866
		STD	0.446	7.379	7.511	71.070	13.708	0.362
	100	Mean	3.511	51.120	130.657	**830.943**[a]	82.973	0.896
		STD	0.683	3.705	10.247	148.632	14.623	0.303
Aroclor-1260	25	Mean	3.872	55.803	127.317	702.234	81.044	1.050
		STD	0.658	7.204	14.838	142.694	13.258	0.278
	50	Mean	3.706	55.290	129.461	645.326	78.855	1.117
		STD	0.706	9.331	13.332	133.467	8.071	0.255
	100	Mean	3.559	52.347	130.312	627.182	86.522	1.237
		STD	0.347	4.814	12.133	74.892	8.774	0.376

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 51. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 13-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)				
			Salivary Glands	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean	20.591	14.904	0.991	6.410	26.247
		STD	2.715	3.111	0.136	1.283	6.022
Aroclor-1016	50	Mean	25.805	16.216	0.963	6.352	29.391
		STD	3.669	4.629	0.268	1.038	7.073
	100	Mean	21.337	17.727	1.182	5.911	27.313
		STD	4.423	6.537	0.343	0.948	4.507
	200	Mean	25.665	14.645	1.101	7.060	27.842
		STD	2.548	4.304	0.220	1.425	5.868
Aroclor-1242	50	Mean	20.122	13.076	1.064	7.029	25.850
		STD	2.638	3.247	0.238	0.845	6.450
	100	Mean	22.884	14.685	1.205	6.891	25.139
		STD	3.228	3.217	0.329	1.121	4.320
Aroclor-1254	25	Mean	21.711	11.843	1.287	6.779	24.709
		STD	3.396	3.095	0.263	0.823	6.809
	50	Mean	23.584	14.748	1.302	6.787	29.197
		STD	4.427	4.013	0.292	1.215	5.915
	100	Mean	19.612	12.025	1.567	5.905	32.526
		STD	1.908	2.129	0.266	1.114	11.187
Aroclor-1260	25	Mean	23.559	16.708	1.132	7.353	28.211
		STD	3.755	3.440	0.288	1.152	7.251
	50	Mean	23.814	14.880	1.240	6.369	34.237
		STD	5.395	2.578	0.443	1.155	14.500
	100	Mean	23.714	14.221	1.189	6.206	25.312
		STD	3.951	2.592	0.357	1.132	5.344

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 52. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)					
			Adrenal Glands	Brain	Heart	Kidneys	Liver	Lungs
Control	0	Mean	0.069	1.946	1.041	2.363	11.597	1.606
		STD	0.017	0.096	0.087	0.250	1.824	0.249
Aroclor-1016	50	Mean	0.086	2.027	1.196	2.781	14.734	1.667
		STD	0.009	0.073	0.120	0.224	1.240	0.166
	100	Mean	0.073	1.990	1.154	2.714	14.865	1.754
		STD	0.013	0.072	0.229	0.434	3.869	0.241
	200	Mean	0.084	1.955	1.046	2.723	13.795	1.546
		STD	0.013	0.090	0.033	0.212	1.191	0.171
Aroclor-1242	50	Mean	0.072	1.949	1.126	2.630	14.267	1.750
		STD	0.009	0.102	0.066	0.432	1.752	0.302
	100	Mean	0.067	1.945	1.075	2.450	12.336	1.675
		STD	0.013	0.046	0.098	0.085	0.991	0.293
Aroclor-1254	25	Mean	0.061	1.943	1.009	2.358	12.403	1.690
		STD	0.009	0.114	0.139	0.195	2.649	0.517
	50	Mean	0.052	1.887	1.064	2.505	13.996	1.566
		STD	0.005	0.097	0.146	0.318	1.621	0.164
	100	Mean	0.068	1.838	1.020	2.721	**15.893[a]**	1.785
		STD	0.017	0.114	0.071	0.329	2.745	0.308
Aroclor-1260	25	Mean	0.077	1.993	1.257	2.775	**15.428[a]**	1.720
		STD	0.009	0.059	0.206	0.300	2.455	0.209
	50	Mean	0.073	2.056	1.145	2.829	**16.418[a]**	1.870
		STD	0.019	0.086	0.058	0.212	1.990	0.248
	100	Mean	0.077	2.003	1.182	**2.851[a]**	**15.907[a]**	1.760
		STD	0.012	0.138	0.215	0.253	2.934	0.051

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 52. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)					
			Pituitary Gland	Salivary Glands	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean	0.027	0.487	0.252	0.024	0.115	0.671
		STD	0.007	0.099	0.075	0.005	0.022	0.145
Aroclor-1016	50	Mean	0.024	0.537	0.360	0.024	0.126	0.697
		STD	0.004	0.115	0.031	0.004	0.032	0.071
	100	Mean	0.029	0.467	0.321	0.025	0.107	0.595
		STD	0.007	0.093	0.095	0.004	0.016	0.127
	200	Mean	0.025	0.471	0.279	0.024	0.102	0.539
		STD	0.004	0.082	0.060	0.003	0.020	0.120
Aroclor-1242	50	Mean	0.023	0.454	0.299	0.025	0.101	0.675
		STD	0.002	0.046	0.111	0.002	0.018	0.171
	100	Mean	0.021	0.435	0.245	0.021	0.130	0.585
		STD	0.003	0.058	0.043	0.003	0.024	0.199
Aroclor-1254	25	Mean	0.022	0.431	0.214	0.024	0.108	0.673
		STD	0.006	0.096	0.069	0.004	0.028	0.113
	50	Mean	0.023	0.427	0.260	0.020	0.103	0.746
		STD	0.003	0.061	0.071	0.004	0.021	0.188
	100	Mean	0.022	0.454	0.222	0.026	0.126	0.735
		STD	0.003	0.109	0.083	0.009	0.038	0.244
Aroclor-1260	25	Mean	0.029	0.552	0.334	0.020	0.132	0.874
		STD	0.003	0.075	0.068	0.004	0.024	0.225
	50	Mean	0.026	0.467	0.343	0.024	0.144	0.676
		STD	0.004	0.043	0.050	0.003	0.029	0.211
	100	Mean	0.028	0.479	0.351	0.025	0.110	0.580
		STD	0.008	0.057	0.174	0.003	0.019	0.164

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 52. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)					
			Adrenal Glands	Brain	Heart	Kidneys	Liver	Lungs
Control	0	Mean	0.022	0.629	0.335	0.761	3.729	0.518
		STD	0.005	0.048	0.011	0.053	0.429	0.081
Aroclor-1016	50	Mean	0.023	0.551	0.326	0.755	3.994	0.452
		STD	0.002	0.054	0.049	0.083	0.379	0.049
	100	Mean	0.020	0.559	0.316	0.753	4.058	0.488
		STD	0.004	0.095	0.015	0.105	0.614	0.068
	200	Mean	0.026	0.601	0.322	0.838	4.237	0.475
		STD	0.004	0.026	0.019	0.083	0.291	0.049
Aroclor-1242	50	Mean	0.023	0.615	0.353	0.814	4.439	0.545
		STD	0.005	0.104	0.049	0.065	0.430	0.086
	100	Mean	0.022	0.624	0.345	0.785	3.936	0.532
		STD	0.006	0.068	0.054	0.086	0.308	0.071
Aroclor-1254	25	Mean	0.020	0.662	0.340	0.802	4.146	0.561
		STD	0.002	0.080	0.023	0.096	0.372	0.094
	50	Mean	0.017	0.623	0.348	0.824	**4.595[a]**	0.515
		STD	0.003	0.070	0.032	0.105	0.421	0.057
	100	Mean	0.024	0.633	0.350	**0.933[a]**	**5.463[a]**	0.609
		STD	0.008	0.069	0.030	0.108	0.979	0.070
Aroclor-1260	25	Mean	0.022	0.578	0.357	0.793	4.393	0.497
		STD	0.004	0.098	0.026	0.058	0.426	0.091
	50	Mean	0.020	0.561	0.312	0.769	4.457	0.507
		STD	0.006	0.055	0.031	0.062	0.459	0.051
	100	Mean	0.022	0.567	0.333	0.803	4.458	0.503
		STD	0.006	0.077	0.058	0.083	0.640	0.095

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 52. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)					
			Pituitary Gland	Salivary Glands	Thymus	Thyroid Gland	Ovary	Uterus
Control	0	Mean	0.009	0.157	0.081	0.008	0.037	0.217
		STD	0.002	0.033	0.021	0.002	0.006	0.050
Aroclor-1016	50	Mean	0.007	0.144	0.099	0.006	0.034	0.189
		STD	0.001	0.016	0.018	0.001	0.008	0.024
	100	Mean	0.008	0.131	0.086	0.007	0.030	0.164
		STD	0.001	0.031	0.014	0.002	0.006	0.027
	200	Mean	0.008	0.144	0.086	0.007	0.031	0.165
		STD	0.001	0.023	0.017	0.001	0.006	0.034
Aroclor-1242	50	Mean	0.007	0.143	0.092	0.008	0.031	0.211
		STD	0.001	0.027	0.028	0.001	0.006	0.059
	100	Mean	0.007	0.140	0.078	0.007	0.041	0.183
		STD	0.001	0.029	0.015	0.001	0.006	0.048
Aroclor-1254	25	Mean	0.007	0.146	0.071	0.008	0.038	0.230
		STD	0.001	0.032	0.017	0.001	0.013	0.050
	50	Mean	0.008	0.141	0.084	0.007	0.035	0.247
		STD	0.001	0.021	0.014	0.002	0.011	0.072
	100	Mean	0.008	0.155	0.077	0.009	0.043	0.251
		STD	0.001	0.034	0.033	0.004	0.011	0.079
Aroclor-1260	25	Mean	0.008	0.160	0.096	0.006	0.037	0.255
		STD	0.002	0.039	0.018	0.002	0.004	0.086
	50	Mean	0.007	0.128	0.093	0.006	0.039	0.185
		STD	0.002	0.023	0.010	0.001	0.010	0.059
	100	Mean	0.008	0.135	0.093	0.007	0.032	0.171
		STD	0.002	0.022	0.030	0.001	0.009	0.075

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 52. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)					
			Adrenal Glands	Heart	Kidneys	Liver	Lungs	Pituitary Gland
Control	0	Mean	3.559	53.543	121.864	598.459	82.249	1.379
		STD	0.987	4.884	16.070	109.253	8.993	0.374
Aroclor-1016	50	Mean	4.217	59.033	157.321	726.428	82.292	1.175
		STD	0.379	5.569	11.118	44.262	8.374	0.204
	100	Mean	3.654	57.795	136.124	743.908	88.063	1.445
		STD	0.596	9.927	18.894	175.596	10.770	0.303
	200	Mean	4.306	53.593	139.923	705.946	79.347	1.301
		STD	0.688	2.776	17.093	55.212	10.720	0.224
Aroclor-1242	50	Mean	3.668	57.960	135.767	737.024	89.766	1.183
		STD	0.317	5.504	27.678	126.400	14.242	0.136
	100	Mean	3.468	55.282	126.068	634.642	86.025	1.056
		STD	0.709	5.190	6.864	56.784	14.417	0.167
Aroclor-1254	25	Mean	3.116	51.981	121.636	637.487	87.135	1.129
		STD	0.468	6.960	11.975	124.982	26.037	0.255
	50	Mean	2.767	56.233	132.934	742.817	83.014	1.223
		STD	0.368	5.686	17.421	89.551	7.789	0.201
	100	Mean	3.703	55.578	148.015	**867.828**[a]	96.805	1.227
		STD	0.813	4.136	15.357	166.974	12.422	0.162
Aroclor-1260	25	Mean	3.840	63.275	139.556	777.412	86.473	1.451
		STD	0.474	11.750	17.879	142.651	11.486	0.201
	50	Mean	3.547	55.815	137.627	**800.541**[a]	90.833	1.273
		STD	0.982	4.246	9.483	113.590	10.463	0.212
	100	Mean	3.888	59.220	142.443	**795.804**[a]	88.244	1.403
		STD	0.854	11.082	9.913	144.097	7.235	0.364

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 52. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 26-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)				
			Salivary Glands	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean	25.044	12.979	1.228	5.893	34.720
		STD	5.209	3.899	0.261	0.968	8.715
Aroclor-1016	50	Mean	26.468	17.774	1.161	6.206	34.325
		STD	5.211	1.862	0.202	1.526	2.662
	100	Mean	23.447	16.032	1.273	5.382	29.726
		STD	4.512	4.449	0.202	0.826	5.421
	200	Mean	24.111	14.236	1.239	5.197	27.489
		STD	4.158	2.664	0.151	0.897	5.623
Aroclor-1242	50	Mean	23.274	15.450	1.280	5.186	34.831
		STD	2.214	6.117	0.159	0.988	9.537
	100	Mean	22.366	12.582	1.089	6.699	30.132
		STD	3.080	2.287	0.180	1.289	10.392
Aroclor-1254	25	Mean	22.213	11.032	1.225	5.592	34.964
		STD	5.167	3.539	0.153	1.525	7.626
	50	Mean	22.613	13.755	1.042	5.472	39.376
		STD	2.925	3.596	0.230	1.167	8.844
	100	Mean	24.612	12.048	1.405	6.907	39.866
		STD	5.145	4.459	0.398	2.248	12.422
Aroclor-1260	25	Mean	27.719	16.842	1.013	6.634	43.763
		STD	3.943	3.748	0.208	1.324	10.982
	50	Mean	22.759	16.723	1.150	7.034	32.585
		STD	2.669	2.644	0.121	1.593	8.995
	100	Mean	24.045	17.237	1.246	5.560	29.476
		STD	3.404	7.851	0.182	1.248	10.489

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 53. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 39-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)					
			Adrenal Glands	Brain	Heart	Kidney	Liver	Lungs
Control	0	Mean	0.077	1.956	1.160	2.762	13.482	1.964
		STD	0.013	0.060	0.173	0.262	2.002	0.303
Aroclor-1016	50	Mean	0.089	1.952	1.209	2.917	14.337	1.900
		STD	0.018	0.102	0.079	0.369	2.472	0.202
	100	Mean	0.078	2.009	1.232	2.808	14.335	1.910
		STD	0.023	0.142	0.153	0.530	2.857	0.407
	200	Mean	0.091	2.080	1.331	3.254	16.225	1.882
		STD	0.011	0.208	0.119	0.270	1.064	0.184
Aroclor-1242	50	Mean	0.077	1.972	1.257	3.105	16.080	1.964
		STD	0.013	0.114	0.111	0.281	2.244	0.179
	100	Mean	0.076	1.960	1.199	2.957	15.945	2.017
		STD	0.016	0.080	0.117	0.492	3.089	0.623
Aroclor-1254	25	Mean	0.064	1.948	1.231	2.756	14.129	1.892
		STD	0.009	0.098	0.128	0.379	2.173	0.174
	50	Mean	0.077	1.917	1.103	2.771	16.352	1.717
		STD	0.031	0.096	0.179	0.582	4.832	0.279
	100	Mean	0.066	1.928	1.085	2.881	16.874	1.686
		STD	0.015	0.044	0.190	0.542	4.006	0.264
Aroclor-1260	25	Mean	0.082	2.041	1.263	2.971	15.957	2.155
		STD	0.015	0.047	0.148	0.277	4.240	0.427
	50	Mean	0.079	1.981	1.290	3.172	16.872	2.006
		STD	0.028	0.124	0.200	0.357	2.959	0.318
	100	Mean	0.072	1.927	1.270	2.913	15.832	2.034
		STD	0.016	0.122	0.185	0.393	3.960	0.496

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 53. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 39-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)					
			Pituitary Gland	Salivary Glands	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean	0.032	0.433	0.261	0.037	0.087	0.845
		STD	0.006	0.049	0.090	0.008	0.026	0.354
Aroclor-1016	50	Mean	0.027	0.465	0.373	0.036	0.122	0.724
		STD	0.002	0.111	0.057	0.007	0.026	0.165
	100	Mean	0.028	0.432	0.288	0.038	0.120	0.754
		STD	0.005	0.064	0.041	0.009	0.028	0.191
	200	Mean	0.031	0.525	0.336	0.041	0.108	0.825
		STD	0.004	0.072	0.086	0.004	0.017	0.099
Aroclor-1242	50	Mean	0.030	0.513	0.341	0.034	0.133	0.692
		STD	0.014	0.089	0.147	0.005	0.041	0.059
	100	Mean	0.029	0.431	0.316	0.039	0.110	0.861
		STD	0.006	0.031	0.055	0.008	0.020	0.293
Aroclor-1254	25	Mean	0.024	0.444	0.407	0.034	0.112	0.781
		STD	0.005	0.062	0.184	0.004	0.019	0.107
	50	Mean	0.024	0.450	0.274	0.034	0.114	0.746
		STD	0.007	0.057	0.068	0.005	0.019	0.104
	100	Mean	0.024	0.377	0.246	0.039	0.092	0.960
		STD	0.007	0.084	0.088	0.006	0.008	0.234
Aroclor-1260	25	Mean	0.038	0.465	0.399	0.036	0.098	0.712
		STD	0.014	0.066	0.208	0.005	0.020	0.156
	50	Mean	0.033	0.533	0.367	0.034	0.124	0.881
		STD	0.008	0.052	0.137	0.008	0.061	0.256
	100	Mean	0.027	0.491	0.296	0.037	0.097	0.750
		STD	0.005	0.054	0.046	0.008	0.027	0.134

N = 6

a. Statistically significant from control at $p \leq 0.05$.

b. Statistically significant from control at $p \leq 0.01$.

Table 53. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 39-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)					
			Adrenal Glands	Brain	Heart	Kidney	Liver	Lungs
Control	0	Mean	0.022	0.577	0.339	0.810	3.929	0.575
		STD	0.003	0.065	0.042	0.078	0.349	0.072
Aroclor-1016	50	Mean	0.024	0.534	0.330	0.793	3.882	0.517
		STD	0.005	0.069	0.029	0.092	0.490	0.050
	100	Mean	0.021	0.555	0.337	0.765	3.888	0.518
		STD	0.006	0.070	0.020	0.085	0.358	0.057
	200	Mean	0.024	0.553	0.351	0.860	4.281	0.496
		STD	0.003	0.094	0.023	0.081	0.160	0.021
Aroclor-1242	50	Mean	0.020	0.496	0.314	0.786	4.012	0.497
		STD	0.005	0.076	0.034	0.166	0.527	0.104
	100	Mean	0.020	0.535	0.326	0.801	4.308	0.546
		STD	0.003	0.051	0.022	0.096	0.556	0.153
Aroclor-1254	25	Mean	0.018	0.539	0.335	0.747	3.842	0.519
		STD	0.004	0.104	0.032	0.054	0.473	0.076
	50	Mean	0.024	0.620	0.350	0.877	5.204	0.548
		STD	0.008	0.119	0.041	0.132	1.516	0.084
	100	Mean	0.022	0.644	0.357	0.944	**5.524**[b]	0.558
		STD	0.003	0.088	0.035	0.068	0.831	0.072
Aroclor-1260	25	Mean	0.021	0.536	0.327	0.772	4.013	0.551
		STD	0.004	0.111	0.046	0.120	0.471	0.066
	50	Mean	0.020	0.510	0.329	0.813	4.293	0.512
		STD	0.005	0.049	0.025	0.060	0.351	0.048
	100	Mean	0.020	0.527	0.341	0.788	4.265	0.537
		STD	0.007	0.117	0.050	0.150	1.167	0.086

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 53. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 39-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)					
			Pituitary Gland	Salivary Glands	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean	0.009	0.127	0.075	0.011	0.025	0.246
		STD	0.002	0.019	0.020	0.002	0.007	0.099
Aroclor-1016	50	Mean	0.007	0.127	0.102	0.010	0.033	0.195
		STD	0.001	0.032	0.015	0.002	0.009	0.037
	100	Mean	0.008	0.120	0.079	0.010	0.033	0.206
		STD	0.001	0.025	0.004	0.001	0.007	0.047
	200	Mean	0.008	0.140	0.088	0.011	0.028	0.218
		STD	0.001	0.025	0.020	0.002	0.004	0.031
Aroclor-1242	50	Mean	0.007	0.127	0.083	0.009	0.033	0.175
		STD	0.003	0.020	0.025	0.002	0.010	0.036
	100	Mean	0.008	0.118	0.086	0.011	0.030	0.233
		STD	0.001	0.016	0.012	0.002	0.005	0.070
Aroclor-1254	25	Mean	0.007	0.122	0.106	0.009	0.031	0.216
		STD	0.001	0.024	0.030	0.001	0.007	0.048
	50	Mean	0.008	0.144	0.087	0.011	0.037	0.239
		STD	0.002	0.020	0.020	0.003	0.009	0.040
	100	Mean	0.008	0.123	0.080	0.013	0.031	0.315
		STD	0.001	0.019	0.018	0.003	0.005	0.057
Aroclor-1260	25	Mean	0.010	0.122	0.097	0.010	0.025	0.182
		STD	0.004	0.027	0.035	0.002	0.005	0.028
	50	Mean	0.008	0.137	0.092	0.009	0.033	0.224
		STD	0.001	0.012	0.027	0.002	0.019	0.055
	100	Mean	0.007	0.133	0.079	0.010	0.026	0.204
		STD	0.002	0.025	0.003	0.003	0.005	0.054

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 53. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 39-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)					
			Adrenal Glands	Heart	Kidney	Liver	Lungs	Pituitary Gland
Control	0	Mean	3.931	59.486	141.325	689.673	100.353	1.633
		STD	0.732	10.116	14.660	102.979	14.796	0.286
Aroclor-1016	50	Mean	4.567	62.130	150.284	737.907	97.276	1.398
		STD	0.945	5.949	24.327	147.511	8.740	0.174
	100	Mean	3.823	61.250	139.024	710.672	95.110	1.402
		STD	0.880	5.577	18.559	115.738	20.100	0.221
	200	Mean	4.414	64.685	158.543	789.137	91.592	1.522
		STD	0.736	9.381	25.618	111.573	14.852	0.245
Aroclor-1242	50	Mean	3.918	63.747	157.651	814.914	99.819	1.521
		STD	0.657	4.292	14.643	98.591	10.076	0.765
	100	Mean	3.838	61.091	150.602	810.443	102.917	1.449
		STD	0.686	4.226	22.134	131.017	31.357	0.279
Aroclor-1254	25	Mean	3.318	63.426	142.053	729.760	97.345	1.242
		STD	0.554	8.564	23.423	139.573	10.978	0.308
	50	Mean	4.047	57.923	145.808	861.486	90.150	1.265
		STD	1.793	11.683	36.347	282.620	17.725	0.424
	100	Mean	3.422	56.203	149.027	873.592	87.396	1.231
		STD	0.725	9.276	25.093	200.784	13.286	0.333
Aroclor-1260	25	Mean	4.016	61.819	145.522	780.213	105.539	1.831
		STD	0.665	6.694	12.476	201.964	20.485	0.673
	50	Mean	4.013	65.251	160.067	850.556	101.263	1.674
		STD	1.413	10.242	14.820	133.455	14.949	0.403
	100	Mean	3.749	66.145	151.134	818.328	105.654	1.413
		STD	0.803	10.943	16.885	173.956	24.917	0.223

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 53. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 39-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)				
			Salivary Glands	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean	22.123	13.417	1.893	4.467	43.373
		STD	2.404	4.805	0.416	1.412	18.814
Aroclor-1016	50	Mean	23.716	19.098	1.855	6.204	37.319
		STD	5.083	2.527	0.433	1.106	9.187
	100	Mean	21.499	14.351	1.893	5.994	37.474
		STD	2.644	2.143	0.375	1.306	8.403
	200	Mean	25.537	16.388	1.981	5.274	39.944
		STD	5.024	4.510	0.291	1.145	6.154
Aroclor-1242	50	Mean	25.932	17.051	1.725	6.681	35.174
		STD	3.926	6.252	0.225	1.746	3.357
	100	Mean	21.977	16.065	1.974	5.595	43.685
		STD	1.323	2.280	0.388	0.993	13.705
Aroclor-1254	25	Mean	22.870	21.103	1.765	5.750	40.333
		STD	3.939	10.176	0.224	0.965	6.911
	50	Mean	23.586	14.346	1.745	5.922	39.093
		STD	3.678	3.752	0.228	0.987	6.599
	100	Mean	19.469	12.683	2.008	4.803	49.651
		STD	4.073	4.232	0.346	0.511	11.657
Aroclor-1260	25	Mean	22.752	19.506	1.780	4.809	34.814
		STD	3.104	10.090	0.255	0.922	7.386
	50	Mean	26.863	18.299	1.703	6.229	44.177
		STD	1.864	6.189	0.347	2.900	11.517
	100	Mean	25.671	15.421	1.950	5.110	39.066
		STD	4.035	2.753	0.457	1.753	7.466

N = 6
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 54. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)						
			Adrenal Glands	Brain	Heart	Kidneys	Liver	Lungs	Pituitary Gland
Control	0	Mean	0.106	2.044	1.422	3.126	16.026	2.159	0.095
		STD	0.023	0.134	0.203	0.373	2.382	0.369	0.106
Aroclor-1016	50	Mean	0.082	1.970	1.277	3.064	14.499	1.972	0.046
		STD	0.016	0.113	0.149	0.323	2.231	0.190	0.024
	100	Mean	0.090	2.055	1.321	3.107	15.065	2.035	0.039
		STD	0.023	0.058	0.042	0.480	2.298	0.491	0.011
	200	Mean	0.108	2.029	1.368	3.811	18.138	2.524	0.035
		STD	0.027	0.107	0.194	1.158	4.791	0.460	0.003
Aroclor-1242	50	Mean	0.075	1.980	1.375	3.117	15.794	2.289	0.026
		STD	0.009	0.140	0.152	0.307	3.246	0.370	0.006
	100	Mean[1]	0.073	2.163	1.229	3.123	16.328	2.149	0.028
		STD	0.011	0.253	0.222	0.513	2.372	0.495	0.007
Aroclor-1254	25	Mean	**0.071**[a]	2.017	1.327	3.045	17.472	2.026	0.032
		STD	0.008	0.143	0.165	0.274	4.531	0.382	0.007
	50	Mean	**0.069**[a]	2.017	1.218	3.127	18.389	1.918	0.030
		STD	0.018	0.151	0.204	0.382	3.275	0.464	0.007
	100	Mean[1]	0.078	2.009	1.283	3.033	18.825	2.204	0.031
		STD	0.016	0.058	0.198	0.474	1.843	0.514	0.011
Aroclor-1260	25	Mean	0.079	1.983	1.326	3.043	17.076	2.074	0.029
		STD	0.014	0.165	0.227	0.413	2.359	0.442	0.005
	50	Mean[1]	0.088	2.000	1.145	2.998	14.573	1.775	0.026
		STD	0.020	0.107	0.101	0.258	1.899	0.355	0.004
	100	Mean	0.096	1.942	1.335	3.407	18.941	2.084	0.036
		STD	0.033	0.067	0.178	0.388	4.873	0.294	0.005

N = 6 unless otherwise noted.
1. N = 5 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 54. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)					
			Salivary Glands	Spleen	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean	0.558	0.664	0.385	0.029	0.098	0.887
		STD	0.065	0.115	0.152	0.002	0.047	0.292
Aroclor-1016	50	Mean	0.450	0.630	0.335	0.030	0.100	0.700
		STD	0.089	0.126	0.142	0.006	0.026	0.117
	100	Mean	0.462	0.565	0.358	0.030	0.091	0.837
		STD	0.062	0.087	0.150	0.003	0.034	0.185
	200	Mean	0.487	0.623	0.277	0.035	0.108	1.084
		STD	0.019	0.124	0.134	0.008	0.053	0.518
Aroclor-1242	50	Mean	0.503	0.608	0.385	0.030	0.129	0.683
		STD	0.066	0.165	0.187	0.004	0.068	0.146
	100	Mean[1]	**0.414[a]**	0.534	0.352	0.033	0.098	0.754
		STD	0.095	0.104	0.206	0.009	0.037	0.163
Aroclor-1254	25	Mean	0.466	0.582	0.503	0.030	0.096	0.723
		STD	0.102	0.087	0.278	0.005	0.024	0.148
	50	Mean	**0.414[a]**	0.498	0.303	0.032	0.097	0.812
		STD	0.055	0.047	0.065	0.004	0.017	0.215
	100	Mean[1]	**0.375[a]**	0.577	0.217	0.033	0.174	0.920
		STD	0.066	0.072	0.085	0.006	0.171	0.261
Aroclor-1260	25	Mean	0.479	0.562	0.373	0.035	0.084	0.770
		STD	0.078	0.087	0.153	0.006	0.019	0.148
	50	Mean[1]	0.465	0.507	0.273	0.027	0.100	0.655
		STD	0.053	0.148	0.110	0.004	0.034	0.198
	100	Mean	0.491	0.601	0.407	0.036	0.129	0.945
		STD	0.064	0.122	0.048	0.010	0.021	0.210

N = 6 unless otherwise noted.
1. N = 5 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 54. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)						
			Adrenal Glands	Brain	Heart	Kidneys	Liver	Lungs	Pituitary Gland
Control	0	Mean	0.024	0.467	0.321	0.706	3.598	0.494	0.021
		STD	0.007	0.076	0.038	0.074	0.274	0.117	0.023
Aroclor-1016	50	Mean	0.021	0.510	0.332	0.790	3.718	0.509	0.012
		STD	0.005	0.061	0.061	0.078	0.360	0.056	0.006
	100	Mean	0.023	0.518	0.333	0.773	3.756	0.522	0.010
		STD	0.008	0.069	0.049	0.086	0.477	0.195	0.002
	200	Mean	0.025	0.477	0.320	0.862	4.100	0.582	0.008
		STD	0.004	0.092	0.067	0.136	0.502	0.091	0.001
Aroclor-1242	50	Mean	0.017	0.453	0.311	0.709	3.552	0.523	0.006
		STD	0.004	0.068	0.025	0.086	0.518	0.107	0.002
	100	Mean[1]	0.019	0.572	0.324	0.820	4.298	0.590	0.007
		STD	0.003	0.063	0.047	0.077	0.381	0.237	0.001
Aroclor-1254	25	Mean	0.016	0.464	0.303	0.699	3.896	0.457	0.007
		STD	0.004	0.070	0.037	0.106	0.255	0.040	0.003
	50	Mean	0.020	0.576	0.343	**0.878[a]**	**5.156[a]**	0.536	0.008
		STD	0.006	0.107	0.048	0.056	0.575	0.105	0.002
	100	Mean[1]	0.024	**0.629[a]**	0.399	**0.946[a]**	**5.885[a]**	0.685	0.010
		STD	0.004	0.058	0.044	0.146	0.740	0.143	0.004
Aroclor-1260	25	Mean	0.019	0.483	0.314	0.731	4.085	0.501	0.007
		STD	0.003	0.124	0.034	0.152	0.745	0.143	0.001
	50	Mean[1]	0.025	0.559	0.321	0.834	4.050	0.494	0.007
		STD	0.008	0.067	0.050	0.082	0.529	0.106	0.002
	100	Mean	0.022	0.455	0.309	0.790	4.332	0.482	0.008
		STD	0.006	0.059	0.015	0.037	0.667	0.037	0.001

N = 6 unless otherwise noted.
1. N = 5 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 54. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)					
			Salivary Glands	Spleen	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean	0.127	0.150	0.088	0.007	0.022	0.201
		STD	0.024	0.029	0.039	0.001	0.011	0.070
Aroclor-1016	50	Mean	0.116	0.160	0.084	0.008	0.025	0.180
		STD	0.021	0.017	0.028	0.001	0.005	0.028
	100	Mean	0.117	0.142	0.088	0.008	0.023	0.213
		STD	0.026	0.030	0.035	0.001	0.010	0.066
	200	Mean	0.115	0.143	0.064	0.008	0.024	0.270
		STD	0.026	0.021	0.028	0.002	0.007	0.191
Aroclor-1242	50	Mean	0.114	0.136	0.085	0.007	0.028	0.160
		STD	0.021	0.025	0.034	0.002	0.011	0.054
	100	Mean[1]	0.112	0.141	0.090	0.009	0.025	0.197
		STD	0.036	0.025	0.044	0.001	0.007	0.022
Aroclor-1254	25	Mean	0.109	0.132	0.109	0.007	0.022	0.170
		STD	0.033	0.016	0.043	0.002	0.008	0.056
	50	Mean	0.119	0.141	0.085	0.009	0.027	0.229
		STD	0.028	0.020	0.013	0.002	0.004	0.060
	100	Mean[1]	0.119	0.180	0.066	**0.011[a]**	0.056	0.281
		STD	0.033	0.022	0.018	0.003	0.058	0.046
Aroclor-1260	25	Mean	0.116	0.135	0.088	0.008	0.020	0.186
		STD	0.034	0.027	0.033	0.002	0.005	0.045
	50	Mean[1]	0.130	0.140	0.076	0.008	0.027	0.184
		STD	0.022	0.039	0.032	0.001	0.006	0.062
	100	Mean	0.114	0.138	0.095	0.008	0.030	0.219
		STD	0.006	0.014	0.010	0.002	0.002	0.043

N = 6 unless otherwise noted.
1. N = 5 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 54. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)					
			Adrenal Glands	Heart	Kidneys	Liver	Lungs	Pituitary Gland
Control	0	Mean	5.214	69.812	153.349	788.590	106.337	4.936
		STD	1.279	10.640	18.740	137.300	22.322	5.732
Aroclor-1016	50	Mean	4.169	64.829	155.938	737.462	100.403	2.359
		STD	0.779	6.3[illegible]	18.372	117.452	11.387	1.282
	100	Mean	4.37[illegible]	64.364	151.443	733.940	99.395	1.904
		STD	1.248	3.3[illegible]4	24.837	117.196	25.836	0.502
	200	Mean	5.312	67.349	186.508	890.232	124.873	1.726
		STD	1.333	8.031	49.366	210.098	25.935	0.107
Aroclor-1242	50	Mean	3.806	69.394	158.197	800.352	115.349	1.351
		STD	0.673	5.537	19.706	168.375	13.279	0.389
	100	Mean[1]	**3.393[a]**	56.562	144.562	754.976	101.676	1.290
		STD	0.432	4.636	18.782	65.152	32.366	0.376
Aroclor-1254	25	Mean	**3.499[a]**	65.656	151.444	862.072	100.204	1.568
		STD	0.355	5.135	15.473	183.903	14.914	0.386
	50	Mean	**3.380[a]**	60.384	155.885	909.960	95.218	1.464
		STD	0.722	8.589	23.115	127.720	21.285	0.333
	100	Mean[1]	3.877	63.782	150.881	936.644	109.488	1.520
		STD	0.729	8.714	22.389	82.328	23.895	0.519
Aroclor-1260	25	Mean	4.021	67.376	153.530	862.310	104.172	1.440
		STD	0.790	13.294	18.317	110.762	18.207	0.268
	50	Mean[1]	4.456	57.304	150.058	728.120	88.472	1.297
		STD	1.203	4.579	12.513	78.373	14.867	0.190
	100	Mean	4.967	68.778	175.593	977.916	107.451	1.834
		STD	1.708	9.178	20.029	258.142	15.178	0.281

N = 6 unless otherwise noted.
1. N = 5 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 54. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 52-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)					
			Salivary Glands	Spleen	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean	27.535	32.813	18.830	1.435	4.862	43.679
		STD	4.841	7.433	7.195	0.163	2.524	15.640
Aroclor-1016	50	Mean	22.770	31.789	16.949	1.535	5.046	35.698
		STD	4.074	4.798	7.022	0.301	1.157	6.758
	100	Mean	22.484	27.438	17.320	1.470	4.403	40.775
		STD	3.177	3.910	7.098	0.163	1.571	8.878
	200	Mean	24.050	30.552	13.670	1.745	5.291	54.030
		STD	1.601	5.048	6.516	0.415	2.434	27.193
Aroclor-1242	50	Mean	25.457	30.836	19.261	1.519	6.532	34.764
		STD	3.602	8.367	9.072	0.216	3.462	8.714
	100	Mean[1]	**19.698**[a]	24.708	15.749	1.527	4.469	34.869
		STD	6.505	3.711	7.693	0.449	1.346	6.786
Aroclor-1254	25	Mean	23.164	28.810	24.357	1.492	4.796	36.011
		STD	5.197	3.361	12.117	0.248	1.399	8.098
	50	Mean	**20.720**[a]	24.716	15.117	1.568	4.809	39.840
		STD	3.976	2.191	3.711	0.235	0.735	8.060
	100	Mean[1]	**18.730**[a]	28.674	10.724	1.668	8.708	45.557
		STD	3.737	3.064	3.968	0.319	8.740	11.828
Aroclor-1260	25	Mean	24.096	28.425	19.277	1.750	4.250	39.355
		STD	2.810	4.801	8.926	0.349	0.974	9.710
	50	Mean[1]	23.277	25.460	13.459	1.367	5.040	32.680
		STD	2.431	7.463	5.025	0.161	1.818	9.090
	100	Mean	25.319	31.056	20.946	1.829	6.652	48.576
		STD	3.586	6.652	2.314	0.512	1.155	9.986

N = 6 unless otherwise noted.
1. N = 5 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 55. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)							
			Adrenal Glands	Brain	Heart	Kidney	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean[3]	0.187	2.092	1.712	3.675	18.517	1.683	0.075	0.495
		STD	0.147	0.040	0.407	1.291	9.048	0.305	0.033	0.079
Aroclor-1016	50	Mean[1]	0.094	2.010	1.276	2.983	15.418	1.634	0.092	0.514
		STD	0.022	0.092	0.144	0.386	2.626	0.182	0.043	0.057
	100	Mean	0.471	1.998	1.523	3.698	19.648	2.012	0.080	0.556
		STD	0.653	0.137	0.199	0.317	2.581	0.446	0.038	0.047
	200	Mean	0.106	1.970	1.467	3.613	18.427	2.025	0.046	0.543
		STD	0.035	0.117	0.250	0.780	4.112	0.304	0.008	0.054
Aroclor-1242	50	Mean[1]	0.179	1.996	1.418	2.975	16.213	1.710	0.059	0.564
		STD	0.196	0.085	0.138	0.492	2.337	0.202	0.047	0.059
	100	Mean[1]	0.085	1.957	1.401	2.984	18.123	1.702	0.089	0.412
		STD	0.015	0.092	0.133	0.201	2.160	0.175	0.077	0.075
Aroclor-1254	25	Mean[2]	0.066	1.955	1.299	3.143	18.882	1.796	0.044	0.472
		STD	0.011	0.036	0.059	0.361	5.212	0.278	0.015	0.043
	50	Mean	0.097	1.987	1.482	3.231	22.092	1.972	0.189	0.489
		STD	0.063	0.070	0.186	0.321	1.887	0.291	0.151	0.067
	100	Mean[1]	0.067	1.973	1.564	3.289	29.600	2.148	0.054	0.425
		STD	0.010	0.116	0.100	0.496	16.000	0.394	0.031	0.067
Aroclor-1260	25	Mean[1]	0.099	1.985	1.431	3.329	17.702	1.617	0.053	0.455
		STD	0.041	0.086	0.211	0.946	4.415	0.235	0.036	0.054
	50	Mean	0.088	2.026	1.420	3.403	18.508	1.683	0.115	0.543
		STD	0.027	0.084	0.264	1.004	6.674	0.332	0.104	0.072
	100	Mean	0.092	1.974	1.364	2.957	18.011	1.661	0.051	0.503
		STD	0.015	0.059	0.172	0.265	4.175	0.137	0.015	0.058

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 55. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)				
			Spleen	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean[3]	1.117	0.299	0.054	0.117	0.888
		STD	0.773	0.019	0.003	0.005	0.262
Aroclor-1016	50	Mean[1]	0.651	0.433	0.047	0.106	1.009
		STD	0.105	0.080	0.014	0.011	0.331
	100	Mean	0.823	0.539	0.045	0.118	0.801
		STD	0.177	0.392	0.009	0.022	0.144
	200	Mean	1.011	0.483	0.051	0.142	1.126
		STD	0.900	0.174	0.012	0.031	0.476
Aroclor-1242	50	Mean[1]	0.679	0.532	0.057	0.335	0.761
		STD	0.102	0.126	0.010	0.519	0.200
	100	Mean[1]	0.645	0.455	0.046	0.097	0.917
		STD	0.079	0.360	0.008	0.014	0.239
Aroclor-1254	25	Mean[2]	0.635	0.396	0.043	0.114	1.044
		STD	0.052	0.157	0.004	0.016	0.316
	50	Mean	0.715	0.477	0.043	0.228	0.910
		STD	0.072	0.230	0.005	0.230	0.235
	100	Mean[1]	0.745	0.381	0.044	0.166	1.819
		STD	0.194	0.056	0.007	0.084	1.123
Aroclor-1260	25	Mean[1]	0.641	0.424	0.049	0.131	0.941
		STD	0.095	0.124	0.013	0.038	0.375
	50	Mean	0.665	0.439	0.048	0.115	1.020
		STD	0.142	0.232	0.010	0.044	0.669
	100	Mean	0.615	0.400	0.047	0.118	1.080
		STD	0.103	0.114	0.013	0.030	0.280

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 55. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)							
			Adrenal Glands	Brain	Heart	Kidney	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean[3]	0.030	0.394	0.311	0.653	3.201	0.307	0.014	0.092
		STD	0.014	0.102	0.060	0.086	0.604	0.038	0.008	0.023
Aroclor-1016	50	Mean[1]	0.021	0.438	0.277	0.648	3.325	0.358	0.020	0.112
		STD	0.007	0.049	0.030	0.079	0.336	0.065	0.010	0.014
	100	Mean	0.098	0.385	0.289	0.707	3.754	0.380	0.016	0.108
		STD	0.151	0.070	0.028	0.099	0.671	0.074	0.009	0.024
	200	Mean	0.019	0.378	0.272	0.668	3.380	0.376	0.009	0.103
		STD	0.004	0.096	0.026	0.095	0.229	0.033	0.003	0.022
Aroclor-1242	50	Mean[1]	0.033	0.398	0.279	0.584	3.192	0.335	0.012	0.112
		STD	0.033	0.074	0.019	0.088	0.466	0.019	0.009	0.018
	100	Mean[1]	0.021	0.488	0.349	0.745	4.485	0.424	0.024	0.103
		STD	0.002	0.073	0.054	0.115	0.521	0.064	0.026	0.023
Aroclor-1254	25	Mean[2]	0.016	0.467	0.310	0.752	4.548	0.427	0.011	0.113
		STD	0.003	0.035	0.024	0.111	1.492	0.051	0.004	0.017
	50	Mean	0.025	0.476	0.354	0.771	5.321	0.469	0.049	0.116
		STD	0.019	0.063	0.056	0.108	1.027	0.070	0.045	0.010
	100	Mean[1]	0.019	0.544	**0.430[a]**	0.901	7.899	0.602	0.015	0.116
		STD	0.005	0.075	0.055	0.143	3.578	0.199	0.008	0.014
Aroclor-1260	25	Mean[1]	0.021	0.451	0.318	0.750	3.892	0.359	0.013	0.105
		STD	0.008	0.115	0.064	0.292	1.043	0.063	0.010	0.034
	50	Mean	0.019	0.449	0.308	0.736	3.910	0.364	0.027	0.122
		STD	0.002	0.089	0.039	0.197	0.957	0.040	0.026	0.038
	100	Mean	0.020	0.436	0.300	0.649	3.919	0.365	0.011	0.111
		STD	0.003	0.046	0.038	0.033	0.657	0.030	0.003	0.017

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 55. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)				
			Spleen	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean[3]	0.186	0.057	0.010	0.022	0.160
		STD	0.073	0.018	0.003	0.005	0.026
Aroclor-1016	50	Mean[1]	0.141	0.094	0.010	0.023	0.215
		STD	0.021	0.017	0.002	0.003	0.054
	100	Mean	0.156	0.095	0.008	0.022	0.153
		STD	0.035	0.053	0.001	0.002	0.035
	200	Mean	0.172	0.091	0.009	0.027	0.211
		STD	0.111	0.037	0.003	0.008	0.086
Aroclor-1242	50	Mean[1]	0.133	0.105	0.011	0.061	0.153
		STD	0.017	0.029	0.001	0.089	0.052
	100	Mean[1]	0.162	0.103	0.011	0.024	0.225
		STD	0.037	0.058	0.002	0.003	0.053
Aroclor-1254	25	Mean[2]	0.151	0.094	0.010	0.027	0.251
		STD	0.010	0.036	0	0.004	0.085
	50	Mean	0.173	0.109	0.010	0.052	0.211
		STD	0.037	0.044	0.002	0.050	0.028
	100	Mean[1]	0.204	0.104	0.012	0.045	0.529
		STD	0.051	0.016	0.001	0.022	0.388
Aroclor-1260	25	Mean[1]	0.143	0.091	0.011	0.029	0.217
		STD	0.034	0.009	0.003	0.007	0.113
	50	Mean	0.143	0.089	0.010	0.024	0.208
		STD	0.018	0.024	0.001	0.005	0.087
	100	Mean	0.134	0.087	0.010	0.026	0.240
		STD	0.007	0.018	0.002	0.006	0.073

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 55. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)						
			Adrenal Glands	Heart	Kidney	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean[3]	8.920	81.643	175.800	885.420	80.465	3.621	23.634
		STD	7.006	18.568	62.044	432.615	14.676	1.635	3.366
Aroclor-1016	50	Mean[1]	4.683	63.644	148.304	765.421	81.448	4.519	25.605
		STD	1.209	7.945	16.369	109.651	10.089	2.009	3.086
	100	Mean	23.577	76.450	185.289	984.231	100.874	3.931	27.911
		STD	32.037	10.784	13.302	115.817	22.624	1.706	2.689
	200	Mean	5.456	75.322	185.889	947.224	103.799	2.315	27.685
		STD	2.153	17.721	51.805	268.233	21.314	0.353	3.703
Aroclor-1242	50	Mean[1]	9.341	71.255	149.555	814.490	85.929	2.947	28.362
		STD	10.770	8.597	27.198	128.129	11.973	2.291	3.626
	100	Mean[1]	4.346	71.583	152.763	924.747	86.970	4.608	21.102
		STD	0.691	5.007	12.866	84.737	7.637	4.185	3.843
Aroclor-1254	25	Mean[2]	3.390	66.448	160.706	964.069	91.929	2.271	24.158
		STD	0.539	3.106	17.114	252.632	14.861	0.800	2.037
	50	Mean	4.974	74.548	162.712	1112.619	99.115	9.647	24.579
		STD	3.471	9.007	16.766	99.400	13.274	7.901	3.239
	100	Mean[1]	3.435	79.407	166.085	1501.796	109.958	2.707	21.630
		STD	0.709	5.956	16.725	833.612	26.435	1.485	3.828
Aroclor-1260	25	Mean[1]	4.960	72.315	167.440	890.427	81.804	2.662	22.947
		STD	1.915	12.091	45.054	213.436	14.446	1.722	2.625
	50	Mean	4.325	69.833	167.298	908.302	82.860	5.713	26.887
		STD	1.133	10.343	45.808	302.186	14.105	5.149	3.989
	100	Mean	4.689	68.981	149.782	912.082	84.052	2.562	25.533
		STD	0.783	6.907	11.949	207.550	4.540	0.761	3.287

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 55. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 78-Week Interim Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)				
			Spleen	Thymus	Thyroid Gland	Ovaries	Uterus
Control	0	Mean[3]	53.455	14.319	2.583	5.595	42.484
		STD	36.931	1.147	0.169	0.302	12.684
Aroclor-1016	50	Mean[1]	32.322	21.648	2.351	5.285	49.983
		STD	4.364	4.408	0.662	0.711	15.264
	100	Mean	41.246	27.649	2.257	5.928	40.171
		STD	8.447	21.606	0.542	1.357	7.347
	200	Mean	53.347	24.741	2.574	7.266	58.167
		STD	51.855	9.262	0.646	1.731	27.366
Aroclor-1242	50	Mean[1]	34.136	26.678	2.875	17.692	38.210
		STD	5.663	6.395	0.629	28.256	10.282
	100	Mean[1]	32.917	22.755	2.331	4.931	46.913
		STD	3.596	16.904	0.391	0.496	12.740
Aroclor-1254	25	Mean[2]	32.542	20.256	2.176	5.801	53.202
		STD	3.155	7.951	0.210	0.731	15.232
	50	Mean	36.050	23.902	2.159	11.335	45.686
		STD	4.027	11.464	0.265	11.262	11.425
	100	Mean[1]	37.709	19.265	2.220	8.295	92.898
		STD	9.420	2.310	0.331	3.902	59.129
Aroclor-1260	25	Mean[1]	32.367	21.416	2.463	6.650	47.282
		STD	5.266	6.326	0.596	2.096	18.024
	50	Mean	32.677	21.369	2.369	5.635	49.361
		STD	5.895	10.291	0.453	1.895	29.446
	100	Mean	31.079	20.160	2.388	5.948	54.768
		STD	4.447	5.129	0.598	1.466	14.383

N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 56. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)							
			Adrenal Gland	Brain	Heart	Kidneys	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean	0.120	1.954	1.651	3.302	15.320	2.531	0.128	0.540
		STD	0.029	0.093	0.442	0.366	3.472	1.954	0.115	0.113
		N	10	31	10	10	31	10	10	10
Aroclor-1016	50	Mean	0.127	**2.057[b]**	1.761	4.512	17.536	2.418	0.182	0.607
		STD	0.049	0.105	0.508	2.069	5.750	0.938	0.159	0.168
		N	10	20	10	10	20	10	10	10
	100	Mean	0.162	1.984	1.842	3.930	**19.184[b]**	2.224	0.161	0.552
		STD	0.062	0.106	0.509	0.593	3.847	1.018	0.124	0.128
		N	10	21	10	10	21	10	10	10
	200	Mean	0.091	2.012	1.650	3.829	**19.677[b]**	1.988	0.110	0.499
		STD	0.026	0.081	0.350	0.910	4.803	0.238	0.132	0.064
		N	10	24	10	10	24	10	10	10
Aroclor-1242	50	Mean	0.224	1.980	1.710	3.477	17.975	2.368	0.091	0.452
		STD	0.128	0.096	0.434	0.479	4.390	1.139	0.102	0.083
		N	10	22	10	10	22	10	10	10
	100	Mean	0.095	1.954	1.626	3.465	**21.162[b]**	1.791	0.190	0.480
		STD	0.038	0.098	0.248	0.432	5.312	0.249	0.213	0.076
		N	10	26	10	10	26	10	10	10
Aroclor-1254	25	Mean	0.111	1.895	1.474	3.521	**22.894[b]**	1.909	0.100	0.433
		STD	0.054	0.104	0.118	0.328	8.212	0.182	0.100	0.053
		N	10	33	10	10	33	10	10	10
	50	Mean	0.078	1.912	1.409	3.301	**30.145[b]**	2.026	0.077	0.431
		STD	0.037	0.074	0.207	0.436	10.105	0.404	0.115	0.080
		N	10	17	10	10	17	10	10	10
	100	Mean	0.081	1.929	1.453	3.182	**33.187[b]**	2.173	0.145	**0.419[a]**
		STD	0.058	0.088	0.270	0.419	10.616	0.417	0.195	0.080
		N	10	20	10	10	20	10	10	10
Aroclor-1260	25	Mean	0.118	1.999	1.572	3.759	19.746	2.241	0.167	0.457
		STD	0.051	0.113	0.202	0.814	6.058	0.749	0.089	0.081
		N	10	19	10	10	19	10	10	10
	50	Mean	0.108	1.985	1.781	4.168	**21.618[b]**	2.116	0.084	0.526
		STD	0.027	0.090	0.273	0.844	6.112	0.596	0.033	0.061
		N	10	21	10	10	21	10	10	10
	100	Mean	0.105	1.955	1.701	3.893	**29.519[b]**	1.806	0.119	0.534
		STD	0.038	0.114	0.211	0.550	10.739	0.188	0.100	0.111
		N	10	22	10	10	22	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 56. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)				
			Spleen	Thymus	Thyroid Gland	Ovary	Uterus
Control	0	Mean	0.673	0.499	0.044	0.162	0.997
		STD	0.092	0.543	0.007	0.072	0.536
		N	10	10	10	10	10
Aroclor-1016	50	Mean	0.863	0.359	0.046	0.124	0.773
		STD	0.262	0.241	0.010	0.054	0.339
		N	10	10	10	10	10
	100	Mean	0.946	0.335	0.037	0.132	0.688
		STD	0.447	0.197	0.007	0.033	0.262
		N	10	10	10	10	10
	200	Mean	0.792	0.325	0.046	0.205	0.926
		STD	0.269	0.176	0.013	0.177	0.704
		N	10	10	10	10	10
Aroclor-1242	50	Mean	0.758	0.420	0.050	0.155	0.662
		STD	0.174	0.196	0.013	0.073	0.192
		N	10	10	10	10	10
	100	Mean	0.960	0.311	0.043	0.128	0.820
		STD	0.918	0.105	0.008	0.030	0.279
		N	10	10	10	10	10
Aroclor-1254	25	Mean	0.594	0.274	0.052	0.126	1.099
		STD	0.081	0.113	0.024	0.035	0.597
		N	10	10	10	10	10
	50	Mean	0.810	0.228	0.043	0.129	0.802
		STD	0.264	0.116	0.007	0.070	0.353
		N	10	10	10	10	10
	100	Mean	0.620	0.256	0.038	0.105	0.785
		STD	0.163	0.110	0.008	0.044	0.501
		N	10	10	10	10	10
Aroclor-1260	25	Mean	0.828	0.314	0.119	0.121	0.628
		STD	0.531	0.119	0.248	0.046	0.170
		N	10	10	10	10	10
	50	Mean	0.821	0.320	0.043	0.142	1.375
		STD	0.178	0.087	0.011	0.035	0.949
		N	10	10	10	10	10
	100	Mean	0.767	0.326	0.042	0.136	0.909
		STD	0.254	0.165	0.007	0.033	0.322
		N	10	10	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 56. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)							
			Adrenal Glands	Brain	Heart	Kidneys	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean	0.027	0.451	0.362	0.730	3.439	0.560	0.030	0.119
		STD	0.008	0.094	0.097	0.127	0.607	0.431	0.029	0.029
		N	10	31	10	10	31	10	10	10
Aroclor-1016	50	Mean	0.033	0.452	0.421	1.113	3.731	0.603	0.053	0.147
		STD	0.017	0.137	0.144	0.627	1.510	0.296	0.062	0.052
		N	10	20	10	10	20	10	10	10
	100	Mean	0.036	0.429	0.395	0.853	**4.052[a]**	0.482	0.037	0.120
		STD	0.017	0.101	0.106	0.193	0.795	0.215	0.030	0.037
		N	10	21	10	10	21	10	10	10
	200	Mean	0.022	0.445	0.383	0.894	**4.201[b]**	0.473	0.029	0.119
		STD	0.008	0.095	0.074	0.213	0.758	0.126	0.043	0.034
		N	10	24	10	10	24	10	10	10
Aroclor-1242	50	Mean	0.056	0.471	0.416	0.820	4.183	0.609	0.023	0.102
		STD	0.043	0.139	0.246	0.318	1.350	0.544	0.030	0.018
		N	10	22	10	10	22	10	10	10
	100	Mean	0.026	0.502	0.443	0.945	**5.341[b]**	0.488	0.059	0.130
		STD	0.012	0.084	0.088	0.179	1.191	0.096	0.076	0.023
		N	10	26	10	10	26	10	10	10
Aroclor-1254	25	Mean	0.030	0.504	0.399	**0.951[a]**	**6.127[b]**	0.515	0.029	0.117
		STD	0.016	0.099	0.061	0.143	2.702	0.071	0.031	0.021
		N	10	33	10	10	33	10	10	10
	50	Mean	0.022	0.533	0.394	0.931	**8.561[b]**	0.562	0.020	0.120
		STD	0.009	0.127	0.063	0.185	3.911	0.092	0.024	0.019
		N	10	17	10	10	17	10	10	10
	100	Mean	0.025	**0.607[b]**	0.457	**1.014[b]**	**10.409[b]**	0.691	0.053	0.134
		STD	0.016	0.117	0.067	0.180	3.577	0.155	0.088	0.033
		N	10	20	10	10	20	10	10	10
Aroclor-1260	25	Mean	0.027	0.429	0.366	0.871	4.105	0.512	0.043	0.106
		STD	0.012	0.098	0.081	0.218	1.008	0.140	0.036	0.021
		N	10	19	10	10	19	10	10	10
	50	Mean	0.023	0.429	0.378	0.884	4.722	0.461	0.017	0.113
		STD	0.008	0.086	0.077	0.202	1.931	0.196	0.007	0.026
		N	10	21	10	10	21	10	10	10
	100	Mean	0.026	0.461	0.422	0.972	**6.909[b]**	0.455	0.030	0.134
		STD	0.011	0.082	0.079	0.204	2.596	0.115	0.027	0.040
		N	10	22	10	10	22	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 56. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Body Weight Ratios (%)				
			Spleen	Thymus	Thyroid Gland	Ovary	Uterus
Control	0	Mean	0.147	0.109	0.010	0.037	0.225
		STD	0.015	0.119	0.002	0.021	0.142
		N	10	10	10	10	10
Aroclor-1016	50	Mean	0.204	0.077	0.012	0.029	0.180
		STD	0.073	0.037	0.006	0.011	0.068
		N	10	10	10	10	10
	100	Mean	0.202	0.071	0.008	0.028	0.151
		STD	0.088	0.037	0.002	0.007	0.069
		N	10	10	10	10	10
	200	Mean	0.183	0.073	0.011	0.047	0.218
		STD	0.060	0.036	0.002	0.038	0.147
		N	10	10	10	10	10
Aroclor-1242	50	Mean	0.183	0.093	0.011	0.035	0.154
		STD	0.096	0.040	0.004	0.015	0.055
		N	10	10	10	10	10
	100	Mean	0.249	0.082	0.012	0.035	0.223
		STD	0.203	0.024	0.002	0.010	0.077
		N	10	10	10	10	10
Aroclor-1254	25	Mean	0.161	0.074	0.014	0.035	0.294
		STD	0.032	0.031	0.005	0.013	0.162
		N	10	10	10	10	10
	50	Mean	**0.222**[a]	0.061	0.012	0.040	0.231
		STD	0.054	0.025	0.004	0.033	0.100
		N	10	10	10	10	10
	100	Mean	0.194	0.078	0.012	0.033	0.246
		STD	0.046	0.028	0.003	0.012	0.150
		N	10	10	10	10	10
Aroclor-1260	25	Mean	0.179	0.071	0.029	0.028	0.145
		STD	0.076	0.024	0.060	0.011	0.038
		N	10	10	10	10	10
	50	Mean	0.175	0.067	0.009	0.030	0.297
		STD	0.053	0.018	0.003	0.009	0.218
		N	10	10	10	10	10
	100	Mean	0.190	0.076	0.010	0.034	0.233
		STD	0.067	0.022	0.002	0.008	0.105
		N	10	10	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 56. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)						
			Adrenal Glands	Heart	Kidneys	Liver	Lungs	Pituitary Gland	Salivary Glands
Control	0	Mean	6.037	83.187	166.253	783.655	127.648	6.520	27.101
		STD	1.476	22.567	17.649	171.489	100.121	5.912	5.207
		N	10	10	10	31	10	10	10
Aroclor-1016	50	Mean	6.248	86.639	220.556	853.023	119.038	9.152	29.832
		STD	2.401	23.645	93.459	285.332	44.538	8.184	7.355
		N	10	10	10	20	10	10	10
	100	Mean	8.248	94.629	**202.214[a]**	**969.906[b]**	113.878	8.289	28.378
		STD	2.8[illegible]	24.752	28.950	206.864	49.735	6.440	6.375
		N	10	10	10	21	10	10	10
	200	Mean	4.55[illegible]	81.770	191.199	**980.147[a]**	98.700	5.461	24.740
		STD	1.388	16.257	52.415	247.151	11.689	6.512	2.901
		N	10	10	10	24	10	10	10
Aroclor-1242	50	Mean	11.333	86.548	175.954	908.683	120.259	4.570	22.782
		STD	6.592	23.307	26.449	226.100	60.810	5.231	3.781
		N	10	10	10	22	10	10	10
	100	Mean	5.025	84.732	180.714	**1085.699[b]**	93.412	10.366	24.813
		STD	2.196	14.269	27.418	280.527	15.274	12.353	3.001
		N	10	10	10	26	10	10	10
Aroclor-1254	25	Mean	5.880	77.644	185.842	**1206.441[b]**	100.306	5.122	22.837
		STD	2.970	7.694	24.245	427.047	8.291	4.987	3.440
		N	10	10	10	33	10	10	10
	50	Mean	4.107	73.693	172.554	**1584.350[b]**	106.001	3.895	22.559
		STD	1.994	12.806	26.667	552.565	23.407	5.540	4.656
		N	10	10	10	17	10	10	10
	100	Mean	4.186	76.011	166.735	**1721.972[b]**	114.075	7.660	21.980
		STD	2.830	12.320	19.497	557.230	22.213	10.545	4.170
		N	10	10	10	20	10	10	10
Aroclor-1260	25	Mean	6.010	80.196	191.416	**983.890[a]**	113.998	8.591	23.261
		STD	2.664	9.762	38.997	279.031	35.336	4.777	3.773
		N	10	10	10	19	10	10	10
	50	Mean	5.418	89.284	209.324	**1085.635[b]**	106.106	4.207	26.292
		STD	1.339	14.231	47.196	271.667	30.608	1.692	2.707
		N	10	10	10	21	10	10	10
	100	Mean	5.326	86.660	198.330	**1509.623[b]**	91.954	6.140	27.106
		STD	1.822	9.757	26.281	541.620	7.783	5.310	4.862
		N	10	10	10	22	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 56. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Termination Female Rats

Test Substance	Conc. (ppm)		Organ-to-Brain Weight Ratios (%)				
			Spleen	Thymus	Thyroid Gland	Ovary	Uterus
Control	0	Mean	33.939	25.318	2.237	8.167	50.266
		STD	4.871	27.871	0.377	3.659	27.002
		N	10	10	10	10	10
Aroclor-1016	50	Mean	42.279	17.834	2.288	6.103	38.262
		STD	11.716	12.409	0.495	2.641	16.970
		N	10	10	10	10	10
	100	Mean	48.539	17.280	1.917	6.812	34.980
		STD	22.003	10.604	0.320	1.831	12.321
		N	10	10	10	10	10
	200	Mean	39.164	16.246	2.300	10.026	46.081
		STD	12.520	9.016	0.658	8.177	35.110
		N	10	10	10	10	10
Aroclor-1242	50	Mean	38.296	21.109	2.504	7.827	33.556
		STD	8.978	9.597	0.684	3.635	10.078
		N	10	10	10	10	10
	100	Mean	50.186	15.953	2.237	6.636	42.409
		STD	49.282	4.908	0.336	1.512	13.522
		N	10	10	10	10	10
Aroclor-1254	25	Mean	31.343	14.483	2.718	6.633	58.037
		STD	5.072	5.897	1.216	2.039	31.077
		N	10	10	10	10	10
	50	Mean	42.505	11.864	2.226	6.726	42.176
		STD	14.754	6.010	0.376	3.577	19.265
		N	10	10	10	10	10
	100	Mean	32.489	13.406	1.994	5.476	41.223
		STD	8.398	5.677	0.373	2.187	26.916
		N	10	10	10	10	10
Aroclor-1260	25	Mean	41.972	15.979	5.973	6.205	31.911
		STD	25.757	5.926	12.285	2.421	8.128
		N	10	10	10	10	10
	50	Mean	41.178	16.027	2.157	7.104	69.444
		STD	9.283	4.395	0.563	1.811	49.103
		N	10	10	10	10	10
	100	Mean	38.937	16.490	2.133	6.910	46.129
		STD	12.424	7.747	0.342	1.472	15.624
		N	10	10	10	10	10

a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 57. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 78-Week Stop Study B Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)		Organ-to-Body Weight Ratios (%)		Organ-to-Brain Weight Ratio (%)
			Brain	Liver	Brain	Liver	Liver
Control*	0	Mean[3]	2.092	18.517	0.394	3.201	885.420
		STD	0.040	9.048	0.102	0.604	432.615
Aroclor-1016	50	Mean	1.954	16.372	0.467	3.706	833.417
		STD	0.110	5.012	0.107	0.502	235.525
	100	Mean	1.973	17.266	0.471	3.245	881.012
		STD	0.109	2.070	0.033	0.413	143.547
	200	Mean[1]	1.974	15.934	0.434	3.461	808.646
		STD	0.085	2.787	0.059	0.401	145.767
Aroclor-1242	50	Mean[1]	1.961	18.304	0.349	3.186	931.145
		STD	0.049	2.975	0.076	0.337	129.466
	100	Mean[1]	1.896	15.457	0.496	3.733	811.377
		STD	0.111	4.340	0.173	0.292	213.970
Aroclor-1254	25	Mean[1]	1.963	18.057	0.446	4.147	931.124
		STD	0.141	2.926	0.046	1.076	221.777
	50	Mean	1.919	17.969	0.482	4.486	936.740
		STD	0.084	2.024	0.059	0.442	101.456
	100	Mean	1.924	20.247	0.405	4.132	1048.832
		STD	0.070	5.911	0.081	0.952	282.024
Aroclor-1260	25	Mean	2.013	19.887	0.360	3.547	986.136
		STD	0.114	2.664	0.026	0.374	102.617
	50	Mean[2]	1.941	19.604	0.406	4.316	1023.818
		STD	0.167	5.583	0.070	2.262	348.580
	100	Mean[1]	1.912	18.064	0.435	4.026	945.506
		STD	0.068	2.744	0.132	1.097	149.001

* Weights from Female 78-Week Interim Termination
N = 6 unless otherwise noted.
1. N = 5 for all organs.
2. N = 4 for all organs.
3. N = 3 for all organs.
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 58. Group Mean Absolute Organ Weights, Organ-to-Body Weight Ratios, and Organ-to-Brain Weight Ratios for the 105-Week Stop Study A Termination Female Rats

Test Substance	Conc. (ppm)		Absolute Organ Weights (g)		Organ-to-Body Weight Ratios (%)		Organ-to-Brain Weight Ratio (%)
			Brain	Liver	Brain	Liver	Liver
Control*	0	Mean	1.954	15.320	0.451	3.439	783.655
		STD	0.093	3.472	0.094	0.607	171.489
		N	31	31	31	31	31
Aroclor-1016	50	Mean	2.039	**20.710[b]**	0.422	4.171	**1015.105[a]**
		STD	0.089	4.817	0.099	0.918	227.719
		N	10	10	10	10	10
	100	Mean	**2.091[b]**	19.134	0.406	3.583	908.571
		STD	0.148	4.149	0.133	0.807	155.641
		N	10	10	10	10	10
	200	Mean	2.033	17.974	0.428	3.584	886.673
		STD	0.099	3.772	0.141	0.400	194.174
		N	7	7	7	7	7
Aroclor-1242	50	Mean	2.013	19.318	0.462	4.203	958.870
		STD	0.079	6.351	0.127	1.040	312.699
		N	10	10	10	10	10
	100	Mean	1.972	20.404	0.463	4.438	1035.282
		STD	0.091	6.686	0.175	1.471	356.167
		N	11	11	11	11	11
Aroclor-1254	25	Mean	1.990	21.871	0.483	5.253	1095.554
		STD	0.091	7.312	0.085	1.802	347.371
		N	11	11	11	11	11
	50	Mean	1.958	24.735	0.432	5.453	1260.318
		STD	0.134	13.703	0.073	3.596	700.184
		N	14	14	14	14	14
	100	Mean	1.951	**24.411[b]**	0.436	**5.372[b]**	**1255.881[b]**
		STD	0.103	6.218	0.093	1.503	330.070
		N	13	13	13	13	13
Aroclor-1260	25	Mean	2.033	**22.263[a]**	0.398	**4.242[a]**	1104.589
		STD	0.166	7.075	0.084	1.005	382.510
		N	14	14	14	14	14
	50	Mean	2.027	**22.221[b]**	0.402	**4.416[a]**	**1097.285[b]**
		STD	0.065	5.101	0.040	1.103	252.697
		N	6	6	6	6	6
	100	Mean	1.984	**22.659[b]**	0.434	**4.861[b]**	**1143.566[b]**
		STD	0.067	3.727	0.081	0.828	192.587
		N	13	13	13	13	13

* Weights from Female 105-Week Termination
a. Statistically significant from control at $p \leq 0.05$.
b. Statistically significant from control at $p \leq 0.01$.

Table 59. Significant Mean Organ-to-Brain Weight Ratio Differences Between Aroclor Test Substances for Male and Female Rats

Organ	Concentration (ppm)	Test Substance	Core Subgroups				Stop Study A Subgroup	
			Male Group Comparisons		Female Group Comparisons		Female Group Comparisons	
			$p<0.05$	$p<0.01$	$p<0.05$	$p<0.01$	$p<0.05$	$p<0.01$
Liver	50	1016	A	A	A	A	A	A
		1242	A	A	AC	A	A	A
		1254	A	A	B	B	A[1]	A
		1260	A	A	C	A	A	A
	100	1016	A	A	A	A	A	A
		1242	A	A	A	A	AB	A
		1254	A	A	B	B	B[1]	A[1]
		1260	A	A	B	A	AB[1]	A[1]
Thyroid Gland	50	1016	A	A	A	A		
		1242	A	A	A	A		
		1254	A	A	A	A		
		1260	A	A	A	A		
	100	1016	A	A	A	A		
		1242	A	A	A	A		
		1254	A	A	A	A		
		1260	A	A	A	A		

1. The footnote (1) indicates comparisons of the Stop Study A subgroup females with the Core subgroup females for which the mean liver-to-brain weight ratios of Core subgroup females is statistically less than the ratio for the indicated Stop Study A subgroup females.

The letter legends indicate comparisons between the four Aroclor test substances. If at least one letter is common to any pair of [both] compared Aroclor test substances (example: 1016A, 1242A), no statistical difference exists between them. If there is no letter in common, a statistical difference exists between the compared Aroclor test substances. See *Summary of Statistical Methods* in Appendix A for a more detailed explanation.